FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Sanchez-Reilly, S
AF Sanchez-Reilly, Sandra
TI The Effects of Cognitive Impairment in Older Cancer Patients
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Editorial Material
C1 [Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Sanchez-Reilly, Sandra] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Sanchez-Reilly, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.; Sanchez-Reilly, S (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
BP 295
EP 296
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300023
ER
PT J
AU Thomas, JD
Back, AL
Gustin, J
Jackson, VA
Jacobsen, J
Landzaat, LH
Levine, SK
Neri, V
Periyakoil, V
Smith, CN
AF Thomas, Jane deLima
Back, Anthony L.
Gustin, Jillian
Jackson, Vicki A.
Jacobsen, Juliet
Landzaat, Lindy H.
Levine, Stacie K.
Neri, Vanessa
Periyakoil, Vyjeyanthi
Smith, Christian Nicole
TI 2017 AAHPM Fellowship Directors Program: Building a Community of
Educators
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Thomas, Jane deLima] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA.
[Back, Anthony L.] Univ Washington, Fred Hutchinson Canc Res Ctr, Sch Med, Seattle, WA 98195 USA.
[Gustin, Jillian] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA.
[Jackson, Vicki A.; Jacobsen, Juliet] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
[Landzaat, Lindy H.] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA.
[Levine, Stacie K.] Univ Chicago, Chicago, IL 60637 USA.
[Neri, Vanessa] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Periyakoil, Vyjeyanthi] Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, Stanford, CA USA.
[Smith, Christian Nicole] Univ Alabama Birmingham, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA P04
BP 305
EP 306
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300035
ER
PT J
AU Sanders, J
Lakin, J
Bernacki, R
Arnold, C
Paladino, J
AF Sanders, Justin
Lakin, Joshua
Bernacki, Rachelle
Arnold, Catherine
Paladino, Joanna
TI Priming the System for Primary Palliative Care: More, Better, and
Earlier Conversations with Seriously Ill Patients
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Sanders, Justin; Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sanders, Justin; Lakin, Joshua] Harvard Med Sch, Boston, MA USA.
[Arnold, Catherine] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Paladino, Joanna] Ariadne Labs, Brookline, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA P10
BP 308
EP 309
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300041
ER
PT J
AU Hwang, J
Battista, V
Jacobowski, N
Mosher, P
Muriel, A
Long, C
AF Hwang, Jennifer
Battista, Vanessa
Jacobowski, Natalie
Mosher, Pamela
Muriel, Anna
Long, Carolyn
TI "The Doctor Is In: Part 2": Challenging Topics at the Intersection of
Pediatric Palliative Care and Psychiatry
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Hwang, Jennifer; Battista, Vanessa; Long, Carolyn] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Jacobowski, Natalie] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mosher, Pamela] Hosp Sick Children, Toronto, ON, Canada.
[Muriel, Anna] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA P18
BP 311
EP 312
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300048
ER
PT J
AU Sudore, R
You, J
Korfage, I
Rietjens, J
Le, G
Heyland, D
AF Sudore, Rebecca
You, John
Korfage, Ida
Rietjens, Judith
Le, Gem
Heyland, Daren
TI Prioritizing Outcomes for Advance Care Planning Research: Consensus from
a Multidisciplinary, International Delphi Panel
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA.
[Sudore, Rebecca; Le, Gem] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[You, John] McMaster Univ, Hamilton, ON, Canada.
[Korfage, Ida; Rietjens, Judith] Erasmus Univ, Med Ctr, Rotterdam, Netherlands.
[Heyland, Daren] Queens Univ, Kingston, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA TH307A
BP 316
EP 317
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300060
ER
PT J
AU Sudore, R
Boscardin, J
Barnes, D
AF Sudore, Rebecca
Boscardin, John
Barnes, Deborah
TI A Patient-Facing Advance Care Planning (ACP) Website Called PREPARE
Increases ACP Documentation and Engagement in a Randomized Trial of
Diverse Older Primary Care Patients at a VA Medical Center
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA.
[Sudore, Rebecca; Boscardin, John; Barnes, Deborah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA TH307B
BP 317
EP 318
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300061
ER
PT J
AU Sudore, R
Heyland, D
Barnes, D
Howard, M
Fassbender, K
Robinson, C
Boscardin, J
You, J
AF Sudore, Rebecca
Heyland, Daren
Barnes, Deborah
Howard, Michelle
Fassbender, Konrad
Robinson, Carole
Boscardin, John
You, John
TI Measuring Advance Care Planning: Optimizing the Advance Care Planning
Engagement Survey
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA.
[Sudore, Rebecca; Barnes, Deborah; Boscardin, John] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Heyland, Daren] Queens Univ, Kingston, ON, Canada.
[Howard, Michelle; You, John] McMaster Univ, Hamilton, ON, Canada.
[Fassbender, Konrad] Covenant Hlth Palliat Inst, Edmonton, AB, Canada.
[Robinson, Carole] Univ British Columbia, Kelowna, BC, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA TH307C
BP 318
EP 318
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300062
ER
PT J
AU Zapata, C
Wistar, E
Horton, C
Lum, H
Sudore, R
AF Zapata, Carly
Wistar, Emily
Horton, Claire
Lum, Hillary
Sudore, Rebecca
TI Using A Video-Based Advance Care Planning (ACP) Website to Facilitate
Group Visits for Diverse Older Adults in Primary Care Is Feasible And
Improves ACP Engagement
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Zapata, Carly; Wistar, Emily; Horton, Claire; Sudore, Rebecca] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Lum, Hillary] Univ Colorado, Aurora, CO USA.
[Lum, Hillary] Eastern Colorado GRECC, Aurora, CO USA.
[Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA TH307D
BP 318
EP 319
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300063
ER
PT J
AU Mullin, J
Macauley, R
AF Mullin, Jonathan
Macauley, Robert
TI Clinical and Ethical Issues in Terminal Gastrointestinal Dysfunction in
Children with Severe Neurological Impairment
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Mullin, Jonathan] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mullin, Jonathan] Boston Childrens Hosp, Boston, MA USA.
[Macauley, Robert] Univ Vermont, Burlington, VT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA TH316
BP 322
EP 323
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300071
ER
PT J
AU Lum, H
Garner, K
Antoni, C
AF Lum, Hillary
Garner, Kimberly
Antoni, Charlie
TI "I Heard Something from Another Veteran'': How to Use Group Visits to
Engage Patients in Advance Care Planning
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Lum, Hillary] Univ Colorado, Aurora, CO USA.
[Lum, Hillary] VA Eastern Colorado, Aurora, CO USA.
[Garner, Kimberly] US Dept Vet Affairs, Little Rock, AR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA TH319
BP 324
EP 324
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300074
ER
PT J
AU Bekelman, D
Allen, L
Hattler, B
Havranek, E
Fairclough, D
McBryde, C
Meek, P
AF Bekelman, David
Allen, Larry
Hattler, Brack
Havranek, Edward
Fairclough, Diane
McBryde, Connor
Meek, Paula
TI Primary Results from the Collaborative Care to Alleviate Symptoms and
Adjust to Illness in Heart Failure (CASA) Randomized Clinical Trial
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Bekelman, David; McBryde, Connor] Univ Colorado, Denver, CO 80202 USA.
[Allen, Larry] Univ Colorado, Sch Med, Aurora, CO USA.
[Hattler, Brack] Denver VA Med Ctr, Denver, CO USA.
[Havranek, Edward] Denver Hlth Med Ctr, Denver, CO USA.
[Fairclough, Diane; Meek, Paula] Univ Colorado, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA TH321D
BP 328
EP 329
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300082
ER
PT J
AU Yeh, IM
Shulman, E
Hester, J
Bernacki, R
AF Yeh, Irene M.
Shulman, Eliza
Hester, Jennifer
Bernacki, Rachelle
TI After the Conversation: Designing an Electronic Health Record for
Dynamic Advance Care Planning
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Yeh, Irene M.; Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Shulman, Eliza] Atrius Hlth, Needham, MA USA.
[Hester, Jennifer] Christ Hosp Hlth Network, Cincinnati, OH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA TH332
BP 330
EP 330
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300085
ER
PT J
AU Shaw, H
Fronk, J
Hui, F
Lorenz, K
Schroeder, K
Kenemuth, R
Bober, S
AF Shaw, Heather
Fronk, Joshua
Hui, Felicia
Lorenz, Karl
Schroeder, Karla
Kenemuth, Ruth
Bober, Sharon
TI The Birds and Bees Do It, So Why Can't We Talk About It? Intimacy and
Sexuality in Serious Illness and at the End of Life
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Shaw, Heather] Stanford Univ, Stanford, CA 94305 USA.
[Fronk, Joshua] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Hui, Felicia; Lorenz, Karl] Stanford Univ, Palo Alto, CA 94304 USA.
[Schroeder, Karla; Kenemuth, Ruth] Stanford Hlth Care, Palo Alto, CA USA.
[Bober, Sharon] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA TH366
BP 343
EP 343
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300110
ER
PT J
AU Decourcey, D
Silverman, M
Wolfe, J
AF Decourcey, Danielle
Silverman, Melanie
Wolfe, Joanne
TI Weighing Distress and Benefit: Understanding the Research Participation
Experiences of Bereaved Parents of Children with Medical Complexity
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Decourcey, Danielle; Silverman, Melanie] Boston Childrens Hosp, Boston, MA USA.
[Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA TH370B
BP 345
EP 346
PG 3
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300115
ER
PT J
AU Straehla, J
Barton, K
Yi-Frazier, J
Baker, S
Bona, K
Wolfe, J
Rosenberg, A
AF Straehla, Joelle
Barton, Krysta
Yi-Frazier, Joyce
Baker, Scott
Bona, Kira
Wolfe, Joanne
Rosenberg, Abby
TI The Benefits and Burdens of Cancer: A Prospective, Longitudinal Cohort
Study of Adolescents and Young Adults
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Straehla, Joelle] Boston Childrens Hosp, Dana Farber Canc Cent, Boston, MA USA.
[Barton, Krysta; Yi-Frazier, Joyce] Seattle Childrens Res Inst, Seattle, WA USA.
[Baker, Scott] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Bona, Kira; Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rosenberg, Abby] Seattle Childrens Hosp, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA TH370D
BP 346
EP 347
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300117
ER
PT J
AU Daubman, BR
Rosenberg, L
Kamdar, M
AF Daubman, Bethany Rose
Rosenberg, Leah
Kamdar, Mihir
TI Novel Palliative Care Delivery Mechanisms in an Increasingly Electronic
World
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Daubman, Bethany Rose] Massachusetts Gen Hosp, North Billerica, MA USA.
[Rosenberg, Leah] Massachusetts Gen Hosp, Cambridge, MA USA.
[Kamdar, Mihir] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA FR402
BP 351
EP 351
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300124
ER
PT J
AU Chen, B
Jacobsen, J
Jones, J
Lewin, W
Thomas, JD
Tuggey, E
AF Chen, Bonnie
Jacobsen, Juliet
Jones, Joshua
Lewin, Warren
Thomas, Jane DeLima
Tuggey, Erica
TI The Professional Working Group-How to Create and Use a Process Group to
Build Community, Prevent Burnout, and Make Work-Life Sustainable
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Chen, Bonnie] Kaiser Permanente, Oakland, CA USA.
[Jacobsen, Juliet] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jones, Joshua] Univ Penn Hlth Syst, Philadelphia, PA USA.
[Lewin, Warren] Mt Sinai Hosp, New York, NY 10029 USA.
[Thomas, Jane DeLima] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tuggey, Erica] Mt Sinai Med Ctr, New York, NY 10029 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA FR417
BP 356
EP 357
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300136
ER
PT J
AU Balkin, E
Wolfe, J
Kirkpatrick, J
Swetz, K
Blume, E
Kaufman, B
AF Balkin, Emily
Wolfe, Joanne
Kirkpatrick, James
Swetz, Keith
Blume, Elizabeth
Kaufman, Beth
TI Pediatric Cardiologist Attitudes About Palliative Care
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Balkin, Emily] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Wolfe, Joanne] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kirkpatrick, James] Univ Washington, Seattle, WA 98195 USA.
[Swetz, Keith] Univ Alabama Birmingham, Birmingham, AL USA.
[Blume, Elizabeth] Boston Childrens Hosp, Boston, MA USA.
[Kaufman, Beth] Lucile Packard Childrens Hosp Stanford, Palo Alto, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA FR419C
BP 358
EP 359
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300139
ER
PT J
AU Lakin, J
Arnold, C
Bernacki, R
Cunningham, R
Gallagher, J
Quigley, M
Lamey, J
Rangarajan, A
AF Lakin, Joshua
Arnold, Catherine
Bernacki, Rachelle
Cunningham, Rebecca
Gallagher, Julia
Quigley, Martha
Lamey, Jan
Rangarajan, Arjun
TI Three Palliative Care Models in Population Health Management Systems
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Lakin, Joshua] Harvard Med Sch, Boston, MA USA.
[Arnold, Catherine; Cunningham, Rebecca] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Gallagher, Julia; Quigley, Martha] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lamey, Jan; Rangarajan, Arjun] Brigham & Womens Phys Org, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA FR452
BP 372
EP 373
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300165
ER
PT J
AU Talebreza, S
Lowery, J
Bernacki, R
AF Talebreza, Shaida
Lowery, Jill
Bernacki, Rachelle
TI Eliciting, Documenting, and Honoring Patient's Goals of Care and
Life-Sustaining Treatment Decisions: Building Systems to Ensure Success
(FR479)
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Talebreza, Shaida] Univ Utah, Salt Lake City, UT USA.
[Lowery, Jill] Vet Hlth Adm, Natl Ctr Ethics Hlth Care, Durham, NC USA.
[Bernacki, Rachelle] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
BP 384
EP 384
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300187
ER
PT J
AU Lindvall, C
Forsyth, A
Barzilay, R
Tulsky, J
AF Lindvall, Charlotta
Forsyth, Alexander
Barzilay, Regina
Tulsky, James
TI Natural Language Processing: An Opportunity to Make Chart Data Come
Alive in Palliative Care Research
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Lindvall, Charlotta] Dana Farber Canc Inst Harvard, Boston, MA USA.
[Forsyth, Alexander; Barzilay, Regina] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Tulsky, James] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA FR481A
BP 385
EP 385
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300189
ER
PT J
AU Temel, J
AF Temel, Jennifer
TI Integrating Palliative and Oncology Care: Where Do We Go from Here?
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Temel, Jennifer] Massachusetts Gen Hosp Canc Ctr, Harvard Med Sch, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA SA500
BP 392
EP 392
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300200
ER
PT J
AU Yeh, I
Reville, B
AF Yeh, Irene
Reville, Barbara
TI The Write Stuff: How to Increase Your Writing Productivity
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Yeh, Irene; Reville, Barbara] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Reville, Barbara] Brigham & Womens, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA SA504
BP 394
EP 394
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300204
ER
PT J
AU Franklin, J
Painter, J
Cooke, K
Schluep, J
AF Franklin, John
Painter, John
Cooke, Kelly
Schluep, John
TI Moral Injury: Invisible Wounds of Combat
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Franklin, John; Painter, John] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Cooke, Kelly] ProHlth Care, Waukesha, WI USA.
[Schluep, John] First Congregat Church Tallmadge, Tallmadge, OH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA SA517
BP 400
EP 401
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300218
ER
PT J
AU Jacobsen, J
Lindenberger, E
Smith, C
AF Jacobsen, Juliet
Lindenberger, Elizabeth
Smith, Cardinale
TI See One, Do One, Coach One: How Clinical Coaching Can Help Trainees and
Colleagues Just When They Need It with Just What They Need
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Jacobsen, Juliet] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lindenberger, Elizabeth; Smith, Cardinale] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA SA516
BP 400
EP 400
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300217
ER
PT J
AU Williams, B
Bailey, FA
Goode, P
Burgio, K
AF Williams, Beverly
Bailey, F. Amos
Goode, Patricia
Burgio, Kathryn
TI ''Just Knowing That I Was Going to Be Questioned About His Last Days'':
Bereaved Next-Of-Kin's Pre-Interview Cognitive and Affective Work (S703)
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Williams, Beverly] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA.
[Bailey, F. Amos] Univ Colorado, Anschutz Med Campus, Aurora, CO USA.
[Goode, Patricia] Univ Alabama Birmingham, Birmingham, AL USA.
[Burgio, Kathryn] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
BP 411
EP 411
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300235
ER
PT J
AU Lee, K
Ganta, N
Horton, J
Chai, E
AF Lee, Kathleen
Ganta, Niharika
Horton, Jay
Chai, Emily
TI Evidence for Morphine or HydromorphoneInduced Neurotoxicity in Renal
Impairment: A Systematic Review (S705)
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Lee, Kathleen] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ganta, Niharika] Univ Penn, Aston, PA USA.
[Horton, Jay] Icahn Sch Med Mt Sinai, Brooklyn, NY USA.
[Chai, Emily] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
BP 412
EP 412
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300237
ER
PT J
AU Ubhayakar, N
Prommer, E
Steckart, MJ
AF Ubhayakar, Nitin
Prommer, Eric
Steckart, M. Jillisa
TI Palliative Care Consultation from the Emergency Department: Rationale
and Patient Characteristics in a Veteran Population
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Ubhayakar, Nitin] Vet Affairs Greater Los Angeles Healthcare, Los Angeles, CA USA.
[Prommer, Eric] Greater Los Angeles Healthcare, Los Angeles, CA USA.
[Steckart, M. Jillisa] Univ Calif Los Angeles, David Geffen Sch Med, Vet Affairs Greater Los Angeles Healthcare, Los Angeles, CA 90095 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA S728
BP 424
EP 425
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300260
ER
PT J
AU Sudore, R
Lum, H
You, J
Hanson, L
Meier, D
Pantilat, S
Matlock, DD
Rietjens, J
Korfage, IJ
Ritchie, C
Kutner, JS
Teno, JM
Thomas, J
Heyland, DK
AF Sudore, Rebecca
Lum, Hillary
You, John
Hanson, Laura
Meier, Diane
Pantilat, Steven
Matlock, Daniel D.
Rietjens, Judith
Korfage, Ida J.
Ritchie, Christine
Kutner, Jean S.
Teno, Joan M.
Thomas, Judy
Heyland, Daren K.
TI Proactive Outpatient Palliative Care Consultations for Persons with
Advanced Cancer: What's in the "Special Sauce''?
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA.
[Sudore, Rebecca; Pantilat, Steven; Ritchie, Christine] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Lum, Hillary] Univ Colorado, Aurora, CO USA.
[Lum, Hillary] Eastern Colorado GRECC, Aurora, CO USA.
[You, John] McMaster Univ, Hamilton, ON, Canada.
[Hanson, Laura] Univ N Carolina, Chapel Hill, NC USA.
[Meier, Diane] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Matlock, Daniel D.; Kutner, Jean S.] Univ Colorado, Sch Med, Aurora, CO USA.
[Rietjens, Judith; Korfage, Ida J.] Erasmus Univ, Med Ctr, Rotterdam, Netherlands.
[Teno, Joan M.] Univ Washington, Seattle, WA 98195 USA.
[Thomas, Judy] Coalit Compassionate Care Calif, Sacramento, CA USA.
[Heyland, Daren K.] Queens Univ, Kingston, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA S739
BP 431
EP 432
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300272
ER
PT J
AU Huang, CHS
Kvale, E
Bailey, FA
Goode, P
Burgio, K
AF Huang, Chao-Hui Sylvia
Kvale, Elizabeth
Bailey, F. Amos
Goode, Patricia
Burgio, Kathryn
TI Association Between Mental Health Diagnoses and Process of Care at the
End Of Life: Findings from the BEACON Trial
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Huang, Chao-Hui Sylvia; Goode, Patricia] Univ Alabama Birmingham, Birmingham, AL USA.
[Kvale, Elizabeth] Univ Alabama Birmingham, Birmingham Ctrat & Support Care, Birmingham, AL USA.
[Bailey, F. Amos] Univ Colorado, Anschutz Med Campus, Aurora, CO USA.
[Burgio, Kathryn] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA S771
BP 449
EP 449
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300303
ER
PT J
AU Hansen, L
Dieckmann, N
Chang, M
Naugler, W
Kolbeck, K
AF Hansen, Lissi
Dieckmann, Nathan
Chang, Michael
Naugler, Willscott
Kolbeck, Kenneth
TI Symptom Distress in Patients with Advanced Hepatocellular Carcinoma
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Hansen, Lissi; Dieckmann, Nathan; Naugler, Willscott; Kolbeck, Kenneth] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Chang, Michael] Portland VA Med Ctr, Portland, VA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA S781
BP 455
EP 455
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300313
ER
PT J
AU Brown, LM
Sawey, K
Liu, R
Baday, YI
Lee, S
Healy, J
Shah, R
Sanchez-Reilly, S
AF Brown, Lisa -Marie
Sawey, Kathryn
Liu, Rosemary
Baday, Yiressy Izaguirre
Lee, Shuko
Healy, Jennifer
Shah, Ronak
Sanchez-Reilly, Sandra
TI Do You Really Know What Palliative Care Is? Developing an Electronic
Palliative Care Information Card
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Brown, Lisa -Marie; Liu, Rosemary; Healy, Jennifer; Shah, Ronak; Sanchez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA.
[Sawey, Kathryn] Univ Hosp New Braunfels, New Braunfels, TX USA.
[Baday, Yiressy Izaguirre] Univ Texas Hlth Sci Ctr San Antonio, Ctr VA Hosp, San Antonio, TX USA.
[Lee, Shuko] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA S784
BP 456
EP 457
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300316
ER
PT J
AU Khan, H
Lee, S
Carretero, E
San-Chez-Reilly, S
AF Khan, Huma
Lee, Shuko
Carretero, Edgar
San-Chez-Reilly, Sandra
TI Serving Those Who Served: The Unique Benefit of Inpatient Hospice at the
VA
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Khan, Huma; San-Chez-Reilly, Sandra] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Lee, Shuko; Carretero, Edgar] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA S783
BP 456
EP 456
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300315
ER
PT J
AU Haverhals, L
Manheim, C
Levy, C
AF Haverhals, Leah
Manheim, Chelsea
Levy, Cali
TI Navigating Multiple Systems to Ensure Delivery of Concurrent Care to US
Veterans with Cancer
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Meeting Abstract
CT Annual Assembly of the
American-Academy-of-Hospice-and-Palliative-Medicine and the
Hospice-and-Palliative-Nurses-Association
CY FEB 22-25, 2017
CL Phoenix, AZ
SP Amer Acad Hospice & Palliat Med, Hosp & Palliat Nurses Assoc
C1 [Haverhals, Leah] Denver VA Med Ctr, Denver, CO USA.
[Manheim, Chelsea] VA Eastern Colorado Hlth Care Syst, Denver, CO USA.
[Levy, Cali] Univ Colorado, Denver, CO 80202 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD FEB
PY 2017
VL 53
IS 2
MA S806
BP 469
EP 469
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA EP1AR
UT WOS:000397118300338
ER
PT J
AU Catalano, OA
Masch, WR
Catana, C
Mahmood, U
Sahani, DV
Gee, MS
Menezes, L
Soricelli, A
Salvatore, M
Gervais, D
Rosen, BR
AF Catalano, Onofrio Antonio
Masch, William Roger
Catana, Ciprian
Mahmood, Umar
Sahani, Dushyant Vasudeo
Gee, Michael Stanley
Menezes, Leon
Soricelli, Andrea
Salvatore, Marco
Gervais, Debra
Rosen, Bruce Robert
TI An overview of PET/MR, focused on clinical applications
SO ABDOMINAL RADIOLOGY
LA English
DT Article
DE PET/MR; MR/PET; Oncologic imaging; Attenuation correction
ID POSITRON-EMISSION-TOMOGRAPHY; CELL LUNG-CANCER; FDG-PET/CT;
MULTIPLE-MYELOMA; RECTAL-CANCER; BREAST-CANCER; LYMPH-NODES; ATTENUATION
CORRECTION; COMPUTED-TOMOGRAPHY; INITIAL-EXPERIENCE
AB Hybrid PET/MR scanners are innovative imaging devices that simultaneously or sequentially acquire and fuse anatomical and functional data from magnetic resonance (MR) with metabolic information from positron emission tomography (PET) (Delso et al. in J Nucl Med 52:1914-1922, 2011; Zaidi et al. in Phys Med Biol 56:3091-3106, 2011). Hybrid PET/MR scanners have the potential to greatly impact not only on medical research but also, and more importantly, on patient management. Although their clinical applications are still under investigation, the increased worldwide availability of PET/MR scanners, and the growing published literature are important determinants in their rising utilization for primarily clinical applications. In this manuscript, we provide a summary of the physical features of PET/MR, including its limitations, which are most relevant to clinical PET/MR implementation and to interpretation. Thereafter, we discuss the most important current and emergent clinical applications of such hybrid technology in the abdomen and pelvis, both in the field of oncologic and non-oncologic imaging, and we provide, when possible, a comparison with clinically consolidated imaging techniques, like for example PET/CT.
C1 [Catalano, Onofrio Antonio; Catana, Ciprian; Mahmood, Umar; Rosen, Bruce Robert] Harvard Med Sch, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, 49 13th St, Charlestown, MA 02129 USA.
[Catalano, Onofrio Antonio; Sahani, Dushyant Vasudeo; Gee, Michael Stanley; Gervais, Debra] Harvard Med Sch, Massachusetts Gen Hosp, Abdominal Radiol, 55 Fruit St, Boston, MA 02114 USA.
[Masch, William Roger] Univ Michigan Hlth Syst, Dept Radiol, Abdominal Imaging, 1550E Med Ctr Dr,SPC5030, Ann Arbor, MI 48109 USA.
[Mahmood, Umar] Harvard Med Sch, Massachusetts Gen Hosp, Inst Precis Med, 55 Fruit St, Boston, MA 02114 USA.
[Gee, Michael Stanley] Harvard Med Sch, Massachusetts Gen Hosp, Martinos Ctr Pediat Radiol, 55 Fruit St, Boston, MA 02114 USA.
[Menezes, Leon] Univ Coll Hosp, Inst Nucl Med, 235 Euston Rd, London NW1 2BU, England.
[Soricelli, Andrea] Univ Naples Parthenope, Via Medina 40, I-80133 Naples, Italy.
[Salvatore, Marco] Fdn SDN, Med Nucl, Via Gianturco 113, I-80113 Naples, Italy.
RP Catalano, OA (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, 49 13th St, Charlestown, MA 02129 USA.; Catalano, OA (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Abdominal Radiol, 55 Fruit St, Boston, MA 02114 USA.
EM onofriocata-lano@yahoo.it
NR 61
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 2366-004X
EI 2366-0058
J9 ABDOM RADIOL
JI Abdom. Radiol.
PD FEB
PY 2017
VL 42
IS 2
BP 631
EP 644
DI 10.1007/s00261-016-0894-5
PG 14
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA EM1ND
UT WOS:000395083400029
PM 27624499
ER
PT J
AU Trevathan, JK
Yousefi, A
Park, HO
Bartoletta, JJ
Ludwig, KA
Lee, KH
Lujan, JL
AF Trevathan, James K.
Yousefi, Ali
Park, Hyung Ook
Bartoletta, John J.
Ludwig, Kip A.
Lee, Kendall H.
Lujan, J. Luis
TI Computational Modeling of Neurotransmitter Release Evoked by Electrical
Stimulation: Nonlinear Approaches to Predicting Stimulation-Evoked
Dopamine Release
SO ACS CHEMICAL NEUROSCIENCE
LA English
DT Article
DE Fast scan cyclic voltammetry; deep brain stimulation; dopamine;
artificial neural network; Volterra kernels; machine learning;
neurochemical sensing
ID SCAN CYCLIC VOLTAMMETRY; CARBON-FIBER MICROELECTRODES; ARTIFICIAL
NEURAL-NETWORKS; MEDIAL FOREBRAIN-BUNDLE; RAT DORSAL STRIATUM;
SUBTHALAMIC NUCLEUS; EXTRACELLULAR DOPAMINE; RESTRICTED DIFFUSION;
KINETIC DIVERSITY; STEREOTAXIC ATLAS
AB Neurochemical changes evoked by electrical stimulation of the nervous system have been linked to both therapeutic and undesired effects of neuromodulation therapies used to treat obsessive compulsive disorder, depression, epilepsy, Parkinson's disease, stroke, hypertension, tinnitus, and many other indications. In fact, interest in better understanding the role of neurochemical signaling in neuromodulation therapies has been a focus of recent government-and industry-sponsored programs whose ultimate goal is to usher in an era of personalized medicine by creating neuromodulation therapies that respond to real-time changes in patient status. A key element to achieving these precision therapeutic interventions is the development of mathematical modeling approaches capable of describing the nonlinear transfer function between neuromodulation parameters and evoked neurochemical changes. Here, we propose two computational modeling frameworks, based on artificial neural networks (ANNs) and Volterra kernels, that can characterize the input/output transfer functions of stimulation-evoked neurochemical release. We evaluate the ability of these modeling frameworks to characterize subject-specific neurochemical kinetics by accurately describing stimulation-evoked dopamine release across rodent (R-2 = 0.83 Volterra kernel, R-2 = 0.86 ANN), swine (R-2 = 0.90 Volterra kernel, R-2 = 0.93 ANN), and non-human primate (R-2 = 0.98 Volterra kernel, R-2 = 0.96 ANN) models of brain stimulation. Ultimately, these models will not only improve understanding of neurochemical signaling in healthy and diseased brains but also facilitate the development of neuromodulation strategies capable of controlling neurochemical release via closed-loop strategies.
C1 [Trevathan, James K.] Mayo Clin, Mayo Grad Sch, 200 First St SW, Rochester, MN 55905 USA.
[Park, Hyung Ook; Bartoletta, John J.; Ludwig, Kip A.; Lee, Kendall H.; Lujan, J. Luis] Mayo Clin, Dept Neurol Surg, 200 First St SW, Rochester, MN 55905 USA.
[Lee, Kendall H.; Lujan, J. Luis] Mayo Clin, Dept Physiol & Biomed Engn, 200 First St SW, Rochester, MN 55905 USA.
[Lee, Kendall H.] Mayo Clin, Dept Phys Med & Rehabil, 200 First St SW, Rochester, MN 55905 USA.
[Yousefi, Ali] Massachusetts Gen Hosp, Dept Neurol Surg, 25 Shattuck St, Boston, MA 02115 USA.
[Yousefi, Ali] Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA.
RP Lujan, JL (reprint author), Mayo Clin, Dept Neurol Surg, 200 First St SW, Rochester, MN 55905 USA.
EM lujan.luis@mayo.edu
FU National Institutes of Health, NINDS [R01 NS084975, R01 NS75013, R01
NS70872]; Grainger Foundation
FX This work was supported by the National Institutes of Health, NINDS (R01
NS084975 award to J.L.L. and R01 NS75013 and R01 NS70872 awards to
K.H.L.), and The Grainger Foundation.
NR 55
TC 0
Z9 0
U1 3
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7193
J9 ACS CHEM NEUROSCI
JI ACS Chem. Neurosci.
PD FEB
PY 2017
VL 8
IS 2
SI SI
BP 394
EP 410
DI 10.1021/acschemneuro.6b00319
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences
& Neurology
GA EL2XH
UT WOS:000394483300022
PM 28076681
ER
PT J
AU Rutrick, D
Stein, DJ
Subramanian, G
Smith, B
Fava, M
Hasler, G
Cha, JH
Gasparini, F
Donchev, T
Ocwieja, M
Johns, D
Gomez-Mancilla, B
AF Rutrick, Daniel
Stein, Dan J.
Subramanian, Ganesan
Smith, Brian
Fava, Maurizio
Hasler, Gregor
Cha, Jang-Ho
Gasparini, Fabrizio
Donchev, Toni
Ocwieja, Magdalena
Johns, Donald
Gomez-Mancilla, Baltazar
TI Mavoglurant Augmentation in OCD Patients Resistant to Selective
Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized,
Placebo-Controlled, Phase 2 Study
SO ADVANCES IN THERAPY
LA English
DT Article
DE AFQ056; Glutamate; Mavoglurant; Obsessive-compulsive disorder;
Psychiatry; Randomized controlled trial; Selective serotonin reuptake
inhibitors
ID OBSESSIVE-COMPULSIVE DISORDER; DOUBLE-BLIND; CONTROLLED TRIAL;
METAANALYSIS; MANAGEMENT; DIAGNOSIS; MODERATE; DRUG
AB To determine if mavoglurant (modified release) as an augmentation therapy to selective serotonin reuptake inhibitors (SSRIs) could have beneficial effects reducing Yale-Brown Obsessive Compulsive Scale (Y-BOCS) total score in patients with obsessive-compulsive disorder (OCD) resistant to SSRI treatment.
This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 2 study. Patients remained on their SSRI treatment and mavoglurant or placebo was added on. Non-smoking men and women aged 18-65 years primarily diagnosed with OCD according to Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.; DSM-IV-TR) criteria were randomized (1:1) to mavoglurant or placebo groups. After 50 patients were randomized, an interim analysis was conducted to determine whether the study should be continued. The primary outcome measure was absolute change in Y-BOCS from baseline at week 17. Safety was assessed by recording adverse events (AEs) and serious adverse events (SAEs).
Interim analysis led to a decision to terminate the study. In total 38 (76.0%) participants completed 17 weeks of treatment and 37 (74.0%) completed the study. There was no significant difference in least squares (LS) mean change from baseline at week 17 in Y-BOCS total score for mavoglurant compared with placebo groups [-6.9 (1.75) vs. -8.0 (1.78), respectively; LS mean difference 1.1; 95% CI -3.9, 6.2; p = 0.671]. The incidence of AEs was higher in the mavoglurant compared with the placebo group (80.8% vs. 70.8%, respectively).
This study of mavoglurant in OCD was terminated because of the lack of efficacy at interim analysis. The study did not support the use of an antagonist of mGluR5 receptors for OCD treatment.
The study was registered with ClinicalTrials.gov: NCT01813019.
This study was sponsored by Novartis Pharma AG, Basel, Switzerland.
C1 [Rutrick, Daniel] Adams Clin Trials, Watertown, MA 02472 USA.
[Stein, Dan J.] Univ Cape Town, Groote Schuur Hosp, Dept Psychiat, MRC Unit Anxiety & Stress Disorders, ZA-7925 Cape Town, South Africa.
[Subramanian, Ganesan] Novartis Healthcare Pvt Ltd, Hyderabad 500081, Andhra Pradesh, India.
[Smith, Brian; Cha, Jang-Ho] Novartis Pharmaceut, Cambridge, MA 02139 USA.
[Fava, Maurizio] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA.
[Hasler, Gregor] Univ Bern, Psychiat Univ Hosp, Div Mol Psychiat, CH-3000 Bern, Switzerland.
[Gasparini, Fabrizio; Ocwieja, Magdalena; Johns, Donald; Gomez-Mancilla, Baltazar] Novartis Pharma AG, Novartis Inst Biomed Res, CH-4056 Basel, Switzerland.
[Donchev, Toni] Psychiat Clin, Sofia 1606, Bulgaria.
[Johns, Donald] Biogen, 300 Binney St, Cambridge, MA 02142 USA.
[Gomez-Mancilla, Baltazar] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada.
RP Gomez-Mancilla, B (reprint author), Novartis Pharma AG, Novartis Inst Biomed Res, CH-4056 Basel, Switzerland.
EM baltazar.gomezmancilla@novartis.com
FU Novartis Pharma AG, Basel, Switzerland; Novartis Pharma AG
FX This study was sponsored by Novartis Pharma AG, Basel, Switzerland. The
article processing charges for this publication were funded by Novartis
Pharma AG. The authors thank Ritu Hans and K Ananda Krishna from
Novartis Healthcare Pvt Ltd, Hyderabad, India, for medical writing
assistance and incorporating subsequent revisions. All named authors
meet the International Committee of Medical Journal Editors (ICJME)
criteria for authorship for this manuscript, take responsibility for the
integrity of the work as a whole, and have given final approval to the
version to be published.
NR 34
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD FEB
PY 2017
VL 34
IS 2
BP 524
EP 541
DI 10.1007/s12325-016-0468-5
PG 18
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EM6SV
UT WOS:000395443300014
PM 28044255
ER
PT J
AU Yajnik, V
Khan, N
Dubinsky, M
Axler, J
James, A
Abhyankar, B
Lasch, K
AF Yajnik, Vijay
Khan, Nabeel
Dubinsky, Marla
Axler, Jeffrey
James, Alexandra
Abhyankar, Brihad
Lasch, Karen
TI Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's
Disease Patients Stratified by Age
SO ADVANCES IN THERAPY
LA English
DT Article
DE Crohn's disease; Ulcerative colitis; Vedolizumab
ID INFLAMMATORY-BOWEL-DISEASE; ANTI-TNF THERAPY; ADVERSE EVENTS; INCREASED
RISK; OLDER AGE; INFECTIONS; THIOPURINES
AB The efficacy and safety of vedolizumab, a gut-selective alpha(4)beta(7) integrin antibody, were demonstrated in the GEMINI 1 and GEMINI 2 clinical trials of adults aged 18-80 years. We investigated the efficacy and safety of vedolizumab in patients stratified by age from the GEMINI trials.
Safety and efficacy, including clinical response, clinical remission, and corticosteroid-free remission, at week 6 and/or 52 were determined post hoc in patients aged < 35, 35 to < 55, and ae55 years.
At baseline, 353, 412, and 130 ulcerative colitis (UC) and 582, 443, and 90 Crohn's disease (CD) patients were aged < 35, 35 to < 55, and ae55. Of these patients, 56 were aged ae65 years (UC: 33, CD: 23). Trends favoring vedolizumab over placebo were observed for most efficacy endpoints irrespective of patient age; some variability between subgroups was observed. Safety profiles of vedolizumab and placebo were similar in all age groups. Vedolizumab-treated patients aged ae55 had the lowest incidence of serious infections (0.9 per 100 person-years) and adverse events leading to hospitalization (14.8 per 100 person-years). There were no age-related differences in the incidence of adverse hematological events, malignancy, or death.
The safety and efficacy of vedolizumab in patients with UC or CD were similar for all age groups. The number of patients in the oldest age group in these analyses was small; thus further studies of vedolizumab in larger cohorts of elderly patients are warranted.
Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International Co.).
C1 [Yajnik, Vijay] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
[Khan, Nabeel] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Dubinsky, Marla] Mt Sinai Hosp, New York, NY 10029 USA.
[Axler, Jeffrey] Univ Toronto, Toronto Digest Dis Associates, Toronto, ON, Canada.
[James, Alexandra; Abhyankar, Brihad] Takeda Dev Ctr Europe Ltd, London, England.
[Lasch, Karen] Takeda Pharmaceut USA Inc, Deerfield, IL USA.
RP Yajnik, V (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
EM VYAJNIK@mgh.harvard.edu
FU Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals
International Co.)
FX Sponsorship, article processing charges, and the open access charge for
this study were funded by Millennium Pharmaceuticals, Inc. (d/b/a Takeda
Pharmaceuticals International Co.). Medical writing assistance was
provided by inVentiv Medical Communications and supported by Takeda
Pharmaceuticals International Co. Publication management support was
provided by Caterina Hatzifoti Ph.D. of Takeda Pharmaceuticals
International. All named authors meet the International Committee of
Medical Journal Editors (ICMJE) criteria for authorship for this
manuscript, had full access to all of the data in this study, and take
complete responsibility for the integrity of the data and accuracy of
the data analysis.
NR 31
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0741-238X
EI 1865-8652
J9 ADV THER
JI Adv. Ther.
PD FEB
PY 2017
VL 34
IS 2
BP 542
EP 559
DI 10.1007/s12325-016-0467-6
PG 18
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EM6SV
UT WOS:000395443300015
PM 28070861
ER
PT J
AU Rodriguez, HR
Dobalian, A
AF Rodriguez, Heather R.
Dobalian, Aram
TI PROVIDER AND ADMINISTRATOR EXPERIENCES WITH PROVIDING HIV TREATMENT AND
PREVENTION SERVICES IN RURAL AREAS
SO AIDS EDUCATION AND PREVENTION
LA English
DT Article
ID MENTAL-HEALTH; UNITED-STATES; MEDICAL-CARE; DEEP SOUTH; INFECTED
PERSONS; CASE-MANAGEMENT; ADULTS; INTERVENTION; FACILITATORS; PHYSICIANS
AB Using Andersen's behavioral model of health services use, this study analyzes data from 62 semistructured interviews of providers and administrators at health clinics and social service agencies in rural Florida. Andersen's model addresses predisposing, enabling, and need factors that influence health services use. ATLASti was used to code all interviews and to extract HIV-related themes. The aim of this study was to: (1) add a new dimension to the literature on HIV care services in rural areas, (2) reveal factors that impact ability to provide care to PLWH in rural areas, and (3) suggest ways in which providers and administrators may address any unmet health care needs of PLWH. Respondents perceived systems factors to be more important determinants of access to care for individuals living with HIV and supported ongoing trainings that would increase staff understanding of the needs of people living with HIV.
C1 [Rodriguez, Heather R.] Cent Connecticut State Univ, Dept Sociol, 1615 Stanley St,SSH 317-03, New Britain, CT 06050 USA.
[Dobalian, Aram] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, Washington, DC USA.
[Dobalian, Aram] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA 90024 USA.
RP Rodriguez, HR (reprint author), Cent Connecticut State Univ, Dept Sociol, 1615 Stanley St,SSH 317-03, New Britain, CT 06050 USA.
EM hrodriguez@ccsu.edu
FU Agency for Healthcare Research and Quality [U01HS14355]; Department of
Veterans Affairs, Veterans Health Administration, Office of Patient Care
Services
FX This work was supported by grant U01HS14355 from the Agency for
Healthcare Research and Quality. Dr Dobalian is supported by the
Department of Veterans Affairs, Veterans Health Administration, Office
of Patient Care Services. The views expressed in this article are those
of the authors and do not necessarily reflect the position or policy of
the Department of Veterans Affairs or the U.S. government.
NR 37
TC 0
Z9 0
U1 0
U2 0
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 370 SEVENTH AVE, SUITE 1200, NEW YORK, NY 10001-1020 USA
SN 0899-9546
EI 1943-2755
J9 AIDS EDUC PREV
JI Aids Educ. Prev.
PD FEB
PY 2017
VL 29
IS 1
BP 77
EP 91
PG 15
WC Education & Educational Research; Public, Environmental & Occupational
Health
SC Education & Educational Research; Public, Environmental & Occupational
Health
GA EM3QP
UT WOS:000395230000007
PM 28195782
ER
PT J
AU Haran, JP
Wilsterman, E
Zeoli, T
Beaudoin, FL
Tjia, J
Hibberd, PL
AF Haran, John P.
Wilsterman, Eric
Zeoli, Tyler
Beaudoin, Francesca L.
Tjia, Jennifer
Hibberd, Patricia L.
TI Elderly patients are at increased risk for treatment failure in
outpatient management of purulent skin infections
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
ID RESISTANT STAPHYLOCOCCUS-AUREUS; COMMUNITY-ACQUIRED PNEUMONIA;
SOFT-TISSUE INFECTIONS; ABSCESSES; VALIDATION; GUIDELINES; DIAGNOSIS;
SEVERITY; OUTCOMES; PLACEBO
AB Objective: Current Infectious Disease Society of America (IDSA) guidelines for the management of purulent skin or soft tissue infections do not account for patient age in treatment recommendations. The study objective was to determine if age was associated with outpatient treatment failure for purulent skin infection after adjusting for IDSA treatment guidelines.
Methods: We conducted a multicenter retrospective study of adult patients treated for a purulent skin infection and discharged home from four emergency departments between April and September 2014. Patients were followed for one month to assess for treatment failure (defined as need for a change in antibiotics, surgical intervention, or hospitalization). We used multivariable logistic regression to examine the role of patient age on treatment failure adjusting for demographic variables (gender, race), comorbidities and severity of infection.
Results: A total of 467 patients met inclusion criteria (mean age 37.9 years [SD 14.0], 48.2% of whom were women). Overall, 12.4% failed initial therapy. Patients 65 years and older (n = 35) were almost 4 times more likely to fail initial ED therapy in follow-up compared with younger patients (adjusted Odds Ratio (OR) 3.87, 95% Confidence Interval (CI) 1.24-12.10). After adjustment, for every 10 years of advancing age there was a 43% increased odds of failing initial treatment (OR 1.43 95% CI 1.09-1.88).
Conclusion: Elderly patients with purulent skin infections, whose providers followed the 2014 IDSA guidelines, were more likely to fail initial treatment than younger patients. This study suggests that there is a need to re-evaluate treatment guidelines in elderly patients. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Haran, John P.; Wilsterman, Eric; Zeoli, Tyler] Univ Massachusetts, Sch Med, Dept Emergency Med, Worcester, MA USA.
[Beaudoin, Francesca L.] Brown Univ, Alpert Sch Med, Dept Emergency Med, Providence, RI 02912 USA.
[Tjia, Jennifer] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Hibberd, Patricia L.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Hibberd, Patricia L.] Massachusetts Gen Hosp, Div Global Hlth, Boston, MA 02114 USA.
RP Haran, JP (reprint author), 55 Lake Ave North, Worcester, MA 01655 USA.
EM john.haran@umassmed.edu
FU Department of Emergency Medicine; NIH [5K24AT003683-09]
FX This study was designed and carried out at the University of
Massachusetts Medical School and was supported by an intradepartmental
grant through the Department of Emergency Medicine. PLH is supported by
an NIH award 5K24AT003683-09.
NR 25
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
EI 1532-8171
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD FEB
PY 2017
VL 35
IS 2
BP 249
EP 254
DI 10.1016/j.ajem.2016.10.060
PG 6
WC Emergency Medicine
SC Emergency Medicine
GA EL9FE
UT WOS:000394924600010
PM 27836315
ER
PT J
AU Pruitt, P
Penn, J
Peak, D
Borczuk, P
AF Pruitt, Peter
Penn, Joshua
Peak, David
Borczuk, Pierre
TI Identifying patients with mild traumatic intracranial hemorrhage at low
risk of decompensation who are safe for ED observation
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article; Proceedings Paper
CT National Annual Meeting of the Society-for-Academic-Emergency-Medicine
CY MAY 12-15, 2015
CL San Diego, CA
SP Soc Acad Emergency Med
DE Traumatic intracranial hemorrhage; Subarachnoid hemorrhage; Subdural
hematoma; Intraparenchymal hemorrhage; Observation medicine
ID DEPARTMENT OBSERVATION UNIT; MINOR HEAD-INJURY; BRAIN-INJURY;
SUBARACHNOID HEMORRHAGE; COMPUTED-TOMOGRAPHY; ADULT PATIENTS;
MANAGEMENT; ADMISSION; PROTOCOL; CARE
AB Background: Patients with traumatic intracranial hemorrhage and mild traumatic brain injury (mTIH) receive broadly variable care which often includes transfer to a trauma center, neurosurgery consultation and ICU admission. However, there may be a low risk cohort of patients who can be managed without utilizing such significant resources.
Objective: Describe mTIH patients who are at low risk of clinical or radiographic decompensation and can be safely managed in an ED observation unit (EDOU).
Methods: Retrospective evaluation of patients age >= 16, GCS >= 13 with ICH on CT. Primary outcomes included clinical/neurologic deterioration, CT worsening or need for neurosurgery.
Results: 1185 consecutive patients were studied. 814 were admitted and 371 observed patients (OP) were monitored in the EDOU or discharged from the ED after a period of observation. None of the OP deteriorated clinically. 299 OP (81%) had a single lesion on CT; 72 had mixed lesions. 120 patients had isolated subarachnoid hemorrhage (iSAH) and they did uniformly well. Of the 119 OP who had subdural hematoma (SDH), 6 had worsening CT scans and 3 underwent burr hole drainage procedures as inpatients due to persistent SDH without new deficit. Of the 39 OP who had cerebral contusions, 3 had worsening CT scans and one required NSG admission. No patient returned to the ED with a complication. Follow-up was obtained on 81% of OP. 2 patients with SDH required burr hole procedure >2 weeks after discharge.
Conclusions: Patients with mTIH, particularly those with iSAH, have very low rates of clinical or radiographic deterioration and may be safe for monitoring in an emergency department observation unit. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Pruitt, Peter] Northwestern Univ, Feinberg Sch Med, Dept Emergency Med, Chicago, IL USA.
[Penn, Joshua] Winchester Hosp, Dept Emergency Med, Winchester, MA USA.
[Peak, David; Borczuk, Pierre] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA.
[Peak, David; Borczuk, Pierre] Harvard Med Sch, Boston, MA USA.
RP Pruitt, P (reprint author), 211 East Ontario St,Suite 200, Chicago, IL 60611 USA.
EM peter.pruitt@northwestern.edu
FU Agency for Healthcare Research and Quality [(AHRQ)T[HYPHEN]32 HS 000078]
FX Dr Pruitt is a National Research Service Award postdoctoral fellow
supported by Agency for Healthcare Research and Quality
(AHRQ)T[HYPHEN]32 HS 000078 (PI: Jane L. Holl, MD, MPH). AHRQ was not
involved in the design or execution of this research.
NR 18
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
EI 1532-8171
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD FEB
PY 2017
VL 35
IS 2
BP 255
EP 259
DI 10.1016/j.ajem.2016.10.064
PG 5
WC Emergency Medicine
SC Emergency Medicine
GA EL9FE
UT WOS:000394924600011
PM 27838043
ER
PT J
AU Beri, N
Marston, NA
Daniels, LB
Nowak, RM
Schreiber, D
Mueller, C
Jaffe, A
Diercks, DB
Wettersten, N
DeFilippi, C
Peacock, WF
Limkakeng, AT
Anand, I
McCord, J
Hollander, JE
Wu, AHB
Apple, FS
Nagurney, JT
Berardi, C
Cannon, CM
Clopton, P
Neath, SX
Christenson, RH
Hogan, C
Vilke, G
Maisel, A
AF Beri, Neil
Marston, Nicholas A.
Daniels, Lori B.
Nowak, Richard M.
Schreiber, Donald
Mueller, Christian
Jaffe, Allan
Diercks, Deborah B.
Wettersten, Nicholas
DeFilippi, Christopher
Peacock, W. Frank
Limkakeng, Alexander T.
Anand, Inder
McCord, James
Hollander, Judd E.
Wu, Alan H. B.
Apple, Fred S.
Nagurney, John T.
Berardi, Cecilia
Cannon, Chad M.
Clopton, Paul
Neath, Sean-Xavier
Christenson, Robert H.
Hogan, Christopher
Vilke, Gary
Maisel, Alan
TI Necessity of hospitalization and stress testing in low risk chest pain
patients
SO AMERICAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE Myocardial infarction; Hospitalization; Discharge; Stress testing;
Copeptin
ID ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROMES; CARDIAC
TROPONIN-T; EMERGENCY-DEPARTMENT; RAPID RULE; INCREMENTAL VALUE;
COPEPTIN
AB Background: Copeptin is a marker of endogenous stress including early myocardial infarction(MI) and has value in early rule out of MI when used with cardiac troponin I(cTnl).
Objectives: The goal of this study was to demonstrate that patients with a normal electrocardiogram and cTnl< 0.040 mu g/l and copeptin< 14 pmol/l at presentation and after 2 h may be candidates for early discharge with outpatient follow-up potentially including stress testing.
Methods: This study uses data from the CHOPIN trial which enrolled 2071 patients with acute chest pain. Of those, 475 patients with normal electrocardiogram and normal cTnI(<0.040 mu g/l) and copeptin< 14 pmol/l at presentation and after 2 h were considered "low risk" and selected for further analysis.
Results: None of the 475 "low risk" patients were diagnosed with MI during the 180 day follow-up period (including presentation). The negative predictive value of this strategy was 100% (95% confidence interval(CI):99.2%-100.0%). Furthermore no one died during follow up. 287 (60.4%) patients in the low risk group were hospitalized. In the "low risk" group, the only difference in outcomes (MI, death, revascularization, cardiac rehospitalization) was those hospitalized underwent revascularization more often (6.3%[95%CI:3.8%-9.7%] versus 0.5%[95%CI:0.0%-2.9%], p = .002). The hospitalized patients were tested significantly more via stress testing or angiogram (68.6%[95%CI:62.9%-74.0%] vs 22.9%[95%Cl:17.1%-29.6%], p < .001). Those tested had less cardiac rehospitalizations during follow-up (1.7% vs 5.1%, p = .040).
Conclusions: In conclusion, patients with a normal electrocardiogram, troponin and copeptin at presentation and after 2 h are at low risk for MI and death over 180 days. These low risk patients may be candidates for early outpatient testing and cardiology follow-up thereby reducing hospitalization. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Beri, Neil; Marston, Nicholas A.] Univ Calif San Diego, Dept Internal Med, La Jolla, CA USA.
[Daniels, Lori B.; Wettersten, Nicholas; Maisel, Alan] Univ Calif San Diego, Dept Internal Med, Div Cardiol, San Diego, CA USA.
[Nowak, Richard M.] Henry Ford Hlth Syst, Dept Emergency Med, Detroit, MI USA.
[Schreiber, Donald] Stanford Univ, Dept Emergency Med, Palo Alto, CA USA.
[Mueller, Christian] Univ Basel Hosp, Dept Internal Med, Div Cardiol, Basel, Switzerland.
[Jaffe, Allan] Mayo Clin, Dept Internal Med, Div Cardiol, Rochester, MN USA.
[Diercks, Deborah B.] Univ Texas Southwestern, Dept Emergency Med, Dallas, TX USA.
[DeFilippi, Christopher] Univ Maryland, Dept Internal Med, Div Cardiol, Baltimore, MD USA.
[Peacock, W. Frank] Baylor Coll Med, Dept Emergency Med, Houston, TX USA.
[Limkakeng, Alexander T.] Duke Univ, Dept Emergency Med, Durham, NC USA.
[Anand, Inder] Vet Affairs Med Ctr, Dept Internal Med, Div Cardiol, Minneapolis, MN USA.
[McCord, James] Henry Ford Hlth Syst, Dept Internal Med, Div Cardiol, Detroit, MI USA.
[Hollander, Judd E.] Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA USA.
[Wu, Alan H. B.] Univ Calif San Francisco, Dept Pathol & Lab Med, San Francisco, CA USA.
[Apple, Fred S.] Univ Minnesota, Hennepin Cty Med Ctr, Dept Pathol, Minneapolis, MN USA.
[Nagurney, John T.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA.
[Berardi, Cecilia] Univ Roma La Sapienza, Sch Med, Rome, Italy.
[Cannon, Chad M.] Univ Kansas, Dept Emergency Med, Kansas City, KS USA.
[Clopton, Paul] Vet Affairs Med Ctr, Stat, San Diego, CA USA.
[Neath, Sean-Xavier; Vilke, Gary] Univ Calif San Diego, Dept Emergency Med, La Jolla, CA USA.
[Christenson, Robert H.] Univ Maryland, Dept Pathol, Baltimore, MD USA.
[Hogan, Christopher] Virginia Commonwealth Univ, Dept Surg, Richmond, VA USA.
RP Beri, N (reprint author), POB 3080, Laguna Hills, CA 92654 USA.
EM neil.beri1@gmail.com
NR 18
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0735-6757
EI 1532-8171
J9 AM J EMERG MED
JI Am. J. Emerg. Med.
PD FEB
PY 2017
VL 35
IS 2
BP 274
EP 280
DI 10.1016/j.ajem.2016.10.072
PG 7
WC Emergency Medicine
SC Emergency Medicine
GA EL9FE
UT WOS:000394924600014
PM 27847253
ER
PT J
AU Wu, CK
Shlipak, MG
Stawski, RS
Peralta, CA
Psaty, BM
Harris, TB
Satterfield, S
Shiroma, EJ
Newman, AB
Odden, MC
AF Wu, Chenkai
Shlipak, Michael G.
Stawski, Robert S.
Peralta, Carmen A.
Psaty, Bruce M.
Harris, Tamara B.
Satterfield, Suzanne
Shiroma, Eric J.
Newman, Anne B.
Odden, Michelle C.
CA Hlth ABC Study
TI Visit-to-Visit Blood Pressure Variability and Mortality and
Cardiovascular Outcomes Among Older Adults: The Health, Aging, and Body
Composition Study
SO AMERICAN JOURNAL OF HYPERTENSION
LA English
DT Article
DE blood pressure; blood pressure variability; hypertension; mortality;
stroke; myocardial infarction; aged
ID ALL-CAUSE MORTALITY; CORONARY-HEART-DISEASE; LONG-TERM;
PROGNOSTIC-SIGNIFICANCE; EPISODIC HYPERTENSION; MYOCARDIAL-INFARCTION;
METAANALYSIS; ASSOCIATION; STROKE; RISK
AB BACKGROUND
Level of blood pressure (BP) is strongly associated with cardiovascular (CV) events and mortality. However, it is questionable whether mean BP can fully capture BP-related vascular risk. Increasing attention has been given to the value of visit-to-visit BP variability.
METHODS
We examined the association of visit-to-visit BP variability with mortality, incident myocardial infarction (MI), and incident stroke among 1,877 well-functioning elders in the Health, Aging, and Body Composition Study. We defined visit-to-visit diastolic BP (DBP) and systolic BP (SBP) variability as the root-mean-square error of person-specific linear regression of BP as a function of time. Alternatively, we counted the number of considerable BP increases and decreases (separately; 10 mm Hg for DBP and 20 mm Hg for SBP) between consecutive visits for each individual.
RESULTS
Over an average follow-up of 8.5 years, 623 deaths (207 from CV disease), 153 MIs, and 156 strokes occurred. The median visit-to-visit DBP and SBP variability was 4.96 mmHg and 8.53 mmHg, respectively. After multivariable adjustment, visit-to-visit DBP variability was related to higher all-cause (hazard ratio (HR) = 1.18 per 1 SD, 95% confidence interval (CI) = 1.01-1.37) and CV mortality (HR = 1.35, 95% CI = 1.051.73). Additionally, individuals having more considerable decreases of DBP (>= 10mm Hg between 2 consecutive visits) had higher risk of allcause (HR = 1.13, 95% CI = 0.99-1.28) and CV mortality (HR = 1.30, 95% CI = 1.05-1.61); considerable increases of SBP (>= 20 mm Hg) were associated with higher risk of all-cause (HR = 1.18, 95% CI = 1.03-1.36) and CV mortality (HR = 1.37, 95% CI = 1.08-1.74).
CONCLUSIONS
Visit-to-visit DBP variability and considerable changes in DBP and SBP were risk factors for mortality in the elderly.
C1 [Wu, Chenkai; Odden, Michelle C.] Oregon State Univ, Sch Biol & Populat Hlth Sci, Corvallis, OR 97331 USA.
[Shlipak, Michael G.; Peralta, Carmen A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Shlipak, Michael G.; Peralta, Carmen A.] San Francisco VA Med Ctr, Kidney Hlth Res Collaborat, Dept Med, San Francisco, CA USA.
[Stawski, Robert S.] Oregon State Univ, Sch Social & Human Hlth Sci, Corvallis, OR 97331 USA.
[Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA USA.
[Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Harris, Tamara B.] NIA, Intramural Res Program, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA.
[Satterfield, Suzanne] Univ Tennessee, Hlth Sci Ctr, Dept Prevent Med, Memphis, TN USA.
[Shiroma, Eric J.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA USA.
[Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
RP Wu, CK (reprint author), Oregon State Univ, Sch Biol & Populat Hlth Sci, Corvallis, OR 97331 USA.
EM wuche@oregonstate.edu
FU National Institute on Aging (NIA) [N01-AG-6-2101, N01-AG-6-2103,
N01-AG-6-2106]; NIA [R01-AG028050]; NINR [R01-NR012459]; Intramural
Research Program of the NIH, National Institute on Aging; National
Institute on Aging [K01AG039387, R01AG46206]
FX The Health ABC Study was supported by National Institute on Aging (NIA)
Contracts N01-AG-6-2101; N01-AG-6-2103; N01-AG-6-2106; NIA grant
R01-AG028050, and NINR grant R01-NR012459, and in part by the Intramural
Research Program of the NIH, National Institute on Aging. Additional
support for this research was provided by National Institute on Aging
(K01AG039387, R01AG46206).
NR 33
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0895-7061
EI 1941-7225
J9 AM J HYPERTENS
JI Am. J. Hypertens.
PD FEB
PY 2017
VL 30
IS 2
BP 151
EP 158
DI 10.1093/ajh/hpw106
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA EO9QV
UT WOS:000397024100010
PM 27600581
ER
PT J
AU Doshi, JA
Lim, R
Li, PX
Young, PP
Lawnicki, VF
Troxel, AB
Volpp, KG
AF Doshi, Jalpa A.
Lim, Raymond
Li, Pengxiang
Young, Peinie P.
Lawnicki, Victor F.
Troxel, Andrea B.
Volpp, Kevin G.
TI Synchronized Prescription Refills and Medication Adherence: A
Retrospective Claims Analysis
SO AMERICAN JOURNAL OF MANAGED CARE
LA English
DT Article
ID ORDER PHARMACY USE; PERSISTENCE; USERS
AB OBJECTIVES: Medication adherence is often suboptimal, especially among patients on multiple chronic medications. We examined the association between synchronized medication refill schedules-which typically reduce organizational effort and logistical demands-and adherence.
STUDY DESIGN: Retrospective study among patients enrolled in Medicare Advantage prescription drug plans.
METHODS: We used 2012 pharmacy, medical, and enrollment data linked with consumer meta-data for Medicare patients filling 2 or more maintenance prescriptions for antihypertensives, lipid-lowering agents, antidiabetic agents, antidepressants, and/or antiosteoporotic agents. Medication adherence for the year was measured using the proportion of days covered (PDC) at the drug class level. Patients were deemed adherent if drug class PDC was = 0.80. Outcomes were compared between 1: 1 propensity score-matched patients on synchronized versus nonsynchronized refill schedules for maintenance medications.
RESULTS: The synchronized refill group showed better adherence than the control group, although the magnitude of effects varied by drug class and specific outcome measure. Mean PDC scores ranged from 0.02 higher for antihypertensives to 0.07 higher for antidepressants in the synchronized refill group relative to the control group (P <. 01). Further, compared with the control group, a larger proportion of synchronized refill group members were deemed adherent, ranging from 6 percentage points higher for antihypertensives to 15 percentage points higher for lipid-lowering agents (P <. 01). Differences between the synchronized and control groups were larger among exclusive users of retail versus mail order pharmacies for maintenance medications.
CONCLUSIONS: Synchronized medication refill schedules were associated with better medication adherence, particularly for patients filling maintenance medications exclusively at retail pharmacies.
C1 [Doshi, Jalpa A.; Lim, Raymond; Li, Pengxiang; Volpp, Kevin G.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Lim, Raymond; Volpp, Kevin G.] Univ Penn, Dept Med Eth, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.] Univ Penn, Dept Hlth Care Management, Philadelphia, PA 19104 USA.
[Doshi, Jalpa A.; Troxel, Andrea B.; Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Young, Peinie P.] Fuse Innovat Lab Cardinal Hlth, Dublin, OH USA.
[Lawnicki, Victor F.] Humana Inc, Louisville, KY USA.
[Troxel, Andrea B.] NYU, Dept Populat Hlth, New York, NY USA.
[Volpp, Kevin G.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Doshi, JA (reprint author), Univ Penn, Med, 1223 Blockley Hall, Philadelphia, PA 19104 USA.; Doshi, JA (reprint author), Univ Penn, Ctr Evidence Based Practice, Econ Evaluat Unit, 1223 Blockley Hall, Philadelphia, PA 19104 USA.; Doshi, JA (reprint author), Univ Penn, Ctr Hlth Incent & Behav Econ, Value Based Insurance Design Initiat, 1223 Blockley Hall, Philadelphia, PA 19104 USA.
EM jdoshi@mail.med.upenn.edu
FU Humana, Inc.
FX Humana, Inc.
NR 18
TC 0
Z9 0
U1 0
U2 0
PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC
PI PLAINSBORO
PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA
SN 1088-0224
J9 AM J MANAG CARE
JI Am. J. Manag. Care
PD FEB
PY 2017
VL 23
IS 2
BP 98
EP +
PG 28
WC Health Care Sciences & Services; Health Policy & Services; Medicine,
General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA EO0OJ
UT WOS:000396397400008
PM 28245653
ER
PT J
AU Chen, JJ
Wu, PT
Middlekauff, HR
Nguyen, KL
AF Chen, Joseph J.
Wu, Pei-Tzu
Middlekauff, Holly R.
Nguyen, Kim-Lien
TI Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic
review of current evidence and future directions
SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
LA English
DT Review
DE aerobic exercise; anthracyclines; cancer; cardiotoxicity
ID SUBCLINICAL CARDIAC DYSFUNCTION; AMERICAN-HEART-ASSOCIATION;
CHILDHOOD-CANCER SURVIVORS; DOX-INDUCED CARDIOTOXICITY; BREAST-CANCER;
DOXORUBICIN CARDIOTOXICITY; PHYSICAL-ACTIVITY; SPORTS-MEDICINE;
CARDIOVASCULAR EVENTS; INDUCED CARDIOMYOCYTE
AB Cancer and cardiovascular disease are major causes of morbidity and mortality worldwide. Older cancer patients often wrestle with underlying heart disease during cancer therapy, whereas childhood cancer survivors are living long enough to face long-term unintended cardiac consequences of cancer therapies, including anthracyclines. Although effective and widely used, particularly in the pediatric population, anthracycline-related side effects including dose-dependent association with cardiac dysfunction limit their usage. Currently, there is only one United States Food and Drug Administration-approved drug, dexrazoxane, available for the prevention and mitigation of cardiotoxicity related to anthracycline therapy. While aerobic exercise has been shown to reduce cardiovascular complications in multiple diseases, its role as a therapeutic approach to mitigate cardiovascular consequences of cancer therapy is in its infancy. This systematic review aims to summarize how aerobic exercise can help to alleviate unintended cardiotoxic side effects and identify gaps in need of further research. While published work supports the benefits of aerobic exercise, additional clinical investigations are warranted to determine the effects of different exercise modalities, timing, and duration to identify optimal aerobic training regimens for reducing cardiovascular complications, particularly late cardiac effects, in cancer survivors exposed to anthracyclines.
C1 [Chen, Joseph J.; Wu, Pei-Tzu; Middlekauff, Holly R.; Nguyen, Kim-Lien] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90024 USA.
[Chen, Joseph J.; Wu, Pei-Tzu; Nguyen, Kim-Lien] Vet Affairs Greater Los Angeles Healthcare Syst, Div Cardiol, Los Angeles, CA USA.
RP Nguyen, KL (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd,MC 111E, Los Angeles, CA 90024 USA.
EM kimliennguyen@mednet.ucla.edu
FU Jonsson Comprehensive Cancer Center Foundation; National Center for
Advancing Translational Sciences Clinical and Translational Sciences
Institute [UL1TR000124]
FX This work was supported by a pilot grant from the Jonsson Comprehensive
Cancer Center Foundation and National Center for Advancing Translational
Sciences Clinical and Translational Sciences Institute grant
UL1TR000124.
NR 62
TC 0
Z9 0
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6135
EI 1522-1539
J9 AM J PHYSIOL-HEART C
JI Am. J. Physiol.-Heart Circul. Physiol.
PD FEB
PY 2017
VL 312
IS 2
BP H213
EP H222
DI 10.1152/ajpheart.00646.2016
PG 10
WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Physiology
GA EN1VF
UT WOS:000395797600003
PM 27923793
ER
PT J
AU Xia, Y
Friedmann, P
Bello, R
Goldstein, D
D'Alessandro, D
AF Xia, Y.
Friedmann, P.
Bello, R.
Goldstein, D.
D'Alessandro, D.
TI Does Lung Donation by Heart Donors Have an Impact on Survival in Heart
Transplant Recipients?
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
ID FOCUS THEME RETRANSPLANTATION; INTERNATIONAL SOCIETY; MORTALITY
PREDICTION; RISK INDEX; REGISTRY; REPORT-2014
AB Lung procurement is increasing during multiorgan recovery and substantially alters the explant process. This study evaluated whether lung donation by a heart donor affects survival in heart transplant recipients. Retrospective analysis of United Network for Organ Sharing (UNOS) adult heart transplantation data from 1998 to 2012 was performed. Lung donors (LDs) were defined as those having at least one lung procured and transplanted. Non-LDs had neither lung transplanted. Heart transplant recipients who had previous transplants, who had heterotopic transplants, who were waitlisted for other organs or who were temporarily delisted were excluded from the analysis. Kaplan-Meier survival analysis and Cox proportional hazards regression were performed. Of 23 590 heart transplant recipients meeting criteria during the study period, 8638 (36.6%) transplants were from LDs. Donors in the LD group had less history of cigarette use (15.5% vs. 29.5%, p < 0.001). On univariate analysis, LDs were associated with improved patient survival (p < 0.001). On multivariate analysis, LDs were not significantly associated with patient survival (adjusted hazard ratio 0.98, 95% confidence interval 0.94-1.03). Analysis of the UNOS registry suggested that donor pulmonary status and lung procurement had no detrimental effect on survival in heart transplant recipients, supporting the present practice of using donor lungs whenever possible.
C1 [Xia, Y.; Friedmann, P.; Bello, R.; Goldstein, D.] Montefiore Med Ctr, Dept Cardiovasc & Thorac Surg, 111 E 210th St, Bronx, NY 10467 USA.
[D'Alessandro, D.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
RP D'Alessandro, D (reprint author), Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
EM dadalessandro@mgh.harvard.edu
FU Health Resources and Services Administration [234-2005-370011C]
FX We thank the United Network for Organ Sharing for access to donor and
recipient data. This work was supported in part by Health Resources and
Services Administration contract 234-2005-370011C.
NR 13
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD FEB
PY 2017
VL 17
IS 2
BP 506
EP 511
DI 10.1111/ajt.13981
PG 6
WC Surgery; Transplantation
SC Surgery; Transplantation
GA EP5KU
UT WOS:000397418300024
PM 27457355
ER
PT J
AU Wood, GJA
Hayden, RP
Tanrikut, C
AF Wood, G. J. A.
Hayden, R. P.
Tanrikut, C.
TI Successful sperm extraction and live birth after radiation, androgen
deprivation and surgical castration for treatment of metastatic prostate
cancer
SO ANDROLOGIA
LA English
DT Article
DE Fertility preservation; IVF-ICSI; metastatic prostate cancer;
radiotherapy; sperm extraction
ID FERTILITY PRESERVATION; TESTICULAR HISTOLOGY; SEMEN PARAMETERS; MEN;
HORMONE; AGONIST; ISSUES; TESTIS
AB Fertility preservation has become an important aspect of cancer treatment given the gonadotoxic effects of oncologic therapies. It is now considered standard of care to offer sperm banking to men undergoing treatment for primaries that affect young individuals. Less is known regarding fertility preservation of patients afflicted with prostate cancer. This cohort has progressively expanded and grown younger in the post-PSA era. Prostatectomy, radiation, chemotherapy and androgen blockade all pose unique challenges to the infertility specialist. Optimum management becomes even more uncertain for those men with metastatic prostate cancer. Most of these individuals will have received multiple forms of therapy, each carrying a distinct insult to the patient's reproductive potential. We describe a case of successful ex vivo sperm extraction and live birth in a patient previously treated with radiation and chronic androgen deprivation for metastatic prostate cancer. The presented case demonstrates that conception after radiation therapy and chronic androgen deprivation is feasible. We propose that fertility counselling and sperm cryopreservation should be considered for all prostate cancer patients. Additionally, for those individuals undergoing external beam radiotherapy, testicular shielding should be routinely offered in the event further family building is desired.
C1 [Hayden, R. P.; Tanrikut, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wood, G. J. A.] Univ Sao Paulo, Sch Med, Hosp Clin, Sao Paulo, Brazil.
RP Tanrikut, C (reprint author), MGH Fertil Ctr, 55 Fruit St,YAW-10A, Boston, MA 02114 USA.
EM ctanrikut@mgh.harvard.edu
NR 22
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0303-4569
EI 1439-0272
J9 ANDROLOGIA
JI Andrologia
PD FEB
PY 2017
VL 49
IS 1
AR e12578
DI 10.1111/and.12578
PG 5
WC Andrology
SC Endocrinology & Metabolism
GA EL3VL
UT WOS:000394547300017
ER
PT J
AU Stone, RM
Garcia, J
AF Stone, Richard M.
Garcia, Jacqueline
TI FLT3 Inhibitors in Mutant FLT3 AML
SO ANNALS OF HEMATOLOGY
LA English
DT Meeting Abstract
ID ACUTE MYELOID-LEUKEMIA; NORMAL CYTOGENETICS
C1 [Stone, Richard M.; Garcia, Jacqueline] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,D2053, Boston, MA 02215 USA.
NR 10
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0939-5555
EI 1432-0584
J9 ANN HEMATOL
JI Ann. Hematol.
PD FEB
PY 2017
VL 96
SU 1
BP S36
EP S37
PG 2
WC Hematology
SC Hematology
GA EK7KT
UT WOS:000394105400030
ER
PT J
AU Walter, RB
Fathi, AT
AF Walter, Roland B.
Fathi, Amir T.
CA SGN33A-001 Study Team
TI Vadastuximab Talirine (33a) plus a Hypomethylating Agent (HMA): A
Well-Tolerated Regimen with High Remission Rate in Frontline Older
Patients with Acute Myeloid Leukemia (AML)
SO ANNALS OF HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Walter, Roland B.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
[Fathi, Amir T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
FU Seattle Genetics Inc. [SGN33A-002]
FX Some members of the SGN33A-002 Team are employees of Seattle Genetics
Inc., Investigators have received trial funding support.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0939-5555
EI 1432-0584
J9 ANN HEMATOL
JI Ann. Hematol.
PD FEB
PY 2017
VL 96
SU 1
MA 96
BP S85
EP S85
PG 1
WC Hematology
SC Hematology
GA EK7KT
UT WOS:000394105400139
ER
PT J
AU Pagani-Estevez, GL
Swetz, KM
McGoon, MD
Frantz, RP
Tointon, SK
Karnyski, AM
Durst, LA
Watson, JC
AF Pagani-Estevez, Gabriel L.
Swetz, Keith M.
McGoon, Michael D.
Frantz, Robert P.
Tointon, Susan K.
Karnyski, Ann M.
Durst, Louise A.
Watson, James C.
TI Characterization of Prostacyclin-associated Leg Pain in Patients with
Pulmonary Arterial Hypertension
SO ANNALS OF THE AMERICAN THORACIC SOCIETY
LA English
DT Article
AB Rationale: Prostacyclinassociated leg pain is a potentially debilitating adverse effect of prostacyclin therapy for patients with pulmonary arterial hypertension (PAH). However, to our knowledge, this entity has not been systematically studied.
Objectives: To characterize the clinical features and metabolic risk factors for prostacyclinassociated leg pain.
Methods: At one academic medical center, we assembled and analyzed a case series of patients with PAH and prostacyclin-associated leg pain.
Measurements and Main Results: Over a period of 2 years, we identified 11 patients with PAH and prostacyclinassociated leg pain who agreed to participate in this study. Subjects underwent a standardized clinical evaluation, electrodiagnostic assessment, and serologic screen for metabolic causes of peripheral neuropathy. All 11 patients were female; their mean (SD) age was 50 (+/- 9) years; their median (interquartile range) PAH duration was 56 (20-96) months; and their prostacyclin therapy duration was a median (interquartile range) of 20 (14-36) months. All patients reported leg pain beginning soon after prostacyclin initiation and varying with dose. All described a neuropathic pain in a symmetric, distal, stocking distribution. Neurologic examination revealed a sensory, small-fiber, predominantly peripheral neuropathy in seven (78%) patients. Results of autonomic reflex testing and thermoregulatory sweat testing were abnormal in 82% and 90% of patients, respectively, suggesting smallfiber neuropathy. Serologic evaluation identified a new, previously unrecognized contributor to neuropathy in eight (73%) patients, including vitamin B-12 deficiency in six (55%), uncompensated hypothyroidism in three (27%), and diabetes mellitus in one (9%).
Conclusions: Chronic prostacyclin-associated leg pain is associated with a small-fiber neuropathy. Treatable metabolic contributors (vitamin B12 deficiency, thyroid dysfunction, or diabetes) appear to be common possible "second hits" that may be underrecognized. We recommend screening for possible metabolic contributors in patients who have otherwise unexplained leg pain in the setting of PAH and current or anticipated prostacyclin therapy.
C1 [Pagani-Estevez, Gabriel L.; Watson, James C.] Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA.
[McGoon, Michael D.; Frantz, Robert P.; Tointon, Susan K.; Karnyski, Ann M.] Mayo Clin, Dept Med, Cardiovasc Div, Rochester, MN USA.
[Watson, James C.] Mayo Clin, Pain Div, Dept Anesthesiol, Rochester, MN USA.
[Swetz, Keith M.] Univ Alabama Birmingham, Sch Med, Ctr Palliat & Support Care, Birmingham, AL USA.
[Swetz, Keith M.; Durst, Louise A.] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Watson, JC (reprint author), Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA.
EM watson.james@mayo.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1546-3222
EI 2325-6621
J9 ANN AM THORAC SOC
JI Ann. Am. Thoracic Society
PD FEB
PY 2017
VL 14
IS 2
BP 206
EP 212
DI 10.1513/AnnalsATS.201609-674OC
PG 7
WC Respiratory System
SC Respiratory System
GA EP5OK
UT WOS:000397428000011
PM 27898216
ER
PT J
AU Parsons, EC
Mattox, EA
Beste, LA
Au, DH
Young, BA
Chang, MF
Palen, BN
AF Parsons, Elizabeth C.
Mattox, Elizabeth A.
Beste, Lauren A.
Au, David H.
Young, Bessie A.
Chang, Michael F.
Palen, Brian N.
TI Development of a Sleep Telementorship Program for Rural Department of
Veterans Affairs Primary Care Providers: Sleep Veterans Affairs
Extension for Community Healthcare Outcomes
SO ANNALS OF THE AMERICAN THORACIC SOCIETY
LA English
DT Article
AB Rationale: Primary care providers (PCPs) frequently encounter sleep complaints, especially in regions with limited specialty care access.
Objectives: The U.S. Department of Veterans Affairs Extension for Community Healthcare Outcomes (VA-ECHO) program (based on Project ECHO) has successfully provided rural PCP education in subspecialty areas, including hepatitis C. Wedescribe the feasibility of an ECHO program for sleep medicine.
Methods: ECHO creates a virtual learning community through video-teleconferencing, combining didactics with individualized clinical case review. We invited multidisciplinary providers to attend up to 10 stand-alone, 1-hour sessions. Invitees completed a needs assessment, which guided curriculum development. After program completion, we examined participant characteristics and self-reported changes in practice and comfort with managing sleep complaints. We surveyed participation barriers among invitees with low/no attendance.
Measurements and Main Results: Of the 39 program participants, 38% worked in rural healthcare. Participants included nurse practitioners (26%), registered nurses (21%), and physicians (15%). Seventeen (44%) completed the summative program evaluation. Respondents anticipated practice change from the program, especially in patient education about sleep disorders (93% of respondents). Respondents reported improved comfort managing sleep complaints, especially sleep-disordered breathing, insomnia, and sleep in post-traumatic stress disorder (80% of respondents each). A follow-up survey of program invitees who attended zero to two sessions reported scheduling conflicts (62%) and lack of protected time (52%) as major participation barriers.
Conclusions: Participants in a pilot sleep medicine VA-ECHO program report practice change and increased comfort managing common sleep complaints. Future work is needed to identify objective measures of return on investment and address participation barriers.
C1 [Parsons, Elizabeth C.; Mattox, Elizabeth A.; Au, David H.; Palen, Brian N.] Vet Affairs Puget Sound Hlth Care Syst, Pulm & Crit Care Sect, Seattle, WA USA.
[Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Nephrol Sect, Hosp & Specialty Med, Seattle, WA USA.
[Beste, Lauren A.] Vet Affairs Puget Sound Hlth Care Syst, Gen Med Serv, Seattle, WA USA.
[Beste, Lauren A.; Au, David H.; Young, Bessie A.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA.
[Parsons, Elizabeth C.; Au, David H.; Palen, Brian N.] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA.
[Beste, Lauren A.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA.
[Young, Bessie A.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA.
[Young, Bessie A.] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA.
[Chang, Michael F.] Vet Affairs Portland Hlth Care Syst, Gastroenterol & Hepatol Serv, Portland, OR USA.
[Chang, Michael F.] Oregon Hlth & Sci Univ, Div Gastroenterol & Hepatol, Portland, OR 97201 USA.
RP Parsons, EC (reprint author), 1660 South Columbian Way,S-111 PULM, Seattle, WA 98108 USA.
EM elizabeth.parsons@va.gov
FU U.S. Department of Veterans Affairs' (VA) Veterans Health Administration
Office of Patient Care Services, Specialty Care Services program office;
VA Office of Rural Health; VA Northwest Health Network (VISN 20); VA
Portland Health Care System (Portland, OR); Boise VA Medical Center
(Boise, ID)
FX Supported in part through funding by the U.S. Department of Veterans
Affairs' (VA) Veterans Health Administration Office of Patient Care
Services, Specialty Care Services program office, the VA Office of Rural
Health, and the VA Northwest Health Network (VISN 20). This material is
the result of work supported with resources and use of the facilities at
the VA Puget Sound Health Care System (Seattle, WA), the VA Portland
Health Care System (Portland, OR), and Boise VA Medical Center (Boise,
ID).
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1546-3222
EI 2325-6621
J9 ANN AM THORAC SOC
JI Ann. Am. Thoracic Society
PD FEB
PY 2017
VL 14
IS 2
BP 267
EP 274
DI 10.1513/AnnalsATS.201605-361BC
PG 8
WC Respiratory System
SC Respiratory System
GA EP5OK
UT WOS:000397428000019
PM 27977293
ER
PT J
AU Ovsiowitz, RS
Pangarkar, S
AF Ovsiowitz, Rebecca S.
Pangarkar, Sanjog
TI Morel-Lavalle lesion
SO APPLIED RADIOLOGY
LA English
DT Editorial Material
C1 [Ovsiowitz, Rebecca S.; Pangarkar, Sanjog] Greater Los Angeles VA Med Ctr, Inpatient Pain Serv, Los Angeles, CA 90073 USA.
[Ovsiowitz, Rebecca S.; Pangarkar, Sanjog] Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA.
RP Ovsiowitz, RS (reprint author), Greater Los Angeles VA Med Ctr, Inpatient Pain Serv, Los Angeles, CA 90073 USA.; Ovsiowitz, RS (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Med, Los Angeles, CA 90095 USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ANDERSON PUBLISHING, INC
PI SCOTCH PLAINS
PA 180 GLENSIDE AVE, SCOTCH PLAINS, NJ 07076 USA
SN 0160-9963
EI 1879-2898
J9 APPL RADIOL
JI Appl. Radiol.
PD FEB
PY 2017
VL 46
IS 2
BP 38
EP 39
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA EP4HA
UT WOS:000397340400006
ER
PT J
AU Durand, ML
Ennis, SC
Baker, JN
Camuso, JM
McEachern, KM
Kotton, CN
Lewis, GD
Garcia, JP
MacGillivray, TE
AF Durand, Marlene L.
Ennis, Stephanie C.
Baker, Joshua N.
Camuso, Janice M.
McEachern, Kathleen M.
Kotton, Camille N.
Lewis, Gregory D.
Garcia, Jose P.
MacGillivray, Thomas E.
TI Topical Polymyxin-Trimethoprim Prophylaxis May Decrease the Incidence of
Driveline Infections in Patients With Continuous-Flow Left Ventricular
Assist Devices
SO ARTIFICIAL ORGANS
LA English
DT Article
DE Left ventricular assist device; Driveline infection; Chronic antibiotic
suppression; Topical antibiotics
ID EXIT-SITE INFECTION; BOSTON KERATOPROSTHESIS; DESTINATION THERAPY;
CLINICAL-OUTCOMES; PREVENTION; EXPERIENCE; TRANSPLANTATION;
ENDOPHTHALMITIS; IMPLANTATION; REGISTRY
AB This retrospective cohort study evaluated the effect of topical polymyxin-trimethoprim (poly) prophylaxis on the incidence of driveline infections (DLIs) in patients with continuous-flow left ventricular assist devices. All 84 cases implanted 2005-2014 with device support >= 30 days were reviewed; support ranged 1 m-5.2 yrs. Beginning 2008, poly was applied to the exit site with dressing changes. Sixty-five patients received poly (poly group) for duration of follow-up, 19 did not (no-poly); group baseline characteristics were similar. No patient developed side effects from poly. Nineteen DLIs (10 in no-poly) occurred; not using poly was a risk factor. 89% of poly group DLIs were superficial, 4 were culture-negative. DLI-related bacteremia occurred in 11% of no-poly group and 0% of poly group. Compared with no-poly, poly group demonstrated improved freedom from DLI by Kaplan-Meier analysis (P < 0.0001) and a 75% lower overall and 95% lower deep DLI incidence (P <= 0.001). Deep DLIs occurred in 31.6% of no-poly vs. 1.5% of poly patients (P = 0.0004), although mean support duration (1 yr) and % support >1 yr (38%) were similar. These findings, which should be confirmed with larger comparative studies, suggest that topical polymyxintrimethoprim prophylaxis may be effective in preventing DLIs.
C1 [Durand, Marlene L.; Kotton, Camille N.] Massachusetts Gen Hosp, Dept Med, Infect Dis Unit, Boston, MA 02114 USA.
[Ennis, Stephanie C.; Camuso, Janice M.; McEachern, Kathleen M.; Garcia, Jose P.; MacGillivray, Thomas E.] Massachusetts Gen Hosp, Dept Cardiac Surg, Boston, MA 02114 USA.
[Lewis, Gregory D.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Baker, Joshua N.] Missouri Baptist Med Ctr, Dept Cardiothorac Surg, St Louis, MO USA.
RP Durand, ML (reprint author), Massachusetts Gen Hosp, Infect Dis Associates, 55 Fruit St, Boston, MA 02114 USA.
EM mdurand@partners.org
NR 29
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-564X
EI 1525-1594
J9 ARTIF ORGANS
JI Artif. Organs
PD FEB
PY 2017
VL 41
IS 2
BP 169
EP 175
DI 10.1111/aor.12726
PG 7
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA EL1KA
UT WOS:000394378000009
PM 27098102
ER
PT J
AU Ghilain, CS
Parlade, MV
McBee, MT
Coman, DC
Owen, T
Gutierrez, A
Boyd, B
Odom, S
Alessandri, M
AF Ghilain, Christine S.
Parlade, Meaghan V.
McBee, Matthew T.
Coman, Drew C.
Owen, Taylor
Gutierrez, Anibal
Boyd, Brian
Odom, Samuel
Alessandri, Michael
TI Validation of the Pictorial Infant Communication Scale for
preschool-aged children with autism spectrum disorder
SO AUTISM
LA English
DT Article
DE autism spectrum disorder; communication; coordinated joint attention;
measurement; parent report
ID PERVASIVE DEVELOPMENTAL DISORDERS; EARLY LANGUAGE-ACQUISITION; JOINT
ATTENTION SKILL; YOUNG-CHILDREN; NONVERBAL-COMMUNICATION; SOCIAL
COMMUNICATION; DOWN-SYNDROME; PLAY; DEFICITS; INTERVENTIONS
AB Joint attention, or the shared focus of attention between objects or events and a social partner, is a crucial milestone in the development of social communication and a notable area of deficit in children with autism spectrum disorder. While valid parent-report screening measures of social communication are available, the majority of these measures are designed to assess a wide range of behaviors. Targeted assessment of joint attention and related skills is primarily limited to semi-structured, examiner-led interactions, which are time-consuming and laborious to score. The Pictorial Infant Communication Scale is an efficient parent-report measure of joint attention that can be used as a complement to structured assessments in fully characterizing early social communication development. This study examined the psychometric properties of the Pictorial Infant Communication Scale. Results revealed a high degree of internal consistency and strong intercorrelations between subscales. Additionally, confirmatory factor analysis supported a three-factor model of joint attention. Furthermore, significant correlations between the Pictorial Infant Communication Scale and direct clinical measures of child joint attention, language skills, and autism spectrum disorder symptom severity were suggestive of concurrent validity. Findings suggest that the Pictorial Infant Communication Scale is a promising tool for measuring joint attention skills in preschool-aged children with autism spectrum disorder.
C1 [Ghilain, Christine S.; Parlade, Meaghan V.; Owen, Taylor; Gutierrez, Anibal; Alessandri, Michael] Univ Miami, Coral Gables, FL 33124 USA.
[Ghilain, Christine S.] Emory Univ, Sch Med, 1547 Clifton Rd NE, Atlanta, GA 30322 USA.
[McBee, Matthew T.] East Tennessee State Univ, Johnson City, TN USA.
[Coman, Drew C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Boyd, Brian; Odom, Samuel] Univ N Carolina, Chapel Hill, NC USA.
RP Ghilain, CS (reprint author), Emory Univ, Sch Med, 1547 Clifton Rd NE, Atlanta, GA 30322 USA.
EM Christine.ghilain@choa.org
FU Institute of Education Sciences, US Department of Education
[R324B070219]
FX The research reported here was supported by the Institute of Education
Sciences, US Department of Education through Grant R324B070219 awarded
to UNC-Chapel Hill.
NR 73
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1362-3613
EI 1461-7005
J9 AUTISM
JI Autism
PD FEB
PY 2017
VL 21
IS 2
BP 203
EP 216
DI 10.1177/1362361316636757
PG 14
WC Psychology, Developmental
SC Psychology
GA EL7GX
UT WOS:000394790200008
PM 27132009
ER
PT J
AU Ferguson, BJ
Marler, S
Altstein, LL
Lee, EB
Akers, J
Sohl, K
McLaughlin, A
Hartnett, K
Kille, B
Mazurek, M
Macklin, EA
McDonnell, E
Barstow, M
Bauman, ML
Margolis, KG
Veenstra-VanderWeele, J
Beversdorf, DQ
AF Ferguson, Bradley J.
Marler, Sarah
Altstein, Lily L.
Lee, Evon Batey
Akers, Jill
Sohl, Kristin
McLaughlin, Aaron
Hartnett, Kaitlyn
Kille, Briana
Mazurek, Micah
Macklin, Eric A.
McDonnell, Erin
Barstow, Mariah
Bauman, Margaret L.
Margolis, Kara Gross
Veenstra-VanderWeele, Jeremy
Beversdorf, David Q.
TI Psychophysiological Associations with Gastrointestinal Symptomatology in
Autism Spectrum Disorder
SO AUTISM RESEARCH
LA English
DT Article
DE autism spectrum disorder; gastrointestinal; autonomic nervous system;
sympathetic; parasympathetic; anxiety; constipation
ID HEART-RATE-VARIABILITY; IRRITABLE-BOWEL-SYNDROME; BRAIN-GUT AXIS;
GENERALIZED ANXIETY DISORDER; SENSORY OVER-RESPONSIVITY; CHILDREN;
SYMPTOMS; HEALTH; METAANALYSIS; DISEASE
AB Autism spectrum disorder (ASD) is often accompanied by gastrointestinal disturbances, which also may impact behavior. Alterations in autonomic nervous system functioning are also frequently observed in ASD. The relationship between these findings in ASD is not known. We examined the relationship between gastrointestinal symptomatology, examining upper and lower gastrointestinal tract symptomatology separately, and autonomic nervous system functioning, as assessed by heart rate variability and skin conductance level, in a sample of 120 individuals with ASD. Relationships with co-occurring medical and psychiatric symptoms were also examined. While the number of participants with significant upper gastrointestinal tract problems was small in this sample, 42.5% of participants met criteria for functional constipation, a disorder of the lower gastrointestinal tract. Heart rate variability, a measure of parasympathetic modulation of cardiac activity, was found to be positively associated with lower gastrointestinal tract symptomatology at baseline. This relationship was particularly strong for participants with co-occurring diagnoses of anxiety disorder and for those with a history of regressive ASD or loss of previously acquired skills. These findings suggest that autonomic function and gastrointestinal problems are intertwined in children with ASD; although it is not possible to assess causality in this data set. Future work should examine the impact of treatment of gastrointestinal problems on autonomic function and anxiety, as well as the impact of anxiety treatment on gastrointestinal problems. Clinicians should be aware that gastrointestinal problems, anxiety, and autonomic dysfunction may cluster in children with ASD and should be addressed in a multidisciplinary treatment plan. Autism Res2017, 10: 276-288. (c) 2016 International Society for Autism Research, Wiley Periodicals, Inc.
C1 [Ferguson, Bradley J.; Beversdorf, David Q.] Univ Missouri, Interdisciplinary Neurosci Program, Columbia, MO 65211 USA.
[Marler, Sarah] Vanderbilt Univ, Med Ctr, Dept Child & Adolescent Psychiat, Nashville, TN USA.
[Altstein, Lily L.; Macklin, Eric A.; McDonnell, Erin; Barstow, Mariah] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
[Lee, Evon Batey] Vanderbilt Univ, Dept Pediat, Nashville, TN USA.
[Lee, Evon Batey] Vanderbilt Univ, Dept Psychiat & Psychol, Nashville, TN USA.
[Ferguson, Bradley J.; Akers, Jill; Sohl, Kristin; Mazurek, Micah; Beversdorf, David Q.] Univ Missouri, Thompson Ctr Autism & Neurodev Disorder, Columbia, MO 65211 USA.
[Sohl, Kristin] Univ Missouri, Dept Child Hlth, Columbia, MO 65211 USA.
[McLaughlin, Aaron] Univ Missouri, Sch Med, Columbia, MO 65211 USA.
[Hartnett, Kaitlyn] Univ Missouri, Coll Arts & Sci, Columbia, MO 65211 USA.
[Kille, Briana] Univ Missouri, Dept Psychol Sci, Columbia, MO 65211 USA.
[Mazurek, Micah] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65211 USA.
[Macklin, Eric A.] Harvard Med Sch, Boston, MA USA.
[Bauman, Margaret L.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Margolis, Kara Gross] Columbia Univ, Dept Pediat, Div Pediat Gastroenterol Hepatol & Nutr, New York, NY 10027 USA.
[Veenstra-VanderWeele, Jeremy] Columbia Univ, Dept Psychiat, New York, NY 10027 USA.
[Veenstra-VanderWeele, Jeremy] Columbia Univ, Sackler Inst Dev Psychobiol, New York, NY 10027 USA.
[Veenstra-VanderWeele, Jeremy] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Veenstra-VanderWeele, Jeremy] New York Presbyterian Hosp Ctr Autism & Developin, New York, NY 10032 USA.
[Beversdorf, David Q.] Univ Missouri, William & Nancy Thompson Chair Radiol, Dept Radiol Neurol & Psychol Sci, Columbia, MO 65211 USA.
RP Beversdorf, DQ (reprint author), Univ Missouri, Dept Radiol, DC 069-10,One Hosp Dr, Columbia, MO 65212 USA.
EM beversdorfd@health.mssouri.edu
FU Health Resources Services Administration (HRSA) [UA3MC11054]; Health
Resources and Services Administration (HRSA) of the U.S. Department of
Health and Human Services (HHS) [UA3 MC11054]
FX This research was supported by a grant given to the Autism Treatment
Network, Autism Intervention Research Network on Physical Health by the
Health Resources Services Administration (HRSA Grant# UA3MC11054). We
would like to sincerely thank the participants, their families, and all
study team members for their time and efforts associated with this
study. This project was supported by the Health Resources and Services
Administration (HRSA) of the U.S. Department of Health and Human
Services (HHS) under cooperative agreement UA3 MC11054 - Autism
Intervention Research Network on Physical Health. This information or
content and conclusions are those of the author and should not be
construed as the official position or policy of, nor should any
endorsements be inferred by HRSA, HHS or the U.S. Government. This work
was conducted through the Autism Speaks Autism Treatment Network serving
as the Autism Intervention Research Network on Physical Health.
NR 66
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1939-3792
EI 1939-3806
J9 AUTISM RES
JI Autism Res.
PD FEB
PY 2017
VL 10
IS 2
BP 276
EP 288
DI 10.1002/aur.1646
PG 13
WC Behavioral Sciences; Psychology, Developmental
SC Behavioral Sciences; Psychology
GA EM9QH
UT WOS:000395645700008
PM 27321113
ER
PT J
AU Mattoo, H
Stone, JH
Pillai, S
AF Mattoo, Hamid
Stone, John H.
Pillai, Shiv
TI Clonally expanded cytotoxic CD4(+) T cells and the pathogenesis of
IgG4-related disease
SO AUTOIMMUNITY
LA English
DT Review
DE IgG4-RD; CD4(+) CTL; fibrosis; lymphoplasmacytic infiltrate
ID REGULATORY IMMUNE-REACTIONS; GRASS-POLLEN IMMUNOTHERAPY; B-CELLS;
SCLEROSING PANCREATITIS; RHEUMATOID-ARTHRITIS; AUTOIMMUNE-DISEASE;
PULMONARY-FIBROSIS; SYSTEMIC-DISEASE; IGG4 PRODUCTION; IFN-GAMMA
AB IgG4-related disease (IgG4-RD) is a systemic condition of unknown cause characterized by highly fibrotic lesions, with dense lymphoplasmacytic infiltrates containing a preponderance of IgG4-expressing plasma cells. CD4(+) T cells and B cells constitute the major inflammatory cell populations in IgG4-RD lesions. IgG4-RD patients with active, untreated disease show a marked expansion of plasmablasts in the circulation. Although the therapeutic depletion of B cells suggests a role for these cells in the disease, a direct role for B cells or IgG4 in the pathogenesis of IgG4-RD is yet to be demonstrated. Among the CD4(+) T-cell subsets, Th2 cells were initially thought to contribute to IgG4-RD pathogenesis, but many previous studies were confounded by the concomitant history of allergic diseases in the patients studied and the failure to use multi-color staining to definitively identify T-cell subsets in tissue samples. More recently, using an unbiased approach to characterize CD4(+) T-cell subsets in patients with IgG4-RD - based on their clonal expansion and ability to infiltrate affected tissue sites - CD4(+) CTLs have been identified as the major CD4(+) T-cell subset in disease lesions as well as in the circulation. CD4(+) CTLs in affected tissues secrete pro-fibrotic cytokines including IL-1, TGF-1, and IFN- as well as cytolytic molecules such as perforin and granzymes A and B. In this review, we examine possible mechanisms by which activated B cells and plasmablasts may collaborate with the expanded CD4(+) CTLs in driving the fibrotic pathology of the disease and describe the lacunae in the field and in our understanding of IgG4-RD pathogenesis.
C1 [Mattoo, Hamid; Stone, John H.; Pillai, Shiv] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
RP Pillai, S (reprint author), Ragon Inst MGH MIT & Harvard, 400 Tech Sq, Cambridge, MA 02139 USA.
EM pillai@helix.mgh.harvard.edu
FU Autoimmune Center of Excellence Award from the National Institutes of
Health [U19 AI 110495]
FX The authors declare that they have no relevant conflicts of interest.
This work was supported by an Autoimmune Center of Excellence Award to
SP from the National Institutes of Health [U19 AI 110495].
NR 63
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0891-6934
EI 1607-842X
J9 AUTOIMMUNITY
JI Autoimmunity
PD FEB
PY 2017
VL 50
IS 1
BP 19
EP 24
DI 10.1080/08916934.2017.1280029
PG 6
WC Immunology
SC Immunology
GA EM1YB
UT WOS:000395112100003
PM 28166682
ER
PT J
AU Lyttle, DN
Gill, JP
Shaw, KM
Thomas, PJ
Chiel, HJ
AF Lyttle, David N.
Gill, Jeffrey P.
Shaw, Kendrick M.
Thomas, Peter J.
Chiel, Hillel J.
TI Robustness, flexibility, and sensitivity in a multifunctional motor
control model
SO BIOLOGICAL CYBERNETICS
LA English
DT Article
DE Adaptive behavior; Aplysia; Central pattern generator; Sensory feedback;
Heteroclinic channel; Limit cycle; Multistability
ID CENTRAL PATTERN GENERATOR; APLYSIA-CALIFORNICA; MATHEMATICAL-MODEL;
FEEDBACK-CONTROL; WINNERLESS COMPETITION; NEURONAL-ACTIVITY;
FEEDING-BEHAVIOR; RETRACTOR MUSCLE; NERVOUS-SYSTEM; BUCCAL MASS
AB Motor systems must adapt to perturbations and changing conditions both within and outside the body. We refer to the ability of a system to maintain performance despite perturbations as "robustness," and the ability of a system to deploy alternative strategies that improve fitness as "flexibility." Different classes of pattern-generating circuits yield dynamics with differential sensitivities to perturbations and parameter variation. Depending on the task and the type of perturbation, high sensitivity can either facilitate or hinder robustness and flexibility. Here we explore the role of multiple coexisting oscillatory modes and sensory feedback in allowing multiphasic motor pattern generation to be both robust and flexible. As a concrete example, we focus on a nominal neuromechanical model of triphasic motor patterns in the feeding apparatus of the marine mollusk Aplysia californica. We find that the model can operate within two distinct oscillatory modes and that the system exhibits bistability between the two. In the "heteroclinic mode," higher sensitivity makes the system more robust to changing mechanical loads, but less robust to internal parameter variations. In the "limit cycle mode," lower sensitivity makes the system more robust to changes in internal parameter values, but less robust to changes in mechanical load. Finally, we show that overall performance on a variable feeding task is improved when the system can flexibly transition between oscillatory modes in response to the changing demands of the task. Thus, our results suggest that the interplay of sensory feedback and multiple oscillatory modes can allow motor systems to be both robust and flexible in a variable environment.
C1 [Lyttle, David N.] Case Western Reserve Univ, Dept Math & Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
[Gill, Jeffrey P.] Case Western Reserve Univ, Dept Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
[Shaw, Kendrick M.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Thomas, Peter J.] Case Western Reserve Univ, Dept Math Appl Math & Stat, 10900 Euclid Ave, Cleveland, OH 44106 USA.
[Chiel, Hillel J.] Case Western Reserve Univ, Dept Biol Neurosci & Biomed Engn, 10900 Euclid Ave, Cleveland, OH 44106 USA.
RP Lyttle, DN (reprint author), Case Western Reserve Univ, Dept Math & Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM dnlyttle@gmail.com
FU Simons Foundation [259837]; Council for the International Exchange of
Scholars; NSF [DMS-1413770, DMS-1010434, IIS-1065489]; NSF Postdoctoral
Fellowship [1309380]
FX This work was partially supported by a Grant from the Simons Foundation
(259837 to Peter Thomas), by the Council for the International Exchange
of Scholars, and by NSF Grants DMS-1413770, DMS-1010434, and
IIS-1065489. David Lyttle was supported by an NSF Postdoctoral
Fellowship (Grant 1309380). The authors would like to thank M. Cullins,
C. Kehl, E. Lothet, J. McManus, and L. Spardy for stimulating
discussions.
NR 90
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-1200
EI 1432-0770
J9 BIOL CYBERN
JI Biol. Cybern.
PD FEB
PY 2017
VL 111
IS 1
BP 25
EP 47
DI 10.1007/s00422-016-0704-8
PG 23
WC Computer Science, Cybernetics; Neurosciences
SC Computer Science; Neurosciences & Neurology
GA EL9RT
UT WOS:000394958400002
PM 28004255
ER
PT J
AU Park, YJ
Battistone, MA
Kim, B
Breton, S
AF Park, Yoo-Jin
Battistone, Maria Agustina
Kim, Bongki
Breton, Sylvie
TI Relative contribution of clear cells and principal cells to luminal pH
in the mouse epididymis
SO BIOLOGY OF REPRODUCTION
LA English
DT Article
DE luminal acidification; V-ATPase; NHE3; CFTR
ID MALE REPRODUCTIVE-TRACT; NA+/H+ EXCHANGER ISOFORM; RENAL
EPITHELIAL-CELLS; KIDNEY COLLECTING DUCT; VACUOLAR H+-ATPASE; V-ATPASE;
INTERCALATED CELLS; RAT EPIDIDYMIS; VAS-DEFERENS; APICAL MEMBRANE
AB While spermatozoa undergo epididymal maturation, they remain quiescent thanks to the establishment of a low luminal pH. This study is aimed at determining how epithelial cells lining the epididymal lumen work together tomaintain and regulate this acidicmilieu. In particular, we examined the relative contribution of clear cells (CCs) and principal cells (PCs) to this process. Functional analysis in the mouse cauda epididymidis (Cd) perfused in vivo showed that the pH of a control solution remained constant at pH 6.6 after perfusion through the Cd lumen. In contrast, the pH of both an acidic (pH 5.8) and alkaline (pH 7.8) perfusate was progressively restored toward the control acidic pH. Pharmacological studies indicated the contribution of cystic fibrosis transmembrane regulator, previously shown to be present in the apical membrane of PCs, to the recovery from an acidic pH of 5.8. In addition, we found that CCs and PCs equally contribute to the recovery from an alkaline of 7.8, via the H+ pumping vacuolar ATPase (V-ATPase) located in CCs, and the Na+/H+ exchanger type 3 (NHE3) located in PCs. Immunofluorescence labeling showed apical membrane accumulation of the V-ATPase in CCs at pH 7.8, and its internalization at pH 5.8 compared to pH 6.6. Immunofluorescence showed expression of NHE3, but absence of NHE2, in PCs located in the Cd. RT-PCR and western blotting showed expression of NHE3 in all epididymal regions. Luminal 8-(4-chlorophenylthio) adenosine 3,5 -cyclic monophosphate (cpt-cAMP) partially inhibited luminal pH recovery from pH 7.8. However, cpt-cAMP induced an increase in V-ATPase apical membrane accumulation at this pH. Cell fractionation studies showed the apical accumulation of NHE3 from intracellular vesicles at pH 7.8 versus 6.6, and prevention of this effect by cpt-cAMP. These results indicate the participation of both CCs and PCs in the regulation of luminal pH in the epididymis. Our study also shows the dual role of PCs in HCO3(-) and H+ secretion, and that this switch from base to acid secretion depends on the luminal environment. Characterization of the respective roles of CCs and PCs in the regulation of the optimal luminal condition for epididymal sperm maturation should provide new frameworks for the evaluation and treatment of male infertility.
Summary Sentence
This study shows the equal contribution of clear and principal cells to proton secretion, and the dual role of principal cells in bicarbonate and proton secretion, depending on luminal cues.
C1 Massachusetts Gen Hosp, Ctr Syst Biol, Div Nephrol, Program Membrane Biol, Boston, MA USA.
[Breton, Sylvie] Harvard Med Sch, Boston, MA USA.
RP Breton, S (reprint author), Simches Res Ctr, 185 Cambridge St,Suite 8-204, Boston, MA 02114 USA.
EM Breton.sylvie@mgh.harvard.edu
FU NIH [HD040793]; Lalor Foundation Fellowships; Boston Area Diabetes and
Endocrinology Research Center [DK57521]; Center for the Study of
Inflammatory Bowel Disease [DK43351]; NIH Shared Instrumentation Grant
[S10 RR031563-01]; Charles and Ann Sanders Research Scholar Award at MGH
FX This work was supported by NIH grant HD040793 (to SB) and by Lalor
Foundation Fellowships (to YJP and MAB). The Microscopy Core facility of
the MGH Program in Membrane Biology receives support from the Boston
Area Diabetes and Endocrinology Research Center (DK57521) and the Center
for the Study of Inflammatory Bowel Disease (DK43351). The Nikon A1R
confocal in the PMB Microscopy Core was purchased using an NIH Shared
Instrumentation Grant S10 RR031563-01. SB is a recipient of the Charles
and Ann Sanders Research Scholar Award at MGH.
NR 66
TC 0
Z9 0
U1 0
U2 0
PU SOC STUDY REPRODUCTION
PI MADISON
PA 1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USA
SN 0006-3363
EI 1529-7268
J9 BIOL REPROD
JI Biol. Reprod.
PD FEB
PY 2017
VL 96
IS 2
BP 366
EP 375
DI 10.1095/biolreprod.116.144857
PG 10
WC Reproductive Biology
SC Reproductive Biology
GA EP3UW
UT WOS:000397308200009
PM 28203710
ER
PT J
AU Sajjadi, AY
Isakoff, SJ
Deng, B
Singh, B
Wanyo, CM
Fang, QQ
Specht, MC
Schapira, L
Moy, B
Bardia, A
Boas, DA
Carp, SA
AF Sajjadi, Amir Y.
Isakoff, Steven J.
Deng, Bin
Singh, Bhawana
Wanyo, Christy M.
Fang, Qianqian
Specht, Michelle C.
Schapira, Lidia
Moy, Beverly
Bardia, Aditya
Boas, David A.
Carp, Stefan A.
TI Normalization of compression-induced hemodynamics in patients responding
to neoadjuvant chemotherapy monitored by dynamic tomographic optical
breast imaging (DTOBI)
SO BIOMEDICAL OPTICS EXPRESS
LA English
DT Article
ID PATHOLOGICAL COMPLETE RESPONSE; NEAR-INFRARED TOMOGRAPHY; PREOPERATIVE
CHEMOTHERAPY; MAMMOGRAPHIC COMPRESSION; CANCER PATIENTS; TUMOR RESPONSE;
THERAPY; SPECTROSCOPY; TISSUE; MRI
AB We characterize novel breast cancer imaging biomarkers for monitoring neoadjuvant chemotherapy (NACT) and predicting outcome. Specifically, we recruited 30 patients for a pilot study in which NACT patients were imaged using dynamic tomographic optical breast imaging (DTOBI) to quantify the hemodynamic changes due to partial mammographic compression. DTOBI scans were obtained pre-treatment (referred to as day 0), as well as 7 and 30 days into therapy on female patients undergoing NACT. We present data for the 13 patients who participated in both day 0 and 7 measurements and had evaluable data, of which 7 also returned for day 30 measurements. We acquired optical images over 2 minutes following 4-8 lbs (18-36 N) of compression. The timecourses of tissue-volume averaged total hemoglobin (HbT), as well as hemoglobin oxygen saturation (SO2) in the tumor vs. surrounding tissues were compared. Outcome prediction metrics based on the differential behavior in tumor vs. normal areas for responders (>50% reduction in maximum diameter) vs. non-responders were analyzed for statistical significance. At baseline, all patients exhibit an initial decrease followed by delayed recovery in HbT, and SO2 in the tumor area, in contrast to almost immediate recovery in surrounding tissue. At day 7 and 30, this contrast is maintained in non-responders; however, in responders, the contrast in hemodynamic time-courses between tumor and normal tissue starts decreasing at day 7 and substantially disappears at day 30. At day 30 into NACT, responding tumors demonstrate "normalization" of compression induced hemodynamics vs. surrounding normal tissue whereas non-responding tumors did not. This data suggests that DTOBI imaging biomarkers, which are governed by the interplay between tissue biomechanics and oxygen metabolism, may be suitable for guiding NACT by offering early predictions of treatment outcome. (C) 2017 Optical Society of America
C1 [Sajjadi, Amir Y.; Deng, Bin; Singh, Bhawana; Wanyo, Christy M.; Boas, David A.; Carp, Stefan A.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Opt Div, Charlestown, MA 02129 USA.
[Sajjadi, Amir Y.; Deng, Bin; Singh, Bhawana; Boas, David A.; Carp, Stefan A.] Harvard Med Sch, Dept Radiol, Charlestown, MA 02129 USA.
[Isakoff, Steven J.; Specht, Michelle C.; Schapira, Lidia; Moy, Beverly; Bardia, Aditya] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Isakoff, Steven J.; Schapira, Lidia; Moy, Beverly; Bardia, Aditya] Harvard Med Sch, Dept Med, Boston, MA 02114 USA.
[Fang, Qianqian] Northeastern Univ, Dept Bioengn, Boston, MA 02115 USA.
[Specht, Michelle C.] Harvard Med Sch, Dept Surg, Boston, MA 02114 USA.
RP Sajjadi, AY (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Opt Div, Charlestown, MA 02129 USA.; Sajjadi, AY (reprint author), Harvard Med Sch, Dept Radiol, Charlestown, MA 02129 USA.
EM asajjadi@nmr.mgh.harvard.edu; sisakoff@mgh.harvard.edu
FU NIH [R00EB011889, R01CA142575, R01CA187595]; Cure Foundation [KG200021]
FX This work was supported by NIH grants R00EB011889, R01CA142575,
R01CA187595 and the Susan G. Komen for the Cure Foundation grant
KG200021. The authors would like to thank Ms. Nancy Nagda for
coordinating patient scheduling, the staff of the MGH Center for Breast
Cancer for their support, and the patients who participated in this
project.
NR 57
TC 0
Z9 0
U1 0
U2 0
PU OPTICAL SOC AMER
PI WASHINGTON
PA 2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA
SN 2156-7085
J9 BIOMED OPT EXPRESS
JI Biomed. Opt. Express
PD FEB 1
PY 2017
VL 8
IS 2
BP 555
EP 569
DI 10.1364/BOE.8.000555
PG 15
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA EK8OA
UT WOS:000394182100007
PM 28270967
ER
PT J
AU Tan, L
Gurbani, D
Weisberg, EL
Hunter, JC
Li, LB
Jones, DS
Ficarro, SB
Mowafy, S
Tam, CP
Rao, SM
Du, GY
Griffin, JD
Sorger, PK
Marto, JA
Westover, KD
Gray, NS
AF Tan, Li
Gurbani, Deepak
Weisberg, Ellen L.
Hunter, John C.
Li, Lianbo
Jones, Douglas S.
Ficarro, Scott B.
Mowafy, Samar
Tam, Chun-Pong
Rao, Suman
Du, Guangyan
Griffin, James D.
Sorger, Peter K.
Marto, Jarrod A.
Westover, Kenneth D.
Gray, Nathanael S.
TI Structure-guided development of covalent TAK1 inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Structure-based design; TAK1 kinase inhibitors; Covalent inhibitors;
2,4-Disubstituted pyrimidine; Structure-activity relationship
ID KAPPA-B ACTIVATION; RESORCYLIC ACID LACTONE; KINASE TAK1;
5Z-7-OXOZEAENOL; DISCOVERY; MECHANISM; REFMAC5; CANCER; GROWTH; CELLS
AB TAK1 (transforming growth factor-beta-activated kinase 1) is an essential intracellular mediator of cytokineand growth factor signaling and a potential therapeutic target for the treatment of immune diseases and cancer. Herein we report development of a series of 2,4-disubstituted pyrimidine covalent TAK1 inhibitors that target Cys 174, a residue immediately adjacent to the 'DFG-motif of the kinase activation loop. Co-crystal structures of TAK1 with candidate compounds enabled iterative rounds of structure-based design and biological testing to arrive at optimized compounds. Lead compounds such as 2 and 10 showed greater than 10-fold biochemical selectivity for TAK1 over the closely related kinases MEK1 and ERK1 which possess an equivalently positioned cysteine residue. These compounds are smaller, more easily synthesized, and exhibit a different spectrum of kinase selectivity relative to previously reported macrocyclic natural product TAK1 inhibitors such as 5Z-7-oxozeanol. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Tan, Li; Ficarro, Scott B.; Mowafy, Samar; Tam, Chun-Pong; Rao, Suman; Du, Guangyan; Marto, Jarrod A.; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Tan, Li; Ficarro, Scott B.; Mowafy, Samar; Tam, Chun-Pong; Rao, Suman; Du, Guangyan; Marto, Jarrod A.; Gray, Nathanael S.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02215 USA.
[Gurbani, Deepak; Hunter, John C.; Li, Lianbo; Westover, Kenneth D.] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
[Gurbani, Deepak; Hunter, John C.; Li, Lianbo; Westover, Kenneth D.] Univ Texas Southwestern Med Ctr Dallas, Dept Radiat Oncol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
[Weisberg, Ellen L.; Griffin, James D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Weisberg, Ellen L.; Griffin, James D.] Harvard Med Sch, Dept Med, Boston, MA 02215 USA.
[Jones, Douglas S.; Rao, Suman; Sorger, Peter K.] Harvard Med Sch, HMS LINCS Ctr, Boston, MA 02215 USA.
[Jones, Douglas S.; Rao, Suman; Sorger, Peter K.] Harvard Med Sch, Lab Syst Pharmacol, Boston, MA 02215 USA.
[Jones, Douglas S.] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Mowafy, Samar] Misr Int Univ, Km 28 Cairo,Ismailia Rd, Cairo, Egypt.
RP Gray, NS (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.; Westover, KD (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Kenneth.Westover@UTSouthwestem.edu; Nathanael_Gray@dfci.harvard.edu
FU LINCS Grant [U54-HL127365]; Welch Research Foundation [1-1829]; CPRIT
[R1207, RP140233]; NIH [CA 154303-05]; Pediatric Low Grade Astrocytoma
(PLGA) foundation; U.S. Department of Energy, Office of Biological and
Environmental Research [DEAC02-06CH11357]
FX NSG and PKS were supported by LINCS Grant U54-HL127365. KDW was
supported by Welch Research Foundation 1-1829, CPRIT R1207 and CPRIT
RP140233. LT and NSG were supported by NIH CA 154303-05 and the
Pediatric Low Grade Astrocytoma (PLGA) foundation. Results shown in this
article are derived from work performed at Argonne National Laboratory,
Structural Biology Center at the Advanced Photon Source. Argonne is
operated by U Chicago Argonne, LLC, for the U.S. Department of Energy,
Office of Biological and Environmental Research under contract
DEAC02-06CH11357.
NR 46
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD FEB 1
PY 2017
VL 25
IS 3
BP 838
EP 846
DI 10.1016/j.bmc.2016.11.035
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
Organic
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA EK8VE
UT WOS:000394201900003
PM 28011204
ER
PT J
AU Gounder, L
Moodley, P
Drain, PK
Hickey, AJ
Moosa, MYS
AF Gounder, Lilishia
Moodley, Pravikrishnen
Drain, Paul K.
Hickey, Andrew J.
Moosa, Mahomed-Yunus S.
TI Hepatic tuberculosis in human immunodeficiency virus co-infected adults:
a case series of South African adults
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HIV; TB; Liver; Granuloma; South Africa
ID LIVER-DISEASES; BLACK PATIENTS; HIV; COHORT
AB Background: Although Mycobacterium tuberculosis (TB) infection may cause extrapulmonary disease in HIV-infected adults, HIV-associated hepatic TB has been poorly characterized. Our objective was to describe hepatic TB in HIV-infected adults.
Methods: Retrospective study of patients diagnosed with hepatic TB from 2005-2012 at Infectious Diseases Clinic, King Edward VIII Hospital, Durban, South Africa.
Results: Among twenty cases of histology-confirmed HIV-associated hepatic TB, median CD4 count was 47 cells/mu l (inter-quartile range 27-107 cells/mu l) and 75% (15/20) of patients had pre-existing pulmonary TB. The most frequent clinical finding was hepatomegaly (85%). Liver enzyme abnormalities included elevated alkaline phosphatase (median 456 u/L, inter-quartile range 322-1,043 u/L) and gamma-glutamyltransferase (median 422 u/L, inter-quartile range 235-736 u/L). Acid-fast bacilli were cultured from liver tissue in 30% (6/20) of patients; 25% (5/20) identified as TB. With standard anti-TB therapy, liver enzymes improved within six months in 92% (11/12) of patients. One year after diagnosis, twelve patients resolved clinically, two patients developed drug-resistant TB and six patients died.
Conclusion: In our case series of HIV-infected patients, hepatic TB occurred in patients with severe immunosuppression, who presented with hepatomegaly and abnormal liver enzymes. More than half of patients had resolution of liver function by six months however the 12-month mortality remained high.
C1 [Gounder, Lilishia; Moosa, Mahomed-Yunus S.] Univ KwaZulu Natal, Dept Infect Dis, Nelson R Mandela Sch Med, Durban, South Africa.
[Gounder, Lilishia; Moodley, Pravikrishnen] Inkosi Albert Luthuli Cent Hosp, Natl Hlth Lab Serv, Dept Virol, 800 Bellair Rd, ZA-4058 Durban, Mayville, South Africa.
[Drain, Paul K.] Univ Washington, Dept Global Hlth Med & Epidemiol, Seattle, WA 98195 USA.
[Drain, Paul K.] Harvard Med Sch, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Hickey, Andrew J.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Moosa, Mahomed-Yunus S.] King Edward VIII Hosp, Durban, South Africa.
RP Gounder, L (reprint author), Univ KwaZulu Natal, Dept Infect Dis, Nelson R Mandela Sch Med, Durban, South Africa.; Gounder, L (reprint author), Inkosi Albert Luthuli Cent Hosp, Natl Hlth Lab Serv, Dept Virol, 800 Bellair Rd, ZA-4058 Durban, Mayville, South Africa.
EM gounder@ukzn.ac.za
NR 31
TC 0
Z9 0
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD FEB 1
PY 2017
VL 17
AR 115
DI 10.1186/s12879-017-2222-2
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA EP4XD
UT WOS:000397382300003
PM 28148232
ER
PT J
AU DeFilipp, Z
Duarte, RF
Snowden, JA
Majhail, NS
Greenfield, DM
Miranda, JL
Arat, M
Baker, KS
Burns, LJ
Duncan, CN
Gilleece, M
Hale, GA
Hamadani, M
Hamilton, BK
Hogan, WJ
Hsu, JW
Inamoto, Y
Kamble, RT
Lupo-Stanghellini, MT
Malone, AK
McCarthy, P
Mohty, M
Norkin, M
Paplham, P
Ramanathan, M
Richart, JM
Salooja, N
Schouten, HC
Schoemans, H
Seber, A
Steinberg, A
Wirk, BM
Wood, WA
Battiwalla, M
Flowers, MED
Savani, BN
Shaw, BE
AF DeFilipp, Z.
Duarte, R. F.
Snowden, J. A.
Majhail, N. S.
Greenfield, D. M.
Miranda, J. L.
Arat, M.
Baker, K. S.
Burns, L. J.
Duncan, C. N.
Gilleece, M.
Hale, G. A.
Hamadani, M.
Hamilton, B. K.
Hogan, W. J.
Hsu, J. W.
Inamoto, Y.
Kamble, R. T.
Lupo-Stanghellini, M. T.
Malone, A. K.
McCarthy, P.
Mohty, M.
Norkin, M.
Paplham, P.
Ramanathan, M.
Richart, J. M.
Salooja, N.
Schouten, H. C.
Schoemans, H.
Seber, A.
Steinberg, A.
Wirk, B. M.
Wood, W. A.
Battiwalla, M.
Flowers, M. E. D.
Savani, B. N.
Shaw, B. E.
CA CIBMTR Late Effects Quality Life
EBMT Complications Quality Life
TI Metabolic syndrome and cardiovascular disease following hematopoietic
cell transplantation: screening and preventive practice recommendations
from CIBMTR and EBMT
SO BONE MARROW TRANSPLANTATION
LA English
DT Review
ID LONG-TERM SURVIVORS; BONE-MARROW-TRANSPLANTATION; BODY-COMPOSITION
ABNORMALITIES; ACUTE LYMPHOBLASTIC-LEUKEMIA; IMPAIRED GLUCOSE-TOLERANCE;
RISK-FACTORS; DIABETES-MELLITUS; SCIENTIFIC STATEMENT; GLOBAL BURDEN;
HEMATOLOGIC MALIGNANCIES
AB Metabolic syndrome (MetS) is a constellation of cardiovascular risk factors that increases the risk of cardiovascular disease, diabetes mellitus and all cause mortality. Long-term survivors of hematopoietic cell transplantation (HCT) have a substantial risk of developing MetS and cardiovascular disease, with the estimated prevalence of MetS being 31-49% among HCT recipients. Although MetS has not yet been proven to impact cardiovascular risk after HCT, an understanding of the incidence and risk factors for MetS in HCT recipients can provide the foundation to evaluate screening guidelines and develop interventions that may mitigate cardiovascular-related mortality. A working group was established through the Center for International Blood and Marrow Transplant Research and the European Group for Blood and Marrow Transplantation with the goal of reviewing literature and recommend practices appropriate to HCT recipients. Here we deliver consensus recommendations to help clinicians provide screening and preventive care for MetS and cardiovascular disease among HCT recipients. All HCT survivors should be advised of the risks of MetS and encouraged to undergo recommended screening based on their predisposition and ongoing risk factors.
C1 [DeFilipp, Z.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.
[Duarte, R. F.] Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain.
[Snowden, J. A.] Univ Sheffield, Sheffield Teaching Hosp NHS Fdn Trust, Dept Haematol, Sheffield, S Yorkshire, England.
[Snowden, J. A.] Univ Sheffield, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
[Majhail, N. S.; Hamilton, B. K.] Cleveland Clin, Dept Hematol & Oncol, Cleveland, OH 44106 USA.
[Greenfield, D. M.] Sheffield Teaching Hosp NHS Fdn Trust, Specialized Canc Serv, Shefflied, England.
[Miranda, J. L.] Univ Cordoba, Maimonides Inst Biomed Res Cordoba IMIBIC, Reina Sofia Univ Hosp,Dept Med, CIBER Fisiopatol Obesidad Nutr CIBEROB,Inst Salud, Cordoba, Spain.
[Arat, M.] Florence Nightingale Sisli Hosp, Hematopoiet Stem Cell Transplantat Unit, Istanbul, Turkey.
[Baker, K. S.; Flowers, M. E. D.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA.
[Burns, L. J.] Univ Minnesota, Natl Marrow Donor Program, Minneapolis, MN USA.
[Duncan, C. N.] Dana Farber Canc Inst, Pediat Stem Cell Transplant, Boston, MA 02115 USA.
[Gilleece, M.] Leeds Teaching Hosp NHS Trust, Leeds, W Yorkshire, England.
[Hale, G. A.] John Hopkins Med, All Childrens Hosp, St Petersburg, FL USA.
[Hamadani, M.; Shaw, B. E.] Med Coll Wisconsin, Dept Med, CIBMTR, 9200W Wisconsin Ave, Milwaukee, WI 53226 USA.
[Hogan, W. J.] Mayo Clin, Dept Internal Med, Div Hematol, Rochester, MN USA.
[Hsu, J. W.; Wirk, B. M.] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL 32610 USA.
[Inamoto, Y.] Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan.
[Kamble, R. T.] Baylor Coll Med, Div Hematol & Oncol, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.
[Lupo-Stanghellini, M. T.] Ist Sci San Raffaele, Hematol & Bone Marrow Transplantat Unit, Milan, Italy.
[Malone, A. K.; Steinberg, A.] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol Oncol, New York, NY 10029 USA.
[McCarthy, P.; Paplham, P.] Roswell Pk Canc Inst, BMT Program, Dept Med, Buffalo, NY 14263 USA.
[Mohty, M.] Univ Paris 06, Paris, France.
[Mohty, M.] Hop St Antoine, AP HP, Paris, France.
[Mohty, M.] INSERM, UMRs 938, Paris, France.
[Ramanathan, M.] UMass Mem Med Ctr, Dept Hematol Oncol & Bone Marrow Transplant, Worcester, MA USA.
[Richart, J. M.] St Louis Univ, Dept Internal Med, Div Hematol & Med Oncol, St Louis, MO 63103 USA.
[Salooja, N.] Hammersmith Hosp, London, England.
[Schouten, H. C.] Maastricht Univ, Med Ctr, Maastricht, Netherlands.
[Schoemans, H.] Univ Hosp Leuven, Dept Hematol, Leuven, Belgium.
[Schoemans, H.] Katholieke Univ Leuven, Leuven, Belgium.
[Seber, A.] Hosp Samaritano, Sao Paulo, Brazil.
[Seber, A.] Assoc Medula Ossea AMEO, Sao Paulo, Brazil.
[Wirk, B. M.] SUNY Stony Brook, Med Ctr, Dept Internal Med, Stony Brook, NY 11794 USA.
[Wood, W. A.] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC USA.
[Battiwalla, M.] NIH, Hematol Branch, Bldg 10, Bethesda, MD 20892 USA.
[Savani, B. N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.
RP Shaw, BE (reprint author), Med Coll Wisconsin, Dept Med, CIBMTR, 9200W Wisconsin Ave, Milwaukee, WI 53226 USA.
EM beshaw@mcw.edu
FU NCI NIH HHS [U24 CA076518]
NR 96
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD FEB
PY 2017
VL 52
IS 2
BP 173
EP 182
DI 10.1038/bmt.2016.203
PG 10
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA EK7VW
UT WOS:000394134300002
PM 27548466
ER
PT J
AU Whangbo, J
Ritz, J
Bhatt, A
AF Whangbo, J.
Ritz, J.
Bhatt, A.
TI Antibiotic-mediated modification of the intestinal microbiome in
allogeneic hematopoietic stem cell transplantation
SO BONE MARROW TRANSPLANTATION
LA English
DT Review
ID VERSUS-HOST-DISEASE; REGULATORY T-CELLS; BONE-MARROW-TRANSPLANTATION;
MOUSE RADIATION CHIMERAS; GUT MICROBIOTA; PROTECTIVE ENVIRONMENT;
INFLAMMATORY DISEASE; SECONDARY DISEASE; BACTERIA; MICE
AB Allogeneic hematopoietic stem cell transplantation (HSCT) is curative for many patients with severe benign and malignant hematologic disorders. The success of allogeneic HSCT is limited by the development of transplant-related complications such as acute graft-versus-host disease (GvHD). Early pre-clinical studies suggested that intestinal microflora contribute to the pathogenesis of acute GvHD, and that growth suppression or eradication of intestinal bacteria prevented the development of acute GvHD even in MHC-mismatched transplants. These observations led to the practice of gut decontamination (GD) with oral non-absorbable antibiotics in patients undergoing allogeneic HSCT as a method of acute GvHD prophylaxis. Microbiome studies in the modern sequencing era are beginning to challenge the benefit of this practice. In this review, we provide a historical perspective on the practice of GD and highlight findings from the limited number of clinical trials evaluating the use of GD for acute GvHD prevention in allogeneic HSCT patients. In addition, we examine the role of the gut microbiota in allogeneic HSCT in the context of recent studies linking the microflora to regulation of intestinal immune homeostasis. We discuss the implications of these findings for future strategies to reduce acute GvHD risk by selective manipulation of the microbiota.
C1 [Whangbo, J.; Ritz, J.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.
[Whangbo, J.; Ritz, J.] Harvard Med Sch, Boston, MA USA.
[Whangbo, J.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
[Bhatt, A.] Stanford Univ, Dept Med, 269 Campus Dr, Stanford, CA 94305 USA.
[Bhatt, A.] Stanford Univ, Dept Genet, 269 Campus Dr, Stanford, CA 94305 USA.
RP Bhatt, A (reprint author), Stanford Univ, Dept Med, 269 Campus Dr, Stanford, CA 94305 USA.; Bhatt, A (reprint author), Stanford Univ, Dept Genet, 269 Campus Dr, Stanford, CA 94305 USA.
EM asbhatt@stanford.edu
FU NCI NIH HHS [K08 CA184420]
NR 60
TC 0
Z9 0
U1 3
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD FEB
PY 2017
VL 52
IS 2
BP 183
EP 190
DI 10.1038/bmt.2016.206
PG 8
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA EK7VW
UT WOS:000394134300003
PM 27526283
ER
PT J
AU Maziarz, RT
Brazauskas, R
Chen, M
McLeod, AA
Martino, R
Wingard, JR
Aljurf, M
Battiwalla, M
Dvorak, CC
Geroge, B
Guinan, EC
Hale, GA
Lazarus, HM
Lee, JW
Liesveld, JL
Ramanathan, M
Reddy, V
Savani, BN
Smith, FO
Strasfeld, L
Taplitz, RA
Ustun, C
Boeckh, MJ
Gea-Banacloche, J
Lindemans, CA
Auletta, JJ
Riches, ML
AF Maziarz, R. T.
Brazauskas, R.
Chen, M.
McLeod, A. A.
Martino, R.
Wingard, J. R.
Aljurf, M.
Battiwalla, M.
Dvorak, C. C.
Geroge, B.
Guinan, E. C.
Hale, G. A.
Lazarus, H. M.
Lee, J-W
Liesveld, J. L.
Ramanathan, M.
Reddy, V.
Savani, B. N.
Smith, F. O.
Strasfeld, L.
Taplitz, R. A.
Ustun, C.
Boeckh, M. J.
Gea-Banacloche, J.
Lindemans, C. A.
Auletta, J. J.
Riches, M. L.
TI Pre-existing invasive fungal infection is not a contraindication for
allogeneic HSCT for patients with hematologic malignancies: a CIBMTR
study
SO BONE MARROW TRANSPLANTATION
LA English
DT Article
ID HEMATOPOIETIC-CELL TRANSPLANTATION; UNRELATED DONORS; ASPERGILLOSIS;
RECIPIENTS; DISEASES; PROPHYLAXIS; FLUCONAZOLE; MORTALITY; VORICONAZOLE;
COMBINATION
AB Patients with prior invasive fungal infection (IFI) increasingly proceed to allogeneic hematopoietic cell transplantation (HSCT). However, little is known about the impact of prior IFI on survival. Patients with pre-transplant IFI (cases; n = 825) were compared with controls (n = 10247). A subset analysis assessed outcomes in leukemia patients pre-and post 2001. Cases were older with lower performance status (KPS), more advanced disease, higher likelihood of AML and having received cord blood, reduced intensity conditioning, mold-active fungal prophylaxis and more recently transplanted. Aspergillus spp. and Candida spp. were the most commonly identified pathogens. 68% of patients had primarily pulmonary involvement. Univariate and multivariable analysis demonstrated inferior PFS and overall survival (OS) for cases. At 2 years, cases had higher mortality and shorter PFS with significant increases in non-relapse mortality (NRM) but no difference in relapse. One year probability of post-HSCT IFI was 24% (cases) and 17% (control, P < 0.001). The predominant cause of death was underlying malignancy; infectious death was higher in cases (13% vs 9%). In the subset analysis, patients transplanted before 2001 had increased NRM with inferior OS and PFS compared with later cases. Pre-transplant IFI is associated with lower PFS and OS after allogeneic HSCT but significant survivorship was observed. Consequently, pre-transplant IFI should not be a contraindication to allogeneic HSCT in otherwise suitable candidates. Documented pre-transplant IFI is associated with lower PFS and OS after allogeneic HSCT. However, mortality post transplant is more influenced by advanced disease status than previous IFI. Pre-transplant IFI does not appear to be a contraindication to allogeneic HSCT.
C1 [Maziarz, R. T.; McLeod, A. A.] Oregon Hlth & Sci Univ, Adult Blood & Marrow Stem Cell Transplant Program, Knight Canc Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
[Brazauskas, R.; Chen, M.] Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.
[Brazauskas, R.] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA.
[Martino, R.] Hosp Santa Creu & Sant Pau, Div Clin Hematol, Barcelona, Spain.
[Wingard, J. R.] Univ Florida, Dept Med, Div Hematol & Oncol, Gainesville, FL USA.
[Aljurf, M.] King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia.
[Battiwalla, M.] NHLBI, Hematol Branch, Bethesda, MD 20892 USA.
[Dvorak, C. C.] Univ Calif San Francisco, Dept Pediat, Med Ctr, San Francisco, CA USA.
[Geroge, B.] Christian Med Coll & Hosp, Dept Hematol, Vellore, Tamil Nadu, India.
[Guinan, E. C.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Hale, G. A.] All Childrens Hosp, Dept Hematol Oncol, St Petersburg, FL USA.
[Lazarus, H. M.] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH USA.
[Lee, J-W] Catholic Univ Korea, Seoul St Marys Hosp, BMT Ctr, Seoul, South Korea.
[Liesveld, J. L.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA.
[Ramanathan, M.] UMass Mem Med Ctr, Dept Med, Div Hematol & Oncol, Worcester, MA USA.
[Reddy, V.] Univ Cent Florida, Coll Med, Dept Internal Med, Orlando, FL 32816 USA.
[Savani, B. N.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.
[Smith, F. O.] Univ Cincinnati, Inst Canc, Cincinnati, OH USA.
[Strasfeld, L.] Oregon Hlth & Sci Univ, Infect Dis Clin, Portland, OR 97201 USA.
[Taplitz, R. A.] UC San Diego Hlth, Infect Dis Program, La Jolla, CA USA.
[Ustun, C.] Univ Minnesota, Med Ctr, Div Hematol Oncol & Transplantat, Dept Med, Minneapolis, MN 55455 USA.
[Boeckh, M. J.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
[Gea-Banacloche, J.] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA.
[Lindemans, C. A.] Univ Med Ctr Utrecht, Pediat Blood & Marrow Transplantat Program, Utrecht, Netherlands.
[Auletta, J. J.] Nationwide Childrens Hosp, Div Hematol Oncol, Columbus, OH USA.
[Auletta, J. J.] Nationwide Childrens Hosp, Div Bone Marrow Transplantat, Columbus, OH USA.
[Auletta, J. J.] Nationwide Childrens Hosp, Div Infect Dis, Columbus, OH USA.
[Riches, M. L.] Univ North Carolina Chapel Hill, Div Hematol Oncol, Chapel Hill, NC USA.
RP Maziarz, RT (reprint author), Oregon Hlth & Sci Univ, Adult Blood & Marrow Stem Cell Transplant Program, Knight Canc Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM maziarzr@ohsu.edu
FU Public Health Service Grant from the National Cancer Institute (NCI)
[U24-CA076518]; National Heart, Lung and Blood Institute (NHLBI);
National Institute of Allergy and Infectious Diseases (NIAID) Grant from
NHLBI [5U10HL069294]; NCI [HHSH250201200016C]; Health Resources and
Services Administration (HRSA/DHHS) Grants from the Office of Naval
Research [N00014-13-1-0039, N00014-14-1-0028]; Actinium Pharmaceuticals;
Allos Therapeutics, Inc.; Amgen, Inc.; Anonymous donation to the Medical
College of Wisconsin; Ariad; Be the Match Foundation; Blue Cross and
Blue Shield Association; Celgene Corporation; Chimerix, Inc.; Fred
Hutchinson Cancer Research Center; Fresenius-Biotech North America,
Inc.; Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; Gentium SpA;
Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell Park
Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff Gordon
Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma Society;
Medac GmbH; The Medical College of Wisconsin; Merck Co, Inc.;
Millennium: The Takeda Oncology Co.; Milliman USA, Inc.; Perkin Elmer,
Inc.; Remedy Informatics; Sanofi US; Seattle Genetics; Sigma-Tau
Pharmaceuticals; Soligenix, Inc.; St. Baldrick's Foundation; StemCyte, A
Global Cord Blood Therapeutics Co.; Stemsoft Software, Inc.; Swedish
Orphan Biovitrum; Tarix Pharmaceuticals; TerumoBCT; Teva Neuroscience,
Inc.; THERAKOS,Inc.; University of Minnesota; University of Utah;
Wellpoint, Inc.
FX The CIBMTR is supported by Public Health Service Grant/Cooperative
Agreement U24-CA076518 from the National Cancer Institute (NCI), the
National Heart, Lung and Blood Institute (NHLBI) and the National
Institute of Allergy and Infectious Diseases (NIAID); a
Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract
HHSH250201200016C with Health Resources and Services Administration
(HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the
Office of Naval Research; and grants from *Actinium Pharmaceuticals;
Allos Therapeutics, Inc.; *Amgen, Inc.; Anonymous donation to the
Medical College of Wisconsin; Ariad; Be the Match Foundation; *Blue
Cross and Blue Shield Association; *Celgene Corporation; Chimerix, Inc.;
Fred Hutchinson Cancer Research Center; Fresenius-Biotech North America,
Inc.; *Gamida Cell Teva Joint Venture Ltd.; Genentech, Inc.; *Gentium
SpA; Genzyme Corporation; GlaxoSmithKline; Health Research, Inc. Roswell
Park Cancer Institute; HistoGenetics, Inc.; Incyte Corporation; Jeff
Gordon Children's Foundation; Kiadis Pharma; The Leukemia & Lymphoma
Society; Medac GmbH; The Medical College of Wisconsin; Merck & Co, Inc.;
Millennium: The Takeda Oncology Co.; *Milliman USA, Inc.; *Miltenyi
Biotec, Inc.; National Marrow Donor Program; Onyx Pharmaceuticals; Optum
Healthcare Solutions, Inc.; Osiris Therapeutics, Inc.; Otsuka America
Pharmaceutical, Inc.; Perkin Elmer, Inc.; *Remedy Informatics; *Sanofi
US; Seattle Genetics; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; St.
Baldrick's Foundation; StemCyte, A Global Cord Blood Therapeutics Co.;
Stemsoft Software, Inc.; Swedish Orphan Biovitrum; *Tarix
Pharmaceuticals; *TerumoBCT; *Teva Neuroscience, Inc.; *THERAKOS,Inc.;
University of Minnesota; University of Utah; and *Wellpoint, Inc. The
views expressed in this article do not reflect the official policy or
position of the National Institute of Health, the Department of the
Navy, the Department of Defense, Health Resources and Services
Administration (HRSA) or any other agency of the US Government.
*Corporate Members
NR 29
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0268-3369
EI 1476-5365
J9 BONE MARROW TRANSPL
JI Bone Marrow Transplant.
PD FEB
PY 2017
VL 52
IS 2
BP 270
EP 278
DI 10.1038/bmt.2016.259
PG 9
WC Biophysics; Oncology; Hematology; Immunology; Transplantation
SC Biophysics; Oncology; Hematology; Immunology; Transplantation
GA EK7VW
UT WOS:000394134300017
PM 27991895
ER
PT J
AU Lee, S
Huang, EJ
AF Lee, Sebum
Huang, Eric J.
TI Modeling ALS and FTD with iPSC-derived neurons
SO BRAIN RESEARCH
LA English
DT Review
DE Induced pluripotent stem cells (iPSCs); Amyotrophic lateral sclerosis
(ALS); Frontotemporal dementia (FM); Frontotemporal lobar degeneration
(FTLD)
ID AMYOTROPHIC-LATERAL-SCLEROSIS; PLURIPOTENT STEM-CELLS; FRONTOTEMPORAL
LOBAR DEGENERATION; HEXANUCLEOTIDE REPEAT EXPANSION; MYOTONIC-DYSTROPHY;
MOTOR-NEURONS; NEURODEGENERATIVE DISEASES; BASOPHILIC INCLUSIONS;
GENETIC CORRECTION; FUS MUTATIONS
AB Recent advances in genetics and neuropathology support the idea that amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTD) are two ends of a disease spectrum. Although several animal models have been developed to investigate the pathogenesis and disease progression in ALS and FTD, there are significant limitations that hamper our ability to connect these models with the neurodegenerative processes in human diseases. With the technical breakthrough in reprogramming biology, it is now possible to generate patient-specific induced pluripotent stem cells (iPSCs) and disease-relevant neuron subtypes. This review provides a comprehensive summary of studies that use iPSC-derived neurons to model ALS and FTD. We discuss the unique capabilities of iPSC-derived neurons that capture some key features of ALS and FTD, and underscore their potential roles in drug discovery. There are, however, several critical caveats that require improvements before iPSC-derived neurons can become highly effective disease models. Published by Elsevier B.V.
C1 [Lee, Sebum; Huang, Eric J.] Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94143 USA.
[Huang, Eric J.] San Francisco VA Med Ctr, Pathol Serv 113B, 505 Parnassus Ave, San Francisco, CA 94143 USA.
RP Huang, EJ (reprint author), Univ Calif San Francisco, Dept Pathol, 505 Parnassus Ave, San Francisco, CA 94143 USA.
EM eric.huang2@ucsf.edu
FU National Institute of Health [0D011915]; Veterans Administrations BLR&D
Merit Review Award [I01 BX0011-8]; Pilot Award [I21 BX1625]; Muscular
Dystrophy Association [217592]; Consortium for Frontotemporal Dementia
Research (CFR)
FX We thank Dr. Bruce Miller (UCSF Memory & Aging Center), Dr. Fen-Biao Gao
(University of Massachusetts) and Dr. Yadong Huang (Gladstone Institute
of Neurological Disease & UCSF) for many insightful discussions. Our
research on ALS and FTD disease mechanism and pathogenesis has been
supported by grants from the National Institute of Health (0D011915),
Veterans Administrations BLR&D Merit Review Award (I01 BX0011-8) and
Pilot Award (I21 BX1625), Muscular Dystrophy Association (Research Grant
#217592), and the Consortium for Frontotemporal Dementia Research (CFR).
NR 72
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD FEB 1
PY 2017
VL 1656
SI SI
BP 88
EP 97
DI 10.1016/j.brainres.2015.10.003
PG 10
WC Neurosciences
SC Neurosciences & Neurology
GA EK8RE
UT WOS:000394190500011
PM 26462653
ER
PT J
AU Tenforde, AS
Nattiv, A
Ackerman, K
Barrack, MT
Fredericson, M
AF Tenforde, Adam S.
Nattiv, Aurelia
Ackerman, Kathryn
Barrack, Michelle T.
Fredericson, Michael
TI Optimising bone health in the young male athlete
SO BRITISH JOURNAL OF SPORTS MEDICINE
LA English
DT Editorial Material
ID RISK-FACTORS; CONSENSUS STATEMENT; TRIAD; PARTICIPATION; DENSITY;
SPORTS; RETURN; PLAY
C1 [Tenforde, Adam S.] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Cambridge, MA 02138 USA.
[Nattiv, Aurelia] Univ Calif Los Angeles, Dept Family Med, Los Angeles, CA USA.
[Nattiv, Aurelia] Univ Calif Los Angeles, Dept Orthopaed Surg, Div Sports Med & Nonoperat Orthopaed, Los Angeles, CA USA.
[Ackerman, Kathryn] Boston Childrens Hosp, Div Sports Med, Boston, MA USA.
[Ackerman, Kathryn] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA.
[Ackerman, Kathryn] Harvard Med Sch, Boston, MA USA.
[Barrack, Michelle T.] Calif State Univ Long Beach, Dept Family & Consumer Sci, Long Beach, CA 90840 USA.
[Fredericson, Michael] Stanford Univ, Sch Med, Div Phys Med & Rehabil, Dept Orthopaed Surg, Palo Alto, CA 94304 USA.
RP Tenforde, AS (reprint author), Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Cambridge, MA 02138 USA.
EM atenforde@partners.org
NR 15
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-3674
EI 1473-0480
J9 BRIT J SPORT MED
JI Br. J. Sports Med.
PD FEB
PY 2017
VL 51
IS 3
BP 148
EP 149
DI 10.1136/bjsports-2016-097000
PG 2
WC Sport Sciences
SC Sport Sciences
GA EL2NF
UT WOS:000394455800006
ER
PT J
AU Baggish, AL
Kovacs, RJ
AF Baggish, Aaron L.
Kovacs, Richard J.
TI Preparticipation cardiovascular screening: clinical partnership is the
only certainty
SO BRITISH JOURNAL OF SPORTS MEDICINE
LA English
DT Editorial Material
ID CARDIOLOGY; RECOMMENDATIONS; DISEASE; SPORTS
C1 [Baggish, Aaron L.] Massachusetts Gen Hosp, Cardiovasc Performance Program, Yawkey Suite 5B,55 Fruit St, Boston, MA 02114 USA.
[Kovacs, Richard J.] Indiana Univ, Krannert Inst Cardiol, Indianapolis, IN 46204 USA.
RP Baggish, AL (reprint author), Massachusetts Gen Hosp, Cardiovasc Performance Program, Yawkey Suite 5B,55 Fruit St, Boston, MA 02114 USA.
EM abaggish@partners.org
NR 6
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0306-3674
EI 1473-0480
J9 BRIT J SPORT MED
JI Br. J. Sports Med.
PD FEB
PY 2017
VL 51
IS 3
BP 150
EP U90
DI 10.1136/bjsports-2016-096954
PG 2
WC Sport Sciences
SC Sport Sciences
GA EL2NF
UT WOS:000394455800007
ER
PT J
AU Richards, KA
Cesario, S
Lim, AH
Best, SL
Deeren, SM
Bushman, W
Safdar, N
AF Richards, Kyle A.
Cesario, Stacy
Lim, Amy H.
Best, Sara L.
Deeren, Susan M.
Bushman, Wade
Safdar, Nasia
TI Utility of routine urinalysis and urine culture testing in an ambulatory
urology clinic: a quality improvement initiative in a Veterans
healthcare facility
SO CANADIAN JOURNAL OF UROLOGY
LA English
DT Article
DE quality control; quality improvement; urine; urine assay; urinary tract
infection
ID INFECTIOUS-DISEASES-SOCIETY; ASYMPTOMATIC BACTERIURIA; PRACTICE
GUIDELINES; TRACT-INFECTION; AMERICA; DIAGNOSIS; ADULTS
AB Introduction: Urinalysis (UA) and urine culture (UCx) are commonly performed tests in the urology clinic. Many of these urine studies are performed prior to the patient visit may not always be indicated, thus contributing to unintended consequences such as antibiotic use and costs without enhancing patient care. Our objective was to perform a quality improvement initiative aimed to assess the utility of routine UA/UCx.
Materials and methods: The practice pattern at our site's Veteran Affairs (VA) urology clinic prior to 2014 was to obtain routine UA/UCx on most clinic visits prior to patient evaluation. Starting in 2014, we designed an intervention whereby our nurse practitioner triaged all new patient referrals and selectively ordered UA/UCx. We performed multivariable logistic regression to assess for predictors of obtaining UA or UCx.
Results: A total of 1308 patients were seen in January March 2013 and 1456 in June-August 2014 and were included in this analysis. Fewer patients in 2014 received UA (59.8% versus 70.0%, p < 0.001) and UCx (49.6% versus 64.2%, p < 0.001). There was a decreased odds of obtaining UA in 2014 (OR 0.52, p < 0.001) as well as a decreased odds of obtaining UCx in 2014 (OR0.38, p < 0.001) on multivariable logistic regression. The results of UA/UCx only rarely resulted in change of management in either cohort (3%). Selective ordering resulted in an estimated cost savings of $4915.08/month in UCx costs alone.
Conclusions: Our quality improvement initiatives reduced rates of UA/UCx testing when providers assess patients prior to ordering these tests. The implication of this initiative is significant cost savings for the healthcare system.
C1 [Richards, Kyle A.; Cesario, Stacy; Lim, Amy H.; Best, Sara L.; Deeren, Susan M.; Bushman, Wade] William S Middleton Mem Vet Adm Med Ctr, Dept Urol, Madison, WI 53705 USA.
[Richards, Kyle A.; Best, Sara L.; Bushman, Wade] Univ Wisconsin Madison, Dept Urol, 1685 Highland Ave, Madison, WI 53705 USA.
[Safdar, Nasia] Univ Wisconsin Madison, Dept Med, Madison, WI USA.
RP Richards, KA (reprint author), Univ Wisconsin Madison, Dept Urol, 1685 Highland Ave, Madison, WI 53705 USA.
FU VA; VAMERIT award
FX This material is the result of work supported with resources and the use
of facilities at the William S. Memorial Veterans Hospital. Dr. Safdar
is supported by a VA funded Patient Safety Center of Inquiry and a
VAMERIT award. The contents do not represent the views of the U. S.
Department of Veterans Affairs or the United States Government.
NR 18
TC 0
Z9 0
U1 0
U2 0
PU CANADIAN J UROLOGY
PI ST LAURENT
PA 2330 WARD ST, STE 604, ST LAURENT, QUEBEC H4M 2V6, CANADA
SN 1195-9479
J9 CAN J UROL
JI Can. J. Urol.
PD FEB
PY 2017
VL 24
IS 1
BP 8627
EP 8633
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA EM5MQ
UT WOS:000395356100004
PM 28263127
ER
PT J
AU Morris, BJ
Klausner, JD
Krieger, JN
Willcox, BJ
Crouse, PD
Pollock, N
AF Morris, Brian J.
Klausner, Jeffrey D.
Krieger, John N.
Willcox, Bradley J.
Crouse, Pierre D.
Pollock, Neil
TI Reply by Authors - Re: Canadian Pediatrics Society position statement on
newborn circumcision: a risk-benefit analysis revisited
SO CANADIAN JOURNAL OF UROLOGY
LA English
DT Letter
ID HUMAN-PAPILLOMAVIRUS INFECTION; URINARY-TRACT-INFECTIONS;
PROSTATE-CANCER; FEMALE PARTNERS; MEN; COLONIZATION; PREVALENCE;
PREVENTION; CLEARANCE; SYPHILIS
C1 [Morris, Brian J.] Univ Sydney, Sch Med Sci, Bldg F13, Sydney, NSW 2006, Australia.
[Morris, Brian J.] Univ Sydney, Bosch Inst, Sydney, NSW, Australia.
[Klausner, Jeffrey D.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
[Klausner, Jeffrey D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA.
[Krieger, John N.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Urol Sect, Seattle, WA USA.
[Willcox, Bradley J.] Univ Hawaii, Kuakini Med Ctr, Dept Res, Honolulu, HI 96822 USA.
[Crouse, Pierre D.] Intramed Med Ctr, Calgary, AB, Canada.
[Pollock, Neil] Univ British Columbia, Pollodc Clin, Vancouver, BC V5Z 1M9, Canada.
[Pollock, Neil] Univ British Columbia, New Westminster & Fac Med, Vancouver, BC V5Z 1M9, Canada.
RP Morris, BJ (reprint author), Univ Sydney, Sch Med Sci, Bldg F13, Sydney, NSW 2006, Australia.
NR 38
TC 0
Z9 0
U1 0
U2 0
PU CANADIAN J UROLOGY
PI ST LAURENT
PA 2330 WARD ST, STE 604, ST LAURENT, QUEBEC H4M 2V6, CANADA
SN 1195-9479
J9 CAN J UROL
JI Can. J. Urol.
PD FEB
PY 2017
VL 24
IS 1
BP 8687
EP 8692
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA EM5MQ
UT WOS:000395356100017
PM 28263140
ER
PT J
AU Spring, LM
Marshall, MR
Warner, ET
AF Spring, Laura M.
Marshall, Megan R.
Warner, Erica T.
TI Mammography decision making: Trends and predictors of provider
communication in the Health Information National Trends Survey, 2011 to
2014
SO CANCER
LA English
DT Article
DE communication; decision making; mammography; surveys and questionnaires
ID BREAST-CANCER STAGE; SCREENING MAMMOGRAPHY; WOMEN; BENEFITS; GUIDELINES;
SURVIVAL; HARMS; RECOMMENDATIONS; DIAGNOSIS; ATTITUDES
AB BACKGROUNDIn 2009, the US Preventive Services Task Force recommended that the decision to initiate screening mammography before age 50 years should be individualized. Herein, the authors examined whether health care providers are communicating regarding mammography decision making with women and whether communication is associated with screening behavior.
METHODSData were drawn from the 2011 to 2014 Health Information National Trends Survey (HINTS). A total of 5915 female respondents aged40 years who responded to the following question were included: Has a doctor or other health professional ever told you that you could choose whether or not to have a mammogram? We used logistic regression to generate odds ratios (ORs) and 95% confidence intervals (95% CIs) for predictors of provider communication and assessed whether provider communication was associated with mammography in the previous 2 years overall and stratified by age.
RESULTSFewer than 50% of the women reported provider communication regarding mammogram choice. Women who reported provider communication were not found to be more likely to report no mammogram within the past 2 years (OR, 1.07; 95% CI, 0.87-1.31) compared with those who did not. When stratified by 10-year age group, provider communication was associated with a higher likelihood of no mammogram only among women age 70 years (OR, 1.64; 95% CI, 1.15-2.34), and was associated with a lower likelihood of no mammogram only among women aged 40 to 49 years (OR, 0.63; 95% CI, 0.43-0.92).
CONCLUSIONSBetween 2011 and 2014, less than one-half of women received communication regarding mammogram choice despite recommendations from the US Preventive Services Task Force. Provider communication regarding mammogram choice can influence screening behavior, particularly for younger and older women. Cancer 2017;123:401-409. (c) 2016 American Cancer Society.
From 2011 to 2014, fewer than one-half of women received provider communication regarding mammogram choice in the study population, despite the recommendations of the US Preventive Services Task Force. Provider communication concerning mammogram choice can influence screening behavior, particularly for women aged 40 to 49 years and those aged 70 years.
C1 [Warner, Erica T.] Massachusetts Gen Hosp, Dept Med, Clin Translat Epidemiol Unit, 55 Fruit St,Bartlett 9, Boston, MA 02114 USA.
[Spring, Laura M.] Massachusetts Gen Hosp, Breast Med Oncol, Boston, MA 02114 USA.
[Marshall, Megan R.] Massachusetts Gen Hosp, Dept Orthoped, Boston, MA 02114 USA.
RP Warner, ET (reprint author), Massachusetts Gen Hosp, Dept Med, Clin Translat Epidemiol Unit, 55 Fruit St,Bartlett 9, Boston, MA 02114 USA.
EM ewarner@mgh.harvard.edu
FU NCI NIH HHS [T32 CA071345, K01 CA188075]
NR 32
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD FEB 1
PY 2017
VL 123
IS 3
BP 401
EP 409
DI 10.1002/cncr.30378
PG 9
WC Oncology
SC Oncology
GA EL6GV
UT WOS:000394719300007
PM 27727457
ER
PT J
AU Kohler, RE
Miller, AR
Gutnik, L
Lee, CN
Gopal, S
AF Kohler, Racquel E.
Miller, Anna R.
Gutnik, Lily
Lee, Clara N.
Gopal, Satish
TI Experiences and perceptions regarding clinical breast exam screening by
trained laywomen in Malawi
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE Breast cancer screening; Lay health worker; Sub-Saharan Africa; Health
education; Qualitative interviews
ID CANCER; HEALTH; AWARENESS; SERVICES; AFRICA
AB Despite the increasing burden, breast cancer control in sub-Saharan Africa is insufficient. Late diagnosis and lack of early detection and screening services contribute to high mortality. Clinical breast exam (CBE) screening can be valuable in low-income countries, including use of community health workers and non-health professionals to conduct exams. We assessed experiences of women who underwent CBE screening by trained laywomen in Lilongwe, Malawi, as part of a pilot program.
The pilot study invited women attending urban health clinics to a breast cancer educational talk followed by CBE screening by trained laywomen. We purposively sampled participants from the pilot study and interviewed them about the screening experience and future cancer education programs and services.
Overall participants had positive experiences and were willing to undergo CBE screening by trained laywomen. Participants were motivated by the educational talk, shared newly acquired cancer knowledge with their social networks, and encouraged others to seek screening. Screened women suggested strategies for future interventions including combining breast and cervical cancer screening, using female providers, partnering with community leaders to increase uptake, and expanding services into the community.
Asymptomatic Malawian women accepted CBE screening by trained laywomen and considered breast cancer an important health issue. Women appreciated combined education and screening services and proposed further linkage of breast and cervical cancer screening. Based on our results, training laywomen to educate the public on breast cancer and conduct CBE is a feasible breast cancer control strategy in sub-Saharan Africa.
C1 [Kohler, Racquel E.] Harvard TH Chan Sch Publ Hlth, Dana Farber Canc Inst, Dept Social & Behav Sci, 450 Brookline Ave, Boston, MA 02115 USA.
[Miller, Anna R.; Gopal, Satish] Univ North Carolina Chapel Hill, Inst Global Hlth & Infect Dis, 130 Mason Farm Rd, Chapel Hill, NC 27514 USA.
[Gutnik, Lily] Univ Utah, Dept Surg, 30 North 1900 East,3B 110 Sch Med, Salt Lake City, UT 84132 USA.
[Lee, Clara N.] Univ North Carolina Chapel Hill, Dept Surg, 7041 Burnett Womack, Chapel Hill, NC 27599 USA.
[Lee, Clara N.; Gopal, Satish] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
[Gopal, Satish] UNC Project Malawi, Lilongwe, Malawi.
RP Kohler, RE (reprint author), Harvard TH Chan Sch Publ Hlth, Dana Farber Canc Inst, Dept Social & Behav Sci, 450 Brookline Ave, Boston, MA 02115 USA.
EM racquel_kohler@dfci.harvard.edu
FU REK's fellowship; UNC Cancer Care Quality Training Program through the
National Cancer Institute [R25 CA116339]; UNC Hopkins Morehouse Tulane
Fogarty Global Health Fellows Program through Fogarty International
Center [R25 TW009340]
FX This study was funded by REK's fellowship with UNC Cancer Care Quality
Training Program through the National Cancer Institute (R25 CA116339)
and LG's fellowship funded by the UNC Hopkins Morehouse Tulane Fogarty
Global Health Fellows Program through Fogarty International Center (R25
TW009340).
NR 26
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
EI 1573-7225
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD FEB
PY 2017
VL 28
IS 2
BP 137
EP 143
DI 10.1007/s10552-016-0844-0
PG 7
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA EL2LV
UT WOS:000394452100006
PM 28097471
ER
PT J
AU Campbell, P
Rebbeck, TR
Nishihara, R
Beck, AH
Begg, CB
Bogdanov, AA
Cao, Y
Coleman, HG
Freeman, GJ
Heng, YJJ
Huttenhower, C
Irizarry, RA
Kip, NS
Michor, F
Nevo, D
Peters, U
Phipps, AI
Poole, EM
Qian, ZR
Quackenbush, J
Robins, H
Rogan, PK
Slattery, ML
Smith-Warner, SA
Song, MY
VanderWeele, TJ
Xia, D
Zabor, EC
Zhang, XH
Wang, ML
Ogino, S
AF Campbell, Peter T.
Rebbeck, Timothy R.
Nishihara, Reiko
Beck, Andrew H.
Begg, Colin B.
Bogdanov, Alexei A.
Cao, Yin
Coleman, Helen G.
Freeman, Gordon J.
Heng, Yujing J.
Huttenhower, Curtis
Irizarry, Rafael A.
Kip, N. Sertac
Michor, Franziska
Nevo, Daniel
Peters, Ulrike
Phipps, Amanda I.
Poole, Elizabeth M.
Qian, Zhi Rong
Quackenbush, John
Robins, Harlan
Rogan, Peter K.
Slattery, Martha L.
Smith-Warner, Stephanie A.
Song, Mingyang
VanderWeele, Tyler J.
Xia, Daniel
Zabor, Emily C.
Zhang, Xuehong
Wang, Molin
Ogino, Shuji
TI Proceedings of the third international molecular pathological
epidemiology (MPE) meeting
SO CANCER CAUSES & CONTROL
LA English
DT Review
DE Molecular pathological epidemiology; Meeting report; Proceedings
ID MICROSATELLITE INSTABILITY STATUS; COLORECTAL-CANCER RISK; LIFE-STYLE
FACTORS; BODY-MASS INDEX; BREAST-CANCER; ASPIRIN USE; ETIOLOGIC
HETEROGENEITY; CIGARETTE-SMOKING; WIDE ASSOCIATION; PIK3CA MUTATION
AB Molecular pathological epidemiology (MPE) is a transdisciplinary and relatively new scientific discipline that integrates theory, methods, and resources from epidemiology, pathology, biostatistics, bioinformatics, and computational biology. The underlying objective of MPE research is to better understand the etiology and progression of complex and heterogeneous human diseases with the goal of informing prevention and treatment efforts in population health and clinical medicine. Although MPE research has been commonly applied to investigating breast, lung, and colorectal cancers, its methodology can be used to study most diseases. Recent successes in MPE studies include: (1) the development of new statistical methods to address etiologic heterogeneity; (2) the enhancement of causal inference; (3) the identification of previously unknown exposure-subtype disease associations; and (4) better understanding of the role of lifestyle/behavioral factors on modifying prognosis according to disease subtype. Central challenges to MPE include the relative lack of transdisciplinary experts, educational programs, and forums to discuss issues related to the advancement of the field. To address these challenges, highlight recent successes in the field, and identify new opportunities, a series of MPE meetings have been held at the Dana-Farber Cancer Institute in Boston, MA. Herein, we share the proceedings of the Third International MPE Meeting, held in May 2016 and attended by 150 scientists from 17 countries. Special topics included integration of MPE with immunology and health disparity research. This meeting series will continue to provide an impetus to foster further transdisciplinary integration of divergent scientific fields.
C1 [Campbell, Peter T.] Amer Canc Soc, Epidemiol Res Program, 250 Williams St NW, Atlanta, GA 30303 USA.
[Rebbeck, Timothy R.; Nevo, Daniel; Poole, Elizabeth M.; Smith-Warner, Stephanie A.; VanderWeele, Tyler J.; Wang, Molin; Ogino, Shuji] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Rebbeck, Timothy R.; Nishihara, Reiko; Freeman, Gordon J.; Qian, Zhi Rong; Ogino, Shuji] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Nishihara, Reiko; Cao, Yin; Smith-Warner, Stephanie A.; Song, Mingyang] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA.
[Beck, Andrew H.; Heng, Yujing J.] Beth Israel Deaconess Canc Ctr, Canc Res Inst, Boston, MA USA.
[Beck, Andrew H.; Heng, Yujing J.] Harvard Med Sch, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA USA.
[Begg, Colin B.; Zabor, Emily C.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
[Bogdanov, Alexei A.] Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA USA.
[Cao, Yin; Song, Mingyang] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA.
[Cao, Yin; Poole, Elizabeth M.; Song, Mingyang; Zhang, Xuehong; Ogino, Shuji] Harvard Med Sch, 450 Brookline Ave,Room SM1036, Boston, MA 02215 USA.
[Cao, Yin] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Coleman, Helen G.] Queens Univ Belfast, Epidemiol & Hlth Serv Res Grp, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
[Huttenhower, Curtis; Irizarry, Rafael A.; Michor, Franziska; Nevo, Daniel; Quackenbush, John] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Huttenhower, Curtis] Broad Inst, Genome Sequencing & Anal Program, Microbial Syst & Communities, Cambridge, MA USA.
[Irizarry, Rafael A.; Michor, Franziska; Quackenbush, John] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Kip, N. Sertac] Geisinger Hlth Syst, Lab Med & Pathol, Danville, PA USA.
[Peters, Ulrike; Phipps, Amanda I.; Robins, Harlan] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, 1124 Columbia St, Seattle, WA 98104 USA.
[Peters, Ulrike; Phipps, Amanda I.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Poole, Elizabeth M.; Zhang, Xuehong] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
[Rogan, Peter K.] Univ Western Ontario, Dept Biochem, London, ON, Canada.
[Slattery, Martha L.] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Xia, Daniel] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Div MPE Mol Pathol Epidemiol, Dept Pathol, 450 Brookline Ave,Room SM1036, Boston, MA 02215 USA.
[Ogino, Shuji] Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA.
RP Campbell, P (reprint author), Amer Canc Soc, Epidemiol Res Program, 250 Williams St NW, Atlanta, GA 30303 USA.; Ogino, S (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.; Ogino, S (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Ogino, S (reprint author), Harvard Med Sch, 450 Brookline Ave,Room SM1036, Boston, MA 02215 USA.; Ogino, S (reprint author), Brigham & Womens Hosp, Div MPE Mol Pathol Epidemiol, Dept Pathol, 450 Brookline Ave,Room SM1036, Boston, MA 02215 USA.; Ogino, S (reprint author), Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA.
EM peter.campbell@cancer.org; Timothy_Rebbeck@dfci.harvard.edu;
reiko.nishihara@mail.harvard.edu; abeck2@bidmc.harvard.edu;
beggc@mskcc.org; Alexei.Bogdanov@umassmed.edu; yic576@mail.harvard.edu;
h.coleman@qub.ac.uk; gordon_freeman@dfci.harvard.edu;
yheng@bidmc.harvard.edu; chuttenh@hsph.harvard.edu;
rafa@jimmy.harvard.edu; nskip@geisinger.edu; michor@jimmy.harvard.edu;
nhdne@channing.harvard.edu; upeters@fredhutch.org;
aphipps@fredhutch.org; nhlip@channing.harvard.edu;
Zhirong_qian@dfci.harvard.edu; johnq@jimmy.harvard.edu;
hrobins@fredhutch.org; progan@uwo.ca; marty.slattery@hsc.utah.edu;
swarner@hsph.harvard.edu; msong2@partners.org;
tvanderw@hsph.harvard.edu; yxia8@partners.org; zabore@mskcc.org;
xuehong.zhang@channing.harvard.edu; stmow@channing.harvard.edu;
Shuji_ogino@dfci.harvard.edu
OI Rogan, Peter/0000-0003-2070-5254
FU NIH - National Cancer Institute, National Human Genome Research
Institute [R13 CA203287]; NIH - National Institute of Environmental
Health Sciences; Dana-Farber Harvard Cancer Center Support Grant [R35
CA197735, P30 CA006516]; Dana-Farber Harvard Cancer Center
FX Grant support: NIH R13 CA203287 (to S.O.: supported by the National
Cancer Institute, National Human Genome Research Institute, and National
Institute of Environmental Health Sciences). R35 CA197735 (to S.O.). P30
CA006516 (Dana-Farber Harvard Cancer Center Support Grant; to E.J.
Benz;). Nodal Award (to S.P.) from Dana-Farber Harvard Cancer Center.
NR 66
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
EI 1573-7225
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD FEB
PY 2017
VL 28
IS 2
BP 167
EP 176
DI 10.1007/s10552-016-0845-z
PG 10
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA EL2LV
UT WOS:000394452100009
PM 28097472
ER
PT J
AU Wang, H
Hoda, RS
Faquin, W
Rossi, ED
Hotchandani, N
Sun, TL
Pusztaszeri, M
Bizzarro, T
Bongiovanni, M
Patel, V
Jhala, N
Fadda, G
Gong, Y
AF Wang, He
Hoda, Raza S.
Faquin, William
Rossi, Esther Diana
Hotchandani, Nihar
Sun, Tianlin
Pusztaszeri, Marc
Bizzarro, Tommaso
Bongiovanni, Massimo
Patel, Viren
Jhala, Nirag
Fadda, Guido
Gong, Yun
TI FNA biopsy of secondary nonlymphomatous malignancies in salivary glands:
A multi-institutional study of 184 cases
SO CANCER CYTOPATHOLOGY
LA English
DT Article
DE ancillary test; fine-needle aspiration biopsy; metastasis;
multi-institutional; salivary gland
ID FINE-NEEDLE-ASPIRATION; RENAL-CELL CARCINOMA; OF-THE-LITERATURE;
PAROTID-GLAND; CYTOLOGY; TUMORS; NEOPLASMS; LESIONS; MANAGEMENT;
DIAGNOSIS
AB BACKGROUNDSecondary malignancies of salivary glands (SMSGs) are among the most common malignant neoplasms to involve the salivary glands. Fine-needle aspiration biopsy (FNAB) of SMSG can present diagnostic challenges. The current report presents the largest such FNAB series to date.
METHODSA search of the pathology database from 6 academic institutions identified 184 FNAB cases of nonlymphomatous SMSG.
RESULTSOf the 184 cases, 171 were of the parotid glands, and 13 were of the submandibular glands; 130 patients were men, and 54 were women, and the mean patient age at diagnosis was 68 years. Metastatic squamous cell carcinoma (SCC) from all sites (n=87) and melanoma (n=67) constituted the majority of SMSGs. Less frequent SMSGs were comprised of metastatic carcinomas from distant organs (n=16), including sites in the breast, lung, kidney, thyroid, pancreatobiliary, prostate, and bladder. Other uncommon SMSGs, including nasopharyngeal carcinoma (n=3), sarcoma (n=4), other metastatic skin-derived carcinomas (n=6), and metastatic chordoma (n=1), also were observed. Ancillary tests were performed on 37 FNAB specimens (20.1%) to aid the evaluation. One hundred forty-seven specimens (79.9%) had a definitive diagnosis with accurate tumor subtyping, 21 (11.4%) had a definitive malignant diagnosis but without specifying subtype, 9 (4.9%) had an indeterminate diagnosis, and 7 (3.8%) had a false-negative diagnosis.
CONCLUSIONSSMSGs originate predominately from the head and neck and are more common in older men. Overall, the FNAB diagnosis of SMSG is accurate, but diagnostic challenges can be encountered, especially in SCC types of SMSG. Ancillary studies are needed for the definitive diagnosis of challenging cases. Cancer Cytopathol 2017;125:91-103. (c) 2016 American Cancer Society. The fine-needle aspiration biopsy diagnosis of secondary nonlymphomatous malignancy is accurate overall. However, diagnostic challenges can be encountered, especially in the squamous cell carcinoma type of secondary nonlymphomatous malignancy.
C1 [Wang, He; Hotchandani, Nihar; Patel, Viren; Jhala, Nirag] Temple Univ Hosp & Med Sch, Dept Pathol & Lab Med, 3401 North Broad St,350-OPB, Philadelphia, PA 19140 USA.
[Hoda, Raza S.; Faquin, William] Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA.
[Rossi, Esther Diana; Bizzarro, Tommaso; Fadda, Guido] Univ Cattolica Sacro Cuore, Dept Anat Pathol & Histol, Rome, Italy.
[Sun, Tianlin; Gong, Yun] Univ Texas MD Anderson Canc Ctr, Div Pathol & Lab Med, Dept Pathol, Houston, TX 77030 USA.
[Pusztaszeri, Marc] Univ Hosp Geneva, Dept Pathol, Geneva, Switzerland.
[Bongiovanni, Massimo] Univ Hosp, Inst Pathol, Lausanne, Switzerland.
RP Wang, H (reprint author), Temple Univ Hosp & Med Sch, Dept Pathol & Lab Med, 3401 North Broad St,350-OPB, Philadelphia, PA 19140 USA.
EM he.wang@tuhs.temple.edu
OI Bongiovanni, Massimo/0000-0001-9846-6682
NR 60
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1934-662X
EI 1934-6638
J9 CANCER CYTOPATHOL
JI Cancer Cytopathol.
PD FEB
PY 2017
VL 125
IS 2
BP 91
EP 103
DI 10.1002/cncy.21798
PG 13
WC Oncology; Pathology
SC Oncology; Pathology
GA EL5DA
UT WOS:000394640600004
PM 28001329
ER
PT J
AU Sawaya, FJ
Morice, MC
Spaziano, M
Mehran, R
Didier, R
Roy, A
Valgimigli, M
Kim, HS
Park, KW
Hong, MK
Kim, BK
Jang, Y
Feres, F
Abizaid, A
Costa, RA
Colombo, A
Chieffo, A
Giustino, G
Stone, GW
Bhatt, DL
Palmerini, T
Gilard, M
AF Sawaya, Fadi J.
Morice, Marie-Claude
Spaziano, Marco
Mehran, Roxana
Didier, Romain
Roy, Andrew
Valgimigli, Marco
Kim, Hyo-Soo
Park, Kyung Woo
Hong, Myeong-Ki
Kim, Byeong-Keuk
Jang, Yangsoo
Feres, Fausto
Abizaid, Alexandre
Costa, Ricardo A.
Colombo, Antonio
Chieffo, Alaide
Giustino, Gennaro
Stone, Gregg W.
Bhatt, Deepak L.
Palmerini, Tullio
Gilard, Martine
TI Short-Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting
Stent Implantation in Women Versus Men: A Sex-Specific Patient-Level
Pooled-Analysis of Six Randomized Trials
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE dual antiplatelet therapy duration; major adverse cardiac events;
drug-eluting stents; women
ID PERCUTANEOUS CORONARY INTERVENTION; COLLABORATIVE METAANALYSIS;
CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; HEART-ASSOCIATION;
CLINICAL-TRIALS; DURATION; EFFICACY; DISEASE; SAFETY
AB Background: Whether the efficacy and safety of dual antiplatelet therapy (DAPT) are uniform between sexes is unclear. We sought to compare clinical outcomes between short-(<= 6 months) versus long-term (>= 1 year) DAPT after drug-eluting stent (DES) placement in women and men. Methods and Results: We pooled individual patient data from6 randomized trials of DAPT (EXCELLENT, OPTIMIZE, PRODIGY, RESET, SECURITY, ITALIC PLUS). The primary outcome was 1-year risk of major adverse cardiac events (MACE). The main secondary outcome was 1-year risk of any bleeding. Out of the 11,473 randomized patients included in the pooled dataset, 3,454 (30%) were females. At 1-year follow-up, women had higher risk of MACE (3.6% vs. 2.8%; P=0.01) but similar risk of bleeding (1.9% vs. 1.6%; P=0.16) as compared with men. Compared with long-term DAPT, short-term DAPT was associated with similar rates of MACE in both women (HR 0.88; 95% CI 0.62-1.25) and men (HR 1.25; 95% CI 0.95-1.6; P interaction50.08)]. At 1-year follow-up, short-term DAPTwas associated with lower rates of bleeding as compared with long-term DAPT in both women (HR 0.84; 95% CI 0.51-1.37) and men (HR 0.58; 95% CI 0.40-0.84; P-interaction50.25). The presence of MVD was associated with higher MACE rates in the short-term DAPT group in women (HR: 1.16; CI 0.60-2.23) and men (HR: 2.29; CI 1.22-4.29; P interaction50.25). Conclusions: Short-term DAPT is associated with similar rates of MACE but lower risk of bleeding when as compared with prolonged DAPT. There was no significant difference between sexes in the population studied. (C) 2016 Wiley Periodicals, Inc.
C1 [Sawaya, Fadi J.; Morice, Marie-Claude; Spaziano, Marco; Roy, Andrew] Hop Prive Jacques Cartier, Inst Cardiovasc Paris, Dept Cardiol, Gen Sante, Massy, France.
[Mehran, Roxana] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Didier, Romain; Gilard, Martine] CHU Cavale Blanche, Dept Cardiol, Brest, France.
[Valgimigli, Marco] Erasmus MC, Thoraxctr, Rotterdam, Netherlands.
[Kim, Hyo-Soo; Park, Kyung Woo] Seoul Natl Univ, Main Hosp, Dept Cardiol, Seoul, South Korea.
[Hong, Myeong-Ki; Kim, Byeong-Keuk; Jang, Yangsoo] Yonsei Univ, Coll Med, Severance Cardiovasc Hosp, Seoul, South Korea.
[Feres, Fausto; Abizaid, Alexandre; Costa, Ricardo A.] Ist Dante Pazzanese Cardiol, Sao Paulo, Brazil.
[Colombo, Antonio; Chieffo, Alaide; Giustino, Gennaro] Ist Sci San Raffaele, Milan, Italy.
[Stone, Gregg W.] Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY USA.
[Stone, Gregg W.] Cardiovasc Res Fdn, New York, NY USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, 75 Francis St, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Med Sch, Boston, MA USA.
[Palmerini, Tullio] Univ Bologna, Dipartimento Cardiotoracovasc, Bologna, Italy.
RP Morice, MC (reprint author), Hop Prive Jacques Cartier, Inst Cardiovasc Paris Sud, Gen Sante, 6 Ave Noyer Lambert, F-91300 Massy, France.
EM mc.morice@icps.com.fr
FU Abbott Vascular; Eli Lilly; Amarin; AstraZeneca; Bristol-Myers Squibb;
Eisai; Ethicon; Forest Laboratories; Ischemix; Medtronic; Pfizer; Roche;
Sanofi Aventis; Medicines Company; Lilly; Sanofi; Daiichi Sankyo; Bayer;
Boston Scientific; CSL Behring; Covidien; Janssen Pharmaceuticals; Maya
Medical; Merck; Osprey Medical Inc.; Regado Biosciences; Watermark
Research Partners
FX Dr. Palmerini has received a speaker fee from Abbott Vascular; and a
research grant from Eli Lilly. Dr. Bhatt discloses the following
relationships-Advisory Board: Cardax, Elsevier Practice Update
Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors:
Boston VA Research Institute, Society of Cardiovascular Patient Care;
Chair: American Heart Association Quality Oversight Committee; Data
Monitoring Committees: Duke Clinical Research Institute, Harvard
Clinical Research Institute, Mayo Clinic, Population Health Research
Institute; Honoraria: American College of Cardiology (Senior Associate
Editor, Clinical Trials and News, ACC.org), Belvoir Publications
(Editor-in-Chief, Harvard Heart Letter), Duke Clinical Research
Institute (clinical trial steering committees), Harvard Clinical
Research Institute (clinical trial steering committee), HMP
Communications (Editor in Chief, Journal of Invasive Cardiology),
Journal of the American College of Cardiology (Guest Editor; Associate
Editor), Population Health Research Institute (clinical trial steering
committee), Slack Publications (Chief Medical Editor, Cardiology Today's
Intervention), Society of Cardiovascular Patient Care
(Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical
Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee
(Vice-Chair), VA CART Research and Publications Committee (Chair);
Research Funding: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai,
Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi
Aventis, The Medicines Company; Royalties: Elsevier (Editor,
Cardiovascular Intervention: A Companion to Braunwald's Heart Disease);
Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical;
Trustee: American College of Cardiology; Unfunded Research: FlowCo, PLx
Pharma, Takeda. Dr. Mehran has received institutional research grant
support from The Medicines Company, AstraZeneca, Bristol-Myers Squibb,
Sanofi, Lilly, and Daiichi Sankyo; has received consulting fees from
Abbott Vascular, AstraZeneca, Bayer, Boston Scientific, CSL Behring,
Covidien, Janssen Pharmaceuticals, Maya Medical, Merck, Osprey Medical
Inc., Regado Biosciences, Watermark Research Partners, and Sanofi; and
serves on the scientific advisory board of Abbott Laboratories, Boston
Scientific Corporation, Covidien, Janssen Pharmaceuticals, The Medicines
Company, and Sanofi. All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose. F.S,
M.C.M, M.S contributed equally to the manuscript.
NR 43
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
EI 1522-726X
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD FEB 1
PY 2017
VL 89
IS 2
BP 178
EP 189
DI 10.1002/ccd.26653
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EM9WL
UT WOS:000395662000005
PM 27426936
ER
PT J
AU Klein, LW
Harjai, KJ
Resnic, F
Weintraub, WS
Anderson, V
Yeh, RW
Feldman, DN
Gigliotti, OS
Rosenfeld, K
Duffy, P
AF Klein, Lloyd W.
Harjai, Kishore J.
Resnic, Fred
Weintraub, William S.
Anderson, Vernon
Yeh, Robert W.
Feldman, Dmitriy N.
Gigliotti, Osvaldo S.
Rosenfeld, Kenneth
Duffy, Peter
TI 2016 Revision of the SCAI Position Statement on Public Reporting
SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
ID PERCUTANEOUS CORONARY INTERVENTION; CARDIOVASCULAR DATA REGISTRY; ACUTE
MYOCARDIAL-INFARCTION; MORTALITY RISK PREDICTION; COLLEGE-OF-CARDIOLOGY;
AMERICAN-COLLEGE; NEW-YORK; CARDIOGENIC-SHOCK; CARDIAC-SURGERY;
UNITED-STATES
C1 [Klein, Lloyd W.] Rush Med Coll, Chicago, IL USA.
[Harjai, Kishore J.] Geisinger Med Clin, Wilkes Barre, PA USA.
[Resnic, Fred] Lahey Hosp & Med Ctr, Burlington, MA USA.
[Resnic, Fred] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Weintraub, William S.] Christiana Care Hlth Syst, Newark, DC USA.
[Anderson, Vernon] Univ Texas, McGovern Med Sch, Hlth Sci Ctr Houston, Houston, TX USA.
[Yeh, Robert W.] Beth Israel Deaconess Med Ctr, Smith Ctr Outcomes Res Cardiol, Boston, MA USA.
[Feldman, Dmitriy N.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
[Gigliotti, Osvaldo S.] Seton Heart Inst, Austin, TX USA.
[Rosenfeld, Kenneth] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA.
[Duffy, Peter] First Hlth, Pinehurst, NC USA.
RP Klein, LW (reprint author), FSCAI, 3000 North Halsted Suite 625, Chicago, IL 60614 USA.
EM lloydklein@comcast.net
NR 40
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1522-1946
EI 1522-726X
J9 CATHETER CARDIO INTE
JI Catheter. Cardiovasc. Interv.
PD FEB 1
PY 2017
VL 89
IS 2
BP 269
EP 279
DI 10.1002/ccd.26818
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EM9WL
UT WOS:000395662000018
PM 27755653
ER
PT J
AU Liu, X
Lieberman, J
AF Liu, Xing
Lieberman, Judy
TI How ICE lights the pyroptosis fire
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Editorial Material
ID HOST-CELL DEATH; NONCANONICAL INFLAMMASOME ACTIVATION; GASDERMIN-D;
INTRACELLULAR LPS; CASPASE-11; GSDMD; PORE; SALMONELLA; MECHANISM;
FAMILY
C1 [Liu, Xing; Lieberman, Judy] Harvard Med Sch, Program Cellular & Mol Med, Childrens Hosp, 200 Longwood Ave,Warren Alpert Bldg 255, Boston, MA 02115 USA.
[Liu, Xing; Lieberman, Judy] Harvard Med Sch, Dept Pediat, 200 Longwood Ave,Warren Alpert Bldg 255, Boston, MA 02115 USA.
RP Lieberman, J (reprint author), Harvard Med Sch, Program Cellular & Mol Med, Childrens Hosp, 200 Longwood Ave,Warren Alpert Bldg 255, Boston, MA 02115 USA.; Lieberman, J (reprint author), Harvard Med Sch, Dept Pediat, 200 Longwood Ave,Warren Alpert Bldg 255, Boston, MA 02115 USA.
EM Judy.Lieberman@childrens.harvard.edu
NR 19
TC 0
Z9 0
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD FEB
PY 2017
VL 24
IS 2
BP 197
EP 199
DI 10.1038/cdd.2016.157
PG 3
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA EN1SE
UT WOS:000395789500003
PM 28060375
ER
PT J
AU Norberg, E
Lako, A
Chen, PH
Stanley, IA
Zhou, F
Ficarro, SB
Chapuy, B
Chen, LF
Rodig, S
Shin, D
Choi, DW
Lee, S
Shipp, MA
Marto, JA
Danial, NN
AF Norberg, Erik
Lako, Ana
Chen, Pei-Hsuan
Stanley, Illana A.
Zhou, Feng
Ficarro, Scott B.
Chapuy, Bjoern
Chen, Linfeng
Rodig, Scott
Shin, Donghyuk
Choi, Dong Wook
Lee, Sangho
Shipp, Margaret A.
Marto, Jarrod A.
Danial, Nika N.
TI Differential contribution of the mitochondrial translation pathway to
the survival of diffuse large B-cell lymphoma subsets
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID NON-HODGKIN-LYMPHOMA; OXIDATIVE STRESS; COMPLEX-I; CANCER METABOLISM;
MASS-SPECTROMETRY; PROTEIN-SYNTHESIS; FUEL CHOICE; TIGECYCLINE;
EXPRESSION; ORGANIZATION
AB Diffuse large B-cell lymphomas (DLBCLs) are a highly heterogeneous group of tumors in which subsets share molecular features revealed by gene expression profiles and metabolic fingerprints. While B-cell receptor (BCR)-dependent DLBCLs are glycolytic, OxPhos-DLBCLs rely on mitochondrial energy transduction and nutrient utilization pathways that provide pro-survival benefits independent of BCR signaling. Integral to these metabolic distinctions is elevated mitochondrial electron transport chain (ETC) activity in OxPhos-DLBCLs compared with BCR-DLBCLs, which is linked to greater protein abundance of ETC components. To gain insights into molecular determinants of the selective increase in ETC activity and dependence on mitochondrial energy metabolism in OxPhos-DLBCLs, we examined the mitochondrial translation pathway in charge of the synthesis of mitochondrial DNA encoded ETC subunits. Quantitative mass spectrometry identified increased expression of mitochondrial translation factors in OxPhos-DLBCL as compared with the BCR subtype. Biochemical and functional assays indicate that the mitochondrial translation pathway is required for increased ETC activity and mitochondrial energy reserves in OxPhos-DLBCL. Importantly, molecular depletion of several mitochondrial translation proteins using RNA interference or pharmacological perturbation of the mitochondrial translation pathway with the FDA-approved inhibitor tigecycline (Tigecyl) is selectively toxic to OxPhos-DLBCL cell lines and primary tumors. These findings provide additional molecular insights into the metabolic characteristics of OxPhos-DLBCLs, and mark the mitochondrial translation pathway as a potential therapeutic target in these tumors.
C1 [Norberg, Erik; Lako, Ana; Chen, Pei-Hsuan; Stanley, Illana A.; Zhou, Feng; Ficarro, Scott B.; Choi, Dong Wook; Marto, Jarrod A.; Danial, Nika N.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Zhou, Feng; Ficarro, Scott B.; Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02115 USA.
[Chapuy, Bjoern; Chen, Linfeng; Shipp, Margaret A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Rodig, Scott; Marto, Jarrod A.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Shin, Donghyuk; Lee, Sangho] Sungkyunkwan Univ, Dept Biol Sci, Suwon 16419, South Korea.
RP Danial, NN (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave,CLSB 11-143, Boston, MA 02115 USA.
EM nika_danial@dfci.harvard.edu
FU US National Institutes of Health [R21 CA178860]; V Foundation for Cancer
Research [F31 CA171400]; Swedish Society for Medical Research (SSMF);
Malin and Lennart Philipson Foundation; Dana-Farber Cancer Institute
Strategic Research Initiative; [CA188881]
FX We thank Elaura Patton, Meghan Tedoldi, and Heather Sun for technical
assistance, Rebecca Acin-Perez and Jose Antonio Enriquez for advice on
mitochondrial supercomplexes, and Benjamin Szlyk for graphics. This work
was supported by the US National Institutes of Health grants R21
CA178860 (NND and JAM), V Foundation for Cancer Research (NND and MAS),
F31 CA171400 (IAS), the Swedish Society for Medical Research (SSMF), and
The Malin and Lennart Philipson Foundation (EN). We also acknowledge
generous support provided through the Dana-Farber Cancer Institute
Strategic Research Initiative and CA188881 (JAM).
NR 60
TC 1
Z9 1
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD FEB
PY 2017
VL 24
IS 2
BP 251
EP 262
DI 10.1038/cdd.2016.116
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA EN1SE
UT WOS:000395789500008
PM 27768122
ER
PT J
AU Rockette-Wagner, B
Storti, KL
Edelstein, S
Delahanty, LM
Galvin, B
Jackson, A
Kriska, AM
AF Rockette-Wagner, Bonny
Storti, Kristi L.
Edelstein, Sharon
Delahanty, Linda M.
Galvin, Bryan
Jackson, Alexandra
Kriska, Andrea M.
TI Measuring Physical Activity and Sedentary Behavior in Youth with Type 2
Diabetes
SO CHILDHOOD OBESITY
LA English
DT Article
ID ACTIVITY RECALL; COMPUTER-SCIENCE; OLDER-ADULTS; SELF-REPORT; US ADULTS;
VALIDITY; CHILDREN; ACCELEROMETER; ADOLESCENTS; HEALTH
AB Background: Lifestyle interventions that encourage increasing physical activity (PA) and losing weight are critical for overweight and obese youth with comorbid conditions. Assessing PA within such lifestyle intervention efforts requires measurement tool(s) that are both accurate and appropriate for these youth. This research compares PA levels and sedentary behavior in an ethnically diverse cohort of overweight/obese youth with type 2 diabetes using both accelerometry and a questionnaire previously validated in the general youth population.
Methods: Spearman's correlations were used to compare time spent sedentary and in different PA intensities between a questionnaire, the three-day PA recall (3DPAR), and an objective PA measure, the ActiGraph accelerometer, in 236 overweight/obese youth with diabetes.
Results: Spearman correlations between 3DPAR and accelerometer results for total PA were small and not significant (rho=0.11, p >0.05 for males and females). Correlations for specific PA intensities (moderate/vigorous and light) were also small and not significant. Sedentary time between instruments was significant, but weakly correlated in females (rho=0.19, p<0.05), but not in males (rho=0.07, p=0.48).
Conclusions: Subjective PA measures validated in the general youth population may not be the best method for differentiating levels of movement in overweight/obese youth with type 2 diabetes, who spend most of their time in light-intensity activity and sedentary pursuits with little or no time spent in moderate/vigorous-intensity activities. Objective measures such as accelerometers that can capture the lower end of the movement scale are likely the more appropriate measures under these conditions.
C1 [Rockette-Wagner, Bonny; Storti, Kristi L.; Kriska, Andrea M.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA.
[Edelstein, Sharon] George Washington Univ, Biostat Ctr, Washington, DC USA.
[Delahanty, Linda M.] Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA.
[Delahanty, Linda M.] Harvard Med Sch, Boston, MA USA.
[Galvin, Bryan] Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA USA.
[Jackson, Alexandra] Washington Univ, St Louis, MO USA.
RP Rockette-Wagner, B (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, 3512 Fifth Ave,Room 305, Pittsburgh, PA 15261 USA.
EM bjr26@pitt.edu
FU NIDDK/NIH [U01-DK61212, U01-DK61230, U01-DK61239, U01DK61242,
U01-DK61254]; National Center for Research Resources (NCRR)
[M01-RR00036, M01-RR00043-45, M01-RR00069, M01-RR00084, M01-RR01066,
M01-RR00125, M01-RR14467]; NCRR Clinical and Translational Science
Awards [UL1-RR024134, UL1-RR024139, UL1-RR024153, UL1-RR024989,
UL1-RR024992, UL1-RR025758, UL1-RR025780]
FX The authors would like to acknowledge the youth and their families who
participated in this important endeavor and the staff of TODAY for their
devotion and hard work. This work was completed with funding from
NIDDK/NIH (grant numbers U01-DK61212, U01-DK61230, U01-DK61239,
U01DK61242, and U01-DK61254); from the National Center for Research
Resources (NCRR) General Clinical Research Centers Program [grant
numbers M01-RR00036 (Washington University School of Medicine),
M01-RR00043-45 (Children's Hospital Los Angeles), M01-RR00069
(University of Colorado Denver), M01-RR00084 (Children's Hospital of
Pittsburgh), M01-RR01066 (Massachusetts General Hospital), M01-RR00125
(Yale University), and M01-RR14467 (University of Oklahoma Health
Sciences Center)]; and from the NCRR Clinical and Translational Science
Awards [grant numbers UL1-RR024134 (Children's Hospital of
Philadelphia), UL1-RR024139 (Yale University), UL1-RR024153 (Children's
Hospital of Pittsburgh), UL1-RR024989 (Case Western Reserve University),
UL1-RR024992 (Washington University), UL1-RR025758 (Massachusetts
General Hospital), and UL1-RR025780 (University of Colorado Denver)].
NR 37
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2153-2168
EI 2153-2176
J9 CHILD OBES
JI Child Obes.
PD FEB
PY 2017
VL 13
IS 1
BP 72
EP 77
DI 10.1089/chi.2015.0151
PG 6
WC Pediatrics
SC Pediatrics
GA EL3FQ
UT WOS:000394505400009
PM 26859798
ER
PT J
AU Dudzinski, DM
Giri, J
Rosenfield, K
AF Dudzinski, David M.
Giri, Jay
Rosenfield, Kenneth
TI Interventional Treatment of Pulmonary Embolism
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE catheter; percutaneous; pulmonary embolism; team-based care;
thrombolysis
ID VENA-CAVA FILTERS; DEEP-VEIN THROMBOSIS; PULSELESS ELECTRICAL-ACTIVITY;
RIGHT HEART; INTRACRANIAL HEMORRHAGE; RHEOLYTIC THROMBECTOMY;
PLASMINOGEN-ACTIVATOR; CARDIOGENIC-SHOCK; EUROPEAN-SOCIETY; TRAUMA
PATIENTS
AB Pulmonary embolism (PE) is a serious and prevalent cause of vascular disease. Nevertheless, optimal treatment for many phenotypes of PE remains uncertain. Treating PE requires appropriate risk stratification as a first step. For the highest-risk PE, presenting as shock or arrest, emergent systemic thrombolysis or embolectomy is reasonable, while for low-risk PE, anticoagulation alone is often chosen. Normotensive patients with PE but with indicia of right heart dysfunction (by biomarkers or imaging) constitute an intermediate-risk group for whom there is controversy on therapeutic strategy. Some intermediate-risk patients with PE may require urgent stabilization, and approximate to 10% will decompensate hemodynamically and suffer high mortality, though identifying these specific patients remains challenging. Systemic thrombolysis is a consideration, but its risks of major and intracranial hemorrhages rival overall harms from intermediate PE. Multiple hybrid pharmacomechanical approaches have been devised to capture the benefits of thrombolysis while reducing its risks, but there is limited aggregate clinical experience with such novel interventional strategies. One method to counteract uncertainty and generate a consensus multidisciplinary prognostic and therapeutic plan is through a Pulmonary Embolism Response Team, which combines expertise from interventional cardiology, interventional radiology, cardiac surgery, cardiac imaging, and critical care. Such a team can help determine which intervention-catheter-directed fibrinolysis, ultrasound-assisted thrombolysis, percutaneous mechanical thrombus fragmentation, or percutaneous or surgical embolectomy-is best suited to a particular patient. This article reviews these various modalities and the background for each.
C1 [Dudzinski, David M.; Rosenfield, Kenneth] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Rosenfield, Kenneth] Massachusetts Gen Hosp, Vasc Med, Boston, MA 02114 USA.
[Giri, Jay] Hosp Univ Penn, Div Cardiovasc Med, 3400 Spruce St, Philadelphia, PA 19104 USA.
RP Dudzinski, DM (reprint author), Massachusetts Gen Hosp, Yawkey 5B,55 Fruit St, Boston, MA 02115 USA.
EM ddudzinski@partners.org
FU St Jude Medical; Abbott Vascular; Cardinal Health; Surmodics; Inari
Medical; Volcano/Philips; Eximo; Capture Vascular; Silk Road; University
of Maryland; VIVA; Atrium/Maquet; Lutonix/Bard; National Institutes of
Health
FX Dr Giri reports research funding to the institution from St Jude
Medical. Dr Rosenfield reports personal fees from Abbott Vascular,
Cardinal Health, Surmodics, Inari Medical, Volcano/Philips, Eximo,
Capture Vascular, Silk Road, University of Maryland, and VIVA Physicians
(a 501c3 educational organization); stock options from Contego,
Embolitech, Shockwave, MD Insider, Valcare, Eximo, Micell, Endospan, and
Silk Road; equity from MD Insider, Janacare, Primacea, PQ Bypass,
Vortex, and Cruzar Systems; and grants from Atrium/Maquet, Lutonix/Bard,
National Institutes of Health. Dr Dudzinski reports no conflicts.
NR 75
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-7640
EI 1941-7632
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD FEB
PY 2017
VL 10
IS 2
AR e004345
DI 10.1161/CIRCINTERVENTIONS.116.004345
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EL3TN
UT WOS:000394542300005
ER
PT J
AU Sarma, A
O'Donoghue, ML
AF Sarma, Amy
O'Donoghue, Michelle L.
TI Conundrums of Platelet Function Testing Does Sex Matter?
SO CIRCULATION-CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
DE Editorials; acute coronary syndrome; platelet aggregation; platelet
function tests; sex
ID PERCUTANEOUS CORONARY INTERVENTION; CLOPIDOGREL-TREATED PATIENTS;
RESPONSE VARIABILITY; ANTIPLATELET THERAPY; REACTIVITY; METAANALYSIS;
THROMBOSIS; OUTCOMES; DISEASE; VARIANT
C1 [Sarma, Amy] Massachusetts Gen Hosp, Div Cardiovasc, Boston, MA 02114 USA.
[O'Donoghue, Michelle L.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 60 Fenwood Rd,7th Floor, Boston, MA 02115 USA.
RP O'Donoghue, ML (reprint author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 60 Fenwood Rd,7th Floor, Boston, MA 02115 USA.
EM modonoghue@partners.org
NR 20
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-7640
EI 1941-7632
J9 CIRC-CARDIOVASC INTE
JI Circ.-Cardiovasc. Interv.
PD FEB
PY 2017
VL 10
IS 2
AR e004872
DI 10.1161/CIRCINTERVENTIONS.117.004872
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EL3TN
UT WOS:000394542300014
ER
PT J
AU Sepucha, KR
Wasfy, JH
AF Sepucha, Karen R.
Wasfy, Jason H.
TI Implementing Shared Decision Making in the Rapidly Evolving Field of
Valvular Heart Disease
SO CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
LA English
DT Editorial Material
DE Editorials; anxiety; chest pain; coronary disease; decision making;
surgeons
ID ASSOCIATION TASK-FORCE; RANDOMIZED-TRIAL; AMERICAN-COLLEGE; GUIDELINE;
AID
C1 [Sepucha, Karen R.] Harvard Med Sch, Massachusetts Gen Hosp, Div Gen Internal Med, Hlth Decis Sci Ctr, Boston, MA USA.
[Wasfy, Jason H.] Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA USA.
RP Sepucha, KR (reprint author), MGH, Hlth Decis Sci Ctr, 50 Staniford St,Suite 802, Boston, MA 02114 USA.
EM ksepucha@mgh.harvard.edu
FU Informed Medical Decisions Foundation
FX Dr Sepucha receives salary support as a medical editor from the Informed
Medical Decisions Foundation, which is now a part of Healthwise, a
not-for-profit foundation that develops and distributes patient
education and decision support materials. Dr Wasfy reports no conflicts.
NR 19
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-7705
EI 1941-7713
J9 CIRC-CARDIOVASC QUAL
JI Circ.-Cardiovasc. Qual. Outcomes
PD FEB
PY 2017
VL 10
IS 2
AR UNSP e003549
DI 10.1161/CIRCOUTCOMES.117.003549
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EL4CP
UT WOS:000394569400019
ER
PT J
AU Spahillari, A
Talegawkar, S
Correa, A
Carr, JJ
Terry, JG
Lima, J
Freedman, JE
Das, S
Kociol, R
de Ferranti, S
Mohebali, D
Mwasongwe, S
Tucker, KL
Murthy, VL
Shah, RV
AF Spahillari, Aferdita
Talegawkar, Sameera
Correa, Adolfo
Carr, J. Jeffrey
Terry, James G.
Lima, Joao
Freedman, Jane E.
Das, Saumya
Kociol, Robb
de Ferranti, Sarah
Mohebali, Donya
Mwasongwe, Stanford
Tucker, Katherine L.
Murthy, Venkatesh L.
Shah, Ravi V.
TI Ideal Cardiovascular Health, Cardiovascular Remodeling, and Heart
Failure in Blacks The Jackson Heart Study
SO CIRCULATION-HEART FAILURE
LA English
DT Article
DE blood pressure; body mass index; heart failure; hypertension; risk
factors
ID LEFT-VENTRICULAR MASS; ATTRIBUTABLE RISKS; AFRICAN-AMERICANS;
ATHEROSCLEROSIS; ASSOCIATION; DISEASE; ALDOSTERONE; PREVALENCE; COHORT;
ETHNICITY
AB Background-The lifetime risk of heart failure (HF) is higher in the black population than in other racial groups in the United States.
Methods and Results-We measured the Life's Simple 7 ideal cardiovascular health metrics in 4195 blacks in the JHS (Jackson Heart Study; 2000-2004). We evaluated the association of Simple 7 metrics with incident HF and left ventricular structure and function by cardiac magnetic resonance (n=1188). Mean age at baseline was 54.4 years (65% women). Relative to 0 to 2 Simple 7 factors, blacks with 3 factors had 47% lower incident HF risk (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.39-0.73; P<0.0001); and those with >= 4 factors had 61% lower HF risk (HR, 0.39; 95% CI, 0.24-0.64; P=0.0002). Higher blood pressure (HR, 2.32; 95% CI, 1.28-4.20; P=0.005), physical inactivity (HR, 1.65; 95% CI, 1.07-2.55; P=0.02), smoking (HR, 2.04; 95% CI, 1.43-2.91; P<0.0001), and impaired glucose control (HR, 1.76; 95% CI, 1.34-2.29; P<0.0001) were associated with incident HF. The age-/sex-adjusted population attributable risk for these Simple 7 metrics combined was 37.1%. Achievement of ideal blood pressure, ideal body mass index, ideal glucose control, and nonsmoking was associated with less likelihood of adverse cardiac remodeling by cardiac magnetic resonance.
Conclusions-Cardiovascular risk factors in midlife (specifically elevated blood pressure, physical inactivity, smoking, and poor glucose control) are associated with incident HF in blacks and represent targets for intensified HF prevention.
C1 [Spahillari, Aferdita; Kociol, Robb] Harvard Med Sch, Div Cardiol, Dept Med, Beth Israel Deaconess Med Ctr, Boston, MA USA.
[Talegawkar, Sameera] George Washington Univ, Milken Inst Sch Publ Hlth, Dept Exercise & Nutr Sci, Washington, DC USA.
[Correa, Adolfo] Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA.
Vanderbilt Univ, Med Ctr, Dept Radiol, Nashville, TN 37232 USA.
[Terry, James G.] Vanderbilt Univ, Dept Radiol, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Terry, James G.] Vanderbilt Univ, Vanderbilt Translat & Clin Cardiovasc Res Ctr, 221 Kirkland Hall, Nashville, TN 37235 USA.
[Lima, Joao] Johns Hopkins Univ, Dept Cardiol, Baltimore, MD USA.
[Freedman, Jane E.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA.
[Das, Saumya; Shah, Ravi V.] Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA USA.
[de Ferranti, Sarah] Childrens Hosp Boston, Dept Pediat, Boston, MA USA.
[Mohebali, Donya] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Mwasongwe, Stanford] Jackson State Univ, Jackson Heart Study, Field Ctr, Jackson, MS USA.
[Tucker, Katherine L.] Univ Massachusetts Lowell, Dept Biomed & Nutr Sci, Lowell, MA USA.
[Murthy, Venkatesh L.] Univ Michigan, Div Cardiovasc Med, Dept Med, Ann Arbor, MI 48109 USA.
RP Shah, RV (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.; Murthy, VL (reprint author), Univ Michigan, 1338 Cardiovasc Ctr, Ann Arbor, MI 48109 USA.
EM vlmurthy@med.umich.edu; rvshah@partners.org
FU National Heart, Lung, and Blood Institute [HHSN268201300046C,
HHSN268201300047C, HHSN268201300048C, HHSN2682013000 49C,
HHSN268201300050C]; National Institute on Minority Health and Health
Disparities; National Institutes of Health [K23HL127099]; American Heart
Association [16SFRN31740000]
FX The JHS is supported by contracts HHSN268201300046C, HHSN268201300047C,
HHSN268201300048C, HHSN2682013000 49C, and HHSN268201300050C from the
National Heart, Lung, and Blood Institute and the National Institute on
Minority Health and Health Disparities. Dr Shah is funded by grants from
the National Institutes of Health (K23HL127099) and the American Heart
Association (16SFRN31740000).
NR 35
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3289
EI 1941-3297
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD FEB
PY 2017
VL 10
IS 2
DI 10.1161/CIRCHEARTFAILURE.116.003682
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EL3LT
UT WOS:000394521300010
ER
PT J
AU Grauballe, MB
Belstrom, D
Ostergaard, JA
Paster, BJ
Schou, S
Flyvbjerg, A
Holmstrup, P
AF Grauballe, M. B.
Belstrom, D.
Ostergaard, J. A.
Paster, B. J.
Schou, S.
Flyvbjerg, A.
Holmstrup, P.
TI Ligature-associated bacterial profiles are linked to type 2 diabetes
mellitus in a rat model and influenced by antibody treatment against
TNF-alpha or RAGE
SO CLINICAL AND EXPERIMENTAL DENTAL RESEARCH
LA English
DT Article
DE anti-RAGE; anti-TNF-alpha; diabetes mellitus; diabetes type 2;
Periodontal disease; Periodontitis; stages
ID CHRONIC PERIODONTITIS; MICROBIAL PROFILES; ORAL MICROBIOME; RODENT
MODELS; INFECTIONS; MICROARRAY; DISEASES; GLUCOSE; HEALTH; PLAQUE
AB There is a bidirectional relationship between periodontal disease (PD) and type 2 diabetes mellitus (T2D). T2D may lead to ecological perturbations in the oral environment, which may facilitate an altered microbiota. However, previous studies have been inconclusive in determining the effect of T2D on oral bacterial profiles. Therefore, we aimed to evaluate the influence of T2D on the ligature-associated bacterial profile in a diabetic rat model with PD and investigated the impact of blocking inflammatory pathways with antibodies targeting either Tumor Necrosis Factor alpha (TNF-alpha) or the receptor of advanced glycation end-products (RAGE). A total of 62 Zucker obese rats (45 T2D) and 17 lean (non-T2D) were divided into 4 treatment groups; lean with PD, obese with PD, obese with PD and anti-TNF-alpha treatment, and obese with PD with anti-RAGE treatment. Periodontal disease was ligature induced. Ligature-associated bacterial profiles were analyzed using Human Oral Microbe Identification Microarray (HOMIM). Ligature-associated bacterial profiles differed between lean and obese rats. Furthermore, treatment with antibodies against TNF-alpha or RAGE had an impact on subgingival bacterial profiles. T2D phenotypes are associated with different ligature-associated bacterial profiles and influenced by treatment with antibodies against TNF-alpha or RAGE.
C1 [Grauballe, M. B.; Holmstrup, P.] Aarhus Univ, Fac Hlth, Sect Periodontol, Dept Dent, Vennelyst Blvd 9, DK-8000 Aarhus C, Denmark.
[Belstrom, D.; Holmstrup, P.] Univ Copenhagen, Fac Hlth & Med Sci, Sect Periodontol Microbiol & Community Dent, Dept Odontol, Copenhagen N, Denmark.
[Ostergaard, J. A.; Flyvbjerg, A.] Aarhus Univ, Fac Hlth, Dept Clin Med, Med Res Labs, Aarhus C, Denmark.
[Ostergaard, J. A.; Flyvbjerg, A.] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus C, Denmark.
[Ostergaard, J. A.; Flyvbjerg, A.] Danish Diabet Acad, Odense, Denmark.
[Paster, B. J.] Forsyth Inst, Dept Microbiol, Cambridge, MA USA.
[Paster, B. J.] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA USA.
[Schou, S.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Odontol, Sect Oral Surg & Oral Pathol, Copenhagen N, Denmark.
[Flyvbjerg, A.] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus, Denmark.
RP Grauballe, MB (reprint author), Aarhus Univ, Fac Hlth, Sect Periodontol, Dept Dent, Vennelyst Blvd 9, DK-8000 Aarhus C, Denmark.
EM mcbg@sund.ku.dk
FU Danish Medical Research Council; Horslev-Fonden; Simon Spies Foundation;
Danish Dental Association; Danish Diabetes Association; Danish Diabetes
Academy; Novo Nordisk Foundation
FX Danish Medical Research Council; Horslev-Fonden; The Simon Spies
Foundation; The Danish Dental Association; The Danish Diabetes
Association; Danish Diabetes Academy; Novo Nordisk Foundation
NR 36
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2057-4347
J9 CLIN EXP DENT RES
JI CLIN. EXP. DENT. RES.
PD FEB
PY 2017
VL 3
IS 1
BP 25
EP 31
DI 10.1002/cre2.54
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA EM0IM
UT WOS:000395002000005
PM 28344834
ER
PT J
AU Kedrin, D
Gandhi, SCC
Wolf, M
Roper, J
Yilmaz, O
Corey, K
Khalili, H
Stanford, FC
Gala, M
AF Kedrin, Dmitriy
Gandhi, Shaan-Chirag Chandrahas
Wolf, Molly
Roper, Jatin
Yilmaz, Omer
Corey, Kathleen
Khalili, Hamed
Stanford, Fatima Cody
Gala, Manish
TI Bariatric Surgery Prior to Index Screening Colonoscopy Is Associated
With a Decreased Rate of Colorectal Adenomas in Obese Individuals
SO CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY
LA English
DT Article
ID BODY-MASS INDEX; GASTRIC BYPASS-SURGERY; WEIGHT CHANGE; CANCER RISK;
METAANALYSIS; MECHANISMS; MORTALITY; ADIPONECTIN; NUTRITION; COHORT
AB OBJECTIVES: Obesity is an important risk factor for the development of colorectal cancer (CRC). Although the impact of bariatric surgery on CRC is conflicting, its impact on precursor lesions is unknown. The aim of this study was to determine whether bariatric surgery before index screening colonoscopy is associated with decreased development of colorectal adenomas.
METHODS: We performed a retrospective cohort study of bariatric surgery patients who had undergone index, screening colonoscopy at an academic center from 2001 to 2014. Patients who had bariatric surgery at least 1 year before index colonoscopy were compared with those who had surgery after colonoscopy, using multivariable logistic regression to control for presurgical body mass index, sex, gender, race, type of surgery, aspirin use, metformin use, smoking, and age at colonoscopy.
RESULTS: One hundred and twenty-five obese individuals who had bariatric surgery before colonoscopy were compared with 223 individuals who had colonoscopy after surgery. Adenomatous polyps were found in 16.8% of individuals who had surgery first vs. 35.5% who had colonoscopy before bariatric surgery (unadjusted odds ratio (OR) 0.37, 95% confidence interval (CI): 0.21-0.64, P=0.0003). After multivariable adjustment, bariatric surgery before index screening colonoscopy was associated with a decreased risk of adenomas at index colonoscopy (adjusted OR 0.37, 95% CI: 0.19-0.69, P=0.002).
CONCLUSIONS: Bariatric surgery is associated with a decreased risk of colorectal adenomas in obese individuals without a family history of CRC.
C1 [Kedrin, Dmitriy; Gandhi, Shaan-Chirag Chandrahas; Wolf, Molly; Corey, Kathleen; Khalili, Hamed; Gala, Manish] Massachusetts Gen Hosp, Div Gastroenterol, 55 Fruit St,GRJ 825-D, Boston, MA 02114 USA.
[Kedrin, Dmitriy; Gandhi, Shaan-Chirag Chandrahas; Wolf, Molly; Corey, Kathleen; Khalili, Hamed; Gala, Manish] Harvard Med Sch, 55 Fruit St,GRJ 825-D, Boston, MA 02114 USA.
[Kedrin, Dmitriy; Roper, Jatin; Yilmaz, Omer] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Gandhi, Shaan-Chirag Chandrahas; Wolf, Molly] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Roper, Jatin] Tufts Med Ctr, Div Gastroenterol, Boston, MA USA.
[Corey, Kathleen; Stanford, Fatima Cody] Massachusetts Gen Hosp, Massachusetts Gen Weight Ctr, Boston, MA 02114 USA.
[Stanford, Fatima Cody] Dept Pediat, Div Endocrinol, Boston, MA USA.
RP Gala, M (reprint author), Massachusetts Gen Hosp, Div Gastroenterol, 55 Fruit St,GRJ 825-D, Boston, MA 02114 USA.; Gala, M (reprint author), Harvard Med Sch, 55 Fruit St,GRJ 825-D, Boston, MA 02114 USA.
EM mgala@mgh.harvard.edu
FU National Institutes of Health [T32 DK007191, R00 AG045144, K23
DK103119]; American College of Gastroenterology
FX This study was supported by the National Institutes of Health (T32
DK007191 to D. K.; R00 AG045144 to H. Y; K23 DK103119 to M. G.) and the
American College of Gastroenterology (Junior Faculty Development Award
to M. G.). Potential competing interests: M. G. has equity interest in
New Amsterdam Genomics.
NR 31
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2155-384X
J9 CLIN TRANSL GASTROEN
JI Clin. Transl. Gastroenterol.
PD FEB
PY 2017
VL 8
AR e73
DI 10.1038/ctg.2017.1
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EP0ZK
UT WOS:000397115000001
PM 28181993
ER
PT J
AU Giugliano, RP
Mach, F
Zavitz, K
Kurtz, C
Schneider, J
Wang, H
Keech, A
Pedersen, TR
Sabatine, MS
Sever, PS
Honarpour, N
Wasserman, SM
Ott, BR
AF Giugliano, Robert P.
Mach, Francois
Zavitz, Kenton
Kurtz, Christopher
Schneider, Jingjing
Wang, Huei
Keech, Anthony
Pedersen, Terje R.
Sabatine, Marc S.
Sever, Peter S.
Honarpour, Narimon
Wasserman, Scott M.
Ott, Brian R.
CA EBBINGHAUS Investigators
TI Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind,
placebo-controlled, multicenter study to assess the effect of evolocumab
on cognitive function in patients with clinically evident cardiovascular
disease and receiving statin background lipid-lowering therapyA
cognitive study of patients enrolled in the FOURIER trial
SO CLINICAL CARDIOLOGY
LA English
DT Article
DE Lipid; Clinical trials; Preventive cardiology; Lipidology; Ischemic
heart disease
ID SERUM-CHOLESTEROL; ALZHEIMERS-DISEASE; REDUCING LIPIDS; METAANALYSIS;
ASSOCIATION; PCSK9; RISK; DEMENTIA; PERFORMANCE; EVENTS
AB Some observational studies raised concern that statins may cause memory impairment, leading to a US Food and Drug Administration warning. Similar questions were raised regarding proprotein convertase subtilisin/kexin-type 9 inhibitors (PCSK9i) and neurocognitive function. No prospectively designed study has evaluated the relationship between long-term PCSK9i use and cognition changes. Patients with prior cardiovascular disease treated with maximally tolerated statin enrolled in FOURIER (the randomized, double-blind, placebo-controlled cardiovascular outcome study of the PCSK9i evolocumab) could participate in this prospective assessment of cognitive function (EBBINGHAUS). Key additional exclusion criteria for EBBINGHAUS were dementia, cognitive impairment, or other significant mental or neurological disorder. Cognitive testing was performed using the Cambridge Neuropsychological Test Automated Battery, a tablet-based tool assessing executive function, working memory, memory function, and psychomotor speed at baseline, weeks 24 and 48, every 48 weeks thereafter, and study end. The primary endpoint was spatial working memory strategy index of executive function (SWMSI). The primary hypothesis was that evolocumab would be noninferior to placebo in the mean change from baseline over time in SWMSI. Fifteen hundred cognitively normal patients completing the assessments provided approximately 97% power to demonstrate that the upper 95% confidence interval for the treatment difference in mean change from baseline in SWMSI over time is <20% of the SD of the mean change in the placebo group. An exploratory analysis will compare neurocognitive function in patients with post-baseline low-density lipoprotein cholesterol <25 mg/dL. EBBINGHAUS will evaluate whether the addition of evolocumab to statin therapy affects cognitive function over time in patients with stable cardiovascular disease.
C1 [Giugliano, Robert P.; Sabatine, Marc S.] Brigham & Womens Hosp, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.
[Mach, Francois] Univ Hosp Geneva, Cantonal Hosp, Div Cardiol, Geneva, Switzerland.
[Zavitz, Kenton] Cambridge Cognit, Cambridge, England.
[Kurtz, Christopher; Schneider, Jingjing; Wang, Huei; Honarpour, Narimon; Wasserman, Scott M.] Amgen Inc, Thousand Oaks, CA USA.
[Keech, Anthony] Univ Sydney, Sydney Med Sch, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia.
[Pedersen, Terje R.] Oslo Univ Hosp, Ctr Prevent Med, Ulleval, Norway.
[Pedersen, Terje R.] Univ Oslo, Fac Med, N-0316 Oslo, Norway.
[Sever, Peter S.] Imperial Coll London, Int Ctr Circulatory Hlth, London, England.
[Ott, Brian R.] Brown Univ, Warren Alpert Med Sch, Dept Neurol, Providence, RI 02912 USA.
RP Giugliano, RP (reprint author), TIMI Study Grp, 350 Longwood Ave,First Floor Off, Boston, MA 02115 USA.
EM rgiugliano@partners.org
FU Amgen; Merck
FX EBBINGHAUS and FOURIER trials were supported by grants from by Amgen to
Dr. Giugliano's institution for the conduct of these studies; Dr.
Giugliano's institution also received research-grant support from Merck
for his participation in another lipid-lowering trial.
NR 46
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-9289
EI 1932-8737
J9 CLIN CARDIOL
JI Clin. Cardiol.
PD FEB
PY 2017
VL 40
IS 2
BP 59
EP 65
DI 10.1002/clc.22678
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EM0WG
UT WOS:000395037800001
PM 28207168
ER
PT J
AU Ho, SB
Monto, A
Peyton, A
Kaplan, DE
Byrne, S
Moon, S
Copans, A
Rossaro, L
Roy, A
Le, H
Dvory-Sobol, H
Zhu, YN
Brainard, DM
Guyer, W
Shaikh, O
Fuchs, M
Morgan, TR
AF Ho, Samuel B.
Monto, Alexander
Peyton, Adam
Kaplan, David E.
Byrne, Sean
Moon, Scott
Copans, Amanda
Rossaro, Lorenzo
Roy, Anupma
Le, Hadley
Dvory-Sobol, Hadas
Zhu, Yanni
Brainard, Diana M.
Guyer, William
Shaikh, Obaid
Fuchs, Michael
Morgan, Timothy R.
CA VALOR Study Team
TI Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus
Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities
SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Article
DE VA; DAA; NS5B Inhibitor; Substance Abuse; Clinical Trial
ID PSYCHIATRIC-ILLNESS; US VETERANS; VELPATASVIR; PREVALENCE; OUTCOMES;
THERAPY; AFFAIRS; ALPHA; CARE
AB BACKGROUND & AIMS: We conducted a phase 4, open-label study with limited exclusion criteria to evaluate the safety and efficacy of sofosbuvir and ribavirin in veterans with hepatitis C virus genotype 2 infection, and compensated cirrhosis. This population is often excluded from clinical studies.
METHODS: We performed a prospective study of treatment-naive (n = 47) and treatment-experienced (n = 19) patients with chronic hepatitis C virus genotype 2 infection and compensated cirrhosis at 15 Department of Veterans Affairs sites. All subjects were given sofosbuvir (400 mg, once daily) plus ribavirin (1000-1200 mg/day) in divided doses for 12 weeks. Patients with major psychiatric diseases or alcohol or substance use disorders were not excluded. The primary endpoint was sustained virologic response 12 weeks after therapy.
RESULTS: Fifty- two patients achieved a sustained virologic response 12 weeks after therapy (79%; 95% confidence interval, 67%-88%); 16 of these patients were treatment experienced (84%; 95% confidence interval, 60%-97%) and 36 were treatment naive (77%; 95% confidence interval, 62%-88%). All patients had at least 1 comorbidity. Thirty-five percent had depression, 24% had posttraumatic stress disorder, and 30% had anxiety disorder. In addition, 29% had current substance use. Of the 7 patients (11%) who discontinued the study treatment prematurely, 3 did so because of adverse events. The most common adverse events were fatigue, anemia, nausea, and headache. Serious adverse events occurred in 8 patients. Only 2 of the serious adverse events (anemia and nausea) were considered to be related to study treatment.
CONCLUSIONS: In a phase 4 study, 12 weeks treatment with sofosbuvir and ribavirin led to a sustained virologic response 12 weeks after therapy in almost 80% of veterans with hepatitis C virus genotype 2 infection, compensated cirrhosis, and multiple comorbidities, regardless of their treatment history. ClinicalTrials. gov, Number: NCT02128542
C1 [Ho, Samuel B.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA.
[Monto, Alexander] San Francisco Vet Affairs Healthcare Syst, San Francisco, CA USA.
[Peyton, Adam] Miami Vet Affairs Healthcare Syst, Miami, FL USA.
[Kaplan, David E.] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA USA.
[Byrne, Sean; Moon, Scott; Copans, Amanda; Rossaro, Lorenzo; Roy, Anupma; Le, Hadley; Dvory-Sobol, Hadas; Zhu, Yanni; Brainard, Diana M.; Guyer, William] Gilead Sci, Foster City, CA USA.
[Shaikh, Obaid] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Fuchs, Michael] Richmond Vet Affairs Med Ctr, Richmond, VA USA.
[Morgan, Timothy R.] Vet Affairs Long Beach Healthcare Syst, Long Beach, CA USA.
RP Ho, SB (reprint author), Vet Affairs San Diego Healthcare Syst, San Diego, CA USA.
EM samuel.ho2@va.gov
FU Gilead Sciences, Inc.
FX Funding for this study was provided by Gilead Sciences, Inc.
NR 20
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1542-3565
EI 1542-7714
J9 CLIN GASTROENTEROL H
JI Clin. Gastroenterol. Hepatol.
PD FEB
PY 2017
VL 15
IS 2
BP 282
EP 288
DI 10.1016/j.cgh.2016.05.024
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EP2XH
UT WOS:000397246400022
PM 27237429
ER
PT J
AU Necchi, A
Pond, GR
Raggi, D
Giannatempo, P
Vogelzang, NJ
Grivas, P
Galsky, MD
Bellmunt, J
Sonpavde, G
AF Necchi, Andrea
Pond, Gregory R.
Raggi, Daniele
Giannatempo, Patrizia
Vogelzang, Nicholas J.
Grivas, Petros
Galsky, Matthew D.
Bellmunt, Joaquim
Sonpavde, Guru
TI Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in
the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic
Review and Meta-Analysis
SO CLINICAL GENITOURINARY CANCER
LA English
DT Review
DE First-line therapy; Meta-analysis; Systemic therapy; Taxanes; Urothelial
carcinoma
ID TRANSITIONAL-CELL CARCINOMA; CISPLATIN-BASED CHEMOTHERAPY;
COOPERATIVE-ONCOLOGY-GROUP; PHASE-II TRIAL; BLADDER-CANCER;
ELDERLY-PATIENTS; PACLITAXEL; THERAPY; UNFIT; COMBINATION
AB Although gemcitabine plus carboplatin (GCa) is the conventional first-line chemotherapy for cisplatin-ineligible metastatic urothelial carcinoma, its results are suboptimal. A meta-analysis evaluated the results of gemcitabine with either carboplatin or a taxane (GT). Literature was searched for studies including GT (paclitaxel or docetaxel) and GCa. We pooled trial level data including response-rate, progression-free survival, overall survival (OS), and Grade 3 to 4 side effects. Trial characteristics and outcomes were univariably compared between GT and GCa. Those factors, which were recorded in > 12 trials, were analyzed. Multivariable regression models were used adjusting for Eastern Cooperative Oncology Group performance status 2 and the presence of visceral metastases. Each trial was weighted by its sample size. Twenty-seven arms of trials totaling 1032 patients were selected, of which 13 contained GT (n = 484) and 14 GCa (n = 548). The percentage of patients with Eastern Cooperative Oncology Group performance status 2 was statistically significantly different between the 2 groups (median, 8.7% vs. 23.9%; P = .003). No efficacy outcome was statistically significantly different. Median OS was 13.2 months (range, 10-15.8 months) for GT and 10 months (range, 3.3-20 months) for GCa (P = .12). However, statistically significant increases in the frequency of Grade 3 to 4 anemia (P = .010) and thrombocytopenia (P = .010) for GCa, and neuropathy (P = .040) for GT were observed. No difference in OS according to treatment was found multivariably (P = .79). In this analysis, a similar response rate and survival and worse neurotoxicity were observed with GT compared with GCa, for which hematologic toxicity was more frequent. GT is an alternative to GCa for advanced cisplatin-ineligible urothelial cancer. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Necchi, Andrea; Raggi, Daniele; Giannatempo, Patrizia] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Via G Venezian 1, I-20133 Milan, Italy.
[Pond, Gregory R.] McMaster Univ, Hamilton, ON, Canada.
[Vogelzang, Nicholas J.] US Oncol Res, Comprehens Ctr Nevada, Dev Therapeut Comm, Las Vegas, NV USA.
[Vogelzang, Nicholas J.] US Oncol Res, Comprehens Ctr Nevada, Co Chair Genitourinary Comm, Las Vegas, NV USA.
[Grivas, Petros] Cleveland Clin, Taussig Canc Inst, Hematol & Oncol, Cleveland, OH USA.
[Galsky, Matthew D.] Mt Sinai Sch Med, Tisch Canc Inst, Genitourinary Med Oncol, New York, NY USA.
[Bellmunt, Joaquim] Dana Farber Canc Inst, Bladder Canc Ctr, Boston, MA USA.
[Sonpavde, Guru] Harvard Med Sch, Boston, MA USA.
[Sonpavde, Guru] UAB Comprehens Canc Ctr, Med Oncol & Hematol, Birmingham, AL USA.
RP Necchi, A (reprint author), Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Via G Venezian 1, I-20133 Milan, Italy.
EM andrea.necchi@istitutotumori.mi.it
NR 46
TC 1
Z9 1
U1 0
U2 0
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1558-7673
EI 1938-0682
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD FEB
PY 2017
VL 15
IS 1
BP 23
EP 30
DI 10.1016/j.clgc.2016.05.003
PG 8
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA EL5AF
UT WOS:000394633100003
PM 27324051
ER
PT J
AU Buisan, O
Orsola, A
Areal, J
Font, A
Oliveira, M
Martinez, R
Ibarz, L
AF Buisan, Oscar
Orsola, Anna
Areal, Joan
Font, Albert
Oliveira, Mario
Martinez, Roberto
Ibarz, Luis
TI Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good
Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical
Cystectomy for Muscle Invasive Bladder Cancer
SO CLINICAL GENITOURINARY CANCER
LA English
DT Article
DE MIBC; Neoadjuvant therapy; NLR; RC; Urothelial cancer
ID CISPLATIN-BASED CHEMOTHERAPY; UROTHELIAL CELL-CARCINOMA;
NEUTROPHIL/LYMPHOCYTE RATIO; CLINICAL-OUTCOMES; GENE-EXPRESSION;
PROGNOSIS
AB Low pretreatment neutrophil-to-lymphocyte ratio might indicate good outcomes after neoadjuvant chemotherapy in muscle invasive bladder cancer. These findings, combined with established risk factors and novel genetic and molecular predictors, should result in an easily available and inexpensive method to improve risk stratification and decision-making regarding neoadjuvant chemotherapy for muscle invasive bladder cancer. Purpose: The pretreatment neutrophil-to-lymphocyte ratio (NLR) has been associated with cancer prognosis, influencing progression and chemosensitivity. We aimed to define the role of the NLR in predicting the outcomes to neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC). Patients and Methods: The data from patients treated with NAC and radical cystectomy for MIBC from 2007 to 2015 at a tertiary care center were reviewed. The clinicopathologic pretreatment, including the NLR, and post-treatment predictors were documented. The NLR was evaluated as a continuous variable on uni- and multivariate analysis and dichotomized in Kaplan-Meier curves. The relationships with outcomes (progression-free survival [PFS], cancer-specific survival [CSS], and overall survival [OS]) were analyzed using Cox regression analysis and log-rank tests. The pathologic response (PR) included any downstaging from the baseline clinical stage to the final pathologic stage. Results: Of 205 patients with MIBC, 75 underwent NAC (median follow-up, 31 months) with a 5-year PFS, CSS, and OS rate of 56%, 60%, and 52%, respectively, and a PR of 38.6%. On multivariate analysis, the PR, PFS, CSS, and OS were predicted by the NLR (hazard ratio > 0.8, 1.25, 1.27, and 1.12, respectively; P < .05 for all). The NLR with age and clinical stage predicted the PR. A NLR threshold of 2.26 better predicted CSS (P < .05) and OS (P = .055). The limitations included the retrospective design and modest number of cases. Conclusion: We have provided initial evidence that a low NLR helps understand the value of the underlying immune system in predicting a good outcome to NAC. The NLR is a simple and accessible biomarker that is easy to implement in clinical practice. In addition to established prognosticators and newer genomic predictors, the NLR could improve therapeutic algorithms and help in decision-making regarding the need for NAC, which is currently underused, in MIBC patients.
C1 [Buisan, Oscar; Areal, Joan; Oliveira, Mario; Martinez, Roberto; Ibarz, Luis] Hosp Badalona Germans Trias & Pujol, Dept Urol, Barcelona, Spain.
[Buisan, Oscar; Areal, Joan; Font, Albert; Oliveira, Mario; Martinez, Roberto; Ibarz, Luis] Autonomous Univ Barcelona, Barcelona, Spain.
[Orsola, Anna] Dana Farber Canc Inst, Bladder Canc Ctr, 450 Brookline Ave, Boston, MA 02215 USA.
[Font, Albert] Hosp Univ GermansTrias & Pujol, Catalan Inst Oncol, Dept Med, Med Oncol Serv, Barcelona, Spain.
RP Orsola, A (reprint author), Dana Farber Canc Inst, Bladder Canc Ctr, 450 Brookline Ave, Boston, MA 02215 USA.
EM annaorsola@gmail.com
NR 32
TC 0
Z9 0
U1 0
U2 0
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1558-7673
EI 1938-0682
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD FEB
PY 2017
VL 15
IS 1
BP 145
EP 151
DI 10.1016/j.clgc.2016.05.004
PG 7
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA EL5AF
UT WOS:000394633100019
PM 27364982
ER
PT J
AU Scott, JL
Wirth, JR
EuDaly, JG
Gilkeson, GS
Cunningham, MA
AF Scott, Jennifer L.
Wirth, Jena R.
EuDaly, Jackie G.
Gilkeson, Gary S.
Cunningham, Melissa A.
TI Plasmacytoid dendritic cell distribution and maturation are altered in
lupus prone mice prior to the onset of clinical disease
SO CLINICAL IMMUNOLOGY
LA English
DT Article
DE Rodent; Dendritic cells; Autoimmunity; Systemic lupus erythematosus
ID I INTERFERON; PDC-TREM; SIGLEC-H; RECEPTOR; ERYTHEMATOSUS; ALPHA;
AUTOIMMUNITY; EXPRESSION; ANTIGEN-2; IMMUNITY
AB Plasmacytoid dendritic cells (pDCs) and their production of type I interferons (IFN) are key pathogenic mediators of systemic lupus erythematosus (SLE). Despite the key role of pDCs in SLE, the mechanism by which pDCs promote disease is not well understood. The first objective for this study was to assess the number and maturation state of pDCs in pre-disease NZM2410 lupus prone mice compared to control mice. Second, we sought to identify mechanisms responsible for the alteration in pDCs in NZM mice prior to onset of clinical disease. We compared the number and percent of pDCs in the spleens and bone marrow (BM) of pre-disease NZM24010 (NZM) mice to C57BL/6 (B6) control mice. In the spleens of pre-disease NZM mice, pDC percent and number were increased. This increase occurs in parallel with a decrease in BM pDC number and percent in the NZM mice. The decrease in BM pDC number suggests the increase in spleen pDCs is a result of altered pDC distribution and not increased production of pDCs in the BM. To determine if pDC developmental potential is altered in lupus prone mice, we cultured BM from NZM and B6 mice in vitro. We found a reduced percentage/number of pDCs developing from the BM of NZM mice compared to B6 mice, which further supports that the increase in pDC number is a result of altered pDC distribution rather than increased pDC production. To better characterize the pDC population, we compared the percentage of mature pDCs in the spleens and BM of NZM mice to controls. In the NZM mice, there is a dramatic reduction in the number of mature pDCs in the BM of NZM mice, suggesting that mature pDCs exit the BM at a higher rate/earlier maturation time compared to healthy mice. We conclude that pDCs contribution to disease pathogenesis in NZM mice may include the alteration of pDC distribution to increase the number of pDCs in the spleen prior to disease onset. (C) 2016 Published by Elsevier Inc.
C1 [Scott, Jennifer L.] Med Univ South Carolina, Coll Grad Studies, Dept Microbiol & Immunol, 173 Ashley Ave,BSB 203, Charleston, SC 29425 USA.
[Wirth, Jena R.; EuDaly, Jackie G.; Gilkeson, Gary S.; Cunningham, Melissa A.] Med Univ South Carolina, Div Rheumatol & Immunol, Dept Med, 96 Jonathan Lucas St,Suite 816, Charleston, SC 29425 USA.
[Gilkeson, Gary S.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, 109 Bee St, Charleston, SC 29401 USA.
RP Cunningham, MA (reprint author), Med Univ South Carolina, Dept Med, 96 Jonathan Lucas St,Suite 912, Charleston, SC 29425 USA.
EM ScottJL@musc.edu; WirthJ@musc.edu; Eudalyjg@musc.edu; Gilkeson@musc.edu;
Cunnima@musc.edu
FU VA merit review grant [BX000470]; NIH grant [UT1 TR000062]; American
Association of Immunology careers in Immunology Fellowship
FX This work was funded by the VA merit review grant BX000470, the NIH
grant UT1 TR000062, and American Association of Immunology careers in
Immunology Fellowship.
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1521-6616
EI 1521-7035
J9 CLIN IMMUNOL
JI Clin. Immunol.
PD FEB
PY 2017
VL 175
BP 109
EP 114
DI 10.1016/j.clim.2016.12.009
PG 6
WC Immunology
SC Immunology
GA EN4FG
UT WOS:000395962800014
PM 28041989
ER
PT J
AU Mao, Y
De Oliveira, IS
Hedgire, S
Prapruttam, D
Harisinghani, M
AF Mao, Y.
De Oliveira, I. S.
Hedgire, S.
Prapruttam, D.
Harisinghani, M.
TI Aetiology, imaging features, and evolution of spontaneous perirenal
haemorrhage
SO CLINICAL RADIOLOGY
LA English
DT Article
ID RENAL-CELL CARCINOMA; PERINEPHRIC HEMORRHAGE; CT FINDINGS; ABDOMINAL
HEMORRHAGE; KIDNEY-DISEASE; MINIMAL FAT; ANGIOMYOLIPOMA; RUPTURE;
DIFFERENTIATION; MANAGEMENT
AB AIM: To evaluate the aetiology, imaging features, and the evolution of spontaneous perirenal haemorrhage detected by imaging.
MATERIALS AND METHODS: In this retrospective study, the hospital database was searched for all cases of spontaneous perinephric haemorrhage detected by imaging between January 2000 and December 2012. Imaging examinations were reviewed and the following parameters were recorded: the location, extension, and total volume of the haematoma, presence of active extravasation, the haematocrit effect, and highest density. The resolution time was calculated using follow-up imaging. The final aetiology for all cases was assessed via clinical, radiological, and histopathological data. Differences in imaging features of haemorrhage according to aetiology group were analysed with independent samples test and Fisher's exact test.
RESULTS: Eighty-one haematomas were identified in 78 patients during this 13-year period. Causes of perirenal haemorrhage included coagulation disorders (22/81, 27.1%), ruptured renal cyst (11/81, 13.6%), rupture of abdominal aortic aneurysm (9/81, 11.1%), renal cell carcinoma (9/81, 11.1%), adrenal masses (9/ 81, 11.1%), polycystic kidney disease (7/81, 8.6%), angiomyolipoma (6/81, 7.4%), renal vascular diseases (2/81, 2.4%), and recurrent pyelonephritis (1/81, 1.2%). Haematomas associated with coagulation abnormalities and vascular diseases presented with larger volumes and were more likely to extent to the pararenal space more so than other groups; ruptured renal cyst and renal cell carcinomas tended to be more associated with subcapsular haematomas. The haematocrit effect and haemorrhage involving renal parenchyma were more often observed in the group with coagulation abnormalities.
CONCLUSION: Imaging features, such as location and extension, could help radiologists identify possible aetiologies of spontaneous perirenal haemorrhage. (C) 2016 The Royal College of Radiologists.
C1 [Mao, Y.] Chongqing Med Univ, Dept Radiol, 1 Youyi Rd, Chongqing 400061, Peoples R China.
[De Oliveira, I. S.; Prapruttam, D.; Harisinghani, M.] Harvard Med Sch, Massachusetts Gen Hosp, Div Abdominal Imaging, 55 Fruit St, Boston, MA 02114 USA.
[Hedgire, S.] Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiovasc Imaging, 55 Fruit St, Boston, MA 02114 USA.
RP Hedgire, S (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Div Cardiovasc Imaging, 55 Fruit St, Boston, MA 02114 USA.
EM Hedgire.Sandeep@mgh.harvard.edu
NR 27
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0009-9260
EI 1365-229X
J9 CLIN RADIOL
JI Clin. Radiol.
PD FEB
PY 2017
VL 72
IS 2
AR 175.e19
DI 10.1016/j.crad.2016.08.010
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA EP3FP
UT WOS:000397268500015
ER
PT J
AU Cellamare, M
Ventz, S
Baudin, E
Mitnick, CD
Trippa, L
AF Cellamare, Matteo
Ventz, Steffen
Baudin, Elisabeth
Mitnick, Carole D.
Trippa, Lorenzo
TI A Bayesian response-adaptive trial in tuberculosis: The endTB trial
SO CLINICAL TRIALS
LA English
DT Article
DE Tuberculosis; clinical trial; Bayesian analysis; adaptive designs;
preliminary outcomes
ID MULTIDRUG-RESISTANT TUBERCULOSIS; I-SPY 2; CLINICAL-TRIALS; PULMONARY
TUBERCULOSIS; TREATMENT OUTCOMES; PHASE-II; DESIGN; BEDAQUILINE;
RANDOMIZATION; GLIOBLASTOMA
AB Purpose: To evaluate the use of Bayesian adaptive randomization for clinical trials of new treatments for multidrug-resistant tuberculosis.
Methods: We built a response-adaptive randomization procedure, adapting on two preliminary outcomes for tuberculosis patients in a trial with five experimental regimens and a control arm. The primary study outcome is treatment success after 73weeks from randomization; preliminary responses are culture conversion at 8weeks and treatment success at 39weeks. We compared the adaptive randomization design with balanced randomization using hypothetical scenarios.
Results: When we compare the statistical power under adaptive randomization and non-adaptive designs, under several hypothetical scenarios we observe that adaptive randomization requires fewer patients than non-adaptive designs. Moreover, adaptive randomization consistently allocates more participants to effective arm(s). We also show that these advantages are limited to scenarios consistent with the assumptions used to develop the adaptive randomization algorithm.
Conclusion: Given the objective of evaluating several new therapeutic regimens in a timely fashion, Bayesian response-adaptive designs are attractive for tuberculosis trials. This approach tends to increase allocation to the effective regimens.
C1 [Cellamare, Matteo; Ventz, Steffen; Trippa, Lorenzo] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA.
[Cellamare, Matteo; Ventz, Steffen; Trippa, Lorenzo] Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
[Cellamare, Matteo] Sapienza Univ Rome, Dept Stat Sci, I-00185 Rome, Italy.
[Ventz, Steffen] Univ Rhode Isl, Dept Comp Sci & Stat, Kingston, RI 02881 USA.
[Baudin, Elisabeth] Epictr MSF, Dept Clin Res, Paris, France.
[Mitnick, Carole D.] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USA.
[Mitnick, Carole D.] Partners Hlth, Boston, MA USA.
RP Cellamare, M (reprint author), Sapienza Univ Rome, Dept Stat Sci, I-00185 Rome, Italy.
EM matteo.cellamare@uniroma1.it
FU Burroughs Wellcome Fund - Regulatory Science and UNITAID; Claudia Adams
Barr Award
FX This work has been partially funded by Burroughs Wellcome Fund -
Regulatory Science and UNITAID and the Claudia Adams Barr Award.
NR 51
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
EI 1740-7753
J9 CLIN TRIALS
JI Clin. Trials
PD FEB
PY 2017
VL 14
IS 1
BP 17
EP 28
DI 10.1177/1740774516665090
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA EL5HR
UT WOS:000394652700002
PM 27559021
ER
PT J
AU Shaw, PA
Yancy, WS
Wesby, L
Ulrich, V
Troxel, AB
Huffman, D
Foster, GD
Volpp, K
AF Shaw, Pamela A.
Yancy, William S., Jr.
Wesby, Lisa
Ulrich, Victoria
Troxel, Andrea B.
Huffman, David
Foster, Gary D.
Volpp, Kevin
TI The design and conduct of Keep It Off: An online randomized trial of
financial incentives for weight-loss maintenance
SO CLINICAL TRIALS
LA English
DT Article
DE Behavioral economics; financial incentive; obesity; pragmatic trial;
randomized trial; weight-loss maintenance
ID LOW-CARBOHYDRATE; UNITED-STATES; RISK-FACTORS; OBESITY; OVERWEIGHT;
METAANALYSIS; PREVALENCE; PREVENTION; DIETS
AB Background Obesity continues to be a serious public health challenge. Rates are increasing worldwide, with nearly 70% of the US adults overweight or obese, leading to increased clinical and economic burden. While successful approaches for achieving weight loss have been identified, techniques for long-term maintenance of initial weight loss have largely been unsuccessful. Financial incentive interventions have been shown in several settings to be successful in motivating participants to adopt healthy behaviors.
Purpose Keep It Off is a three-arm randomized controlled trial that compares the efficacy of a lottery-based incentive, traditional direct payment incentive, and control of daily feedback without any incentive for weight-loss maintenance. This design allows comparison of a traditional direct payment incentive with one based on behavioral economic principles that consider the underlying psychology of decision-making.
Methods Participants were randomized in a 2:1 ratio for each active arm relative to control, with a targeted 188 participants in total. Eligible participants were those aged 30-80 who lost at least 11lb (5kg) during the first 4months of participation in Weight Watchers, a national weight-loss program, with whom we partnered. The interventions lasted 6months (Phase I); participants were followed for an additional 6months without intervention (Phase II). The primary outcome is weight change from baseline to the end of Phase I, with the change at the end of Phase II a key secondary endpoint. Keep It Off is a pragmatic trial that recruited, consented, enrolled, and followed patients electronically. Participants were provided a wireless weight scale that electronically transmitted daily self-monitored weights. Weights were verified every 3months at a Weight Watchers center local to the participant and electronically transmitted.
Results Using the study web-based platform, we integrated recruitment, enrollment, and follow-up procedures into a digital platform that required little staff effort to implement and manage. We randomized 191 participants in less than 1year. We describe the design of Keep It Off and implementation of enrollment.
Lessons Learned We demonstrated that our pragmatic design was successful in rapid accrual of participants in a trial of interventions to maintain weight loss.
Limitations Despite the nationwide reach of Weight Watchers, the generalizability of study findings may be limited by the characteristics of its members. The interventions under study are appropriate for settings where an entity, such as an employer or health insurance company, could offer them as a benefit.
Conclusions Keep It Off was implemented and conducted with minimal staff effort. This study has the potential to identify a practical and effective weight-loss maintenance strategy.
C1 [Shaw, Pamela A.; Troxel, Andrea B.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, 606 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
[Shaw, Pamela A.; Wesby, Lisa; Ulrich, Victoria; Troxel, Andrea B.; Huffman, David; Volpp, Kevin] Univ Penn, Leonard Davis Inst Hlth Econ, Perelman Sch Med, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Shaw, Pamela A.; Wesby, Lisa; Ulrich, Victoria; Troxel, Andrea B.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA.
[Yancy, William S., Jr.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Yancy, William S., Jr.] US Dept Vet Affairs, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Huffman, David] Univ Oxford, Dept Econ, Oxford, England.
[Foster, Gary D.] Weight Watchers Int, Dept Sci & Innovat, New York, NY USA.
[Foster, Gary D.] Temple Univ, Ctr Obes Res & Educ, Philadelphia, PA USA.
[Volpp, Kevin] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Volpp, Kevin] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Volpp, Kevin] Univ Penn, Wharton Sch, Dept Hlth Care Syst, Philadelphia, PA 19104 USA.
RP Shaw, PA (reprint author), Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, 606 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM shawp@mail.med.upenn.edu
FU National Institute on Aging of the National Institutes of Health
[R01-AG045045]
FX This study was sponsored by the National Institute on Aging of the
National Institutes of Health under award no. R01-AG045045 (Volpp and
Yancy, MPIs).
NR 34
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1740-7745
EI 1740-7753
J9 CLIN TRIALS
JI Clin. Trials
PD FEB
PY 2017
VL 14
IS 1
BP 29
EP 36
DI 10.1177/1740774516669679
PG 8
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA EL5HR
UT WOS:000394652700003
PM 27646508
ER
PT J
AU Powe, CE
AF Powe, Camille E.
TI Early Pregnancy Biochemical Predictors of Gestational Diabetes Mellitus
SO CURRENT DIABETES REPORTS
LA English
DT Review
DE Gestational diabetes mellitus; Pregnancy; Biomarkers; Prediction
ID HORMONE-BINDING GLOBULIN; C-REACTIVE PROTEIN; PLACENTAL GROWTH-FACTOR;
FASTING PLASMA-GLUCOSE; PRO RENIN RECEPTOR; INSULIN SENSITIVITY INDEXES;
RANDOMIZED CONTROLLED-TRIAL; POLYCYSTIC-OVARY-SYNDROME; SERUM GLYCATED
ALBUMIN; EARLY 2ND TRIMESTER
AB Purpose of Review Universal oral glucose tolerance-based screening is employed to identify pregnant women with gestational diabetes mellitus (GDM), as treatment of this condition decreases the risk of associated complications. A simple and accurate blood test which identifies women at low or high risk for GDM in the first trimester would have the potential to decrease costs and improve outcomes through prevention or treatment. This review summarizes published data on early pregnancy biomarkers which have been tested as predictors of GDM.
Recent Findings A large number of first-trimester biochemical predictors of GDM have been reported, mostly in small case-control studies. These include glycemic markers (fasting glucose, post-load glucose, hemoglobin A1C), inflammatory markers (C-reactive protein, tumor necrosis factor-alpha), insulin resistance markers (fasting insulin, sex hormone-binding globulin), adipocyte-derived markers (adiponectin, leptin), placenta-derived markers (follistatin-like-3, placental growth factor, placental exosomes), and others (e.g., glycosylated fibronectin, soluble (pro) renin receptor, alanine aminotransferase, ferritin). A few large studies suggest that first-trimester fasting glucose or hemoglobin A1C may be useful for identifying women who would benefit from early GDM treatment.
Summary To translate the findings from observational studies of first-trimester biomarkers for GDM to clinical practice, trials or cost-effectiveness analyses of screening and treatment strategies based on these novel biomarkers are needed.
C1 [Powe, Camille E.] Massachusetts Gen Hosp, Dept Med, Div Endocrinol, Diabet Unit, 50 Staniford St,Suite 340, Boston, MA 02114 USA.
[Powe, Camille E.] Harvard Med Sch, 50 Staniford St,Suite 340, Boston, MA 02114 USA.
RP Powe, CE (reprint author), Massachusetts Gen Hosp, Dept Med, Div Endocrinol, Diabet Unit, 50 Staniford St,Suite 340, Boston, MA 02114 USA.; Powe, CE (reprint author), Harvard Med Sch, 50 Staniford St,Suite 340, Boston, MA 02114 USA.
EM cpowe@partners.org
NR 119
TC 0
Z9 0
U1 0
U2 0
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1534-4827
EI 1539-0829
J9 CURR DIABETES REP
JI Curr. Diabetes Rep.
PD FEB
PY 2017
VL 17
IS 2
AR 12
DI 10.1007/s11892-017-0834-y
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EO7KE
UT WOS:000396868800006
PM 28229385
ER
PT J
AU Martin-Gayo, E
Yu, XG
AF Martin-Gayo, Enrique
Yu, Xu G.
TI Dendritic Cell Immune Responses in HIV-1 Controllers
SO CURRENT HIV/AIDS REPORTS
LA English
DT Article
DE HIV-1 controllers; Dendritic cells; Dendritic cell immune responses; CD8
Tcells; HIV-1 immune defense
ID IMMUNODEFICIENCY-VIRUS TYPE-1; CD4(+) T-CELLS; HIV-1-INFECTED ELITE
CONTROLLERS; GMP-AMP SYNTHASE; INTERFERON RESPONSE; TRANS-INFECTION;
DC-SIGN; RECEPTORS; PATHWAY; RESTRICTION
AB Purpose of Review Robust HIV-1-specific CD8 T cell responses are currently regarded as the main correlate of immune defense in rare individuals who achieve natural, drug-free control of HIV-1; however, the mechanisms that support evolution of such powerful immune responses are not well understood. Dendritic cells (DCs) are specialized innate immune cells critical for immune recognition, immune regulation, and immune induction, but their possible contribution to HIV-1 immune defense in controllers remains ill-defined.
Recent Findings Recent studies suggest that myeloid DCs from controllers have improved abilities to recognize HIV-1 through cytoplasmic immune sensors, resulting in more potent, cell-intrinsic type I interferon secretion in response to viral infection. This innate immune response may facilitate DC-mediated induction of highly potent antiviral HIV-1-specific T cells. Moreover, protective HLA class I isotypes restricting HIV-1-specific CD8 T cells may influence DC function through specific interactions with innate myelomonocytic MHC class I receptors from the leukocyte immunoglobulin-like receptor family.
Summary Bi-directional interactions between dendritic cells and HIV-1-specific T cells may contribute to natural HIV-1 immune control, highlighting the importance of a fine-tuned interplay between innate and adaptive immune activities for effective antiviral immune defense.
C1 [Martin-Gayo, Enrique; Yu, Xu G.] Ragon Inst MGH, Massachusetts Gen Hosp, Harvard, Cambridge, MA 02139 USA.
[Martin-Gayo, Enrique; Yu, Xu G.] MIT, Ragon Inst MGH, Cambridge, MA 02139 USA.
Massachusetts Gen Hosp, Cambridge, MA 02139 USA.
RP Yu, XG (reprint author), MIT, Ragon Inst MGH, 400 Technology Sq, Cambridge, MA 02139 USA.
EM EGAYO@mgh.harvard.edu; xyu@mgh.harvard.edu
NR 70
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1548-3568
EI 1548-3576
J9 CURR HIV-AIDS REP
JI Curr. Hiv/Aids Rep.
PD FEB
PY 2017
VL 14
IS 1
BP 1
EP 7
DI 10.1007/s11904-017-0345-0
PG 7
WC Infectious Diseases
SC Infectious Diseases
GA EM2RH
UT WOS:000395162800001
PM 28110421
ER
PT J
AU Reyes, S
Varagic, J
Ahmad, S
VonCannon, J
Kon, ND
Wang, H
Groban, L
Cheng, CP
Dell'Italia, LJ
Ferrario, CM
AF Reyes, Santiago
Varagic, Jasmina
Ahmad, Sarfaraz
VonCannon, Jessica
Kon, Neal D.
Wang, Hao
Groban, Leanne
Cheng, Che Ping
Dell'Italia, Louis J.
Ferrario, Carlos M.
TI Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/ Chymase Axis
Require a Revision of Therapeutic Approaches in Human Heart Disease
SO CURRENT HYPERTENSION REPORTS
LA English
DT Review
DE Intracrine; Angiotensin-(1-12); Chymase; Cardiomyocyte;
Angiotensin-converting enzyme inhibitor; Angiotensin receptor blockers
ID ANGIOTENSIN-CONVERTING-ENZYME; HIGH-RISK PATIENTS; LEFT-VENTRICULAR
DYSFUNCTION; RANDOMIZED CONTROLLED-TRIAL; HIGH CARDIOVASCULAR RISK;
CORONARY-ARTERY-DISEASE; II-RECEPTOR BLOCKERS; BLOOD-PRESSURE;
MYOCARDIAL-INFARCTION; FORMING PATHWAYS
AB Purpose of the Review Drugs targeting the renin-angiotensin system (RAS), namely angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers, are the most commonly prescribed drugs for patients with or at risk for cardiovascular events. However, new treatment strategies aimed at mitigating the rise of the heart failure pandemic are warranted because clinical trials show that RAS blockers have limited benefits in halting disease progression. The main goal of this review is to put forward the concept of an intracrine RAS signaling through the novel angiotensin-(1-12)/chymase axis as the main source of deleterious angiotensin II (Ang II) in cardiac maladaptive remodeling leading to heart failure (HF).
Recent Findings Expanding traditional knowledge, Ang II can be produced in tissues independently from the circulatory renin-angiotensin system. In the heart, angiotensin-(1-12) [Ang-(1-12)], a recently discovered derivative of angiotensinogen, is a precursor of Ang II, and chymase rather than ACE is the main enzyme contributing to the direct production of Ang II from Ang-(1-12). The Ang-(1-12)/chymase axis is an independent intracrine pathway accounting for the trophic, contractile, and pro-arrhythmic Ang II actions in the human heart. Ang-(1-12) expression and chymase activity have been found elevated in the left atrial appendage of heart disease subjects, suggesting a pivotal role of this axis in the progression of HF.
Summary Recent meta-analysis of large clinical trials on the use of ACE inhibitors and angiotensin receptor blockers in cardiovascular disease has demonstrated an imbalance between patients that significantly benefit from these therapeutic agents and those that remain at risk for heart disease progression. Looking to find an explanation, detailed investigation on the RAS has unveiled a previously unrecognized complexity of substrates and enzymes in tissues ultimately associated with the production of Ang II that may explain the shortcomings of ACE inhibition and angiotensin receptor blockade. Discovery of the Ang-(1-12)/chymase axis in human hearts, capable of producing Ang II independently from the circulatory RAS, has led to the notion that a tissue-delimited RAS signaling in an intracrine fashion may account for the deleterious effects of Ang II in the heart, contributing to the transition from maladaptive cardiac remodeling to heart failure. Targeting intracellular RAS signaling may improve current therapies aimed at reducing the burden of heart failure.
C1 [Reyes, Santiago; Varagic, Jasmina; Ahmad, Sarfaraz; VonCannon, Jessica; Ferrario, Carlos M.] Wake Forest Univ Hlth Sci, Dept Gen Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA.
[Varagic, Jasmina; VonCannon, Jessica; Groban, Leanne] Wake Forest Univ Hlth Sci, Cardiovasc Sci Ctr, Med Ctr Blvd, Winston Salem, NC 27157 USA.
[Kon, Neal D.] Wake Forest Univ Hlth Sci, Dept Cardiothorac Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA.
[Wang, Hao; Groban, Leanne] Wake Forest Univ Hlth Sci, Dept Anesthesiol, Med Ctr Blvd, Winston Salem, NC 27157 USA.
[Wang, Hao] Wake Forest Univ Hlth Sci, Dept Internal Med Mol Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
[Cheng, Che Ping] Wake Forest Univ Hlth Sci, Dept Internal Med Cardiovasc Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.
[Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL USA.
[Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Microbiol & Physiol, Birmingham, AL USA.
[Dell'Italia, Louis J.] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL USA.
[Dell'Italia, Louis J.] Birmingham Vet Affairs Med Ctr, Dept Vet Affairs, Birmingham, AL USA.
[Ferrario, Carlos M.] Wake Forest Univ Hlth Sci, Dept Internal Med, Dept Nephrol, Med Ctr Blvd, Winston Salem, NC 27157 USA.
[Ferrario, Carlos M.] Wake Forest Univ Hlth Sci, Dept Physiol Pharmacol, Med Ctr Blvd, Winston Salem, NC 27157 USA.
RP Ferrario, CM (reprint author), Wake Forest Univ Hlth Sci, Dept Gen Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA.; Ferrario, CM (reprint author), Wake Forest Univ Hlth Sci, Dept Internal Med, Dept Nephrol, Med Ctr Blvd, Winston Salem, NC 27157 USA.; Ferrario, CM (reprint author), Wake Forest Univ Hlth Sci, Dept Physiol Pharmacol, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM cferrari@wakehealth.edu
NR 121
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1522-6417
EI 1534-3111
J9 CURR HYPERTENS REP
JI Curr. Hypertens. Rep.
PD FEB
PY 2017
VL 19
IS 2
AR 16
DI 10.1007/s11906-017-0708-3
PG 11
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA EP3CK
UT WOS:000397259900003
PM 28233239
ER
PT J
AU Brizzi, K
AF Brizzi, Kate
TI Neurologic Manifestation of Chikungunya Virus
SO CURRENT INFECTIOUS DISEASE REPORTS
LA English
DT Review
DE Chikungunya; Neurology; Mosquito-borne viruses; Encephalitis;
Guillain-Barre syndrome
ID GUILLAIN-BARRE-SYNDROME; REUNION-ISLAND; SOUTH-INDIA; INFECTION;
OUTBREAK; EPIDEMIC; FEVER
AB Purpose of Review Chikungunya virus (CHIKV) is a RNA arbovirus that typically causes fevers and arthralgias, but reports of neurologic findings have become increasingly common. This article reviews our current understanding of CHIKV-associated neurologic manifestations.
Recent Findings In the last 5 years, CHIKV endemicity has spread to the Americas and the number of cases of CHIKVrelated disease has dramatically increased. Evidence suggests increasing neurovirulence of the virus, particularly among the critically ill. The spectrum of neurologic manifestations of the disease includes encephalitis, myelitis, and Guillain-Barre syndrome, but isolated reports of cranial neuropathies and cognitive deficits associated with recent infection also are reported.
Summary Though neurologic symptoms associated with CHIKVremain relatively uncommon, their frequency appears to be increasing. Clinicians treating patients with neurologic symptoms from CHIKVendemic areas should be aware of the growing association between CHIKVand neurologic sequelae to help guide diagnostics. Research into the optimal treatment of the disease is needed to inform treatment practices.
C1 [Brizzi, Kate] Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA.
RP Brizzi, K (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA.
EM kbrizzi@partners.org
NR 44
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3847
EI 1534-3146
J9 CURR INFECT DIS REP
JI Curr. Infect. Dis. Rep.
PD FEB
PY 2017
VL 19
IS 2
AR 6
DI 10.1007/s11908-017-0561-1
PG 6
WC Infectious Diseases
SC Infectious Diseases
GA EM0HH
UT WOS:000394998900002
PM 28233188
ER
PT J
AU McFaline-Figueroa, JR
Wen, PY
AF McFaline-Figueroa, J. Ricardo
Wen, Patrick Y.
TI The Viral Connection to Glioblastoma
SO CURRENT INFECTIOUS DISEASE REPORTS
LA English
DT Review
DE Glioblastoma; Cytomegalovirus; Immunotherapy; Valganciclovir;
Herpesvirus
ID HUMAN CYTOMEGALOVIRUS; BRAIN-TUMORS; PERIPHERAL-BLOOD; SARCOMA-VIRUS;
VALGANCICLOVIR; GLIOMA; HERPESVIRUSES; ASSOCIATION; INFECTION; CELLS
AB Purpose of Review The high incidence of and mortality from glioblastoma are matched by a lack of effective therapies. Previous research suggests an association between viral infection and glioma formation. In this manuscript, we review the available evidence for this association and the efficacy of treatment strategies targeted against viral infection.
Recent Findings We find that while a wide array of viruses can drive glioma tumor formation in vitro and in xenograft models, the most convincing association is with the human Cytomegalovirus (HCMV). Detection of HCMV in glioblastoma resected from living patients suggests it may either drive gliomagenesis, support tumor growth, or reactivate silently in these tumors. However, there is conflicting evidence on its ubiquity and its role in tumor formation. Valganciclovir may extend survival in glioblastoma patients, though adequate data on its efficacy and mechanism of action are lacking. Immunotherapy provides the opportunity to specifically target the virus and possibly, glioblastoma, though there are no large, randomized trials testing its efficacy to date.
Summary Overall, despite mounting evidence for an association between HCMVand glioblastoma, its role as an oncogenic factor and a therapeutic target remains controversial.
C1 [McFaline-Figueroa, J. Ricardo] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.
[McFaline-Figueroa, J. Ricardo] Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA.
[Wen, Patrick Y.] Harvard Med Sch, 450 Brookline Ave, Boston, MA 02215 USA.
[Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Inst, Ctr Neurooncol, 450 Brookline Ave, Boston, MA 02215 USA.
RP McFaline-Figueroa, JR (reprint author), Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.; McFaline-Figueroa, JR (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA.
EM jmcfalinefigueroa@partners.org; pwen@partners.org
NR 35
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3847
EI 1534-3146
J9 CURR INFECT DIS REP
JI Curr. Infect. Dis. Rep.
PD FEB
PY 2017
VL 19
IS 2
AR 5
DI 10.1007/s11908-017-0563-z
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA EM0HH
UT WOS:000394998900001
PM 28233187
ER
PT J
AU McFarlane, AC
Lawrence-Wood, E
Van Hooff, M
Malhi, GS
Yehuda, R
AF McFarlane, Alexander Cowell
Lawrence-Wood, Eleanor
Van Hooff, Miranda
Malhi, Gin S.
Yehuda, Rachel
TI The Need to Take a Staging Approach to the Biological Mechanisms of PTSD
and its Treatment
SO CURRENT PSYCHIATRY REPORTS
LA English
DT Review
DE PTSD; Staging; Subsyndromal; Neurobiology; Inflammation; Medical
comorbidity; Duration of illness; Longitudinal course; Delayed onset;
Treatment
ID POSTTRAUMATIC-STRESS-DISORDER; PROSPECTIVE COHORT; POLICE OFFICERS;
MENTAL-HEALTH; AFGHANISTAN VETERANS; MILITARY DEPLOYMENT; TRAUMATIC
STRESSORS; ARMED-FORCES; SYMPTOMS; RISK
AB Despite the substantial body of neurobiological research, no specific drug target has been developed to treat PTSD and there are substantial limitations with the available interventions. We propose that advances are likely to depend on the development of better classification of the heterogeneity of PTSD using a staging approach of disease. A primary rationale for staging is to highlight the probability that distinct therapeutic approaches need to be utilised according to the degree of biological progression of the disorder. Prospective studies, particularly of military populations, provide substantial evidence about the emerging biological abnormalities that precede the full-blown disorder. These need to be targeted with tailored interventions to prevent disease progression. Equally, the neurobiology of chronic unremitting PTSD needs to be differentiated from the acute disorder which emerges across a spectrum of severity, and this range of presentations correspondingly needs to be addressed with differing therapeutic strategies. The staging approach also needs to take account of the range of somatic pathological outcomes that are being identified as a consequence of traumatic stress exposure. PTSD should be conceptualised as a systemic disorder underpinned a range of biological dysregulation, including metabolic and altered immune function, reflected in the increased rates of cardiovascular and autoimmune disease. The effectiveness of novel treatments needs to be judged across their effectiveness in addressing the spectrum of trauma-related pathology.
C1 [McFarlane, Alexander Cowell; Lawrence-Wood, Eleanor; Van Hooff, Miranda] Univ Adelaide, Ctr Traumat Stress Studies, Level 2,122 Frome St, Adelaide, SA 5000, Australia.
[Malhi, Gin S.] Univ Sydney, Sydney Med Sch, Dept Psychiat, Edward Ford Bldg A27,Fisher Rd, Sydney, NSW 2006, Australia.
[Yehuda, Rachel] Mt Sinai Sch Med, Traumat Stress Studies Div, James J Peters VA Med Ctr, 130 West Kingsbridge Rd, Bronx, NY USA.
RP McFarlane, AC (reprint author), Univ Adelaide, Ctr Traumat Stress Studies, Level 2,122 Frome St, Adelaide, SA 5000, Australia.
EM alexander.mcfarlane@adelaide.edu.au
FU National Health Medical and Research Council of Australia [568970]
FX This research was funded by program grant number 568970 of the National
Health Medical and Research Council of Australia.
NR 80
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3812
EI 1535-1645
J9 CURR PSYCHIAT REP
JI Curr. Psychiatry Rep.
PD FEB
PY 2017
VL 19
IS 2
AR 10
DI 10.1007/s11920-017-0761-2
PG 9
WC Psychiatry
SC Psychiatry
GA EO7UP
UT WOS:000396895900003
PM 28168596
ER
PT J
AU Speed, JM
Trinh, QD
Choueiri, TK
Sun, M
AF Speed, Jacqueline M.
Quoc-Dien Trinh
Choueiri, Toni K.
Sun, Maxine
TI Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of
Contemporary Data
SO CURRENT UROLOGY REPORTS
LA English
DT Article
DE Recurrent renal cell carcinoma; Surveillance in renal cell; Biomarkers
in renal cell; Risk factors for renal cell recurrence; Localized renal
cell carcinoma; Treatment of localized renal cell carcinoma
ID NEPHRON-SPARING SURGERY; URINARY COLLECTING SYSTEM; POSTOPERATIVE
PROGNOSTIC NOMOGRAM; PARTIAL NEPHRECTOMY; RADICAL NEPHRECTOMY; KIDNEY
CANCER; FOLLOW-UP; MOLECULAR SIGNATURES; TUMOR SIZE; EXPRESSION
AB Purpose of Review Patients with localized renal cell carcinoma (RCC) are at risk of recurrence. The purpose of this review was to characterize the literature on recurrence rates and risk factors after diagnosis of localized RCC.
Recent Findings Our search revealed that existing data examining the prevalence of recurrence rates predominantly originates from cohorts of patients diagnosed and treated in the 1980s to 1990s, and may therefore not be as useful for counseling for current patients today. Many nomograms including the Cindolo Recurrence Risk Formula, the University of California-Los Angeles (UCLA) Integrated Scoring System (UISS), the SSIGN score, the Kattan nomogram, and the Karakiewicz nomogram have shown value in identifying patients at higher risk for recurrence. Biomarkers and gene assays have shown promise in augmenting the predictive accuracy of some of the aforementioned predictive models, especially when multiple gene markers are used in combination. However, more work is needed in not only developing a model but also validating it in other settings prior to clinical use. Adjuvant therapy is a promising new treatment strategy for patients with high-risk disease. Importantly, too many surveillance strategies exist. This may stem from the lack of a consensus in the urological community in how to follow these patients, as well as the variable guideline recommendations.
Summary In conclusion, contemporary recurrence rates are needed. Recurrence risk prediction models should be developed based on a series of more contemporary patients, and externally validated prior to routine clinical practice. Surveillance strategies following treatment of localized RCC need to be identified and standardized. Finally, there is a trend toward personalizing surveillance regimens to more appropriately screen patients at higher risk of recurrence.
C1 [Speed, Jacqueline M.; Quoc-Dien Trinh; Sun, Maxine] Brigham & Womens Hosp, 45 Francis St,ASB 2-3, Boston, MA 02115 USA.
[Choueiri, Toni K.] Dana Farber Canc Inst, Dana 1230,44 Binney St, Boston, MA 02215 USA.
RP Sun, M (reprint author), Brigham & Womens Hosp, 45 Francis St,ASB 2-3, Boston, MA 02115 USA.
EM jmspeed@partners.org; trinh.qd@gmail.com;
Toni_Choueiri@DFCI.HARVARD.EDU; maxinesun@gmail.com
NR 92
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1527-2737
J9 CURR UROL REP
JI Curr. Urol. Rep.
PD FEB
PY 2017
VL 18
IS 2
AR 15
DI 10.1007/s11934-017-0661-3
PG 11
WC Urology & Nephrology
SC Urology & Nephrology
GA EM3AQ
UT WOS:000395187300007
PM 28213859
ER
PT J
AU Shamsi, MM
Chekachak, S
Soudi, S
Quinn, LS
Ranjbar, K
Chenari, J
Yazdi, MH
Mandavi, M
AF Shamsi, M. Molanouri
Chekachak, S.
Soudi, S.
Quinn, L. S.
Ranjbar, K.
Chenari, J.
Yazdi, M. H.
Mandavi, M.
TI Combined effect of aerobic interval training and selenium nanoparticles
on expression of IL-15 and IL-10/TNF-a ratio in skeletal muscle of 4T1
breast cancer mice with cachexia
SO CYTOKINE
LA English
DT Article
DE 4T1 breast cancer; Cachexia; Interleukin-15; Inflammation; Aerobic
interval training
ID TUMOR-BEARING RATS; RESISTANCE EXERCISE; ANTIOXIDANT SUPPLEMENTATION;
MOLECULAR-MECHANISMS; PHYSICAL-ACTIVITY; OXIDATIVE STRESS;
ADIPOSE-TISSUE; CELL-GROWTH; TNF-ALPHA; INTERLEUKIN-15
AB Cancer cachexia is characterized by inflammation, loss of skeletal muscle and adipose tissue mass, and functional impairment. Oxidative stress and inflammation are believed to regulate pathways controlling skeletal muscle wasting. The aim of this study was to determine the effects of aerobic interval training and the purported antioxidant treatment, selenium nanoparticle supplementation, on expression of IL-15 and inflammatory cytokines in 4T1 breast cancer-bearing mice with cachexia. Selenium nanopar-ticle supplementation accelerated cachexia symptoms in tumor-bearing mice, while exercise training prevented muscle wasting in tumor-bearing mice. Also, aerobic interval training enhanced the anti-inflammatory indices IL-10/TNF-alpha ratio and IL-15 expression in skeletal muscle in tumor-bearing mice. However, combining exercise training and antioxidant supplementation prevented cachexia and muscle wasting and additionally decreased tumor volume in 4T1 breast cancer mice. These finding suggested that combining exercise training and antioxidant supplementation could be a strategy for managing tumor volume and preventing cachexia in breast cancer. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Shamsi, M. Molanouri; Chekachak, S.; Ranjbar, K.] Tarbiat Modares Univ, Fac Humanities, Phys Educ & Sport Sci Dept, POB 14117-13116, Tehran, Iran.
[Soudi, S.] Tarbiat Modares Univ, Fac Med Sci, Dept Immunol, POB 14117-13116, Tehran, Iran.
[Quinn, L. S.] Univ Washington, VA Puget Sound Hlth Care Syst, Res Serv, Seattle, WA 98108 USA.
[Quinn, L. S.] Univ Washington, Div Gerontol & Geriatr Med, Dept Med, Seattle, WA 98108 USA.
[Chenari, J.] Univ Tehran Med Sci, Neurosci Inst, Brain & Spinal Cord Injury Res Ctr, Tehran, Iran.
[Yazdi, M. H.] Univ Tehran Med Sci, Sch Pharm, Dept Pharmaceut Biotechnol, Tehran, Iran.
[Yazdi, M. H.] Univ Tehran Med Sci, Sch Pharm, Biotechnol Res Ctr, Tehran, Iran.
[Mandavi, M.] Pasteur Inst Iran, Dept Immunol, 69 Pasteur Ave, Tehran, Iran.
RP Shamsi, MM (reprint author), Tarbiat Modares Univ, Fac Humanities, Phys Educ & Sport Sci Dept, POB 14117-13116, Tehran, Iran.; Soudi, S (reprint author), Tarbiat Modares Univ, Fac Med Sci, Dept Immunol, POB 14117-13116, Tehran, Iran.
EM molanouri@modares.ac.ir; soodabeh.chekachak@modares.ac.ir;
Soudi@modares.ac.ir; quinnL@uw.edu; kia.ranjbar@modares.ac.ir;
chenari.jamal@gmail.com; mohammadhossein61@gmail.com;
mandavivac@gmail.com
FU Research Center of Tarbiat Modarres University (TMU), Tehran, Iran
FX This work was supported by the Research Center of Tarbiat Modarres
University (TMU), Tehran, Iran. We wish to thank Professor Yaghob
Fathoallahy for his kind help and sincere cooperation.
NR 73
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD FEB
PY 2017
VL 90
BP 100
EP 108
DI 10.1016/j.cyto.2016.11.005
PG 9
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA EL1QM
UT WOS:000394396100015
ER
PT J
AU Andrews, JS
Trupin, L
Hough, CL
Daikh, DI
Yelin, EH
Katz, PP
AF Andrews, James S.
Trupin, Laura
Hough, Catherine L.
Daikh, David I.
Yelin, Edward H.
Katz, Patricia P.
TI Serum biomarkers of inflammation and muscle strength among women with
systemic lupus erythematosus
SO CYTOKINE
LA English
DT Article
DE Systemic lupus erythematosus; Inflammation; Cytokines; Outcomes research
ID ACTIVITY QUESTIONNAIRE; PHYSICAL FUNCTION; VALIDITY; DISEASE
AB Objectives: Muscle strength is an important determinant of physical function in women with systemic lupus erythematosus (SLE). Serum biomarkers of inflammation, including interleukin-6 (IL-6) and C Reactive Protein (CRP), are associated with differences in muscle strength among individuals without rheumatologic disease. We examined whether serum levels of IL-6 and CRP are associated with upper and lower extremity muscle strength among adult women with SLE.
Methods: One hundred thirty-six women with SLE participated in this cross-sectional study. High- sensitivity CRP was analyzed by nephelometry. IL-6 serum levels were analyzed by high sensitivity enzyme-linked immunosorbent assay. Upper and lower extremity muscle strength were assessed by grip strength and peak torque of knee extension and flexion, respectively. Regression analyses modeled asso-ciations of CRP and IL-6 with upper and lower extremity muscle strength controlling for age, SLE dura-tion, physical activity, prednisone use, BMI, plaquenil use, and pain.
Results: Higher serum levels of IL-6 and CRP were associated with significantly weaker upper and lower extremity muscle strength even when controlling for covariates.
Conclusions: Increased serum IL-6 and CRP are associated with clinically significant differences in upper and lower extremity muscle strength and may be useful in identifying those at risk for weakness and decreased physical function. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Andrews, James S.; Hough, Catherine L.] Univ Washington, Dept Med, Seattle, WA USA.
[Trupin, Laura; Daikh, David I.; Yelin, Edward H.; Katz, Patricia P.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA.
[Daikh, David I.] San Francisco VA Med Ctr, Dept Med, San Francisco, CA USA.
RP Andrews, JS (reprint author), Univ Washington, Div Rheumatol, Box 356420,959 NE Pacific St, Seattle, WA 98195 USA.
EM jsa1@uw.edu
FU NIH/NIAMS grant [P60 AR053308]; NIH/NCRR UCSF-CTSI Grant [UL1 RR024131];
Rosalind Russell/Ephraim Engleman Rheumatology Research Center for
Arthritis
FX This research was supported by NIH/NIAMS grant P60 AR053308 and by
NIH/NCRR UCSF-CTSI Grant Number UL1 RR024131, and by the Rosalind
Russell/Ephraim Engleman Rheumatology Research Center for Arthritis.
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-4666
EI 1096-0023
J9 CYTOKINE
JI Cytokine
PD FEB
PY 2017
VL 90
BP 109
EP 112
DI 10.1016/j.cyto.2016.11.003
PG 4
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA EL1QM
UT WOS:000394396100016
PM 27863333
ER
PT J
AU Park, IJK
Wang, LJ
Williams, DR
Alegria, M
AF Park, Irene J. K.
Wang, Lijuan
Williams, David R.
Alegria, Margarita
TI Does Anger Regulation Mediate the Discrimination-Mental Health Link
Among Mexican-Origin Adolescents? A Longitudinal Mediation Analysis
Using Multilevel Modeling
SO DEVELOPMENTAL PSYCHOLOGY
LA English
DT Article
DE anger regulation; anxiety; depression; Mexican-origin adolescents;
racial/ethnic discrimination
ID PERCEIVED DISCRIMINATION; EMOTION REGULATION; INTERNALIZING SYMPTOMS;
AMERICAN ADOLESCENTS; SOCIOECONOMIC-STATUS; FUTURE-DIRECTIONS;
BETWEEN-PERSON; WITHIN-PERSON; LATINO YOUTH; RACISM
AB Although prior research has consistently documented the association between racial/ethnic discrimination and poor mental health outcomes, the mechanisms that underlie this link are still unclear. The present 3-wave longitudinal study tested the mediating role of anger regulation in the discrimination-mental health link among 269 Mexican-origin adolescents (M-age = 14.1 years, SD = 1.6; 57% girls), 12 to 17 years old. Three competing anger regulation variables were tested as potential mediators: outward anger expression, anger suppression, and anger control. Longitudinal mediation analyses were conducted using multilevel modeling that disaggregated within-person effects from between-person effects. Results indicated that outward anger expression was a significant mediator; anger suppression and anger control were not significant mediators. Within a given individual, greater racial/ethnic discrimination was associated with more frequent outward anger expression. In turn, more frequent outward anger expression was associated with higher levels of anxiety and depression at a given time point. Gender, age, and nativity status were not significant moderators of the hypothesized mediation models. By identifying outward anger expression as an explanatory mechanism in the discrimination-distress link among Latino youths, this study points to a malleable target for prevention and intervention efforts aimed at mitigating the detrimental impact of racism on Latino youths' mental health during the developmentally critical period of adolescence.
C1 [Park, Irene J. K.] Indiana Univ Sch Med, Dept Psychiat, South Bend, IN 46617 USA.
[Wang, Lijuan] Univ Notre Dame, Dept Psychol, Notre Dame, IN 46556 USA.
[Williams, David R.] Harvard Univ, Dept Social & Behav Sci, Harvard TH Chan Sch Publ Hlth, Cambridge, MA 02138 USA.
[Williams, David R.] Harvard Univ, Dept African & African Amer Studies, Cambridge, MA 02138 USA.
[Alegria, Margarita] Massachusetts Gen Hosp, Dept Med, Dispar Res Unit, Boston, MA 02114 USA.
[Alegria, Margarita] Harvard Med Sch, Dept Psychiat, Boston, MA USA.
RP Park, IJK (reprint author), Indiana Univ Sch Med, Dept Psychiat, South Bend, IN 46617 USA.
EM ijpark@iupui.edu
FU National Institute of Mental Health of the National Institutes of Health
[R21MH097675]
FX This research was supported by the National Institute of Mental Health
of the National Institutes of Health under Award R21MH097675 (Irene
Park, Principal Investigator). The content is solely the responsibility
of the authors and does not necessarily represent the official views of
the National Institutes of Health. We thank the participating families,
community agencies, and the research staff for their contributions to
the larger project: Rosemary Salinas, Misel Ramirez Vasoli, Amarilys
Castillo, Jaqueline Martinez, Kristina Martinez, Margaret Schmid, Carlos
Uzcategui, and Kimberly Widawski. We are indebted to our community
consultant, Gilberto Perez Jr., M. S. W., A. C. S. W., for his liaison
work and to Jennifer Burke-Lefever, Ph.D., for her consultation on
project implementation.
NR 73
TC 1
Z9 1
U1 0
U2 0
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0012-1649
EI 1939-0599
J9 DEV PSYCHOL
JI Dev. Psychol.
PD FEB
PY 2017
VL 53
IS 2
BP 340
EP +
DI 10.1037/dev0000235
PG 13
WC Psychology, Developmental
SC Psychology
GA EN1SB
UT WOS:000395789200012
PM 27893238
ER
PT J
AU Powers, MA
Bardsley, J
Cypress, M
Duker, P
Funnell, MM
Fischl, AH
Maryniuk, MD
Siminerio, L
Vivian, E
AF Powers, Margaret A.
Bardsley, Joan
Cypress, Marjorie
Duker, Paulina
Funnell, Martha M.
Fischl, Amy Hess
Maryniuk, Melinda D.
Siminerio, Linda
Vivian, Eva
TI Diabetes Self-management Education and Support in Type 2 Diabetes A
Joint Position Statement of the American Diabetes Association, the
American Association of Diabetes Educators, and the Academy of Nutrition
and Dietetics
SO DIABETES EDUCATOR
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; GLYCEMIC CONTROL;
CLINICAL-OUTCOMES; DECISION-MAKING; METAANALYSIS; CARE; ADULTS; PEOPLE;
NEEDS
AB Diabetes educators are well positioned to help optimize care of the student with diabetes within the school setting.
C1 [Powers, Margaret A.] Int Diabet Ctr Pk Nicollet, Minneapolis, MN 55416 USA.
[Bardsley, Joan] MedStar Hlth Res Inst, Hyattsville, MD USA.
[Bardsley, Joan] MedStar Nursing, Hyattsville, MD USA.
[Cypress, Marjorie] ABQ Hlth Partners, Albuquerque, NM USA.
[Duker, Paulina] LifeScan, Dubai, U Arab Emirates.
[Funnell, Martha M.] Univ Michigan, Sch Med, Ann Arbor, MI USA.
[Fischl, Amy Hess] Univ Chicago, Chicago, IL 60637 USA.
[Maryniuk, Melinda D.] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Siminerio, Linda] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Vivian, Eva] Univ Wisconsin, Madison, WI USA.
RP Powers, MA (reprint author), Int Diabet Ctr Pk Nicollet, Minneapolis, MN 55416 USA.
EM margaret.powers@parknicollet.com
NR 82
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-7217
EI 1554-6063
J9 DIABETES EDUCATOR
JI Diabetes Educ.
PD FEB
PY 2017
VL 43
IS 1
BP 40
EP 53
DI 10.1177/0145721716689694
PG 14
WC Endocrinology & Metabolism; Public, Environmental & Occupational Health
SC Endocrinology & Metabolism; Public, Environmental & Occupational Health
GA EL8VB
UT WOS:000394897300005
PM 28118121
ER
PT J
AU Wyte-Lake, T
Claver, M
Der-Martirosian, C
Davis, D
Dobalian, A
AF Wyte-Lake, Tamar
Claver, Maria
Der-Martirosian, Claudia
Davis, Darlene
Dobalian, Aram
TI Developing a Home-Based Primary Care Disaster Preparedness Toolkit
SO DISASTER MEDICINE AND PUBLIC HEALTH PREPAREDNESS
LA English
DT Article
DE community health planning; disaster planning; emergency preparedness;
home health agencies; standard of care; veterans health
ID ADULTS
AB Objective: Health agencies working with the homebound play a vital role in bolstering a community's resiliency by improving the preparedness of this vulnerable population. Nevertheless, this role is one for which agencies lack training and resources, which leaves many homebound at heightened risk. This study examined the utility of an evidence-based Disaster Preparedness Toolkit in Veterans Health Administration (VHA) Home-Based Primary Care (HBPC) programs.
Methods: We conducted an online survey of all VHA HBPC program managers (N = 77/146; 53% response rate).
Results: Respondents with fewer years with the HBPC program rated the toolkit as being more helpful (P<0.05). Of those who implemented their program's disaster protocol most frequently, two-thirds strongly agreed that the toolkit was relevant. Conversely, of those who implemented their disaster protocols very infrequently or never, 23% strongly agreed that the topics covered in the toolkit were relevant to their work (P<0.05).
Conclusion: This toolkit helps support programs as they fulfill their preparedness requirements, especially practitioners who are new to their position in HBPC. Programs that implement disaster protocols infrequently may require additional efforts to increase understanding of the toolkit's utility. Engaging all members of the team with their diverse clinical expertise could strengthen a patient's personal preparedness plan.
C1 [Wyte-Lake, Tamar; Claver, Maria; Der-Martirosian, Claudia; Dobalian, Aram] Vet Hlth Adm, Vet Emergency Management Evaluat Ctr, 16111 Plummer St,MS 152, Los Angeles, CA 91343 USA.
[Davis, Darlene] US Dept Vet Affairs, Natl Off, Home Based Primary Care, Tampa, FL USA.
RP Wyte-Lake, T (reprint author), Vet Hlth Adm, Vet Emergency Management Evaluat Ctr, 16111 Plummer St,MS 152, Los Angeles, CA 91343 USA.
EM tamar.wyte@va.gov
NR 22
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1935-7893
EI 1938-744X
J9 DISASTER MED PUBLIC
JI Dis. Med. Public Health Prep.
PD FEB
PY 2017
VL 11
IS 1
BP 56
EP 63
DI 10.1017/dmp.2016.145
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EM6TB
UT WOS:000395444000012
PM 27839522
ER
PT J
AU Mihos, CG
Larrauri-Reyes, M
Yucel, E
Santana, O
AF Mihos, Christos G.
Larrauri-Reyes, Maiteder
Yucel, Evin
Santana, Orlando
TI Clinical presentation and echocardiographic characteristics of Uhl's
anomaly
SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED
TECHNIQUES
LA English
DT Article
DE congenital heart disease; echocardiography; heart failure; right
ventricle; right ventricular dysfunction; Uhl's anomaly
ID SPECTRUM; ADULT
AB Uhl's anomaly is a rare cardiac malformation that results in partial or complete absence of the right ventricular myocardium. It most commonly presents in prenatal or newborn infants; however, it may also be found in some adults as advanced right-sided heart failure. Differential diagnoses include arrhythmogenic right ventricular dysplasia and Ebstein's anomaly. Herein, we describe the clinical presentation of Uhl's anomaly in a previously undiagnosed middle-aged adult, and review the echocardiographic criteria used to diagnose and differentiate this rare, albeit important, myocardial disorder.
C1 [Mihos, Christos G.; Yucel, Evin] Massachusetts Gen Hosp, Harvard Med Sch, Cardiac Ultrasound Lab, Boston, MA USA.
[Larrauri-Reyes, Maiteder; Santana, Orlando] Columbia Univ, Mt Sinai Heart Inst, Div Cardiol, Miami Beach, FL USA.
RP Mihos, CG (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Cardiac Ultrasound Lab, Boston, MA USA.
EM cmihos@mgh.harvard.edu
NR 10
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-2822
EI 1540-8175
J9 ECHOCARDIOGR-J CARD
JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech.
PD FEB
PY 2017
VL 34
IS 2
BP 299
EP 302
DI 10.1111/echo.13430
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EP5GT
UT WOS:000397407700020
PM 28032368
ER
PT J
AU Zhang, ZB
Liu, YN
Huang, H
Gao, MH
Wu, D
Kong, Q
Zhang, YL
AF Zhang, Zhibin
Liu, Yanan
Huang, Hao
Gao, Minghui
Wu, Di
Kong, Qing
Zhang, Yuelin
TI The NLR protein SUMM2 senses the disruption of an immune signaling MAP
kinase cascade via CRCK3
SO EMBO REPORTS
LA English
DT Article
DE plant immunity; MAP kinase cascade; MPK4; CRCK3; SUMM2
ID PSEUDOMONAS-SYRINGAE EFFECTOR; RECEPTOR-LIKE KINASE; SYSTEMIC
ACQUIRED-RESISTANCE; NADPH OXIDASE RBOHD; INNATE IMMUNITY; III EFFECTOR;
DISEASE-RESISTANCE; PLANT IMMUNITY; ARABIDOPSIS-THALIANA; CYTOPLASMIC
KINASE
AB MAP kinase signaling is an integral part of plant immunity. Disruption of the MEKK1-MKK1/2-MPK4 kinase cascade results in constitutive immune responses mediated by the NLR protein SUMM2, but the molecular mechanism is so far poorly characterized. Here, we report that SUMM2 monitors a substrate protein of MPK4, CALMODULIN-BINDING RECEPTOR-LIKE CYTOPLASMIC KINASE 3 (CRCK3). Similar to SUMM2, CRCK3 was isolated from a suppressor screen of mkk1 mkk2 and is required for the autoimmunity phenotypes in mekk1, mkk1 mkk2, and mpk4 mutants. In wild-type plants, CRCK3 is mostly phosphorylated. MPK4 interacts with CRCK3 and can phosphorylate CRCK3 in vitro. In mpk4 mutant plants, phosphorylation of CRCK3 is substantially reduced, suggesting that MPK4 phosphorylates CRCK3 in vivo. Further, CRCK3 associates with SUMM2 in planta, suggesting SUMM2 senses the disruption of the MEKK1-MKK1/2-MPK4 kinase cascade through CRCK3. Our study suggests that a MAP kinase substrate is used as a guardee or decoy for monitoring the integrity of MAP kinase signaling.
C1 [Zhang, Zhibin; Liu, Yanan; Wu, Di; Kong, Qing; Zhang, Yuelin] Univ British Columbia, Dept Bot, Vancouver, BC, Canada.
[Huang, Hao; Gao, Minghui] Natl Inst Biol Sci, Beijing, Peoples R China.
[Zhang, Zhibin] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA USA.
[Zhang, Zhibin] Harvard Med Sch, Dept Pediat, Boston, MA USA.
[Kong, Qing] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Kong, Qing] Harvard Med Sch, Dept Genet, Boston, MA USA.
RP Zhang, YL (reprint author), Univ British Columbia, Dept Bot, Vancouver, BC, Canada.
EM yuelin.zhang@ubc.ca
FU Natural Sciences and Engineering Research Council (NSERC) of Canada
[249922]
FX We thank Mr. Rowan van Wersch from UBC for careful reading of the
manuscript and Dr. Sophien Kamoun from Sainsbury Laboratories for
discussion of the manuscript. Natural Sciences and Engineering Research
Council (NSERC) of Canada is thanked for their financial support to Y.Z.
(Grant #249922).
NR 68
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-221X
EI 1469-3178
J9 EMBO REP
JI EMBO Rep.
PD FEB
PY 2017
VL 18
IS 2
BP 292
EP 302
DI 10.15252/embr.201642704
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA EL5JJ
UT WOS:000394657100012
PM 27986791
ER
PT J
AU Karpahakis, A
Dibra, I
Pipinikas, C
Feber, A
Morris, T
Francis, J
Oukrif, D
Mandair, D
Pericleous, M
Mohmaduvesh, M
Serra, S
Ogunbiyi, O
Novelli, M
Luong, T
Asa, SL
Kulke, M
Tourripanakis, C
Meyer, T
Caplin, M
Beck, S
Thirlwell, C
AF Karpahakis, Anna
Dibra, Ilarpreet
Pipinikas, Christodoulos
Feber, Andrew
Morris, Tiffany
Francis, Joshua
Oukrif, Dahmane
Mandair, Dalvinder
Pericleous, Marinas
Mohmaduvesh, Mullan
Serra, Stefano
Ogunbiyi, Olagunju
Novelli, Marco
Luong, TuVinh
Asa, Sylvia L.
Kulke, Matthew
Tourripanakis, Christos
Meyer, Tim
Caplin, Martyn
Beck, Stephan
Thirlwell, Christina
TI Progressive epigenetic dysregulation in neuroendocrine tumour liver
metastases
SO ENDOCRINE-RELATED CANCER
LA English
DT Letter
C1 [Karpahakis, Anna; Dibra, Ilarpreet; Pipinikas, Christodoulos; Feber, Andrew; Morris, Tiffany; Oukrif, Dahmane; Mandair, Dalvinder; Novelli, Marco; Meyer, Tim; Beck, Stephan; Thirlwell, Christina] UCL, London, England.
[Karpahakis, Anna; Mandair, Dalvinder; Pericleous, Marinas; Mohmaduvesh, Mullan; Ogunbiyi, Olagunju; Luong, TuVinh; Tourripanakis, Christos; Meyer, Tim; Caplin, Martyn; Thirlwell, Christina] Royal Free Hosp, London, England.
[Francis, Joshua] Broad Inst, Boston, MA USA.
[Serra, Stefano; Asa, Sylvia L.] UHN Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Kulke, Matthew] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Thirlwell, C (reprint author), UCL, London, England.; Thirlwell, C (reprint author), Royal Free Hosp, London, England.
EM christina.thirhvell@ucl.ac.uk
FU UCL Experimental Cancer Medicine Centre; NIHR UCLH Biomedical Research
Centre; Cancer Research UK; Medical Research Council; Wellcome Trust
FX This work was supported by the UCL Experimental Cancer Medicine Centre,
NIHR UCLH Biomedical Research Centre, Cancer Research UK, Medical
Research Council and The Wellcome Trust.
NR 10
TC 0
Z9 0
U1 0
U2 0
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 1351-0088
EI 1479-6821
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD FEB
PY 2017
VL 24
IS 2
BP L21
EP L25
DI 10.1530/ERC-16-0419
PG 5
WC Oncology; Endocrinology & Metabolism
SC Oncology; Endocrinology & Metabolism
GA EN3IZ
UT WOS:000395903500004
PM 28049633
ER
PT J
AU Patel, RB
Tannenbaum, S
Viana-Tejedor, A
Guo, J
Im, K
Morrow, DA
Scirica, BM
AF Patel, Ravi B.
Tannenbaum, Sara
Viana-Tejedor, Ana
Guo, Jianping
Im, KyungAh
Morrow, David A.
Scirica, Benjamin M.
TI Serum potassium levels, cardiac arrhythmias, and mortality following
non-ST-elevation myocardial infarction or unstable angina: insights from
MERLIN-TIMI 36
SO EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE
LA English
DT Article
DE Arrhythmias; acute coronary syndrome; potassium levels; myocardial
infarction; cardiovascular death; ventricular tachycardia
ID ACUTE CORONARY SYNDROMES; VENTRICULAR-ARRHYTHMIAS; RISK; HYPERKALEMIA;
FIBRILLATION; MAGNITUDE; OUTCOMES
AB Background: In acute coronary syndrome (ACS), potassium levels <3.5 mEq/L are associated with ventricular arrhythmias. Current guidelines therefore recommend a potassium target >4.0 mEq/L in ACS. Our study evaluated the association between potassium levels, cardiac arrhythmias, and cardiovascular death in patients with non-ST-segment elevation myocardial infarction or unstable angina.
Methods: Potassium levels were measured in 6515 patients prior to randomization to receive either ranolazine or a placebo in the MERLIN-TIMI 36 trial. A seven-day continuous electrocardiographic assessment was obtained to determine the incidence of non-sustained ventricular tachycardia (NSVT) and ventricular pauses. The association between potassium levels and cardiovascular death was evaluated using a Cox proportional hazards regression model with multivariable adjustment.
Results: NSVT lasting for at least eight consecutive beats occurred more frequently at potassium levels <3.5 mEq/L than at potassium levels 5 mEq/L (10.1 vs. 4.5%, p=0.03 for trend), whereas the inverse pattern was observed for ventricular pauses >3 s, which occurred more frequently at potassium levels 5 mEq/L than at potassium levels <3.5 mEq/L (5.9 vs. 2.0%, p=0.03 for trend). There was a U-shaped relationship between the potassium level at admission and both early and late risk of cardiovascular death. Compared with patients with potassium levels of 3.5 to <4 mEq/L, a potassium level <3.5 mEq/L was associated with an increased risk of cardiovascular death at day 14 (2.4 vs. 0.8%, HRadj 3.1, p=0.02) and at one year (6.4 vs. 3.0%, HRadj 2.2, p=0.01). The risk of cardiovascular death at one year was also significantly increased at potassium levels 4.5 mEq/L and a similar trend was noted at potassium levels 5 mEq/L.
Conclusions: The lowest risk of cardiovascular death was observed in patients with admission potassium levels between 3.5 and 4.5 mEq/L. Both lower and higher levels of potassium were associated with tachyarrhythmias and bradyarrhythmias, suggesting a potential mechanistic explanation for the increased risk of cardiovascular death at the extremes of potassium homeostasis.
C1 [Patel, Ravi B.; Tannenbaum, Sara; Guo, Jianping; Im, KyungAh; Morrow, David A.; Scirica, Benjamin M.] Brigham & Womens Hosp, Dept Med, Div Cardiol, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.
[Viana-Tejedor, Ana] Hosp Clin San Carlos, Madrid, Spain.
RP Scirica, BM (reprint author), Brigham & Womens Hosp, Cardiovascular Div, TIMI Study Grp, 350 Longwood Ave, Boston, MA 02115 USA.
EM bscirica@partners.org
FU NHLBI NIH HHS [T32 HL007381]
NR 26
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 2048-8726
EI 2048-8734
J9 EUR HEART J-ACUTE CA
JI Eur. Heart J.-Acute Cardiovasc. Care
PD FEB
PY 2017
VL 6
IS 1
BP 18
EP 25
DI 10.1177/2048872615624241
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EL7DD
UT WOS:000394780400003
PM 26714972
ER
PT J
AU Luo, L
Guo, KH
Fan, WG
Lu, YH
Chen, LZ
Wang, Y
Shao, YJ
Wu, GX
Xu, J
Lu, LH
AF Luo, Li
Guo, Kaihua
Fan, Wenguo
Lu, Yinghong
Chen, Lizhi
Wang, Yang
Shao, Yijia
Wu, Gongxiong
Xu, Jie
Lu, Lanhai
TI Niche astrocytes promote the survival, proliferation and neuronal
differentiation of co-transplanted neural stem cells following ischemic
stroke in rats
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article; Proceedings Paper
CT 2nd Workshop on Paediatric Virology
CY OCT 08, 2016
CL Athens, GREECE
DE niche astrocyte; neural stem cells; middle cerebral artery occlusion;
ischemia; cell transplantation; stem cell therapy
ID THERAPY; EXPRESSION; BRAIN; INJURY
AB Niche astrocytes have been reported to promote neuronal differentiation through juxtacrine signaling. However, the effects of astrocytes on neuronal differentiation following ischemic stroke are not fully understood. In the present study, transplanted astrocytes and neural stem cells (NSCs) were transplanted into the ischemic striatum of transient middle cerebral artery occlusion (MCAO) model rats 48 h following surgery. It was observed that the co-transplantation of astrocytes and NSCs resulted in a higher ratio of survival and proliferation of the transplanted NSCs, and neuronal differentiation, in MCAO rats compared with NSC transplantation alone. These results demonstrate that the co-administration of astrocytes promotes the survival and neuronal differentiation of NSCs in the ischemic brain. These results suggest that the co-transplantation of astrocytes and NSCs is more effective than NSCs alone in the production of neurons following ischemic stroke in rats.
C1 [Luo, Li; Fan, Wenguo; Lu, Lanhai] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guanghua Sch Stomatol, 56 LingYuanXi Rd, Guangzhou 510055, Guangdong, Peoples R China.
[Luo, Li; Fan, Wenguo; Lu, Lanhai] Sun Yat Sen Univ, Hosp Stomatol, Inst Stomatol Res, 56 LingYuanXi Rd, Guangzhou 510055, Guangdong, Peoples R China.
[Luo, Li; Guo, Kaihua; Lu, Yinghong; Chen, Lizhi; Wang, Yang; Shao, Yijia; Xu, Jie] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Anat & Neurobiol, 74 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China.
[Luo, Li] Guangdong Pharmaceut Univ, Sch Basic Med, Dept Anat, Guangzhou 510006, Guangdong, Peoples R China.
[Wu, Gongxiong] Harvard Med Sch, Div Res, Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Lu, LH (reprint author), Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, Guanghua Sch Stomatol, 56 LingYuanXi Rd, Guangzhou 510055, Guangdong, Peoples R China.; Lu, LH (reprint author), Sun Yat Sen Univ, Hosp Stomatol, Inst Stomatol Res, 56 LingYuanXi Rd, Guangzhou 510055, Guangdong, Peoples R China.; Xu, J (reprint author), Sun Yat Sen Univ, Zhongshan Sch Med, Dept Anat & Neurobiol, 74 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China.
EM xujie@mail.sysu.edu.cn; lvlanhai@mail.sysu.edu.cn
FU National Natural Science Foundation of China for Youth [81000562];
Fundamental Research Funds for the Central Universities [14ykpy33];
Medical Scientific Research Foundation of Guangdong Province, China
[A2015131]
FX The present study was supported by The National Natural Science
Foundation of China for Youth (grant no. 81000562), the Fundamental
Research Funds for the Central Universities (grant no. 14ykpy33) and
Medical Scientific Research Foundation of Guangdong Province, China
(grant no. A2015131).
NR 25
TC 0
Z9 0
U1 0
U2 0
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD FEB
PY 2017
VL 13
IS 2
BP 645
EP 650
DI 10.3892/etm.2016.4016
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA EL9GH
UT WOS:000394927900044
PM 28352345
ER
PT J
AU Metkar, U
Kurra, S
Quinzi, D
Albanese, S
Lavelle, WF
AF Metkar, Umesh
Kurra, Swamy
Quinzi, David
Albanese, Stephen
Lavelle, William F.
TI Magnetically controlled growing rods for scoliosis surgery
SO EXPERT REVIEW OF MEDICAL DEVICES
LA English
DT Review
DE Juvenile scoliosis; early onset scoliosis (EOS); growing rods; magnetic
growing rods (Magec); magnetically controlled growing rods
ID EARLY-ONSET SCOLIOSIS; SPINAL DEFORMITY; YOUNG-CHILDREN; GROWTH RODS;
FOLLOW-UP; FUSION; COMPLICATIONS; SINGLE; INSTRUMENTATION; MULTICENTER
AB Introduction: Early onset scoliosis can be both a disfiguring as well as a life threatening condition. When more conservative treatments fail, pediatric spinal surgeons are forced to consider operative interventions. Traditionally, these interventions have involved the insertion of a variety of implants into the patient with a limited number of anchor points controlling the spine. In the past, these pediatric patients have had multiple surgeries for elective lengthening of these devices to facilitate their growth while attempting to control the scoliosis. These patients often experience a physical and emotional toll from their multiple repeated surgeries. Growing spine techniques have also had a noted high complication rate due to implant dislodgement and infections. Recently, the development of non-invasively, self-lengthening growing rods has occurred. These devices have the potential to allow for the devices to be lengthened magnetically in a conscious patient in the surgeon's office.Areas covered: This review summarized previously published articles in the English literature using a key word search in PubMed for: magnetically controlled growing rods', Magec rods', magnetic growing rods' and growing rods'.Expert commentary: Magnetically controlled growing rods have an advantage over growing rods in lengthening the growing spine in the absence of repetitive surgeries.
C1 [Metkar, Umesh] BIDMC, Spine Ctr, Boston, MA USA.
[Kurra, Swamy; Albanese, Stephen; Lavelle, William F.] SUNY Upstate Med Univ, Dept Orthoped Surg, 750 E Adams St, Syracuse, NY 13210 USA.
[Quinzi, David] SUNY Upstate Med Univ, 750 E Adams St, Syracuse, NY 13210 USA.
RP Lavelle, WF (reprint author), SUNY Upstate Med Univ, Dept Orthoped Surg, 750 E Adams St, Syracuse, NY 13210 USA.
EM lavellew@upstate.edu
FU IntegraLife; DePuy; Medtronic; Vertebral Technologies, Inc.; Sigmus,
Inc.; Spinal Kinetics, Inc.; K2M, Inc; Providence Technolgies; Stryker
FX W. Lavelle received grants from IntegraLife, DePuy, Medtronic, Vertebral
Technologies, Inc. Sigmus, Inc. Spinal Kinetics, Inc. K2M, Inc,
Providence Technolgies, Stryker that are outside of the submitted work.
The authors have no other relevant affiliations or financial involvement
with any organization or entity with a financial interest in or
financial conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
NR 48
TC 1
Z9 1
U1 1
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1743-4440
EI 1745-2422
J9 EXPERT REV MED DEVIC
JI Expert Rev. Med. Devices
PD FEB
PY 2017
VL 14
IS 2
BP 117
EP 126
DI 10.1080/17434440.2016.1274230
PG 10
WC Engineering, Biomedical
SC Engineering
GA EM1TB
UT WOS:000395098800004
PM 28044467
ER
PT J
AU Mahajan, N
Wu, HJ
Bennett, RL
Troche, C
Licht, JD
Weber, JD
Maggi, LB
Tomasson, MH
AF Mahajan, Nitin
Wu, Hua-Jun
Bennett, Richard L.
Troche, Catalina
Licht, Jonathan D.
Weber, Jason D.
Maggi, Leonard B., Jr.
Tomasson, Michael H.
TI Sabotaging of the oxidative stress response by an oncogenic noncoding
RNA
SO FASEB JOURNAL
LA English
DT Article
DE ACA11; multiple myeloma; NRF2; ROS; snoRNA
ID SMALL NUCLEOLAR RNAS; MULTIPLE-MYELOMA; GENE-EXPRESSION; CANCER; CELLS;
TRANSLOCATION; MMSET; FGFR3
AB Overexpression of the multiple myeloma set domain (MMSET) Wolf-Hirschhorn syndrome candidate 1 gene, which contains an orphan box H/ACA class small nucleolar RNA, ACA11, in an intron, is associated with several cancer types, including multiple myeloma (MM). ACA11 and MMSET are overexpressed cotranscriptionally as a result of the t(4; 14) chromosomal translocation in a subset of patients with MM. RNA sequencing of CD138(+) tumor cells from t(4; 14)-positive and -negativeMMpatient bone marrow samples revealed an enhanced oxidative phosphorylation mRNA signature. Supporting these data, ACA11 overexpression in a t(4; 14)-negative MM cell line, MM1. S, demonstrated enhanced reactive oxygen species (ROS) levels. In addition, an enhancement of cell proliferation, increased soft agar colony size, and elevated ERK1/2 phosphorylation were observed. This ACA11-driven hyperproliferative phenotype depended on increased ROS levels as exogenously added antioxidants attenuate the increased proliferation. A major transcriptional regulator of the cellular antioxidant response, nuclear factor (erythroid-derived 2)-like 2 (NRF2), shuttled to the nucleus, as expected, in response to ACA11-driven increases in ROS; however, transcriptional up-regulation of some of NRF2's antioxidant target genes was abrogated in the presence of ACA11 overexpression. These data show for the first time that ACA11 promotes proliferation through inhibition of NRF2 function resulting in sustained ROS levels driving cancer cell proliferation.-Mahajan, N., Wu, H.-J., Bennett, R. L., Troche, C., Licht, J. D., Weber, J. D., Maggi, L. B., Jr., Tomasson, M. H. Sabotaging of the oxidative stress response by an oncogenic noncoding RNA.
C1 [Mahajan, Nitin; Weber, Jason D.; Maggi, Leonard B., Jr.; Tomasson, Michael H.] Washington Univ, Siteman Canc Ctr, Sch Med, Dept Med,Div Oncol, Box 8069,660 South Euclid Ave, St Louis, MO 63110 USA.
[Wu, Hua-Jun] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Bennett, Richard L.; Troche, Catalina; Licht, Jonathan D.] Univ Florida, Coll Med, Univ Florida Hlth Canc Ctr, Dept Med,Div Hematol & Oncol, Gainesville, FL USA.
RP Maggi, LB; Tomasson, MH (reprint author), Washington Univ, Siteman Canc Ctr, Sch Med, Dept Med,Div Oncol, Box 8069,660 South Euclid Ave, St Louis, MO 63110 USA.
EM lmaggi@dom.wustl.edu; tomasson@dom.wustl.edu
FU U.S. National Institutes of Health, National Cancer Institute
[R01-CA174743, R01-CA-175349]
FX This work was supported, in part, by the U.S. National Institutes of
Health, National Cancer Institute (Grants R01-CA174743 to M.H.T. and
L.B.M., and R01-CA-175349 to M.H.T.). The authors thank M. Bates
(University of Iowa, Iowa City, IA, USA) for her critical review. The
authors also thank all the members of the M.H.T. laboratory for
discussion and suggestions, and the Genome Technology Access Center
(Department of Genetics, Washington University School of Medicine) for
help with genomic analysis.
NR 31
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD FEB
PY 2017
VL 31
IS 2
BP 482
EP 490
DI 10.1096/fj.201600654R
PG 9
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA EK9HR
UT WOS:000394235400005
PM 28148777
ER
PT J
AU Carnemolla, R
Villa, CH
Greineder, CF
Zaitsev, S
Patel, KR
Kowalska, MA
Atochin, DN
Cines, DB
Siegel, DL
Esmon, CT
Muzykantov, VR
AF Carnemolla, Ronald
Villa, Carlos H.
Greineder, Colin F.
Zaitsev, Sergei
Patel, Kruti R.
Kowalska, M. Anna
Atochin, Dmitriy N.
Cines, Douglas B.
Siegel, Don L.
Esmon, Charles T.
Muzykantov, Vladimir R.
TI Targeting thrombomodulin to circulating red blood cells augments its
protective effects in models of endotoxemia and ischemia-reperfusion
injury
SO FASEB JOURNAL
LA English
DT Article
DE sepsis; inflammation; coagulation; pharmacokinetics; drug delivery
ID ACTIVATED PROTEIN-C; DISSEMINATED INTRAVASCULAR COAGULATION; HUMAN
SOLUBLE THROMBOMODULIN; HEMOLYTIC-UREMIC SYNDROME; REDUCES INFARCT
VOLUME; LECTIN-LIKE DOMAIN; SEVERE SEPSIS; SEPTIC SHOCK; MEMBRANE
RIGIDITY; FUSION PROTEIN
AB Endothelial thrombomodulin (TM) regulates coagulation and inflammation via several mechanisms, including production of activated protein C (APC). Recombinant APC and soluble fragments of TM (sTM) have been tested in settings associated with insufficiency of the endogenous TM/APC pathway, such as sepsis. We previously designed a fusion protein of TM [single-chain variable fragment antibody (scFv)/TM] targeted to red blood cells (RBCs) to improve pharmacokinetics and antithrombotic effects without increasing bleeding. Here, scFv/TM was studied in mouse models of systemic inflammation and ischemia-reperfusion injury. Injected concomitantly with or before endotoxin, scFv/TM provided more potent protection against liver injury and release of pathological mediators than sTM, showing similar efficacy at up to 50-fold lower doses. scFv/TM provided protection when injected after endotoxin, whereas sTM did not, and augmented APC production by thrombin similar to 50-fold more than sTM. However, scFv/TM injected after endotoxin did not reduce thrombin/antithrombin complexes; nor did antibodies that block APC anticoagulant activity suppress the prophylactic anti-inflammatory effect of scFv/TM. Therefore, similar to endogenous TM, RBC-anchored scFv/TM activates several protective pathways. Finally, scFv/TM was more effective at reducing cerebral infarct volume and alleviated neurological deficits than sTM after cerebral ischemia/reperfusion injury. These results indicate that RBC-targeted scFv/TM exerts multifaceted cytoprotective effects and may find utility in systemic and focal inflammatory and ischemic disorders.
C1 [Carnemolla, Ronald; Villa, Carlos H.; Greineder, Colin F.; Zaitsev, Sergei; Muzykantov, Vladimir R.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.
[Carnemolla, Ronald; Villa, Carlos H.; Greineder, Colin F.; Zaitsev, Sergei; Esmon, Charles T.; Muzykantov, Vladimir R.] Univ Penn, Ctr Targeted Therapeut & Translat Nanomed, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA.
[Villa, Carlos H.; Zaitsev, Sergei; Cines, Douglas B.; Siegel, Don L.] Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA.
[Villa, Carlos H.; Zaitsev, Sergei; Cines, Douglas B.; Siegel, Don L.] Univ Penn, Lab Med, Philadelphia, PA 19104 USA.
[Patel, Kruti R.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Kowalska, M. Anna] Childrens Hosp Philadelphia, Dept Pediat, Div Hematol, Philadelphia, PA 19104 USA.
[Kowalska, M. Anna] Polish Acad Sci, Inst Med Biol, Lodz, Poland.
[Atochin, Dmitriy N.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Div Cardiol, Charlestown, MA USA.
[Esmon, Charles T.] Oklahoma Med Res Fdn, Dept Pathol, Oklahoma City, OK USA.
[Esmon, Charles T.] Oklahoma Med Res Fdn, Dept Biochem & Mol Biol, Coagulat Biol Lab, Oklahoma City, OK USA.
RP Muzykantov, VR (reprint author), Univ Penn, Perelman Sch Med, TRC 10-125,3400 Civ Ctr Blvd,Bldg 421, Philadelphia, PA 19104 USA.
EM muzykant@mail.med.upenn.edu
FU U.S. National Institutes of Health, National Heart, Lung, and Blood
Institute [R01 HL121134, R01 HL125462, R01 HL116916-01, R01 HL091950,
K08-HL 130430, 7UM1 HL120877-TACTIC]
FX The authors thank Dr. Mortimer Poncz, The Children's Hospital of
Philadelphia, for his scientific counsel and support of the study. This
work was supported by U.S. National Institutes of Health, National
Heart, Lung, and Blood Institute Grants R01 HL121134, R01 HL125462, R01
HL116916-01, R01 HL091950, K08-HL 130430, and 7UM1 HL120877-TACTIC. The
authors declare no conflicts of interest.
NR 68
TC 0
Z9 0
U1 0
U2 0
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD FEB
PY 2017
VL 31
IS 2
BP 761
EP 770
DI 10.1096/fj.201600912R
PG 10
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics; Cell Biology
GA EK9HR
UT WOS:000394235400028
PM 27836986
ER
PT J
AU Isakoff, SJ
Puhalla, S
Domchek, SM
Friedlander, M
Kaufman, B
Robson, M
Telli, ML
Dieras, V
Han, HS
Garber, JE
Johnson, EF
Maag, D
Qin, Q
Giranda, VL
Shepherd, SP
AF Isakoff, Steven J.
Puhalla, Shannon
Domchek, Susan M.
Friedlander, Michael
Kaufman, Bella
Robson, Mark
Telli, Melinda L.
Dieras, Veronique
Han, Hyo Sook
Garber, Judy E.
Johnson, Eric F.
Maag, David
Qin, Qin
Giranda, Vincent L.
Shepherd, Stacie P.
TI A randomized Phase II study of veliparib with temozolomide or
carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in
BRCA1/2 metastatic breast cancer: design and rationale
SO FUTURE ONCOLOGY
LA English
DT Article
DE BRCA1; BRCA2; breast cancer; DNA damage; PARP; PARP inhibitor; PARP
trapping; synthetic lethality; veliparib
ID POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; OLAPARIB MAINTENANCE THERAPY;
PRIMARY PERITONEAL CANCER; PARP INHIBITORS; EPITHELIAL OVARIAN;
CLINICAL-TRIAL; FALLOPIAN-TUBE; DNA-DAMAGE; COMBINATION; ABT-888
AB Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I-III clinical trials, including Phase III studies in non-small-cell lung cancer, ovarian cancer and breast cancer. Tumor cells with deleterious BRCA1 or BRCA2 mutations are deficient in homologous recombination DNA repair and are intrinsically sensitive to platinum therapy and poly(ADP-ribose) polymerase inhibitors. We describe herein the design and rationale of a Phase II trial investigating whether the addition of veliparib to temozolomide or carboplatin/paclitaxel provides clinical benefit over carboplatin/paclitaxel with placebo in patients with locally recurrent or metastatic breast cancer harboring a deleterious BRCA1 or BRCA2 germline mutation
C1 [Isakoff, Steven J.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Puhalla, Shannon] Univ Pittsburgh, Dept Med, Inst Canc, Pittsburgh, PA 15232 USA.
[Domchek, Susan M.] Univ Penn, Basser Ctr BRCA, Philadelphia, PA 19104 USA.
[Friedlander, Michael] Royal Hosp Women, Gynaecol Canc Ctr, Sydney, NSW 2031, Australia.
[Kaufman, Bella] Chaim Sheba Med Ctr, Dept Gen Oncol, IL-52621 Ramat Gan, Israel.
[Robson, Mark] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10022 USA.
[Telli, Melinda L.] Stanford Univ, Dept Med Oncol, Sch Med, Stanford, CA 94305 USA.
[Dieras, Veronique] Inst Curie, Dept Med Oncol, F-75248 Paris, France.
[Han, Hyo Sook] H Lee Moffitt Canc Ctr & Res Inst, Ctr Womens Oncol, Tampa, FL 33612 USA.
[Garber, Judy E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Johnson, Eric F.; Maag, David; Qin, Qin; Giranda, Vincent L.; Shepherd, Stacie P.] AbbVie Inc, Chicago, IL 60064 USA.
RP Isakoff, SJ (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
EM SISAKOFF@mgh.harvard.edu
FU Genentech; Pharmamar; AbbVie; Covance-Bayer; Lilly; Incyte; Novartis;
Pfizer; AstraZeneca; BioMarin; Puma; Clovis; Medivation; Myriad;
Corcept; Karyopharm; Merrimack; Prescient; TapImmune; Myriad Genetics;
Ambry Genetics; AbbVie Inc.
FX SJ Isakoff: Consultant - AbbVie, Myriad; Research support - Genentech,
Pharmamar, AbbVie. S Puhalla: Consultant - AbbVie, Celldex, Pfizer;
Research funding to institution, AbbVie, Covance-Bayer, Lilly, Incyte,
Novartis, Pfizer, Genentech, AstraZeneca, BioMarin, Puma. S Domchek:
Consulting, EMD Serono, AbbVie; Research support (institution) - AbbVie,
Clovis, AstraZeneca, Pharmamar. M Friedlander: Advisory boards and
honoraria - AstraZeneca, Roche and Pfizer. B Kaufman: Nothing to report.
M Robson: Consulting - AstraZeneca; Research support (institution) -
AbbVie, BioMarin, Medivation, AstraZeneca, Myriad. M Telli: Research
funding (institution) - AbbVie, BioMarin, Medivation, Pharmamar;
Consultant - AstraZeneca. V Dieras: Honoraria - AB Roche Genentech,
Novartis, Pfizer, AbbVie; Symposia - Roche Genentech, Novartis, Pfizer.
HS Han: Research support (institution) - AbbVie, Corcept, Incyte,
Karyopharm, Merrimack, Prescient, TapImmune. JE Garber: Consulting or
Advisory Role Biogen, GTx Pharmaceuticals (spouse), Helix, Novartis
(spouse), Pfizer (spouse), Pfizer, Sequenom, SV Life Sciences (spouse);
Research Funding - Myriad Genetics, Novartis (spouse), Pfizer (spouse),
Ambry Genetics. E Johnson, D Maag, Q Qin, VL Giranda, SP Shepherd:
AbbVie employees and stock owners. AbbVie Inc. provided financial
support for this study and participated in the design, study conduct,
analysis and interpretation of the data, as well as the writing, review
and approval of this manuscript. The authors have no other relevant
affiliations or financial involvement with any organization or entity
with a financial interest in or financial conflict with the subject
matter or materials discussed in the manuscript apart from those
disclosed.; Medical writing support was provided by D Eickermann, PhD,
TRM Oncology, Atlanta, GA, funded by AbbVie Inc.
NR 60
TC 1
Z9 1
U1 0
U2 0
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PD FEB
PY 2017
VL 13
IS 4
BP 307
EP 320
DI 10.2217/fon-2016-0412
PG 14
WC Oncology
SC Oncology
GA EL1QI
UT WOS:000394394600004
PM 27739325
ER
PT J
AU Neto, JL
Lee, JM
Afridi, A
Gillis, T
Guide, JR
Dempsey, S
Lager, B
Alonso, I
Wheeler, VC
Pinto, RM
AF Luis Neto, Joao
Lee, Jong-Min
Afridi, Ali
Gillis, Tammy
Guide, Jolene R.
Dempsey, Stephani
Lager, Brenda
Alonso, Isabel
Wheeler, Vanessa C.
Pinto, Ricardo Mouro
TI Genetic Contributors to Intergenerational CAG Repeat Instability in
Huntington's Disease Knock-In Mice
SO GENETICS
LA English
DT Article
DE Huntington's disease; intergenerational CAG repeat instability; HD
knock-in mouse models; genetic background
ID NON-MENDELIAN TRANSMISSION; MYOTONIC-DYSTROPHY LOCUS;
MACHADO-JOSEPH-DISEASE; SINGLE SPERM ANALYSIS; AGE-OF-ONSET; (CAG)(N)
REPEAT; TRINUCLEOTIDE REPEATS; REDUCED PENETRANCE; HAPLOTYPE ANALYSIS;
TRANSGENIC MICE
AB Huntington's disease (HD) is a neurodegenerative disorder caused by the expansion of a CAG trinucleotide repeat in exon 1 of the HTT gene. Longer repeat sizes are associated with increased disease penetrance and earlier ages of onset. Intergenerationally unstable transmissions are common in HD families, partly underlying the genetic anticipation seen in this disorder. HD CAG knock-in mouse models also exhibit a propensity for intergenerational repeat size changes. In this work, we examine intergenerational instability of the CAG repeat in over 20,000 transmissions in the largest HD knock-in mouse model breeding datasets reported to date. We confirmed previous observations that parental sex drives the relative ratio of expansions and contractions. The large datasets further allowed us to distinguish effects of paternal CAG repeat length on the magnitude and frequency of expansions and contractions, as well as the identification of large repeat size jumps in the knock-in models. Distinct degrees of intergenerational instability were observed between knock-in mice of six background strains, indicating the occurrence of trans-acting genetic modifiers. We also found that lines harboring a neomycin resistance cassette upstream of Htt showed reduced expansion frequency, indicative of a contributing role for sequences in cis, with the expanded repeat as modifiers of intergenerational instability. These results provide a basis for further understanding of the mechanisms underlying intergenerational repeat instability.
C1 [Luis Neto, Joao; Lee, Jong-Min; Afridi, Ali; Gillis, Tammy; Guide, Jolene R.; Wheeler, Vanessa C.; Pinto, Ricardo Mouro] Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St, Boston, MA 02114 USA.
[Luis Neto, Joao; Alonso, Isabel] UnIGENe, Inst Biol Mol & Celular, P-4200 Oporto, Portugal.
[Luis Neto, Joao; Alonso, Isabel] Inst Invest & Inovacao Saude, P-4200 Oporto, Portugal.
[Luis Neto, Joao] Univ Porto, Grad Program Areas Basic & Appl Biol, Abel Salazar Biomed Sci Inst, P-4050 Oporto, Portugal.
[Alonso, Isabel] Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4050 Oporto, Portugal.
[Lee, Jong-Min; Wheeler, Vanessa C.; Pinto, Ricardo Mouro] Harvard Med Sch, Dept Neurol, Boston, MA 02115 USA.
[Dempsey, Stephani] Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.
[Lager, Brenda] CHDI Fdn, Princeton, NJ 08540 USA.
RP Wheeler, VC; Pinto, RM (reprint author), Massachusetts Gen Hosp, Ctr Human Genet Res, 185 Cambridge St, Boston, MA 02114 USA.
EM Wheeler@helix.mgh.harvard.edu; RMouroPinto@mgh.harvard.edu
FU Fundacao para a Ciencia e a Tecnologia (FCT) [SFRH/BD/51705/2011];
National Institutes of Health [NS049206]
FX J.L.N. is a recipient of a Fundacao para a Ciencia e a Tecnologia (FCT)
fellowship (SFRH/BD/51705/2011; www.fct.pt). This work was supported by
the National Institutes of Health [NS049206] grant attributed to V.C.W.
NR 58
TC 0
Z9 0
U1 0
U2 0
PU GENETICS SOCIETY AMERICA
PI BETHESDA
PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA
SN 0016-6731
EI 1943-2631
J9 GENETICS
JI Genetics
PD FEB
PY 2017
VL 205
IS 2
BP 503
EP 516
DI 10.1534/genetics.116.195578
PG 14
WC Genetics & Heredity
SC Genetics & Heredity
GA EK7ZY
UT WOS:000394144900004
PM 27913616
ER
PT J
AU Schnell-Inderst, P
Iglesias, CP
Arvandi, M
Ciani, O
Gothe, RM
Peters, J
Blom, AW
Taylor, RS
Siebert, U
AF Schnell-Inderst, Petra
Iglesias, Cynthia P.
Arvandi, Marjan
Ciani, Oriana
Gothe, Raffaella Matteucci
Peters, Jaime
Blom, Ashley W.
Taylor, Rod S.
Siebert, Uwe
TI A bias-adjusted evidence synthesis of RCT and observational data: the
case of total hip replacement
SO HEALTH ECONOMICS
LA English
DT Article
DE medical devices; health technology assessment; generalized evidence
synthesis; bias adjustment; expert elicitation
ID RANDOMIZED CONTROLLED-TRIALS; CEMENTED ALL-POLYETHYLENE; SECONDARY DATA
SOURCES; EXTERNAL VALIDITY; MEDICAL DEVICES; ARTHROPLASTY; OUTCOMES;
DESIGN; EUROPE; AGE
AB Evaluation of clinical effectiveness of medical devices differs in some aspects from the evaluation of pharmaceuticals. One of the main challenges identified is lack of robust evidence and a will to make use of experimental and observational studies (OSs) in quantitative evidence synthesis accounting for internal and external biases. Using a case study of total hip replacement to compare the risk of revision of cemented and uncemented implant fixation modalities, we pooled treatment effect estimates from OS and RCTs, and simplified existing methods for bias-adjusted evidence synthesis to enhance practical application. We performed an elicitation exercise using methodological and clinical experts to determine the strength of beliefs about the magnitude of internal and external bias affecting estimates of treatment effect. We incorporated the bias-adjusted treatment effects into a generalized evidence synthesis, calculating both frequentist and Bayesian statistical models. We estimated relative risks as summary effect estimates with 95% confidence/credibility intervals to capture uncertainty. When we compared alternative approaches to synthesizing evidence, we found that the pooled effect size strongly depended on the inclusion of observational data as well as on the use bias-adjusted estimates. We demonstrated the feasibility of using observational studies in meta-analyses to complement RCTs and incorporate evidence from a wider spectrum of clinically relevant studies and healthcare settings. To ensure internal validity, OS data require sufficient correction for confounding and selection bias, either through study design and primary analysis, or by applying post-hoc bias adjustments to the results. (c) 2017 The Authors. Health Economics published by John Wiley & Sons, Ltd.
C1 [Schnell-Inderst, Petra; Arvandi, Marjan; Gothe, Raffaella Matteucci; Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & Hlth Technol As, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Eduard Wallnoefer Ctr I, A-6060 Hall In Tirol, Austria.
[Iglesias, Cynthia P.] Univ York, Dept Hlth Sci, Heslington, England.
[Iglesias, Cynthia P.] Univ York, Ctr Hlth Econ, York, N Yorkshire, England.
[Iglesias, Cynthia P.] Univ York, Hull & York Med Sch, York, N Yorkshire, England.
[Iglesias, Cynthia P.] Luxemboug Inst Hlth, Luxembourg, Luxembourg.
[Ciani, Oriana; Peters, Jaime; Taylor, Rod S.] Univ Exeter, Sch Med, Inst Hlth Serv Res, Exeter, Devon, England.
[Ciani, Oriana] Bocconi Univ, Ctr Res Hlth & Social Care Management, Milan, Italy.
[Blom, Ashley W.] Univ Bristol, Musculoskeletal Res Unit, Bristol, Avon, England.
[Siebert, Uwe] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA USA.
[Siebert, Uwe] Harvard Med Sch, Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA USA.
[Siebert, Uwe] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA.
RP Schnell-Inderst, P (reprint author), UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & Hlth Technol As, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Eduard Wallnoefer Ctr I, A-6060 Hall In Tirol, Austria.
EM petra.schnell-inderst@umit.at
FU European Community [HEALTH-F3-2012-305694]
FX The research leading to these results has received funding from the
European Community's Seventh Framework Programme under grant agreement
HEALTH-F3-2012-305694 (Project MedtecHTA 'Methods for Health Technology
Assessment of Medical Devices: a European Perspective'). We are
extremely grateful to the clinical and methodological experts who took
the time from their busy schedules to participate in the study. Without
their support, we would have never achieved the results presented in
this manuscript. All errors are ours.
NR 53
TC 5
Z9 5
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9230
EI 1099-1050
J9 HEALTH ECON
JI Health Econ.
PD FEB
PY 2017
VL 26
SU S1
BP 46
EP 69
DI 10.1002/hec.3474
PG 24
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA EL5FE
UT WOS:000394646200005
PM 28139089
ER
PT J
AU Hung, J
Levine, RA
AF Hung, Judy
Levine, Robert A.
TI Pixels or Pixie Dust? Grading of mitral regurgitation using intensity
analysis of continuous wave Doppler
SO HEART
LA English
DT Editorial Material
ID QUANTIFICATION; FLOW; AREA
C1 [Hung, Judy; Levine, Robert A.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Hung, J (reprint author), Massachusetts Gen Hosp, Echocardiog, Blake 256,55 Fruit St, Boston, MA 02114 USA.
EM jhung@mgh.harvard.edu
NR 6
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1355-6037
EI 1468-201X
J9 HEART
JI Heart
PD FEB
PY 2017
VL 103
IS 3
BP 177
EP 178
DI 10.1136/heartjnl-2016-310293
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EL3HM
UT WOS:000394510200002
PM 27609944
ER
PT J
AU Kim, JH
Ko, YA
Hedley, J
MacNamara, J
Awad, M
Taylor, W
Healy, S
Aida, H
Le, NA
Wilson, PW
White, M
Sperling, LS
Wilson, JS
Baggish, AL
AF Kim, Jonathan H.
Ko, Yi-An
Hedley, Jeff
MacNamara, James
Awad, Mosaab
Taylor, William
Healy, Sean
Aida, Hiroshi
Le, Ngoc-Anh
Wilson, Peter W.
White, Melissa
Sperling, Laurence S.
Wilson, Joseph S., Jr.
Baggish, Aaron L.
TI The impact of moderate distance recreational running and ageing on
cardiac physiology
SO HEART
LA English
DT Article
ID PROLONGED ENDURANCE EXERCISE; BRAIN NATRIURETIC PEPTIDE; TROPONIN-I;
VENTRICULAR DYSFUNCTION; HEART-FAILURE; BIOMARKERS; RECOMMENDATIONS;
INCREASES; ASSAY; RUN
AB Objective Exercise-induced cardiac dysfunction and corollary biomarker release have been documented following long-distance running events. To what degree these processes occur during shorter distance running events is unknown.
Methods 72 healthy recreational runners (54% male/46% female) recruited by age (group 1 (18-20 years old, N=19); group 2 (45-50 years old, N=27); group 3 (70-75 years old, N= 26)) were studied with echocardiography and biochemical profiling during participation in a 10 km running race.
Results Despite age-dependent baseline differences in ventricular size and diastolic tissue velocities, there were no significant within group or across group decrements in ventricular systolic or diastolic function following race completion. Postrace increases in cardiac troponin-I (cTnI), B-type natriuretic peptide (BNP) and high-sensitivity C-reactive protein (hs-CRP) were common and demonstrated distinct age dependent profiles. Specifically, BNP increases were most pronounced among older runners (group 3 Delta: 16 +/- 22 pg/mL, p=0.001), hs-CRP increased only among younger runners (group 1 Delta: 1.5 +/- 2.7 mg/L, p=0.03) and cTnI increased in both younger (group 1 Delta: 0.01 +/- 0.02 ng/mL, p=0.028) and older (group 3 Delta: 0.01 +/- 0.01 ng/mL, p=0.007) runners, but not middle aged runners (group 2 Delta: 0.00 +/- 0.00 ng/mL, p=0.57).
Conclusions Moderate distance recreational running leads to distinct age-dependent biomarker release but is not associated with cardiac fatigue, a proposed stimulus for pathologic cardiac remodelling that has been observed following longer distance running events.
C1 [Kim, Jonathan H.; Hedley, Jeff; MacNamara, James; Awad, Mosaab; Taylor, William; Healy, Sean; Aida, Hiroshi; Wilson, Peter W.; Sperling, Laurence S.] Emory Clin Cardiovasc Res Inst, Div Cardiol, Atlanta, GA USA.
[Kim, Jonathan H.; Wilson, Joseph S., Jr.] Atlanta Track Club, Atlanta, GA USA.
[Ko, Yi-An] Emory Univ, Dept Biostat & Bioinformat, Atlanta, GA USA.
[Le, Ngoc-Anh; Wilson, Peter W.] Vet Affairs Med Ctr, Biomarker Core Lab, Atlanta, GA 30033 USA.
[White, Melissa] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA.
[Baggish, Aaron L.] Massachusetts Gen Hosp, Cardiovasc Performance Program, Boston, MA 02114 USA.
RP Kim, JH (reprint author), Emory Univ, Sch Med, Clin Cardiovasc Res Inst, 1462 Clifton Rd,NE,Suite 502, Atlanta, GA 30322 USA.
EM jonathan.kim@emory.edu
FU National Institutes of Health [K23 HL128795]
FX JHK is supported by the National Institutes of Health (K23 HL128795).
NR 28
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1355-6037
EI 1468-201X
J9 HEART
JI Heart
PD FEB
PY 2017
VL 103
IS 3
BP 219
EP 226
DI 10.1136/heartjnl-2016-310059
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EL3HM
UT WOS:000394510200009
PM 27530134
ER
PT J
AU Young, RH
AF Young, Robert H.
TI Additional historical comments on pre-invasive testicular germ cell
malignancy
SO HISTOPATHOLOGY
LA English
DT Letter
C1 [Young, Robert H.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Young, RH (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-0167
EI 1365-2559
J9 HISTOPATHOLOGY
JI Histopathology
PD FEB
PY 2017
VL 70
IS 3
BP 499
EP 499
DI 10.1111/his.13061
PG 1
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA EM0CG
UT WOS:000394985800018
PM 27629103
ER
PT J
AU Spracklen, CN
Smith, CJ
Saftlas, AF
Triche, EW
Bjonnes, A
Keating, BJ
Saxena, R
Breheny, PJ
Dewan, AT
Robinson, JG
Hoh, J
Ryckman, KK
AF Spracklen, Cassandra N.
Smith, Caitlin J.
Saftlas, Audrey F.
Triche, Elizabeth W.
Bjonnes, Andrew
Keating, Brendan J.
Saxena, Richa
Breheny, Patrick J.
Dewan, Andrew T.
Robinson, Jennifer G.
Hoh, Josephine
Ryckman, Kelli K.
TI Genetic predisposition to elevated levels of C-reactive protein is
associated with a decreased risk for preeclampsia
SO HYPERTENSION IN PREGNANCY
LA English
DT Article
DE C-reactive protein; genetic epidemiology; genetic risk score;
preeclampsia
ID HIGH BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; BIRTH-WEIGHT; LATER LIFE;
PREGNANCY; VARIANTS; DYSLIPIDEMIA; HYPERTENSION; PATHOGENESIS;
METAANALYSIS
AB Objective: To examine the association between genetic predisposition to elevated C-reactive protein (CRP)and risk for preeclampsia using validated genetic loci for C-reactive protein. Methods: Preeclampsia cases (n = 177) and normotensive controls (n = 116) were selected from live birth certificates to nulliparous Iowa women during the period August 2002-May 2005. Disease status was verified by the medical chart review. Genetic predisposition to CRP was estimated by a genetic risk score on the basis of established loci for CRP levels. Logistic regression analyses were used to evaluate the relationships between the genotype score and preeclampsia. Replication analyses were performed in an independent, US population of preeclampsia cases (n = 516) and controls (n = 1,097) of European ancestry. Results: The genetic risk score (GRS) related to higher levels of CRP demonstrated a significantly decreased risk of preeclampsia (OR 0.89, 95% CI 0.82-0.96). When the GRS was analyzed by quartile, an inverse linear trend was observed (p = 0.0006). The results were similar after adjustments for the body mass index (BMI), smoking, and leisure-time physical activity. In the independent replication population, the association with the CRP GRS was also marginally significant (OR 0.97, 95% CI 0.92, 1.02). Meta-analysis of the two studies was statistically significant (OR 0.95, 95% CI 0.90, 0.99). Conclusion: Our data suggest an inverse, counterintuitive association between the genetic predisposition to elevated levels of CRP and a decreased risk of preeclampsia. This suggests that the blood CRP level is a marker of preeclampsia, but it does not appear to be a factor on the causal pathway.
C1 [Spracklen, Cassandra N.; Smith, Caitlin J.; Saftlas, Audrey F.; Robinson, Jennifer G.; Ryckman, Kelli K.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, 145 Riverside Dr,S471 CPHB, Iowa City, IA 52242 USA.
[Triche, Elizabeth W.] Brown Univ, Div Biol & Med, Dept Epidemiol, Providence, RI 02912 USA.
[Bjonnes, Andrew; Saxena, Richa] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Bjonnes, Andrew; Saxena, Richa] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Bjonnes, Andrew; Saxena, Richa] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Keating, Brendan J.] Univ Penn, Dept Surg, Penn Transplant Inst, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Keating, Brendan J.] Childrens Hosp Philadelphia, Div Genet, Philadelphia, PA 19104 USA.
[Breheny, Patrick J.] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA.
[Dewan, Andrew T.] Yale Sch Publ Hlth, Div Chron Dis Epidemiol, New Haven, CT USA.
[Hoh, Josephine] Yale Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT USA.
RP Ryckman, KK (reprint author), Univ Iowa, Coll Publ Hlth, Dept Epidemiol, 145 Riverside Dr,S471 CPHB, Iowa City, IA 52242 USA.
EM kelli-ryckman@uiowa.edu
FU National Institute of Child Health and Human Development; National
Institutes of Health [R01 HD32579]; Verto Institute; Society for
Obstetric Anesthesia and Perinatology
FX The SOPHIA study was supported by the National Institute of Child Health
and Human Development, National Institutes of Health R01 HD32579 and the
Verto Institute. The replication study was funded in part by a Gertie
Marx Grant from the Society for Obstetric Anesthesia and Perinatology.
NR 36
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1064-1955
EI 1525-6065
J9 HYPERTENS PREGNANCY
JI Hypertens. Pregnancy
PD FEB
PY 2017
VL 36
IS 1
BP 30
EP 35
DI 10.1080/10641955.2016.1223303
PG 6
WC Obstetrics & Gynecology; Physiology; Peripheral Vascular Disease
SC Obstetrics & Gynecology; Physiology; Cardiovascular System & Cardiology
GA EM2XJ
UT WOS:000395178800005
PM 27657194
ER
PT J
AU Jian, YQ
Ye, J
Qi, H
Deng, CY
Deng, SP
Li, FR
AF Jian, You-Qiang
Ye, Jian
Qi, Hui
Deng, Chun-Yan
Deng, Shao-Ping
Li, Fu-Rong
TI Anti-CD45RB and donor-specific spleen cells transfusion inhibition
allograft skin rejection mediated by memory T cells
SO IMMUNOLOGY AND CELL BIOLOGY
LA English
DT Article
AB Donor-reactive memory T (Tm) cells mediate accelerated rejection, which is known as a barrier to the survival of transplanted organs. Selective interference with the anti-CD45RB monoclonal antibody (a-CD45RB) reliably induces donor-specific tolerance. In this study, pre-sensitization to female C57BL/6 mice with the skin of female BLAB/c mice generated a large number of Tm cells and resulted in rapid rejection of the secondly transplanted allografts. alpha-CD45RB did induce the tolerance to skin allograft primarily transplanted but failed to induce tolerance in the pre-sensitized mice. Donor-specific spleen cell transfusion (DST) alone also failed to induce the tolerance in the pre-sensitized recipients. Interestingly, combination of alpha-CD45RB with DST inhibited the rejection induced by memory T cells in the pre-sensitized mice. CD25+ T-cell depletion in alpha-CD45RB combined with DST therapy recipients could prevent skin allograft tolerance from establishing. In addition, adoptive transfer of donorprimed memory T cells into the tolerant recipients markedly broke the established tolerance. Our findings indicate that aCD45RB and DST can synergistically inhibit the accelerated rejection mediated by memory T cells and induce long-term skin allograft acceptance in mice.
C1 [Jian, You-Qiang; Ye, Jian; Li, Fu-Rong] Jinan Univ, Clin Med Coll 2, Dept Gen Surg, Shenzhen Peoples Hosp, Shenzhen, Peoples R China.
[Jian, You-Qiang; Ye, Jian; Qi, Hui; Deng, Chun-Yan; Deng, Shao-Ping; Li, Fu-Rong] Jinan Univ, Clin Med Coll 2, Key Lab Stem Cell & Cellular Therapy, Shenzhen Peoples Hosp, 1017 Dongmen North Rd, Shenzhen 518020, Peoples R China.
[Deng, Shao-Ping] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA.
[Li, Fu-Rong] Shenzhen Cell Therapy Publ Serv Platform, Shenzhen, Peoples R China.
RP Li, FR (reprint author), Jinan Univ, Clin Med Coll 2, Key Lab Stem Cell & Cellular Therapy, Shenzhen Peoples Hosp, 1017 Dongmen North Rd, Shenzhen 518020, Peoples R China.; Deng, SP (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA.
EM sdeng10@yahoo.com; frli62@163.com
FU National Natural Science Foundation of China [30772042]; Natural Science
Foundation of Guangdong [S2013010014832]; Science and Technology Project
of Shenzhen [JCYJ20120618153743791, GJHZ20120618153934353]
FX This work was supported by the National Natural Science Foundation of
China (No. 30772042), and The Natural Science Foundation of Guangdong
(No.S2013010014832) and The Science and Technology Project of Shenzhen
(JCYJ20120618153743791, GJHZ20120618153934353).
NR 45
TC 0
Z9 0
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0818-9641
EI 1440-1711
J9 IMMUNOL CELL BIOL
JI Immunol. Cell Biol.
PD FEB
PY 2017
VL 95
IS 2
BP 189
EP 197
DI 10.1038/icb.2016.88
PG 9
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA EL1EY
UT WOS:000394364500013
PM 27616751
ER
PT J
AU Truong-Bolduc, QC
Khan, NS
Vyas, JM
Hooper, DC
AF Truong-Bolduc, Q. C.
Khan, N. S.
Vyas, J. M.
Hooper, D. C.
TI Tet38 Efflux Pump Affects Staphylococcus aureus Internalization by
Epithelial Cells through Interaction with CD36 and Contributes to
Bacterial Escape from Acidic and Nonacidic Phagolysosomes
SO INFECTION AND IMMUNITY
LA English
DT Article
DE CD36; S. aureus; endosomes; internalization; survival
ID SMALL-COLONY VARIANTS; ENDOTHELIAL-CELLS; INFECTIONS; RESISTANCE;
ADHERENCE; RECEPTOR; PHAGOCYTOSIS; EXPRESSION; APOPTOSIS; IMMUNITY
AB We previously reported that the Tet38 efflux pump is involved in internalization of Staphylococcus aureus by A549 lung epithelial cells. A lack of tet38 reduced bacterial uptake by A549 cells to 36% of that of the parental strain RN6390. Using invasion assays coupled with confocal microscopy imaging, we studied the host cell receptor(s) responsible for bacterial uptake via interaction with Tet38. We also assessed the ability of S. aureus to survive following alkalinization of the phagolysosomes by chloroquine. Antibody to the scavenger receptor CD36 reduced the internalization of S. aureus RN6390 by A549 cells, but the dependence on CD36 was reduced in QT7 tet38, suggesting that an interaction between Tet38 and CD36 contributed to S. aureus internalization. Following fusion of the S. aureus-associated endosomes with lysosomes, alkalinization of the acidic environment with chloroquine led to a rapid increase in the number of S. aureus RN6390 bacteria in the cytosol, followed by a decrease shortly thereafter. This effect of chloroquine was not seen in the absence of intact Tet38 in mutant QT7. These data taken together suggest that Tet38 plays a role both in bacterial internalization via interaction with CD36 and in bacterial escape from the phagolysosomes.
C1 [Truong-Bolduc, Q. C.; Khan, N. S.; Vyas, J. M.; Hooper, D. C.] Harvard Med Sch, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02115 USA.
RP Hooper, DC (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02115 USA.
EM dhooper@mgh.harvard.edu
FU U.S. Public Health Service from the National Institutes of Health
[R37-AI23988, P01-AI083214]
FX This work was supported by U.S. Public Health Service grants R37-AI23988
and P01-AI083214 (M. Gilmore, Principal Investigator) from the National
Institutes of Health to D.C.H.
NR 41
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD FEB
PY 2017
VL 85
IS 2
AR e00862-16
DI 10.1128/IAI.00862-16
PG 13
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EL4RZ
UT WOS:000394609900019
ER
PT J
AU Dohlman, TH
Ding, J
Dana, R
Chauhan, SK
AF Dohlman, Thomas H.
Ding, Julia
Dana, Reza
Chauhan, Sunil K.
TI T Cell-Derived Granulocyte-Macrophage Colony-Stimulating Factor
Contributes to Dry Eye Disease Pathogenesis by Promoting CD11b+Myeloid
Cell Maturation and Migration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE cornea; dry eye; Th17 cell; granulocyte-macrophage colony-stimulating
factor; monocyte/macrophage
ID CYTOKINE GM-CSF; DENDRITIC CELLS; HUMAN-MONOCYTES; OCULAR-SURFACE; TH17
CELLS; AUTOIMMUNITY; INFLAMMATION; EXPRESSION; INDUCTION; BARRIER
AB PURPOSE. Growing evidence suggests that granulocyte-macrophage colony-stimulating factor (GM-CSF) contributes to T helper 17 (Th17) cell-associated immunoinflammatory diseases. The purpose of this study was to evaluate the effect of T cell-derived GM-CSF on CD11b+ myeloid cell function in dry eye disease (DED).
METHODS. In a murine model of DED, quantitative real-time PCR and ELISA were used to measure GM-CSF expression at the ocular surface, and flow cytometry was used to enumerate GM-CSF producing Th17 cells. A granulocyte-macrophage colony-stimulating factor neutralizing antibody was used topically in vivo and in an in vitro culture system to evaluate the role of GM-CSF in recruiting and maturing CD11b+ cells. Clinical disease severity was evaluated after topical administration of GM-CSF neutralizing antibody.
RESULTS. In dry eye disease, GM-CSF is significantly upregulated at the ocular surface and the frequency of GM-CSF producing Th17 cells is significantly increased in the draining lymph nodes. In vitro neutralization of GM-CSF from CD4+ T cells derived from DED mice suppresses major histocompatibility complex II expression by CD11b+ cells and CD11b+ cell migration. Topical neutralization of GM-CSF in a murine model of DED suppresses CD11b+ maturation and migration, as well as Th17 cell induction, yielding a reduction in clinical signs of disease.
CONCLUSIONS. T helper 17 cell-derived GM-CSF contributes to DED pathogenesis by promoting CD11b+ cell activation and migration to the ocular surface.
C1 [Dohlman, Thomas H.; Ding, Julia; Dana, Reza; Chauhan, Sunil K.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA USA.
RP Dana, R; Chauhan, SK (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM reza_dana@meei.harvard.edu; sunil_chauhan@meei.harvard.edu
FU National Institute of Health [EY024602, EY020889]
FX The authors thank Susanne Eiglmeier for her assistance in editing and
preparing the manuscript. Supported in part by National Institute of
Health Grants EY024602 (SKC) and EY020889 (RD).
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2017
VL 58
IS 2
DI 10.1167/iovs.16-20789
PG 7
WC Ophthalmology
SC Ophthalmology
GA EO8LC
UT WOS:000396939600073
ER
PT J
AU Jakobs, TC
AF Jakobs, Tatjana C.
TI Ex Vivo Imaging of the Murine Optic Nerve Head
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Editorial Material
C1 [Jakobs, Tatjana C.] Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02115 USA.
RP Jakobs, TC (reprint author), Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02115 USA.
EM Tatjana_Jakobs@meei.harvard.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2017
VL 58
IS 2
DI 10.1167/iovs.17-21422
PG 1
WC Ophthalmology
SC Ophthalmology
GA EO8LC
UT WOS:000396939600004
PM 28152143
ER
PT J
AU Kim, EC
Toyono, T
Berlinicke, CA
Zack, DJ
Jurkunas, U
Usui, T
Jun, AS
AF Kim, Eun Chul
Toyono, Tetsuya
Berlinicke, Cynthia A.
Zack, Donald J.
Jurkunas, Ula
Usui, Tomohiko
Jun, Albert S.
TI Screening and Characterization of Drugs That Protect Corneal Endothelial
Cells Against Unfolded Protein Response and Oxidative Stress
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE drug screening; corneal endothelial cells; unfolded protein response;
oxidative stress; Fuchs' endothelial corneal dystrophy
ID ENDOPLASMIC-RETICULUM STRESS; FUCHS DYSTROPHY; ACTIVATION; APOPTOSIS;
DAMAGE; RATS
AB PURPOSE. To screen for and characterize compounds that protect corneal endothelial cells against unfolded protein response (UPR) and oxidative stress.
METHODS. Bovine corneal endothelial cells (BCECs) were treated for 48 hours with 640 compounds from a Food and Drug Administration (FDA)-approved drug library and then challenged with thapsigargin or H2O2 to induce UPR or oxidative stress, respectively. Cell viability was measured using the CellTiter-Glo survival assay. Selected "hits" were subjected to further dose-response testing, and their ability to modulate expression of UPR and oxidative stress markers was assessed by RT-PCR, Western blot, and measurement of protein carbonyl and 8-hydroxydeoxyguanosine (8-OHdG) adducts in immortalized human corneal endothelial cells (iHCECs).
RESULTS. Forty-one drugs at 20 mu M and 55 drugs at 100 mu M increased survival of H2O2-challenged cells, and 8 drugs at 20 mu M and 2 drugs at 100 mu M increased survival of thapsigargin-challenged cells, compared with untreated control cells. Nicergoline, ergothioneine, nimesulide, oxotremorine, and mefenamic acid increased survival of both H2O2- and thapsigargin-challenged cells. Oxotremorine altered DNA damage inducible 3 (CHOP) gene expression, glucose-regulated protein 78 kDa (GRP78) and activating transcription factor 4 (ATF4) protein expression, and protein carbonyl and 8-OHdG levels. Mefenamic acid altered GRP78 protein expression and protein carbonyl and 8-OHdG levels.
CONCLUSIONS. Oxotremorine and mefenamic acid are potential survival factors for corneal endothelial cells under UPR and oxidative stress. The described assay can be further expanded to screen additional drugs for potential therapeutic effect in corneal endothelial diseases such as Fuchs' endothelial corneal dystrophy.
C1 [Kim, Eun Chul; Toyono, Tetsuya; Berlinicke, Cynthia A.; Zack, Donald J.; Jun, Albert S.] Johns Hopkins Med Inst, Wilmer Eye Inst, 600 N Broadway,Wilmer Woods 376, Baltimore, MD 21287 USA.
[Kim, Eun Chul] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Seoul, South Korea.
[Toyono, Tetsuya; Usui, Tomohiko] Univ Tokyo, Dept Ophthalmol, Tokyo, Japan.
[Zack, Donald J.] Johns Hopkins Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.
[Zack, Donald J.] Johns Hopkins Med Inst, Inst Med Genet, Baltimore, MD 21205 USA.
[Jurkunas, Ula] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Boston, MA USA.
RP Jun, AS (reprint author), Johns Hopkins Med Inst, Wilmer Eye Inst, 600 N Broadway,Wilmer Woods 376, Baltimore, MD 21287 USA.
EM aljun@jhmi.edu
FU J. Willard and Alice S. Marriott Foundation (Bethesda, MD, USA);
National Eye Institute (Bethesda, MD, USA) [EY 019874]; Japan Eye Bank
Association (Tokyo, Japan); EBAA Richard Lindstrom Research Grant
(Washington, DC, USA); Guerrieri Family Foundation (Salisbury, MD, USA)
FX Supported by grants from the J. Willard and Alice S. Marriott Foundation
(Bethesda, MD, USA), Margaret Andrews, Edward Colburn, Lorraine Collins,
Richard Dianich, Mary Finegan, Barbara and Peter Freeman, Stanley
Friedler, MD, Ida Jeffries, Herbert Kasoff, Diane Kemker, Jean Mattison,
Florenz Ourisman, Lee Silverman, Norman Tunkel, PhD, the National Eye
Institute EY 019874 (all to ASJ; Bethesda, MD, USA), Japan Eye Bank
Association (Tokyo, Japan) and EBAA Richard Lindstrom Research Grant
(TT; Washington, DC, USA), and generous support from the Guerrieri
Family Foundation (Salisbury, MD, USA).
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2017
VL 58
IS 2
DI 10.1167/iovs.16-20147
PG 9
WC Ophthalmology
SC Ophthalmology
GA EO8LC
UT WOS:000396939600022
PM 28159976
ER
PT J
AU Wang, R
Seifert, P
Jakobs, TC
AF Wang, Rui
Seifert, Philip
Jakobs, Tatjana C.
TI Astrocytes in the Optic Nerve Head of Glaucomatous Mice Display a
Characteristic Reactive Phenotype
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE astrocytes; glial lamina; glaucoma; electron microscopy; confocal
microscopy
ID ELEVATED INTRAOCULAR-PRESSURE; RETROGRADE AXOPLASMIC-TRANSPORT; INDUCED
OCULAR HYPERTENSION; RETINAL GANGLION-CELLS; LAMINA-CRIBROSA; DBA/2J
MICE; RAT GLAUCOMA; MOUSE MODEL; INHERITED GLAUCOMA; AXONAL-TRANSPORT
AB PURPOSE. Optic nerve head astrocytes, a subtype of white-matter astrocytes, become reactive early in the course of glaucoma. It was shown recently that in the DBA/2J mouse model of inherited glaucoma optic nerve astrocytes extend new longitudinal processes into the axon bundles before ganglion cell loss becomes apparent. The present study aims at testing whether this behavior of astrocytes is typical of early glaucomatous damage.
METHODS. Mice expressing green fluorescent protein in individual astrocytes were used to evaluate the early response of astrocytes in the glial lamina of the optic nerve head after increasing the IOP using the microbead occlusion method. Tissue sections from the glial lamina were imaged consecutively by confocal and electron microscopy.
RESULTS. Confocal and electron microscope images show that astrocytes close to the myelination transition zone in the hypertensive nerve heads extend new processes that follow the longitudinal axis of the optic nerve and invade axon bundles in the nerve head. Ultrastructurally, the longitudinal processes were largely devoid of subcellular organelles except for degenerating mitochondria.
CONCLUSIONS. The longitudinal processes are a common feature of glaucomatous optic nerve astrocytes, whereas they are not observed after traumatic nerve injury. Thus, astrocytes appear to fine-tune their responses to the nature and/or timing of the injury to the neurons that they surround.
C1 [Wang, Rui] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China.
[Wang, Rui; Seifert, Philip; Jakobs, Tatjana C.] Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA.
RP Jakobs, TC (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM Tatjana_Jakobs@meei.harvard.edu
FU NIH [2R01EY019703, R01EY022092, P30EY003790]; Chinese Scholarship
Council; Research to Prevent Blindness
FX Supported by NIH Grants 2R01EY019703 and R01EY022092, the NIH Core Grant
for vision research P30EY003790, and grants from the Chinese Scholarship
Council and Research to Prevent Blindness.
NR 69
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2017
VL 58
IS 2
DI 10.1167/iovs.16-20571
PG 9
WC Ophthalmology
SC Ophthalmology
GA EO8LC
UT WOS:000396939600028
ER
PT J
AU Williams, M
Lewis, W
Franco, W
AF Williams, Maura
Lewis, William
Franco, Walfre
TI Loss of Tryptophan Fluorescence Correlates With Mechanical Stiffness
Following Photo-Crosslinking Treatment of Rabbit Cornea
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE keratoconus; photocrosslinking; fluorescence; spectroscopy
ID KERATOCONUS; RIBOFLAVIN; COLLAGEN; MICROSCOPY; LIGHT; IRRADIATION;
GENERATION; EYES; TIME
AB PURPOSE. A clinical treatment option for keratoconus involves the use of UV-initiated photo-crosslinking with riboflavin to increase corneal stiffness. Our study investigates whether endogenous fluorescence changes following treatment for keratoconus can be correlated to alterations in the stiffness of the cornea, thereby guiding treatment of keratoconus.
METHODS. A total of 78 ex vivo rabbit eyes were treated with either riboflavin-dextran solution plus UV light, dextran solution plus UV light, or riboflavin-dextran solution only for half treatment (2.84 J/cm(2)), standard treatment (5.28 J/cm(2)), or prolonged treatment (15.84 J/cm(2)) times. Fluorescent spectroscopy was performed on all samples before and after treatment. The stress-strain relationship was measured for all samples using a uniaxial tensiometer following treatment.
RESULTS. We found a dose-dependent decrease in the 290/340 nm excitation/emission fluorescence pair with increase in corneal stiffening following treatment that was significant (P < 0.01) for both standard (5.28 J/cm(2) total fluence) and prolonged treatment (15.84 J/cm(2)) times. We did not observe a significant change in this excitation/emission pair for the dextranplus-UV or riboflavin-only treatment groups.
CONCLUSIONS. Loss of fluorescence intensity at the 290/340 nm excitation/emission pair could offer a noninvasive, in situ measurement for guiding the photo-crosslinking treatment of keratoconus. Larger relative decreases in this pair are significantly correlated with longer treatment times and with increases in stiffness and Young's modulus.
C1 [Williams, Maura; Lewis, William; Franco, Walfre] Harvard Med Sch, Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA USA.
RP Franco, W (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 50 Blossom St, Boston, MA 02114 USA.
EM wfranco@mgh.harvard.edu
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2017
VL 58
IS 2
DI 10.1167/iovs.16-20750
PG 6
WC Ophthalmology
SC Ophthalmology
GA EO8LC
UT WOS:000396939600048
PM 28196224
ER
PT J
AU Batson, L
Rizzolo, D
AF Batson, Lora
Rizzolo, Denise
TI Otosclerosis: An update on diagnosis and treatment
SO JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS
LA English
DT Article
DE otosclerosis; hearing loss; bone remodeling; audiometry; cochlear
implant; otic capsule
ID FAR-ADVANCED OTOSCLEROSIS; HEARING-LOSS; MEASLES-VIRUS; COCHLEAR
IMPLANTATION; STAPEDOTOMY; PREVALENCE
AB Otosclerosis is a complex and progressive disease of pathological bone remodeling that affects the otic capsule of the temporal bone, resulting in hearing loss. Although traditional diagnostic methods are still used, improvements in technology and research have paved the way for additional diagnostic techniques and advancements. The traditional treatment of otosclerosis, stapes surgery, is now being augmented or replaced by innovations in hearing aid technology and cochlear implants. Earlier diagnosis of otosclerosis can occur through understanding of the cause, risk factors, and current diagnostic testing.
C1 [Batson, Lora] Massachusetts Gen Hosp, Dept Rheumatol, Boston, MA 02114 USA.
[Rizzolo, Denise] Kean Univ, PA Program, Union, NJ USA.
[Rizzolo, Denise] Pace Complet Program, New York, NY USA.
RP Batson, L (reprint author), Massachusetts Gen Hosp, Dept Rheumatol, Boston, MA 02114 USA.
NR 35
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1547-1896
EI 0893-7400
J9 JAAPA-J AM ACAD PHYS
JI JAAPA-J. Am. Acad. Physician Assist.
PD FEB
PY 2017
VL 30
IS 2
BP 17
EP 22
DI 10.1097/01.JAA.0000511784.21936.1b
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA EP3KQ
UT WOS:000397281600007
PM 28060022
ER
PT J
AU Phillips, HR
Smith, DA
AF Phillips, Hayden R., III
Smith, David A.
TI A patient with a curious case of cyclical vomiting
SO JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS
LA English
DT Article
DE cannabis; hyperemesis syndrome; cyclical vomiting; abdominal pain;
cannabis adverse reactions; excessive bathing
ID CANNABINOID HYPEREMESIS
AB Cannabis-related ED visits are on the rise due to wider legalization and availability of marijuana, and habitual daily use is increasingly common. Cannabis abuse has long been associated with various short-term and longterm adverse reactions. One such reaction is cannabinoid hyperemesis syndrome: cyclical vomiting, nausea, and abdominal pain that only resolves with a warm bath or shower. Healthcare providers must understand the signs and symptoms of cannabinoid hyperemesis syndrome so the problem can be recognized early and patients avoid unnecessary testing.
C1 [Phillips, Hayden R., III] Sacred Heart Hosp, ED, Allentown, PA 18104 USA.
[Smith, David A.] Salus Univ, PA Program, Elkins Pk, PA USA.
[Smith, David A.] Philadelphia VA Med Ctr, Surg ICU, Philadelphia, PA USA.
[Smith, David A.] Mercy Suburban Hosp East Norriton, ED, Norristown, PA USA.
RP Phillips, HR (reprint author), Sacred Heart Hosp, ED, Allentown, PA 18104 USA.
NR 7
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1547-1896
EI 0893-7400
J9 JAAPA-J AM ACAD PHYS
JI JAAPA-J. Am. Acad. Physician Assist.
PD FEB
PY 2017
VL 30
IS 2
DI 10.1097/01.JAA.0000511789.29560.74
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA EP3KQ
UT WOS:000397281600003
ER
PT J
AU Janjua, SA
Pursnani, A
Mayrhofer, T
Puchner, SB
Liu, T
Lu, MT
Maurovich-Horvat, P
Woodard, PK
Chou, E
Fteg, JL
Truong, QA
Ferencik, M
Hoffmann, U
AF Janjua, Sumbal A.
Pursnani, Amit
Mayrhofer, Thomas
Puchner, Stefan B.
Liu, Ting
Lu, Michael T.
Maurovich-Horvat, Pal
Woodard, Pamela K.
Chou, Eric
Fteg, Jerome L.
Truong, Quynh A.
Ferencik, Maros
Hoffmann, Udo
TI Statin Use Is Associated With Fewer High-Risk Plaques on Coronary CT
Angiography
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Letter
ID ACUTE CHEST-PAIN; COMPUTED-TOMOGRAPHY; TRIAL; THERAPY
C1 [Janjua, Sumbal A.; Pursnani, Amit; Mayrhofer, Thomas; Puchner, Stefan B.; Liu, Ting; Lu, Michael T.; Maurovich-Horvat, Pal; Woodard, Pamela K.; Chou, Eric; Fteg, Jerome L.; Truong, Quynh A.; Ferencik, Maros; Hoffmann, Udo] Massachusetts Gen Hosp, Div Cardiac MR PET CT, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA.
RP Janjua, SA (reprint author), Massachusetts Gen Hosp, Div Cardiac MR PET CT, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA.
EM sjanjua@partners.org
FU National Heart, Lungy and Blood Institute [U01HL092040, U01HL092022];
Bayer; Astellas; National Institutes of Health; National Institutes of
Health/National Heart, Lung, and Blood Institute [K23HL098320,
L30HL093896]; St. Jude Medical, American College of Radiology Imaging
Network; Duke Clinical Research Institute; American Heart Association
[13FTF16450001]; National Institutes of Health/National Heart, Lung, and
Blood Institute, HeartFlow Inc.; Siemens Healthcare; American College of
Radiology Imaging Network; Genentech
FX This work was supported by grants from the National Heart, Lungy and
Blood Institute (U01HL092040 and U01HL092022). The contents of this
letter are solely the responsibility of the authors and do not represent
the official views of the National Heart, Lung, and Blood Institute or
the U.S. Department of Health and Human Services. Dr. Woodard has
received research support from Bayer and Astellas; and funding from the
National Institutes of Health. Dr. Truong has received support from the
National Institutes of Health/National Heart, Lung, and Blood Institute
(K23HL098320 and L30HL093896), St. Jude Medical, American College of
Radiology Imaging Network, and Duke Clinical Research Institute. Dr.
Ferencik has received grant support from the American Heart Association
(13FTF16450001). Dr. Hoffmann has received grant support from National
Institutes of Health/National Heart, Lung, and Blood Institute,
HeartFlow Inc., Siemens Healthcare, American College of Radiology
Imaging Network, and Genentech. All other authors have reported that
they have no relationships relevant to the contents of this paper to
disclose.
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
EI 1876-7591
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD FEB
PY 2017
VL 10
IS 2
BP 208
EP 210
DI 10.1016/j.jcmg.2016.02.020
PG 3
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA EL9FV
UT WOS:000394926500015
PM 27085451
ER
PT J
AU Thobakgale, C
Naidoo, K
McKinnon, LR
Werner, L
Samsunder, N
Karim, SA
Ndung'u, T
Altfeld, M
Naidoo, K
AF Thobakgale, Christina
Naidoo, Kewreshini
McKinnon, Lyle R.
Werner, Lise
Samsunder, Natasha
Karim, Salim Abdool
Ndung'u, Thumbi
Altfeld, Marcus
Naidoo, Kogieleum
TI Interleukin 1-Beta (IL-1 beta) Production by Innate Cells Following TLR
Stimulation Correlates With TB Recurrence in ART-Treated HIV-Infected
Patients
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE Toll-like receptor; monocytes; myeloid dendritic cells; HIV/TB
coinfection; TB recurrence
ID MYCOBACTERIUM-TUBERCULOSIS; ANTIRETROVIRAL THERAPY; DENDRITIC CELLS;
IN-VITRO; MACROPHAGES; SUSCEPTIBILITY; IMMUNITY; RISK; REINFECTION;
EXPRESSION
AB Background: Tuberculosis (TB) remains a major cause of global morbidity and mortality, especially in the context of HIV coinfection because immunity is not completely restored following antiretroviral therapy (ART). The identification of immune correlates of risk for TB disease could help in the design of host-directed therapies and clinical management. This study aimed to identify innate immune correlates of TB recurrence in HIV+ ART-treated individuals with a history of previous successful TB treatment.
Methods: Twelve participants with a recurrent episode of TB (cases) were matched for age, sex, time on ART, pre-ART CD4 count with 12 participants who did not develop recurrent TB in 60 months of follow-up (controls). Cryopreserved peripheral blood mononuclear cells from time-points before TB recurrence were stimulated with ligands for Toll-like receptors (TLR) including TLR-2, TLR-4, and TLR-7/8. Multicolor flow cytometry and intracellular cytokine staining were used to detect IL-1 beta, TNF-alpha, IL-12, and IP10 responses from monocytes and myeloid dendritic cells (mDCs).
Results: Elevated production of IL-1 beta from monocytes following TLR-2, TLR-4, and TLR-7/8 stimulation was associated with reduced odds of TB recurrence. In contrast, production of IL-1 beta from both monocytes and mDCs following Bacillus Calmette-Guerin (BCG) stimulation was associated with increased odds of TB recurrence (risk of recurrence increased by 30% in monocytes and 42% in mDCs, respectively).
Conclusion: Production of IL-1 beta by innate immune cells following TLR and BCG stimulations correlated with differential TB recurrence outcomes in ART-treated patients and highlights differences in host response to TB.
C1 [Thobakgale, Christina; Naidoo, Kewreshini; Ndung'u, Thumbi] Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, Durban, South Africa.
[Thobakgale, Christina; McKinnon, Lyle R.; Werner, Lise; Samsunder, Natasha; Karim, Salim Abdool; Naidoo, Kogieleum] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Ctr AIDS Programme Res South Afr, Durban, South Africa.
[Thobakgale, Christina; Ndung'u, Thumbi] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA.
[Thobakgale, Christina; Ndung'u, Thumbi] Harvard Univ, Boston, MA 02115 USA.
[McKinnon, Lyle R.; Karim, Salim Abdool; Naidoo, Kogieleum] CAPRISA, MRC HIV TB Pathogenesis & Treatment Res Unit, Durban, South Africa.
[McKinnon, Lyle R.; Ndung'u, Thumbi] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada.
[Ndung'u, Thumbi; Altfeld, Marcus] Univ KwaZulu Natal, Nelson R Mandela Sch Med, KwaZulu Natal Res Inst TB & HIV, Durban, South Africa.
[Ndung'u, Thumbi] Max Planck Inst Infect Biol, Berlin, Germany.
[Altfeld, Marcus] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany.
RP Thobakgale, C (reprint author), Univ KwaZulu Natal, Nelson R Mandela Sch Med, Duke Med Res Inst, HIV Pathogenesis Programme, Room 114, ZA-4001 Durban, South Africa.
EM thobakgalec@ukzn.ac.za
FU Doris Duke Charitable Foundation; South African Medical Research
Council; Howard Hughes Medical Institute [55007065, 55007427]; Centers
for Disease Control and Prevention (CDC) Cooperative Agreement
[UY2G/PS001350-02]; US National Institutes for Health's Comprehensive
International Program of Research on AIDS grant [AI51794]; Columbia
University-South Africa Fogarty AIDS International Training and Research
Program (AITRP) [D43 TW000231]; KwaZulu-Natal Department of Health; US
President's Emergency Plan for AIDS Relief (PEPFAR); South African
Research Chairs Initiative; Victor Daitz Foundation [64809]
FX Supported by Doris Duke Charitable Foundation and the South African
Medical Research Council. The TRUTH study was supported by the Howard
Hughes Medical Institute, Grant # 55007065 and the Centers for Disease
Control and Prevention (CDC) Cooperative Agreement Number
UY2G/PS001350-02. The research infrastructures to conduct this trial,
including the data management, laboratory and pharmacy cores, were
established through the US National Institutes for Health's
Comprehensive International Program of Research on AIDS grant (CIPRA,
Grant # AI51794). Kogieleum Naidoo was supported by the Columbia
University-South Africa Fogarty AIDS International Training and Research
Program (AITRP, Grant # D43 TW000231). Patient care was supported by the
KwaZulu-Natal Department of Health and the US President's Emergency Plan
for AIDS Relief (PEPFAR).; T.N. is an International Early Career
Scientist of the Howard Hughes Medical Institute (Grant # 55007427) and
received additional funding from the South African Research Chairs
Initiative and the Victor Daitz Foundation (Grant # 64809). The
remaining authors have no conflicts of interest to disclose.
NR 39
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD FEB 1
PY 2017
VL 74
IS 2
BP 213
EP 220
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EN4SS
UT WOS:000395997800019
PM 27654812
ER
PT J
AU Zhu, AX
Baron, AD
Malfertheiner, P
Kudo, M
Kawazoe, S
Pezet, D
Weissinger, F
Brandi, G
Barone, CA
Okusaka, T
Wada, Y
Park, JO
Ryoo, BY
Cho, JY
Chung, HC
Li, CP
Yen, CJ
Lee, KD
Chang, SC
Yang, L
Abada, PB
Chau, I
AF Zhu, Andrew X.
Baron, Ari David
Malfertheiner, Peter
Kudo, Masatoshi
Kawazoe, Seiji
Pezet, Denis
Weissinger, Florian
Brandi, Giovanni
Barone, Carlo A.
Okusaka, Takuji
Wada, Yoshiyuki
Park, Joon Oh
Ryoo, Baek-Yeol
Cho, Jae Yong
Chung, Hyun Cheol
Li, Chung-Pin
Yen, Chia-Jui
Lee, Kuan-Der
Chang, Shao-Chun
Yang, Ling
Abada, Paolo B.
Chau, Ian
TI Ramucirumab as Second-Line Treatment in Patients With Advanced
Hepatocellular Carcinoma Analysis of REACH Trial Results by Child-Pugh
Score
SO JAMA ONCOLOGY
LA English
DT Article
ID PHASE-III TRIAL; 1ST-LINE THERAPY; SORAFENIB; EFFICACY; MULTICENTER;
BEVACIZUMAB; CIRRHOSIS; SURVIVAL; BRIVANIB; PLACEBO
AB IMPORTANCE REACH is the first phase 3 trial to provide information on hepatocellular cancer (HCC) in the second-line (postsorafenib) setting categorized by Child-Pugh score, a scoring system used to measure the severity of chronic liver disease. This exploratory analysis demonstrates the relationship between a potential ramucirumab survival benefit, severity of liver disease, and baseline a-fetoprotein (aFP).
OBJECTIVE To assess treatment effects and tolerability of ramucirumab by Child-Pugh score in patients with HCC enrolled in the REACH trial.
DESIGN, SETTINGS, AND PARTICIPANTS Randomized, double-blind, phase 3 trial of ramucirumab and best supportive care vs placebo and best supportive care as second-line treatment in patients with HCC enrolled between November 4, 2010 and April 18, 2013, from 154 global sites. Overall, 643 patients were randomized and included in this analysis; 565 patients considered Child-Pugh class A (Child-Pugh scores 5 and 6) and 78 patients considered class B (Child-Pugh scores 7 and 8).
INTERVENTIONS Ramucirumab (8mg/kg) or placebo intravenously plus best supportive care every 2 weeks.
MAIN OUTCOMES AND MEASURES Overall survival (OS), defined as time from randomization to death from any cause.
RESULTS In the randomized population of 643 patients (mean [SD] age, 62.8 [11.1] years) in this analysis, a potential ramucirumab OS benefit was observed for patients with a Child-Pugh score of 5 (hazard ratio [HR], 0.80; 95% CI, 0.63-1.02; P =.06) but no apparent benefit for patients with Child-Pugh scores of 6 or 7 and 8. In patients with baseline aFP levels of 400 ng/mL (to convert ng/mL to mu g/L, multiply by 1.0) or more, a ramucirumab OS benefit was significant for a score of Child-Pugh 5 9HR, 0.61; 95% CI, 0.43-0.87; P =.01) and Child-Pugh 6 (HR, 0.64; 95% CI, 0.42-0.98; P =.04), but was not significant for Child-Pugh 7 and 8. The overall safety profile of ramucirumab, regardless of Child-Pugh score, was considered manageable. Regardless of treatment arm, patients with Child-Pugh scores of 7 and 8 experienced a higher incidence of grade 3 or higher treatment-emergent adverse events, including ascites and asthenia, and special-interest events, including liver injury and/or failure and bleeding, compared with patients with Child-Pugh scores of 5 or 6.
CONCLUSIONS AND RELEVANCE In unselected patients, a trend for ramucirumab survival benefit was observed only for patients with a Child-Pugh score of 5. In patients with baseline aFP levels of 400 ng/mL or more, a ramucirumab survival benefit was observed for Child-Pugh scores of 5 and 6. Ramucirumab had a manageable toxic effect profile. These results support the ongoing REACH-2 study of ramucirumab in patients with advanced HCC with underlying Child-Pugh A cirrhosis and baseline aFP levels of 400 ng/mL or more.
C1 [Zhu, Andrew X.] Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02115 USA.
[Zhu, Andrew X.] Harvard Med Sch, 55 Fruit St, Boston, MA 02115 USA.
[Baron, Ari David] Calif Pacific Med Ctr, San Francisco, CA USA.
[Malfertheiner, Peter] Otto von Guericke Univ, Magdeburg, Germany.
[Kudo, Masatoshi] Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osaka, Japan.
[Kawazoe, Seiji] Saga Ken Med Ctr Koseikan, Saga, Japan.
[Pezet, Denis] CHU Estaing, Dept Surg, Clermont Ferrand, France.
[Weissinger, Florian] Evangel Krankenhaus Bielefeld, Bielefeld, Germany.
[Brandi, Giovanni] Policlin St Orsola Malpighi, Bologna, Italy.
[Barone, Carlo A.] Univ Cattolica Sacro Cuore, Rome, Italy.
[Okusaka, Takuji] Natl Canc Ctr, Div Hepatobiliary & Pancreat Oncol, Tokyo, Japan.
[Wada, Yoshiyuki] Natl Hosp Org, Kyushu Med Ctr, Fukuoka, Japan.
[Park, Joon Oh] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea.
[Ryoo, Baek-Yeol] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
[Cho, Jae Yong] Gangnam Severance Hosp, Seoul, South Korea.
[Chung, Hyun Cheol] Yonsei Univ, Coll Med, Canc Metastasis Res Ctr, Yonsei Canc Ctr, Shinchon Dong, South Korea.
[Li, Chung-Pin] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol & Hepatol, Taipei, Taiwan.
[Li, Chung-Pin] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
[Yen, Chia-Jui] Natl Cheng Kung Univ Hosp, Tainan, Taiwan.
[Lee, Kuan-Der] Chang Gung Mem Hosp, Chiayi, Taiwan.
[Chang, Shao-Chun] Eli Lilly & Co, Bridgewater, NJ USA.
[Yang, Ling] AstraZeneca, Wilmington, DE USA.
[Abada, Paolo B.] Eli Lilly & Co, Indianapolis, IN 46285 USA.
[Chau, Ian] Royal Marsden NHS Fdn Trust, London, England.
[Chau, Ian] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England.
RP Zhu, AX (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St, Boston, MA 02115 USA.; Zhu, AX (reprint author), Harvard Med Sch, 55 Fruit St, Boston, MA 02115 USA.
EM azhu@partners.org
FU Eli Lilly and Company
FX This research was supported by Eli Lilly and Company.
NR 30
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2374-2445
J9 JAMA ONCOL
JI JAMA Oncol.
PD FEB 1
PY 2017
VL 3
IS 2
BP 235
EP 243
DI 10.1001/jamaoncol.2016.4115
PG 9
WC Oncology
SC Oncology
GA EM9PU
UT WOS:000395644400015
ER
PT J
AU Scott, AR
Alore, EA
Naik, AD
Berger, DH
Suliburk, JW
AF Scott, Aaron R.
Alore, Elizabeth A.
Naik, Aanand D.
Berger, David H.
Suliburk, James W.
TI Mixed-Methods Analysis of Factors Impacting Use of a Postoperative
mHealth App
SO JMIR MHEALTH AND UHEALTH
LA English
DT Article
DE mHealth; colorectal surgery; smartphone apps
ID PROMOTE PHYSICAL-ACTIVITY; COLORECTAL SURGERY; HOSPITAL READMISSION;
ENHANCED RECOVERY; MOBILE APPS; PROGRAM; COMPLICATIONS; INTERVENTIONS;
QUALITY; PATIENT
AB Background: Limited communication and care coordination following discharge from hospitals may contribute to surgical complications. Smartphone apps offer a novel mechanism for communication and care coordination. However, factors which may affect patient app use in a postoperative, at-home setting are poorly understood.
Objective: The objectives of this study were to (1) gauge interest in smartphone app use among patients after colorectal surgery and (2) better understand factors affecting patient app use in a postoperative, at-home setting.
Methods: A prospective feasibility study was performed at a hospital that principally serves low socioeconomic status patients. After colorectal surgery, patients were enrolled and given a smartphone app, which uses previously validated content to provide symptom-based recommendations. Patients were instructed to use the app daily for 14 days after discharge. Demographics and usability data were collected at enrollment. Usability was measured with the System Usability Scale (SUS). At follow-up, the SUS was repeated and patients underwent a structured interview covering ease of use, willingness to use, and utility of use. Two members of the research team independently reviewed the field notes from follow-up interviews and extracted the most consistent themes. Chart and app log reviews identified clinical endpoints.
Results: We screened 115 patients, enrolled 20 patients (17.4%), and completed follow-up interviews with 17 patients (85%). Reasons for nonenrollment included: failure to meet inclusion criteria (47/115, 40.9%), declined to participate (26/115, 22.6%), and other reasons (22/115, 19.1%). There was no difference in patient ratings between usability at first-use and after extended use, with SUS scores greater than the 95th percentile at both time points. Despite high usability ratings, 6/20 (30%) of patients never used the app at home after hospital discharge and 2/20 (10%) only used the app once. Interviews revealed three themes related to app use: (1) patient-related barriers could prevent use even though the app had high usability scores; (2) patients viewed the app as a second opinion, rather than a primary source of information; and (3) many patients viewed the app as an external burden.
Conclusions: Use patterns in this study, and response rates after prompts to contact the operative team, suggest that apps need to be highly engaging to be adopted by patients. The growing penetration of smartphones and the proliferation of app-based interventions are unlikely to improve care coordination and communication, unless apps address the barriers and patient perceptions identified in this study. This study shows that high usability alone is not sufficient to motivate patients to use smartphone apps in the postoperative period.
C1 [Scott, Aaron R.; Alore, Elizabeth A.; Berger, David H.; Suliburk, James W.] Baylor Coll Med, Michael E DeBakey Dept Surg, One Baylor Plaza,BCM 390, Houston, TX 77030 USA.
[Naik, Aanand D.; Berger, David H.] Hlth Serv Res & Dev Ctr Innovat, Michael E DeBakey Vet Affairs Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA.
[Naik, Aanand D.] Baylor Coll Med, Alkek Dept Med, Houston, TX 77030 USA.
[Suliburk, James W.] Ben Taub Gen Hosp, Dept Surg, Houston, TX 77030 USA.
RP Suliburk, JW (reprint author), Baylor Coll Med, Michael E DeBakey Dept Surg, One Baylor Plaza,BCM 390, Houston, TX 77030 USA.
EM suliburk@bcm.edu
FU Cancer Prevention and Research Institute of Texas [RP140102]; Gordon and
Betty Moore Foundation Early-Career Investigator [4603]; VA Health
Services Research and Development Center of Innovation grant [CIN
13-413]; Seamless Mobile Health, Inc.
FX Dr Scott holds a trainee grant from the Cancer Prevention and Research
Institute of Texas (RP140102). Dr Suliburk holds a Gordon and Betty
Moore Foundation Early-Career Investigator Award (#4603). Dr Naik
receives support from a VA Health Services Research and Development
Center of Innovation grant (CIN 13-413). This study was sponsored by
Seamless Mobile Health, Inc. Sponsorship was limited to access to app,
patient compensation, and the cost of a mobile hot-spot used to allow
patients to download the app. The authors retained full editorial rights
and have no other commercial interest with the sponsor. The Department
of Veterans Health was not a performance site for this study and was not
involved with any research activities associated with the commercial
sponsor.
NR 43
TC 0
Z9 0
U1 0
U2 0
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA
SN 2291-5222
J9 JMIR MHEALTH UHEALTH
JI JMIR mHealth uHealth
PD FEB
PY 2017
VL 5
IS 2
AR e11
DI 10.2196/mhealth.6728
PG 13
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA EN2JY
UT WOS:000395837000003
PM 28179215
ER
PT J
AU Smiley, SL
Elmasry, H
Hooper, MW
Niaura, RS
Hamilton, AB
Milburn, NG
AF Smiley, Sabrina L.
Elmasry, Hoda
Hooper, Monica Webb
Niaura, Raymond S.
Hamilton, Alison B.
Milburn, Norweeta G.
TI Feasibility of Ecological Momentary Assessment of Daily Sexting and
Substance Use Among Young Adult African American Gay and Bisexual Men: A
Pilot Study
SO JMIR RESEARCH PROTOCOLS
LA English
DT Article
DE ecological momentary assessment; mobile phone; text messaging; sexting;
marijuana; alcohol; young adult; gay and bisexual; African American
ID MARIJUANA USE; SEX; ADOLESCENTS; STUDENTS; BEHAVIOR; RISK
AB Background: Recent evidence suggests that sexualized text communication ("sexting") is associated with substance use and sexual risk behaviors among young adults, yet little is known about this relationship among young adult African American gay and bisexual men, a population disproportionately impacted by HIV in the United States. Rapid advances in mobile phone technology indicate a clear need for research using mobile health (mHealth) methods such as ecological momentary assessment (EMA) to serve as a viable counterpart to retrospective evaluation methods by using real-time data collection to assess sexting and substance use among this population.
Objective: The objective of this pilot study was to (1) describe the EMA study design and protocol, (2) characterize the study population, and (3) assess the feasibility of a random prompt text message-based thrice-daily EMA over 14 days, as a means of prospectively studying sexting, marijuana, and alcohol use among a sample of young adult African American gay and bisexual men ages 21 to 25.
Methods: Participants were recruited through flyers and snowball sampling during spring and summer 2015 at a community-based HIV/AIDS prevention, care, and support organization in Washington, DC. Eligible participants were enrolled in a one-time in-person study visit that consisted of informed written consent to participate in the study, a self-administered survey, a semi-structured interview, and enrollment and training in EMA data collection. Commencing the day after the study visit, a random prompt survey was texted to participants on their personal mobile phones 3 times a day over a 14-day data collection period assessing mood, texts sent, texts received, sexts sent, sexts received, marijuana want, marijuana use, and alcohol use.
Results: EMA feasibility was tested with 25 self-identified African American gay (n=16) and bisexual (n=9) men (mean age of 23.48 years, SD 1.5). Each random prompt survey had 8 questions with responses including yes/no and Likert scale options. There were 104 total days of EMA observation, and the retention rate was 72% (18 out of 25 participants). Participants responded to the random prompt surveys with a 57.3% compliance rate providing a total of 544 completed surveys out of 949 surveys. The overall mean response time to complete a survey was 6.1 minutes. There were significant positive associations between EMA texts sent and received questions (rho 0.84, P <.001) as well as sexts sent and received queries (rho 0.72, P <.001).
Conclusions: The use of an EMA protocol has the potential to be a very useful research tool for understanding episodic behaviors such as sexting and substance use in this relatively understudied and underserved population, and has implications for practice. Additional research is needed on how to maximize survey compliance.
C1 [Smiley, Sabrina L.; Elmasry, Hoda; Niaura, Raymond S.] Truth Initiat, Schroeder Inst Tobacco Res & Policy Studies, 900 G St NW,Fourth Floor, Washington, DC 20001 USA.
[Hooper, Monica Webb] Case Western Reserve Univ, Sch Med, Case Comprehens Canc Ctr, Cleveland, OH USA.
[Niaura, Raymond S.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA.
[Niaura, Raymond S.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
[Hamilton, Alison B.; Milburn, Norweeta G.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
[Hamilton, Alison B.] Vet Adm Greater Los Angeles Healthcare Syst, Vet Adm Ctr Study Healthcare Innovat Implementat, Los Angeles, CA USA.
RP Smiley, SL (reprint author), Truth Initiat, Schroeder Inst Tobacco Res & Policy Studies, 900 G St NW,Fourth Floor, Washington, DC 20001 USA.
EM ssmiley@truthinitiative.org
FU National Institute on Drug Abuse [R25DA035692, 5R25DA035692]
FX At the time of the study, Sabrina L Smiley was a Scholar with the
HIV/AIDS, Substance Abuse, and Trauma Training Program at the University
of California Los Angeles supported through an award from the National
Institute on Drug Abuse (R25DA035692). The research reported in this
publication was supported by the National Institute on Drug Abuse under
grant number 5R25DA035692. The content is solely the responsibility of
the authors and does not necessarily represent the official views of the
National Institutes of Health.
NR 23
TC 0
Z9 0
U1 0
U2 0
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA
SN 1929-0748
J9 JMIR RES PROTOC
JI JMIR RES. Protoc.
PD FEB
PY 2017
VL 6
IS 2
AR e9
DI 10.2196/resprot.6520
PG 11
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA EN2KH
UT WOS:000395837900014
PM 28153816
ER
PT J
AU Neilan, A
Dunville, R
Ocfemia, MCB
Salomon, J
Francke, J
Wang, LY
Bulteel, A
Hsu, K
DiNenno, E
Parker, R
Walensky, R
Freedberg, K
Ciaranello, A
AF Neilan, Anne
Dunville, Richard
Ocfemia, M. Cheryl Banez
Salomon, Joshua
Francke, Jordan
Wang, Li Yan
Bulteel, Alex
Hsu, Kathy
DiNenno, Elizabeth
Parker, Robert
Walensky, Rochelle
Freedberg, Kenneth
Ciaranello, Andrea
TI SCREENING ADOLESCENTS AND YOUNG ADULTS FOR HIV IN THE UNITED STATES: A
COST-EFFECTIVENESS ANALYSIS
SO JOURNAL OF ADOLESCENT HEALTH
LA English
DT Meeting Abstract
C1 [Neilan, Anne; Francke, Jordan; Bulteel, Alex; Parker, Robert; Walensky, Rochelle; Freedberg, Kenneth; Ciaranello, Andrea] Massachusetts Gen Hosp, Boston, MA USA.
[Dunville, Richard; Ocfemia, M. Cheryl Banez; Wang, Li Yan; DiNenno, Elizabeth] Ctr Dis Control & Prevent, Atlanta, GA USA.
[Salomon, Joshua] Harvard Sch Publ Hlth, Boston, MA USA.
[Hsu, Kathy] Boston Med Ctr, Massachusetts Dept Publ Hlth, Boston, MA USA.
FU US Centers for Disease Control and Prevention National Center for HIV,
Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic
Modeling Agreement [6NU38PS004644]; National Institute of Allergy and
Infectious Diseases; Eunice Kennedy Shriver National Institute for Child
Health and Human Development [NIAID T32 AI007433, R01 HD079214, R01
AI042006, R01 AI112340]
FX This research was funded by US Centers for Disease Control and
Prevention National Center for HIV, Viral Hepatitis, STD, and TB
Prevention Epidemiologic and Economic Modeling Agreement 6NU38PS004644
as well as the National Institute of Allergy and Infectious Diseases and
the Eunice Kennedy Shriver National Institute for Child Health and Human
Development (NIAID T32 AI007433, R01 HD079214, R01 AI042006, R01
AI112340).
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1054-139X
EI 1879-1972
J9 J ADOLESCENT HEALTH
JI J. Adolesc. Health
PD FEB
PY 2017
VL 60
IS 2
MA 32
BP S18
EP S18
PG 1
WC Psychology, Developmental; Public, Environmental & Occupational Health;
Pediatrics
SC Psychology; Public, Environmental & Occupational Health; Pediatrics
GA EP3GL
UT WOS:000397270700033
ER
PT J
AU Rimmelin, D
Abou-Arraj, NE
Kerkar, AP
Gupta, J
Gupta, N
AF Rimmelin, Dodie
Abou-Arraj, Nadeem E.
Kerkar, Ashwini P.
Gupta, Jaya
Gupta, Nupur
TI USING NEEDLELESS TECHNOLOGY TO EVALUATE THE PREVALENCE OF ANEMIA IN
YOUNG ADOLESCENT FEMALES IN RURAL INDIA
SO JOURNAL OF ADOLESCENT HEALTH
LA English
DT Meeting Abstract
C1 [Rimmelin, Dodie] Harvard Med Sch, Boston, MA USA.
[Abou-Arraj, Nadeem E.; Kerkar, Ashwini P.] Boston Univ, Sch Med, Boston, MA USA.
[Gupta, Jaya] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Gupta, Nupur] Massachusetts Gen Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1054-139X
EI 1879-1972
J9 J ADOLESCENT HEALTH
JI J. Adolesc. Health
PD FEB
PY 2017
VL 60
IS 2
MA 52
BP S30
EP S30
PG 1
WC Psychology, Developmental; Public, Environmental & Occupational Health;
Pediatrics
SC Psychology; Public, Environmental & Occupational Health; Pediatrics
GA EP3GL
UT WOS:000397270700053
ER
PT J
AU Rinaudo, PF
Hsu, J
AF Rinaudo, Paolo F.
Hsu, John
TI To freeze or not to freeze: heating the debate but cooling the practice?
SO JOURNAL OF ASSISTED REPRODUCTION AND GENETICS
LA English
DT Editorial Material
ID ASSISTED-REPRODUCTIVE-TECHNOLOGIES; IMPAIRED ENDOMETRIAL RECEPTIVITY;
IN-VITRO FERTILIZATION; THAWED EMBRYO-TRANSFER; TRIAL COMPARING FRESH;
OVARIAN STIMULATION; FROZEN; PREGNANCIES; INFERTILITY; RESPONDERS
C1 [Rinaudo, Paolo F.] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
[Hsu, John] Massachusetts Gen Hosp, Mongan Inst, Boston, MA 02114 USA.
[Hsu, John] Harvard Med Sch, Dept Hlth Care Policy, Cambridge, MA USA.
RP Rinaudo, PF (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA.
EM rinaudop@obgyn.ucsf.edu
NR 17
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1058-0468
EI 1573-7330
J9 J ASSIST REPROD GEN
JI J. Assist. Reprod. Genet.
PD FEB
PY 2017
VL 34
IS 2
BP 187
EP 189
DI 10.1007/s10815-017-0870-1
PG 3
WC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology
SC Genetics & Heredity; Obstetrics & Gynecology; Reproductive Biology
GA EP5IH
UT WOS:000397411700005
PM 28091759
ER
PT J
AU Chen, YH
Chauhan, SK
Tan, XH
Dana, R
AF Chen, Yihe
Chauhan, Sunil K.
Tan, Xuhua
Dana, Reza
TI Interleukin-7 and-15 maintain pathogenic memory Th17 cells in
autoimmunity
SO JOURNAL OF AUTOIMMUNITY
LA English
DT Article
DE Memory Th17; Maintenance; IL-7; IL-15
ID CD8 T-CELLS; BASAL HOMEOSTATIC PROLIFERATION; ADVANCED SOLID TUMORS;
RHEUMATOID-ARTHRITIS; STAT5 ACTIVATION; CHRONIC COLITIS; DRY EYE; IL-7;
INFLAMMATION; GENERATION
AB Th17 cells are principal mediators of many autoimmune conditions. Recently, memory Th17 cells have been revealed as crucial in mediating the chronicity of various refractory autoimmune disorders; however, the underlying mechanisms maintaining memory Th17 cells have remained elusive. Here, using a preclinical model of ocular autoimmune disease we show that both IL-7 and IL-15 are critical for maintaining pathogenic memory Th17 cells. Neutralization of these cytokines leads to substantial reduction of memory Th17 cells; both IL-7 and IL-15 provide survival signals via activating STAT5, and IL-15 provides additional proliferation signals via activating both STAT5 and Akt. Topical neutralization of ocular IL-7 or IL-15 effectively reduces memory Th17 cells at the inflammatory site and draining lymphoid tissues, while topical neutralization of IL-17 alone, the major pathogenic cytokine secreted by Th17 cells, does not diminish memory Th17 cells at the draining lymphoid tissues. Our results suggest that the effective removal of pathogenic memory Th17 cells via abolishing environmental IL-7 or IL-15 is likely to be a novel strategy in the treatment of autoimmune diseases. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Chen, Yihe; Chauhan, Sunil K.; Tan, Xuhua; Dana, Reza] Harvard Med Sch, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
RP Dana, R (reprint author), Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM reza_dana@meei.harvard.edu
FU National Institutes of Health [EY20889]
FX This work was supported by National Institutes of Health (grant
EY20889).
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0896-8411
EI 1095-9157
J9 J AUTOIMMUN
JI J. Autoimmun.
PD FEB
PY 2017
VL 77
BP 96
EP 103
DI 10.1016/j.jaut.2016.11.003
PG 8
WC Immunology
SC Immunology
GA EL5AO
UT WOS:000394634000009
PM 27899224
ER
PT J
AU Turcotte, R
Wu, JW
Lin, CP
AF Turcotte, Raphael
Wu, Juwell W.
Lin, Charles P.
TI Intravital multiphoton photoconversion with a cell membrane dye
SO JOURNAL OF BIOPHOTONICS
LA English
DT Article
DE Photoconversion; multiphoton; intravital microscopy; cell tracking; bone
marrow; two-photon fluorescence microscopy
ID FLUORESCENT PROTEIN; IN-VIVO; MICROSCOPY; TRACKING
AB Photoconversion, an irreversible shift in a fluorophore emission spectrum after light exposure, is a powerful tool for marking cellular and subcellular compartments and tracking their dynamics in vivo. This paper reports on the photoconversion properties of Di-8-ANEPPS, a commercially available membrane dye. When illuminated with near-infrared femtosecond laser pulses, Di-8-ANEPPS undergoes multiphoton photoconversion as indicated by the supralinear dependence of the conversion rate (pc) on the incident power (pcIexc2.27), and by the ability to photoconvert a thin optical section in a three-dimensional matrix. The characteristic emission spectrum changed from red to blue, and ratiometric analysis on single cells in vitro revealed a 65-fold increase in the blue to red wavelength ratio after photoconversion. The spectral shift is preserved in vivo for hours, making Di-8-ANEPPS a useful dye for intravital cell marking and tracking applications.
C1 [Lin, Charles P.] Harvard Med Sch, Massachusetts Gen Hosp, Wellman Ctr Photomed, CPZN 8238,185 Cambridge St, Boston, MA 02114 USA.
[Lin, Charles P.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Syst Biol, CPZN 8238,185 Cambridge St, Boston, MA 02114 USA.
RP Lin, CP (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Wellman Ctr Photomed, CPZN 8238,185 Cambridge St, Boston, MA 02114 USA.
EM lin@helix.mgh.harvard.edu
FU NIH [CA086355, HL099997, EB017274, CA194596]
FX This work was support by NIH CA086355, HL099997, EB017274, and CA194596.
NR 18
TC 0
Z9 0
U1 1
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1864-063X
EI 1864-0648
J9 J BIOPHOTONICS
JI J. Biophotonics
PD FEB
PY 2017
VL 10
IS 2
BP 206
EP 210
DI 10.1002/jbio.201600077
PG 5
WC Biochemical Research Methods; Biophysics; Optics
SC Biochemistry & Molecular Biology; Biophysics; Optics
GA EL8CN
UT WOS:000394847900002
PM 27433967
ER
PT J
AU Chandra, A
Lin, T
Young, T
Tong, W
Ma, XY
Tseng, WJ
Kramer, I
Kneissel, M
Levine, MA
Zhang, YJ
Cengel, K
Liu, XS
Qin, L
AF Chandra, Abhishek
Lin, Tiao
Young, Tiffany
Tong, Wei
Ma, Xiaoyuan
Tseng, Wei-Ju
Kramer, Ina
Kneissel, Michaela
Levine, Michael A.
Zhang, Yejia
Cengel, Keith
Liu, X. Sherry
Qin, Ling
TI Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by
Protecting Bone-Forming Cells and Their Progenitors Through Distinct
Mechanisms
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE RADIOTHERAPY; SCL-AB; OSTEOBLASTS; MESENCHYMAL PROGENITORS; DNA REPAIR
ID MESENCHYMAL STEM-CELLS; TRABECULAR BONE; POSTMENOPAUSAL WOMEN;
IRRADIATION ALTERS; MINERAL DENSITY; MURINE MODEL; IN-VIVO; ANTIBODY;
MICE; RADIOTHERAPY
AB Focal radiotherapy is frequently associated with skeletal damage within the radiation field. Our previous in vitro study showed that activation of Wnt/beta-catenin pathway can overcome radiation-induced DNA damage and apoptosis of osteoblastic cells. Neutralization of circulating sclerostin with a monoclonal antibody (Scl-Ab) is an innovative approach for treating osteoporosis by enhancing Wnt/beta-catenin signaling in bone. Together with the fact that focal radiation increases sclerostin amount in bone, we sought to determine whether weekly treatment with Scl-Ab would prevent focal radiotherapy-induced osteoporosis in mice. MicroCT and histomorphometric analyses demonstrated that Scl-Ab blocked trabecular bone structural deterioration after radiation by partially preserving osteoblast number and activity. Consistently, trabecular bone in sclerostin null mice was resistant to radiation via the same mechanism. Scl-Ab accelerated DNA repair in osteoblasts after radiation by reducing the number of gamma-H2AX foci, a DNA double-strand break marker, and increasing the amount of Ku70, a DNA repair protein, thus protecting osteoblasts from radiation-induced apoptosis. In osteocytes, apart from using similar DNA repair mechanism to rescue osteocyte apoptosis, Scl-Ab restored the osteocyte canaliculi structure that was otherwise damaged by radiation. Using a lineage tracing approach that labels all mesenchymal lineage cells in the endosteal bone marrow, we demonstrated that radiation damage to mesenchymal progenitors mainly involves shifting their fate to adipocytes and arresting their proliferation ability but not inducing apoptosis, which are different mechanisms from radiation damage to mature bone forming cells. Scl-Ab treatment partially blocked the lineage shift but had no effect on the loss of proliferation potential. Taken together, our studies provide proof-of-principle evidence for a novel use of Scl-Ab as a therapeutic treatment for radiation-induced osteoporosis and establish molecular and cellular mechanisms that support such treatment. (C) 2016 American Society for Bone and Mineral Research.
C1 [Chandra, Abhishek; Lin, Tiao; Young, Tiffany; Tong, Wei; Ma, Xiaoyuan; Tseng, Wei-Ju; Zhang, Yejia; Liu, X. Sherry; Qin, Ling] Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.
[Lin, Tiao] Sun Yat Sen Univ, Musculoskeletal Oncol Ctr, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
[Tong, Wei] Huazhong Univ Sci & Technol, Dept Orthopaed Surg, Union Hosp, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
[Kramer, Ina; Kneissel, Michaela] Novartis Inst BioMed Res, Musculoskeletal Dis Area, Basel, Switzerland.
[Levine, Michael A.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Levine, Michael A.] Childrens Hosp Philadelphia, Div Endocrinol & Diabet, Philadelphia, PA 19104 USA.
[Levine, Michael A.] Childrens Hosp Philadelphia, Ctr Bone Hlth, Philadelphia, PA 19104 USA.
[Zhang, Yejia] Univ Penn, Philadelphia Vet Affairs Med Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Zhang, Yejia] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Cengel, Keith] Univ Penn, Dept Radiat Oncol, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Qin, L (reprint author), Univ Penn, Perelman Sch Med, Dept Orthopaed Surg, 424 Stemmler Hall,36th St & Hamilton Walk, Philadelphia, PA 19104 USA.
EM qinling@mail.med.upenn.edu
FU NIH [NIH/NIAMS R01AR066098, R01DK095803, K01AR066743, P30AR050950];
NICHD [1K08HD049598]
FX We thank Dr Henry Kronenberg from Harvard Medical School and Dr Robert
Gagel and Dr Huifang Liu from the MD Anderson Cancer Center for their
kind suggestions and advice on this project. We thank Dr Eileen Shore
for providing qRT-PCR primers for DKK1, PPAR gamma, and aP2 genes. This
study was supported by NIH grants NIH/NIAMS R01AR066098, R01DK095803 (to
LQ), K01AR066743 (to XSL), P30AR050950 (to Penn Center for
Musculoskeletal Disorders), and NICHD 1K08HD049598 (to YZ). The authors
gratefully thank Martin Heyworth, MD, for critically editing the
manuscript.
NR 54
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2017
VL 32
IS 2
BP 360
EP 372
DI 10.1002/jbmr.2996
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EO8JL
UT WOS:000396935300018
PM 27635523
ER
PT J
AU Fulzele, K
Lai, F
Dedic, C
Saini, V
Uda, Y
Shi, C
Tuck, P
Aronson, JL
Liu, XL
Spatz, JM
Wein, MN
Pajevic, PD
AF Fulzele, Keertik
Lai, Forest
Dedic, Christopher
Saini, Vaibhav
Uda, Yuhei
Shi, Chao
Tuck, Padrig
Aronson, Jenna L.
Liu, Xiaolong
Spatz, Jordan M.
Wein, Marc N.
Pajevic, Paola Divieti
TI Osteocyte-Secreted Wnt Signaling Inhibitor Sclerostin Contributes to
Beige Adipogenesis in Peripheral Fat Depots
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE SCLEROSTIN; BEIGE ADIPOCYTES; OSTEOCYTES; LEAN PHENOTYPE
ID BONE-MINERAL DENSITY; WHITE ADIPOSE-TISSUE; POSTMENOPAUSAL WOMEN;
ENERGY-METABOLISM; BODY-COMPOSITION; ADIPOCYTE DIFFERENTIATION;
GLUCOSE-HOMEOSTASIS; PARATHYROID-HORMONE; IN-VITRO; RECEPTOR
AB Cells of the osteoblast lineage are increasingly identified as participants in whole-body metabolism by primarily targeting pancreatic insulin secretion or consuming energy. Osteocytes, the most abundant bone cells, secrete a Wnt-signaling inhibitor called sclerostin. Here we examined three mouse models expressing high sclerostin levels, achieved through constitutive or inducible loss of the stimulatory subunit of G-proteins (Gs alpha in mature osteoblasts and/or osteocytes). These mice showed progressive loss of white adipose tissue (WAT) with tendency toward increased energy expenditure but no changes in glucose or insulin metabolism. Interestingly beige adipocytes were increased extensively in both gonadal and inguinal WAT and had reduced canonical beta-catenin signaling. To determine if sclerostin directly contributes to the increased beige adipogenesis, we engineered an osteocytic cell line lacking Gsa which has high sclerostin secretion. Conditioned media from these cells significantly increased expression of UCP1 in primary adipocytes, and this effect was partially reduced after depletion of sclerostin from the conditioned media. Similarly, treatment of Gs alpha-deficient animals with sclerostin-neutralizing antibody partially reduced the increased UCP1 expression in WAT. Moreover, direct treatment of sclerostin to wild-type mice significantly increased UCP1 expression in WAT. These results show that osteocytes and/or osteoblasts secrete factors regulating beige adipogenesis, at least in part, through the Wnt-signaling inhibitor sclerostin. Further studies are needed to assess metabolic effects of sclerostin on adipocytes and other metabolic tissues. (C) 2016 American Society for Bone and Mineral Research.
C1 [Fulzele, Keertik; Lai, Forest; Dedic, Christopher; Uda, Yuhei; Shi, Chao; Pajevic, Paola Divieti] Boston Univ, Henry M Goldman Sch Dent Med, Mol & Cell Biol, Boston, MA 02215 USA.
[Saini, Vaibhav; Tuck, Padrig; Aronson, Jenna L.; Liu, Xiaolong; Spatz, Jordan M.; Wein, Marc N.] Harvard Med Sch, Massachusetts Gen Hosp, Endocrine Unit, Boston, MA USA.
RP Fulzele, K; Pajevic, PD (reprint author), 700 Albany St,W201C, Boston, MA 02118 USA.
EM kfulzele@bu.edu; pdivieti@bu.edu
FU NIH [AR060221, AR059655, DK079161]; GAP award from ASBMR; P&F award from
Boston University Clinical and Translational Science Institute (CTSI)
[NIH 1UL1TR001430]; P&F award from Center for Skeletal Research (CSR) of
Massachusetts General Hospital [NIH NIAMS P30 AR066261]; P&F award from
Boston Area Diabetes Endocrinology Research Center (BADERC)
FX This work was supported by NIH grants AR060221, AR059655, and DK079161
to PDP. This work was also partially supported by a GAP award from ASBMR
to KF, a P&F award from Boston University Clinical and Translational
Science Institute (CTSI) (NIH 1UL1TR001430) to KF, a P&F award from
Center for Skeletal Research (CSR) of Massachusetts General Hospital
(NIH NIAMS P30 AR066261), and a P&F award from Boston Area Diabetes
Endocrinology Research Center (BADERC) to PDP. We thank Michaela
Kneissel and Novartis for providing the anti-sclerostin antibody.
NR 59
TC 2
Z9 2
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-0431
EI 1523-4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2017
VL 32
IS 2
BP 373
EP 384
DI 10.1002/jbmr.3001
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EO8JL
UT WOS:000396935300019
PM 27653320
ER
PT J
AU Kittiskulnam, P
Carrero, JJ
Chertow, GM
Kaysen, GA
Delgado, C
Johansen, KL
AF Kittiskulnam, Piyawan
Carrero, Juan J.
Chertow, Glenn M.
Kaysen, George A.
Delgado, Cynthia
Johansen, Kirsten L.
TI Sarcopenia among patients receiving hemodialysis: weighing the evidence
SO JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
LA English
DT Article
DE Low muscle mass; Sarcopenia; Handgrip strength; Gait speed; Hemodialysis
ID CLINICALLY RELEVANT WEAKNESS; SKELETAL-MUSCLE MASS; BIOIMPEDANCE
SPECTROSCOPY; ALTERNATIVE DEFINITIONS; FUNCTIONAL IMPAIRMENT;
PHYSICAL-DISABILITY; OLDER WOMEN; LEAN MASS; PREVALENCE; CUTPOINTS
AB BackgroundThere is no consensus on how best to define low muscle mass in patients with end-stage renal disease. Use of muscle mass normalized to height-squared has been suggested by geriatric societies but may underestimate sarcopenia, particularly in the setting of excess adiposity. We compared four definitions of low muscle mass in a prevalent hemodialysis cohort.
MethodsACTIVE/ADIPOSE enrolled prevalent patients receiving hemodialysis from the San Francisco and Atlanta areas from June 2009 to August 2011. Whole-body muscle mass was estimated using bioelectrical impedance spectroscopy, performed before a midweek dialysis session (n=645; age 56.714.5years, 41% women). We defined low muscle mass as muscle mass of 2SD or more below sex-specific bioelectrical impedance spectroscopy-derived means for young adults (18-49years) from National Health and Nutrition Examination Survey and indexed to height(2), body weight (percentage), body surface area (BSA) by the DuBois formula, or Quetelet's body mass index (BMI). We compared prevalence of low muscle mass among the four methods and assessed their correlation with strength and physical performance.
ResultsThe prevalence of low muscle mass ranged from 8 to 32%. Muscle mass indexed to height(2) classified the smallest percentage of patients as having low muscle mass, particularly among women, whereas indexing by BSA classified the largest percentage. Low muscle mass/height(2) was present almost exclusively among normal or underweight patients, whereas indexing to body weight and BMI classified more overweight and obese patients as having low muscle mass. Handgrip strength was lower among those with low muscle mass by all methods except height(2). Handgrip strength was directly and modestly correlated with muscle mass normalized by percentage of body weight, BSA, and BMI (=0.43, 0.56, and, 0.64, respectively) and less so with muscle/height(2) (=0.31, P<0.001). The difference in grip strength among patients with low vs. normal muscle mass was largest according to muscle/BMI (-6.84kg, 95% CI -8.66 to -5.02, P<0.001). There were significant direct correlations of gait speed with muscle mass indexed to percentage of body weight, BSA, and BMI but not with muscle mass indexed to height(2).
ConclusionsSkeletal muscle mass normalized to height(2) may underestimate the prevalence of low muscle mass, particularly among overweight and obese patients on hemodialysis. Valid detection of sarcopenia among obese patients receiving hemodialysis requires adjustment for body size.
C1 [Kittiskulnam, Piyawan; Delgado, Cynthia; Johansen, Kirsten L.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA.
[Kittiskulnam, Piyawan; Delgado, Cynthia; Johansen, Kirsten L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Kittiskulnam, Piyawan] Chulalongkorn Univ, Div Nephrol, Dept Med, Bangkok, Thailand.
[Kittiskulnam, Piyawan] King Chulalongkorn Mem Hosp, Thai Red Cross Soc, Bangkok, Thailand.
[Carrero, Juan J.] Karolinska Inst, Div Renal Med, Ctr Mol Med, Stockholm, Sweden.
[Chertow, Glenn M.] Stanford Univ, Dept Med, Div Nephrol, Sch Med, Stanford, CA 94305 USA.
[Kaysen, George A.] Univ Calif Davis, Div Nephrol, Sacramento, CA 95616 USA.
[Kaysen, George A.] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95616 USA.
RP Johansen, KL (reprint author), 111 J San Francisco VA Med Ctr, Nephrol Sect, 4150 Clement St, San Francisco, CA 94121 USA.
EM kirsten.johansen@ucsf.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[N01-DK-7-0005, KD-7-5004, K24DK085153]; Department of Veterans Affairs,
Clinical Science Research and Development Program [1IK2CX000527-01A2];
International Society of Nephrology; Stockholm County Council; Swedish
Research Council
FX This work was supported through contracts N01-DK-7-0005 and KD-7-5004
from the National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK). Dr. Johansen's effort was also supported by
K24DK085153 from the NIDDK. Dr. Delgado's work is supported by the
Department of Veterans Affairs, Clinical Science Research and
Development Program under Career Development Award 1IK2CX000527-01A2.
Her contribution is the result of work supported with the resources and
the use of facilities at the San Francisco VA Medical Center. This work
has been made possible in part by an International Society of Nephrology
funded Fellowship to Dr. Kittiskulnam. Dr. Carrero-Roig acknowledges
grant support from Stockholm County Council and the Swedish Research
Council.
NR 39
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2190-5991
EI 2190-6009
J9 J CACHEXIA SARCOPENI
JI J. Caxhexia Sarcopenia Muscle
PD FEB
PY 2017
VL 8
IS 1
BP 57
EP 68
DI 10.1002/jcsm.12130
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA EM0FJ
UT WOS:000394993900007
PM 27897415
ER
PT J
AU McClatchey, PM
Wu, F
Olfert, IM
Ellis, CG
Goldman, D
Reusch, JEB
Frisbee, JC
AF McClatchey, P. Mason
Wu, Fan
Olfert, I. Mark
Ellis, Christopher G.
Goldman, Daniel
Reusch, Jane E. B.
Frisbee, Jefferson C.
TI Impaired Tissue Oxygenation in Metabolic Syndrome Requires Increased
Microvascular Perfusion Heterogeneity
SO JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
LA English
DT Article
DE Microcirculation; Oxygenation; Rodent models of obesity; Blood flow
control; Simulation
ID OBESE ZUCKER RATS; SKELETAL-MUSCLE; EXERCISE CAPACITY; BLOOD-FLOW;
DYSFUNCTION; RESISTANCE; MORTALITY; MODELS; SYSTEM; MEN
AB Metabolic syndrome (MS) in obese Zucker rats (OZR) is associated with impaired skeletal muscle performance and blunted hyperemia. Studies suggest that reduced O-2 diffusion capacity is required to explain compromised muscle performance and that heterogeneous microvascular perfusion distribution is critical. We modeled tissue oxygenation during muscle contraction in control and OZR skeletal muscle using physiologically realistic relationships. Using a network model of Krogh cylinders with increasing perfusion asymmetry and increased plasma skimming, we predict increased perfusion heterogeneity and decreased muscle oxygenation in OZR, with partial recovery following therapy. Notably, increasing O-2 delivery had less impact on VO2 than equivalent decreases in O-2 delivery, providing a mechanism for previous empirical work associating perfusion heterogeneity and impaired O-2 extraction. We demonstrate that increased skeletal muscle perfusion asymmetry is a defining characteristic of MS and must be considered to effectively model and understand blood-tissue O-2 exchange in this model of human disease.
C1 [McClatchey, P. Mason] Univ Colorado Anschutz Med Campus, Div Endocrinol, Aurora, CO USA.
[McClatchey, P. Mason; Reusch, Jane E. B.] Univ Colorado Anschutz Med Campus, Dept Bioengn, Aurora, CO USA.
[McClatchey, P. Mason] Denver Vet Affairs Med Ctr, Dept Med, Denver, CO USA.
[Wu, Fan; Reusch, Jane E. B.] Novartis Inst BioMed Res, Drug Metab & Pharmacokinet, E Hanover, NJ USA.
[Olfert, I. Mark] West Virginia Univ, Div Exercise Physiol, Hlth Sci Ctr, Morgantown, WV 26506 USA.
[Ellis, Christopher G.; Goldman, Daniel; Frisbee, Jefferson C.] Univ Western Ontario, Dept Med Biophys, Schulich Sch Med & Dent, Med Sci Bldg,M407,1151 Richmond St North, London, ON N6A 5C1, Canada.
RP Frisbee, JC (reprint author), Univ Western Ontario, Dept Med Biophys, Schulich Sch Med & Dent, Med Sci Bldg,M407,1151 Richmond St North, London, ON N6A 5C1, Canada.
EM jfrisbee@uwo.ca
FU American Heart Association [IRG 14330015, EIA 0740129N]; National
Institutes of Health [RR 2865AR, R01 DK64668]; VA Merit Review
[BX002046]; CU SOM Center for Women's Health Research, Bioengineering
[5T32HL072738]
FX This work was supported by the American Heart Association (IRG 14330015,
EIA 0740129N) and the National Institutes of Health (RR 2865AR; R01
DK64668), VA Merit Review BX002046 (JEBR), CU SOM Center for Women's
Health Research, Bioengineering T32 (5T32HL072738).
NR 34
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1937-5387
EI 1937-5395
J9 J CARDIOVASC TRANSL
JI J. Cardiovasc. Transl. Res.
PD FEB
PY 2017
VL 10
IS 1
BP 69
EP 81
DI 10.1007/s12265-017-9732-6
PG 13
WC Cardiac & Cardiovascular Systems; Medicine, Research & Experimental
SC Cardiovascular System & Cardiology; Research & Experimental Medicine
GA EM0MP
UT WOS:000395012700008
ER
PT J
AU Wink, LK
Pedapati, EV
Horn, PS
McDougle, CJ
Erickson, CA
AF Wink, Logan K.
Pedapati, Ernest V.
Horn, Paul S.
McDougle, Christopher J.
Erickson, Craig A.
TI Multiple Antipsychotic Medication Use in Autism Spectrum Disorder
SO JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
LA English
DT Article
DE autism; autism spectrum disorder; antipsychotics; physcopharmacology;
irritability
ID CHILDREN; ADOLESCENTS; POLYPHARMACY; ARIPIPRAZOLE; PROGRAM
AB Objective: The purpose of this study was to explore the use of multiple antipsychotic medications in patients with autism spectrum disorder (ASD) by reviewing the longitudinal medication management of 1100 patients consecutively treated for behavioral symptoms associated with ASD at a tertiary care specialty clinic.
Methods: We identified all patients with ASD treated with daily doses of two or more antipsychotics for at least two visits at our clinic. For each patient meeting inclusion criteria, diagnostic and demographic data were collected. To evaluate clinical need and effectiveness of antipsychotic medications in this sample, we reviewed symptoms targeted with each antipsychotic medication and concomitant medications prescribed. Clinical Global Impressions-Severity (CGI-S) and Clinical Global Impressions-Improvement (CGI-I) scale ratings had been completed at the time of each visit, and the duration of treatment with antipsychotic medications was determined. To evaluate the safety and tolerability of antipsychotic medication use in ASD, we reviewed reported adverse effects and calculated body mass index (BMI) change with treatment.
Results: Seventy patients met the inclusion criteria (6.4% of our sample). The majority of patients were moderately to severely ill Caucasian males, as determined by baseline mean CGI-S of 4.7 (SD=0.8), and were diagnosed with autistic disorder and comorbid intellectual disability. The mean age was 15.1 years (SD=10.9), the primary targeted symptoms were agitation/irritability, physical aggression, and self-injury. The majority of patients remained on two or more antipsychotics for >1 year. In this population, patients demonstrated greater symptomatic improvement and generally tolerated treatment without significant adverse effects.
Conclusions: The use of two or more antipsychotic medications may be increasingly common in patients with ASD. This retrospective study demonstrates that this treatment approach may be of some clinical benefit, and is generally well tolerated. Prospective studies focusing on the efficacy and safety of concomitant antipsychotic medication usage in ASD should be considered.
C1 [Wink, Logan K.; Pedapati, Ernest V.; Horn, Paul S.; Erickson, Craig A.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA.
[McDougle, Christopher J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Lurie Ctr Autism, Boston, MA USA.
[McDougle, Christopher J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pediat, Lurie Ctr Autism, Boston, MA USA.
[McDougle, Christopher J.] Harvard Med Sch, MassGen Hosp Children, Boston, MA USA.
RP Wink, LK (reprint author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave MLC 4002, Cincinnati, OH 45229 USA.
EM logan.wink@cchmc.org
FU Indiana University School of Medicine Department of Psychiatry; Autism
Speaks; John Merck Fund; Riovant Sciences Ltd.; Simons Research
Foundation; SynapDx; United Stated Department of Defense
FX This work was supported by the Indiana University School of Medicine
Department of Psychiatry. Dr. Wink's current research is supported by
Autism Speaks, the John Merck Fund, Riovant Sciences Ltd., the Simons
Research Foundation, SynapDx, and the United Stated Department of
Defense.
NR 14
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5463
EI 1557-8992
J9 J CHILD ADOL PSYCHOP
JI J. Child Adolesc. Psychopharmacol.
PD FEB
PY 2017
VL 27
IS 1
BP 91
EP +
DI 10.1089/cap.2015.0123
PG 5
WC Pediatrics; Pharmacology & Pharmacy; Psychiatry
SC Pediatrics; Pharmacology & Pharmacy; Psychiatry
GA EL1JJ
UT WOS:000394376300012
PM 26465194
ER
PT J
AU Nurok, M
Cheng, J
Romeo, GR
Vecino, SM
Fields, KG
YaDeau, JT
AF Nurok, Michael
Cheng, Jennifer
Romeo, Giulio R.
Vecino, Stephanie M.
Fields, Kara G.
YaDeau, Jacques T.
TI Dexamethasone and perioperative blood glucose in patients undergoing
total joint arthroplasty: A retrospective study
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Article
DE Dexamethasone; Blood glucose; Arthroplasty, replacement, hip;
Arthroplasty, replacement, knee; Diabetes mellitus
ID RANDOMIZED CONTROLLED-TRIAL; INDUCED HYPERGLYCEMIA; POSTOPERATIVE
NAUSEA; LONGITUDINAL-DATA; GLYCEMIC CONTROL; OBESE-PATIENTS; PAIN;
SURGERY; RATS
AB Study objective: Perioperative dexamethasone is commonly used to prevent nausea. It can also increase blood glucose levels, and recent concern about its blood glucose-elevating effect in humans has been raised. This study aimed to demonstrate relationships between dexamethasone administration and elevated perioperative blood glucose in patients undergoing total joint arthroplasty.
Design: Retrospective study.
Setting: Academic, orthopedic hospital.
Patients: A total of 625 patients (18-99 years) who underwent total hip or total knee arthroplasty with an ASA <= 3 were included in the study.
Interventions: Patients who received dexamethasone perioperatively were compared to those who did not receive dexamethasone.
Measurements: The primary outcome, which was any postoperative glucose >200 mg/dl, was compared between groups using multiple logistic regression. Demographic information, intraoperative information, incidence of postoperative nausea and vomiting, white blood cell count, medication use, and length of stay were also collected.
Main results: Perioperative dexamethasone (median [1st quartile, 3rd quartile] dose = 4 [4, 8] mg) was administered to 76% of patients. Only 5.6% (95% CI: 3.8-7.5) of patients had postoperative glucose levels >200 mg/d1. After covariate adjustment, there was no evidence of a difference in odds of experiencing postoperative glucose levels >200 mg/dl (odds ratio [95% CI]: 0.76 [0.28-2.07]; P = 0594) and maximum glucose levels (P = 0.518) between groups. Dexamethasone-treated patients had greater changes in white blood cell count between baseline and postoperative days 0-1. There was no evidence of a difference in wound healing and length of stay between groups.
Conclusions: There was no evidence of an association between perioperative dexamethasone administration and the odds of having postoperative glucose levels >200 mg/dl or higher maximum glucose levels. However, these findings may not be generalizable to patients having different baseline characteristics or procedures. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Nurok, Michael; Cheng, Jennifer; YaDeau, Jacques T.] Hosp Special Surg, Dept Anesthesiol, 535 E 70th St, New York, NY 10021 USA.
[Romeo, Giulio R.] Joslin Diabet Ctr, Dept Mol & Cellular Pharmacol, Boston, MA 02215 USA.
[Vecino, Stephanie M.] Weill Cornell Med Coll, Dept Anesthesiol, New York, NY USA.
[Fields, Kara G.] Hosp Special Surg, Healthcare Res Inst, 535 E 70th St, New York, NY 10021 USA.
RP Nurok, M (reprint author), Cedars Sinai Heart Inst, 127 San Vicente Blvd,Suite 3100, Los Angeles, CA 90048 USA.
EM Michael.Nurok@cshs.org
FU Research and Education Fund of the Department of Anesthesiology at the
Hospital for Special Surgery; National Center for Advancing
Translational Science of the National Institutes of Health [UL1TR000457]
FX This work was supported by the Research and Education Fund of the
Department of Anesthesiology at the Hospital for Special Surgery and the
National Center for Advancing Translational Science of the National
Institutes of Health (UL1TR000457).
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0952-8180
EI 1873-4529
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD FEB
PY 2017
VL 37
BP 116
EP 122
DI 10.1016/j.jclinane.2016.11.012
PG 7
WC Anesthesiology
SC Anesthesiology
GA EN4GE
UT WOS:000395965200029
PM 28235499
ER
PT J
AU Goldstein, KM
Callegari, LS
AF Goldstein, Karen M.
Callegari, Lisa S.
TI Should a history of assisted reproductive technology be another
consideration when assessing cardiovascular risk?
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Editorial Material
ID HYPERTENSIVE DISORDERS; PRECONCEPTION CARE; PREGNANCY; RECOMMENDATIONS;
MORTALITY; DISEASE; STATE
C1 [Goldstein, Karen M.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA.
[Goldstein, Karen M.] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA.
[Callegari, Lisa S.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA USA.
[Callegari, Lisa S.] Univ Washington, Dept Obstet & Gynecol, Seattle, WA 98195 USA.
[Callegari, Lisa S.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
RP Goldstein, KM (reprint author), Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA.
EM karen.goldstein@va.gov
NR 16
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD FEB
PY 2017
VL 19
IS 2
BP 170
EP 172
DI 10.1111/jch.12937
PG 3
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA EL3GP
UT WOS:000394507900010
PM 28194918
ER
PT J
AU Perez, CM
Munoz, F
Andriankaja, OM
Ritchie, CS
Martinez, S
Vergara, J
Vivaldi, J
Lopez, L
Campos, M
Joshipura, KJ
AF Perez, Cynthia M.
Munoz, Francisco
Andriankaja, Oelisoa M.
Ritchie, Christine S.
Martinez, Sasha
Vergara, Jose
Vivaldi, Jose
Lopez, Lydia
Campos, Maribel
Joshipura, Kaumudi J.
TI Cross-sectional associations of impaired glucose metabolism measures
with bleeding on probing and periodontitis
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE bleeding on probing; impaired fasting glucose; impaired glucose
tolerance; impaired glycated haemoglobin; insulin resistance;
periodontitis; pre-diabetes
ID NUTRITION EXAMINATION SURVEY; CONTINUOUS NATIONAL-HEALTH; BETA-CELL
FUNCTION; INSULIN-RESISTANCE; DIABETES-MELLITUS; FASTING GLUCOSE;
ORAL-HEALTH; DISEASE; ADULTS; INFLAMMATION
AB Aim: This study assessed the associations of pre-diabetes and insulin resistance with bleeding on probing (BOP) and periodontitis among adults.
Materials and methods: We included 1191 Hispanic adults aged 40-65 years, free of diabetes, enrolled in San Juan Overweight Adults Longitudinal Study. Pre-diabetes was defined as impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or impaired glycated haemoglobin. Impaired one-hour plasma glucose (1hPG) was defined as levels >155 mg/dl. Insulin resistance was defined using the study population-specific 75th percentile (HOMA-IR >= 3.13). High BOP was defined as percentage of teeth with bleeding >= 30%. Periodontitis was defined according to the CDC/AAP definition.
Results: After multivariable adjustment for age, gender, education, smoking status, alcohol consumption, physical activity, obesity, HDL-C, and plaque index, pre-diabetes with and without 1hPG, IFG, impaired 1hPG, IGT, and HOMA-IR were significantly associated with high BOP; pre-diabetes, IFG, and impaired 1hPG were significantly associated with severe periodontitis. Most of these associations remained significant when the analyses were restricted to non-smokers.
Conclusions: This study suggests associations between pre-diabetes and insulin resistance with BOP and periodontitis. Given the high prevalence of impaired glucose metabolism and periodontitis, the assessment of the temporal sequence of these associations is of utmost importance.
C1 [Perez, Cynthia M.] Univ Puerto Rico, Dept Biostat & Epidemiol, Grad Sch Publ Hlth, Med Sci Campus,POB 365067, San Juan, PR 00936 USA.
[Munoz, Francisco; Andriankaja, Oelisoa M.; Martinez, Sasha; Campos, Maribel; Joshipura, Kaumudi J.] Univ Puerto Rico, Ctr Clin Res & Hlth Promot, Sch Dent Med, Med Sci Campus, San Juan, PR 00936 USA.
[Ritchie, Christine S.] San Francisco VA Med Ctr, Ctr Res Aging Jewish Home San Francisco, San Francisco, CA USA.
[Vergara, Jose; Vivaldi, Jose] Univ Puerto Rico, Sch Dent Med, Med Sci Campus, San Juan, PR 00936 USA.
[Joshipura, Kaumudi J.] Harvard Univ, Dept Epidemiol, Harvard TH Chan Sch Publ Hlth, Cambridge, MA 02138 USA.
RP Perez, CM (reprint author), Univ Puerto Rico, Dept Biostat & Epidemiol, Grad Sch Publ Hlth, Med Sci Campus,POB 365067, San Juan, PR 00936 USA.
EM cynthia.perez1@upr.edu
FU NIDCR NIH HHS [K23 DE025313, R01 DE020111]; NIMHD NIH HHS [U54 MD007587]
NR 40
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0303-6979
EI 1600-051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD FEB
PY 2017
VL 44
IS 2
BP 142
EP 149
DI 10.1111/jcpe.12662
PG 8
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA EM8ML
UT WOS:000395565400003
PM 27978601
ER
PT J
AU Comer, JS
Furr, JM
Kerns, CE
Miguel, E
Coxe, S
Elkins, RM
Carpenter, AL
Cornacchio, D
Cooper-Vince, CE
DeSerisy, M
Chou, T
Sanchez, AL
Khanna, M
Franklin, ME
Garcia, AM
Freeman, JB
AF Comer, Jonathan S.
Furr, Jami M.
Kerns, Caroline E.
Miguel, Elizabeth
Coxe, Stefany
Elkins, R. Meredith
Carpenter, Aubrey L.
Cornacchio, Danielle
Cooper-Vince, Christine E.
DeSerisy, Mariah
Chou, Tommy
Sanchez, Amanda L.
Khanna, Muniya
Franklin, Martin E.
Garcia, Abbe M.
Freeman, Jennifer B.
TI Internet-Delivered, Family-Based Treatment for Early-Onset OCD: A Pilot
Randomized Trial
SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
LA English
DT Article
DE behavioral telehealth; videoteleconferencing; OCD; early intervention;
early childhood
ID OBSESSIVE-COMPULSIVE DISORDER; MENTAL-HEALTH-CARE; COGNITIVE-BEHAVIOR
THERAPY; CHILDREN; ADOLESCENTS; TECHNOLOGY; SERIES
AB Objective: Despite advances in supported treatments for early onset obsessive-compulsive disorder ( OCD), progress has been constrained by regionally limited expertise in pediatric OCD. Videoteleconferencing ( VTC) methods have proved useful for extending the reach of services for older individuals, but no randomized clinical trials ( RCTs) have evaluated VTC for treating early onset OCD. Method: RCT comparing VTC-delivered family based cognitive-behavioral therapy ( FB-CBT) versus clinic-based FB-CBT in the treatment of children ages 4-8 with OCD ( N = 22). Pretreatment, posttreatment, and 6-month follow-up assessments included mother-/therapist-reports and independent evaluations masked to treatment condition. Primary analyses focused on treatment retention, engagement and satisfaction. Hierarchical linear modeling preliminarily evaluated the effects of time, treatment condition, and their interactions. "Excellent response" was defined as a 1 or 2 on the Clinical Global Impressions-Improvement Scale. Results: Treatment retention, engagement, alliance and satisfaction were high across conditions. Symptom trajectories and family accommodation across both conditions showed outcomes improving from baseline to posttreatment, and continuing through follow-up. At posttreatment, 72.7% of Internet cases and 60% of Clinic cases showed "excellent response," and at follow-up 80% of Internet cases and 66.7% of Clinic cases showed " excellent response." Significant condition differences were not found across outcomes. Conclusions: VTC methods may offer solutions to overcoming traditional barriers to care for early onset OCD by extending the reach of real-time expert services regardless of children's geographic proximity to quality care.
C1 [Comer, Jonathan S.; Furr, Jami M.; Miguel, Elizabeth; Coxe, Stefany; Cornacchio, Danielle; Chou, Tommy; Sanchez, Amanda L.] Florida Int Univ, Dept Psychol, Miami, FL 33199 USA.
[Kerns, Caroline E.; Elkins, R. Meredith; Carpenter, Aubrey L.] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA.
[Cooper-Vince, Christine E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cooper-Vince, Christine E.] Harvard Univ, Dept Psychiat, Cambridge, MA 02138 USA.
[DeSerisy, Mariah] Fordham Univ, Dept Psychol, Bronx, NY 10458 USA.
[Khanna, Muniya] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Khanna, Muniya; Franklin, Martin E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.
[Garcia, Abbe M.; Freeman, Jennifer B.] Brown Univ, Dept Psychiat & Human Behav, Providence, RI 02912 USA.
RP Comer, JS (reprint author), Florida Int Univ, Dept Psychol, Ctr Children & Families, Mental Hlth Intervent & Technol, 11200 SW 8th St, Miami, FL 33199 USA.
EM jocomer@fiu.edu
FU International OCD Foundation (IOCDF); NIH [K23 MH090247]
FX This work was principally supported by the International OCD Foundation
(IOCDF), as well by the NIH (K23 MH090247). Abbe M. Garcia and Jennifer
B. Freeman receive book royalties from Oxford University Press.
NR 31
TC 0
Z9 0
U1 1
U2 1
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-006X
EI 1939-2117
J9 J CONSULT CLIN PSYCH
JI J. Consult. Clin. Psychol.
PD FEB
PY 2017
VL 85
IS 2
BP 178
EP 186
DI 10.1037/ccp0000155
PG 9
WC Psychology, Clinical
SC Psychology
GA EM0FI
UT WOS:000394993800008
PM 27869451
ER
PT J
AU Schreuder, WH
van den Berg, H
Westermann, AM
Peacock, ZS
de Lange, J
AF Schreuder, Willem Hans
van den Berg, Henk
Westermann, Anne Marie
Peacock, Zachary Scott
de lange, Jan
TI Pharmacological and surgical therapy for the central giant cell
granuloma: A long-term retrospective cohort study
SO JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY
LA English
DT Article
DE Central giant cell granuloma; Interferon; Calcitonin; Maxilla; Mandible;
Benign bone lesion
ID INTRALESIONAL CORTICOSTEROID INJECTION; CALCITONIN NASAL SPRAY;
OF-THE-LITERATURE; ANTIANGIOGENIC THERAPY; INTERFERON-ALPHA; ALTERNATIVE
TREATMENT; REPARATIVE GRANULOMA; RADIOLOGIC FEATURES; JAWS; LESIONS
AB Purpose: This is a retrospective cohort study of patients with a central giant cell granuloma (CGCG) treated at a single center to assess and compare the different surgical and non-surgical approaches.
Material and methods: A cohort with a single histologically proven non-syndrome-related CGCG was selected and reviewed. Patients were allocated to group I (surgery), group II (pharmacotherapy), and group III (pharmacotherapy and surgery). The primary outcome was long-term radiologic response using computed tomography. Secondary outcomes were intermediate radiologic responses and occurrence and severity of side effects.
Results: Thirty-three subjects were included in the study. The surgical group (n = 4) included 1 patient with progression during follow-up and a relatively high post-surgical morbidity. Twenty-nine patients started on various pharmacological treatment regimens (groups II and III). Fourteen patients could be managed without addjtional surgery. One of these lesions showed progression during follow-up. The other 15 lesions underwent additional surgery, and none showed progression during follow-up. Interferon treatment was associated with the most side effects.
Conclusion: Pharmacological agents have a role in the treatment of aggressive and non-aggressive CGCGs by limiting the renewed progression during long-term follow up and the extent and morbidity of surgical treatment. (C) 2016 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
C1 [Schreuder, Willem Hans; de lange, Jan] Acad Ctr Dent Amsterdam, Acad Med Ctr, Dept Oral & Maxillofacial Surg, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
[Schreuder, Willem Hans; van den Berg, Henk; Westermann, Anne Marie; de lange, Jan] Univ Amsterdam, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
[van den Berg, Henk] Emma Children Hosp, Acad Med Ctr, Dept Pediat Oncol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
[Westermann, Anne Marie] Acad Med Ctr, Dept Med Oncol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
[Peacock, Zachary Scott] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Fruit St 55, Boston, MA 02114 USA.
[Peacock, Zachary Scott] Harvard Sch Dent Med, Fruit St 55, Boston, MA 02114 USA.
RP Schreuder, WH (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Oral & Maxillofacial Surg, POB 22660, NL-1100 DD Amsterdam, Netherlands.
EM w.h.schreuder@amc.uva.nl; h.vandenberg@amc.uva.nl;
a.m.westermann@amc.uva.nl; zpeacock@partners.org; j.delange@amc.uva.nl
FU Dutch Government ZonMW Priority Medicines and Rare Disease Program
FX This research project was supported by the Dutch Government ZonMW
Priority Medicines and Rare Disease Program.
NR 82
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1010-5182
EI 1878-4119
J9 J CRANIO MAXILL SURG
JI J. Cranio-MaxilloFac. Surg.
PD FEB
PY 2017
VL 45
IS 2
BP 232
EP 243
DI 10.1016/j.jcms.2016.11.011
PG 12
WC Dentistry, Oral Surgery & Medicine; Surgery
SC Dentistry, Oral Surgery & Medicine; Surgery
GA EL9DK
UT WOS:000394919400011
PM 28087284
ER
PT J
AU Schonfeld, DJ
Shekunov, J
Jellinek, M
Stein, MT
AF Schonfeld, David J.
Shekunov, Julia
Jellinek, Michael
Stein, Martin T.
TI A 9-Year-Old Girl Discovers That Her Mother Was Murdered
SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS
LA English
DT Editorial Material
DE bereavement; loss of parent; guilt; funeral participation; internal
representation
ID CHILDHOOD BEREAVEMENT; DEATH
AB CASE: Susan was a 9-year-old girl living with her mother; she had never met her father. Her mother returned one evening from her job as a cocktail waitress and Susan met her at the apartment door to let her know they had run out of cat food. Her mother said she would go and buy some the next morning because it was late and she was tired, but Susan insisted she go out that evening because the cat had not eaten all day. Her mother was fatally shot in the parking lot of the convenience store shortly thereafter; since there was no robbery involved, the police suspected it was someone that she knew. Susan's extended family had her move out of the apartment that evening and relocate to live with her aunt and uncle out-of-state. The transition happened quickly. Susan was unable to return to her apartment to pick up any additional belongings and never returned to say goodbye to her friends. The family decided she was too young to attend the funeral.
Susan had trouble fitting in with her aunt and uncle's family; they had 2 children who were 8 and 6 years old, and Susan felt she was being treated like a baby. She resented having a bedtime (her mother allowed her to stay up as late as she wished), and she complained that the work at school was boring and her classmates were childish. When the family went to a festival in town, she left abruptly without telling them, which frightened Susan's aunt and uncle. They wanted to be supportive but felt that she needed more structure than her mother had provided her. Susan's aunt and uncle sought bereavement support for Susan from her pediatrician and parenting advice for themselves.
C1 [Schonfeld, David J.] Univ Southern Calif, Sch Social Work, Natl Ctr Sch Crisis & Bereavement, Los Angeles, CA 90007 USA.
[Schonfeld, David J.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Shekunov, Julia] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jellinek, Michael] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
[Stein, Martin T.] Univ Calif San Diego, Rady Childrens Hosp, San Diego, CA 92103 USA.
RP Schonfeld, DJ (reprint author), Univ Southern Calif, Sch Social Work, Natl Ctr Sch Crisis & Bereavement, Los Angeles, CA 90007 USA.; Schonfeld, DJ (reprint author), Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
NR 5
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0196-206X
EI 1536-7312
J9 J DEV BEHAV PEDIATR
JI J. Dev. Behav. Pediatr.
PD FEB-MAR
PY 2017
VL 38
IS 2
SU S
BP S76
EP S78
PG 3
WC Behavioral Sciences; Psychology, Developmental; Pediatrics
SC Behavioral Sciences; Psychology; Pediatrics
GA EL4AW
UT WOS:000394563500025
PM 28141729
ER
PT J
AU LaMotte, AD
Taft, CT
Weatherill, RP
Eckhardt, CI
AF LaMotte, Adam D.
Taft, Casey T.
Weatherill, Robin P.
Eckhardt, Christopher I.
TI Social Skills Deficits as a Mediator Between PTSD Symptoms and Intimate
Partner Aggression in Returning Veterans
SO JOURNAL OF FAMILY PSYCHOLOGY
LA English
DT Article
DE posttraumatic stress disorder; social information processing; social
skills; violence; aggression
ID POSTTRAUMATIC-STRESS-DISORDER; MARITALLY VIOLENT; MILITARY VETERANS; MEN
AB This study examined social skills deficits as a mediator of the relationship between posttraumatic stress disorder (PTSD) symptoms and use of intimate partner aggression (IPA) among returning veterans. Prior research with veterans has focused on PTSD-related deficits at the decoding stage of McFall's (1982) social information processing model, and the current study adds to this literature by examining social skills deficits at the decision stage. Participants were 92 male veterans recruited from the greater Boston area. PTSD symptoms were assessed through clinician interview, IPA use was assessed through self-and partner report, and social skills deficits were assessed in a laboratory task in which veterans listened to a series of problematic marital situations and responded with what they would say or do in the situation. Responses were coded for social competency. Bivariate correlations revealed several significant associations among PTSD symptoms, social skills deficits, and use of IPA. When all PTSD symptom clusters were entered into a regression predicting social skills deficits, only emotional numbing emerged as a unique predictor. Finally, social skills deficits significantly mediated the relationship between veterans' PTSD symptoms and use of psychological (but not physical) IPA. Findings extend prior research on McFall's (1982) social information processing model as it relates to veterans' PTSD symptoms and use of IPA. More research is needed to understand the associations between PTSD symptoms and deficits at each individual step of this model.
C1 [LaMotte, Adam D.; Taft, Casey T.; Weatherill, Robin P.] VA Boston Healthcare Syst, Natl Ctr PTSD, Behav Sci Div, Boston, MA USA.
[Taft, Casey T.; Weatherill, Robin P.] Boston Univ, Dept Psychiat, Sch Med, Boston, MA 02215 USA.
[Eckhardt, Christopher I.] Purdue Univ, Dept Psychol Serv, W Lafayette, IN 47907 USA.
RP Taft, CT (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, Behav Sci Div, Boston, MA USA.; Taft, CT (reprint author), VA Boston Healthcare Syst 116B 4, 150 South Huntington Ave, Boston, MA 02130 USA.
EM casey.taft@va.gov
FU Department of Veterans Affairs Merit Review Grant
FX This research was supported by a Department of Veterans Affairs Merit
Review Grant awarded to Casey T. Taft. The contents of this article do
not represent the views of the U.S. Department of Veterans Affairs or
the U.S. Government.
NR 24
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0893-3200
EI 1939-1293
J9 J FAM PSYCHOL
JI J. Fam. Psychol.
PD FEB
PY 2017
VL 31
IS 1
BP 105
EP 110
DI 10.1037/fam0000215
PG 6
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA EN1QW
UT WOS:000395785900013
PM 27148936
ER
PT J
AU McGinn, MM
Hoerster, KD
Stryczek, KC
Malte, CA
Jakupcak, M
AF McGinn, Meghan M.
Hoerster, Katherine D.
Stryczek, Krysttel C.
Malte, Carol A.
Jakupcak, Matthew
TI Relationship Satisfaction, PTSD Symptom Severity, and Mental Healthcare
Utilization Among OEF/OIF Veterans
SO JOURNAL OF FAMILY PSYCHOLOGY
LA English
DT Article
DE mental health care utilization; PTSD; relationship satisfaction
ID AFGHANISTAN VETERANS; COUPLE THERAPY; IRAQ; BARRIERS; SERVICES; STRESS;
MODEL
AB Despite the availability of evidence-based PTSD treatments at most facilities within the VA Healthcare System, most Iraq and Afghanistan veterans returning from deployments with posttraumatic stress symptoms do not receive an adequate dose of mental health treatment, prompting the need to identify potential barriers to or facilitators of mental health care utilization. Previous research demonstrated self-reported mental health care utilization in the prior year varies as a function of PTSD symptom severity, and the interaction of PTSD symptom severity and romantic relationship satisfaction (Meis et al., 2010). We extended these findings by objectively measuring the degree of utilization over a 1-year period (i. e., number of sessions attended) in a sample of 130 Iraq and Afghanistan veterans who presented to primary care/deployment health and completed an initial mental health evaluation. Results indicated main and interactive effects of PTSD symptom severity and relationship satisfaction, such that greater PTSD symptom severity was associated with greater utilization at average to high relationship satisfaction (p < .05), but not low relationship satisfaction. Implications for future research and couple/family based interventions for veterans with PTSD are discussed.
C1 [McGinn, Meghan M.; Hoerster, Katherine D.; Stryczek, Krysttel C.; Malte, Carol A.; Jakupcak, Matthew] VA Puget Sound Healthcare Syst, 1660 South Columbian Way, Seattle, WA 98108 USA.
[McGinn, Meghan M.; Hoerster, Katherine D.; Jakupcak, Matthew] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
RP McGinn, MM (reprint author), VA Puget Sound Healthcare Syst, 1660 South Columbian Way, Seattle, WA 98108 USA.
EM meghan.mcginn@va.gov
FU Department of Veterans Affairs Office of Academic Affiliations, Advanced
Fellowship Program in Mental Illness Research and Treatment; VA Puget
Sound Healthcare System, Seattle, Washington; University of Washington
School of Medicine, Department of Psychiatry & Behavioral Sciences,
Seattle, Washington
FX This material is the result of work supported by resources from the
Department of Veterans Affairs Office of Academic Affiliations, Advanced
Fellowship Program in Mental Illness Research and Treatment, the VA
Puget Sound Healthcare System, Seattle, Washington, and the University
of Washington School of Medicine, Department of Psychiatry & Behavioral
Sciences, Seattle, Washington. The views expressed in this article are
those of the authors and do not necessarily reflect the position or
policy of the Department of Veterans Affairs or the United States
Government. Some of the ideas and data from an earlier version of this
article were presented at the 2013 American Psychological Association's
Annual Convention in Honolulu, HI.
NR 22
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0893-3200
EI 1939-1293
J9 J FAM PSYCHOL
JI J. Fam. Psychol.
PD FEB
PY 2017
VL 31
IS 1
BP 111
EP 116
DI 10.1037/fam0000224
PG 6
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA EN1QW
UT WOS:000395785900014
PM 27668933
ER
PT J
AU Moradi, A
Braun, Y
Oflazoglu, K
Meijs, T
Ring, D
Chen, N
AF Moradi, A.
Braun, Y.
Oflazoglu, K.
Meijs, T.
Ring, D.
Chen, N.
TI Factors associated with subluxation in mallet fracture
SO JOURNAL OF HAND SURGERY-EUROPEAN VOLUME
LA English
DT Article
DE Mallet fracture; subluxation; factor
ID DISTAL INTERPHALANGEAL JOINT; FINGER FRACTURES; FIXATION
AB Radiographs and medical record of all adult patients with a mallet fracture in three hospitals between 2004 and 2014 were reviewed. International Classification of Diseases, Ninth Revision (ICD-9) codes and text search in radiographic reports were used to identify all acute patients with potential mallet fractures in our institutional database. Manually checking, 392 true mallet fractures were identified among them, 78 had subluxation at the time of diagnosis and 19 had subluxation at a later time point during treatment. Fragment size, fragment displacement, and interval between injury and treatment were associated with initial and late subluxation. Subluxation was not observed when the fracture size was less than 39% of the total articular surface. For each 1% increase in total articular surface involvement in fractures with more than 39% involvement, the risk of subluxation increased by 4% and for each 1% of displacement, the risk of subluxation increased by 4%. Level of Evidence: IV
C1 [Moradi, A.; Braun, Y.; Oflazoglu, K.; Meijs, T.; Ring, D.; Chen, N.] Harvard Med Sch, Massachusetts Gen Hosp, Orthoped Hand & Upper Extrem Serv, Boston, MA USA.
[Moradi, A.] Mashhad Univ Med Sci, Orthoped Res Ctr, Mashhad, Iran.
RP Ring, D (reprint author), Harvard Med Sch, Orthoped Hand & Upper Extrem Serv, Massachusetts Gen Hosp, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
NR 17
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1753-1934
EI 2043-6289
J9 J HAND SURG-EUR VOL
JI J. Hand Surg.-Eur. Vol.
PD FEB
PY 2017
VL 42
IS 2
BP 176
EP 181
DI 10.1177/1753193416669929
PG 6
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA EL7GR
UT WOS:000394789600010
PM 27697897
ER
PT J
AU Wheldon, CW
Kolar, SK
Hernandez, ND
Daley, EM
AF Wheldon, Christopher W.
Kolar, Stephanie K.
Hernandez, Natalie D.
Daley, Ellen M.
TI Factorial Invariance and Convergent Validity of the Group-Based Medical
Mistrust Scale across Gender and Ethnoracial Identity
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Medical mistrust; psychometrics; minorities; measurement
ID HEALTH-CARE; PERCEIVED DISADVANTAGES; AFRICAN-AMERICAN; FIT INDEXES;
SATISFACTION; TRUST
AB The objective of this study was to assess the factorial invariance and convergent validity of the Group-Based Medical Mistrust Scale (GBMMS) across gender (male and female) and ethnoracial identity (Latino and Black). Minority students (N = 686) attending a southeastern university were surveyed in the fall of 2011. Psychometric analysis of the GBMMS was performed. A three-factor solution fit the data after the omission of two problematic items. This revised version of the GBMMS exhibited sufficient configural, metric, and scalar invariance. Convergence of the GBMMS with conceptually related measures provided further evidence of validity; however, there was variation across ethnoracial identity. The GBMMS has viable psychometric properties across gender and ethnoracial identity in Black and Latino populations.
C1 [Wheldon, Christopher W.] NCI, Div Canc Control & Populat Sci, Room 3E-212,9609 Med Ctr Dr, Bethesda, MD 20892 USA.
[Kolar, Stephanie K.] US Dept Vet Affairs, Washington, DC USA.
[Hernandez, Natalie D.] Univ S Florida, Dept Community Hlth & Prevent Med, Tampa, FL USA.
[Daley, Ellen M.] Univ S Florida, Dept Community & Family Hlth, Tampa, FL USA.
RP Wheldon, CW (reprint author), NCI, Div Canc Control & Populat Sci, Room 3E-212,9609 Med Ctr Dr, Bethesda, MD 20892 USA.
EM christopher.wheldon@nih.gov
NR 19
TC 0
Z9 0
U1 0
U2 0
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
EI 1548-6869
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD FEB
PY 2017
VL 28
IS 1
BP 88
EP 99
PG 12
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA EL6JU
UT WOS:000394729200012
PM 28238990
ER
PT J
AU Makaroun, LK
Bowman, C
Duan, K
Handley, N
Wheeler, DJ
Pierluissi, E
Chen, AH
AF Makaroun, Lena K.
Bowman, Chelsea
Duan, Kevin
Handley, Nathan
Wheeler, Daniel J.
Pierluissi, Edgar
Chen, Alice Hm
TI Specialty Care Access in the Safety Net-the Role of Public Hospitals and
Health Systems
SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED
LA English
DT Article
DE Specialty care; access to care; safety net; health care reform
ID ELECTRONIC REFERRALS; PROVIDERS; GASTROENTEROLOGY; CENTERS
AB Access to specialty care in the United States safety net, already strained, is facing increasing pressure with an influx of patients following the passage of the Affordable Care Act (ACA). We surveyed 18 public hospitals and health systems across the country to describe the current state of specialty care delivery in safety-net systems. We elicited information regarding challenges, provider models, metrics of access and productivity, and strategies for improving access. Based on our findings, we propose a framework for assessing and improving specialty care access with a focus on population health planning.
C1 [Makaroun, Lena K.] Univ Washington, Dept Med, Div Geriatr, Seattle, WA 98195 USA.
[Makaroun, Lena K.] VA Puget Sound Healthcare Syst, Seattle, WA USA.
[Bowman, Chelsea] Palo Alto Med Fdn, Palo Alto, CA USA.
[Duan, Kevin; Pierluissi, Edgar] Univ Calif San Francisco, Dept Med, Div Hosp Med, San Francisco, CA 94143 USA.
[Handley, Nathan] Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.
[Wheeler, Daniel J.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA.
[Pierluissi, Edgar] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA.
[Chen, Alice Hm] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA.
RP Makaroun, LK (reprint author), Univ Washington, Dept Med, Div Geriatr, VA Puget Sound Healthcare Syst, 1660 South Columbia Way,S-152, Seattle, WA 98108 USA.
EM makaroun@uw.edu
NR 33
TC 0
Z9 0
U1 0
U2 0
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1049-2089
EI 1548-6869
J9 J HEALTH CARE POOR U
JI J. Health Care Poor Underserved
PD FEB
PY 2017
VL 28
IS 1
BP 566
EP 581
PG 16
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA EL6JU
UT WOS:000394729200041
PM 28239019
ER
PT J
AU Lee, MH
Appleton, KM
El-Shewy, HM
Sorci-Thomas, MG
Thomas, MJ
Lopes-Virella, MF
Luttrell, LM
Hammad, SM
Klein, RL
AF Lee, Mi-Hye
Appleton, Kathryn M.
El-Shewy, Hesham M.
Sorci-Thomas, Mary G.
Thomas, Michael J.
Lopes-Virella, Maria F.
Luttrell, Louis M.
Hammad, Samar M.
Klein, Richard L.
TI S1P in HDL promotes interaction between SR-BI and S1PR1 and activates
S1PR1-mediated biological functions: calcium flux and S1PR1
internalization
SO JOURNAL OF LIPID RESEARCH
LA English
DT Article
DE high density lipoprotein; sphingosine 1-phosphate; protein-fragment
complementation assay; scavenger receptor BI; S1P receptors
ID HIGH-DENSITY-LIPOPROTEIN; RECEPTOR CLASS-B; APOLIPOPROTEIN-A-I;
ENDOTHELIAL-CELL MIGRATION; NITRIC-OXIDE SYNTHASE; SCAVENGER RECEPTOR;
SPHINGOSINE 1-PHOSPHATE; PLASMA-MEMBRANE; MASS-SPECTROMETRY;
PROTEIN-KINASE
AB HDL normally transports about 50-70% of plasma sphingosine 1-phosphate (S1P), and the S1P in HDL reportedly mediates several HDL-associated biological effects and signaling pathways. The HDL receptor, SR-BI, as well as the cell surface receptors for S1P (S1PRs) may be involved partially and/or completely in these HDL-induced processes. Here we investigate the nature of the HDL-stimulated interaction between the HDL receptor, SR-BI, and S1PR1 using a protein-fragment complementation assay and confocal microscopy. In both primary rat aortic vascular smooth muscle cells and HEK293 cells, the S1P content in HDL particles increased intracellular calcium concentration, which was mediated by S1PR1. Mechanistic studies performed in HEK293 cells showed that incubation of cells with HDL led to an increase in the physical interaction between the SR-BI and S1PR1 receptors that mainly occurred on the plasma membrane. Model recombinant HDL (rHDL) particles formed in vitro with S1P incorporated into the particle initiated the internalization of S1PR1, whereas rHDL without supplemented S1P did not, suggesting that S1P transported in HDL can selectively activate S1PR1. In conclusion, these data suggest that S1P in HDL stimulates the transient interaction between SR-BI and S1PRs that can activate S1PRs and induce an elevation in intracellular calcium concentration.
C1 [Lee, Mi-Hye; El-Shewy, Hesham M.; Lopes-Virella, Maria F.; Luttrell, Louis M.; Klein, Richard L.] Med Univ South Carolina, Div Endocrinol Metab & Med Genet, Dept Med, Coll Pharm, Charleston, SC 29425 USA.
[Appleton, Kathryn M.; Luttrell, Louis M.] Med Univ South Carolina, Dept Pharmaceut & Biomed Sci, Coll Pharm, Charleston, SC USA.
[Hammad, Samar M.] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC USA.
[Sorci-Thomas, Mary G.] Med Coll Wisconsin, Dept Med, Div Endocrinol Metab & Clin Nutr, Milwaukee, WI 53226 USA.
[Thomas, Michael J.] Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA.
[Lopes-Virella, Maria F.; Luttrell, Louis M.; Klein, Richard L.] Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
RP Klein, RL (reprint author), Med Univ South Carolina, Div Endocrinol Metab & Med Genet, Dept Med, Coll Pharm, Charleston, SC 29425 USA.; Klein, RL (reprint author), Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC 29401 USA.
EM kleinrl@musc.edu
FU Department of Veterans Affairs Merit Review Program; National Institutes
of Health/National Heart, Lung, and Blood Institute [HL079274, HL127649,
HL112276]; National Institutes of Health [RR027777]; National Cancer
Institute Center Grant [5P30CA12197]
FX This work was supported by the Department of Veterans Affairs Merit
Review Program (M.L.V. and R.L.K.) and by National Institutes of
Health/National Heart, Lung, and Blood Institute Grants HL079274
(S.M.H.), HL127649, and HL112276 (M.S.T.). The FLIPRTETRA
facility was supported by National Institutes of Health Grant RR027777
(L.M.L.). The mass spectroscopy analyses were performed in the Mass
Spectrometer Facility of the Comprehensive Cancer Center of Wake Forest
School of Medicine supported in part by National Cancer Institute Center
Grant 5P30CA12197. The contents of this manuscript do not represent the
views of the Department of Veterans Affairs or the United States
Government. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National
Institutes of Health.
NR 57
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0022-2275
EI 1539-7262
J9 J LIPID RES
JI J. Lipid Res.
PD FEB
PY 2017
VL 58
IS 2
BP 325
EP 338
DI 10.1194/jlr.M070706
PG 14
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA EM1WW
UT WOS:000395108900003
PM 27881715
ER
PT J
AU Berko, ER
Cho, MT
Eng, C
Shao, YR
Sweetser, DA
Waxler, J
Robin, NH
Brewer, F
Donkervoort, S
Mohassel, P
Bonnemann, CG
Bialer, M
Moore, C
Wolfe, LA
Tifft, CJ
Shen, YF
Retterer, K
Millan, F
Chung, WK
AF Berko, Esther R.
Cho, Megan T.
Eng, Christine
Shao, Yunru
Sweetser, David A.
Waxler, Jessica
Robin, Nathaniel H.
Brewer, Fallon
Donkervoort, Sandra
Mohassel, Payam
Bonnemann, Carsten G.
Bialer, Martin
Moore, Christine
Wolfe, Lynne A.
Tifft, Cynthia J.
Shen, Yufeng
Retterer, Kyle
Millan, Francisca
Chung, Wendy K.
TI De novo missense variants in HECW2 are associated with
neurodevelopmental delay and hypotonia
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
DE intellectual disability; whole exome sequencing; de novo; HECW2;
neurodevelopmental delay
ID SEVERE INTELLECTUAL DISABILITY; UBIQUITIN LIGASE; MUTATIONS; P73;
MAINTENANCE; DISORDERS; DEFECTS; NEURONS; SERVER; BRAIN
AB Background The causes of intellectual disability (ID) are diverse and de novo mutations are increasingly recognised to account for a significant proportion of ID.
Methods and results In this study, we performed whole exome sequencing on a large cohort of patients with ID or neurodevelopmental delay and identified four novel de novo predicted deleterious missense variants in HECW2 in six probands with ID/developmental delay and hypotonia. Other common features include seizures, strabismus, nystagmus, cortical visual impairment and dysmorphic facial features. HECW2 is an ubiquitin ligase that stabilises p73, a crucial mediator of neurodevelopment and neurogenesis.
Conclusion This study implicates pathogenic genetic variants in HECW2 as potential causes of neurodevelopmental disorders in humans.
C1 [Berko, Esther R.; Chung, Wendy K.] Columbia Univ, Med Ctr, Dept Pediat, New York, NY 10032 USA.
[Cho, Megan T.; Retterer, Kyle; Millan, Francisca] GeneDx, Gaithersburg, MD USA.
[Eng, Christine; Shao, Yunru] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
[Shao, Yunru] Texas Childrens Hosp, Houston, TX 77030 USA.
[Sweetser, David A.; Waxler, Jessica] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Robin, Nathaniel H.; Brewer, Fallon] Univ Alabama Birmingham, Birmingham, AL USA.
[Donkervoort, Sandra; Mohassel, Payam; Bonnemann, Carsten G.] NINDS, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
[Bialer, Martin; Moore, Christine] Cohen Childrens Med Ctr NY, New Hyde Pk, NY USA.
[Wolfe, Lynne A.; Tifft, Cynthia J.] NIH, Off Clin Director, Bldg 10, Bethesda, MD 20892 USA.
[Wolfe, Lynne A.; Tifft, Cynthia J.] NIH, Undiagnosed Dis Program, Bldg 10, Bethesda, MD 20892 USA.
[Shen, Yufeng] Columbia Univ, Med Ctr, Dept Syst Biol, New York, NY 10032 USA.
[Shen, Yufeng] Columbia Univ, Med Ctr, Dept Biomed Informat, New York, NY 10032 USA.
[Chung, Wendy K.] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA.
RP Chung, WK (reprint author), Columbia Univ, Med Ctr, New York, NY 10032 USA.
EM wkc15@columbia.edu
FU Simons Foundation
FX This work was supported in part by a grant from the Simons Foundation.
NR 35
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD FEB
PY 2017
VL 54
IS 2
BP 93
EP 99
DI 10.1136/jmedgenet-2016-103943
PG 7
WC Genetics & Heredity
SC Genetics & Heredity
GA EM7WS
UT WOS:000395523600002
PM 27389779
ER
PT J
AU Hou, Y
Lee, S
Agrawal, V
Romano, J
Baldini, EH
Chen, AB
Kozono, DE
Killoran, JH
Wagar, M
Hacker, FL
Aerts, HJWL
Lewis, JH
Mak, RH
AF Hou, Ying
Lee, Stephanie
Agrawal, Vishesh
Romano, John
Baldini, Elizabeth H.
Chen, Aileen B.
Kozono, David E.
Killoran, Joseph H.
Wagar, Matthew
Hacker, Fred L.
Aerts, Hugo J. W. L.
Lewis, John H.
Mak, Raymond H.
TI Inter-scan and inter-observer tumour volume delineation variability on
cone beam computed tomography in patients treated with stereotactic body
radiation therapy for early-stage non-small cell lung cancer
SO JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY
LA English
DT Article
DE CBCT; inter-observer variability; inter-scan variability; NSCLC; SBRT
ID PULMONARY NODULES; RADIOTHERAPY; CT; OUTCOMES
AB IntroductionQuantification of volume changes on cone beam computed tomography (CBCT) during lung stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC) may provide a useful radiological marker for radiation response and for adaptive treatment planning. This study quantifies inter-scan and inter-observer variability in tumour volume delineation on CBCT.
MethodsThree clinicians independently contoured the primary gross tumour volume (GTV) manually on CBCTs taken immediately before SBRT treatment (pre) and after the same SBRT treatment (post) for 19 NSCLC patients. Relative volume differences (RVD) were calculated between the pre- and post-CBCTs for a given treatment and between any two of three observers for a given CBCT. Coefficient of variation (CV) was used to quantitatively measure and compare the extent of variability.
ResultsInter-observer variability had a significantly higher CV of 0.150.13 compared to inter-scan CV of 0.03 +/- 0.04 with P<0.0001. The greatest variability was observed with tumours (<2cm in diameter) versus larger tumours with 95% limit of agreement (LOA) (Mean +/- Standard Deviation) of 1.90%+/- 19.55% vs. -0.97%+/- 12.26% for inter-scan RVD and 29.99%+/- 73.84% vs. 9.37%+/- 29.95% for inter-observer RVD respectively.
ConclusionsInter-observer variability was greater than inter-scan variability for tumour volume delineation on CBCT with greatest variability for small tumours (<2cm in diameter). LOA for inter-scan variability (similar to 12%) helps defines a threshold for clinically meaningful tumour volume change during SBRT treatment for tumours with diameter greater than 2cm, with larger thresholds needed for smaller tumours.
C1 [Hou, Ying; Lee, Stephanie; Agrawal, Vishesh; Romano, John; Baldini, Elizabeth H.; Chen, Aileen B.; Kozono, David E.; Killoran, Joseph H.; Wagar, Matthew; Hacker, Fred L.; Aerts, Hugo J. W. L.; Lewis, John H.; Mak, Raymond H.] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
[Baldini, Elizabeth H.; Chen, Aileen B.; Kozono, David E.; Killoran, Joseph H.; Wagar, Matthew; Hacker, Fred L.; Aerts, Hugo J. W. L.; Lewis, John H.; Mak, Raymond H.] Harvard Med Sch, Boston, MA USA.
RP Mak, RH (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, 450 Brookline Ave,JF518, Boston, MA 02115 USA.
EM rmak@partners.org
FU Kaye Award
FX This work was funded in part by a Kaye Award. Accepted as a poster at
AAPM 2015.
NR 17
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1754-9477
EI 1754-9485
J9 J MED IMAG RADIAT ON
JI J. Med. Imag. Radiat. Oncol.
PD FEB
PY 2017
VL 61
IS 1
BP 93
EP 98
DI 10.1111/1754-9485.12537
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA EL9SL
UT WOS:000394960300013
PM 27709803
ER
PT J
AU Chen, M
Albuquerque, FC
Hirsch, J
Tarr, RW
AF Chen, Michael
Albuquerque, Felipe C.
Hirsch, Joshua
Tarr, Robert W.
TI Improving the likelihood of manuscript acceptance; a primer for trainees
and young investigators
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Editorial Material
DE Political
ID STROKE
C1 [Chen, Michael] Rush Univ, Dept Neurol Sci, Med Ctr, Chicago, IL 60612 USA.
[Albuquerque, Felipe C.] Barrow Neurol Inst, Div Neurol Surg, 350 W Thomas Rd, Phoenix, AZ 85013 USA.
[Hirsch, Joshua] Massachusetts Gen Hosp, NeuroEndovasc Program, Boston, MA 02114 USA.
[Tarr, Robert W.] Univ Hosp Case Med Ctr, Dept Radiol, Wright Patterson AFB, OH USA.
RP Chen, M (reprint author), Rush Univ, Med Ctr, Dept Neurol Surg & Neurol Sci, 1725 West Harrison St,Suite 855, Chicago, IL 60612 USA.
EM michael_chen@rush.edu
NR 8
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD FEB
PY 2017
VL 9
IS 2
BP 115
EP 116
DI 10.1136/neurintsurg-2015-011670
PG 2
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA EL4TS
UT WOS:000394614400007
PM 25665983
ER
PT J
AU Nogueira, RG
Kemmling, A
Souza, LM
Payabvash, S
Hirsch, JA
Yoo, AJ
Lev, MH
AF Nogueira, Raul G.
Kemmling, Andre
Souza, Leticia M.
Payabvash, Seyedmehdi
Hirsch, Joshua A.
Yoo, Albert J.
Lev, Michael H.
TI Clinical diffusion mismatch better discriminates infarct growth than
mean transit time-diffusion weighted imaging mismatch in patients with
middle cerebral artery-M1 occlusion and limited infarct core
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE Stroke; CT perfusion; Thrombectomy; MRI; Thrombolysis
ID EVALUATION TRIAL EPITHET; ACUTE STROKE; ISCHEMIC-STROKE;
COMPUTED-TOMOGRAPHY; MAGNETIC-RESONANCE; POOLED ANALYSIS; DWI MISMATCH;
REPERFUSION; SELECTION; THERAPY
AB Background and purpose Our purpose was to compare clinical diffusion mismatch (CDM) and mean transit time (MTT)-diffusion mismatch as predictors of infarct growth in patients with proximal middle cerebral artery (MCA) occlusion and small infarct core on presentation.
Methods Retrospective analysis of consecutive stroke patients with: (1) MCA-M1 occlusion; (2) MRI performed 10h from symptoms onset; and (3) baseline MRI-diffusion weighted imaging (DWI) volume 25mL. Definitions included: CDM=baseline National Institutes of Health Stroke Scale (NIHSS) score 8 and DWI volume 25mL; MTT-DWI mismatch=visually assessed unthresholded MTT lesion ((MTT-DWI))/DWI) 20% and 10mL larger than the DWI lesion; and significant infarct growth (>20% (5mL) increase in infarct volume on follow-up). Uni-/multivariate analyses were performed to define the predictors of infarct growth.
Results 63 stroke patients with MCA-M1 occlusions and MRI within 10h of onset were evaluated. 20 patients were excluded on the basis of DWI volume >25mL leaving 43 patients (mean age 75.8years; median NIHSS=13) in the study cohort. On univariate analysis, larger admission DWI volume (p<0.0001), baseline NIHSS score 8 (p=0.001), lack of IV and/or endovascular treatment (p=0.021), glucose levels >125mg/dL (p=0.024), poor CT angiography collaterals (p=0.046), and lower admission Alberta Stroke Program Early CT score (ASPECTS) (p=0.049) predicted infarct growth. Baseline NIHSS score 8 was the only independent predictor of stroke growth in the multivariate analysis (p=0.001). All patients had MTT-DWI mismatch >20%. There was no significant association between the amount of MTT-DWI mismatch and infarct growth (p=0.33).
Conclusions CDM is the most powerful predictor of infarct growth in patients with MCA-M1 occlusion and small infarct core. Most of these patients will have a significant oligemic MTT lesion regardless of admission NIHSS score.
C1 [Nogueira, Raul G.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA.
[Nogueira, Raul G.] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA.
[Nogueira, Raul G.] Emory Univ, Sch Med, Dept Neurosurg, Atlanta, GA USA.
[Nogueira, Raul G.] Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA.
[Kemmling, Andre; Souza, Leticia M.; Payabvash, Seyedmehdi; Hirsch, Joshua A.; Yoo, Albert J.; Lev, Michael H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neuroradiol, Boston, MA USA.
RP Nogueira, RG (reprint author), Emory Fac Off Bldg,80 Jesse Hill Dr SE,Room 333, Atlanta, GA 30303 USA.
EM rnoguei@emory.edu
FU Penumbra Inc.; GE Healthcare
FX RGN: principal investigator for the TREVO-2 and DAWN trials (Stryker
Neurovascular); steering committee member of the SWIFT and SWIFT-Prime
Trials, Core Lab of the STAR Trial (Covidien/ev3 Neurovascular), and
executive committee member of the 3D Separator Trial (Penumbra). AJY:
research grant from Penumbra Inc. MHL: research support from GE
Healthcare, and consultant to CoAxia, GE Healthcare, and Millennium
Pharmaceuticals.
NR 21
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD FEB
PY 2017
VL 9
IS 2
BP 127
EP 130
DI 10.1136/neurintsurg-2014-011602
PG 4
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA EL4TS
UT WOS:000394614400010
PM 26957483
ER
PT J
AU Deipolyi, A
Bailin, A
Hirsch, JA
Walker, TG
Oklu, R
AF Deipolyi, Amy
Bailin, Alexander
Hirsch, Joshua A.
Walker, T. Gregory
Oklu, Rahmi
TI Bilateral inferior petrosal sinus sampling: experience in 327 patients
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE Angiography; Catheter; Technique; MRI; Tumor
ID DEPENDENT CUSHINGS-SYNDROME; DIFFERENTIAL-DIAGNOSIS; PITUITARY; DISEASE;
DESMOPRESSIN; HORMONE
AB Objective To describe findings and outcomes of 331 bilateral inferior petrosal sinus sampling (BIPSS) procedures performed in 327 patients evaluated for Cushing disease (CD).
Materials and methods The radiology department's electronic database was searched to identify all BIPSS procedures (1990-2013). Electronic medical records were used to identify demographics, laboratory, procedural, surgical and pathologic findings.
Results A total of 331 BIPSS procedures were performed in 327 patients (254 F, 73 M), mean age 41 (range 7-81) years. The overall technical success rate was 88% for bilateral cannulation, though nearly two-thirds of the technical failures had unilateral sampling that diagnosed CD. Of the 331 BIPSS procedures, 40 were performed without, and 291 with stimulation by Acthrel or desmopressin. Sensitivity was 89-94% for unstimulated BIPSS, 96% for stimulated BIPSS, and 77% for MRI. BIPSS lateralization was accurate in about half of patients, compared with 75% accuracy for MRI. Mean inferior petrosal sinus (IPS):peripheral adrenocorticotropic hormone ratio was 17.3 (SE 1.8) at baseline, and 99.2 (SE 14.8) at 3min, with decreasing values over time. All patients with follow-up after surgical resection for centralizing BIPSS were reported to be cured, with cortisol levels significantly decreased from 19 to 4g/dL (p<0.0001). Complications from BIPSS were rare, including groin hematoma (2.5%), but no thromboembolic complications were seen.
Conclusions BIPSS remains the gold standard' for diagnosing CD. Stimulation with Acthrel or desmopressin is key to increasing specificity. When only one IPS can be successfully cannulated, results may still be diagnostic. BIPSS findings cannot be used to accurately lateralize lesions within the pituitary.
C1 [Deipolyi, Amy] NYU, Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, New York, NY 10016 USA.
[Bailin, Alexander; Walker, T. Gregory] Harvard Med Sch, Massachusetts Gen Hosp, Vasc & Intervent Radiol, Boston, MA USA.
[Hirsch, Joshua A.] Harvard Med Sch, Massachusetts Gen Hosp, Div Intervent Neuroradiol, Boston, MA USA.
[Oklu, Rahmi] Mayo Clin, Vasc & Intervent Radiol, Scottsdale, AZ USA.
[Oklu, Rahmi] Harvard Med Sch, Biomaterials Innovat Res Ctr, Brigham & Womens Hosp, Dept Med, Cambridge, MA USA.
Mayo Clin, Div Intervent Radiol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.
RP Oklu, R (reprint author), Mayo Clin, Div Intervent Radiol, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.
EM oklu.rahmi@mayo.edu
OI Deipolyi, Amy/0000-0003-3144-386X
NR 17
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD FEB
PY 2017
VL 9
IS 2
BP 196
EP 199
DI 10.1136/neurintsurg-2015-012164
PG 4
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA EL4TS
UT WOS:000394614400024
PM 26880723
ER
PT J
AU Hirsch, JA
Fargen, K
Ducruet, AF
Tarr, RW
AF Hirsch, Joshua A.
Fargen, Kyle
Ducruet, Andrew F.
Tarr, Robert W.
TI JNIS podcasts: the early part of our journey
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE Technology
ID ACUTE ISCHEMIC-STROKE; TRIALS
AB Podcasts are an area of innovation in the neurointerventional space that has the potential to convey information in ways that traditional journal articles in peer-reviewed journals do not. BMJ maintains an archive of all of its podcasts on the Journal of NeuroInterventional Surgery (JNIS) website. We sought to analyze this early JNIS podcast experience and assess the impact of content elements and an increased presence in social media.
C1 [Hirsch, Joshua A.] Massachusetts Gen Hosp, NeuroEndovasc Program, Boston, MA 02114 USA.
[Fargen, Kyle] Med Univ South Carolina, Dept Neurosurg, Charleston, SC USA.
[Ducruet, Andrew F.] UPMC, Dept Neurosurg, Pittsburgh, PA USA.
[Tarr, Robert W.] Univ Hosp Case Med Ctr, Dept Radiol, Cleveland, OH USA.
RP Hirsch, JA (reprint author), Massachusetts Gen Hosp, NeuroEndovasc Program, Boston, MA 02114 USA.
EM hirsch@snisonline.org
NR 11
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD FEB
PY 2017
VL 9
IS 2
BP 211
EP 214
DI 10.1136/neurintsurg-2015-012170
PG 4
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA EL4TS
UT WOS:000394614400027
PM 26763788
ER
PT J
AU Fargen, KM
Ducruet, AF
Hyer, M
Hirsch, JA
Tarr, RW
AF Fargen, Kyle M.
Ducruet, Andrew F.
Hyer, Madison
Hirsch, Joshua A.
Tarr, Robert W.
TI Expanding the social media presence of the Journal of
Neurointerventional Surgery: editor's report
SO JOURNAL OF NEUROINTERVENTIONAL SURGERY
LA English
DT Article
DE Economics; Technology
ID IMPACT
AB The use of social media is pervasive throughout society and serves many purposes. Traditional forms of advertising are being upended as vendors recognize the unique abilities of social media platforms to target their messages to specific customers. Peer reviewed medical and professional journals are beginning to develop their own initiatives using social media to advertize unique content. We present the nascent Journal of NeuroInterventional Surgery experience.
C1 [Fargen, Kyle M.; Hyer, Madison] Med Univ South Carolina, Dept Neurosurg, Charleston, SC USA.
[Ducruet, Andrew F.] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA.
[Hirsch, Joshua A.] Harvard Med Sch, Massachusetts Gen Hosp, Neuroendovasc Serv, Boston, MA USA.
[Tarr, Robert W.] Univ Hosp Case Med Ctr, Dept Radiol, Cleveland, OH USA.
RP Fargen, KM (reprint author), 96 Jonathan Lucas St,CSB 301, Charleston, SC 29425 USA.
EM Fargen@musc.edu
NR 6
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1759-8478
EI 1759-8486
J9 J NEUROINTERV SURG
JI J. NeuroInterventional Surg.
PD FEB
PY 2017
VL 9
IS 2
BP 215
EP 218
DI 10.1136/neurintsurg-2015-012251
PG 4
WC Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA EL4TS
UT WOS:000394614400028
PM 26927814
ER
PT J
AU Mulvey, TM
Peppercorn, J
AF Mulvey, Therese Marie
Peppercorn, Jeffrey
TI Capturing High-Value Cancer Care in the Wild
SO JOURNAL OF ONCOLOGY PRACTICE
LA English
DT Editorial Material
ID AMERICAN SOCIETY; FRAMEWORK
C1 [Mulvey, Therese Marie; Peppercorn, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Mulvey, TM (reprint author), 102 Endicott St, Danvers, MA 01923 USA.
EM tmmulvey@partners.org
FU Pfizer
FX Pfizer
NR 5
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 1554-7477
EI 1935-469X
J9 J ONCOL PRACT
JI J. Oncol. Pract.
PD FEB 1
PY 2017
VL 13
IS 2
BP 67
EP +
DI 10.1200/JOP.2016.019430
PG 3
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA EP3LD
UT WOS:000397282900002
ER
PT J
AU Ferrell, BR
Temel, JS
Temin, S
Smith, TJ
AF Ferrell, Betty R.
Temel, Jennifer S.
Temin, Sarah
Smith, Thomas J.
TI Integration of Palliative Care Into Standard Oncology Care: ASCO
Clinical Practice Guideline Update Summary
SO JOURNAL OF ONCOLOGY PRACTICE
LA English
DT Editorial Material
ID CANCER AMERICAN SOCIETY; CELL LUNG-CANCER
C1 City Hope Med Ctr, Duarte, CA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ferrell, Betty R.] Amer Soc Clin Oncol, 2318 Mill Rd,Ste 800, Alexandria, VA 22314 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
RP Ferrell, BR (reprint author), Amer Soc Clin Oncol, 2318 Mill Rd,Ste 800, Alexandria, VA 22314 USA.
EM guidelines@asco.org
FU Helsinn Therapeutics (Inst); Pfizer (Inst)
FX Helsinn Therapeutics (Inst), Pfizer (Inst)
NR 9
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 1554-7477
EI 1935-469X
J9 J ONCOL PRACT
JI J. Oncol. Pract.
PD FEB 1
PY 2017
VL 13
IS 2
BP 119
EP +
DI 10.1200/JOP.2016.017897
PG 4
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA EP3LD
UT WOS:000397282900019
ER
PT J
AU Neuss, M
Rocque, G
Zuckerman, D
Chiang, A
Katta, S
Wollins, D
Kamin, D
Edge, S
AF Neuss, Michael
Rocque, Gabrielle
Zuckerman, Dan
Chiang, Anne
Katta, Sweatha
Wollins, Dana
Kamin, Deborah
Edge, Stephen
TI Establishing a Core Set of Performance Measures to Improve Value in
Cancer Care: ASCO Consensus Conference Recommendation Report
SO JOURNAL OF ONCOLOGY PRACTICE
LA English
DT Editorial Material
ID UNITED-STATES
C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
St Lukes Mt States Tumor Inst, Boise, ID USA.
Amer Soc Clin Oncol, Alexandria, VA USA.
Roswell Pk Canc Inst, Buffalo, NY USA.
RP Neuss, M (reprint author), Michael Neuss, 2220 Pierce Ave, Nashville, MD USA.; Rocque, G (reprint author), 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA.
EM michael.n.neuss@vanderbilt.edu; cancerpolicy@asco.org
FU PackHealth; Medscape; Carevive Systems; Genentech; OncoMed; Millennium;
Onyx; Boehringer Ingelheim; Eli Lilly; Bristol Myers Squibb; Medivation
FX PackHealth, Medscape, Carevive Systems, Genentech; OncoMed, Millennium,
Onyx, Boehringer Ingelheim, Eli Lilly, Bristol Myers Squibb, Medivation
NR 7
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 1554-7477
EI 1935-469X
J9 J ONCOL PRACT
JI J. Oncol. Pract.
PD FEB 1
PY 2017
VL 13
IS 2
BP 135
EP +
DI 10.1200/JOP.2016.017954
PG 10
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA EP3LD
UT WOS:000397282900022
ER
PT J
AU Fell, GL
Cho, BS
Pan, A
Nose, V
Anez-Bustillos, L
Dao, DT
Baker, MA
Nandivada, P
Gura, KM
Puder, M
AF Fell, Gillian L.
Cho, Bennet S.
Pan, Amy
Nose, Vania
Anez-Bustillos, Lorenzo
Dao, Duy T.
Baker, Meredith A.
Nandivada, Prathima
Gura, Kathleen M.
Puder, Mark
TI A Comparison of Fish Oil Sources for Parenteral Lipid Emulsions in a
Murine Model
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article
DE parenteral lipid emulsions; fish oil; parenteral nutrition-associated
liver disease; intestinal failure; USP 729
ID INJECTABLE EMULSIONS; LIVER
AB Background: Fat emulsions are important components of parenteral nutrition (PN). Fish oil (FO) emulsions reverse cholestasis in PN-associated liver disease. There are 2 FO monographs. One is FO; rich in omega-3 fatty acids (NFO). The other, omega-3 acids, (PFO), is enriched in omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The purpose of this study is to compare the effects of 20% NFO and PFO emulsions produced in the laboratory in a murine model. Methods: Emulsions were compounded containing different oils: soybean oil (SO), NFO, and two PFOs differing in percentage of fatty acids as triglycerides (PFO66 and PFO90). Chow-fed mice received saline, one of the above emulsions, or a commercial FO (OM) intravenously (2.4 g/kg/day) for 19 days. On day 19, animals were euthanized. Livers, spleens, and lungs were procured for histologic analysis. Results: OM, SO, NFO, and PFO90 were well-tolerated clinically. PFO66 resulted in tachypnea and lethargy for 1 minute following injections. At euthanasia, PFO66 and PFO90 groups had organomegaly. Histologically, these groups had splenic and hepatic fat-laden macrophages, and lungs had scattered fat deposits. Other groups had normal organs. Conclusions: PFO emulsions present an attractive possibility for improving inflammation in PN-dependent patients by concentrating anti-inflammatory EPA and DHA. However, 20% PFO emulsions were poorly tolerated and precipitated adverse end organ sequelae, suggesting that they may not be safe. Development of novel manufacturing methods may achieve safe 20% PFO parenteral emulsions, but by established formulation methods, these emulsions were clinically suboptimal despite meeting pharmacopeial standards.
C1 [Fell, Gillian L.; Cho, Bennet S.; Pan, Amy; Anez-Bustillos, Lorenzo; Dao, Duy T.; Baker, Meredith A.; Puder, Mark] Boston Childrens Hosp, Vasc Biol Program, 300 Longwood Ave,Fegan 3, Boston, MA 02115 USA.
[Fell, Gillian L.; Cho, Bennet S.; Pan, Amy; Anez-Bustillos, Lorenzo; Dao, Duy T.; Baker, Meredith A.; Puder, Mark] Boston Childrens Hosp, Dept Surg, 300 Longwood Ave,Fegan 3, Boston, MA 02115 USA.
[Nose, Vania] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Nandivada, Prathima] Beth Israel Deaconess Med Ctr, Dept Surg, 330 Brookline Ave, Boston, MA 02215 USA.
[Gura, Kathleen M.] Boston Childrens Hosp, Dept Pharm, Boston, MA USA.
RP Puder, M (reprint author), Boston Childrens Hosp, Vasc Biol Program, 300 Longwood Ave,Fegan 3, Boston, MA 02115 USA.; Puder, M (reprint author), Boston Childrens Hosp, Dept Surg, 300 Longwood Ave,Fegan 3, Boston, MA 02115 USA.
EM mark.puder@childrens.harvard.edu
OI Baker, Meredith/0000-0002-9947-9546
FU Boston Children's Hospital Surgical Foundation; National Institutes of
Health (NIH) [1F32DK104525-01]; Joshua Ryan Rappaport Fellowship; NIH
[5T32HL007734-22, T35HL110843]
FX The NFO, PFO66, and PFO90 oils used in this study were generously
donated by Pronova Biopharma (all contributors). The Boston Children's
Hospital Surgical Foundation provided funding for this study (all
contributors). BASF provided funding for this study (all contributors).
G.L. Fell received funding through the National Institutes of Health
(NIH; grant 1F32DK104525-01). P. Nandivada received funding through the
Joshua Ryan Rappaport Fellowship. M.A. Baker received funding through
the NIH (grant 5T32HL007734-22). B.S. Cho received funding through the
NIH (grant T35HL110843).
NR 23
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0148-6071
EI 1941-2444
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
PD FEB
PY 2017
VL 41
IS 2
BP 181
EP 187
DI 10.1177/0148607116640275
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA EL8UW
UT WOS:000394896800006
PM 26993989
ER
PT J
AU Kudsk, KA
Munoz-del-Rio, A
Busch, RA
Kight, CE
Schoeller, DA
AF Kudsk, Kenneth A.
Munoz-del-Rio, Alejandro
Busch, Rebecca A.
Kight, Cassandra E.
Schoeller, Dale A.
TI Stratification of Fat-Free Mass Index Percentiles for Body Composition
Based on National Health and Nutrition Examination Survey III
Bioelectric Impedance Data
SO JOURNAL OF PARENTERAL AND ENTERAL NUTRITION
LA English
DT Article
DE nutrition assessment; nutrition; outcomes research; quality; nutrition
support practice; adult; life cycle
ID LENGTH-OF-STAY; HOSPITAL ADMISSION; POSTOPERATIVE COMPLICATIONS;
NHANES-III; MALNUTRITION; OUTCOMES; CANCER; RISK; SURGERY; IMPACT
AB Background: Loss of protein mass and lower fat-free mass index (FFMI) are associated with longer length of stay, postsurgical complications, and other poor outcomes in hospitalized patients. Normative data for FFMI of U.S. populations do not exist. This work aims to create a stratified FFMI percentile table for the U.S. population using the large bioelectric impedance analysis data obtained from National Health and Nutrition Examination Surveys (NHANES). Methods: Fat-free mass (FFM) was calculated from the NHANES III bioelectric impedance analysis and anthropometric data for males and females ages 12 to >90 years for 3 race/ethnicities (non-Hispanic white, non-Hispanic black, and Mexican American). FFM was normalized by subject height to create an FFMI distribution table for the U.S. population. Selected percentiles were obtained by age, sex, and race/ethnicity. Data were collapsed by race/ethnicity before and after removing obese and underweight participants to create an FFMI decile table for males and females 12 years and older for the healthy-weight U.S. population. Results: FFMI increased during adolescent growth but stabilized in the early 20s. The FFMI deciles were similar by race/ethnicity, with age group remaining relatively stable between ages 25 and 80 years. The FFMI deciles for males and females were significantly different. Conclusions: After eliminating the obese and extremely thin, FFMI percentiles remain stable during adult years allowing creation of age- and race/ethnicity-independent decile tables for males and females. These tables allow stratification of individuals for nutrition intervention trials to depict changing nutrition status during medical, surgical, and nutrition interventions.
C1 [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Vet Adm Surg Serv, Madison, WI USA.
[Kudsk, Kenneth A.; Munoz-del-Rio, Alejandro; Busch, Rebecca A.] Univ Wisconsin, Dept Surg, Sch Med & Publ Hlth, Madison, WI USA.
[Munoz-del-Rio, Alejandro] Univ Wisconsin, Dept Radiol, Madison, WI 53706 USA.
[Munoz-del-Rio, Alejandro] Univ Wisconsin, Dept Med Phys, 1530 Med Sci Ctr, Madison, WI 53706 USA.
[Kight, Cassandra E.] Univ Wisconsin Hosp & Clin, Clin Nutr Serv, Madison, WI 53792 USA.
[Schoeller, Dale A.] Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr, Madison, WI 53706 USA.
RP Kudsk, KA (reprint author), William S Middleton Mem Vet Adm Med Ctr, Clin Sci Ctr G5 341, 600 Highland Ave, Madison, WI 53792 USA.
EM kudsk@surgery.wisc.edu
FU National Institutes of Health Surgical Oncology Research Training
Program [T32CA090217]
FX The project described was supported in part by the National Institutes
of Health Surgical Oncology Research Training Program (grant number
T32CA090217; to R.A.B.). This material is the result of work supported
with the resources and use of facilities at the William S. Middleton
Memorial Veterans Hospital, Madison, Wisconsin. The contents of this
article do not represent the views of the Department of Veterans Affairs
or the U.S. government.
NR 35
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0148-6071
EI 1941-2444
J9 JPEN-PARENTER ENTER
JI J. Parenter. Enter. Nutr.
PD FEB
PY 2017
VL 41
IS 2
BP 249
EP 257
DI 10.1177/0148607115592672
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA EL8UW
UT WOS:000394896800013
PM 26092851
ER
PT J
AU Neumeyer, AM
Sokoloff, NC
McDonnell, E
Macklin, EA
McDougle, CJ
Misra, M
AF Neumeyer, Ann M.
Sokoloff, Natalia Cano
McDonnell, Erin
Macklin, Eric A.
McDougle, Christopher J.
Misra, Madhusmita
TI Bone Accrual in Males with Autism Spectrum Disorder
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID MINERAL DENSITY; PHYSICAL-ACTIVITY; MUSCLE STRENGTH; GASTROINTESTINAL
SYMPTOMS; SEX STEROIDS; YOUNG-ADULTS; VITAMIN-D; CHILDREN; ADOLESCENTS;
CHILDHOOD
AB Objective To test the hypothesis that bone accrual over a 4-year period is reduced in boys with autism spectrum disorder (ASD) compared with typically developing controls. Study design Twenty-five boys with ASD and 24 controls were assessed for bone outcomes. Fourteen boys with ASD and 11 controls were assessed both at baseline and after 4 years. The mean subject age was 11.0 +/- 1.6 years at study initiation and 14.9 +/- 1.6 years at follow-up. Bone mineral density (BMD) was measured at the spine, hip, and whole body using dual-energy X-ray absorptiometry and normalized for age, race, and sex (BMD z-scores). Height adjustments were performed as well. We assessed medical history, physical activity using questionnaires, vitamin D and calcium intake using food records, and serum calcium, phosphorus, 25(OH)-vitamin D, and pubertal hormone levels.
Results Boys with ASD had lower spine, hip, and whole body BMD z-scores compared with controls. In those subjects assessed both at baseline and after 4 years, bone accrual rates did not differ between the 2 groups; however, spine and hip BMD z-scores remained lower in the boys with ASD than in controls at follow-up. Notably, the ASD group was less physically active at both time points.
Conclusion Although pubertal bone accrual was similar to that in controls, BMD in children with ASD remained low over a 4-year follow-up period, suggesting that low BMD is a consequence of prepubertal factors, such as low physical activity. Studies are needed to investigate the causes and consequences of decreased BMD, to assess BMD in females and adults with ASD, and to evaluate therapeutic interventions.
C1 [Neumeyer, Ann M.; Sokoloff, Natalia Cano; McDougle, Christopher J.] Massachusetts Gen Hosp, Lurie Ctr Autism, Lexington, MA 02421 USA.
[Neumeyer, Ann M.; Macklin, Eric A.; McDougle, Christopher J.] Harvard Med Sch, Boston, MA USA.
[McDonnell, Erin; Macklin, Eric A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Misra, Madhusmita] Massachusetts Gen Hosp, Pediat Endocrine Unit, Boston, MA 02114 USA.
[Misra, Madhusmita] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA.
RP Neumeyer, AM (reprint author), MassGeneral Hosp Children, Lurie Ctr, 1 Maguire Rd, Lexington, MA 02421 USA.
EM aneumeyer@mgh.harvard.edu
FU NCATS NIH HHS [KL2 TR001100]; NCRR NIH HHS [UL1 RR025758]; NICHD NIH HHS
[K24 HD071843]
NR 39
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD FEB
PY 2017
VL 181
BP 195
EP +
DI 10.1016/j.jpeds.2016.10.080
PG 13
WC Pediatrics
SC Pediatrics
GA EN8KL
UT WOS:000396249200031
PM 27887681
ER
PT J
AU Shellhaas, RA
Chang, T
Wusthoff, CJ
Soul, JS
Massey, SL
Chu, CJ
Cilio, MR
Bonifacio, SL
Abend, NS
Tsuchida, TN
Glass, HC
AF Shellhaas, Renee A.
Chang, Taeun
Wusthoff, Courtney J.
Soul, Janet S.
Massey, Shavonne L.
Chu, Catherine J.
Cilio, M. Roberta
Bonifacio, Sonia L.
Abend, Nicholas S.
Tsuchida, Tammy N.
Glass, Hannah C.
CA Neonatal Seizure Registry Study Gr
TI Treatment Duration After Acute Symptomatic Seizures in Neonates: A
Multicenter Cohort Study
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID ARTERIAL ISCHEMIC-STROKE; VARIABILITY; RECURRENCE; OUTCOMES
AB We aimed to define determinants of duration of treatment for acute symptomatic neonatal seizures in a contemporary multicenter observational cohort study. After adjustment for potential confounders, only study site and seizure etiology remained significantly associated with the chance of continuing antiseizure medication after discharge to home.
C1 [Shellhaas, Renee A.] Univ Michigan, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA.
[Chang, Taeun; Tsuchida, Tammy N.] George Washington Univ, Sch Med, Dept Neurol, Childrens Natl Hlth Syst, Washington, DC USA.
[Wusthoff, Courtney J.; Bonifacio, Sonia L.] Stanford Univ, Dept Neurol, Palo Alto, CA 94304 USA.
[Wusthoff, Courtney J.; Bonifacio, Sonia L.] Stanford Univ, Dept Pediat, Palo Alto, CA 94304 USA.
[Soul, Janet S.] Boston Childrens Hosp, Dept Neurol, Boston, MA USA.
[Massey, Shavonne L.; Abend, Nicholas S.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA.
[Massey, Shavonne L.; Abend, Nicholas S.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
[Chu, Catherine J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Cilio, M. Roberta; Glass, Hannah C.] Univ Calif San Francisco, Dept Neurol, Benioff Childrens Hosp, San Francisco, CA USA.
[Cilio, M. Roberta; Glass, Hannah C.] Univ Calif San Francisco, Dept Pediat, Benioff Childrens Hosp, San Francisco, CA USA.
[Glass, Hannah C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Shellhaas, RA (reprint author), CS Mott Childrens Hosp, Pediat Neurol, Room 12-733,1540 E Hosp Dr, Ann Arbor, MI 48109 USA.
EM shellhaa@med.umich.edu
FU Pediatric Epilepsy Research Foundation; National Institutes of Health
(NIH) [R21HD083409]; American Sleep Medicine Foundation;
Patient-Centered Outcomes Research Institute [2015C2-1507-31187];
Thrasher Foundation; Cerebral Palsy International Research Foundation;
NIH [R01 HD076258, R01 NS066929, K23 NS092923, K23 NS076550, K23
NS66137]; Boston Children's Hospital Intellectual and Developmental
Disabilities Research Center; Epilepsy Foundation; Citizens United for
Research in Epilepsy; Cerebral Palsy Alliance [PG2314]; Patient-Centered
Outcomes Research Institute
FX Supported by the Pediatric Epilepsy Research Foundation. R.S. receives
support from the National Institutes of Health (NIH; R21HD083409), the
American Sleep Medicine Foundation, Patient-Centered Outcomes Research
Institute (2015C2-1507-31187), and the Pediatric Epilepsy Research
Foundation; serves as a consultant for the Epilepsy Study Consortium;
and receives honoraria from UpToDate. T.C. receives support from the
Pediatric Epilepsy Research Foundation, the Thrasher Foundation, and the
Cerebral Palsy International Research Foundation. J.S. receives support
from NIH (R01 HD076258 and R01 NS066929) and Boston Children's Hospital
Intellectual and Developmental Disabilities Research Center. C.C.
receives research support from NIH (K23 NS092923) and the Pediatric
Epilepsy Research Foundation. S.B. receives support from NIH. N.A.
receives support from NIH (K23 NS076550) and the Pediatric Epilepsy
Research Foundation. T.T. receives support from the Epilepsy Foundation,
Citizens United for Research in Epilepsy, and NIH. H.G. receives support
from NIH (K23 NS66137), the Cerebral Palsy Alliance (PG2314),
Patient-Centered Outcomes Research Institute, and the Pediatric Epilepsy
Research Foundation. The authors declare no conflicts of interest.
NR 15
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD FEB
PY 2017
VL 181
BP 298
EP +
DI 10.1016/j.jpeds.2016.10.039
PG 5
WC Pediatrics
SC Pediatrics
GA EN8KL
UT WOS:000396249200048
PM 27829512
ER
PT J
AU Ellinger, RL
Jakien, KM
Gallun, FJ
AF Ellinger, Rachel L.
Jakien, Kasey M.
Gallun, Frederick J.
TI The role of interaural differences on speech intelligibility in complex
multi- talker environments
SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
LA English
DT Article
ID MASKING-LEVEL DIFFERENCES; CANCELLATION THEORY; TIME DIFFERENCES;
EQUALIZATION; INTENSITY; RELEASE; PHASE
AB Interaural differences in time (ITDs) and interaural differences in level (ILDs) contribute to a listener's ability to achieve spatial release from masking (SRM), and help to improve speech intelligibility in noisy environments. In this study, the extent to which ITDs and ILDs contribute to SRM and the relationships with aging and hearing loss were examined. SRM was greatest when stimuli were presented with consistent ITD and ILD, relative to ITD or ILD alone, all of which produced greater SRM than when ITD and ILD cues were in conflict with each other. This pattern was independent of age and hearing loss.
C1 [Ellinger, Rachel L.; Jakien, Kasey M.; Gallun, Frederick J.] US Dept Vet Affairs, Natl Ctr Rehabilitat Auditory Res, VA Portland Hlth Care Syst, 3710 Southwest US Vet Hosp Rd,P5 NCRAR, Portland, OR 97239 USA.
[Ellinger, Rachel L.] Northwestern Univ, Commun Sci & Disorders Dept, 2240 Campus Dr, Evanston, IL 60208 USA.
[Jakien, Kasey M.; Gallun, Frederick J.] Oregon Hlth & Sci Univ, Dept Otolaryngol Head & Neck Surg, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
RP Gallun, FJ (reprint author), US Dept Vet Affairs, Natl Ctr Rehabilitat Auditory Res, VA Portland Hlth Care Syst, 3710 Southwest US Vet Hosp Rd,P5 NCRAR, Portland, OR 97239 USA.
EM RachelEllinger@gmail.com; Kasey.Jakien@va.gov; Frederick.Gallun@va.gov
FU National Institutes of Health/National Institute on Deafness and Other
Communication Disorders (NIH/NIDCD) [R01 DC011828]; Department of
Veterans Affairs Rehabilitation Research & Development Service; Reed
College Department of Psychology
FX Thank you to all of the participants who volunteered their time to be
involved in this experiment. Thank you to Sean Kampel, Meghan Stansell,
and Nirmal Srinivasan for help with data collection, Kathryn Oleson for
help with data analysis, and Enriqueta CansecoGonzalez for advisement
while working on this experiment and the thesis document. This work was
supported by National Institutes of Health/National Institute on
Deafness and Other Communication Disorders (NIH/NIDCD; R01 DC011828),
Department of Veterans Affairs Rehabilitation Research & Development
Service (VA RR&D), and Reed College Department of Psychology. The
contents of this article are the private views of the authors and should
not be assumed to represent the views of the Department of Veterans
Affairs or the United States Government.
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ACOUSTICAL SOC AMER AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0001-4966
EI 1520-8524
J9 J ACOUST SOC AM
JI J. Acoust. Soc. Am.
PD FEB
PY 2017
VL 141
IS 2
BP EL170
EP EL176
DI 10.1121/1.4976113
PG 7
WC Acoustics; Audiology & Speech-Language Pathology
SC Acoustics; Audiology & Speech-Language Pathology
GA EM4VD
UT WOS:000395310100015
PM 28253635
ER
PT J
AU Folmer, RL
Vachhani, J
McMillan, GP
Watson, C
Kidd, GR
Feeney, MP
AF Folmer, Robert L.
Vachhani, Jay
McMillan, Garnett P.
Watson, Charles
Kidd, Gary R.
Feeney, M. Patrick
TI Validation of a Computer-Administered Version of the Digits-in-Noise
Test for Hearing Screening in the United States
SO JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY
LA English
DT Article
DE assessment; computer -administered; digits-in-noise; hearing screening;
hearing test
ID QUALITY-OF-LIFE; OLDER-ADULTS; COGNITIVE DYSFUNCTION; HANDICAP
INVENTORY; TELEPHONE; IMPAIRMENT; MILD; INTELLIGIBILITY; DEMENTIA;
PEOPLE
AB Background: The sooner people receive treatment for hearing loss (HL), the quicker they are able to recognize speech and to master hearing aid technology. Unfortunately, a majority of people with HL wait until their impairments have progressed from moderate to severe levels before seeking auditory rehabilitation. To increase the number of individuals with HL who pursue and receive auditory rehabilitation, it is necessary to improve methods for identifying and informing these people via widely accessible hearing screening procedures. Screening for HL is the first in a chain of events that must take place to increase the number of patients who enter the hearing health-care system. New methods for hearing screening should be readily accessible through a common medium (e.g., telephone or computer) and should be relatively easy and quick for people to self-administer.
Purpose: The purpose of this study was to assess a digits-in-noise (DIN) hearing screening test that was delivered via personal computer.
Research Design: Participants completed the Hearing Handicap Inventory for Adults (HHIA) questionnaire, audiometric testing in a sound booth, and computerized DIN testing. During the DIN test, sequences of three spoken digits were presented in noise via headphones at varying signal-to-noise ratios (SNRs). Participants entered each three-digit sequence they heard using an on-screen keypad.
Study Sample: Forty adults (16 females, 24 males) participated in the study, of whom 20 had normal hearing and 20 had HL (pure-tone average [PTA] thresholds for 0.5, 1, 2, and 4 kHz >25 dB HL).
Data Collection and Analysis: DIN SNR and PTA data were analyzed and compared for each ear tested. Receiver operating characteristic curves based on these data were plotted. A measure of overall accuracy of a screening test is the area under the receiver operating characteristic curve (AUC). This measures the average true positive rate across false positives at varying DIN SNR cutoffs. Larger values of the AUC indicate, on average, more accurate screening tests. HHIA responses were analyzed and compared to PTA and DIN SNR results using Pearson correlation statistics.
Results: HHIA scores were positively correlated with audiometric PTA and DIN SNR results (p < 0.001 for all correlations). For an HL criterion of one or more frequencies from 0.25 to 8 kHz >25 dB HL, the AUC for the DIN test was 0.95. When a criterion of hearling level was set at one or more frequencies from 0.25 to 8 kHz >20 dB HL, the AUC for the DIN test was 0.96.
Conclusions: The computer version of the DIN test demonstrated excellent sensitivity and specificity for our sample of 40 participants. AUC results (>= 0.95) suggest that this DIN test administered via computer should be very useful for adult hearing screening.
C1 [Folmer, Robert L.; Vachhani, Jay; McMillan, Garnett P.; Feeney, M. Patrick] Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA.
[Folmer, Robert L.; Feeney, M. Patrick] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA.
[McMillan, Garnett P.] Oregon Hlth & Sci Univ, Dept Prevent Med, Portland, OR 97201 USA.
[Watson, Charles] Commun Disorders Technol Inc, Bloomington, IN USA.
[Kidd, Gary R.] Indiana Univ, Bloomington, IN USA.
RP Folmer, RL (reprint author), Portland VA Med Ctr, Natl Ctr Rehabil Auditory Res, Portland, OR 97239 USA.
EM robert.folmer@va.gov
FU NIH/NIDCD [R21 DC011769 01]; VA National Center for Rehabilitative
Auditory Research - VA RR&D Center of Excellence at Portland VA Medical
Center [C9230C]
FX This research was supported by grant R21 DC011769 01 from NIH/NIDCD.
Additional support was provided by the VA National Center for
Rehabilitative Auditory Research (funded by VA RR&D Center of Excellence
grant C9230C) at Portland VA Medical Center.
NR 39
TC 0
Z9 0
U1 1
U2 1
PU AMER ACAD AUDIOLOGY
PI RESTON
PA 11730 PLAZA DR, STE 300, RESTON, VA 20190 USA
SN 1050-0545
EI 2157-3107
J9 J AM ACAD AUDIOL
JI J. Am. Acad. Audiol.
PD FEB
PY 2017
VL 28
IS 2
BP 161
EP 169
DI 10.3766/jaaa.16038
PG 9
WC Audiology & Speech-Language Pathology; Otorhinolaryngology
SC Audiology & Speech-Language Pathology; Otorhinolaryngology
GA EL2VL
UT WOS:000394478500007
PM 28240983
ER
PT J
AU Brink, JA
AF Brink, James A.
TI Is Achieving "Just Culture" Just Culture, or Something More?
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
C1 [Brink, James A.] Massachusetts Gen Hosp, 55 Fruit St,FND 216, Boston, MA 02114 USA.
RP Brink, JA (reprint author), Massachusetts Gen Hosp, 55 Fruit St,FND 216, Boston, MA 02114 USA.
EM jabrink@partners.org
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD FEB
PY 2017
VL 14
IS 2
BP 143
EP 144
DI 10.1016/j.jacr.2016.12.018
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA EL2VJ
UT WOS:000394478300001
PM 28161019
ER
PT J
AU Rehani, B
Brown, I
Dandekar, S
Sarkodie, B
Mwango, G
Rehani, MM
Lau, L
Zhang, YC
Dillon, WP
AF Rehani, Bhavya
Brown, Isaiah
Dandekar, Shebani
Sarkodie, Benjamin
Mwango, Gladys
Rehani, Madan M.
Lau, Lawrence
Zhang, Yi C.
Dillon, William P.
TI Radiology Education in Africa: Analysis of Results From 13 African
Countries
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
C1 [Rehani, Bhavya; Brown, Isaiah; Dandekar, Shebani; Zhang, Yi C.; Dillon, William P.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Sarkodie, Benjamin] Univ Ghana, Sch Med, Accra, Ghana.
[Mwango, Gladys] Univ Nairobi, Nairobi, Kenya.
[Rehani, Madan M.] Massachusetts Gen Hosp, Dept Radiol, Harvard Med Sch, Boston, MA 02114 USA.
RP Rehani, B (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave, San Francisco, CA 94143 USA.
EM bhavya.rehani@ucsf.edu
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD FEB
PY 2017
VL 14
IS 2
BP 247
EP 252
DI 10.1016/j.jacr.2016.08.012
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA EL2VJ
UT WOS:000394478300022
PM 27818015
ER
PT J
AU Swan, JS
Furtado, VF
Keller, LA
Lotti, JB
Saltalamacchia, CA
Lennes, IT
Salazar, GM
AF Swan, J. Shannon
Furtado, Vanessa F.
Keller, Lisa A.
Lotti, Judith Borsody
Saltalamacchia, Catherine A.
Lennes, Inga T.
Salazar, Gloria M.
TI Pilot Study of a Patient-Centered Radiology Process Model
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Patient experience; quality of life; patient-centered care;
psychometrics
ID TESTING MORBIDITIES INDEX
AB Purpose: The Radiology Process Model (RPM) was previously described in terms of its conceptual basis and proposed survey items. The current study describes the first pilot application of the RPM in the field and the results of initial psychometric analysis.
Methods: We used an Institutional Review Board approved pilot RPM survey in 100 patients having outpatient interventional radiology procedures. The 24 survey items had 4 or 5 levels of severity. We assessed for missing data, items that patients found confusing, any suggestions by patients for additional items and clarity of items from patient feedback. Factor analysis was performed and internal consistency measured. Construct validity was assessed by correlation of patient responses to the items as a summated scale with a visual analog scale (VAS) they completed indicating their interventional radiology experience.
Results: The visual analog scale and the RPM summated scale were strongly correlated (r = 0.7). Factor analysis showed four factors: interactions with facility and doctors/staff; time-sensitive aspects, pain, and anxiety. The items showed high internal consistency (alpha: 0.86) as a group and approximately 0.7 to 0.9 by the factors. Analysis shows that two items could be deleted (cost and communication between radiologist and referrers). Revision of two items and potential addition of others are discussed.
Conclusions: The RPM shows initial evidence of psychometric validity and internal consistency reliability. Minor changes are anticipated before wider use.
C1 [Swan, J. Shannon] Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA.
[Swan, J. Shannon; Lennes, Inga T.; Salazar, Gloria M.] Harbor Med Sch, Boston, MA USA.
[Furtado, Vanessa F.; Lotti, Judith Borsody; Saltalamacchia, Catherine A.; Salazar, Gloria M.] MGH Imaging, Boston, MA USA.
[Keller, Lisa A.] Univ Massachusetts, Dept Educ Policy Res & Adm, Amherst, MA 01003 USA.
[Lennes, Inga T.] MGH Canc Ctr, Boston, MA USA.
RP Swan, JS (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA.; Swan, JS (reprint author), Harbor Med Sch, Boston, MA USA.
EM jsswan@mgh.harvard.edu
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD FEB
PY 2017
VL 14
IS 2
BP 274
EP 281
DI 10.1016/j.jacr.2016.08.024
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA EL2VJ
UT WOS:000394478300028
PM 27927589
ER
PT J
AU Liu, JB
Huffman, KM
Palis, BE
Shulman, LN
Winchester, DP
Ko, CY
Hall, BL
AF Liu, Jason B.
Huffman, Kristopher M.
Palis, Bryan E.
Shulman, Lawrence N.
Winchester, David P.
Ko, Clifford Y.
Hall, Bruce L.
TI Reliability of the American College of Surgeons Commission on Cancer's
Quality of Care Measures for Hospital and Surgeon Profiling
SO JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
LA English
DT Article
ID LYMPH-NODES; MIX ADJUSTMENT; COLON-CANCER; LUNG-CANCER; DATA-BASE;
PATIENT; RETRIEVAL; RESECTION; NUMBER; RISK
AB BACKGROUND: Efforts to improve healthcare quality involve profiling hospitals and providers. Whether cancer-specific measures can be used reliably for profiling purposes has not been reported.
STUDY DESIGN: Hospitals and surgeons were profiled with 3 measures assessing the adequacy of lymphadenectomy for colon (ie at least 12 regional lymph nodes [12RLN] are removed and pathologically examined for resected colon cancer), gastric (ie at least 15 regional lymph nodes [G15RLN] are removed and pathologically examined for resected gastric cancer), and non-small cell lung (ie at least 10 regional lymph nodes [10RLN] are removed and pathologically examined for American Joint Committee on Cancer stage IA, IB, IIA, and IIB resected non-small cell lung cancer) cancers using hierarchical models. National Cancer Data Base cases spanning 2010 to 2013 were included if they met measure eligibility. Reliability estimates for hospital and surgeon performance across cumulative years of data (2013, 2012 to 2013, 2011 to 2013, and 2010 to 2013) were calculated with and without risk adjustment. Surgeon caseload minimums were projected to achieve reliabilities of 0.40 and 0.70.
RESULTS: Reliability estimates tended to increase with longer periods of data collection but at different rates, depending on measure, level of aggregation, and performance outlier status. Profiling hospitals using 12RLN with 2 years of data yielded a median reliability of 0.72 (interquartile range [IQR] 0.55 to 0.83); however, 4 years of data yielded a median reliability of only 0.31 (IQR 0.14 to 0.54) for surgeons. The G15RLN performance was poor overall; 10RLN had high reliability at both hospital (0.74; IQR 0.50 to 0.86) and surgeon (0.61; IQR 0.34 to 0.80) levels using 1 year of data, but the literature questions this measure's validity. Few surgeons could achieve appropriate levels of reliability regardless of increased data collection duration.
CONCLUSIONS: Profiling hospitals based on measures such as these can achieve acceptable reliability in reasonable timeframes, but does not always. Either lower levels of reliability should be accepted to profile surgeons with these measures or longer timeframes should be used. (J Am Coll Surg 2017; 224: 180e190. (C) 2016 by the American College of Surgeons. Published by Elsevier Inc. All rights reserved.)
C1 [Liu, Jason B.; Huffman, Kristopher M.; Palis, Bryan E.; Winchester, David P.; Ko, Clifford Y.; Hall, Bruce L.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA.
[Liu, Jason B.] Univ Chicago Hosp, Dept Surg, Chicago, IL 60637 USA.
[Shulman, Lawrence N.] Univ Penn, Dept Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Ko, Clifford Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA.
[Ko, Clifford Y.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Hall, Bruce L.] Washington Univ, Dept Surg, St Louis, MO USA.
[Hall, Bruce L.] Washington Univ, Ctr Hlth Policy, St Louis, MO USA.
[Hall, Bruce L.] Washington Univ, Olin Business Sch, St Louis, MO USA.
[Hall, Bruce L.] St Louis Vet Affairs Med Ctr, St Louis, MO USA.
[Hall, Bruce L.] BJC Healthcare, St Louis, MO USA.
RP Liu, JB (reprint author), Amer Coll Surg, 633 N St Clair,22nd Floor, Chicago, IL 60611 USA.
EM jliu@facs.org
FU Department of Surgery, University of Chicago Hospitals; American College
of Surgeons Clinical Scholar in Residence Program
FX Dr Liu is supported by a research fellowship from the Department of
Surgery, University of Chicago Hospitals and the American College of
Surgeons Clinical Scholar in Residence Program.
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1072-7515
EI 1879-1190
J9 J AM COLL SURGEONS
JI J. Am. Coll. Surg.
PD FEB
PY 2017
VL 224
IS 2
BP 180
EP 190E8
DI 10.1016/j.jamcollsurg.2016.10.053
PG 19
WC Surgery
SC Surgery
GA EO9PC
UT WOS:000397019600013
PM 27979711
ER
PT J
AU McGrath, ER
Go, AS
Chang, YC
Borowsky, LH
Fang, MC
Reynolds, K
Singer, DE
AF McGrath, Emer R.
Go, Alan S.
Chang, Yuchiao
Borowsky, Leila H.
Fang, Margaret C.
Reynolds, Kristi
Singer, Daniel E.
TI Use of Oral Anticoagulant Therapy in Older Adults with Atrial
Fibrillation After Acute Ischemic Stroke
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE ischemic stroke; atrial fibrillation; oral anticoagulants;
decision-making
ID ANTITHROMBOTIC THERAPY; RANDOMIZED-TRIALS; RISK-FACTORS; WARFARIN USE;
PREVENTION; METAANALYSIS; PROPHYLAXIS; POPULATION; PREVALENCE; MORTALITY
AB OBJECTIVES: To explore barriers to anticoagulation in older adults with atrial fibrillation (AF) at high risk of stroke and to identify opportunities for interventions that might increase use of oral anticoagulants (OACs).
DESIGN: Retrospective cohort study.
SETTING: Two large community-based AF cohorts.
PARTICIPANTS: Individuals with ischemic stroke surviving hospitalization (N = 1,405, mean age 79).
MEASUREMENTS: Using structured chart review, reasons for nonuse of OAC were identified, and 1-year poststroke survival was assessed. Logistic regression was used to identify correlates of OAC nonuse.
RESULTS: Median CHA(2)DS(2)-VASc score was 5, yet 44% of participants were not prescribed an OAC at discharge. The most-frequent (nonmutually exclusive) physician reasons for not prescribing OAC included fall risk (26.7%), poor prognosis (19.3%), bleeding history (17.1%), participant or family refusal (14.9%), older age (11.0%), and dementia (9.4%). Older age (odds ratio (OR) = 8.96, 95% confidence interval (CI) = 5.01-16.04 for aged = 85 vs < 65) and disability (OR = 12.58, 95% CI = 5.82-27.21 for severe vs no deficit) were the most-important independent predictors of nonuse of OACs. By 1 year, 42.5% of those not receiving an OAC at discharge had died, versus 19.1% of those receiving an OAC (P <.001), far higher than recurrent stroke rates.
CONCLUSION: Despite very high stroke risk, more than 40% of participants were not discharged with an OAC. Dominant reasons included fall risk, poor prognosis, older age, and dementia. These individuals' high 1-year mortality rate confirmed their high level of comorbidity. To improve anticoagulation decisions and outcomes in this population, future research should focus on strategies to mitigate fall risk, improve assessment of risks and benefits of anticoagulation in individuals with AF, and determine whether newer anticoagulants are safer in complex elderly and frail individuals.
C1 [McGrath, Emer R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[McGrath, Emer R.] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA.
[McGrath, Emer R.; Chang, Yuchiao; Singer, Daniel E.] Harvard Med Sch, Boston, MA USA.
[Go, Alan S.] Kaiser Permanente Northern Calif, Div Res, Oakland, CA USA.
[Go, Alan S.] Univ Calif San Francisco, Dept Med Epidemiol & Biostat, San Francisco, CA 94143 USA.
[Go, Alan S.] Stanford Univ, Sch Med, Dept Hlth Res, Stanford, CA 94305 USA.
[Go, Alan S.] Stanford Univ, Sch Med, Dept Policy, Stanford, CA 94305 USA.
[Chang, Yuchiao; Borowsky, Leila H.; Singer, Daniel E.] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA.
[Fang, Margaret C.] Univ Calif San Francisco, Div Hosp Med, San Francisco, CA 94143 USA.
[Reynolds, Kristi] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA.
RP Go, AS (reprint author), Kaiser Permanente, Div Res, 2000 Broadway St, Oakland, CA 94612 USA.; Singer, DE (reprint author), Massachusetts Gen Hosp, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM alan.s.go@kp.org; desinger@mgh.harvard.edu
FU National Institute on Aging [R01 AG15478]; National Heart, Lung and
Blood Institute [RC2HL101589, U19 HL091179]; Eliot B. and Edith C.
Shoolman fund of Massachusetts General Hospital (Boston, MA)
FX This study was supported by the National Institute on Aging (R01
AG15478), the National Heart, Lung and Blood Institute (RC2HL101589 and
U19 HL091179) and the Eliot B. and Edith C. Shoolman fund of
Massachusetts General Hospital (Boston, MA).
NR 40
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD FEB
PY 2017
VL 65
IS 2
BP 241
EP 248
DI 10.1111/jgs.14688
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA EO9KD
UT WOS:000397006700008
PM 28039855
ER
PT J
AU de Mazieres, CL
Morley, JE
Levy, C
Agenes, F
Barbagallo, M
Cesari, M
Barreto, PD
Donini, LM
Fitten, J
Franco, A
Izquierdo, M
Kane, RA
Martin, FC
Onder, G
Ouslander, J
Pitkala, K
Saliba, D
Sinclair, A
Manas, LR
Vellas, B
Rolland, Y
AF de Mazieres, Clarisse Laffon
Morley, John E.
Levy, Cari
Agenes, Fabien
Barbagallo, Mario
Cesari, Matteo
Barreto, Philipe De Souto
Donini, Lorenzo Maria
Fitten, Jaime
Franco, Alain
Izquierdo, Mikel
Kane, Rosalie A.
Martin, Finbarr C.
Onder, Graziano
Ouslander, Joseph
Pitkala, Kaisu
Saliba, Debra
Sinclair, Alan
Rodriguez Manas, Leocadio
Vellas, Bruno
Rolland, Yves
TI Prevention of Functional Decline by Reframing the Role of Nursing Homes?
SO JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
LA English
DT Article
DE Nursing home; prevention; functional decline; frailty
ID EMERGENCY-DEPARTMENT VISITS; RANDOMIZED CONTROLLED-TRIAL; OLDER-ADULTS;
HIP FRACTURE; GERIATRIC ASSESSMENT; STIMULATION THERAPY; PHYSICAL
RESTRAINTS; ELDERLY-PATIENTS; RESIDENTS; INTERVENTIONS
AB Institutionalization is generally a consequence of functional decline driven by physical limitations, cognitive impairments, and/or loss of social supports. At this stage, intervention to reverse functional losses is often too late. To be more effective, geriatric medicine must evolve to intervene at an earlier stage of the disability process. Could nursing homes (NHs) transform from settings in which many residents dwell to settings in which the NH residents and those living in neighboring communities benefit from staff expertise to enhance quality of life and maintain or slow functional decline? A task force of clinical researchers met in Toulouse on December 2, 2015, to address some of these challenges: how to prevent or slow functional decline and disabilities for NH residents and how NHs may promote the prevention of functional decline in community-dwelling frail elderly. The present article reports the main results of the Task Force discussions to generate a new paradigm. (C) 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine. Published by Elsevier Inc. All rights reserved.
C1 [de Mazieres, Clarisse Laffon; Cesari, Matteo; Barreto, Philipe De Souto; Vellas, Bruno; Rolland, Yves] CHU Toulouse, Toulouse Univ Hosp, Dept Geriatr Med, Gerontopole, Toulouse, France.
[de Mazieres, Clarisse Laffon; Cesari, Matteo; Barreto, Philipe De Souto; Vellas, Bruno; Rolland, Yves] INSERM, UMR 1027, Toulouse, France.
[Morley, John E.] St Louis Univ, Sch Med, Div Geriatr Med, St Louis, MO 63104 USA.
[Morley, John E.] St Louis Univ, Sch Med, Div Endocrinol, St Louis, MO USA.
[Levy, Cari] Denver VA Med Ctr, Denver Seattle Ctr Innovat, Denver, CO USA.
[Levy, Cari] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA.
[Agenes, Fabien] Embassy France US, Off Sci & Technol, French Consulate Los Angeles, Los Angeles, CA USA.
[Barbagallo, Mario] Univ Palermo, Geriatr Unit, Palermo, Italy.
[Donini, Lorenzo Maria] Sapienza Univ Rome, Rome, Italy.
[Fitten, Jaime] Univ Calif Los Angeles, David Geffen Sch Med, Psychiat & Behav Sci, Los Angeles, CA 90095 USA.
[Fitten, Jaime] Greater Los Angeles VA, Geriatr Psychiat, Sepulveda Campus, Los Angeles, CA USA.
[Martin, Finbarr C.] Univ Nice Sophia Antipolis, Nice, France.
[Izquierdo, Mikel] Univ Publ Navarra, Dept Hlth Sci, Pamplona, Spain.
[Kane, Rosalie A.] Univ Minnesota, Sch Publ Hlth, Ctr Aging, Div Hlth Policy & Management, Minneapolis, MN USA.
[Martin, Finbarr C.] Kings Coll London, London, England.
[Onder, Graziano] Univ Cattolica Sacro Cuore, Ctr Med Invecchiamento, Dept Geriatr, Rome, Italy.
[Ouslander, Joseph] Florida Atlantic Univ, Charles E Schmidt Coll Med, Boca Raton, FL 33431 USA.
[Ouslander, Joseph] Florida Atlantic Univ, Christine E Lynn Coll Nursing, Boca Raton, FL 33431 USA.
[Pitkala, Kaisu] Univ Helsinki, Helsinki Univ Hosp, Unit Primary Hlth Care, Dept Gen Practice & Primary Hlth Care, Helsinki, Finland.
[Saliba, Debra] Univ Calif Los Angeles, UCLA JH Borun Ctr Gerontol Res, Los Angeles, CA USA.
[Saliba, Debra] Los Angeles Vet Adm, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA.
[Sinclair, Alan] Fdn Diabet Res Older People, Medici Med Practice, Diabet Frail, Luton, Beds, England.
[Rodriguez Manas, Leocadio] Univ Europea Madrid, Hosp Univ Getafe, Dept Geriatr, Getafe, Spain.
[Rodriguez Manas, Leocadio] Univ Europea Madrid, Sch Hlth Sci, Getafe, Spain.
RP de Mazieres, CL (reprint author), Toulouse Univ Hosp, Dept Geriatr Med, Gerontopole, 224 Ave Casselardit,TSA 40031, F-31059 Toulouse 9, France.
EM laffondemazieres.c@chu-toulouse.fr
FU Office for Science and Technology of the Consulate General of France in
Los Angeles, USA
FX This work was supported by an educational grant from the Office for
Science and Technology of the Consulate General of France in Los
Angeles, USA.
NR 54
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1525-8610
EI 1538-9375
J9 J AM MED DIR ASSOC
JI J. Am. Med. Dir. Assoc.
PD FEB 1
PY 2017
VL 18
IS 2
BP 105
EP 110
DI 10.1016/j.jamda.2016.11.019
PG 6
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA EP3TB
UT WOS:000397303500005
ER
PT J
AU Biermann, JS
Chow, W
Reed, DR
Lucas, D
Adkins, DR
Agulnik, M
Benjamin, RS
Brigman, B
Budd, GT
Curry, WT
Didwania, A
Fabbri, N
Hornicek, FJ
Kuechle, JB
Lindskog, D
Mayerson, J
McGarry, SV
Million, L
Morris, CD
Movva, S
O'Donnell, RJ
Randall, RL
Rose, P
Santana, VM
Satcher, RL
Schwartz, H
Siegel, HJ
Thornton, K
Villalobos, V
Bergman, MA
Scavone, JL
AF Biermann, J. Sybil
Chow, Warren
Reed, Damon R.
Lucas, David
Adkins, Douglas R.
Agulnik, Mark
Benjamin, Robert S.
Brigman, Brian
Budd, G. Thomas
Curry, William T.
Didwania, Aarati
Fabbri, Nicola
Hornicek, Francis J.
Kuechle, Joseph B.
Lindskog, Dieter
Mayerson, Joel
McGarry, Sean V.
Million, Lynn
Morris, Carol D.
Movva, Sujana
O'Donnell, Richard J.
Randall, R. Lor
Rose, Peter
Santana, Victor M.
Satcher, Robert L.
Schwartz, Herbert
Siegel, Herrick J.
Thornton, Katherine
Villalobos, Victor
Bergman, Mary Anne
Scavone, Jillian L.
TI NCCN Guidelines (R) Insights Bone Cancer, Version 2.2017 Featured
Updates to the NCCN Guidelines
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID LOCALIZED EWING-SARCOMA; CHILDRENS-ONCOLOGY-GROUP; SARCOMA/PRIMITIVE
NEUROECTODERMAL TUMOR; REFRACTORY SOLID TUMORS; GROUP PHASE-II;
PROGNOSTIC-FACTORS; PEDIATRIC-ONCOLOGY; YOUNG-ADULTS; NEOADJUVANT
CHEMOTHERAPY; SINGLE-INSTITUTION
AB The NCCN Guidelines for Bone Cancer provide interdisciplinary recommendations for treating chordoma, chondrosarcoma, giant cell tumor of bone, Ewing sarcoma, and osteosarcoma. These NCCN Guidelines Insights summarize the NCCN Bone Cancer Panel's guideline recommendations for treating Ewing sarcoma. The data underlying these treatment recommendations are also discussed.
C1 [Biermann, J. Sybil; Lucas, David] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Chow, Warren] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Reed, Damon R.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Adkins, Douglas R.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Adkins, Douglas R.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Agulnik, Mark; Didwania, Aarati] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Benjamin, Robert S.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Brigman, Brian] Duke Canc Inst, Durham, NC USA.
[Budd, G. Thomas] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA.
[Budd, G. Thomas] Taussig Canc Inst, Cleveland Clin, Cleveland, OH USA.
[Curry, William T.; Hornicek, Francis J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Fabbri, Nicola] Mem Sloan Kettering Canc Ctr, New Rochelle, NY USA.
[Kuechle, Joseph B.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Lindskog, Dieter] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA.
[Mayerson, Joel] Ohio State Univ, James Canc Hosp & Solove Res Inst, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[McGarry, Sean V.] Fred Pamela Buffett Canc Ctr, Omaha, NE USA.
[Million, Lynn] Stanford Canc Inst, Stanford, CA USA.
[Morris, Carol D.] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Movva, Sujana] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[O'Donnell, Richard J.] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Randall, R. Lor] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Rose, Peter] Mayo Clin, Canc Ctr, Rochester, MN USA.
[Santana, Victor M.] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA.
[Schwartz, Herbert] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Siegel, Herrick J.] Univ Alabama Birmingham, Ctr Comprehens Canc, Tuscaloosa, AL 35487 USA.
[Thornton, Katherine] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Villalobos, Victor] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA.
[Bergman, Mary Anne; Scavone, Jillian L.] Natl Comprehens Canc Network, Seattle, WA USA.
RP Biermann, JS (reprint author), Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
FU Astellas; AstraZeneca; Celldex Therapeutics; Clovis Oncology; Genomic
Health, Inc.; Kyowa Hakko Kirin; Jazz Pharmaceuticals; Novartis
Pharmaceuticals Corporation; NOVOCURE; Merck Co., Inc
FX This activity is supported by educational grants from Astellas,
AstraZeneca, Celldex Therapeutics, Clovis Oncology, Genomic Health,
Inc., Kyowa Hakko Kirin, Jazz Pharmaceuticals, Novartis Pharmaceuticals
Corporation, and NOVOCURE. This activity is supported by an independent
educational grant from Merck Co., Inc.
NR 75
TC 0
Z9 0
U1 1
U2 1
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD FEB
PY 2017
VL 15
IS 2
BP 155
EP 167
PG 13
WC Oncology
SC Oncology
GA EL9GA
UT WOS:000394927100002
PM 28188186
ER
PT J
AU Kumar, SK
Callander, NS
Alsina, M
Atanackovic, D
Biermann, JS
Chandler, JC
Costello, C
Faiman, M
Fung, HC
Gasparetto, C
Godby, K
Hofmeister, C
Holmberg, L
Holstein, S
Huff, CA
Kassim, A
Liedtke, M
Martin, T
Omel, J
Raje, N
Reu, FJ
Singhal, S
Somlo, G
Stockerl-Goldstein, K
Treon, SP
Weber, D
Yahalom, J
Shead, DA
Kumar, R
AF Kumar, Shaji K.
Callander, Natalie S.
Alsina, Melissa
Atanackovic, Djordje
Biermann, J. Sybil
Chandler, Jason C.
Costello, Caitlin
Faiman, Matthew
Fung, Henry C.
Gasparetto, Cristina
Godby, Kelly
Hofmeister, Craig
Holmberg, Leona
Holstein, Sarah
Huff, Carol Ann
Kassim, Adetola
Liedtke, Michaela
Martin, Thomas
Omel, James
Raje, Noopur
Reu, Frederic J.
Singhal, Seema
Somlo, George
Stockerl-Goldstein, Keith
Treon, Steven P.
Weber, Donna
Yahalom, Joachim
Shead, Dorothy A.
Kumar, Rashmi
TI Multiple Myeloma, Version 3.2017 Clinical Practice Guidelines in
Oncology
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Review
ID STEM-CELL TRANSPLANTATION; HIGH-DOSE THERAPY; DONOR LYMPHOCYTE
INFUSIONS; TERM-FOLLOW-UP; SINGLE-AGENT CARFILZOMIB; NEWLY-DIAGNOSED
MYELOMA; FRONT AUTOLOGOUS TRANSPLANTATION; BORTEZOMIB PLUS
DEXAMETHASONE; INTERNATIONAL STAGING SYSTEM; BONE-MARROW-TRANSPLANTATION
AB Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone marrow causing skeletal damage, a hallmark of multiple myeloma. Other MM-related complications include hypercalcemia, renal insufficiency, anemia, and infections. The NCCN Multiple Myeloma Panel members have developed guidelines for the management of patients with various plasma cell dyscrasias, including solitary plasmacytoma, smoldering myeloma, multiple myeloma, systemic light chain amyloidosis, and Waldenstrom's macroglobulinemia. The recommendations specific to the diagnosis and treatment of patients with newly diagnosed MM are discussed in this article.
C1 [Kumar, Shaji K.] Mayo Clin, Ctr Canc, Rochester, MN USA.
[Callander, Natalie S.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA.
[Alsina, Melissa] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Atanackovic, Djordje] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Biermann, J. Sybil] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Chandler, Jason C.] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA.
[Costello, Caitlin] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA.
[Faiman, Matthew] Univ Hosp Seidman, Ctr Canc, Case Comprehens Canc Ctr, Cleveland, OH USA.
[Faiman, Matthew] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA.
[Fung, Henry C.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Gasparetto, Cristina] Duke Canc Inst, Durham, NC USA.
[Godby, Kelly] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Hofmeister, Craig] Ohio State Univ, James Canc Hosp, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Hofmeister, Craig] Solove Res Inst, Columbus, OH USA.
[Holmberg, Leona] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA 98104 USA.
[Holstein, Sarah] Fred Pamela Buffett Canc Ctr, Omaha, NE USA.
[Huff, Carol Ann] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Kassim, Adetola] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Liedtke, Michaela] Stanford Canc Inst, Stanford, CA USA.
[Martin, Thomas] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Raje, Noopur] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Reu, Frederic J.] Univ Hosp Seidman, Ctr Canc, Case Comprehens Canc Ctr, Cleveland, OH USA.
[Reu, Frederic J.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA.
[Singhal, Seema] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Somlo, George] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Stockerl-Goldstein, Keith] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Stockerl-Goldstein, Keith] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Treon, Steven P.] Dana Farber Brigham & Womens Canc Ctr, Milford, MA USA.
[Weber, Donna] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Yahalom, Joachim] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
RP Kumar, SK (reprint author), Mayo Clin, Ctr Canc, Rochester, MN USA.
NR 174
TC 0
Z9 0
U1 1
U2 1
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD FEB
PY 2017
VL 15
IS 2
BP 230
EP +
PG 26
WC Oncology
SC Oncology
GA EL9GA
UT WOS:000394927100008
PM 28188192
ER
PT J
AU Angulo, MT
Moreno, JA
Lippner, G
Barabasi, AL
Liu, YY
AF Angulo, Marco Tulio
Moreno, Jaime A.
Lippner, Gabor
Barabasi, Albert-Laszlo
Liu, Yang-Yu
TI Fundamental limitations of network reconstruction from temporal data
SO JOURNAL OF THE ROYAL SOCIETY INTERFACE
LA English
DT Article
DE network reconstruction; system identification; networked systems
ID COMPLEX NETWORKS; BIOLOGICAL NETWORKS; IDENTIFIABILITY; DYNAMICS;
SYSTEMS; DISTINGUISHABILITY; INFERENCE; PROFILES; MODELS
AB Inferring properties of the interaction matrix that characterizes how nodes in a networked system directly interact with each other is a well-known network reconstruction problem. Despite a decade of extensive studies, network reconstruction remains an outstanding challenge. The fundamental limitations governing which properties of the interaction matrix (e.g. adjacency pattern, sign pattern or degree sequence) can be inferred from given temporal data of individual nodes remain unknown. Here, we rigorously derive the necessary conditions to reconstruct any property of the interaction matrix. Counterintuitively, we find that reconstructing any property of the interaction matrix is generically as difficult as reconstructing the interaction matrix itself, requiring equally informative temporal data. Revealing these fundamental limitations sheds light on the design of better network reconstruction algorithms that offer practical improvements over existing methods.
C1 [Angulo, Marco Tulio] Univ Nacl Autonoma Mexico, Inst Math, Juriquilla 76230, Mexico.
[Moreno, Jaime A.] Univ Nacl Autonoma Mexico, Inst Engn, Cdmx 04510, Mexico.
[Lippner, Gabor] Northeastern Univ, Dept Math, Boston, MA 02115 USA.
[Barabasi, Albert-Laszlo] Northeastern Univ, Ctr Complex Networks Res, Boston, MA 02115 USA.
[Barabasi, Albert-Laszlo; Liu, Yang-Yu] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.
[Barabasi, Albert-Laszlo] Cent European Univ, Ctr Network Sci, H-1052 Budapest, Hungary.
[Liu, Yang-Yu] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Liu, Yang-Yu] Harvard Med Sch, Boston, MA 02115 USA.
RP Liu, YY (reprint author), Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.; Liu, YY (reprint author), Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.; Liu, YY (reprint author), Harvard Med Sch, Boston, MA 02115 USA.
EM yyl@channing.harvard.edu
FU CONACyT, Mexico [207609]; John Templeton Foundation: Mathematical and
Physical Sciences grant [PFI-777]; European Commission (CIMPLEX)
[641191]
FX This work was supported by CONACyT, Mexico (grant no. 207609), the John
Templeton Foundation: Mathematical and Physical Sciences grant PFI-777
and European Commission grant no. 641191 (CIMPLEX)
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1742-5689
EI 1742-5662
J9 J R SOC INTERFACE
JI J. R. Soc. Interface
PD FEB 1
PY 2017
VL 14
IS 127
AR 20160966
DI 10.1098/rsif.2016.0966
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN4ZT
UT WOS:000396016100023
ER
PT J
AU Jayakumar, P
Teunis, T
Gimenez, BB
Verstreken, F
Di Mascio, L
Jupiter, JB
AF Jayakumar, Prakash
Teunis, Teun
Bravo Gimenez, Beatriz
Verstreken, Frederik
Di Mascio, Livio
Jupiter, Jesse B.
TI AO Distal Radius Fracture Classification: Global Perspective on Observer
Agreement
SO JOURNAL OF WRIST SURGERY
LA English
DT Article
DE distal radius fracture; classification; reliability; reproducibility
ID INTRAOBSERVER AGREEMENT; INTEROBSERVER; RELIABILITY; REPRODUCIBILITY;
SURGEONS; SYSTEMS
AB Background The primary objective of this study was to test interobserver reliability when classifying fractures by consensus by AO types and groups among a large international group of surgeons. Secondarily, we assessed the difference in inter- and intraobserver agreement of the AO classification in relation to geographical location, level of training, and subspecialty.
Methods A randomized set of radiographic and computed tomographic images from a consecutive series of 96 distal radius fractures (DRFs), treated between October 2010 and April 2013, was classified using an electronic web-based portal by an invited group of participants on two occasions.
Results Interobserver reliability was substantial when classifying AO type A fractures but fair and moderate for type B and C fractures, respectively. No difference was observed by location, except for an apparent difference between participants from India and Australia classifying type B fractures. No statistically significant associations were observed comparing interobserver agreement by level of training and no differences were shown comparing subspecialties. Intra-rater reproducibility was substantial for fracture types and fair for fracture groups with no difference accounting for location, training level, or specialty.
Conclusion Improved definition of reliability and reproducibility of this classification may be achieved using large international groups of raters, empowering decision making on which system to utilize.
Level of Evidence Level III
C1 [Jayakumar, Prakash; Teunis, Teun; Jupiter, Jesse B.] OLVG, Dept Gen Surg, Amsterdam, Netherlands.
[Bravo Gimenez, Beatriz] Univ Complutense, Hosp Univ Doce Octubre, Orthopaed Upper Extrem Serv, Madrid, Spain.
[Verstreken, Frederik] Univ Antwerp Hosp, Monica Hosp, Dept Hand Surg, Edegem, Belgium.
[Di Mascio, Livio] Barts & Royal London Hosp, Dept Trauma & Orthopaed Surg, London, England.
RP Jupiter, JB (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Orthopaed Hand & Upper Extrem Serv, 55 Fruit St, Boston, MA 02114 USA.
EM jjupiter1@partners.org
NR 22
TC 0
Z9 0
U1 0
U2 0
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 2163-3916
EI 2163-3924
J9 J WRIST SURG
JI J. WRIST SURG.
PD FEB
PY 2017
VL 6
IS 1
BP 46
EP 53
DI 10.1055/s-0036-1587316
PG 8
WC Orthopedics
SC Orthopedics
GA EL3HS
UT WOS:000394510800007
PM 28119795
ER
PT J
AU Tavera-Mendoza, LE
Brown, M
AF Tavera-Mendoza, Luz E.
Brown, Myles
TI A less invasive method for orthotopic injection of breast cancer cells
into the mouse mammary gland
SO LABORATORY ANIMALS
LA English
DT Article
DE surgery; tumor model
AB Breast cancer is the most common type of cancer diagnosed in women, and the second most common cause of cancer-related deaths in women in North America. The use of laboratory mice in research is an essential tool for the study of breast cancer biology and for pre-clinical therapeutic development. While subcutaneous flank injections of cancer cells are widely used for studying breast cancer biology and for exploring novel therapies, orthotopic xenografting of tumors into the mouse mammary gland allow for the study of breast cancers in a biologically relevant microenvironment. In this study we report a modification of the method of orthotopic injections of cancer cells into the mouse mammary gland which greatly reduces the effects of surgery in mice including decreased wound size, procedure time and anesthesia. It also removes the risk of accidentally puncturing the peritoneal cavity. Consequently post-operative animal handling and stress are significantly reduced. All of these advantages are present without compromising procedure success rate. Therefore, this modification makes orthotopic mammary gland injection a more efficient procedure and greatly improves animal welfare.
C1 [Tavera-Mendoza, Luz E.; Brown, Myles] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Div Mol & Cellular Oncol, Boston, MA USA.
[Brown, Myles] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.
RP Brown, M (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM myles_brown@dfci.harvard.edu
NR 5
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0023-6772
EI 1758-1117
J9 LAB ANIM-UK
JI Lab. Anim.
PD FEB
PY 2017
VL 51
IS 1
BP 85
EP 88
DI 10.1177/0023677216640706
PG 4
WC Veterinary Sciences; Zoology
SC Veterinary Sciences; Zoology
GA EL8UK
UT WOS:000394895400008
PM 26994106
ER
PT J
AU Maxfield, AZ
Korkmaz, H
Gregorio, LL
Busaba, NY
Gray, ST
Holbrook, EH
Guo, R
Bleier, BS
AF Maxfield, Alice Z.
Korkmaz, Hakan
Gregorio, Luciano L.
Busaba, Nicolas Y.
Gray, Stacey T.
Holbrook, Eric H.
Guo, Rong
Bleier, Benjamin S.
TI General Antibiotic Exposure Is Associated With Increased Risk of
Developing Chronic Rhinosinusitis
SO LARYNGOSCOPE
LA English
DT Article
DE Antibiotics; side effects; microbiome; chronic rhinosinusitis; quality
of life
ID NASAL POLYPS; P-GLYCOPROTEIN; MICROBIOME; RESISTANCE; MANAGEMENT;
DIVERSITY; SECRETION; SINUSITIS; CHILDREN; DISEASE
AB Objective: Antibiotic use and chronic rhinosinusitis (CRS) have been independently associated with microbiome diversity depletion and opportunistic infections. This study was undertaken to investigate whether antibiotic use may be an unrecognized risk factor for developing CRS.
Study Design: Case-control study of 1,162 patients referred to a tertiary sinus center for a range of sinonasal disorders.
Methods: Patients diagnosed with CRS according to established consensus criteria (n = 410) were assigned to the case group (273 without nasal polyps [CRSsNP], 137 with nasal polyps [CRSwNP]). Patients with all other diagnoses (n = 752) were assigned to the control group. Chronic rhinosinusitis disease severity was determined using a validated quality of life (QOL) instrument. The class, diagnosis, and timing of previous nonsinusitis-related antibiotic exposures were recorded. Results were validated using a randomized administrative data review of 452 (38.9%) of patient charts. The odds ratio of developing CRS following antibiotic exposure were calculated, as well as the impact of antibiotic use on the subsequent QOL.
Results: Antibiotic use significantly increased the odds of developing CRSsNP (odds ratio: 2.21, 95% confidence interval, 1.66-2.93, P < 0.0001) as compared to nonusers. Antibiotic exposure was significantly associated with worse CRS QOL scores (P = 0.0009) over at least the subsequent 2 years. These findings were confirmed by the administrative data review.
Conclusion: Use of antibiotics more than doubles the odds of developing CRSsNP and is associated with a worse QOL for at least 2 years following exposure. These findings expose an unrecognized and concerning consequence of general antibiotic use.
C1 [Maxfield, Alice Z.; Gregorio, Luciano L.; Busaba, Nicolas Y.; Gray, Stacey T.; Holbrook, Eric H.; Bleier, Benjamin S.] Harvard Med Sch, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA USA.
[Korkmaz, Hakan] Ordu Univ, Fac Med, Dept Otorhinolaryngol, Ordu, Turkey.
[Guo, Rong] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Stat, Boston, MA USA.
RP Bleier, BS (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM benjamin_bleier@meei.harvard.edu
NR 41
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD FEB
PY 2017
VL 127
IS 2
BP 296
EP 302
DI 10.1002/lary.26232
PG 7
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA EL9TI
UT WOS:000394962600011
PM 27549904
ER
PT J
AU Kohli, P
Naik, AN
Harruff, EE
Nguyen, SA
Schlosser, RJ
Soler, ZM
AF Kohli, Preeti
Naik, Akash N.
Harruff, E. Emily
Nguyen, Shaun A.
Schlosser, Rodney J.
Soler, Zachary M.
TI The Prevalence of Olfactory Dysfunction in Chronic Rhinosinusitis
SO LARYNGOSCOPE
LA English
DT Review
DE Olfaction; smell; chronic rhinosinusitis; sinusitis; prevalence
ID ENDOSCOPIC SINUS SURGERY; QUALITY-OF-LIFE; COMPUTED-TOMOGRAPHY FINDINGS;
CLINICAL-PRACTICE GUIDELINE; SMELL IDENTIFICATION TEST;
PLACEBO-CONTROLLED TRIAL; NASAL POLYPOSIS; DOUBLE-BLIND; DISEASE
SEVERITY; ALLERGIC RHINITIS
AB Objectives: Many studies have reported that olfactory dysfunction frequently occurs in chronic rhinosinusitis (CRS) populations; however, the prevalence and degree of olfactory loss has not been systematically studied. The aims of this study were to use combined data to report the prevalence of olfactory dysfunction and to calculate weighted averages of olfactory test scores in CRS patients.
Data Sources: A search was conducted in PubMed and Scopus, following the methods of Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines.
Review Methods: Studies reporting the prevalence of olfactory dysfunction using objective measures or olfactory test scores using validated scales were included.
Results: A total of 47 articles were included in a systematic review and 35 in the pooled data analysis. The prevalence of olfactory dysfunction in chronic rhinosinusitis was found to be 30.0% using the Brief Smell Identification Test, 67.0% using the 40-item Smell Identification Test, and 78.2% using the total Sniffin' Sticks score. Weighted averages 6 standard deviation of olfactory test scores were 25.96 +/- 7.11 using the 40-item Smell Identification Test, 8.60 +/- 2.81 using the Brief Smell Identification Test, 21.96 +/- 8.88 using total Sniffin' Sticks score, 5.65 +/- 1.51 using Sniffin' Sticks-Threshold, 9.21 +/- 4.63 using Sniffin' Sticks-Discrimination, 9.47 +/- 3.92 using Sniffin' Sticks-Identification, and 8.90 +/- 5.14 using the Questionnaire for Olfactory Disorders-Negative Statements.
Conclusions: In CRS populations, a significant percentage of patients experience olfactory dysfunction, and mean olfactory scores are within the dysosmic range.
C1 [Kohli, Preeti; Naik, Akash N.; Harruff, E. Emily; Nguyen, Shaun A.; Schlosser, Rodney J.; Soler, Zachary M.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA.
[Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Dept Surg, Charleston, SC USA.
RP Kohli, P (reprint author), Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, 135 Rutledge Ave,MSC 550, Charleston, SC 29425 USA.
EM pkohli89@gmail.com
FU National Institute on Deafness and Other Communication Disorders,
National Institutes of Health, Bethesda, Maryland, U.S.A [R03
DC013651-01]; Entellus; Intersect; Optinose; IntersectENT
FX This work was supported by grants from the National Institute on
Deafness and Other Communication Disorders, one of the National
Institutes of Health, Bethesda, Maryland, U.S.A. (R03 DC013651-01; PI:
Z.M.S.).; Z.M.S. is supported by grants from Entellus, Intersect, and
Optinose, which are not affiliated with this study. Z.M.S. is a
consultant for Olympus, which is not affiliated with this study. R.J.S.
is supported by grants from OptiNose, Entellus, and IntersectENT, none
of which are associated with this study. R.J.S. is a consultant for
Olympus and Meda, which are not affiliated with this study. S.A.N. is a
consultant for Roche Products Limited (United Kingdom) and CSL Behring,
which are not affiliated with this study.
NR 74
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD FEB
PY 2017
VL 127
IS 2
BP 309
EP 320
DI 10.1002/lary.26316
PG 12
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA EL9TI
UT WOS:000394962600013
PM 27873345
ER
PT J
AU Byne, W
AF Byne, William
TI Sustaining Progress Toward LGBT Health Equity: A Time for Vigilance,
Advocacy, and Scientific Inquiry
SO LGBT HEALTH
LA English
DT Editorial Material
DE barriers to care; clinical research; gender identity; health
disparities; public policy and advocacy; sexual orientation
C1 [Byne, William] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Byne, William] James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY 10468 USA.
RP Byne, W (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Byne, W (reprint author), James J Peters VA Med Ctr, Dept Psychiat, Bronx, NY 10468 USA.
EM william.byne@mssm.edu
NR 18
TC 0
Z9 0
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2325-8292
EI 2325-8306
J9 LGBT HEALTH
JI LGBT Health
PD FEB
PY 2017
VL 4
IS 1
BP 1
EP 3
DI 10.1089/lgbt.2016.0211
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EL3GC
UT WOS:000394506600001
PM 28051348
ER
PT J
AU Awad, MM
Chu, QSC
Gandhi, L
Stephenson, JJ
Govindan, R
Bradford, DS
Bonomi, PD
Ellison, DM
Eaton, KD
Fritsch, H
Munzert, G
Johnson, BE
Socinski, MA
AF Awad, Mark M.
Chu, Quincy S-C
Gandhi, Leena
Stephenson, Joe J.
Govindan, Ramaswamy
Bradford, Daniel S.
Bonomi, Philip D.
Ellison, David M.
Eaton, Keith D.
Fritsch, Holger
Munzert, Gerd
Johnson, Bruce E.
Socinski, Mark A.
TI An open-label, phase II study of the polo-like kinase-1 (P1k-1)
inhibitor, BI 2536, in patients with relapsed small cell lung cancer
(SCLC)
SO LUNG CANCER
LA English
DT Article
DE Small cell lung cancer; Plk-1 inhibition; Polo-like kinase; BI 2536
ID ADVANCED SOLID TUMORS; TRIAL; PLK1; TOPOTECAN; VOLASERTIB; THERAPY;
POLO-LIKE-KINASE-1; CARCINOMA; NETWORK
AB Objectives: This phase II, open-label study was designed to evaluate the response rate to the polo-like kinase 1 (Plk-1) inhibitor BI 2536 in patients with sensitive-relapsed small cell lung cancer (SCLC). Secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response, and safety.
Materials and methods: Patients were treated with the recommended phase II dose of 200 mg of BI 2536 intravenously every 21 days. This was a two-stage design with an early stopping rule in place if responses were not seen in at least 2 of the first 18 enrolled patients.
Results and conclusion: Twenty-three patients were enrolled in the study and 21 patients were evaluable for response. No responses were observed and all 23 patients have progressed. The median PFS was 1.4 months. Treatment was generally well tolerated and the most frequent adverse events were neutropenia, fatigue, nausea, vomiting, and constipation. BI 2536 is not effective in the treatment of sensitive relapsed SCLC. The criteria for expanding the trial to the second stage were not achieved, and the study was terminated for a lack of efficacy. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Awad, Mark M.; Gandhi, Leena; Johnson, Bruce E.] Harvard Med Sch, Lowe Ctr Thorac Oncol, Dana Farber Canc Inst, Boston, MA USA.
[Chu, Quincy S-C] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada.
[Stephenson, Joe J.] Canc Ctr Carolinas, Greenville, SC USA.
[Govindan, Ramaswamy] Washington Univ, Sch Med, St Louis, MO USA.
[Bradford, Daniel S.] Highlands Oncol Grp, Fayetteville, AR USA.
[Bonomi, Philip D.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Ellison, David M.] Charleston Hematol Oncol Associates, Charleston, SC USA.
[Eaton, Keith D.] Seattle Canc Care Alliance, Seattle, WA USA.
[Fritsch, Holger; Munzert, Gerd] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany.
[Socinski, Mark A.] Univ Pittsburgh, Pittsburgh, PA USA.
RP Johnson, BE (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM bruce_johnson@dfci.harvard.edu
NR 38
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0169-5002
EI 1872-8332
J9 LUNG CANCER
JI Lung Cancer
PD FEB
PY 2017
VL 104
BP 126
EP 130
DI 10.1016/j.lungcan.2016.12.019
PG 5
WC Oncology; Respiratory System
SC Oncology; Respiratory System
GA EN2LE
UT WOS:000395840900020
PM 28212994
ER
PT J
AU Vatansever, F
Hamblin, MR
AF Vatansever, Fatma
Hamblin, Michael R.
TI Surface-initiated polymerization with poly(n-hexylisocyanate) to
covalently functionalize silica nanoparticles
SO MACROMOLECULAR RESEARCH
LA English
DT Article
DE polymeric nanocomposites; inorganic-organic interfacing; controlled
polymerization; surface initiated polymerization; nanoparticle surface
modification; titanium catalyst; n-hexyl isocyanate polymerization
ID ISOCYANATE); POLYMERS
AB New methods are needed for covalent functionalization of nanoparticles-surface with organic polymer coronas to generate polymeric nanocomposite in a controlled manner. Here we report the use of a surface-initiated polymerization approach, mediated by titanium(IV) catalysis, to grow poly(n-hexylisocyanate) chains from silica surface. Two pathways were used to generate the interfacing in these nano-hybrids. In the first one, the nanoparticles were "seeded" with SiCl4, followed by reaction with 1,6-hexanediol to form hydroxyl groups attached directly to the surface via O-Si-O bonding. In the second pathway, the nanoparticles were initially exposed to a 9:1 mixture of trimethyl silyl chloride and chlorodimethyl octenyl silane which was then followed by hydroboration of the double bonds, to afford hydroxyl groups with a spatially controlled density and surface-attachment via O-Si-C bonding. These functionalized surfaces were then activated with the titanium tetrachloride catalyst. In our approach, surface tethered catalyst provided the sites for n-hexyl isocyanate monomer insertion to "build up" the surface-grown polymer layers from the "bottom-up". A final end-capping, to seal off the chain ends, was done via acetyl chloride. Compounds were characterized by Fourier transform infrared spectroscopy (FTIR), H-1 nuclear magnetic resonance spectroscopy (NMR), gas chromatography-mass spectrometry (GC-MS), gel permeation chromatography (GPC), and thermogravimetric analyses.
C1 [Vatansever, Fatma] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Vatansever, Fatma; Hamblin, Michael R.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Boston, MA 02139 USA.
RP Vatansever, F (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.; Vatansever, F; Hamblin, MR (reprint author), Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA.; Hamblin, MR (reprint author), Harvard Mit Div Hlth Sci & Technol, Boston, MA 02139 USA.
EM vatansever.fatma@mgh.harvard.edu; hamblin@helix.mgh.harvard.edu
FU US NIH [R01AI050875]
FX MRH was supported by US NIH grant R01AI050875.
NR 38
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1598-5032
EI 2092-7673
J9 MACROMOL RES
JI Macromol. Res.
PD FEB
PY 2017
VL 25
IS 2
BP 97
EP 107
DI 10.1007/s13233-017-5009-9
PG 11
WC Polymer Science
SC Polymer Science
GA EM1CC
UT WOS:000395054600001
ER
PT J
AU Esmaeili, M
Bathen, TF
Rosen, BR
Andronesi, OC
AF Esmaeili, Morteza
Bathen, Tone F.
Rosen, Bruce R.
Andronesi, Ovidiu C.
TI Three-dimensional MR spectroscopic imaging using adiabatic spin echo and
hypergeometric dual-band suppression for metabolic mapping over the
entire brain
SO MAGNETIC RESONANCE IN MEDICINE
LA English
DT Article
DE magnetic resonance spectroscopy imaging (MRSI); hypergeometric dual band
(HGDB); adiabatic spin echo (ASE); brain; lipid suppression
ID OUTER-VOLUME SUPPRESSION; LIPID SUPPRESSION; MAGNETIC-RESONANCE;
ANALYTIC SOLUTIONS; WATER-SUPPRESSION; SPECTRAL QUALITY; BLOCH EQUATION;
H-1 MRSI; K-SPACE; PULSES
AB PurposeLarge lipid and water signals in MR spectroscopic imaging (MRSI) complicate brain metabolite quantification. In this study, we combined adiabatic hypergeometric dual-band (HGDB) lipid and water suppression with gradient offset independent adiabatic (GOIA) spin echo to improve three-dimensional (3D) MRSI of the entire brain.
Methods3D MRSI was acquired at 3T with a 32-channel coil. HGDB pulses were used before excitation and during echo time. A brain slab was selected with GOIA-W(16,4) pulses, weighted phase encoded stack of spirals, and real-time motion/shim correction. HGDB alone or in combination with OVS and MEGA (MEscher-GArwood) was compared with OVS only and no suppression.
ResultsThe combined HGDB pulses suppressed lipids to 2%-3% of their full unsuppressed signal. The HGDB lipid suppression was on average 5 times better than OVS suppression. HGDB+MEGA provided 30% more suppression compared with a previously described HGDB+OVS scheme. The number of voxels with good metabolic fits was significantly larger in the HGDB data (91%-94%) compared with the OVS data (59%-80%).
ConclusionHGDB pulses provided efficient lipid and water suppression for full brain 3D MRSI. The HGDB suppression is superior to traditional OVS, and it can be combined with adiabatic spin echo to provide a sequence that is robust to B-1 inhomogeneity. Magn Reson Med 77:490-497, 2017. (c) 2016 International Society for Magnetic Resonance in Medicine
C1 [Esmaeili, Morteza; Rosen, Bruce R.; Andronesi, Ovidiu C.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA.
[Esmaeili, Morteza; Bathen, Tone F.] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Olav Kyrres Gate 9, Trondheim, Norway.
RP Esmaeili, M (reprint author), Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, Olav Kyrres Gate 9, Trondheim, Norway.
EM m.esmaeili@ntnu.no; ovidiu@nmr.mgh.harvard.edu
FU National Cancer Institute [1K22CA178269-01]; MGH-MIT Strategic
Initiative; Liaison Committee [46056808]; Norwegian University of
Science and Technology; National Institutes of Health Shared
Instrumentation Grant Program; High-End Instrumentation Grant Program
[S10RR021110]; Center for Functional Neuroimaging Technologies
[P41EB015896]
FX Grant sponsor: National Cancer Institute; Grant number: 1K22CA178269-01
(O.C.A.); Grant sponsor: MGH-MIT Strategic Initiative's Grand Challenge
3 on Neuroscience (O.C.A.); Grant sponsor: Liaison Committee between the
Central Norway Regional Health Authority (Grant number: 46056808) and
the Norwegian University of Science and Technology (M.E.); Grant
sponsor: National Institutes of Health Shared Instrumentation Grant
Program and/or High-End Instrumentation Grant Program; Grant number:
S10RR021110 B.R.R.); Grant sponsor: MR experiments were performed at the
Athinoula A. Martinos Center for Biomedical Imaging; Grant sponsor:
Center for Functional Neuroimaging Technologies; Grant number:
P41EB015896 [a P41 Regional Resource supported by the National Institute
of Biomedical Imaging and Bioengineering, National Institutes of
Health]) (B.R.R.)
NR 40
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0740-3194
EI 1522-2594
J9 MAGN RESON MED
JI Magn. Reson. Med.
PD FEB
PY 2017
VL 77
IS 2
BP 490
EP 497
DI 10.1002/mrm.26115
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA EL3UL
UT WOS:000394544700005
PM 26840906
ER
PT J
AU Poulsen, C
Wakeman, DG
Atefi, SR
Luu, P
Konyn, A
Bonmassar, G
AF Poulsen, Catherine
Wakeman, Daniel G.
Atefi, Seyed Reza
Luu, Phan
Konyn, Amy
Bonmassar, Giorgio
TI Polymer thick film technology for improved simultaneous dEEG/MRI
recording: Safety and MRI data quality
SO MAGNETIC RESONANCE IN MEDICINE
LA English
DT Article
DE fMRI; BOLD; eccentricity maps; anthropomorphic head phantom; ISO10974;
temperature measurements; B1 maps
ID HIGH-FIELD MRI; EEG CAP; BALLISTOCARDIOGRAM ARTIFACT; FUNCTIONAL MRI;
FMRI SIGNAL; BOLD FMRI; 7 TESLA; ELECTRODES; REMOVAL; HEAD
AB PurposeTo develop a 256-channel dense-array electroencephalography (dEEG) sensor net (the Ink-Net) using high-resistance polymer thick film (PTF) technology to improve safety and data quality during simultaneous dEEG/MRI.
MethodsHeating safety was assessed with temperature measurements in an anthropomorphic head phantom during a 30-min, induced-heating scan at 7T. MRI quality assessment used B1 field mapping and functional MRI (fMRI) retinotopic scans in three humans at 3T. Performance of the 256-channel PTF Ink-Net was compared with a 256-channel MR-conditional copper-wired electroencephalography (EEG) net and to scans with no sensor net. A visual evoked potential paradigm assessed EEG quality within and outside the 3T scanner.
ResultsPhantom temperature measurements revealed nonsignificant heating (ISO 10974) in the presence of either EEG net. In human B1 field and fMRI scans, the Ink-Net showed greatly reduced cross-modal artifact and less signal degradation than the copper-wired net, and comparable quality to MRI without sensor net. Cross-modal ballistocardiogram artifact in the EEG was comparable for both nets.
ConclusionHigh-resistance PTF technology can be effectively implemented in a 256-channel dEEG sensor net for MR conditional use at 7T and with significantly improved structural and fMRI data quality as assessed at 3T. Magn Reson Med 77:895-903, 2017. (c) 2016 International Society for Magnetic Resonance in Medicine
C1 [Poulsen, Catherine; Luu, Phan; Konyn, Amy] Elect Geodes Inc, 500 East 4th Ave,Suite 200, Eugene, OR 97403 USA.
[Wakeman, Daniel G.; Atefi, Seyed Reza; Bonmassar, Giorgio] Harvard Med Sch, Massachusetts Gen Hosp, AA Martinos Ctr, Charlestown, MA USA.
RP Poulsen, C (reprint author), Elect Geodes Inc, 500 East 4th Ave,Suite 200, Eugene, OR 97403 USA.
EM cpoulsen@egi.com
FU National Institute of Neurological Disorders and Stroke [R44NS071988,
U01 NS075026]; National Institute of Biomedical Imaging and
Bioengineering [R21EB016449]; National Institutes of Health Office of
the Director [S10OD010759]; National Center for Research Resources
[P41RR14075]; MIND Institute
FX Grant sponsor: National Institute of Neurological Disorders and Stroke;
Grant numbers: R44NS071988, U01 NS075026; Grant sponsor: National
Institute of Biomedical Imaging and Bioengineering; Grant number:
R21EB016449; Grant sponsor: National Institutes of Health Office of the
Director; Grant number: S10OD010759; Grant sponsor: National Center for
Research Resources; Grant number: P41RR14075; Grant sponsor: the MIND
Institute.
NR 55
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0740-3194
EI 1522-2594
J9 MAGN RESON MED
JI Magn. Reson. Med.
PD FEB
PY 2017
VL 77
IS 2
BP 895
EP 903
DI 10.1002/mrm.26116
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA EL3UL
UT WOS:000394544700048
PM 26876960
ER
PT J
AU Aires, J
Casanova, C
Vernal, S
Nascimento, M
Rodrigues, S
Lerner, EA
Roselino, AM
AF Aires, Juliana
Casanova, Claudio
Vernal, Sebastian
Nascimento, Margarida
Rodrigues, Sandra
Lerner, Ethan A.
Roselino, Ana Maria
TI Maxadilan-simile expression in Nyssomyia neivai, a sandfly vector in an
endemic region of Brazil, and its immunogenicity in patients with
American tegumentary leishmaniasis
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Maxadilan protein; leishmaniasis; Psychodidae
ID FLY LUTZOMYIA-LONGIPALPIS; VISCERAL LEISHMANIASIS; CUTANEOUS
LEISHMANIASIS; SALIVARY-GLANDS; SOUTHERN BRAZIL; INFECTION; PSYCHODIDAE;
PEPTIDE; DIPTERA; PHLEBOTOMINAE
AB BACKGROUND Maxadilan (Max) is a salivary component in the sandfly Lutzomyia longipalpis (Lutz & Neiva 1912), a vector of visceral leishmaniasis. Max has a powerful vasodilatory effect and is a candidate vaccine that has been tested in experimental leishmaniasis. Nyssomyia neivai (Pinto 1926) is a vector of the pathogen responsible for American tegumentary leishmaniasis (ATL) in Brazil.
OBJECTIVE We searched for Max expression in Ny. neivai and for antibodies against Max in ATL patients.
METHODS cDNA and protein were extracted from the cephalic segment, including salivary glands, of Ny. neivai and analysed by polymerase chain reaction, DNA sequencing, and blotting assays. The results were compared with data obtained from Lu. longipalpis samples. We quantified antibodies against Max in serum samples from 41 patients with ATL (31 and 10 with the cutaneous and mucocutaneous forms, respectively) and 63 controls from the endemic northeastern region of Sao Paulo state, using enzyme-linked immunosorbent assay.
FINDINGS Recognition of a Max-simile peptide by specific antibodies confirmed expression of a Max sequence in Ny. neivai (GenBank EF601123.1). Compared to controls, patients with ATL presented higher levels of antibodies against Max (p = 0.004); 24.4% of the patients with ATL and 3.2% of the controls presented anti-Max levels above the cutoff index (p = 0.014). The anti-Max levels were not associated with the specific clinical form of ATL, leishmanin skin test response, absence or presence of amastigotes in histopathologic exam, results of indirect immunofluorescence testing for leishmaniasis, or duration of cutaneous form disease. MAIN C
CONCLUSION High serum anti-Max levels did not protect patients against ATL, but confirmed previous natural exposure to Ny. neivai bites in this ATL endemic region.
C1 [Aires, Juliana; Vernal, Sebastian; Roselino, Ana Maria] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Div Dermatol, Ribeirao Preto, SP, Brazil.
[Casanova, Claudio] Secretaria Estado Saude Sao Paulo, Superintendencia Controle Endemias, Mogi Guacu, SP, Brazil.
[Nascimento, Margarida] Univ Sao Paulo, Hosp Clin, Fac Med Ribeirao Preto, Lab Sorol, Ribeirao Preto, SP, Brazil.
[Rodrigues, Sandra; Roselino, Ana Maria] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Mol Biol Lab, Ribeirao Preto, SP, Brazil.
[Lerner, Ethan A.] Massachusetts Gen Hosp, Harvard Med Sch, Cutaneous Biol Res Ctr, Boston, MA 02114 USA.
RP Roselino, AM (reprint author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Div Dermatol, Ribeirao Preto, SP, Brazil.; Roselino, AM (reprint author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Clin Med, Mol Biol Lab, Ribeirao Preto, SP, Brazil.
EM amfrosel@fmrp.usp.br
FU FAEPA; University Hospital; Ribeirao Preto Medical School; University of
Sao Paulo, Brazil; CAPES
FX FAEPA, University Hospital, Ribeirao Preto Medical School, University of
Sao Paulo, Brazil.; SV received a scholarship from CAPES.
NR 30
TC 0
Z9 0
U1 1
U2 1
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD FEB
PY 2017
VL 112
IS 2
BP 116
EP 122
DI 10.1590/0074-02760160351
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA EK8ED
UT WOS:000394155800005
PM 28177045
ER
PT J
AU Roberts, SE
Thibaudeau, S
Burrell, JC
Zager, EL
Cullen, DK
Levin, LS
AF Roberts, S. E.
Thibaudeau, S.
Burrell, J. C.
Zager, E. L.
Cullen, D. K.
Levin, L. S.
TI To reverse or not to reverse? A systematic review of autograft polarity
on functional outcomes following peripheral nerve repair surgery
SO MICROSURGERY
LA English
DT Review
ID REGENERATING MOTOR AXONS; REINNERVATION; GUIDANCE; MUSCLES; GRAFTS
AB Background: The literature describing the best clinical practice for proximal- distal autograft orientation, otherwise known as nerve graft polarity, is inconsistent. With existing disparities in the peripheral nerve literature, the clinical question remains whether reversing nerve autograft polarity bears an advantage for nerve regeneration.
Methods: A comprehensive review of the literature using Embase and PubMed databases (1940June 2015) was performed to retrieve all original articles on the effects of nerve autograft polarity on nerve regeneration and functional recovery following primary repair of peripheral nerve defects.
Results: The initial database search yielded 318 titles. Duplicate exclusion, title review and full text review yielded six articles which directly compared nerve autograft polarity. Histological, morphometric, electrophysiological, and behavioral outcomes were reviewed. All retained articles were animal studies, of which none demonstrated significant differences in outcomes between the normal and reversed polarity groups. A reversed graft may ensure that regenerating nerve fibers are not lost at branching points, however this may not translate into improved function.
Conclusion: There is insufficient data to suggest that nerve autograft polarity has an impact on nerve regeneration and functional outcomes.
C1 [Roberts, S. E.; Burrell, J. C.; Zager, E. L.; Cullen, D. K.] Univ Pennsylvania, Perelman Sch Med, Dept Neurosurgery, Philadelphia, PA USA.
[Roberts, S. E.; Burrell, J. C.; Cullen, D. K.] Vet Affairs Med Ctr, Philadelphia, PA USA.
[Thibaudeau, S.; Levin, L. S.] Hosp Univ Pennsylvania, Div Plast Surg & Dept Orthoped Surg, Philadelphia, PA USA.
RP Thibaudeau, S (reprint author), 3737 Market St Suite 600, Philadelphia, PA 19104 USA.
EM sthiba@gmail.com
NR 31
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0738-1085
EI 1098-2752
J9 MICROSURG
JI Microsurgery
PD FEB
PY 2017
VL 37
IS 2
BP 169
EP 174
DI 10.1002/micr.30133
PG 6
WC Surgery
SC Surgery
GA EP4ED
UT WOS:000397332600013
PM 27935644
ER
PT J
AU Casassus, F
Tearney, GJ
Seguy, B
Poustis, P
Coste, P
Gerbaud, E
AF Casassus, Frederic
Tearney, Guillermo J.
Seguy, Benjamin
Poustis, Pierre
Coste, Pierre
Gerbaud, Edouard
TI Minimalist immediate mechanical intervention approach in the management
of an acute proximal left anterior descending artery occlusion with
extensive thrombus burden in the left main coronary artery
SO MINERVA CARDIOANGIOLOGICA
LA English
DT Letter
ID ELEVATION MYOCARDIAL-INFARCTION; RANDOMIZED-TRIAL; PRIMARY PCI;
ASPIRATION; STEMI; NO
C1 [Casassus, Frederic; Seguy, Benjamin; Poustis, Pierre; Coste, Pierre; Gerbaud, Edouard] Hop Haut Leveque, CHU Bordeaux, Soins Intensifs Cardiolog, Plateau Cardiol Interventionnelle, 5 Ave Magellan, F-33604 Pessac, France.
[Tearney, Guillermo J.] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA.
[Tearney, Guillermo J.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA USA.
Harvard MIT, Div Hlth Sci & Technol, Cambridge, MA USA.
[Tearney, Guillermo J.] Harvard Med Sch, Dept Pathol, Wellman Ctr Photomedicine & Massachusetts Gen Hos, Boston, MA USA.
RP Gerbaud, E (reprint author), Hop Haut Leveque, CHU Bordeaux, Soins Intensifs Cardiolog, Plateau Cardiol Interventionnelle, 5 Ave Magellan, F-33604 Pessac, France.
EM edouard.gerbaud@chu-bordeaux.fr
FU Canon, Inc.
FX Guillermo J. Tearney receives royalties from Terumo Corporation and MIT.
Guillermo J. Tearney's lab receives sponsored research from Canon, Inc.
NR 7
TC 0
Z9 0
U1 0
U2 0
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0026-4725
EI 1827-1618
J9 MINERVA CARDIOANGIOL
JI Minerva Cardioangiol.
PD FEB
PY 2017
VL 65
IS 1
BP 102
EP 105
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EP5HE
UT WOS:000397408800015
ER
PT J
AU Oduro, K
Masia, R
Sillero, MC
Ebb, D
Mark, E
Hedley-Whyte, ET
AF Oduro, Kwadwo
Masia, Ricard
Sillero, Maria Cobos
Ebb, David
Mark, Eugene
Hedley-Whyte, E. Tessa
TI Metastatic Atypical Teratoid Rhabdoid Tumor (ATRT) in an Adolescent
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 22
BP 9A
EP 9A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300023
ER
PT J
AU Chebib, I
Kurzawa, P
Mullen, JT
Johnstone, SE
Deshpande, V
Nielsen, GP
AF Chebib, Ivan
Kurzawa, Pawel
Mullen, John T.
Johnstone, Sarah E.
Deshpande, Vikram
Nielsen, G. Petur
TI Prognostic Value of Myogenic Differentiation in Dedifferentiated
Liposarcoma
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Med Sch, Boston, MA USA.
Poznan Univ Med Sci, Poznan, Poland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 42
BP 14A
EP 14A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300043
ER
PT J
AU Larque, AB
Deshpande, V
Nielsen, GP
Chebib, I
AF Larque, Ana B.
Deshpande, Vikram
Nielsen, G. Petur
Chebib, Ivan
TI Prognostic Features in Uniformly Treated Synovial Sarcoma
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Larque, Ana B.; Deshpande, Vikram; Nielsen, G. Petur; Chebib, Ivan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 62
BP 18A
EP 19A
PG 2
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300063
ER
PT J
AU Biernacka, A
Deshpande, Y
Brachtel, E
AF Biernacka, Anna
Deshpande, Yikram
Brachtel, Elena
TI Loss of XIST - The Potential Breast Cancer X Factor
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Med Sch, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 118
BP 32A
EP 32A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300119
ER
PT J
AU Gonzales-Ericcson, P
Mayer, IA
Jovanovic, B
Lehmann, B
Estrada, MV
Kuba, G
Abramson, V
Mayer, E
Dillon, P
Aditya, B
Chang, J
Forero, A
Meszoely, I
Grau, A
Pietenpol, J
Sanders, M
AF Gonzales-Ericcson, Paula
Mayer, Ingrid A.
Jovanovic, Bojana
Lehmann, Brian
Estrada, Monica V.
Kuba, Gabriela
Abramson, Vandana
Mayer, Erica
Dillon, Patrick
Aditya, Bardia
Chang, Jenny
Forero, Andres
Meszoely, Ingrid
Grau, Ana
Pietenpol, Jennifer
Sanders, Melinda
TI Histopathologic Subgroups of AR plus TNBC Predict Pathologic Complete
Response to Neoadjuvant Chemotherapy in Localized Breast Cancer
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
Dana Farber Canc Ctr, Boston, MA USA.
Univ Virginia, Hlth Sci Ctr, Charlottesville, VA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Methodist Hosptal Res Inst, Houston, TX USA.
Univ Alabama Birmingham, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 164
BP 43A
EP 43A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300164
ER
PT J
AU Kuba, MG
Lester, SC
Bowman, T
Garber, J
Dillon, DA
AF Kuba, Maria G.
Lester, Susan C.
Bowman, Teresa
Garber, Judy
Dillon, Deborah A.
TI Breast Cancer in Li-Fraumeni Syndrome: Morphologic Evaluation of
Invasive and In Situ Carcinomas
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 202
BP 53A
EP 53A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300202
ER
PT J
AU Papadodima, S
Masia, R
Stone, JR
AF Papadodima, Stavroula
Masia, Ricard
Stone, James R.
TI Cardiac Iron Overload Following Liver Transplantation in Patients
without Hemochromatosis
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Univ Athens, Athens, Greece.
Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 320
BP 84A
EP 84A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300320
ER
PT J
AU Darras, N
Agarwal, S
Faquin, WC
Wang, HH
Sacks, BA
Nishino, M
AF Darras, Natasha
Agarwal, Shweta
Faquin, William C.
Wang, Helen H.
Sacks, Barry A.
Nishino, Michiya
TI ThyroSeq Testing for Indeterminate Thyroid Nodules: An Institutional
Experience
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 358
BP 92A
EP 93A
PG 2
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300358
ER
PT J
AU Eng, G
Rao, RA
Chebib, I
AF Eng, George
Rao, Rema A.
Chebib, Ivan
TI Use of Novel Image Analysis to Characterize and Quantify Nuclear
Features of Papillary Thyroid Carcinoma
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
2New York Presbyterian Hosp, New York, NY USA.
Weill Cornell Med Coll, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 364
BP 94A
EP 94A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300364
ER
PT J
AU Hang, JF
Charu, V
Zhang, MJL
Vandenbussche, C
AF Hang, Jen-Fan
Charu, Vivek
Zhang, Mingjuan L.
Vandenbussche, Christopher
TI Maximum N/C Ratio in the "Atypical Urothelial Cells" Category Correlates
with Follow-Up Malignant Results in Liquid-Based Voided Urine Specimens
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 375
BP 97A
EP 97A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300375
ER
PT J
AU Hoda, RS
Arpin, R
Rosenbaum, MW
Pitman, MB
AF Hoda, Raza S.
Arpin, Ronald
Rosenbaum, Matthew W.
Pitman, Martha B.
TI Risk of Malignancy in Pancreatic Cysts with High-Grade Atypical Cytology
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Hoda, Raza S.; Arpin, Ronald; Rosenbaum, Matthew W.; Pitman, Martha B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 378
BP 98A
EP 98A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300378
ER
PT J
AU Rosenbaum, MW
England, JS
Hoda, RS
Arpin, R
Le, L
Forcione, DG
Iafrate, A
Pitman, MB
AF Rosenbaum, Matthew W.
England, Jonathan S.
Hoda, Raza S.
Arpin, Ronald
Le, Long
Forcione, David G.
Iafrate, Anthony
Pitman, Martha B.
TI Next Generation Sequencing Adds Value to Cytology and Fluorescence In
Situ Hybridization in the Diagnosis of Bile Duct Brushing Specimens
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Rosenbaum, Matthew W.; England, Jonathan S.; Hoda, Raza S.; Arpin, Ronald; Le, Long; Forcione, David G.; Iafrate, Anthony; Pitman, Martha B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 438
BP 113A
EP 114A
PG 2
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300438
ER
PT J
AU Dewar, R
Tambouret, RH
AF Dewar, Rajan
Tambouret, Rosemary H.
TI Can Pathology Skills Be Learnt Exclusively Through Online Resources?:
MOOC for PAPs - A Massive Open Online Course to Raise Pap Smear
Cytoscreener Workforce in Low and Middle Income Countries
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Univ Michigan, Ann Arbor, MI 48109 USA.
Udhavum Ullangal NGO, Madras, Tamil Nadu, India.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Med Sch, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 549
BP 139A
EP 139A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300548
ER
PT J
AU Farhat, N
Xu, B
Onernek, AM
Tuttle, RM
Roman, B
Katabi, N
Nose, V
Sadow, PM
Tallini, G
Faquin, W
Ghossein, R
AF Farhat, Nada
Xu, Bin
Onernek, Ayse Mine
Tuttle, R. Michael
Roman, Benjamin
Katabi, Nora
Nose, Vania
Sadow, Peter M.
Tallini, Giovanni
Faquin, William
Ghossein, Ronald
TI Should Subcentimeter Non-Invasive Encapsulated, Follicular Variant of
Papillary Thyroid Carcinoma (NI-EFV PTC) Be Diagnosed as Non-Invasive
Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features
(NIFTP)?
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Bologna, Sch Med, Bologna, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 581
BP 147A
EP 147A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300580
ER
PT J
AU Hernandez-Prera, J
Machado, R
Asa, SL
Baloch, Z
Faquin, W
Ghossein, R
LiVolsi, VA
Lloyd, RV
Mete, O
Nikiforov, Y
Thompson, LDR
Turk, AT
Seethala, RR
Suster, S
Urken, ML
Wenig, BM
AF Hernandez-Prera, Juan
Machado, Rosalie
Asa, Sylvia L.
Baloch, Zubair
Faquin, William
Ghossein, Ronald
LiVolsi, Virginia A.
Lloyd, Ricardo V.
Mete, Ozgur
Nikiforov, Yuri
Thompson, Lester D. R.
Turk, Andrew T.
Seethala, Raja R.
Suster, Saul
Urken, Mark L.
Wenig, Bruce M.
TI Pathologic Reporting of Tall Call Variant of Papillary Thyroid Cancer:
Have We Reached Consensus?
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Mt Sinai Beth Israel, New York, NY USA.
Univ Toronto, Toronto, ON, Canada.
Univ Penn, Philadelphia, PA 19104 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
Univ Wisconsin, Madison, WI USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Southern Calif Permanente Med Grp, Woodland Hills, CA USA.
Columbia Univ, New York, NY USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 582
BP 147A
EP 148A
PG 2
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300581
ER
PT J
AU Arora, KS
Michelakos, T
Cai, L
Ting, DT
Ferrone, C
Ferrone, S
Deshpande, V
AF Arora, Kshitij S.
Michelakos, Theodoros
Cai, Lei
Ting, David T.
Ferrone, Cristina
Ferrone, Soldano
Deshpande, Vikram
TI Colonic Carcinomas with Sporadic Loss of Mismatch Repair Proteins Are
Associated with Loss of HLA Class I
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Arora, Kshitij S.; Michelakos, Theodoros; Cai, Lei; Ting, David T.; Ferrone, Cristina; Ferrone, Soldano; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 631
BP 159A
EP 159A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300630
ER
PT J
AU Choi, WT
Brown, I
Ushiku, T
Yozu, M
Setia, N
Srivastava, A
Johncilla, M
Pai, RK
Fukayama, M
Misdraji, J
Lauwers, GY
AF Choi, Won-Tak
Brown, Ian
Ushiku, Tetsuo
Yozu, Masato
Setia, Namrata
Srivastava, Amitabh
Johncilla, Melanie
Pai, Rish K.
Fukayama, Masashi
Misdraji, Joseph
Lauwers, Gregory Y.
TI Gastric Pyloric Gland Adenoma: A Multicenter Clinicopathologic Study of
65 Cases
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 UCSF Med Ctr, San Francisco, CA USA.
Envoi Pathol, Kelvin Grove, Qld, Australia.
Univ Tokyo, Tokyo, Japan.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Chicago, Chicago, IL 60637 USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Mayo Clin, Phoenix, AZ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 662
BP 166A
EP 166A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300661
ER
PT J
AU Horvath, B
Brown, I
Setia, N
Mattia, A
Lamps, L
Lauwers, GE
Misdraji, J
AF Horvath, Bela
Brown, Ian
Setia, Namrata
Mattia, Anthony
Lamps, Laura
Lauwers, Gregory E.
Misdraji, Joseph
TI A Crohn's-Like Appearance Characterizes Actinomycotic Appendicitis
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Envoi Specialist Pathologists, Kelvin Grove, Qld, Australia.
Univ Chicago, Chicago, IL 60637 USA.
Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 698
BP 175A
EP 175A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300697
ER
PT J
AU Jayakumar, R
Qin, J
Siddiqi, MA
Gupta, R
AF Jayakumar, Rajeswari
Qin, Jia
Siddiqi, M. A.
Gupta, Raavi
TI EZH2 as a Useful Diagnostic Tool for Grading Gastrointestinal (GI)
Neuroendocrine Tumors
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Suny Downstate Med Ctr, Brooklyn, NY 11203 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 707
BP 177A
EP 178A
PG 2
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300706
ER
PT J
AU Jeck, WR
Arora, KS
Brachtel, E
Deshpande, V
AF Jeck, William Richard
Arora, Kshitij S.
Brachtel, Elena
Deshpande, Vikram
TI Harnessing TCGA RNAseq Data as a Springboard to Novel Tumor Markers
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Jeck, William Richard; Arora, Kshitij S.; Brachtel, Elena; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 708
BP 178A
EP 178A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467300707
ER
PT J
AU Oduro, K
Arora, KS
Deshpande, V
AF Oduro, Kwadwo
Arora, Kshitij S.
Deshpande, Vikram
TI Chromogenic In Situ Hybridization (CISH) Based Tracking of Donor Derived
Lymphocytes Augments the Histologic Evaluation of Human Acute Graft
versus Host Disease (GVHD)
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Oduro, Kwadwo; Arora, Kshitij S.; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 765
BP 191A
EP 191A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301038
ER
PT J
AU Rosenbaum, MW
Bledsoe, JR
Kem, M
Huynh, T
Mino-Kenudson, M
AF Rosenbaum, Matthew W.
Bledsoe, Jacob R.
Kem, Marina
Huynh, Tiffany
Mino-Kenudson, Mari
TI Immune Checkpoint Expression and the Tumor Immune Environment in
Colorectal Carcinoma
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Massachusetts, Sch Med, Worcester, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 789
BP 197A
EP 197A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301062
ER
PT J
AU Calagua, C
Shaw, K
Russo, J
Schaefer, R
Lis, R
Zhang, ZW
Loda, M
Taplin, ME
Balk, SP
Sun, Y
Ye, HH
AF Calagua, Carla
Shaw, Kristin
Russo, Joshua
Schaefer, Rachel
Lis, Rosina
Zhang, Zhenwei
Loda, Massimo
Taplin, Mary-Ellen
Balk, Steven P.
Sun, Yue
Ye, Huihui
TI Effect of Neoadjuvant Intense Androgen Deprivation Therapy in PD-L1
Expression in Prostate Cancer
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 873
BP 217A
EP 217A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301146
ER
PT J
AU Elfandy, H
Pederzoli, F
Pullman, E
Tyekucheva, S
Schultz, N
Loda, M
AF Elfandy, Habiba
Pederzoli, Filippo
Pullman, Eli
Tyekucheva, Svitlana
Schultz, Nicholas
Loda, Massimo
TI Molecular Characterization of Prostatic Adenocarcinoma Gleason 4,
Cribriform Pattern
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA.
Cairo Univ, Natl Canc Inst, Cairo, Egypt.
Univ Vita Salute San Raffaele, Milan, Italy.
George Washington Univ, Washington, DC USA.
Harvard Sch Publ Hlth, Boston, MA USA.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
Harvard Med Sch, BWH, Boston, MA USA.
DFCI, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 897
BP 222A
EP 223A
PG 2
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301171
ER
PT J
AU Kandukuri, S
Choueiri, TK
Hirsch, MS
AF Kandukuri, Shivani
Choueiri, Toni K.
Hirsch, Michelle S.
TI PD-L1 Expression in High Grade Locally-Advanced Renal Cell Carcinoma
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 949
BP 234A
EP 234A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301223
ER
PT J
AU Montaser, L
Calagua, C
Schaefer, R
Lis, R
Zhang, ZW
Loda, M
Taplin, ME
Balk, SP
Ye, HH
AF Montaser, Laleh
Calagua, Carla
Schaefer, Rachel
Lis, Rosina
Zhang, Zhenwei
Loda, Massimo
Taplin, Mary-Ellen
Balk, Steven P.
Ye, Huihui
TI Effect of Neoadjuvant Intense Androgen Deprivation Therapy in
Neuroendocrine Differentiation of Prostate Cancer
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 East Tennessee State Univ, Johnson City, TN USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 987
BP 244A
EP 244A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301261
ER
PT J
AU Obeng, RC
Lorentz, A
Alqassab, U
Laganosky, D
Keith, C
Lian, F
Ogan, K
Master, VA
Pattaras, JG
Rossi, M
Arnold, R
Goecks, J
Petros, JA
Osunkoya, AO
AF Obeng, Rebecca C.
Lorentz, Adam
Alqassab, Usama
Laganosky, Dean
Keith, Christopher
Lian, Fei
Ogan, Kenneth
Master, Viraj A.
Pattaras, John G.
Rossi, Michael
Arnold, Rebecca
Goecks, Jeremy
Petros, John A.
Osunkoya, Adeboye O.
TI Genomic Mapping of Primary Unifocal and Multifocal Renal Cell Carcinoma
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Emory Univ, Atlanta, GA 30322 USA.
Beth Isreal Deaconess Med Ctr, Boston, MA USA.
George Washington Univ, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 995
BP 246A
EP 246A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301269
ER
PT J
AU Bennett, J
Nardi, V
Rouzbahman, M
Morales-Oyarvide, V
Kim, KR
Nielsen, GP
Oliva, E
AF Bennett, Jennifer
Nardi, Valentina
Rouzbahman, Marjan
Morales-Oyarvide, Vicente
Kim, Kyu-Rae
Nielsen, G. P.
Oliva, Esther
TI Inflammatory Myofibroblastic Tumor of the Uterus: A Clinicopathological,
Immunohistochemical, and Molecular Analysis of 13 Cases
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Lahey Hosp, Burlington, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Toronto Gen Hosp, Toronto, ON, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Ulsan, Seoul, South Korea.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1109
BP 275A
EP 276A
PG 2
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301385
ER
PT J
AU Bennett, J
Pesci, A
Badrinarain, J
Da Silva, A
Oliva, E
AF Bennett, Jennifer
Pesci, Anna
Badrinarain, Jason
Da Silva, Annacarolina
Oliva, Esther
TI Mismatch Repair Protein Expression in Endometrioid Carcinoma of the
Ovary: Incidence and Clinicopathologic Associations in 77 Cases
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Lahey Hosp, Burlington, MA USA.
Osped Sacro Cuore Don Calabria, Verona, Italy.
Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bennett, Jennifer; Pesci, Anna; Badrinarain, Jason; Da Silva, Annacarolina; Oliva, Esther] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1110
BP 276A
EP 276A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301386
ER
PT J
AU Bosse, T
Nout, RA
McAlpine, JN
McConechy, M
Britton, H
Ganesan, R
Steele, JC
Harrison, BT
Oliva, E
Matias-Guiu, X
Gilks, B
Soslow, R
AF Bosse, Tjalling
Nout, Remi A.
McAlpine, Jessica N.
McConechy, Melissa
Britton, Heidi
Ganesan, Raji
Steele, Jane C.
Harrison, Beth T.
Oliva, Esther
Matias-Guiu, Xavier
Gilks, Blake
Soslow, Robert
TI Molecular Classification of Grade 3 Endometrioid Endometrial Cancers
Identifies Distinct Prognostic Subgroups
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Leiden Univ, Med Ctr, Leiden, Netherlands.
Univ British Columbia, Vancouver, BC, Canada.
BC Canc Agcy, Vancouver, BC, Canada.
Birmingham Womens HS Fdn Trust, Birmingham, W Midlands, England.
Massachussets Gen Hosp, Boston, MA USA.
Hosp Arnau Vilanova, Lleida, Spain.
Hosp Univ Bellvitge, Lleida, Spain.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
McGill Univ, Montreal, PQ, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1113
BP 277A
EP 277A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301389
ER
PT J
AU Chiang, S
Hensley, M
Antonescu, CR
Oliva, E
Soslow, R
AF Chiang, Sarah
Hensley, Martee
Antonescu, Cristina R.
Oliva, Esther
Soslow, Robert
TI BCOR Is a Robust Diagnostic Immunohistochemical Marker of
YWHAE-Rearranged High-Grade Endometrial Stromal Sarcoma
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1125
BP 280A
EP 280A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301401
ER
PT J
AU Howitt, BE
Garcia, E
Shall, LM
Lindeman, NI
MacConaill, LE
Dong, F
Hirsch, MS
Nucci, MR
Crum, CP
McCluggage, WG
Mirkovic, J
AF Howitt, Brooke E.
Garcia, Elizabeth
Shall, Lynette M.
Lindeman, Neal I.
MacConaill, Laura E.
Dong, Fei
Hirsch, Michelle S.
Nucci, Marisa R.
Crum, Christopher P.
McCluggage, W. Glenn
Mirkovic, Jelena
TI Targeted Genomic Profiling of Female Adnexal Tumors of Probable Wolffian
Origin
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Harvard Med Sch, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1162
BP 289A
EP 289A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301438
ER
PT J
AU Kiystel-Whittemore, M
Oliva, E
AF Kiystel-Whittemore, Melissa
Oliva, Esther
TI Patterns of Recurrences in Grade 1 Endometrioid Endometrial
Adenocarcinoma (EEC)
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Kiystel-Whittemore, Melissa; Oliva, Esther] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1186
BP 294A
EP 295A
PG 2
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301462
ER
PT J
AU Stolnicu, S
Barsan, I
Hoang, L
Terinte, C
Pesci, A
Aviel-Ronen, S
Kiyokawa, T
Alvarado-Cabrero, I
Park, K
Oliva, E
Soslow, R
AF Stolnicu, Simon
Barsan, Iulia
Hoang, Lien
Terinte, Cristina
Pesci, Anna
Aviel-Ronen, Sarit
Kiyokawa, Takako
Alvarado-Cabrero, Isabel
Park, Kay
Oliva, Esther
Soslow, Robert
TI International Endocervical Criteria and Classification: Mucinous
Endocervical Adenocarcinomas (MEA)
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Univ Med & Pharm, Targu Mures, Romania.
Vancouver Gen Hosp, Vancouver, BC, Canada.
Inst Oncol, Iasi, Romania.
Osped Sacro Coure Don Calabria, Negrar, Italy.
Sheba Med Ctr, Tel Hashomer, Israel.
Jikei Univ, Sch Med, Tokyo, Japan.
Hosp Oncol, Mexico City, DF, Mexico.
MSKCC, New York, NY USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1245
BP 310A
EP 310A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301521
ER
PT J
AU Stolnicu, S
Barsan, I
Hoang, L
Terinte, C
Pesci, A
Aviel-Ronen, S
Kiyokawa, T
Alvarado-Cabrero, I
Park, K
Oliva, E
Soslow, R
AF Stolnicu, Simona
Barsan, Iulia
Hoang, Lien
Terinte, Cristina
Pesci, Anna
Aviel-Ronen, Sarit
Kiyokawa, Takako
Alvarado-Cabrero, Isabel
Park, Kay
Oliva, Esther
Soslow, Robert
TI International Endocervical Adenocarcinoma Criteria and Classification
(IECC)
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Univ Med & Pharm, Targu Mures, Mures, Romania.
Vancouver Gen Hosp, Vancouver, BC, Canada.
Inst Oncol, Iasi, Romania.
Osped Sacro Coure Don Calabria, Negrar, Italy.
Sheba Med Ctr, Tel Hashomer, Israel.
Jikei Univ, Sch Med, Tokyo, Japan.
Hosp Oncol, Mexico City, DF, Mexico.
MSKCC, New York, NY USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1244
BP 310A
EP 310A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301520
ER
PT J
AU Wong, A
Borger, D
Oliva, E
AF Wong, Adele
Borger, Darrell
Oliva, Esther
TI Clinicopathological Features of Uterine Neuroendocrine Tumors (NET)s
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
KK Womens & Childrens Hosp, Singapore, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1265
BP 315A
EP 315A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301541
ER
PT J
AU Wong, A
Arora, KS
Ordulu, Z
Deshpande, V
Oliva, E
AF Wong, Adele
Arora, Kshitij S.
Ordulu, Zehra
Deshpande, Vikram
Oliva, Esther
TI TERRA Amplified (+) Primary Leiomyosarcomas (LMS) of the Gynecologic
(GYN)-Tract
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
KK Womens & Childrens Hosp, Singapore, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1266
BP 315A
EP 315A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301542
ER
PT J
AU Bundele, MM
Weinreb, I
Xu, B
Chiosea, S
Faquin, W
Dias-Santagata, D
Seethala, RR
AF Bundele, Manish M.
Weinreb, Ilan
Xu, Bin
Chiosea, Simon
Faquin, William
Dias-Santagata, Dora
Seethala, Raja R.
TI Mucoacinar Carcinoma: A Rare Intercalated Duct/Acinar Variant of
Mucoepidermoid Carcinoma, Hybrid Tumor, or Distinct Entity?
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Tan Tock Seng Hosp, SG, Singapore, Singapore.
Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Hlth Network, Toronto, ON, Canada.
Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1294
BP 322A
EP 322A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301570
ER
PT J
AU Jo, VY
Chau, NG
Hornick, JL
Krane, JF
Sholl, LM
AF Jo, Vickie Y.
Chau, Nicole G.
Hornick, Jason L.
Krane, Jeffrey F.
Sholl, Lynette M.
TI Recurrent IDH2 R172X Mutations Define Sinonasal Undifferentiated
Carcinoma
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Harvard Med Sch, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1310
BP 326A
EP 326A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301586
ER
PT J
AU Boiocchi, L
Ferry, JA
Deshpande, V
AF Boiocchi, Leonardo
Ferry, Judith A.
Deshpande, Vikram
TI Lymph Node Fibrosis in IgG4-Related Disease
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Boiocchi, Leonardo; Ferry, Judith A.; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1362
BP 339A
EP 339A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301638
ER
PT J
AU Boyer, D
McKelvie, P
de Leval, L
Edlefsen, KL
Ko, YH
Aberman, Z
Kovach, A
Masih, A
Nishino, H
Weiss, L
Meeker, A
Nardi, V
Palisoc, M
Shao, LN
Pittaluga, S
Ferry, JA
Harris, N
Sohani, A
AF Boyer, Daniel
McKelvie, Penelope
de Leval, Laurence
Edlefsen, Kerstin L.
Ko, Young-Hyeh
Aberman, Zachary
Kovach, Alexandra
Masih, Aneal
Nishino, Ha
Weiss, Lawrence
Meeker, Alan
Nardi, Valentina
Palisoc, Maryknoll
Shao, Lina
Pittaluga, Stefania
Ferry, Judith A.
Harris, Nancy
Sohani, Aliyah
TI Fibrin-Associated EBV plus Large B-Cell Lymphoma: An Indolent Neoplasm
Distinct from DLBCL-CI
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Univ Michigan, Ann Arbor, MI 48109 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
St Vincents Hosp, Melbourne, Vic, Australia.
CHU Vaudois, Lausanne, Switzerland.
Univ Washington, Seattle, WA 98195 USA.
Sungkyunkwan Univ, Seoul, South Korea.
Florida Int Univ, Miami, FL 33199 USA.
Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
Holmes Reg Med Ctr, Melbourne, FL USA.
North Shore Med Ctr, Salem, MA USA.
NeoGen Labs, Aliso Viejo, CA USA.
Johns Hopkins Univ, Baltimore, MD USA.
NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1363
BP 339A
EP 340A
PG 2
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301639
ER
PT J
AU Crotty, R
Pozdnyakova, O
Chen, YB
Ballen, K
Hasserjian, RP
AF Crotty, Rory
Pozdnyakova, Olga
Chen, Yi-Bin
Ballen, Karen
Hasserjian, Robert P.
TI Lymphoid Proliferations Following Umbilical Cord Stem Cell Transplant
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1381
BP 344A
EP 344A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467301657
ER
PT J
AU Margolskee, E
Mikita, G
Oak, J
Allen, MB
Zuo, Z
Wang, S
Arber, DA
George, T
Hasserjian, RP
Orazi, A
AF Margolskee, Elizabeth
Mikita, Geoffrey
Oak, Jean
Allen, M. B.
Zuo, Zhuang
Wang, Sa
Arber, Daniel A.
George, Tracy
Hasserjian, Robert P.
Orazi, Attilio
TI Acute Myeloid Leukemia with Erythroid Predominance: Are All Cases
MDS-Related?
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
Stanford Univ, Stanford, CA 94305 USA.
Univ New Mexico, Albuquerque, NM 87131 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1452
BP 362A
EP 362A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302031
ER
PT J
AU Maryamchik, E
Van Cott, EM
AF Maryamchik, Elena
Van Cott, Elizabeth M.
TI The Effects of Rivaroxaban on Activated Protein C Resistance and Protein
S Testing
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Maryamchik, Elena; Van Cott, Elizabeth M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1454
BP 363A
EP 363A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302033
ER
PT J
AU Shih, A
Bledsoe, JR
McKelvie, P
Harris, N
Zukerberg, L
AF Shih, Angela
Bledsoe, Jacob R.
McKelvie, Penny
Harris, Nancy
Zukerberg, Lawrence
TI CD5-Negative Mantle Cell Lymphoma Shows a More Indolent Outcome and
Variable SOX11 Staining
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Shih, Angela; Bledsoe, Jacob R.; McKelvie, Penny; Harris, Nancy; Zukerberg, Lawrence] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1513
BP 378A
EP 378A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302092
ER
PT J
AU Tashakori, M
Sanchez, J
Michalowski, SM
Louissaint, A
Inamdar, KV
Gomez-Gelvez, J
Carey, JL
Menon, MP
AF Tashakori, Mehrnoosh
Sanchez, Jessica
Michalowski, Susan M.
Louissaint, Abner
Inamdar, Kedar V.
Gomez-Gelvez, Juan
Carey, John L.
Menon, Madhu P.
TI Follicular Lymphoma Transforming to Double and Triple Hit Lymphoma; a
Clinicopathologic, Morphologic and Cytogenetic Analysis
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Henry Ford Hlth Syst, Detroit, MI USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1525
BP 380A
EP 381A
PG 2
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302104
ER
PT J
AU Weinberg, OK
Gibson, CJ
Pozdnyakova, O
Kuo, FC
Ebert, B
Hasserjian, RP
AF Weinberg, Olga K.
Gibson, Christopher J.
Pozdnyakova, Olga
Kuo, Frank C.
Ebert, Benjamin
Hasserjian, Robert P.
TI Specific Dysplastic Findings Correlate with Gene Mutations in De Novo
AML
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Boston Childrens Hosp, Boston, MA USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1542
BP 385A
EP 385A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302121
ER
PT J
AU Wertheim, G
Pillai, V
Sargent, R
Paessler, M
Lewen, M
Li, J
Master, S
Carroll, M
Luskin, M
AF Wertheim, Gerald
Pillai, Vinodh
Sargent, Rachel
Paessler, Michele
Lewen, Margaret
Li, Jie
Master, Stephen
Carroll, Martin
Luskin, Marlise
TI EVI1 Immunohistochemistry Identifies AML Subtypes with Distinct Genetics
and Prognosis
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Childrens Hosp Phila, Philadelphia, PA USA.
Hosp Univ Penn, Philadelphia, PA USA.
Weill Cornell Med Coll, New York, NY USA.
Boston Childrens Hosp, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1544
BP 385A
EP 386A
PG 2
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302122
ER
PT J
AU Wong, WJ
Baltay, MT
Kuo, FC
Fuhrman, K
Hasserjian, RP
Pozdnyakova, O
AF Wong, Waihay J.
Baltay, Michele T.
Kuo, Frank C.
Fuhrman, Kit
Hasserjian, Robert P.
Pozdnyakova, Olga
TI Integrated Molecular and Histologic Analysis Identifies Distinctive Gene
Expression Patterns in Primary Myelofibrosis
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Nanostring Technol Inc, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1546
BP 386A
EP 386A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302124
ER
PT J
AU Xia, D
Sayed, S
Moloo, Z
Gakinya, S
Mutuiri, A
Courville, EL
Hasseijian, RP
Sohani, A
AF Xia, Daniel
Sayed, Shahin
Moloo, Zahir
Gakinya, Samuel
Mutuiri, Anderson
Courville, Elizabeth L.
Hasseijian, Robert P.
Sohani, Aliyah
TI Clinicopathologic Characterization of Nodular Lymphocyte Predominant
Hodgkin Lymphoma from Kenya
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Aga Khan Univ Hosp, Nairobi, Kenya.
Univ Minnesota, Minneapolils, MN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1547
BP 386A
EP 386A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302125
ER
PT J
AU Fu, XJ
Bautista, P
Lennerz, JK
Onozato, M
Iafrate, A
Yagi, Y
AF Fu, Xiujun
Bautista, Pinky
Lennerz, Jochen K.
Onozato, Maristela
Iafrate, Anthony
Yagi, Yukako
TI Apply a Confocal WSI Scanner for FISH Slides Imaging, 3D Reconstruction,
and Semi-Automated Diagnosis
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Med Sch, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1585
BP 396A
EP 396A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302163
ER
PT J
AU Faulkner-Jones, BE
Law, C
Rosen, M
Rosen, D
Luffman, CI
Rosen, S
AF Faulkner-Jones, Beverly E.
Law, Charles
Rosen, Milan
Rosen, Devin
Luffman, Christina I.
Rosen, Seymour
TI Renal Biopsy Data Analysis from Whole Slide Imaging: A Novel "Holistic"
Approach
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 BIDMC, Boston, MA USA.
Kitware Inc, Clifton Pk, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1624
BP 406A
EP 406A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302201
ER
PT J
AU Lee, M
de Gonzalez, AK
Remotti, HE
Gandhi, M
Levinson, S
Deshpande, V
Lagana, SM
AF Lee, Michael
de Gonzalez, Anne Koehne
Remotti, Helen E.
Gandhi, Manoj
Levinson, Shauna
Deshpande, Vikram
Lagana, Stephen M.
TI In-Situ Hybridization for Glypican-3 RNA Is More Sensitive Than
Immunohistochemistry in Hepatocellular Carcinoma
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Columbia Univ, New York, NY USA.
Affymetrix, Santa Clara, CA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1679
BP 419A
EP 419A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302252
ER
PT J
AU Solomon, D
Goode, B
Hyun, MD
Joseph, NM
Van Ziffle, J
Butowski, N
Brat, DJ
Kleinschmidt-DeMasters, B
Rodriguez, F
Louis, DN
Yong, W
Lopes, B
Rosenblum, M
Tihan, T
Bollen, A
Perry, A
AF Solomon, David
Goode, Benjamin
Hyun, Michael D.
Joseph, Nancy M.
Van Ziffle, Jessica
Butowski, Nicholas
Brat, Daniel J.
Kleinschmidt-DeMasters, Bette
Rodriguez, Fausto
Louis, David N.
Yong, William
Lopes, Beatriz
Rosenblum, Marc
Tihan, Tank
Bollen, Andrew
Perry, Arie
TI A Recurrent Kinase Domain Mutation p.D463H in PRKCA Defines Chordoid
Glioma of the Third Ventricle
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
Emory Univ, Atlanta, GA 30322 USA.
Univ Colorado, Denver, CO 80202 USA.
Johns Hopkins Univ, Baltimore, MD USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Univ Virginia, Charlottesville, VA USA.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1753
BP 437A
EP 437A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302327
ER
PT J
AU Williams, E
Kim, J
Muzikansky, A
Shaw, M
Iafrate, J
Plotkin, S
Suva, M
Stemmer-Rachamimov, A
AF Williams, Erik
Kim, James
Muzikansky, Alona
Shaw, McKenzie
Iafrate, John
Plotkin, Scott
Suva, Mario
Stemmer-Rachamimov, Anat
TI Molecular and Histologic Features of a Series of Sporadic and Familial
Schwannomas
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Broad Inst MIT & Harvard, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1763
BP 439A
EP 439A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302337
ER
PT J
AU Nowak, JA
Wu, YR
Qian, ZR
Rubinson, DA
Morales-Oyarvide, V
Dunne, RF
Findeis-Hosey, JJ
Hornick, JL
Brais, L
Da Silva, A
Welch, M
Yuan, C
Kozak, M
Ducar, M
Thorner, A
Wollison, B
Fuchs, C
Ogino, S
Hezel, A
Koong, A
Wolpin, B
AF Nowak, Jonathan A.
Wu, Yiru
Qian, Zhirong
Rubinson, Douglas A.
Morales-Oyarvide, Vicente
Dunne, Richard F.
Findeis-Hosey, Jennifer J.
Hornick, Jason L.
Brais, Lauren
Da Silva, Annacarolina
Welch, Marisa
Yuan, Chen
Kozak, Margaret
Ducar, Matthew
Thorner, Aaron
Wollison, Bruce
Fuchs, Charles
Ogino, Shuji
Hezel, Aram
Koong, Albert
Wolpin, Brian
TI Molecular Correlates of Major Morphologic Subtypes of Pancreatic Ductal
Adenocarcinoma
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Rochester, Rochester, NY USA.
Stanford Univ, Stanford, CA 94305 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1803
BP 449A
EP 449A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302377
ER
PT J
AU Marino-Enriquez, A
Kuo, FC
Baltay, M
Demetri, G
Lindeman, NI
Fletcher, J
Sholl, LM
AF Marino-Enriquez, Adrian
Kuo, Frank C.
Baltay, Michele
Demetri, George
Lindeman, Neal I.
Fletcher, Jonathan
Sholl, Lynette M.
TI Identification of Sarcoma Fusion Genes by Multiplex Detection of
Aberrant 3 ' to 5 ' Expression Ratios
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1847
BP 459A
EP 460A
PG 2
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302420
ER
PT J
AU Glass, CH
Redig, AJ
Hung, YP
French, C
Sholl, LM
AF Glass, Carolyn H.
Redig, Amanda J.
Hung, Yin P.
French, Christopher
Sholl, Lynette M.
TI SMARCA4 Loss in Lung Cancer Is Associated with Distinct
Clinicopathologic Features
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1926
BP 479A
EP 479A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302498
ER
PT J
AU Hung, YR
Dong, F
Nardi, V
Watkins, JC
Godleski, J
Dal Cin, P
Crum, CP
Chirieac, LR
AF Hung, Yin (Rex)
Dong, Fei
Nardi, Valentina
Watkins, Jaclyn C.
Godleski, John
Dal Cin, Paola
Crum, Christopher P.
Chirieac, Lucian R.
TI A Subset of Diffuse Malignant Peritoneal Mesothelioma Have Novel ALK
Rearrangements and Distinct Clinicopathologic Features
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1931
BP 480A
EP 480A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302503
ER
PT J
AU Hwang, DH
Mentzer, SJ
Johnson, BE
Sholl, LM
AF Hwang, David H.
Mentzer, Steven J.
Johnson, Bruce E.
Sholl, Lynette M.
TI Next Generation Sequencing Frequently Contradicts Surgical Pathology
Impression of Relatedness of Multiple Tumors in the Lung
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1932
BP 480A
EP 480A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302504
ER
PT J
AU Jin, Y
Matsubara, O
Yamanaka, K
Mark, E
AF Jin, Yasuto
Matsubara, Osamu
Yamanaka, Kazuki
Mark, Eugene
TI Intratumoral Programmed Cell Death-Ligand 1 (PD-L1) and Intratumoral
CD8(+) T Cell Expression in Lung Cancer
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Kyosai Hosp, Hiratsuka, Kanagawa, Japan.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Med Sch, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1935
BP 481A
EP 481A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302507
ER
PT J
AU Ordulu, Z
Kem, M
Huynh, T
Dias-Santagata, D
Iafrate, J
Mino-Kenudson, M
AF Ordulu, Zebra
Kem, Marina
Huynh, Tiffany
Dias-Santagata, Dora
Iafrate, John
Mino-Kenudson, Mari
TI PDL-1 Expression in Synchronous Lung Nodules: Association with Driver
Mutations and CD8+Cytotoxic T Lymphocytes
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Ordulu, Zebra; Kem, Marina; Huynh, Tiffany; Dias-Santagata, Dora; Iafrate, John; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1963
BP 487A
EP 487A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302534
ER
PT J
AU Ritterhouse, L
Vivero, M
Mino-Kenudson, M
Sholl, LM
Iafrate, J
Nardi, V
Dong, F
AF Ritterhouse, Lauren
Vivero, Marina
Mino-Kenudson, Mari
Sholl, Lynette M.
Iafrate, John
Nardi, Valentina
Dong, Fei
TI GNAS Mutations in Mucinous and Non-Mucinous Lung Carcinomas
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1977
BP 491A
EP 491A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302548
ER
PT J
AU Rosen, LE
Ananthanarayanan, V
Gallan, A
Tjota, MY
Attanoos, R
Alchami, FS
Brcic, L
Butnor, K
Hiroshima, K
Klampatsa, A
Litzky, L
Marchevsky, AM
Medeiros, F
Montero-Fernandez, MA
Moore, DA
Nabeshima, K
Pavlisko, EN
Sharma, A
Sheaff, M
Walts, AE
Galateau, F
Le Stang, N
Krausz, T
Husain, AN
AF Rosen, Lauren E.
Ananthanarayanan, Vijayalakshmi
Gallan, Alexander
Tjota, Melissa Yuwono
Attanoos, Richard
Alchami, Fouad S.
Brcic, Luka
Butnor, Kelly
Hiroshima, Kenzo
Klampatsa, Astero
Litzky, Leslie
Marchevsky, Alberto M.
Medeiros, Filomena
Montero-Fernandez, M. Angeles
Moore, David A.
Nabeshima, Kazuki
Pavlisko, Elizabeth N.
Sharma, Anupama
Sheaff, Michael
Walts, Ann E.
Galateau, Francoise
Le Stang, Nolwenn
Krausz, Thomas
Husain, Aliya N.
TI Nuclear Grade, Necrosis and Solid Growth Pattern Predict Survival in
Epithelioid Malignant Mesothelioma: An International, Multi
Institutional Study
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Univ Chicago, Chicago, IL 60637 USA.
Loyola, Maywood, IL USA.
Univ Wales Coll Cardiff, Cardiff, S Glam, Wales.
Med Univ Graz, Graz, Austria.
Univ Vermont, Burlington, VT USA.
Tokyo Womens Med Ctr, Kawadacho, Japan.
Univ Penn, Philadelphia, PA 19104 USA.
Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
Basildon & Thurrock Univ Hosp, Basildon, England.
Royal Brompton & Harefield Hosp, London, England.
Univ Leicester, Leicester, Leics, England.
Fukuoka Univ, Fukuoka, Japan.
Duke Univ, Durham, NH USA.
Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
Barts Hlth NHS Trust, London, England.
Ctr Leon Berard, Lyon, France.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1980
BP 492A
EP 492A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302551
ER
PT J
AU Shih, A
Fu, XJ
Hariri, L
Huynh, T
Mark, E
Yagi, Y
Mino-Kenudson, M
AF Shih, Angela
Fu, Xiujun
Hariri, Lida
Huynh, Tiffany
Mark, Eugene
Yagi, Yukako
Mino-Kenudson, Mari
TI Alveolar Framework Alterations in Fibrosing Interstitial Lung Disease: A
Three-Dimensional Reconstruction Study
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Shih, Angela; Fu, Xiujun; Hariri, Lida; Huynh, Tiffany; Mark, Eugene; Yagi, Yukako; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1992
BP 495A
EP 495A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302563
ER
PT J
AU Shih, A
Uruga, H
Muzikansky, A
Bozkurtlar, E
Chung, JH
Hariri, L
Minami, Y
Moreira, AL
Wang, H
Yoshizawa, A
Mino-Kenudson, M
AF Shih, Angela
Uruga, Hironori
Muzikansky, Alona
Bozkurtlar, Emine
Chung, Jin-Haeng
Hariri, Lida
Minami, Yuko
Moreira, Andre L.
Wang, He
Yoshizawa, Akihiko
Mino-Kenudson, Mari
TI Reproducibility in Classification of Small Lung Adenocarcinomas: An
International Interobserver Study
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Marmara Univ, Istanbul, Turkey.
Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea.
Ibarakihigashi Natl Hosp, Natl Hosp Org, Naka, Ibaraki, Japan.
NYU, Langone Med Ctr, New York, NY USA.
Temple Univ, Sch Med, Philadelphia, PA 19122 USA.
Kyoto Univ Hosp, Kyoto, Japan.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 1993
BP 495A
EP 495A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302564
ER
PT J
AU Zhang, MJL
Kem, M
Campo, MJ
Huynh, T
Gainor, JF
Mino-Kenudson, M
AF Zhang, Mingjuan L.
Kem, Marina
Campo, Meghan J.
Huynh, Tiffany
Gainor, Justin F.
Mino-Kenudson, Mari
TI Differential Expression of Immune Inhibitory Markers in Association with
the Immune Microenvironment in Resected Lung Adenocarcinomas
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Zhang, Mingjuan L.; Kem, Marina; Campo, Meghan J.; Huynh, Tiffany; Gainor, Justin F.; Mino-Kenudson, Mari] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 2012
BP 500A
EP 500A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302583
ER
PT J
AU Crotty, R
Prasad, S
Brachtel, E
Deshpande, V
AF Crotty, Rosy
Prasad, Shilpa
Brachtel, Elena
Deshpande, Vikram
TI XIST as a Tool for Resolving Specimen Contamination Events
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Boston Univ, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 2028
BP 504A
EP 504A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302599
ER
PT J
AU Maglantay, RJ
Cunningham, VL
Goodwin, MT
Feeney, M
Keefe, J
Sohani, A
Tambouret, RH
AF Maglantay, Remegio J.
Cunningham, Vickie L.
Goodwin, Michele T.
Feeney, Margaret
Keefe, Joan
Sohani, Aliyah
Tambouret, Rosemary H.
TI Evaluation of Body Fluids: Detection of Malignancy in Specimens
Submitted for Cell Count and Differential in the Hematology Laboratory
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Maglantay, Remegio J.; Cunningham, Vickie L.; Goodwin, Michele T.; Feeney, Margaret; Keefe, Joan; Sohani, Aliyah; Tambouret, Rosemary H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 2059
BP 511A
EP 511A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302630
ER
PT J
AU Maglantay, RJ
Wang, JL
Pozdnyakova, O
Ly, A
AF Maglantay, Remegio J.
Wang, Jessica L.
Pozdnyakova, Olga
Ly, Amy
TI Comparison of Two Methods for Cytologic Evaluation of Cerebrospinal
Fluids
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Atrius Hlth, Needham, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 2060
BP 512A
EP 512A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302631
ER
PT J
AU Qin, J
Tambouret, RH
AF Qin, Jia
Tambouret, Rosemary H.
TI Rapid FNA Diagnosis of Lymphadenopathy
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Qin, Jia; Tambouret, Rosemary H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 2078
BP 516A
EP 516A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302649
ER
PT J
AU Wong, A
Bhan, A
Lennerz, JK
Brachtel, E
AF Wong, Adele
Bhan, Atul
Lennerz, Jochen K.
Brachtel, Elena
TI HER2/ERBB2 Testing in Breast Carcinoma by Next Generation Sequencing
SO MODERN PATHOLOGY
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Med Sch, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD FEB
PY 2017
VL 30
SU 2
MA 2101
BP 522A
EP 522A
PG 1
WC Pathology
SC Pathology
GA EL2RO
UT WOS:000394467302672
ER
PT J
AU Bedoya, F
Frigault, MJ
Maus, MV
AF Bedoya, Felipe
Frigault, Matthew J.
Maus, Marcela V.
TI The Flipside of the Power of Engineered T Cells: Observed and Potential
Toxicities of Genetically Modified T Cells as Therapy
SO MOLECULAR THERAPY
LA English
DT Review
ID CHIMERIC ANTIGEN RECEPTORS; CYTOKINE RELEASE SYNDROME; ACUTE
MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; VERSUS-HOST-DISEASE;
GENE-TRANSFER; MANAGEMENT; BLINATUMOMAB; REMISSIONS; REGRESSION
AB Autologous T cells modified to recognize novel antigen targets are a novel form of therapy for cancer. We review the various potential forms of observed and hypothetical toxicities associated with genetically modified T cells. Despite the focus on toxicities in this review, re-directed T cells represent a powerful and highly effective form of anti-cancer therapy; we remain optimistic that the common toxicities will become routinely manageable and that some theoretical toxicity will be exceedingly rare, if ever observed.
C1 [Bedoya, Felipe; Frigault, Matthew J.; Maus, Marcela V.] Massachusetts Gen Hosp, Ctr Canc, Cellular Immunotherapy Program, Boston, MA 02114 USA.
[Bedoya, Felipe; Frigault, Matthew J.; Maus, Marcela V.] Harvard Med Sch, Boston, MA 02115 USA.
RP Maus, MV (reprint author), 149 13th St,Room 7-219, Charlestown, MA 02129 USA.
EM mvmaus@mgh.harvard.edu
FU NIH [K08CA166039]; Gabrielle's Angel Foundation; V Foundation
FX M. V. M. was supported by NIH K08CA166039, Gabrielle's Angel Foundation,
and the V Foundation.
NR 57
TC 0
Z9 0
U1 1
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD FEB 1
PY 2017
VL 25
IS 2
BP 314
EP 320
DI 10.1016/j.ymthe.2016.11.011
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA EP3UT
UT WOS:000397307900005
PM 28153085
ER
PT J
AU Gyorgy, B
Sage, C
Indzhykulian, AA
Scheffer, DI
Brisson, AR
Tan, S
Wu, XD
Volak, A
Mu, DK
Tamvakologos, PI
Li, YQ
Fitzpatrick, Z
Ericsson, M
Breakefield, XO
Corey, DP
Maguire, CA
AF Gyorgy, Bence
Sage, Cyrille
Indzhykulian, Artur A.
Scheffer, Deborah I.
Brisson, Alain R.
Tan, Sisareuth
Wu, Xudong
Volak, Adrienn
Mu, Dakai
Tamvakologos, Panos I.
Li, Yaqiao
Fitzpatrick, Zachary
Ericsson, Maria
Breakefield, Xandra O.
Corey, David P.
Maguire, Casey A.
TI Rescue of Hearing by Gene Delivery to Inner-Ear Hair Cells Using
Exosome-Associated AAV
SO MOLECULAR THERAPY
LA English
DT Article
ID ADENOASSOCIATED VIRUS VECTORS; EFFICIENT TRANSDUCTION; EXTRACELLULAR
VESICLES; IN-VIVO; THERAPY; DEAFNESS; ROBUST; MICE; TMHS
AB Adeno-associated virus (AAV) is a safe and effective vector for gene therapy for retinal disorders. Gene therapy for hearing disorders is not as advanced, in part because gene delivery to sensory hair cells of the inner ear is inefficient. Although AAV transduces the inner hair cells of the mouse cochlea, outer hair cells remain refractory to transduction. Here, we demonstrate that a vector, exosome-associated AAV (exo-AAV), is a potent carrier of transgenes to all inner ear hair cells. ExoAAV1-GFP is more efficient than conventional AAV1-GFP, both in mouse cochlear explants in vitro and with direct cochlear injection in vivo. Exo-AAV shows no toxicity in vivo, as assayed by tests of auditory and vestibular function. Finally, exo-AAV1 gene therapy partially rescues hearing in a mouse model of hereditary deafness (lipoma HMGIC fusion partner-like 5/ tetraspan membrane protein of hair cell stereocilia [Lhfpl5/ Tmh(-/-)]). Exo-AAV is a powerful gene delivery system for hair cell research and may be useful for gene therapy for deafness.
C1 [Gyorgy, Bence; Sage, Cyrille; Indzhykulian, Artur A.; Scheffer, Deborah I.; Wu, Xudong; Tamvakologos, Panos I.; Li, Yaqiao; Corey, David P.] Harvard Med Sch, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.
[Gyorgy, Bence; Sage, Cyrille; Indzhykulian, Artur A.; Scheffer, Deborah I.; Wu, Xudong; Tamvakologos, Panos I.; Li, Yaqiao; Corey, David P.] Harvard Med Sch, Howard Hughes Med Inst, 220 Longwood Ave, Boston, MA 02115 USA.
[Gyorgy, Bence; Volak, Adrienn; Mu, Dakai; Fitzpatrick, Zachary; Breakefield, Xandra O.; Maguire, Casey A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Bldg 149, Charlestown, MA 02129 USA.
[Gyorgy, Bence; Volak, Adrienn; Mu, Dakai; Fitzpatrick, Zachary; Breakefield, Xandra O.; Maguire, Casey A.] Harvard Med Sch, NeuroDiscovery Ctr, Bldg 149, Charlestown, MA 02129 USA.
[Brisson, Alain R.; Tan, Sisareuth] Univ Bordeaux, IPB, CNRS, Mol Imaging & NanoBioTechnol,UMR 5248,CBMN, Allee Geoffroy St Hilaire, F-33600 Pessac, France.
[Ericsson, Maria] Harvard Med Sch, Dept Cell Biol, 220 Longwood Ave, Boston, MA 02115 USA.
[Breakefield, Xandra O.] Harvard Med Sch, Program Neurosci, Bldg 149, Charlestown, MA 02129 USA.
RP Corey, DP (reprint author), Harvard Med Sch, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.; Corey, DP (reprint author), Harvard Med Sch, Howard Hughes Med Inst, 220 Longwood Ave, Boston, MA 02115 USA.; Maguire, CA (reprint author), Massachusetts Gen Hosp, Dept Neurol, Bldg 149, Charlestown, MA 02129 USA.
EM dcorey@hms.harvard.edu; cmaguire@mgh.harvard.edu
FU NIH/NINDS [R21 NS081374-01]; NIH/NIDCD [R01 DC002281]; American Brain
Tumor Association Discovery grant; Cure Alzheimer's Fund
FX This work was supported by NIH/NINDS grant R21 NS081374-01 (C.A.M.),
NIH/NIDCD grant R01 DC002281 (D.P.C.), an American Brain Tumor
Association Discovery grant (C.A.M.), and a Cure Alzheimer's Fund
(C.A.M.). We acknowledge the Nucleic Acid Quantitation Core at MGH
Neuroscience Center for quantitative PCR analysis. B.G. is an Associate
and D.P.C. is an Investigator of the Howard Hughes Medical Institute. We
thank Hunter Elliott (Harvard, Image and Data Analysis Core) for
assistance with image analysis. We also thank Nick Andrews and Trishala
Chari (Boston Children's Hospital, Neurodevelopmental Behavioral Core)
for helping with behavioral analysis.
NR 28
TC 1
Z9 1
U1 3
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1525-0016
EI 1525-0024
J9 MOL THER
JI Mol. Ther.
PD FEB 1
PY 2017
VL 25
IS 2
BP 379
EP 391
DI 10.1016/j.ymthe.2016.12.010
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA EP3UT
UT WOS:000397307900011
PM 28082074
ER
PT J
AU Raskind, WH
Friedman, JR
Roze, E
Meneret, A
Chen, DH
Bird, TD
AF Raskind, Wendy H.
Friedman, Jennifer R.
Roze, Emmanuel
Meneret, Aurelie
Chen, Dong-Hui
Bird, Thomas D.
TI ADCY5-related dyskinesia: Comments on characteristic manifestations and
variant-associated severity
SO MOVEMENT DISORDERS
LA English
DT Letter
ID FAMILIAL DYSKINESIA; FACIAL MYOKYMIA
C1 [Raskind, Wendy H.] Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA.
[Raskind, Wendy H.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Raskind, Wendy H.; Bird, Thomas D.] US Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Seattle, WA 98174 USA.
[Friedman, Jennifer R.] Univ Calif San Diego, Dept Neurosci & Pediat, San Diego, CA 92103 USA.
[Friedman, Jennifer R.] Rady Childrens Hosp, San Diego, CA USA.
[Roze, Emmanuel; Meneret, Aurelie] UPMC Univ Paris 06, Sorbonne Univ, Inst Cerveau & Moelle Epiniere, Inserm,CNRS,UMR 7225,UMR S 1127,U1127, Paris, France.
[Roze, Emmanuel; Meneret, Aurelie] Hop La Pitie Salpetriere, AP HP, Dept Neurol, Paris, France.
[Chen, Dong-Hui; Bird, Thomas D.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
RP Raskind, WH (reprint author), Univ Washington, Dept Med Med Genet, Seattle, WA 98195 USA.; Raskind, WH (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.; Raskind, WH (reprint author), US Dept Vet Affairs, Geriatr Res Educ & Clin Ctr, Seattle, WA 98174 USA.
EM wendyrun@uw.edu
FU National Institute of Neurological Diseases and Stroke [R01 NS069719];
Department of Veterans Affairs; Athena Diagnostics; CNRS; INSERM
(COSSEC),; AP-HP (DRC-PHRC); MerzPharma; Orkyn; Aguettant; IP sante;
Ultragenix; UCB pharma; Teva; Sanofi-Genzyme; Dystonia Coalition;
Dystonia Medical Research Foundation; Movement Disorders Society; JNLF
(Journees de Neurologie en Langue Francaise)
FX Dr. Raskind is funded by the National Institute of Neurological Diseases
and Stroke (R01 NS069719) and the Department of Veterans Affairs. She
receives licensing fees from Athena Diagnostics for Patent 7655401
"Mutations in PKCc are the cause for spinocerebellar ataxia." Dr.
Friedman reports family financial interest in biotechnology. Dr. Roze
received research support from CNRS, INSERM (COSSEC), AP-HP (DRC-PHRC),
MerzPharma, Orkyn, Aguettant, IP sante, Ultragenix, UCB pharma; served
on scientific advisory boards for Orkyn, Ultragenix, and Merz-Pharma;
received speech honoraria from Orkyn, Aguettant, Merz-Pharma, and
Ultragenix; and received travel funding from Teva, Sanofi-Genzyme, the
Dystonia Coalition, the Dystonia Medical Research Foundation, and the
Movement Disorders Society. Dr. Meneret received a grant from JNLF
(Journees de Neurologie en Langue Francaise). Dr. Chen receives
licensing fees from Athena Diagnostics for Patent 7655401 "Mutations in
PKCc are the cause for spinocerebellar ataxia." Dr. Bird receives
licensing fees from Athena Diagnostics for Patent 7655401 "Mutations in
PKCc are the cause for spinocerebellar ataxia." He is funded by the
Department of Veterans Affairs.
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD FEB
PY 2017
VL 32
IS 2
BP 305
EP 306
DI 10.1002/mds.26888
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA EM9QJ
UT WOS:000395645900026
PM 27933653
ER
PT J
AU Wang, CN
AF Wang, Changning
TI A Novel PET Imaging Probe Targeting Monoacylglycerol Lipase In The Brain
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Meeting Abstract
CT Forum of the
Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis
(ACTRIMS)
CY FEB 23-25, 2017
CL Orlando, FL
SP Americas Comm Treatment & Res Multiple Sclerosis
C1 [Wang, Changning] Harvard Med Sch, Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
EI 1477-0970
J9 MULT SCLER J
JI Mult. Scler. J.
PD FEB
PY 2017
VL 23
IS 1
SU 1
MA P124
BP 64
EP 64
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA EM5YB
UT WOS:000395388800147
ER
PT J
AU Gong, YX
Schumacher, SE
Wu, WH
Tang, FY
Beroukhim, R
Chan, TA
AF Gong, Yongxing
Schumacher, Steven E.
Wu, Wei H.
Tang, Fanying
Beroukhim, Rameen
Chan, Timothy A.
TI Pan-Cancer Analysis Links PARK2 to BCL-XL-Dependent Control of Apoptosis
SO NEOPLASIA
LA English
DT Article
ID MYC-DRIVEN LYMPHOMAGENESIS; COPY-NUMBER ALTERATION; CELL-DEATH;
LUNG-CANCER; MITOCHONDRIAL DEPOLARIZATION; PROTEIN FAMILY; GENE; LIGASE;
MICE; ASSOCIATION
AB Mutation of the PARK2 gene can promote both Parkinson's Disease and cancer, yet the underlying mechanisms of how PARK2 controls cellular physiology is incompletely understood. Here, we show that the PARK2 tumor suppressor controls the apoptotic regulator BCL-XL and modulates programmed cell death. Analysis of approximately 10,000 tumor genomes uncovers a striking pattern of mutual exclusivity between PARK2 genetic loss and amplification of BCL2L1, implicating these genes in a common pathway. PARK2 directly binds to and ubiquitinates BCL-XL. Inactivation of PARK2 leads to aberrant accumulation of BCL-XL both in vitro and in vivo, and cancer-specific mutations in PARK2 abrogate the ability of the ubiquitin E3 ligase to target BCL-XL for degradation. Furthermore, PARK2 modulates mitochondrial depolarization and apoptosis in a BCL-XL-dependent manner. Thus, like genes at the nodal points of growth arrest pathways such as p53, the PARK2 tumor suppressor is able to exert its antiproliferative effects by regulating both cell cycle progression and programmed cell death.
C1 [Gong, Yongxing; Wu, Wei H.; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY USA.
[Schumacher, Steven E.] Broad Inst Harvard, Cambridge, MA USA.
[Schumacher, Steven E.] MIT, Cambridge, MA USA.
[Schumacher, Steven E.; Beroukhim, Rameen; Chan, Timothy A.] Dana Farber Canc Inst, Dept Canc Biol, Cambridge, MA USA.
[Schumacher, Steven E.; Beroukhim, Rameen; Chan, Timothy A.] Weill Cornell Coll Med, New York, NY USA.
[Tang, Fanying; Chan, Timothy A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA.
[Beroukhim, Rameen] Dana Farber Canc Inst, Ctr Canc Genome Characterizat, Boston, MA USA.
[Beroukhim, Rameen; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY USA.
[Beroukhim, Rameen; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Immunogen & Precis Oncol Platform, New York, NY USA.
RP Chan, TA (reprint author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 10065, New York, NY USA.
EM chant@mskcc.org
FU National Institutes of Health [RO1 NS086875-01, R01 CA188228]; MSKCC
Brain Tumor Center; Sontag Foundation; Pediatric Low-Grade Astrocytoma
Foundation; Frederick Adler Fund; Paine Webber Chair
FX This work was supported by the National Institutes of Health (RO1
NS086875-01 and R01 CA188228) (T.A.C. and R.B.), the MSKCC Brain Tumor
Center (T.A.C.), the Sontag Foundation (T.A.C. and R.B.), the Pediatric
Low-Grade Astrocytoma Foundation (R.B.), the Frederick Adler Fund
(T.A.C.), and the Paine Webber Chair (T.A.C.).
NR 46
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD FEB
PY 2017
VL 19
IS 2
BP 75
EP 83
DI 10.1016/j.neo.2016.12.006
PG 9
WC Oncology
SC Oncology
GA EO9JO
UT WOS:000397005200003
PM 28038320
ER
PT J
AU Jones, C
Karajannis, MA
Jones, DTW
Kieran, MW
Monje, M
Baker, SJ
Becher, OJ
Cho, YJ
Gupta, N
Hawkins, C
Hargrave, D
Haas-Kogan, DA
Jabado, N
Li, XN
Mueller, S
Nicolaides, T
Packer, RJ
Persson, AI
Phillips, JJ
Simonds, EF
Stafford, JM
Tang, YJ
Pfister, SM
Weiss, WA
AF Jones, Chris
Karajannis, Matthias A.
Jones, David T. W.
Kieran, Mark W.
Monje, Michelle
Baker, Suzanne J.
Becher, Oren J.
Cho, Yoon-Jae
Gupta, Nalin
Hawkins, Cynthia
Hargrave, Darren
Haas-Kogan, Daphne A.
Jabado, Nada
Li, Xiao-Nan
Mueller, Sabine
Nicolaides, Theo
Packer, Roger J.
Persson, Anders I.
Phillips, Joanna J.
Simonds, Erin F.
Stafford, James M.
Tang, Yujie
Pfister, Stefan M.
Weiss, William A.
TI Pediatric high-grade glioma: biologically and clinically in need of new
thinking
SO NEURO-ONCOLOGY
LA English
DT Article
DE clinical trials; DIPG; genomics; glioma; pediatric
ID INTRINSIC PONTINE GLIOMA; CHILDRENS ONCOLOGY GROUP; BRAIN-STEM GLIOMA;
CANCER-STUDY-GROUP; PHASE-III TRIAL; MALIGNANT GLIOMAS;
HYPERFRACTIONATED RADIOTHERAPY; PILOCYTIC ASTROCYTOMAS; THERAPEUTIC
TARGETS; GENOMIC LANDSCAPE
AB High-grade gliomas in children are different from those that arise in adults. Recent collaborative molecular analyses of these rare cancers have revealed previously unappreciated connections among chromatin regulation, developmental signaling, and tumorigenesis. As we begin to unravel the unique developmental origins and distinct biological drivers of this heterogeneous group of tumors, clinical trials need to keep pace. It is important to avoid therapeutic strategies developed purely using data obtained from studies on adult glioblastoma. This approach has resulted in repetitive trials and ineffective treatments being applied to these children, with limited improvement in clinical outcome. The authors of this perspective, comprising biology and clinical expertise in the disease, recently convened to discuss the most effective ways to translate the emerging molecular insights into patient benefit. This article reviews our current understanding of pediatric high-grade glioma and suggests approaches for innovative clinical management.
C1 [Jones, Chris] Inst Canc Res, Div Mol Pathol, London, England.
[Jones, Chris] Inst Canc Res, Div Canc Therapeut, London, England.
[Karajannis, Matthias A.] NYU, Langone Med Ctr, Div Pediat Hematol Oncol, New York, NY USA.
[Jones, David T. W.; Pfister, Stefan M.] German Canc Res Ctr, Div Pediat Neurooncol, Heidelberg, Germany.
[Pfister, Stefan M.] Univ Heidelberg Hosp, Dept Pediat Hematol & Oncol, Heidelberg, Germany.
[Kieran, Mark W.] Dana Farber Canc Inst, Pediat Med Neurooncol, Boston, MA 02115 USA.
[Monje, Michelle; Cho, Yoon-Jae] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA USA.
[Baker, Suzanne J.] St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.
[Becher, Oren J.] Duke Univ, Med Ctr, Dept Pediat, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA.
[Becher, Oren J.] Duke Univ, Med Ctr, Dept Pathol, Preston Robert Tisch Brain Tumor Ctr, Durham, NC 27710 USA.
[Gupta, Nalin; Mueller, Sabine; Nicolaides, Theo; Persson, Anders I.; Phillips, Joanna J.; Simonds, Erin F.; Weiss, William A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.
[Gupta, Nalin; Mueller, Sabine; Nicolaides, Theo; Persson, Anders I.; Phillips, Joanna J.; Simonds, Erin F.; Weiss, William A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Gupta, Nalin; Mueller, Sabine; Nicolaides, Theo; Persson, Anders I.; Phillips, Joanna J.; Simonds, Erin F.; Weiss, William A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
[Hawkins, Cynthia] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumour Res Ctr, Toronto, ON, Canada.
[Hargrave, Darren] Great Ormond St Hosp Sick Children, Neurooncol & Expt Therapeut, London, England.
[Haas-Kogan, Daphne A.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Jabado, Nada] McGill Univ, Dept Pediat, Montreal, PQ, Canada.
[Li, Xiao-Nan] Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Brain Tumor Program, Houston, TX 77030 USA.
[Packer, Roger J.] Childrens Natl Hlth Syst, Ctr Neurosci & Behav Med, Washington, DC USA.
[Stafford, James M.] NYU, Dept Biochem, Langone Med Ctr, New York, NY 10016 USA.
[Tang, Yujie] Shanghai Jiao Tong Univ, Sch Med, Key Lab Cell Differentiat & Apoptosis, Natl Minist Educ,Dept Pathophysiol, Shanghai, Peoples R China.
RP Jones, C (reprint author), Inst Canc Res, Div Mol Pathol, 15 Cotswold Rd, Sutton, Surrey, England.; Jones, C (reprint author), Inst Canc Res, Div Canc Therapeut, 15 Cotswold Rd, Sutton, Surrey, England.
EM chris.jones@icr.ac.uk
NR 90
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD FEB
PY 2017
VL 19
IS 2
BP 153
EP 161
DI 10.1093/neuonc/now101
PG 9
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA EP3KF
UT WOS:000397280500003
ER
PT J
AU Rosenberg, S
Verreault, M
Schmitt, C
Guegan, J
Guehennec, J
Levasseur, C
Marie, Y
Bielle, F
Mokhtari, K
Hoang-Xuan, K
Ligon, K
Sanson, M
Delattre, JY
Idbaih, A
AF Rosenberg, Shai
Verreault, Maite
Schmitt, Charlotte
Guegan, Justine
Guehennec, Jeremy
Levasseur, Camille
Marie, Yannick
Bielle, Franck
Mokhtari, Karima
Hoang-Xuan, Khe
Ligon, Keith
Sanson, Marc
Delattre, Jean-Yves
Idbaih, Ahmed
TI Multi-omics analysis of primary glioblastoma cell lines shows
recapitulation of pivotal molecular features of parental tumors
SO NEURO-ONCOLOGY
LA English
DT Article
DE cancer; cell lines; genome; glioblastoma
ID LUNG-CANCER; HETEROGENEITY; CHALLENGES; SIGNATURES; MUTATIONS;
LANDSCAPE; PROFILES; SUBTYPES; SAMPLES; MODELS
AB Background. Glioblastoma (GBM) is the deadliest primary brain cancer in adults. Emerging innovative therapies hold promise for personalized cancer treatment. Improving therapeutic options depends on research relying on relevant preclinical models. In this line we have established in the setting of the GlioTex project (GBM and Experimental Therapeutics) a GBM patient-derived cell line (GBM-PDCL) library. A multi-omic approach was used to determine the molecular landscape of PDCL and the extent to which they represent GBM tumors.
Methods. Single nucleotide polymorphism array, expression arrays, exome sequencing, and RNA sequencing were used to measure and compare the molecular landscapes of 20 samples representing 10 human GBM tumors and paired GBM-PDCLs.
Results. Copy number variations were similar for a median of 85% of the genome and for 59% of the major focal events. Somatic point mutations were similar in a median of 41%. Mutations in GBM driver and " druggable" genes were maintained in 67% of events. Mutations that were not conserved in the PDCL were mainly low allelic fraction and/ or non-driver mutations. Based on RNA expression profiling, PDCLs cluster closely to their parental tumor with overexpression of pathways associated with cancer progression in PDCL.
Conclusions. Overall, PDCLs recapitulate pivotal molecular alterations of paired-parental tumors supporting their use as a preclinical model of GBM. However, some driver aberrations are lost or gained in the passage from tumor to PDCL. Our results support using PDCL as a relevant preclinical model of GBM. Further investigations of changes between PDCLs and their parental tumor may provide insights into GBM biology.
C1 [Rosenberg, Shai; Verreault, Maite; Schmitt, Charlotte; Guegan, Justine; Levasseur, Camille; Bielle, Franck; Mokhtari, Karima; Hoang-Xuan, Khe; Sanson, Marc; Delattre, Jean-Yves; Idbaih, Ahmed] UPMC Univ Paris 06, Sorbonne Univ, INSERM,U1127,CNRS,UMR 7225, UMR S 1127,Inst Cerveau & Moelle Epiniere,ICM, F-75013 Paris, France.
[Guegan, Justine] ICM, IHU A ICM, Bioinformat Biostat Core Facil, Inst Cerveau & Moelle Epiniere, F-75013 Paris, France.
[Marie, Yannick] Inst Cerveau & Moelle Epiniere ICM, Plateforme Gonotypage Sequencage, F-75013 Paris, France.
[Bielle, Franck; Mokhtari, Karima] Hop Univ La Pitie Salpetriere Charles Foix, AP HP, Serv Neuropathol Escourolle, F-75013 Paris, France.
[Hoang-Xuan, Khe; Sanson, Marc; Delattre, Jean-Yves; Idbaih, Ahmed] Hop Univ La Pitie Salpetriere Charles Foix, AP HP, Serv Neurol Mazarin 2, 47-83 Blvd Hop, F-75013 Paris, France.
[Rosenberg, Shai] Hadassah Hebrew Univ, Med Ctr, Jerusalem, Israel.
[Ligon, Keith] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Idbaih, A (reprint author), Hop Univ La Pitie Salpetriere Charles Foix, AP HP, Serv Neurol Mazarin 2, 47-83 Blvd Hop, F-75013 Paris, France.
EM ahmed.idbaih@aphp.fr
FU Foundation ARC pour la Recherche sur le Cancer; Institut Universitaire
de Cancerologie (IUC); OncoNeuroTheque; Hadassah France
FX This work is part of the GlioTex (Glioblastoma and Experimental
Therapeutics) project funded by the Foundation ARC pour la Recherche sur
le Cancer; The Institut Universitaire de Cancerologie (IUC);
OncoNeuroTheque; Hadassah France.
NR 28
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD FEB
PY 2017
VL 19
IS 2
BP 219
EP 228
DI 10.1093/neuonc/now160
PG 10
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA EP3KF
UT WOS:000397280500009
ER
PT J
AU Wahl, M
Phillips, JJ
Molinaro, AM
Lin, Y
Perry, A
Haas-Kogan, DA
Costello, JF
Dayal, M
Butowski, N
Clarke, JL
Prados, M
Nelson, S
Berger, MS
Chang, SM
AF Wahl, Michael
Phillips, Joanna J.
Molinaro, Annette M.
Lin, Yi
Perry, Arie
Haas-Kogan, Daphne A.
Costello, Joseph F.
Dayal, Manisha
Butowski, Nicholas
Clarke, Jennifer L.
Prados, Michael
Nelson, Sarah
Berger, Mitchel S.
Chang, Susan M.
TI Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular
subtype in a phase II study of adjuvant temozolomide
SO NEURO-ONCOLOGY
LA English
DT Article
DE clinical trials; low-grade glioma; molecular markers
ID RADIATION-THERAPY; HEMISPHERIC GLIOMAS; RESPONSE ASSESSMENT; PLUS
PROCARBAZINE; RANDOMIZED-TRIAL; TERM; OLIGODENDROGLIOMA; RADIOTHERAPY;
RESECTION; EXTENT
AB Background. Optimal adjuvant management of adult low-grade gliomas is controversial. Recently described tumor classification based on molecular subtype has the potential to individualize adjuvant therapy but has not yet been evaluated as part of a prospective trial.
Methods. Patients aged 18 or older with newly diagnosed World Health Organization grade II low-grade gliomas and gross residual disease after surgical resection were enrolled in the study. Patients received monthly cycles of temozolomide for up to 1 year or until disease progression. For patients with available tissue, molecular subtype was assessed based upon 1p/19q codeletion and isocitrate dehydrogenase-1 R132H mutation status. The primary outcome was radiographic response rate; secondary outcomes included progression-free survival (PFS) and overall survival (OS).
Results. One hundred twenty patients were enrolled with median follow-up of 7.5 years. Overall response rate was 6%, with median PFS and OS of 4.2 and 9.7 years, respectively. Molecular subtype was associated with rate of disease progression during treatment (P<. 001), PFS (P=. 007), and OS (P<. 001). Patients with 1p/19q codeletion demonstrated a 0% risk of progression during treatment. In an exploratory analysis, pretreatment lesion volume was associated with both PFS (P<. 001) and OS (P<. 001).
Conclusions. While our study failed to meet the primary endpoint for objective radiographic response, patients with high-risk low-grade glioma receiving adjuvant temozolomide demonstrated a high rate of radiographic stability and favorable survival outcomes while meaningfully delaying radiotherapy. Patients with 1p/19q codeletion are potential candidates for omission of adjuvant radiotherapy, but further work is needed to directly compare chemotherapy with combined modality therapy.
C1 [Wahl, Michael] Univ Calif San Francisco, Dept Radiat Oncol, 1600 Div St,Suite H1031, San Francisco, CA 94143 USA.
[Phillips, Joanna J.; Perry, Arie] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA.
[Phillips, Joanna J.; Molinaro, Annette M.; Lin, Yi; Perry, Arie; Costello, Joseph F.; Butowski, Nicholas; Clarke, Jennifer L.; Prados, Michael; Berger, Mitchel S.; Chang, Susan M.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA.
[Molinaro, Annette M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA.
[Lin, Yi] China Med Univ, Affiliated Hosp 1, Dept Neurosurg, Taichung, Taiwan.
[Haas-Kogan, Daphne A.] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA.
[Dayal, Manisha; Nelson, Sarah] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA USA.
[Clarke, Jennifer L.; Nelson, Sarah] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Clarke, Jennifer L.; Nelson, Sarah] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA USA.
RP Wahl, M (reprint author), Univ Calif San Francisco, Dept Radiat Oncol, 1600 Div St,Suite H1031, San Francisco, CA 94143 USA.
EM Michael.Wahl@ucsf.edu
FU Roche; Dabierre family
FX This study was funded by Roche, with support from the Dabierre family.
NR 41
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD FEB
PY 2017
VL 19
IS 2
BP 242
EP 251
DI 10.1093/neuonc/now176
PG 10
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA EP3KF
UT WOS:000397280500011
ER
PT J
AU Coutinho, AM
Coutu, JP
Lindemer, ER
Rosas, HD
Rosen, BR
Salat, DH
AF Coutinho, Artur Martins
Coutu, Jean-Philippe
Lindemer, Emily Rose
Rosas, H. Diana
Rosen, Bruce R.
Salat, David H.
TI Differential associations between systemic markers of disease and
cortical thickness in healthy middle-aged and older adults
SO NEUROIMAGE
LA English
DT Article
DE Magnetic resonance imaging; Gray matter; Aging; Insulin; Kidney;
Cholesterol
ID HUMAN CEREBRAL-CORTEX; MAGNETIC-RESONANCE IMAGES; MILD COGNITIVE
IMPAIRMENT; SURFACE-BASED ANALYSIS; TEMPORAL-LOBE ATROPHY; WHITE-MATTER
LESIONS; ALZHEIMERS-DISEASE; DIABETES-MELLITUS; BLOOD-PRESSURE; BRAIN
VOLUME
AB Aside from cortical damage associated with age, cerebrovascular and neurodegenerative diseases, it's an outstanding question if factors of global health, including normal variation in blood markers of metabolic and systemic function, may also be associated with individual variation in brain structure. This cross-sectional study included 138 individuals between 40 to 86 years old who were physically healthy and cognitively intact. Eleven markers (total cholesterol, HDL, LDL, triglycerides, insulin, fasting glucose, glycated hemoglobin, creatinine, blood urea nitrogen, albumin, total protein) and five derived indicators (estimated glomerular filtration rate, creatinine clearance rate, insulin-resistance, average glucose, and cholesterol/HDL ratio) were obtained from blood sampling of all participants. Ti-weighted 3T MRI scans were used to evaluate gray matter cortical thickness. The markers were clustered into five factors, and factor scores were related to cortical thickness by general linear model. Two factors, one linked to insulin/metabolic health and the other to kidney function (KFF) showed regionally selective associations with cortical thickness including lateral and medial temporal, temporoparietal, and superior parietal regions for both factors and frontoparietal regions for KFF. An association between the increasing cholesterol and greater thickness in frontoparietal and occipital areas was also noted. Associations persisted independently of age, presence of cardiovascular risk factors and ApoE gene status. These findings may provide information on distinct mechanisms of inter-individual cortical variation as well as factors contributing to trajectories of cortical thinning with advancing age.
C1 [Coutinho, Artur Martins; Coutu, Jean-Philippe; Lindemer, Emily Rose; Rosas, H. Diana; Rosen, Bruce R.; Salat, David H.] Harvard Med Sch, Massachusetts Gen Hosp, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Charlestown, MA USA.
[Coutinho, Artur Martins] Univ Sao Paulo, Dept Radiol, Sch Med, Ctr Med Nucl LIM 43, Sao Paulo, Brazil.
[Coutinho, Artur Martins] Hosp Sirio Libanes, Nucl Med & PET CT Serv, Sao Paulo, Brazil.
[Coutu, Jean-Philippe] Biospective Inc, Montreal, PQ, Canada.
[Lindemer, Emily Rose] MIT, Harvard Massachusetts Inst Technol Div Hlth Sci &, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Rosas, H. Diana] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA.
[Rosen, Bruce R.; Salat, David H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA.
[Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA USA.
RP Coutinho, AM (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Room 2301,149 13th St, Charlestown, MA 02129 USA.
EM artur.coutinho@hc.fm.usp.br
FU National Institutes of Health NIH [R01NR010827, NS042861, NS058793];
Center for Functional Neuroimaging Technologies [P41RR14075]; Biomedical
Technology Program of the National Center for Research Resources (NCRR);
NCRR Shared Instrumentation Grant Program; High-End Instrumentation
Grant Program [S1ORR021110, S10RR019307, S10RR019254, S10RR023043]
FX This work was supported by the National Institutes of Health NIH (grant
number R01NR010827, using resources provided by NIH grants NS042861,
NS058793); by the Center for Functional Neuroimaging Technologies
(P41RR14075), a P41 Regional Resource supported by the Biomedical
Technology Program of the National Center for Research Resources (NCRR),
NIH; and by the NCRR Shared Instrumentation Grant Program and/or
High-End Instrumentation Grant Program (grant numbers S1ORR021110, ,
S10RR019307, S10RR019254 and S10RR023043).
NR 57
TC 0
Z9 0
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD FEB 1
PY 2017
VL 146
BP 19
EP 27
DI 10.1016/j.neuroimage.2016.11.021
PG 9
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA EL3ZX
UT WOS:000394560700002
PM 27847345
ER
PT J
AU Piantoni, G
Halgren, E
Cash, SS
AF Piantoni, Giovanni
Halgren, Eric
Cash, Sydney S.
TI Spatiotemporal characteristics of sleep spindles depend on cortical
location
SO NEUROIMAGE
LA English
DT Article
DE Sleep; Spindles; Local; Co-occurrence; Propagation
ID SURFACE-BASED ANALYSIS; EYE-MOVEMENT SLEEP; HUMAN K-COMPLEX; SLOW
OSCILLATION; INDIVIDUAL-DIFFERENCES; EPILEPTIC ACTIVITY; INTRACRANIAL
EEG; CEREBRAL-CORTEX; HUMANS; BRAIN
AB Since their discovery almost one century ago, sleep spindles, 0.5-2 s long bursts of oscillatory activity at 9-16 Hz during NREM sleep, have been thought to be global and relatively uniform throughout the cortex. Recent work, however, has brought this concept into question but it remains unclear to what degree spindles are global or local and if their properties are uniform or location-dependent. We addressed this question by recording sleep in eight patients undergoing evaluation for epilepsy with intracranial electrocorticography, which combines high spatial resolution with extensive cortical coverage.
We find that spindle characteristics are not uniform but are strongly influenced by the underlying cortical regions, particularly for spindle density and fundamental frequency. We observe both highly isolated and spatially distributed spindles, but in highly skewed proportions: while most spindles are restricted to one or very few recording channels at any given time, there are spindles that occur over widespread areas, often involving lateral prefrontal cortices and superior temporal gyri. Their co-occurrence is affected by a subtle but significant propagation of spindles from the superior prefrontal regions and the temporal cortices towards the orbitofrontal cortex.
This work provides a brain-wide characterization of sleep spindles as mostly local graphoelements with heterogeneous characteristics that depend on the underlying cortical area. We propose that the combination of local characteristics and global organization reflects the dual properties of the thalamo-cortical generators and provides a flexible framework to support the many functions ascribed to sleep in general and spindles specifically.
C1 [Piantoni, Giovanni; Cash, Sydney S.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Piantoni, Giovanni; Cash, Sydney S.] Harvard Med Sch, Boston, MA USA.
[Halgren, Eric] Univ Calif San Diego, La Jolla, CA 92093 USA.
RP Piantoni, G (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA.
EM gio@gpiantoni.com
FU BIAL Foundation [220/12]; Office of Naval Research [N00014-13-1-0672];
National Institute of Health [R01 EB009282, MH099645]
FX This work was supported by BIAL Foundation (220/12) to GP; Office of
Naval Research (N00014-13-1-0672); and National Institute of Health (R01
EB009282 and MH099645). We thank Jason Naftulin and Mia Borzello for
their support and assistance in gathering data; Jean-Baptiste
Eichenlaub, Alice Lam, and Sujith Vijayan for helpful comments on the
manuscript; the staff of the Epilepsy Monitoring Unit at MGH for
technical assistance; and the patients for their participation.
NR 74
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD FEB 1
PY 2017
VL 146
BP 236
EP 245
DI 10.1016/j.neuroimage.2016.11.010
PG 10
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA EL3ZX
UT WOS:000394560700021
PM 27840241
ER
PT J
AU Williams, VJ
Hayes, JP
Forman, DE
Salat, DH
Sperling, RA
Verfaellie, M
Hayes, SM
AF Williams, Victoria J.
Hayes, Jasmeet P.
Forman, Daniel E.
Salat, David H.
Sperling, Reisa A.
Verfaellie, Mieke
Hayes, Scott M.
TI Cardiorespiratory fitness is differentially associated with cortical
thickness in young and older adults
SO NEUROIMAGE
LA English
DT Article
DE Aerobic fitness; Physical activity; Lifespan; Aging; Brain maintenance;
MRI
ID WHITE-MATTER INTEGRITY; VOXEL-BASED MORPHOMETRY; SURFACE-BASED ANALYSIS;
HUMAN CEREBRAL-CORTEX; AGE-RELATED-CHANGES; PHYSICAL-ACTIVITY; AEROBIC
FITNESS; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; COORDINATE SYSTEM
AB Aging is associated with reductions in gray matter volume and cortical thickness. One factor that may play a role in mitigating age-associated brain decline is cardiorespiratory fitness (CRF). Although previous work has identified a positive association between CRF and gray matter volume, the relationship between CRF and cortical thickness, which serves as a more sensitive indicator of gray matter integrity, has yet to be assessed in healthy young and older adults. To address this gap in the literature, 32 young and 29 older adults completed treadmill-based progressive maximal exercise testing to assess CRF (peak VO2), and structural magnetic resonance imaging (MRI) to determine vertex-wise surface-based cortical thickness metrics. Results indicated a significant CRF by age group interaction such that Peak VO2 was associated with thicker cortex in older adults but with thinner cortex in young adults. Notably, the majority of regions demonstrating a positive association between peak VO2 and cortical thickness in older adults overlapped with brain regions showing significant age related cortical thinning. Further, when older adults were categorized as high or low fit based on normative data, we observed a stepwise pattern whereby cortex was thickest in young adults, intermediate in high fit older adults and thinnest in low fit older adults. Overall, these results support the notion that CRF-related neuroplasticity may reduce although not eliminate age-related cortical atrophy.
C1 [Williams, Victoria J.; Verfaellie, Mieke; Hayes, Scott M.] VA Boston Healthcare Syst, Memory Disorders Res Ctr, 151A,150 South Huntington Ave, Boston, MA 02130 USA.
[Williams, Victoria J.; Verfaellie, Mieke; Hayes, Scott M.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Williams, Victoria J.; Hayes, Jasmeet P.; Salat, David H.; Verfaellie, Mieke; Hayes, Scott M.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA USA.
[Hayes, Jasmeet P.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Hayes, Jasmeet P.; Verfaellie, Mieke; Hayes, Scott M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Forman, Daniel E.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Forman, Daniel E.] Univ Pittsburgh, Med Ctr, Geriatr Cardiol Sect, Pittsburgh, PA USA.
[Salat, David H.] MGH Radiol, Athinoula A Martins Ctr Biomed Imaging, Charlestown, MA USA.
[Sperling, Reisa A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA.
[Sperling, Reisa A.] Brigham & Womens Hosp, Dept Neurol, Ctr Alzheimers Res & Treatment, 75 Francis St, Boston, MA 02115 USA.
RP Williams, VJ (reprint author), VA Boston Healthcare Syst, Memory Disorders Res Ctr, 151A,150 South Huntington Ave, Boston, MA 02130 USA.
EM tori85@gmail.com
FU Department of Veterans Affairs, Rehabilitation, Research & Development
Service [e7822w]; Department of Veterans Affairs, Clinical Science
Research & Development Services; National Institute of Aging
[K24AG035007]
FX This work was supported by the Department of Veterans Affairs,
Rehabilitation, Research & Development Service (Career Development Award
e7822w awarded to S.M.H.), the Department of Veterans Affairs, Clinical
Science Research & Development Services (M.V.), and the National
Institute of Aging (K24AG035007 awarded to R.A.S.). Assistance with
participant recruitment was provided by the Massachusetts Alzheimer's
Disease Research Center (P50-AG005134), and the Boston University
Alzheimer's Disease Center (P30-AG13846). This work was further
supported with resources and use of facilities at the Neuroimaging
Research for Veterans Center, VA Boston Healthcare System. The authors
thank Kelly Allsup, M.A., Pantel Vokonas, M.D., Huiting Liu, M.A.,
Margaret Cadden, and Rebecca Lysiak for assistance with data collection.
The contents of this article do not represent the views of the U.S.
Department of Veterans Affairs, the National Institutes of Health, or
the United States Government. The authors have no conflicts of interest
to report.
NR 62
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
EI 1095-9572
J9 NEUROIMAGE
JI Neuroimage
PD FEB 1
PY 2017
VL 146
BP 1084
EP 1092
DI 10.1016/j.neuroimage.2016.10.033
PG 9
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA EL3ZX
UT WOS:000394560700094
PM 27989841
ER
PT J
AU Armstrong, RA
Mckee, AC
Stein, TD
Alvarez, VE
Cairns, NJ
AF Armstrong, R. A.
Mckee, A. C.
Stein, T. D.
Alvarez, V. E.
Cairns, N. J.
TI A quantitative study of tau pathology in 11 cases of chronic traumatic
encephalopathy
SO NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
LA English
DT Article
DE astrocytic tangles; chronic traumatic encephalopathy; neurofibrillary
tangles; principal components analysis; tau
ID ARGYROPHILIC GRAIN DISEASE; FRONTOTEMPORAL LOBAR DEGENERATION;
ALZHEIMERS-DISEASE; DEMENTIA-PUGILISTICA; DIAGNOSTIC-CRITERIA;
FRONTAL-CORTEX; PICKS-DISEASE; BRAIN-INJURY; HEAD-INJURY; NEUROPATHOLOGY
AB Aims: To quantify tau pathology of chronic traumatic encephalopathy (CTE) and investigate influence of dot-like lesions (DL), brain region, comorbidity and sporting career length. Methods: Densities of neurofibrillary tangles (NFT), astrocytic tangles (AT), DL, oligodendroglial inclusions (GI), neuropil threads (NT), vacuoles, neurons and enlarged neurons (EN) were measured in tau-immunoreactive sections of upper cortical laminae of frontal and temporal lobes, hippocampus (HC), amygdala and substantia nigra (SN) in 11 cases of CTE. Results: DL were a consistent finding in CTE. Densities of NFT, NT and DL were greatest in sectors CA1 and CA2 of the HC. Densities of AT were lower than NFT, small numbers of GI were recorded in temporal lobe and low densities of vacuoles and EN were consistently present. beta-Amyloid-containing neuritic plaques (NP) also occurred at low density. Densities of NFT, NT, DL and AT were greater in sulci than gyri, while vacuole density was greater in gyri. Principal components analysis (PCA) suggested that sporting career length and densities of NFT in entorhinal cortex, NT in CA2 and SN and vacuolation in the DG were significant sources of variation among cases. Conclusion: DL are frequent in CTE suggesting affinity with argyrophilic grain disease (AGD) and Parkinson's disease dementia (PD-Dem). Densities of AT in all regions and NT/DL in sectors CA2/4 were consistent features of CTE. The 11 cases are neuropathologically heterogeneous which may result from genetic diversity, and variation in anatomical pathways subjected to trauma.
C1 [Armstrong, R. A.] Aston Univ, Vis Sci, Birmingham B4 7ET, W Midlands, England.
[Mckee, A. C.] VA Boston HealthCare Syst, Boston, MA USA.
[Mckee, A. C.; Alvarez, V. E.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Mckee, A. C.; Stein, T. D.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.
[Stein, T. D.; Alvarez, V. E.] Dept Vet Affairs Med Ctr, Bedford, MA USA.
[Cairns, N. J.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.
[Cairns, N. J.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
RP Armstrong, RA (reprint author), Aston Univ, Vis Sci, Birmingham B4 7ET, W Midlands, England.
EM R.A.Armstrong@aston.ac.uk
FU National Institute of Neurological Disorders and Stroke [1UO1NS086659-
01]; Department of Veterans Affairs, the Veterans Affairs Biorepository
[CSP 501]; Translational Research Center for Traumatic Brain Injury and
Stress Disorders (TRACTS); Veterans Affairs Rehabilitation Research and
Development Traumatic Brain Injury Center of Excellence [B6796-C];
National Institute of Aging Boston University Alzheimer's Disease Center
[P30AG13846, 0572063345-5]; Charles F. and Joanne Knight Alzheimer's
Disease Research Center, Washington University School of Medicine, St.
Louis, MO, USA from the National Institute on Aging [P50 AG05681, P01
AG03991]
FX The authors gratefully acknowledge the use of the resources and
facilities at the Edith Nourse Rogers Memorial Veterans Hospital
(Bedford, MA, USA). We also gratefully acknowledge the help of all
members of the Chronic Traumatic Encephalopathy Program at Boston
University School of Medicine, VA Boston and the Bedford VA, as well as
the individuals and families whose participation and contributions made
this work possible. This work was supported by the National Institute of
Neurological Disorders and Stroke (1UO1NS086659- 01); Department of
Veterans Affairs, the Veterans Affairs Biorepository (CSP 501); the
Translational Research Center for Traumatic Brain Injury and Stress
Disorders (TRACTS); the Veterans Affairs Rehabilitation Research and
Development Traumatic Brain Injury Center of Excellence (B6796-C); and
the National Institute of Aging Boston University Alzheimer's Disease
Center (P30AG13846; supplement 0572063345-5). This work was supported by
the Charles F. and Joanne Knight Alzheimer's Disease Research Center,
Washington University School of Medicine, St. Louis, MO, USA (P50
AG05681 and P01 AG03991) from the National Institute on Aging.
NR 42
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-1846
EI 1365-2990
J9 NEUROPATH APPL NEURO
JI Neuropathol. Appl. Neurobiol.
PD FEB
PY 2017
VL 43
IS 2
BP 154
EP 166
DI 10.1111/nan.12323
PG 13
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA EO8JB
UT WOS:000396934200005
PM 26998921
ER
PT J
AU Waring, JD
Dimsdale-Zucker, HR
Flannery, S
Budson, AE
Kensinger, EA
AF Waring, J. D.
Dimsdale-Zucker, H. R.
Flannery, S.
Budson, A. E.
Kensinger, E. A.
TI Effects of mild cognitive impairment on emotional scene memory
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Aging; Mild cognitive impairment; Selective memory; Emotion; Divided
attention
ID ALZHEIMERS ASSOCIATION WORKGROUPS; OLDER-ADULTS; RECOGNITION MEMORY;
DIAGNOSTIC GUIDELINES; NATIONAL INSTITUTE; DIVIDED ATTENTION; FALSE
RECOGNITION; SELECTIVE MEMORY; NEURAL PROCESSES; WORKING-MEMORY
AB Young and older adults experience benefits in attention and memory for emotional compared to neutral information, but this memory benefit is greatly diminished in Alzheimer's disease (AD). Little is known about whether this impairment arises early or late in the time course between healthy aging and AD. This study compared memory for positive, negative, and neutral items with neutral backgrounds between patients with mild cognitive impairment (MCI) and healthy older adults. We also used a divided attention condition in older adults as a possible model for the deficits observed in MCI patients. Results showed a similar pattern of selective memory for emotional items while forgetting their backgrounds in older adults and MCI patients, but MCI patients had poorer memory overall. Dividing attention during encoding disproportionately reduced memory for backgrounds (versus items) relative to a full attention condition. Participants performing in the lower half on the divided attention task qualitatively and quantitatively mirrored the results in MCI patients. Exploratory analyses comparing lower- and higher-performing MCI patients showed that only higher-performing MCI patients had the characteristic scene memory pattern observed in healthy older adults. Together, these results suggest that the effects of emotion on memory are relatively well preserved for patients with MCI, although emotional memory patterns may start to be altered once memory deficits become more pronounced.
C1 [Waring, J. D.] St Louis Univ, Dept Psychol, Morrissey Hall,3700 Lindell Blvd, St Louis, MO 63103 USA.
[Waring, J. D.; Dimsdale-Zucker, H. R.; Kensinger, E. A.] Boston Coll, Dept Psychol, Chestnut Hill, MA 02167 USA.
[Dimsdale-Zucker, H. R.] Univ Calif Davis, Dept Psychol, Davis, CA 95616 USA.
[Flannery, S.; Budson, A. E.] VA Boston Healthcare Syst, Ctr Translat Cognit Neurosci, Boston, MA USA.
[Flannery, S.; Budson, A. E.] Boston Univ, Alzheimers Dis Ctr, Sch Med, Dept Neurol, Boston, MA USA.
RP Waring, JD (reprint author), St Louis Univ, Dept Psychol, Morrissey Hall,3700 Lindell Blvd, St Louis, MO 63103 USA.
EM waringjd@slu.edu
FU National Institutes of Health [MH080833, P30 AG13846]; Boston University
Alzheimer's Disease Center; American Psychological Association
FX Support for this research was provided by National Institutes of Health
grants MH080833 (EAK) and P30 AG13846 (AEB), the Boston University
Alzheimer's Disease Center, and the American Psychological Association
(JDW).
NR 72
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
EI 1873-3514
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD FEB
PY 2017
VL 96
BP 240
EP 248
DI 10.1016/j.neuropsychologia.2017.01.011
PG 9
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA EM3LQ
UT WOS:000395216900024
PM 28089697
ER
PT J
AU Gallinat, C
Keuthen, NJ
Stefini, A
Backenstrass, M
AF Gallinat, Christina
Keuthen, Nancy J.
Stefini, Annette
Backenstrass, Matthias
TI The assessment of skin picking in adolescence: psychometric properties
of the Skin Picking Scale-Revised (German version)
SO NORDIC JOURNAL OF PSYCHIATRY
LA English
DT Article
DE Excoriation; adolescence; skin picking scale; reliability; validity
ID EXPLORATORY FACTOR-ANALYSIS; SELF-REPORT INSTRUMENT;
PSYCHOLOGICAL-RESEARCH; BODY DISSATISFACTION; GENDER-DIFFERENCES;
QUALITY-ASSURANCE; PREVALENCE; STUDENTS; DERMATILLOMANIA; COMORBIDITY
AB Background: Skin picking disorder has received growing attention since the release of DSM-5, yet there are no evidence-based assessment instruments for adolescent samples.Aim: The present study examines the psychometric properties of the Skin Picking Scale-Revised (SPS-R, German version) in adolescents.Methods: A total of 76 adolescents (96% female) completed the SPS-R, the Clinical Psychological Diagnostic System (KPD-38), and a questionnaire assessing demographics and clinical characteristics online.Results: The SPS-R had high internal consistency (=0.89) and significant small-to-medium correlations with reduced competence skills, psychological impairment, general life satisfaction, social support, and social problems on the KPD-38. Similar to prior findings for adults, an exploratory factor analysis suggested a two-factor model for the SPS-R in adolescents. Group comparisons failed to show significant differences on SPS-R scores between participants with and without dermatological conditions.Conclusions: The current results suggest that the SPS-R can be useful in adolescent samples as a reliable and valid instrument for the assessment of skin picking severity. Future research investigating scale validity and factor structure in a clinical sample of adolescent skin pickers is warranted.
C1 [Gallinat, Christina] Univ Heidelberg Hosp, Ctr Psychotherapy Res, Bergheimer Str 54, D-69115 Heidelberg, Germany.
[Keuthen, Nancy J.] Harvard Med Sch, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA USA.
[Stefini, Annette] Univ Heidelberg Hosp, Gen Psychiat, Heidelberg, Germany.
[Backenstrass, Matthias] Hosp Stuttgart, Inst Clin Psychol, Stuttgart, Germany.
[Backenstrass, Matthias] Heidelberg Univ, Inst Psychol, Dept Clin Psychol & Psychotherapy, Heidelberg, Germany.
RP Gallinat, C (reprint author), Univ Heidelberg Hosp, Ctr Psychotherapy Res, Bergheimer Str 54, D-69115 Heidelberg, Germany.
EM christina.gallinat@med.uni-heidelberg.de
NR 29
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0803-9488
EI 1502-4725
J9 NORD J PSYCHIAT
JI Nord. J. Psychiatr.
PD FEB
PY 2017
VL 71
IS 2
BP 145
EP 150
DI 10.1080/08039488.2016.1259427
PG 6
WC Psychiatry
SC Psychiatry
GA EL2IE
UT WOS:000394442500010
PM 27885889
ER
PT J
AU Cummings, DE
Schauer, PR
AF Cummings, David E.
Schauer, Philip R.
TI Endoscopic Gastric Plication for Obesity: Where Might It Fit in the
Scheme of Things?
SO OBESITY
LA English
DT Editorial Material
ID SURGERY; WEIGHT
C1 [Cummings, David E.] Univ Washington, Seattle, WA 98195 USA.
[Cummings, David E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Schauer, Philip R.] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA.
RP Cummings, DE (reprint author), Univ Washington, Seattle, WA 98195 USA.; Cummings, DE (reprint author), VA Puget Sound Hlth Care Syst, Seattle, WA USA.
EM davidec@u.washington.edu
FU Johnson Johnson; Ethicon; Medtronic; The Medicines Company; Pacira
Pharmaceuticals
FX Dr. Cummings reports research funding from Johnson & Johnson, and he is
on the Scientific Advisory Board of Metavention. Dr. Schauer reports
grants and consulting fees from Ethicon, grants from Medtronic,
consulting fees from The Medicines Company, and grants from Pacira
Pharmaceuticals, as well as stock in SE Healthcare Quality Consulting
and SurgiQuest.
NR 7
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD FEB
PY 2017
VL 25
IS 2
BP 284
EP 285
DI 10.1002/oby.21766
PG 2
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA EL9WF
UT WOS:000394970100006
PM 28124503
ER
PT J
AU Pearl, RL
Wadden, TA
Hopkins, CM
Shaw, JA
Hayes, MR
Bakizada, ZM
Alfaris, N
Chao, AM
Pinkasavage, E
Berkowitz, RI
Alamuddin, N
AF Pearl, Rebecca L.
Wadden, Thomas A.
Hopkins, Christina M.
Shaw, Jena A.
Hayes, Matthew R.
Bakizada, Zayna M.
Alfaris, Nasreen
Chao, Ariana M.
Pinkasavage, Emilie
Berkowitz, Robert I.
Alamuddin, Naji
TI Association Between Weight Bias Internalization and Metabolic Syndrome
Among Treatment-Seeking Individuals with Obesity
SO OBESITY
LA English
DT Article
ID STIGMA; DISCRIMINATION; OVERWEIGHT; HEALTH; ADULTS; DEPRESSION; IMPACT;
METAANALYSIS; ATTITUDES; RACISM
AB Objective: Weight stigma is a chronic stressor that may increase cardiometabolic risk. Some individuals with obesity self-stigmatize ( i. e., weight bias internalization, WBI). No study to date has examined whether WBI is associated with metabolic syndrome.
Methods: Blood pressure, waist circumference, and fasting glucose, triglycerides, and high-density lipoprotein cholesterol were measured at baseline in 178 adults with obesity enrolled in a weight-loss trial. Medication use for hypertension, dyslipidemia, and prediabetes was included in criteria for metabolic syndrome. One hundred fifty-nine participants ( 88.1% female, 67.3% black, mean BMI541.1 kg/m(2)) completed the Weight Bias Internalization Scale and Patient Health Questionnaire ( PHQ-9, to assess depressive symptoms). Odds ratios and partial correlations were calculated adjusting for demographics, BMI, and PHQ-9 scores.
Results: Fifty-one participants ( 32.1%) met criteria for metabolic syndrome. Odds of meeting criteria for metabolic syndrome were greater among participants with higher WBI, but not when controlling for all covariates ( OR=1.46, 95% CI=1.00-2.13, P=0.052). Higher WBI predicted greater odds of having high triglycerides ( OR=1.88, 95% CI=1.14-3.09, P=0.043). Analyzed categorically, high ( vs. low) WBI predicted greater odds of metabolic syndrome and high triglycerides ( Ps<0.05).
Conclusions: Individuals with obesity who self-stigmatize may have heightened cardiometabolic risk. Biological and behavioral pathways linking WBI and metabolic syndrome require further exploration.
C1 [Pearl, Rebecca L.; Wadden, Thomas A.; Hopkins, Christina M.; Shaw, Jena A.; Hayes, Matthew R.; Bakizada, Zayna M.; Chao, Ariana M.; Pinkasavage, Emilie; Berkowitz, Robert I.; Alamuddin, Naji] Univ Penn, Dept Psychiat, Ctr Weight & Eating Disorders, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Hopkins, Christina M.] Duke Univ, Dept Psychol, Durham, NC 27706 USA.
[Hayes, Matthew R.] Univ Penn, Sch Nursing, Dept Biobehav Hlth Sci, Philadelphia, PA 19104 USA.
[Alfaris, Nasreen] Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, Weight Ctr, Boston, MA 02114 USA.
[Chao, Ariana M.] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA.
[Berkowitz, Robert I.] Childrens Hosp Philadelphia, Dept Psychiat & Behav Sci, Philadelphia, PA 19104 USA.
[Alamuddin, Naji] Univ Penn, Dept Med, Inst Diabet Obes & Metab, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Pearl, RL (reprint author), Univ Penn, Dept Psychiat, Ctr Weight & Eating Disorders, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM rpearl@mail.med.upenn.edu
FU Eisai Pharmaceutical Co.; NRSA postdoctoral fellowship from the NINR/NIH
[T32NR007100]
FX This study was supported by an investigator-initiated grant from Eisai
Pharmaceutical Co. (TAW). AMC was supported by an NRSA postdoctoral
fellowship from the NINR/NIH #T32NR007100.
NR 42
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD FEB
PY 2017
VL 25
IS 2
BP 317
EP 322
DI 10.1002/oby.21716
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA EL9WF
UT WOS:000394970100012
PM 28124502
ER
PT J
AU Thomas, GA
Cartmel, B
Harrigan, M
Fiellin, M
Capozza, S
Zhou, Y
Ercolano, E
Gross, CP
Hershman, D
Ligibel, J
Schmitz, K
Li, FY
Sanft, T
Irwin, ML
AF Thomas, Gwendolyn A.
Cartmel, Brenda
Harrigan, Maura
Fiellin, Martha
Capozza, Scott
Zhou, Yang
Ercolano, Elizabeth
Gross, Cary P.
Hershman, Dawn
Ligibel, Jennifer
Schmitz, Kathryn
Li, Fang-Yong
Sanft, Tara
Irwin, Melinda L.
TI The Effect of Exercise on Body Composition and Bone Mineral Density in
Breast Cancer Survivors Taking Aromatase Inhibitors
SO OBESITY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; ADJUVANT HORMONAL-THERAPY; POSTMENOPAUSAL
WOMEN; PHYSICAL-ACTIVITY; WEIGHT-LOSS; MASS INDEX; FOLLOW-UP; RISK;
PREVENTION; TAMOXIFEN
AB Objective: This study examined the effect of 12 months of aerobic and resistance exercise versus usual care on changes in body composition in postmenopausal breast cancer survivors taking aromatase inhibitors ( AIs).
Methods: The Hormones and Physical Exercise study enrolled 121 breast cancer survivors and randomized them to either supervised twice-weekly resistance exercise training and 150 min/wk of aerobic exercise ( N=61) or a usual care ( N=60) group. Dual-energy X-ray absorptiometry scans were conducted at baseline, 6 months, and 12 months to assess changes in body mass index, percent body fat, lean body mass, and bone mineral density.
Results: At 12 months, the exercise group relative to the usual care group had a significant increase in lean body mass ( 0.32 vs. -0.88 kg, P=0.03), a decrease in percent body fat ( -1.4% vs. 0.48%, P = 0.03), and a decrease in body mass index ( 0.73 vs. 0.17 kg/m(2), P=0.03). Change in bone mineral density was not significantly different between groups at 12 months ( 0.001 vs. -0.006 g/cm(2), P=0.37).
Conclusions: A combined resistance and aerobic exercise intervention improved body composition in breast cancer survivors taking AIs. Exercise interventions may help to mitigate the negative side effects of AIs and improve health outcomes in breast cancer survivors.
C1 [Thomas, Gwendolyn A.] Syracuse Univ, Dept Exercise Sci, Syracuse, NY 13210 USA.
[Cartmel, Brenda; Harrigan, Maura; Fiellin, Martha; Capozza, Scott; Zhou, Yang; Ercolano, Elizabeth; Gross, Cary P.; Li, Fang-Yong; Sanft, Tara; Irwin, Melinda L.] Yale Univ, Yale Canc Ctr, New Haven, CT USA.
[Hershman, Dawn] Columbia Univ, New York, NY USA.
[Ligibel, Jennifer] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Schmitz, Kathryn] Penn State Univ, Hershey, PA USA.
RP Thomas, GA (reprint author), Syracuse Univ, Dept Exercise Sci, Syracuse, NY 13210 USA.
EM gwthomas@syr.edu
OI Irwin, Michael/0000-0001-5801-274X
FU National Cancer Institute [R01 CA132931]; Breast Cancer Research
Foundation; Yale Cancer Center Support Grant [P30 CA016359]; Clinical
and Translational Science Award from the National Center for Advancing
Translational Science, a component of the National Institutes of Health
[UL1 TR000142]
FX This research was supported by National Cancer Institute Grant No. R01
CA132931 and in part by a grant from the Breast Cancer Research
Foundation (to MLI), Yale Cancer Center Support Grant No. P30 CA016359,
and Clinical and Translational Science Award Grant No. UL1 TR000142 from
the National Center for Advancing Translational Science, a component of
the National Institutes of Health. Certain data used in this study were
obtained from the Connecticut Tumor Registry, located in the Connecticut
Department of Public Health.
NR 37
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD FEB
PY 2017
VL 25
IS 2
BP 346
EP 351
DI 10.1002/oby.21729
PG 6
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA EL9WF
UT WOS:000394970100016
PM 28026901
ER
PT J
AU Xiao, L
Lv, N
Rosas, LG
Au, D
Ma, J
AF Xiao, Lan
Lv, Nan
Rosas, Lisa G.
Au, David
Ma, Jun
TI Validation of Clinic Weights from Electronic Health Records Against
Standardized Weight Measurements in Weight Loss Trials
SO OBESITY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; PRIMARY-CARE; LIFE-STYLE; UNITED-STATES;
OBESITY; INTERVENTION; VALIDITY; ADULTS
AB Objective: To validate clinic weights in electronic health records against researcher-measured weights for outcome assessment in weight loss trials.
Methods: Clinic and researcher-measured weights from a published trial ( BE WELL) were compared using Lin's concordance correlation coefficient, Bland and Altman's limits of agreement, and polynomial regression model. Changes in clinic and researcher-measured weights in BE WELL and another trial, ELITE, were analyzed using growth curve modeling.
Results: Among BE WELL ( n = 330) and E-LITE ( n = 241) participants, 96% and 90% had clinic weights ( mean [ SD] of 5.8 [ 6.1] and 3.7 [ 3.9] records) over 12 and 15 months of follow-up, respectively. The concordance correlation coefficient was 0.99, and limits of agreement plots showed no pattern between or within treatment groups, suggesting overall good agreement between researcher-measured and nearest-in-time clinic weights up to 3 months. The 95% confidence intervals for predicted percent differences fell within 63% for clinic weights within 3 months of the researcher-measured weights. Furthermore, the growth curve slopes for clinic and researcher-measured weights by treatment group did not differ significantly, suggesting similar inferences about treatment effects over time, in both trials.
Conclusions: Compared with researcher-measured weights, close-in-time clinic weights showed high agreement and inference validity. Clinic weights could be a valid pragmatic outcome measure in weight loss studies.
C1 [Xiao, Lan; Lv, Nan; Rosas, Lisa G.; Ma, Jun] Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA.
[Rosas, Lisa G.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA.
[Au, David] Univ Washington, Div Pulm & Crit Care Med, VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA 98195 USA.
[Ma, Jun] Univ Illinois, Dept Hlth Policy & Adm, Sch Publ Hlth, Chicago, IL 60607 USA.
[Ma, Jun] Univ Illinois, Div Acad Internal Med & Geriatr, Dept Med, Coll Med, Chicago, IL 60607 USA.
RP Ma, J (reprint author), Palo Alto Med Fdn, Res Inst, Palo Alto, CA 94301 USA.; Ma, J (reprint author), Univ Illinois, Dept Hlth Policy & Adm, Sch Publ Hlth, Chicago, IL 60607 USA.; Ma, J (reprint author), Univ Illinois, Div Acad Internal Med & Geriatr, Dept Med, Coll Med, Chicago, IL 60607 USA.
EM maj2015@uic.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases;
American Heart Association [0830362N]; National Heart, Lung, and Blood
Institute [R01HL094466]; Palo Alto Medical Foundation Research Institute
FX The E-LITE study was supported by grant R34DK080878 from the National
Institute of Diabetes and Digestive and Kidney Diseases and a Scientist
Development Grant award (0830362N) from the American Heart Association,
and the BE WELL study was supported by grant R01HL094466 from the
National Heart, Lung, and Blood Institute. This study was also supported
by internal funding from the Palo Alto Medical Foundation Research
Institute.
NR 21
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD FEB
PY 2017
VL 25
IS 2
BP 363
EP 369
DI 10.1002/oby.21737
PG 7
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA EL9WF
UT WOS:000394970100019
PM 28059466
ER
PT J
AU Wilson, ER
Kyle, TK
Nadglowski, JF
Stanford, FC
AF Wilson, Elizabeth Ruth
Kyle, Theodore K.
Nadglowski, Joseph F., Jr.
Stanford, Fatima Cody
TI Obesity Coverage Gap: Consumers Perceive Low Coverage for Obesity
Treatments Even When Workplace Wellness Programs Target BMI
SO OBESITY
LA English
DT Article
ID WEIGHT-LOSS; COST-EFFECTIVENESS; CLINICAL EFFECTIVENESS; FINANCIAL
INCENTIVES; OVERWEIGHT; SURGERY; EMPLOYEES; SAVINGS; ADULTS; STATES
AB Objective: Evidence-based obesity treatments, such as bariatric surgery, are not considered essential health benefits under the Affordable Care Act. Employer-sponsored wellness programs with incentives based on biometric outcomes are allowed and often used despite mixed evidence regarding their effectiveness. This study examines consumers' perceptions of their coverage for obesity treatments and exposure to workplace wellness programs.
Methods: A total of 7,378 participants completed an online survey during 2015-2016. Respondents answered questions regarding their health coverage for seven medical services and exposure to employer wellness programs that target weight or body mass index ( BMI). Using chi(2) tests, associations between perceptions of exposure to employer wellness programs and coverage for medical services were examined. Differences between survey years were also assessed.
Results: Most respondents reported they did not have health coverage for obesity treatments, but more of the respondents with employer wellness programs reported having coverage. Neither the perception of coverage for obesity treatments nor exposure to wellness programs increased between 2015 and 2016.
Conclusions: Even when consumers have exposure to employer wellness programs that target BMI, their health insurance often excludes obesity treatments. Given the clinical and cost-effectiveness of such treatments, reducing that coverage gap may mitigate obesity's individual-and population-level effects.
C1 [Wilson, Elizabeth Ruth] Harvard Kennedy Sch, Cambridge, MA USA.
[Kyle, Theodore K.] ConscienHealth, Pittsburgh, PA USA.
[Kyle, Theodore K.; Nadglowski, Joseph F., Jr.] Obes Act Coalit, Tampa, FL USA.
[Stanford, Fatima Cody] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med Gastroenterol, Weight Ctr, Boston, MA 02115 USA.
[Stanford, Fatima Cody] Harvard Med Sch, Dept Pediat Endocrinol, Weight Ctr, MGH, Boston, MA 02115 USA.
RP Stanford, FC (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Med Gastroenterol, Weight Ctr, Boston, MA 02115 USA.; Stanford, FC (reprint author), Harvard Med Sch, Dept Pediat Endocrinol, Weight Ctr, MGH, Boston, MA 02115 USA.
EM fstanford@mgh.harvard.edu
FU Obesity Action Coalition
FX This work was funded by the Obesity Action Coalition.
NR 33
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD FEB
PY 2017
VL 25
IS 2
BP 370
EP 377
DI 10.1002/oby.21746
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA EL9WF
UT WOS:000394970100020
PM 28063213
ER
PT J
AU Quinot, C
Dumas, O
Henneberger, PK
Varraso, R
Wiley, AS
Speizer, FE
Goldberg, M
Zock, JP
Camargo, CA
Le Moual, N
AF Quinot, C.
Dumas, O.
Henneberger, P. K.
Varraso, R.
Wiley, A. S.
Speizer, F. E.
Goldberg, M.
Zock, J. P.
Camargo, C. A., Jr.
Le Moual, N.
TI Development of a job-task-exposure matrix to assess occupational
exposure to disinfectants among US nurses
SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID HEALTH-CARE PROFESSIONALS; OBSTRUCTIVE PULMONARY-DISEASE; IN-HOSPITAL
WORKERS; NEW-ONSET ASTHMA; RISK-FACTORS; CLEANING PRODUCTS; WORKPLACE;
QUESTIONNAIRE; PERFORMANCE; PREVENTION
AB Objectives Occupational exposure to disinfectants is associated with work-related asthma, especially in healthcare workers. However, little is known about the specific products involved. To evaluate disinfectant exposures, we designed job-exposure (JEM) and job-task-exposure (JTEM) matrices, which are thought to be less prone to differential misclassification bias than self-reported exposure. We then compared the three assessment methods: self-reported exposure, JEM and JTEM.
Methods Disinfectant use was assessed by an occupational questionnaire in 9073 US female registered nurses without asthma, aged 49-68 years, drawn from the Nurses' Health Study II. A JEM was created based on self-reported frequency of use (1-3, 4-7 days/week) of 7 disinfectants and sprays in 8 nursing jobs. We then created a JTEM combining jobs and disinfection tasks to further reduce misclassification. Exposure was evaluated in 3 classes (low, medium, high) using product-specific cut-offs (eg, <30%, 30-49.9%, >= 50%, respectively, for alcohol); the cut-offs were defined from the distribution of self-reported exposure per job/task.
Results The most frequently reported disinfectants were alcohol (weekly use: 39%), bleach (22%) and sprays (20%). More nurses were classified as highly exposed by JTEM (alcohol 41%, sprays 41%, bleach 34%) than by JEM (21%, 30%, 26%, respectively). Agreement between JEM and JTEM was fair-to-moderate (kappa 0.3-0.5) for most disinfectants. JEM and JTEM exposure estimates were heterogeneous in most nursing jobs, except in emergency room and education/administration.
Conclusions The JTEM may provide more accurate estimates than the JEM, especially for nursing jobs with heterogeneous tasks. Use of the JTEM is likely to reduce exposure misclassification.
C1 [Quinot, C.; Dumas, O.; Varraso, R.; Goldberg, M.; Le Moual, N.] INSERM, U1168, VIMA Aging & Chron Dis, Epidemiol & Publ Hlth Approaches, F-94807 Villejuif, France.
[Quinot, C.; Dumas, O.; Varraso, R.; Goldberg, M.; Le Moual, N.] Univ Versailles St Quentin En Yvelines, UMR S 1168, F-78180 Montigny Le Bretonneux, France.
[Dumas, O.; Wiley, A. S.; Speizer, F. E.; Camargo, C. A., Jr.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
[Dumas, O.; Wiley, A. S.; Speizer, F. E.; Camargo, C. A., Jr.] Harvard Med Sch, Boston, MA USA.
[Dumas, O.; Camargo, C. A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Henneberger, P. K.] NIOSH, Div Resp Dis Studies, Morgantown, WV 26505 USA.
[Goldberg, M.] INSERM, UVSQ, UMS 011, Villejuif, France.
[Zock, J. P.] Netherlands Inst Hlth Serv Res NIVEL, Utrecht, Netherlands.
[Zock, J. P.] Ctr Res Environm Epidemiol CREAL, ISGlobal, Barcelona, Spain.
[Zock, J. P.] UPF, Barcelona, Spain.
[Zock, J. P.] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain.
RP Quinot, C (reprint author), INSERM, UMRS 1168, VIMA Aging & Chron Dis, Epidemiol & Publ Hlth Approaches, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.
EM catherine.quinot@inserm.fr
RI LeMoual, Nicole/R-8976-2016
OI LeMoual, Nicole/0000-0002-2723-5569
FU Centers for Disease Control and Prevention [R01 OH-10359]; National
Institutes of Health [UM1 CA176726]; Hubert Curien Partnerships for
French-Dutch cooperation; French Ministry of Higher Education and
Research; OCW Dutch Ministry (Ministerie van Onderwijs, Cultuur en
Wetenschap) [PHC Van Gogh 33653RF]; University of Versailles
Saint-Quentin-en-Yvelines EDSP doctoral grant
FX Centers for Disease Control and Prevention R01 OH-10359; National
Institutes of Health UM1 CA176726; Hubert Curien Partnerships for
French-Dutch cooperation, French Ministry of Higher Education and
Research and OCW Dutch Ministry (Ministerie van Onderwijs, Cultuur en
Wetenschap) PHC Van Gogh 33653RF; University of Versailles
Saint-Quentin-en-Yvelines EDSP doctoral grant.
NR 40
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1351-0711
EI 1470-7926
J9 OCCUP ENVIRON MED
JI Occup. Environ. Med.
PD FEB
PY 2017
VL 74
IS 2
BP 130
EP 137
DI 10.1136/oemed-2016-103606
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EL3KB
UT WOS:000394516900008
PM 27566782
ER
PT J
AU Rathi, VK
Wang, B
Ross, JS
Downing, NS
Kesselheim, AS
Gray, ST
AF Rathi, Vinay K.
Wang, Bo
Ross, Joseph S.
Downing, Nicholas S.
Kesselheim, Aaron S.
Gray, Stacey T.
TI Clinical Evidence Supporting US Food and Drug Administration Premarket
Approval of High-Risk Otolaryngologic Devices, 2000-2014
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE otolaryngology; medical device; FDA; premarket approval
ID MEDICAL DEVICES; FDA APPROVAL; THERAPY; TRIALS
AB The US Food and Drug Administration (FDA) approves high-risk medical devices based on premarket pivotal clinical studies demonstrating reasonable assurance of safety and effectiveness and may require postapproval studies (PAS) to further inform benefit-risk assessment. We conducted a cross-sectional analysis using publicly available FDA documents to characterize industry-sponsored pivotal studies and PAS of high-risk devices used in the treatment of otolaryngologic diseases. Between 2000 and 2014, the FDA approved 23 high-risk otolaryngologic devices based on 28 pivotal studies. Median enrollment was 118 patients (interquartile range, 67-181), and median duration of longest primary effectiveness end point follow-up was 26 weeks (interquartile range, 16-96). Fewer than half were randomized (n = 13, 46%), blinded (n = 12, 43%), or controlled (n = 10, 36%). The FDA required 23 PASs for 16 devices (70%): almost two-thirds (n = 15, 65%) monitored long-term performance, and roughly one-third (n = 8, 35%) focused on subgroups. Otolaryngologists should be aware of limitations in the strength of premarket evidence when considering the use of newly approved devices.
C1 [Rathi, Vinay K.; Wang, Bo; Ross, Joseph S.; Downing, Nicholas S.; Kesselheim, Aaron S.; Gray, Stacey T.] Massachusetts Eye & Ear Infirm, Dept Otolaryngology Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA.
RP Gray, ST (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngology Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA.
EM stacey_gray@meei.harvard.edu
NR 26
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
EI 1097-6817
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD FEB
PY 2017
VL 156
IS 2
BP 285
EP 288
DI 10.1177/0194599816684094
PG 4
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA EL8WP
UT WOS:000394901400010
PM 28093943
ER
PT J
AU Nipp, RD
Zanconato, A
Zheng, H
Ferrone, CR
Lillemoe, KD
Wo, JY
Hong, TS
Clark, JW
Ryan, DP
Fernandez-del Castillo, C
AF Nipp, Ryan D.
Zanconato, Andrea
Zheng, Hui
Ferrone, Cristina R.
Lillemoe, Keith D.
Wo, Jennifer Y.
Hong, Theodore S.
Clark, Jeffrey W.
Ryan, David P.
Fernandez-del Castillo, Carlos
TI Predictors of Early Mortality After Surgical Resection of Pancreatic
Adenocarcinoma in the Era of Neoadjuvant Treatment
SO PANCREAS
LA English
DT Article
DE pancreatic neoplasms; neoadjuvant therapy; combined modality therapy;
comorbidity; aged
ID AGE COMORBIDITY INDEX; CONSECUTIVE PANCREATICODUODENECTOMIES; DUCTAL
ADENOCARCINOMA; GERIATRIC ASSESSMENT; PROGNOSTIC-FACTORS; CANCER
STATISTICS; TUMOR GRADE; SURVIVAL; FOLFIRINOX; OUTCOMES
AB Objectives: Neoadjuvant treatments are increasingly used for patients with pancreatic ductal adenocarcinoma (PDAC), yet some experience early mortality after resection. We sought to identify predictors of early mortality after PDAC resection and determine their interaction with neo-adjuvant therapy.
Methods: We performed a retrospective study of patients with PDAC resection from March 2011 to March 2014. We compared those who died within one year after surgery to those living beyond 1 year, and those who received neoadjuvant therapy to those taken directly to surgery. We used logistic regression to identify predictors of early mortality and determine their interaction with neoadjuvant therapy.
Results: Of 191 patients who underwent resection, 59 (30.9%) died within 1 year and 79 (41.4%) received neoadjuvant therapy. Early mortality patients were older, with higher comorbidity, and more likely to have lymph node positivity. Patients receiving neoadjuvant therapy were younger, with lower comorbidity, and more likely to have upfront unresectable disease. Predictors of early mortality included: higher comorbidity, poorly differentiated tumor grade, and lymph node positivity. We found that neoadjuvant therapy moderated the effects of comorbidity and lymph node positivity on early mortality risk.
Conclusions: We identified predictors of early mortality after PDAC resection and determined their interaction with neoadjuvant therapy.
C1 [Nipp, Ryan D.; Clark, Jeffrey W.; Ryan, David P.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med Oncol, Boston, MA USA.
[Zanconato, Andrea; Ferrone, Cristina R.; Lillemoe, Keith D.; Fernandez-del Castillo, Carlos] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA.
[Zheng, Hui] Harvard Med Sch, Massachusetts Gen Hosp, Biostat Ctr, Boston, MA USA.
[Wo, Jennifer Y.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA USA.
RP Nipp, RD (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA.
EM RNipp@MGH.Harvard.edu
NR 50
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0885-3177
EI 1536-4828
J9 PANCREAS
JI Pancreas
PD FEB
PY 2017
VL 46
IS 2
BP 183
EP 189
DI 10.1097/MPA.0000000000000731
PG 7
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EL2JS
UT WOS:000394446500007
PM 27846142
ER
PT J
AU Hagmann, SHF
LaRocque, RC
Ryan, ET
AF Hagmann, Stefan H. F.
LaRocque, Regina C.
Ryan, Edward T.
TI Preparing Pediatric International Travelers for Travelers' Diarrhea
Insights From the Global TravEpiNet
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Letter
ID CHILDREN
C1 [Hagmann, Stefan H. F.] Steven & Alexandra Cohen Childrens Med Ctr New Yo, Div Pediat Infect Dis, New Hyde Pk, NY 11040 USA.
[Hagmann, Stefan H. F.] Hofstra Northwell Sch Med, Hempstead, NY 11549 USA.
[LaRocque, Regina C.; Ryan, Edward T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[LaRocque, Regina C.; Ryan, Edward T.] Harvard Univ, Dept Med, Boston, MA 02115 USA.
RP Hagmann, SHF (reprint author), Steven & Alexandra Cohen Childrens Med Ctr New Yo, Div Pediat Infect Dis, New Hyde Pk, NY 11040 USA.; Hagmann, SHF (reprint author), Hofstra Northwell Sch Med, Hempstead, NY 11549 USA.
EM shagmann@northwell.edu
FU NCEZID CDC HHS [U01 CK000175, U01 CK000490]
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD FEB
PY 2017
VL 36
IS 2
BP 242
EP 243
DI 10.1097/INF.0000000000001402
PG 3
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA EL1AI
UT WOS:000394352500030
PM 28079839
ER
PT J
AU Marathe, CS
Rayner, CK
Lange, K
Bound, M
Wishart, J
Jones, KL
Kahn, SE
Horowitz, M
AF Marathe, Chinmay S.
Rayner, Christopher K.
Lange, Kylie
Bound, Michelle
Wishart, Judith
Jones, Karen L.
Kahn, Steven E.
Horowitz, Michael
TI Relationships of the early insulin secretory response and oral
disposition index with gastric emptying in subjects with normal glucose
tolerance
SO PHYSIOLOGICAL REPORTS
LA English
DT Article
DE Gastric emptying; insulin secretory response; oral disposition index;
oral glucose tolerance test
ID DEPENDENT DIABETES-MELLITUS; GLUCAGON-LIKE PEPTIDE-1; INHIBITORY
POLYPEPTIDE; POSTPRANDIAL GLYCEMIA; INCRETIN RESPONSES; CARBOHYDRATE
MEAL; DUODENAL GLUCOSE; HEALTHY-SUBJECTS; HORMONES; EXTRACTION
AB The oral disposition index, the product of the early insulin secretory response during an oral glucose tolerance test and insulin sensitivity, is used widely for both the prediction of, and evaluation of the response to interventions, in type 2 diabetes. Gastric emptying, which determines small intestinal exposure of nutrients, modulates postprandial glycemia. The aim of this study was to determine whether the insulin secretory response and the disposition index (DI) related to gastric emptying in subjects with normal glucose tolerance. Thirty-nine subjects consumed a 350 mL drink containing 75 g glucose labeled with Tc-99m-sulfur colloid. Gastric emptying (by scintigraphy), blood glucose (G) and plasma insulin (I) were measured between t = 0-120 min. The rate of gastric emptying was derived from the time taken for 50% emptying (T-50) and expressed as kcal/min. The early insulin secretory response was estimated by the ratio of the change in insulin (Delta I0-30) to that of glucose at 30 min (Delta G(0-30)) represented as Delta I0-30/Delta G(0-30). Insulin sensitivity was estimated as 1/fasting insulin and the DI was then calculated as Delta I0-30/Delta G(0-30) x 1/fasting insulin. There was a direct relationship between Delta G(0-30) and gastric emptying (r = 0.47, P = 0.003). While there was no association of either Delta I0-30 (r = -0.16, P = 0.34) or fasting insulin (r = 0.21, P = 0.20), there were inverse relationships between the early insulin secretory response (r = -0.45, P = 0.004) and the DI (r = -0.33, P = 0.041), with gastric emptying. We conclude that gastric emptying is associated with both insulin secretion and the disposition index in subjects with normal glucose tolerance, such that when gastric emptying is relatively more rapid, both the early insulin secretory response and the disposition index are less. These findings should be interpreted as "hypothesis generating" and provide the rationale for longitudinal studies to examine the impact of baseline rate of gastric emptying on the prospective risk of type 2 diabetes.
C1 [Marathe, Chinmay S.; Rayner, Christopher K.; Lange, Kylie; Bound, Michelle; Wishart, Judith; Jones, Karen L.; Horowitz, Michael] Univ Adelaide, Royal Adelaide Hosp, Discipline Med, Adelaide, SA, Australia.
[Marathe, Chinmay S.; Rayner, Christopher K.; Lange, Kylie; Bound, Michelle; Wishart, Judith; Jones, Karen L.; Horowitz, Michael] Univ Adelaide, Ctr Res Excellence Translating Nutr Sci Good Hlth, Adelaide, SA, Australia.
[Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA USA.
[Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA.
RP Marathe, CS (reprint author), Univ Adelaide, Royal Adelaide Hosp, Ctr Res Excellence CRE Translating Nutr Sci Good, Adelaide, SA 5005, Australia.
EM chinmaymarathe@gmail.com
FU National Health and Medical Research Council, Australia
FX This study was funded by a grant from the National Health and Medical
Research Council, Australia.
NR 29
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2051-817X
J9 PHYSIOL REP
JI PHYSIOL. REP.
PD FEB
PY 2017
VL 5
IS 4
AR e13122
DI 10.14814/phy2.13122
PG 6
WC Physiology
SC Physiology
GA EP5PN
UT WOS:000397431000013
ER
PT J
AU Tritos, NA
Biller, BMK
AF Tritos, Nicholas A.
Biller, Beverly M. K.
TI Pegvisomant: a growth hormone receptor antagonist used in the treatment
of acromegaly
SO PITUITARY
LA English
DT Article
DE Acromegaly; Growth hormone; Growth hormone receptor (antagonist);
Pegvisomant; Pituitary adenoma
ID LONG-TERM TREATMENT; FACTOR-I; SOMATOSTATIN ANALOGS; CLINICAL-PRACTICE;
NUDE-MICE; EXPERIENCE; RESISTANT; THERAPY; SAFETY; RADIOTHERAPY
AB To review published data on pegvisomant and its therapeutic role in acromegaly.
Electronic searches of the published literature were conducted using the keywords: acromegaly, growth hormone (GH) receptor (antagonist), pegvisomant, therapy. Relevant articles (n = 141) were retrieved and considered for inclusion in this manuscript.
Pegvisomant is a genetically engineered, recombinant growth hormone receptor antagonist, which is effective in normalizing serum insulin-like growth factor 1 (IGF-1) levels in the majority of patients with acromegaly and ameliorating symptoms and signs associated with GH excess. Pegvisomant does not have direct antiproliferative effects on the underlying somatotroph pituitary adenoma, which is the etiology of GH excess in the vast majority of patients with acromegaly. Therefore, patients receiving pegvisomant monotherapy require regular pituitary imaging in order to monitor for possible increase in tumor size. Adverse events in patients on pegvisomant therapy include skin rashes, lipohypertrophy at injection sites, and idiosyncratic liver toxicity (generally asymptomatic transaminitis that is reversible upon drug discontinuation), thus necessitating regular patient monitoring.
Pegvisomant is an effective therapeutic agent in patients with acromegaly who are not in remission after undergoing pituitary surgery. It mitigates excess GH action, as demonstrated by IGF-1 normalization, but has no direct effects on pituitary tumors causing acromegaly. Regular surveillance for possible tumor growth and adverse effects (hepatotoxicity, skin manifestations) is warranted.
C1 [Tritos, Nicholas A.; Biller, Beverly M. K.] Massachusetts Gen Hosp, Neuroendocrine Unit, Zero Emerson Pl 112, Boston, MA 02114 USA.
[Tritos, Nicholas A.; Biller, Beverly M. K.] Harvard Med Sch, Boston, MA 02115 USA.
RP Tritos, NA (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, Zero Emerson Pl 112, Boston, MA 02114 USA.; Tritos, NA (reprint author), Harvard Med Sch, Boston, MA 02115 USA.
EM ntritos@partners.org
FU Ipsen; Novartis; Novo Nordisk; Pfizer
FX NAT has received institution-directed research support from Ipsen,
Novartis, Novo Nordisk and Pfizer and has consulted for Ipsen. BMKB has
received institution-directed research support from Novartis and has
consulted for Novartis, Ipsen and Pfizer.
NR 57
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1386-341X
EI 1573-7403
J9 PITUITARY
JI Pituitary
PD FEB
PY 2017
VL 20
IS 1
BP 129
EP 135
DI 10.1007/s11102-016-0753-y
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EN5QO
UT WOS:000396060800017
PM 27631335
ER
PT J
AU Maiti, A
Terracina, KA
Das, A
Chatterjee, S
AF Maiti, Abhishek
Terracina, Katherine A.
Das, Avash
Chatterjee, Saurav
TI A tale of two hearts
SO POSTGRADUATE MEDICAL JOURNAL
LA English
DT Editorial Material
ID TRANSPLANTATION
C1 [Maiti, Abhishek; Terracina, Katherine A.] Univ Texas Hlth Sci Ctr Houston, Dept Internal Med, Houston, TX 77030 USA.
[Das, Avash] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA.
[Chatterjee, Saurav] St Lukes Roosevelt Hosp Mt Sinai Hlth Syst, Div Cardiol, New York, NY USA.
RP Maiti, A (reprint author), 6431 Fannin,MSB 1-134, Houston, TX 77030 USA.
EM abhishek.maiti87@gmail.com
NR 4
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0032-5473
EI 1469-0756
J9 POSTGRAD MED J
JI Postgrad. Med. J.
PD FEB
PY 2017
VL 93
IS 1096
BP 107
EP 107
DI 10.1136/postgradmedj-2016-134309
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA EL5MI
UT WOS:000394664800012
PM 27466412
ER
PT J
AU Der-Martirosian, C
Radcliff, TA
Gable, AR
Riopelle, D
Hagigi, FA
Brewster, P
Dobalian, A
AF Der-Martirosian, Claudia
Radcliff, Tiffany A.
Gable, Alicia R.
Riopelle, Deborah
Hagigi, Farhad A.
Brewster, Pete
Dobalian, Aram
TI Assessing Hospital Disaster Readiness Over Time at the US Department of
Veterans Affairs
SO PREHOSPITAL AND DISASTER MEDICINE
LA English
DT Article
DE assessment; capabilities; disaster readiness; emergency management;
hospital preparedness
ID EMERGENCY MANAGEMENT; SURGE CAPACITY; PREPAREDNESS
AB Introduction: There have been numerous initiatives by government and private organizations to help hospitals become better prepared for major disasters and public health emergencies. This study reports on efforts by the US Department of Veterans Affairs (VA), Veterans Health Administration, Office of Emergency Management's (OEM) Comprehensive Emergency Management Program (CEMP) to assess the readiness of VA Medical Centers (VAMCs) across the nation.
Hypothesis/Problem: This study conducts descriptive analyses of preparedness assessments of VAMCs and examines change in hospital readiness over time.
Methods: To assess change, quantitative analyses of data from two phases of preparedness assessments (Phase I: 2008-2010; Phase II: 2011-2013) at 137 VAMCs were conducted using 61 unique capabilities assessed during the two phases. The initial five-point Likert-like scale used to rate each capability was collapsed into a dichotomous variable: "not-developed = 0" versus "developed = 1." To describe changes in preparedness over time, four new categories were created from the Phase I and Phase II dichotomous variables: (1) rated developed in both phases; (2) rated not-developed in Phase I but rated developed in Phase II; (3) rated not-developed in both phases; and (4) rated developed in Phase I but rated not-developed in Phase II.
Results: From a total of 61 unique emergency preparedness capabilities, 33 items achieved the desired outcome - they were rated either "developed in both phases" or "became developed" in Phase II for at least 80% of VAMCs. For 14 items, 70%-80% of VAMCs achieved the desired outcome. The remaining 14 items were identified as "low-performing" capabilities, defined as less than 70% of VAMCs achieved the desired outcome.
Conclusion: Measuring emergency management capabilities is a necessary first step to improving those capabilities. Furthermore, assessing hospital readiness over time and creating robust hospital readiness assessment tools can help hospitals make informed decisions regarding allocation of resources to ensure patient safety, provide timely access to high-quality patient care, and identify best practices in emergency management during and after disasters. Moreover, with some minor modifications, this comprehensive, all-hazardsbased, hospital preparedness assessment tool could be adapted for use beyond the VA.
C1 [Der-Martirosian, Claudia] 16111 Plummer St MS 152, North Hills, CA 91343 USA.
[Der-Martirosian, Claudia; Radcliff, Tiffany A.; Gable, Alicia R.; Hagigi, Farhad A.; Dobalian, Aram] US Dept Vet Affairs, Vet Emergency Management Evaluat Ctr, North Hills, CA USA.
[Radcliff, Tiffany A.] Texas A&M Univ, Sch Publ Hlth, Dept Hlth Policy Management, College Stn, TX USA.
[Riopelle, Deborah] VA Greater Angeles Healthcare Syst, VA Hlth Serv Res & Dev Ctr Study Healthcare Innov, North Hills, CA USA.
[Hagigi, Farhad A.] Univ Calif Angeles, Sch Med, Dept Family Med, Los Angeles, CA USA.
[Hagigi, Farhad A.] Univ Calif Angeles, Anderson Sch Management, Los Angeles, CA USA.
[Brewster, Pete] Dept Vet Affairs, Vet Hlth Adm, Off Emergency Management, Martinsburg, WV USA.
[Dobalian, Aram] Univ Calif Angeles, Fielding Sch Publ Hlth, Dept Hlth Policy & Management, Los Angeles, CA USA.
[Dobalian, Aram] Univ Calif Angeles, Sch Nursing, Los Angeles, CA USA.
RP Der-Martirosian, C (reprint author), 16111 Plummer St MS 152, North Hills, CA 91343 USA.
EM Claudia.Der-Martirosian@va.gov
FU Department of Veterans Affairs (VA), Veterans Health Administration,
Office of Patient Care Services (PCS; Washington DC, USA)
FX This material is based upon work supported by the Department of Veterans
Affairs (VA), Veterans Health Administration, Office of Patient Care
Services (PCS; Washington DC, USA). The views expressed in this article
are those of the authors and do not necessarily reflect the position or
policy of the VA or the US government.
NR 32
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1049-023X
EI 1945-1938
J9 PREHOSPITAL DISASTER
JI Prehospital Disaster Med.
PD FEB
PY 2017
VL 32
IS 1
BP 46
EP 57
DI 10.1017/S1049023X16001266
PG 12
WC Emergency Medicine
SC Emergency Medicine
GA EL5LY
UT WOS:000394663800007
PM 27964767
ER
PT J
AU Teran, VG
Fuentes, MA
Atallah, DG
Yang, Y
AF Teran, Vincenzo G.
Fuentes, Milton A.
Atallah, Devin G.
Yang, Yi
TI Risk and Protective Factors Impacting Burnout in Bilingual, Latina/o
Clinicians: An Exploratory Study
SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE
LA English
DT Article
DE job burnout; Latina/os; training; bilingualism; psychotherapy
ID MENTAL-HEALTH-SERVICES; RESIDENTS; AMERICANS; SPANISH; ACCESS; STAFF;
CARE
AB While there is a paucity of information in the research examining the training and professional experience of bilingual, Latina/o clinicians who provide mental health services in Spanish, a growing body of research has highlighted a series of challenges unique to this group of providers, including their concerns about burnout due to such challenges. This exploratory study is the first (to the best of our knowledge) to measure the levels of burnout among these clinicians and to examine the interrelationship between burnout and sociodemographic and individual characteristics. The extent to which these clinicians experience the challenges identified in previous studies was also investigated. Participants included 66 bilingual, English-Spanish, Latina/o clinicians. The results suggest that bilingual, Latina/o clinicians endorse lower degrees of burnout relative to their monolingual, English counterparts and that specific sociodemographic and individual characteristics influence burnout. Furthermore, the results support previous research findings highlighting the unique set of challenges encountered by these clinicians. Understanding the characteristics and dynamics that contribute to and protect against burnout has major implications for the training, support, and retention of bilingual, English-Spanish, Latina/o psychologists.
C1 [Teran, Vincenzo G.] Cambridge Hlth Alliance, Harvard Med Sch, 163 Gore St, Cambridge, MA 02141 USA.
[Fuentes, Milton A.] Montclair State Univ, Montclair, NJ USA.
[Atallah, Devin G.] Pontif Cathol Univ, Santiago, Chile.
[Yang, Yi] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA.
RP Teran, VG (reprint author), Cambridge Hlth Alliance, Harvard Med Sch, 163 Gore St, Cambridge, MA 02141 USA.
EM vteran@cha.harvard.edu
NR 32
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0735-7028
EI 1939-1323
J9 PROF PSYCHOL-RES PR
JI Prof. Psychol.-Res. Pract.
PD FEB
PY 2017
VL 48
IS 1
BP 22
EP 29
DI 10.1037/pro0000126
PG 8
WC Psychology, Multidisciplinary
SC Psychology
GA EM6JY
UT WOS:000395419900003
ER
PT J
AU Edmunds, JM
Brodman, DM
Ringle, VA
Read, KL
Kendall, PC
Beidas, RS
AF Edmunds, Julie M.
Brodman, Douglas M.
Ringle, Vanesa A.
Read, Kendra L.
Kendall, Philip C.
Beidas, Rinad S.
TI Examining Adherence to Components of Cognitive-Behavioral Therapy for
Youth Anxiety After Training and Consultation
SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE
LA English
DT Article
DE evidence-based practice; cognitive-behavioral therapy; training;
fidelity; adherence
ID MENTAL-HEALTH SYSTEM; AFFORDABLE CARE ACT; TREATMENT INTEGRITY;
DISSEMINATION TRIAL; PATIENT PROTECTION; TREATMENT FIDELITY; EXPOSURE
THERAPY; IMPLEMENTATION; STRATEGIES; DISORDERS
AB The present study examined 115 service providers' adherence to components of cognitive-behavioral therapy (CBT) for youth anxiety before training, postworkshop training, and after 3 months of weekly consultation. Adherence was measured using a role play with a trained actor. We examined differences in individual adherence to CBT components across time and the relationship between number of consultation sessions attended and adherence ratings after consultation. Findings indicated that somatic arousal identification and relaxation were the most used treatment components before training. Adherence to all components of CBT increased after workshop training, except the usage of problem-solving. Adherence to problem-solving, positive reinforcement, the identification of anxious self-talk, and the creation of coping thoughts increased after consultation but usage of problem-solving remained low compared with other treatment components. Overall adherence remained less than optimal at the final measurement point. The number of consultation sessions attended predicted postconsultation adherence to identification of somatic arousal, identification of anxious self-talk, and positive reinforcement. Implications include tailoring future training based on baseline levels of adherence and spending more time during training and consultation on underutilized CBT components, such as problem-solving. Limitations of the present study, including how adherence was measured, are discussed. This study adds to the implementation science literature by providing more nuanced information on changes in adherence over the course of training and consultation of service providers.
C1 [Edmunds, Julie M.] Massachusetts Gen Hosp, Boston, MA USA.
[Edmunds, Julie M.] Harvard Med Sch, Dept Psychiat, Boston, MA USA.
[Brodman, Douglas M.] New York Univ Langone Med Ctr, New York, NY USA.
[Brodman, Douglas M.; Read, Kendra L.; Beidas, Rinad S.] Temple Univ, Clin Psychol, Philadelphia, PA 19122 USA.
[Ringle, Vanesa A.] Univ Miami, Coral Gables, FL 33124 USA.
[Read, Kendra L.] Seattle Childrens Hosp, Seattle, WA USA.
[Read, Kendra L.] Univ Washington Sch Med, Dept Psychiat & Behav Sci, Seattle, WA USA.
[Kendall, Philip C.] Temple Univ, Philadelphia, PA 19122 USA.
[Kendall, Philip C.] Virginia Commonwealth Univ, Psychiat Clin, Richmond, VA 23284 USA.
[Beidas, Rinad S.] Univ Penn, Philadelphia, PA 19104 USA.
[Beidas, Rinad S.] Univ Penn Perelman Sch Med, Dept Psychiat, Philadelphia, PA USA.
RP Edmunds, JM (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Dept Psychiat, 151 Merrimac St,3rd Floor, Boston, MA 02114 USA.
EM jedmunds@mgh.harvard.edu
FU National Institute of Mental Health [MH083333, MH099179, MH086438, R25
MH080916]; Implementation Research Institute (IRI) at the George Warren
Brown School of Social Work, Washington University in St. Louis; Quality
Enhancement Research Initiative (QUERI); Department of Veterans Affairs
Contract, Veterans Health Administration, Office of Research and
Development; Health Services Research and Development Service
FX FUNDING FOR this research project was supported by the following grants
from the National Institute of Mental Health: MH083333 and MH099179
(Rinad S. Beidas) and MH086438 (Philip C. Kendall). In addition, the
preparation of this article was supported in part by the Implementation
Research Institute (IRI) at the George Warren Brown School of Social
Work, Washington University in St. Louis, through an award from the
National Institute of Mental Health (R25 MH080916) and the Quality
Enhancement Research Initiative (QUERI), Department of Veterans Affairs
Contract, Veterans Health Administration, Office of Research and
Development, and Health Services Research and Development Service. Rinad
S. Beidas was an IRI fellow from 2012 to 2014.
NR 44
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0735-7028
EI 1939-1323
J9 PROF PSYCHOL-RES PR
JI Prof. Psychol.-Res. Pract.
PD FEB
PY 2017
VL 48
IS 1
BP 54
EP 61
DI 10.1037/pro0000100
PG 8
WC Psychology, Multidisciplinary
SC Psychology
GA EM6JY
UT WOS:000395419900007
ER
PT J
AU Zhang, X
AF Zhang, Xi
TI Detergents: Friends not foes for high-performance membrane proteomics
toward precision medicine
SO PROTEOMICS
LA English
DT Review
DE Detergents; Membrane protein; Posttranslational modification; Precision
medicine; Structural proteomics; Target engagement; Technology
ID CYTOCHROME-C-OXIDASE; PROTEIN-COUPLED RECEPTOR; TANDEM
MASS-SPECTROMETRY; PHOTOSYNTHETIC REACTION CENTER; SIZE-EXCLUSION
CHROMATOGRAPHY; ALKYL GLYCOSIDE DETERGENTS; HUMAN GAMMA-SECRETASE;
BLUE-NATIVE/SDS-PAGE; AGE-RELATED-CHANGES; GATED ION-CHANNEL
AB Precision medicine, particularly therapeutics, emphasizes the atomic-precise, dynamic, and systems visualization of human membrane proteins and their endogenous modifiers. For years, bottom-up proteomics has grappled with removing and avoiding detergents, yet faltered at the therapeutic-pivotal membrane proteins, which have been tackled by classical approaches and are known for decades refractory to single-phase aqueous or organic denaturants. Hydrophobicity and aggregation commonly challenge tissue and cell lysates, biofluids, and enriched samples. Frequently, expected membrane proteins and peptides are not identified by shotgun bottom-up proteomics, let alone robust quantitation. This review argues the cause of this proteomic crisis is not detergents per se, but the choice of detergents. Recently, inclusion of compatible detergents for membrane protein extraction and digestion has revealed stark improvements in both quantitative and structural proteomics. This review analyzes detergent properties behind recent proteomic advances, and proposes that rational use of detergents may reconcile outstanding membrane proteomics dilemmas, enabling ultradeep coverage and minimal artifacts for robust protein and endogenous PTM measurements. The simplicity of detergent tools confers bottom-up membrane proteomics the sophistication toward precision medicine.
C1 [Zhang, Xi] Massachusetts Gen Hosp, Dept Anesthesia, Crit Care & Pain Med, 32 Fruit St, Boston, MA 02114 USA.
[Zhang, Xi] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA.
RP Zhang, X (reprint author), Massachusetts Gen Hosp, Dept Anesthesia, Crit Care & Pain Med, 32 Fruit St, Boston, MA 02114 USA.
EM xi.zhang.edu@gmail.com
FU National Institute of General Medical Sciences [GM058448]; Department of
Anesthesia, Critical Care and Pain Medicine, Massachusetts General
Hospital
FX The author thanks Dr. Shelagh M. Ferguson-Miller for discussions of
detergents and membrane proteins. The author also thanks Dr. Royd
Carlson for helping with editing the manuscript. Early stage of this
work was supported in part by the National Institute of General Medical
Sciences (GM058448, to Dr. Keith W. Miller) and the Department of
Anesthesia, Critical Care and Pain Medicine, Massachusetts General
Hospital.
NR 177
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1615-9853
EI 1615-9861
J9 PROTEOMICS
JI Proteomics
PD FEB
PY 2017
VL 17
IS 3-4
SI SI
AR UNSP 1600209
DI 10.1002/pmic.201600209
PG 18
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA EO9MM
UT WOS:000397012800002
ER
PT J
AU Irwin, K
AF Irwin, Kelly
TI Tobacco treatment for patients with severe mental illness and cancer
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Irwin, Kelly] Massachusetts Gen Hosp, Boston, MA 02114 USA.
FU National Cancer Institute [5 R01 CA166147-05]; Program in Cancer
Outcomes Research Training Fellowship [R25CA092203]
FX National Cancer Institute (5 R01 CA166147-05) and Program in Cancer
Outcomes Research Training Fellowship, (R25CA092203)
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA 15.1
BP 25
EP 25
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700050
ER
PT J
AU Park, E
AF Park, Elyse
TI Tobacco assistance for recently diagnosed cancer patients: Who does not
receive assistance?
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Park, Elyse] Massachusetts Gen Hosp, Boston, MA 02114 USA.
FU National Cancer Institute [5 R01 CA166147-05]
FX National Cancer Institute (5 R01 CA166147-05)
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA 15.3
BP 25
EP 26
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700052
ER
PT J
AU Perez, G
AF Perez, Giselle
TI Smoking cessation program needs among Black and Hispanic cancer patients
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Perez, Giselle] Massachusetts Gen Hosp, Boston, MA 02114 USA.
FU National Cancer Institute [3R01CA166147 - 02S1]
FX National Cancer Institute (3R01CA166147 - 02S1).
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA 15.2
BP 25
EP 25
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700051
ER
PT J
AU Cooley, M
AF Cooley, Mary
TI Decision support for symptom self-management during cancer treatment
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Cooley, Mary] Dana Farber Canc Inst, Boston, MA 02115 USA.
FU Patient Centered Outcomes Research Institute [PI-12-001]
FX This work was supported by The Patient Centered Outcomes Research
Institute grant PI-12-001.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA 17.1
BP 27
EP 27
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700056
ER
PT J
AU Corveleyn, A
AF Corveleyn, Amy
TI Proactive psychiatry consultation and case management for patients with
cancer and serious mental illness and their caregivers: A pilot study
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Corveleyn, Amy] Massachusetts Gen Hosp, Boston, MA 02114 USA.
FU American Cancer Society
FX American Cancer Society
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA 17.4
BP 28
EP 29
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700059
ER
PT J
AU Jacobs, J
AF Jacobs, Jamie
TI Patient, family, and stakeholder engagement in a PCORI-funded study
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Jacobs, Jamie] Massachusetts Gen Hosp, Boston, MA 02114 USA.
FU Patient-Centered Outcomes Research Institute Award [IHS-1306-03616]
FX Research reported in this publication was funded through a
Patient-Centered Outcomes Research Institute Award (IHS-1306-03616). The
statements presented in this work are solely the responsibility of the
authors and do not necessarily represent the views of the
Patient-Centered Outcomes Research Institute (PCORI), its board of
governors, or methodology committee.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA 17.3
BP 28
EP 28
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700058
ER
PT J
AU Braun, I
AF Braun, Ilana
TI Key informants' perspectives on medical marijuana use in oncology
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Braun, Ilana] Dana Farber Canc Inst, Boston, MA USA.
FU Hans and Mavis Lopater Foundation
FX The Hans and Mavis Lopater Foundation.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA 24.4
BP 39
EP 39
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700085
ER
PT J
AU Muriel, A
Brand, S
Renzi, D
Loucas, C
AF Muriel, Anna
Brand, Sarah
Renzi, Danielle
Loucas, Caitlyn
TI Psychosocial risk and predictors of mood in parents of children with
cancer
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Muriel, Anna; Brand, Sarah; Renzi, Danielle] Dana Farber Canc Inst, Boston, MA USA.
[Loucas, Caitlyn] Amer Univ, Washington, DC 20016 USA.
FU Harvard University Milton Fund
FX Harvard University Milton Fund
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA 26.1
BP 41
EP 41
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700090
ER
PT J
AU Irwin, K
Fields, L
Corveleyn, A
Park, ER
Greer, J
Jacobs, J
Ryan, D
Pirl, W
AF Irwin, Kelly
Fields, Lauren
Corveleyn, Amy
Park, Elyse R.
Greer, Joseph
Jacobs, Jamie
Ryan, David
Pirl, William
TI Proactive psychiatry consultation for patients with severe mental
illness and cancer: A pilot study
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Irwin, Kelly; Fields, Lauren; Corveleyn, Amy; Park, Elyse R.; Jacobs, Jamie; Ryan, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Greer, Joseph] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Pirl, William] Sylvester Canc Ctr, Miami, FL USA.
FU National Institutes of Health/National Cancer Institute Program in
Cancer Outcomes Research Training; American Cancer Society;
Massachusetts General Hospital Cancer Center; Department of Psychiatry
FX National Institutes of Health/National Cancer Institute Program in
Cancer Outcomes Research Training, American Cancer Society Institutional
Review Grant, Massachusetts General Hospital Cancer Center and
Department of Psychiatry
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA 28.2
BP 45
EP 45
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700099
ER
PT J
AU Reese, J
Beach, MC
Smith, KC
Bantug, ET
Casale, KE
Porter, LS
Bober, SL
Tulsky, JA
Daly, MB
Lepore, SJ
AF Reese, Jennifer
Beach, Mary Catherine
Smith, Katherine Clegg
Bantug, Elissa T.
Casale, Kristen E.
Porter, Laura S.
Bober, Sharon L.
Tulsky, James A.
Daly, Mary B.
Lepore, Stephen J.
TI Effective patient-provider communication about sexual concerns in breast
cancer: A qualitative study of patients and providers
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Reese, Jennifer; Casale, Kristen E.; Daly, Mary B.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
[Beach, Mary Catherine; Smith, Katherine Clegg] Johns Hopkins Sch Med, Baltimore, MD USA.
[Bantug, Elissa T.] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
[Porter, Laura S.] Duke Univ, Med Ctr, Durham, NC 27706 USA.
[Bober, Sharon L.; Tulsky, James A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lepore, Stephen J.] Temple Univ, Philadelphia, PA 19122 USA.
FU American Cancer Society [MRSG-14-031-CPPB]; National Cancer Institute
[R21CA191354, P30CA006927]
FX This study was supported by MRSG-14-031-CPPB from the American Cancer
Society and R21CA191354 and P30CA006927 from the National Cancer
Institute.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA T12
BP 51
EP 52
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700113
ER
PT J
AU Fields, L
Corveleyn, A
Pirl, W
Park, E
Greer, J
Kotagiri, N
Hagan, T
Irwin, K
AF Fields, Lauren
Corveleyn, Amy
Pirl, William
Park, Elyse
Greer, Joseph
Kotagiri, Nayanika
Hagan, Teresa
Irwin, Kelly
TI Tailoring research design for patients with severe mental illness and
cancer
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Fields, Lauren; Corveleyn, Amy; Park, Elyse; Greer, Joseph; Hagan, Teresa; Irwin, Kelly] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Pirl, William] Sylvester Canc Ctr, Miami, FL USA.
[Kotagiri, Nayanika] Tufts Univ, Medford, MA 02155 USA.
FU National Institutes of Health/National Cancer Institute Program in
Cancer Outcomes Research Training; American Cancer Society;
Massachusetts General Hospital Cancer Center; Department of Psychiatry
FX National Institutes of Health/National Cancer Institute Program in
Cancer Outcomes Research Training, American Cancer Society Institutional
Review Grant, Massachusetts General Hospital Cancer Center, and
Department of Psychiatry
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA T24
BP 56
EP 57
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700125
ER
PT J
AU Friedman, E
Park, E
Traeger, L
AF Friedman, Emily
Park, Elyse
Traeger, Lara
TI Depression and psychosocial support service utilization among lung
cancer patients
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Friedman, Emily; Park, Elyse; Traeger, Lara] Massachusetts Gen Hosp, Boston, MA 02114 USA.
FU National Institutes of Health/National Cancer Institute [U54-CA156732]
FX This study was funded by grant U54-CA156732 to Drs Park and Cannon from
the National Institutes of Health/National Cancer Institute.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA T64
BP 73
EP 74
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700165
ER
PT J
AU Rabin, J
Perez, GK
Hall, DL
Hagan, T
Quain, K
Jimenez, R
Park, ER
Peppercorn, J
AF Rabin, Julia
Perez, Giselle K.
Hall, Daniel L.
Hagan, Teresa
Quain, Katharine
Jimenez, Rachel
Park, Elyse R.
Peppercorn, Jeffrey
TI Prevalence and predictors of fear of recurrence among adult patients
with cancer
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Rabin, Julia; Perez, Giselle K.; Hall, Daniel L.; Hagan, Teresa; Quain, Katharine; Jimenez, Rachel; Park, Elyse R.; Peppercorn, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA.
FU MGH Cancer Center
FX This study was funded by the MGH Cancer Center.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA T67
BP 75
EP 75
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700168
ER
PT J
AU Geller, J
Ranby, K
Maikovich-Fong, A
Simoneau, T
Kilbourn, K
Avram, D
AF Geller, Jessica
Ranby, Krista
Maikovich-Fong, Andrea
Simoneau, Teri
Kilbourn, Kristin
Avram, David
TI Perceived social support effectiveness: A dyadic predictor of
psychosocial distress in patients undergoing autologous hematopoietic
stem cell transplant (HSCT)
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Geller, Jessica; Simoneau, Teri] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Ranby, Krista; Kilbourn, Kristin; Avram, David] Univ Colorado, Denver, CO 80202 USA.
[Maikovich-Fong, Andrea] Colorado Blood Canc Inst Presbyterian, Denver, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA F2
BP 78
EP 79
PG 2
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700177
ER
PT J
AU Park, E
Stephenson, E
Moore, C
Levy, D
Muriel, A
AF Park, Eliza
Stephenson, Elise
Moore, Cynthia
Levy, David
Muriel, Anna
TI How does cancer stage influence parenting concerns? Parenting concerns
questionnaire scores in adults with metastatic and nonmetastatic cancer
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Park, Eliza; Stephenson, Elise; Levy, David] Univ N Carolina, Chapel Hill, NC USA.
[Moore, Cynthia] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Muriel, Anna] Dana Farber Canc Inst, Boston, MA 02115 USA.
FU University Cancer Research Fund of North Carolina; National Center for
Advancing Translational Sciences (NCATS), National Institutes of Health
[1UL1TR001111, 1KL2TR001109, R03 CA126394-01]
FX The study was supported by the University Cancer Research Fund of North
Carolina and the National Center for Advancing Translational Sciences
(NCATS), National Institutes of Health, through grant awards
1UL1TR001111 and 1KL2TR001109 (Dr. Park) and R03 CA126394-01 (Dr
Muriel).
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA F6
BP 80
EP 80
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700181
ER
PT J
AU Strauss, N
Rabin, J
Temel, B
Philpotts, L
Ostroff, J
Park, ER
Perez, GK
AF Strauss, Nicole
Rabin, Julia
Temel, Brandon
Philpotts, Lisa
Ostroff, Jamie
Park, Elyse R.
Perez, Giselle K.
TI Smoking cessation interventions for Black and Hispanic cancer patients:
A systematic review of tobacco trials
SO PSYCHO-ONCOLOGY
LA English
DT Meeting Abstract
C1 [Strauss, Nicole; Rabin, Julia; Temel, Brandon; Philpotts, Lisa; Park, Elyse R.; Perez, Giselle K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ostroff, Jamie] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
FU National Cancer Institute [3R01CA166147 - 02S1]
FX This study was funded by the National Cancer Institute (3R01CA166147 -
02S1).
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1057-9249
EI 1099-1611
J9 PSYCHO-ONCOLOGY
JI Psycho-Oncol.
PD FEB
PY 2017
VL 26
SU 1
SI SI
MA F22
BP 87
EP 87
PG 1
WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences,
Biomedical
SC Oncology; Psychology; Biomedical Social Sciences
GA EL9UX
UT WOS:000394966700196
ER
PT J
AU Schmidt, EM
Krahn, DD
McGuire, MH
Tavakoli, S
Wright, DM
Solares, HE
Lemke, S
Trafton, J
AF Schmidt, Eric M.
Krahn, Dean D.
McGuire, Marsden H.
Tavakoli, Sara
Wright, David M.
Solares, Hugo E.
Lemke, Sonne
Trafton, Jodie
TI Using Organizational and Clinical Performance Data to Increase the Value
of Mental Health Care
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE mental health services; veterans; quality improvement; quality
indicators; program evaluation; organization and administration
ID QUALITY-OF-CARE; INFORMATION-TECHNOLOGY; ACCOUNTABLE CARE; SERVICES;
IMPLEMENTATION; IMPROVEMENT; CONTINUITY; INSURANCE; SCIENCE; SYSTEM
AB U.S. health systems, policy makers, and patients increasingly demand high-value care that improves health outcomes at lower cost. This study describes the initial design and analysis of the Mental Health Management System (MHMS), a performance data and quality improvement tool used by the Veterans Health Administration (VHA) to increase the value of its mental health care. The MHMS evaluates access to and quality of mental health care, organizational structure and efficiency, implementation of innovative treatment options, and, in collaboration with management, resource needs for delivering care. Performance on 31 measures was calculated for all U.S. VHA facilities (N = 139). Pearson correlations revealed that better access to care was significantly associated with fewer mental health provider staffing vacancies (r = -.24) and higher staff-topatient ratios for psychiatrists (r =.19) and other outpatient mental health providers (r =.27). Higher staff-to-patient ratios were significantly associated with higher performance on a number of patient and provider satisfaction measures (range of r =.18-.51) and continuity of care measures (range of r =.26-.43). Relationships observed between organizational and clinical performance measures suggest that the MHMS is a robust informatics and quality improvement tool that can serve as a model for health systems planning to adopt a value perspective. Future research should expand the MHMS framework to measure patient and health systems costs and psychosocial outcomes, as well as evaluate whether quality improvement solutions implemented as a result of using organizational information leads to higher-value mental health care.
C1 [Schmidt, Eric M.; Tavakoli, Sara; Wright, David M.; Solares, Hugo E.; Lemke, Sonne; Trafton, Jodie] Vet Affairs Palo Alto Hlth Care Syst, Menlo Pk, CA USA.
[Krahn, Dean D.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA.
[McGuire, Marsden H.] Vet Affairs Cent Off, Washington, DC USA.
[McGuire, Marsden H.] Johns Hopkins Univ, Baltimore, MD USA.
[Schmidt, Eric M.; Trafton, Jodie] Stanford Univ, Stanford, CA USA.
[McGuire, Marsden H.] Univ Maryland, College Pk, MD USA.
[Tavakoli, Sara; Wright, David M.; Solares, Hugo E.; Lemke, Sonne; Trafton, Jodie] VA Off Mental Hlth Operat, Washington, DC USA.
RP Trafton, J (reprint author), Vet Affairs Palo Alto Hlth Care Syst, Menlo Pk, CA USA.
EM jodie.trafton@va.gov
FU Department of Veterans Affairs (VA) Office of Academic Affiliations
Advanced Fellowship in Health Services Research and Development (HSRD);
VA HSRD Service
FX Dr. Eric M. Schmidt was supported by the Department of Veterans Affairs
(VA) Office of Academic Affiliations Advanced Fellowship in Health
Services Research and Development (HSR&D) and the VA HSR&D Service.
NR 43
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
EI 1939-148X
J9 PSYCHOL SERV
JI Psychol. Serv.
PD FEB
PY 2017
VL 14
IS 1
BP 13
EP 22
DI 10.1037/ser0000098
PG 10
WC Psychology, Clinical
SC Psychology
GA EM0QJ
UT WOS:000395022500002
PM 28134553
ER
PT J
AU Dopp, AR
Hanson, RF
Saunders, BE
Dismuke, CE
Moreland, AD
AF Dopp, Alex R.
Hanson, Rochelle F.
Saunders, Benjamin E.
Dismuke, Clara E.
Moreland, Angela D.
TI Community-Based Implementation of Trauma-Focused Interventions for
Youth: Economic Impact of the Learning Collaborative Model
SO PSYCHOLOGICAL SERVICES
LA English
DT Article
DE cost-effectiveness; implementation; trauma-focused cognitive-behavioral
therapy; training; community services
ID COST-EFFECTIVENESS; CHILD MALTREATMENT; ADOLESCENTS; DISORDERS;
DISSEMINATION; CLINICIAN
AB This study investigated the economics of the learning collaborative (LC) model in the implementation of Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT), an evidence-based intervention for traumatic stress in youth. We evaluated the cost-effectiveness of the LC model based on data from 13 LCs completed in the southeastern United States. Specifically, we calculated cost-effectiveness ratios (CERs) for 2 key service outcomes: (a) clinician TF-CBT competence, based on pre-and post-LC self-ratings (n = 574); and (b) trauma-related mental health symptoms (i.e.,traumatic stress and depression), selfand caregiver-reported, for youth who received TF-CBT (n = 1,410). CERs represented the cost of achieving 1 standard unit of change on a measure (i.e., d = 1.0). The results indicated that (a) costs of $18,679 per clinician were associated with each unit increase in TF-CBT competency and (b) costs from $5,318 to $6,548 per youth were associated with each unit decrease in mental health symptoms. Thus, although the impact of LC participation on clinician competence did not produce a favorable CER, subsequent reductions in youth psychopathology demonstrated high cost-effectiveness. Clinicians and administrators in community provider agencies should consider these findings in their decisions about implementation of evidence-based interventions for youth with traumatic stress disorders.
C1 [Dopp, Alex R.; Hanson, Rochelle F.; Saunders, Benjamin E.; Moreland, Angela D.] Med Univ South Carolina, Columbia, SC USA.
[Dismuke, Clara E.] Med Univ South Carolina, Charleston, SC 29425 USA.
[Dismuke, Clara E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP Dopp, AR (reprint author), Univ Arkansas, Dept Psychol Sci, 216 Mem Hall, Fayetteville, AR 72701 USA.
EM dopp@uark.edu
FU National Institute of Mental Health [5 R34 MH104470]; Substance Abuse
and Mental Health Services Administration [5 U79 SM061269]; Duke
Endowment [1582-SP]
FX This research was supported by grants from the National Institute of
Mental Health (5 R34 MH104470), Substance Abuse and Mental Health
Services Administration (5 U79 SM061269), and the Duke Endowment
(1582-SP). We sincerely thank the many families who participated in this
project as well as the therapists and other community professionals, too
numerous to mention individually, who participated in the learning
collaboratives. Finally, we extend special thanks to Faraday Davies,
Sara delMas, and Emily Fanguy for their assistance with data collection
and management.
NR 41
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1541-1559
EI 1939-148X
J9 PSYCHOL SERV
JI Psychol. Serv.
PD FEB
PY 2017
VL 14
IS 1
BP 57
EP 65
DI 10.1037/ser0000131
PG 9
WC Psychology, Clinical
SC Psychology
GA EM0QJ
UT WOS:000395022500006
PM 28134556
ER
PT J
AU Moore, JT
AF Moore, Jon T.
TI Multicultural and Idiosyncratic Considerations for Measuring the
Relationship Between Religious and Secular Forms of Spirituality With
Positive Global Mental Health
SO PSYCHOLOGY OF RELIGION AND SPIRITUALITY
LA English
DT Article
DE secular; multicultural; spiritual values; belief in God; mental health
ID WELL-BEING QUESTIONNAIRE; VALIDATION; PSYCHOLOGY; SCALE; LIFE;
INVOLVEMENT; FITNESS
AB The current study espouses an alternative methodology using an ideologically diverse sample of 4,667 respondents who reported their spirituality levels (i.e., the extent one lives in accordance with one's self-defined spiritual values) and their mental health levels. The sample predominately included agnostic, atheist, Buddhist, Christian, Jewish, and spiritual nonreligious participants. Multigroup analyses within structural equation models revealed that spirituality held a large relationship strength with mental health for both religious and secular forms of spirituality, even with multiple configurations determining the constituents of the secular group. An exploratory analysis demonstrated that when spirituality, demographic factors, social support, and spiritual coping usage were all examined as predictors of mental health, religious and secular forms of spirituality were the only variables that maintained a large predictive strength. The results indicated that living in accordance with one's spiritual values, even when defined in a variety of ways, is characteristic of greater mental health.
C1 [Moore, Jon T.] Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, 9600 Vet Dr A-116, Tacoma, WA 98493 USA.
[Moore, Jon T.] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA.
RP Moore, JT (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Amer Lake Div, 9600 Vet Dr A-116, Tacoma, WA 98493 USA.
EM jonmoorephd@gmail.com
NR 72
TC 0
Z9 0
U1 0
U2 0
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1941-1022
EI 1943-1562
J9 PSYCHOL RELIG SPIRIT
JI Psychol. Relig. Spiritual.
PD FEB
PY 2017
VL 9
IS 1
BP 21
EP 33
DI 10.1037/rel0000083
PG 13
WC Psychology, Multidisciplinary; Religion
SC Psychology; Religion
GA EM8JJ
UT WOS:000395557100003
ER
PT J
AU McCaffery, JM
Jablonski, KA
Franks, PW
Delahanty, LM
Aroda, V
Marrero, D
Hamman, RF
Horton, ES
Dagogo-Jack, S
Wylie-Rosett, J
Barrett-Connor, E
Kitabchi, A
Knowler, WC
Wing, RR
Florez, JC
AF McCaffery, Jeanne M.
Jablonski, Kathleen A.
Franks, Paul W.
Delahanty, Linda M.
Aroda, Vanita
Marrero, David
Hamman, Richard F.
Horton, Edward S.
Dagogo-Jack, Samuel
Wylie-Rosett, Judith
Barrett-Connor, Elizabeth
Kitabchi, Abbas
Knowler, William C.
Wing, Rena R.
Florez, Jose C.
CA Diabet Prevention Program Res Grp
TI Replication of the Association of BDNF and MC4R Variants With Dietary
Intake in the Diabetes Prevention Program
SO PSYCHOSOMATIC MEDICINE
LA English
DT Article
DE obesity; diet; total caloric intake; BDNF; MC4R; FTO
ID NEUROTROPHIC FACTOR BDNF; GENOME-WIDE ASSOCIATION; EXCESSIVE
WEIGHT-GAIN; BODY-MASS INDEX; ENERGY-INTAKE; LIFE-STYLE; FOOD-FREQUENCY;
MELANOCORTIN-4 RECEPTOR; MACRONUTRIENT INTAKE; OBESITY
AB Objective: Genomewide association studies (GWAS) have identified consistent associations with obesity, with a number of studies implicating eating behavior as a primary mechanism. Few studies have replicated genetic associations with dietary intake. This study evaluates the association between obesity susceptibility loci and dietary intake.
Methods: Data were obtained as part of the Diabetes Prevention Program (DPP), a clinical trial of diabetes prevention in persons at high risk of diabetes. The association of 31 genomewide association studies identified obesity risk alleles with dietary intake, measured through a food frequency questionnaire, was investigated in 3,180 participants from DPP at baseline.
Results: The minor allele at BDNF, identified as protective against obesity, was associated with lower total caloric intake (beta = -106.06, SE = 33.13; p = .0014) at experimentwide statistical significance (p = .0016), whereas association of MC4R rs571312 with higher caloric intake reached nominal significance (beta = 61.32, SE = 26.24; p = .0194). Among non-Hispanic white participants, the association of BDNF rs2030323 with total caloric intake was stronger (beta = -151.99, SE = 30.09; p < .0001), and association of FTO rs1421085 with higher caloric intake (beta = 56.72, SE = 20.69; p = .0061) and percentage fat intake (beta = 0.37, SE = 0.08; p =. 0418) was also observed.
Conclusions: These results demonstrate with the strength of independent replication that BDNF rs2030323 is associated with 100 to 150 greater total caloric intake per allele, with additional contributions of MC4R and, in non-Hispanic white individuals, FTO. As it has been argued that an additional 100 kcal/d could account for the trends in weight gain, prevention focusing on genetic profiles with high dietary intake may help to quell adverse obesity trends.
C1 [McCaffery, Jeanne M.; Wing, Rena R.] Miriam Hosp, Weight Control & Diabet Res Ctr, Providence, RI 02906 USA.
[McCaffery, Jeanne M.; Wing, Rena R.] Brown Univ, Warren Alpert Sch, Providence, RI 02912 USA.
[Jablonski, Kathleen A.] George Washington Univ, Biostat Ctr, Rockville, MD USA.
[Franks, Paul W.] Lund Univ, Dept Clin Sci, Genet & Mol Epidemiol Unit, Malmo, Sweden.
Umea Univ, Dept Med, Umea, Sweden.
Harvard Sch Publ Hlth, Dept Nutr, Boston, MA USA.
[Delahanty, Linda M.] Massachusetts Gen Hosp, Ctr Diabet, Boston, MA 02114 USA.
Harvard Med Sch, Dept Med, Boston, MA USA.
[Aroda, Vanita] Medstar Hlth Res Inst, Hyattsville, MD USA.
[Marrero, David] Indiana Univ, Indianapolis, IN 46204 USA.
[Hamman, Richard F.] Univ Colorado Denver, Dept Epidemiol, Colorado Sch Publ Hlth, Aurora, CO USA.
[Horton, Edward S.] Joslin Diabet Ctr, Boston, MA 02215 USA.
[Dagogo-Jack, Samuel] Univ Tennessee, Memphis, TN USA.
[Wylie-Rosett, Judith] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Barrett-Connor, Elizabeth] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Kitabchi, Abbas] Univ Pittsburgh, Pittsburgh, PA USA.
[Knowler, William C.] Natl Inst Diabet & Digest & Kidney Dis, Diabet Epidemiol & Clin Res Sect, Phoenix, AZ USA.
[Florez, Jose C.] Massachusetts Gen Hosp, Diabet Unit, Diabet Res Ctr, Boston, MA 02114 USA.
[Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
Harvard Med Sch, Dept Med, Boston, MA USA.
Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
RP McCaffery, JM (reprint author), Miriam Hosp, Weight Control & Diabet Res Ctr, Providence, RI 02906 USA.; McCaffery, JM (reprint author), Brown Univ, Warren Alpert Sch, Providence, RI 02912 USA.; McCaffery, JM (reprint author), George Washington Univ, Ctr Biostat, Diabet Prevent Program Coordinating Ctr, 6110 Execut Blvd,Suite 750, Rockville, MD 20852 USA.
EM dppmail@bsc.gwu.edu
FU NIDDK of the National Institutes of Health; NIDDK; Indian Health
Service; General Clinical Research Center Program, National Center for
Research Resources; Office of Research on Minority Health; National
Institute of Child Health and Human Development; National Institute on
Aging; Centers for Disease Control and Prevention, Office of Research on
Women's Health; Department of Veterans Affairs; American Diabetes
Association
FX Diabetes Prevention Program: The NIDDK of the National Institutes of
Health provided funding to the clinical centers and the Coordinating
Center for the design and conduct of the study; and collection,
management, analysis, and interpretation of the data. The Southwestern
American Indian Centers were supported directly by the NIDDK and the
Indian Health Service. The General Clinical Research Center Program,
National Center for Research Resources supported data collection at many
of the clinical centers. Funding for data collection and participant
support was also provided by the Office of Research on Minority Health,
the National Institute of Child Health and Human Development, the
National Institute on Aging, the Centers for Disease Control and
Prevention, Office of Research on Women's Health, the Department of
Veterans Affairs, and the American Diabetes Association. Bristol-Myers
Squibb and Parke-Davis provided medication. This research was also
supported, in part, by the intramural research program of the NIDDK.
LifeScan Inc, Health O Meter, Hoechst Marion Roussel, Inc, Merck-Medco
Managed Care, Inc, Merck and Co, Nike Sports Marketing, Slim Fast Foods
Co, and Quaker Oats Co donated materials, equipment, or medicines for
concomitant conditions. McKesson BioServices Corp, Matthews Media Group,
Inc, and the Henry M. Jackson Foundation provided support services under
subcontract with the Coordinating Center. The opinions expressed are
those of the investigators and do not necessarily reflect the views of
the Indian Health Service or other funding agencies. A complete list of
centers, investigators, and staff can be found in the online Appendix,
Supplemental Digital Content 2, http://links.lww.com/PSYMED/A316.
NR 55
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD FEB-MAR
PY 2017
VL 79
IS 2
BP 224
EP 233
DI 10.1097/PSY.0000000000000380
PG 10
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA EL2IH
UT WOS:000394442800012
PM 27551991
ER
PT J
AU van Loon, J
Even, AJG
Aerts, HJWL
Ollers, M
Hoebers, F
van Elmpt, W
Dubois, L
Dingemans, AMC
Lalisang, RI
Kempers, P
Brans, B
Winnepenninckx, V
Speel, EJ
Thunnissen, E
Smits, KM
Boellaard, R
Vugts, DJ
De Ruysscher, D
Lambin, P
AF van Loon, Judith
Even, Aniek J. G.
Aerts, Hugo J. W. L.
Ollers, Michel
Hoebers, Frank
van Elmpt, Wouter
Dubois, Ludwig
Dingemans, Anne-Marie C.
Lalisang, Roy I.
Kempers, Pascal
Brans, Boudewijn
Winnepenninckx, Veronique
Speel, Ernst-Jan
Thunnissen, Eric
Smits, Kim M.
Boellaard, Ronald
Vugts, Danielle J.
De Ruysscher, Dirk
Lambin, Philippe
TI PET imaging of zirconium-89 labelled cetuximab: A phase I trial in
patients with head and neck and lung cancer
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Article
DE Zr-89-cetuximab; EGFR; Immuno-PET; Phase I trial
ID GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; PLUS CETUXIMAB; 1ST-LINE
CHEMOTHERAPY; EGFR-INHIBITION; IMMUNO-PET; EXPRESSION; RADIOTHERAPY;
CARCINOMA; SURVIVAL
AB Background and purpose: PET imaging of cetuximab uptake may help selecting cancer patients with the highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer (89)zr-cetuximab and to assess tumour uptake.
Methods: Two dose schedules were used; two consecutive doses of 60 MBq Zr-89-cetuximab or a single dose of 120 MBq, both preceded by 400 mg/m(2) of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2). Because tumour uptake could not be assessed satisfactorily, a third step was added including EGFR overexpressing tumours.
Results: Nine patients were included (6 NSCLC; 3 HNC). No additional toxicity was associated with administration of 89Zr-cetuximab compared to standard cetuximab. A tumour to blood ratio (TBR) > 1 was observed in all but one patient, with a maximum of 4.56. TBR was not different between dose schedules. There was a trend for higher TBR at intervals > 5 days after injection.
Conclusions: Both presented 89Zr-cetuximab administration schedules are safe. The recommended dose for future trials is 60 MBq, with a minimum time interval for scanning of 6 days. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [van Loon, Judith; Even, Aniek J. G.; Aerts, Hugo J. W. L.; Ollers, Michel; Hoebers, Frank; van Elmpt, Wouter; Dubois, Ludwig; Smits, Kim M.; De Ruysscher, Dirk; Lambin, Philippe] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Radiat Oncol MAASTRO, Maastricht, Netherlands.
[Aerts, Hugo J. W. L.] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA USA.
[Aerts, Hugo J. W. L.] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Radiol, Boston, MA USA.
[Dingemans, Anne-Marie C.] Maastricht Univ, Med Ctr, Dept Pulmonol, Maastricht, Netherlands.
[Lalisang, Roy I.] Maastricht Univ, Med Ctr, Dept Med Oncol, Maastricht, Netherlands.
[Kempers, Pascal; Brans, Boudewijn] Maastricht Univ, Med Ctr, Dept Nucl Med, Maastricht, Netherlands.
[Winnepenninckx, Veronique; Speel, Ernst-Jan] Maastricht Univ, Med Ctr, Dept Pathol, Maastricht, Netherlands.
[Thunnissen, Eric] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands.
[Boellaard, Ronald; Vugts, Danielle J.] Vrije Univ Amsterdam, Med Ctr, Dept Radiol & Nucl Med, Amsterdam, Netherlands.
[De Ruysscher, Dirk] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Radiat Oncol, Leuven, Belgium.
RP van Loon, J (reprint author), MAASTRO Clin, Dr Tanslaan 12, NL-6229 ET Maastricht, Netherlands.
EM Judith.vanloon@maastro.nl
FU CTMM framework (AIRFORCE); EU 6th and 7th framework program (Euroxy,
Metoxia and ARTFORCE); Kankeronderzoekfonds Limburg (Health Foundation
Limburg); National Institute of Health [NIH-USA U01 CA 143062-01]; Dutch
Cancer Society [KWF UM 2008-4210, 2009-4454, 2011-5020, KWF MAC
2013-6425]
FX We acknowledge financial support from the CTMM framework (AIRFORCE), EU
6th and 7th framework program (Euroxy, Metoxia and ARTFORCE), Interreg
(www.eurocat.info), Kankeronderzoekfonds Limburg (Health Foundation
Limburg), the National Institute of Health (NIH-USA U01 CA 143062-01)
and the Dutch Cancer Society (KWF UM 2008-4210, 2009-4454, 2011-5020 and
KWF MAC 2013-6425).
NR 33
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-8140
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD FEB
PY 2017
VL 122
IS 2
BP 267
EP 273
DI 10.1016/jsadonc.2016.11.020
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA EM9BZ
UT WOS:000395607300016
PM 28012793
ER
PT J
AU Melzer, AC
Ghassemieh, BJ
Gillespie, SE
Lindenauer, PK
McBurnie, MA
Mularski, RA
Naureckas, ET
Vollmer, WM
Au, DH
AF Melzer, Anne C.
Ghassemieh, Bijan J.
Gillespie, Suzanne E.
Lindenauer, Peter K.
McBurnie, Mary Ann
Mularski, Richard A.
Naureckas, Edward T.
Vollmer, William M.
Au, David H.
TI Patient characteristics associated with poor inhaler technique among a
cohort of patients with COPD
SO RESPIRATORY MEDICINE
LA English
DT Article
DE Chronic obstructive pulmonary disease (COPD); Inhaled therapy;
Technique; Adherence
ID OBSTRUCTIVE PULMONARY-DISEASE; METERED-DOSE INHALER; INCORRECT
INHALATION TECHNIQUE; HEALTH LITERACY; ASTHMA; MANAGEMENT; ADHERENCE;
EDUCATION
AB Background: Inhaled therapies are the cornerstone of pharmacologic management for COPD. Each device requires a unique series of steps to be most effective, making appropriate instruction in inhaler technique a key part of the management of COPD.
Objectives: Examine characteristics of patients and devices associated with poor technique among patients with COPD.
Methods: Cross-sectional study of subjects with COPD using at least one of: metered dose inhaler, Advair Diskus, Spiriva Handihaler, identified from the COPD Outcomes-based Network for Clinical Effectiveness and Research Translation (CONCERT) registry. Technique was assessed face-to-face using manufacturer provided dummy inhalers, with standardized checklists for each device. We used logistic regression to model associations with poor inhaler technique, defined as an error in >= 20% of the steps, as a function of patient characteristics, with educational attainment the primary predictor.
Results: 688 individuals meet eligibility criteria, 65.5% had poor technique for at least one device. In adjusted analyses, Black race was associated with poor technique (OR 3.25, 95%CI 1.86-5.67) while greater than high school education was associated with decreased odds of poor technique (OR 0.35, 95% CI 0.17-0.70 for trade school/some college, OR 0.25, 95%Cl 0.11-0.61 for college or more, p <= 0.001 for test of linear trend). The percentage of errors varied between devices, with subjects making proportionally the most errors for MDIs.
Conclusions: Poor inhaler technique is common among individuals with COPD, varies between devices, and is associated with race and educational attainment. Tailored educational interventions to teach inhaler technique should be part of the process of initiating and monitoring inhaled therapies. Published by Elsevier Ltd.
C1 [Melzer, Anne C.; Ghassemieh, Bijan J.; Au, David H.] Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA.
[Melzer, Anne C.; Au, David H.] VA Puget Sound, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA.
[Gillespie, Suzanne E.; McBurnie, Mary Ann; Mularski, Richard A.; Vollmer, William M.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA.
[Lindenauer, Peter K.] Baystate Med Ctr, Dept Med, Springfield, MA 01199 USA.
[Naureckas, Edward T.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
[Melzer, Anne C.] VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Mailstop S-152, Seattle, WA 98108 USA.
RP Melzer, AC (reprint author), Univ Washington, Div Pulm & Crit Care, Seattle, WA 98195 USA.; Melzer, AC (reprint author), VA Puget Sound, Ctr Innovat Vet Ctr & Value Driven Care, Seattle, WA USA.; Melzer, AC (reprint author), VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Mailstop S-152, Seattle, WA 98108 USA.; Melzer, AC (reprint author), 1 Vet Dr, Minneapolis, MN 55417 USA.
EM acmelzer@uw.edu
FU National Heart, Lung, and Blood Institute [HL101618]
FX This material is based upon work supported by the Department of Veterans
Affairs, Health Services Research and Development (HSR&D), who provided
access to data, office space, and programming and data management. The
views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs. We would like to acknowledge the other member sites of the
CONCERT Consortium, without whom this project could not have been
completed. Dr. Au has personally reviewed the data, understands the
statistical methods employed for efficacy analysis, and confirms an
understanding of this analysis, that the methods are clearly described
and that they are a fair way to report the results. Dr. Melzer was
supported by an institutional F-32 (HL007287) through the University of
Washington Department of Pulmonary and Critical Care. Additional support
was received through the VA Health Services Research and Development
(HSR&D). Support for this project was also provided by the National
Heart, Lung, and Blood Institute (HL101618) for the CONCERT group. The
views presented are that of the researchers and do not necessary reflect
those of the Department of Veterans Affairs.
NR 39
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO LTD
PI LONDON
PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND
SN 0954-6111
EI 1532-3064
J9 RESP MED
JI Respir. Med.
PD FEB
PY 2017
VL 123
BP 124
EP 130
DI 10.1016/j.rmed.2016.12.011
PG 7
WC Cardiac & Cardiovascular Systems; Respiratory System
SC Cardiovascular System & Cardiology; Respiratory System
GA EL1QY
UT WOS:000394397300018
PM 28137488
ER
PT J
AU Madden, EB
Robinson, RM
Kendall, DL
AF Madden, Elizabeth Brookshire
Robinson, Reva M.
Kendall, Diane L.
TI Phonological Treatment Approaches for Spoken Word Production in Aphasia
SO SEMINARS IN SPEECH AND LANGUAGE
LA English
DT Review
DE Aphasia; anomia; phonology; treatment; phonomotor
ID PHONOMOTOR TREATMENT; COMPONENTS-ANALYSIS; NAMING IMPAIRMENTS; LEXICAL
ACCESS; THERAPY; RETRIEVAL; ANOMIA; ALEXIA; REHABILITATION; PROGRAM
AB This article provides an overview of phonological treatment approaches for anomia in individuals with aphasia. The role of phonology in language processing, as well as the impact of phonological impairment on communication is initially discussed. Then, traditional phonologically based treatment approaches, including phonological, orthographic, indirect, guided, and mixed cueing methods, are described. Collectively, these cueing treatment approaches aim to facilitate word retrieval by stimulating residual phonological abilities. An alternative treatment approach, phonomotor treatment, is also examined. Phonomotor treatment aims to rebuild sublexical, phonological sequence knowledge and phonological awareness as a means to strengthen lexical processing and whole-word naming. This treatment is supported by a parallel-distributed processing model of phonology and therefore promotes multimodal training of individual phonemes and phoneme sequences in an effort to enhance the neural connectivity supporting underlying phonological processing mechanisms. The article concludes with suggestions for clinical application and implementation.
C1 [Madden, Elizabeth Brookshire] Florida State Univ, Sch Commun Sci & Disorders, Tallahassee, FL 32306 USA.
[Robinson, Reva M.] Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98195 USA.
[Kendall, Diane L.] Univ Washington, Dept Speech & Hearing Sci, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA.
[Kendall, Diane L.] Univ Pretoria, Dept Speech Language Pathol & Audiol, Pretoria, South Africa.
RP Madden, EB (reprint author), 201 West Bloxham St, Tallahassee, FL 32306 USA.
EM ebmadden@fsu.edu
FU United States Department of Veterans Affairs [RRD3-15-12W,
1I01RX001145-01A1]
FX The authors would like to acknowledge the United States Department of
Veterans Affairs for providing tremendous funding for aphasia research,
especially for the two grants (#RRD3-15-12W and #1I01RX001145-01A1) that
supported this work.
NR 46
TC 0
Z9 0
U1 0
U2 0
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0734-0478
EI 1098-9056
J9 SEMIN SPEECH LANG
JI Semin. Speech Lang.
PD FEB
PY 2017
VL 38
IS 1
BP 62
EP 74
DI 10.1055/s-0036-1597258
PG 13
WC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
SC Audiology & Speech-Language Pathology; Linguistics; Rehabilitation
GA EM6CC
UT WOS:000395399400008
PM 28201838
ER
PT J
AU Pfeiffer, PN
Valenstein, M
Ganoczy, D
Henry, J
Dobscha, SK
Piette, JD
AF Pfeiffer, Paul N.
Valenstein, Marcia
Ganoczy, Dara
Henry, Jennifer
Dobscha, Steven K.
Piette, John D.
TI Pilot study of enhanced social support with automated telephone
monitoring after psychiatric hospitalization for depression
SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
LA English
DT Article
DE Depression; Discharge; Inpatient; Peer support; Family; Mobile;
Monitoring
ID PEER SUPPORT; PSYCHOMETRIC PROPERTIES; RANDOMIZED-TRIAL; CARE; SUICIDE;
SCALE; INTERVENTION; PREFERENCES; PATIENT; CRISIS
AB Following discharge, patients hospitalized for depression are at high risk for poor retention in outpatient care and adverse outcomes.
Pilot tests a post-hospital monitoring and enhanced support program for depression.
48 patients at a Veterans Affairs Medical Center discharged following a depression-related inpatient stay received weekly visits or phone calls for 6 months from their choice of either a family member/friend (n = 19) or a certified peer support specialist (n = 29). Participants also completed weekly automated telephone monitoring calls assessing depressive symptoms and antidepressant medication adherence.
Over 90% of participants were more satisfied with their care due to the service. The mean change from baseline to 6 months in depression symptoms was -7.9 (p < 0.05) according to the Patient Health Questionnaire and -11.2 (p < 0.05) according to the Beck Depression Inventory-II for those supported by a family member/friend, whereas those supported by a peer specialist had mean changes of -3.5 (p < 0.05) and -1.7 (p > 0.10), respectively.
Increased contact with a chosen support person coupled with automated telephone monitoring after psychiatric hospitalization is an acceptable service for patients with depression. Those who received the service, and particularly those supported by a family member/friend, experienced reductions in symptoms of depression.
C1 [Pfeiffer, Paul N.; Valenstein, Marcia; Piette, John D.] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA.
[Pfeiffer, Paul N.; Valenstein, Marcia; Ganoczy, Dara; Henry, Jennifer; Piette, John D.] VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, Ann Arbor, MI 48105 USA.
[Dobscha, Steven K.] Portland VA Med Ctr, VA Ctr Vet Involvement Care, Portland, MI USA.
[Dobscha, Steven K.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Piette, John D.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
RP Pfeiffer, PN (reprint author), Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA.; Pfeiffer, PN (reprint author), VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, Ann Arbor, MI 48105 USA.
EM ppfeiffe@umich.edu
NR 30
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0933-7954
EI 1433-9285
J9 SOC PSYCH PSYCH EPID
JI Soc. Psychiatry Psychiatr. Epidemiol.
PD FEB
PY 2017
VL 52
IS 2
BP 183
EP 191
DI 10.1007/s00127-016-1288-2
PG 9
WC Psychiatry
SC Psychiatry
GA EM3EL
UT WOS:000395197200010
PM 27783130
ER
PT J
AU Ramanadhan, S
Nagler, RH
McCloud, R
Kohler, R
Viswanath, K
AF Ramanadhan, Shoba
Nagler, Rebekah H.
McCloud, Rachel
Kohler, Racquel
Viswanath, Kasisomayajula
TI Graphic health warnings as activators of social networks: A field
experiment among individuals of low socioeconomic position
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE Social networks; Low socioeconomic position; Tobacco; Egocentric;
Graphic health warnings
ID CIGARETTE PACK WARNINGS; INTERPERSONAL-COMMUNICATION; SMOKING-CESSATION;
MEDIA CAMPAIGN; SMOKERS; CONSEQUENCES; MESSAGES; TALKING; LABELS;
INTERVENTIONS
AB Rationale: Graphic health warnings (GHWs) on cigarette packages present an important tobacco control opportunity, particularly for vulnerable populations suffering a disproportionate tobacco burden. One mechanism by which GHWs may influence smoking outcomes is by prompting interpersonal discussions within health discussion networks (the set of personal contacts with whom an individual discusses health issues).
Objective: The study examined the association between GHW-prompted conversations within health discussion networks and key tobacco-related outcomes, with attention to valence and content of the discussions.
Method: Between August 2013 and April 2014, we recruited 1200 individuals from three communities in Massachusetts, emphasizing recruitment of individuals of low socioeconomic position (SEP) and members of other selected vulnerable groups. Respondents were exposed to the nine GHWs proposed by the FDA in 2011, asked a series of questions, and assessed at follow-up a few weeks later.
Results: A total of 806 individuals were included in this analysis. About 51% of respondents reported having a health discussion network, with significantly lower reports among African-Americans and Hispanics compared to Whites. Around 70% of respondents (smokers and nonsmokers) with health discussion networks reported having one or more conversations about the GHWs with network members, the bulk of which were negative and focused on warning others about smoking. For smokers, we found a small but positive association between the percentage of network conversations that were negative and reports of quit attempts.
Conclusion: The results point to a potential mechanism by which GHWs may impact tobacco-related outcomes, prompting further inquiry into the role of health discussion networks (and discussion networks, more broadly) in tobacco control among low SEP individuals. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Ramanadhan, Shoba; McCloud, Rachel; Kohler, Racquel; Viswanath, Kasisomayajula] Dana Farber Canc Inst, Ctr Community Based Res, 450 Brookline Ave,LW601, Boston, MA 02215 USA.
[Ramanadhan, Shoba; Kohler, Racquel; Viswanath, Kasisomayajula] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave, Boston, MA 02115 USA.
[Nagler, Rebekah H.] Univ Minnesota, Sch Journalism & Mass Commun, 206 Church St SE, Minneapolis, MN 55455 USA.
RP Ramanadhan, S (reprint author), 450 Brookline Ave,LW 601, Boston, MA 02215 USA.
EM shoba_ramanadhan@dfci.harvard.edu; nagle026@umn.edu;
rachel_faulkenberry@dfci.harvard.edu; racquel_kohler@dfci.harvard.edu;
vish_viswanath@dfci.harvard.edu
FU National Cancer Institute [3P50CA148596-03S1]
FX The authors thank our community partners in Boston, Lawrence, and
Worcester, MA for their assistance and support in recruiting and
retaining study participants. The study was funded by the National
Cancer Institute (3P50CA148596-03S1, Viswanath Study PI). The content is
solely the responsibility of the authors and does not necessarily
represent the official views of the National Institutes of Health. The
authors also thank three anonymous reviewers for their insightful
comments and critiques.
NR 66
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD FEB
PY 2017
VL 175
BP 219
EP 227
DI 10.1016/j.socscimed.2016.12.044
PG 9
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA EM5OG
UT WOS:000395360500026
PM 28108053
ER
PT J
AU El Husseini, N
Fonarow, GC
Smith, EE
Ju, C
Schwamm, LH
Hernandez, AF
Schulte, PJ
Xian, Y
Goldstein, LB
AF El Husseini, Nada
Fonarow, Gregg C.
Smith, Eric E.
Ju, Christine
Schwamm, Lee H.
Hernandez, Adrian F.
Schulte, Phillip J.
Xian, Ying
Goldstein, Larry B.
TI Renal Dysfunction Is Associated With Poststroke Discharge Disposition
and In-Hospital Mortality: Findings From Get With The Guidelines-Stroke
SO STROKE
LA English
DT Article
DE acute kidney injury; glomerular filtration rate; kidney disease;
Medicare; outcomes; stroke
ID CHRONIC KIDNEY-DISEASE; ISCHEMIC-STROKE; OUTCOMES; POPULATION; REGISTRY;
FAILURE; CODES; RISK
AB Background and Purpose Kidney disease is a frequent comorbidity in patients presenting with acute ischemic stroke. We evaluated whether the estimated glomerular filtration rate (eGFR) on admission is associated with poststroke in-hospital mortality or discharge disposition.
Methods In this cohort study, data from ischemic stroke patients in Get With The Guidelines-Stroke linked to fee-for-service Medicare data were analyzed. The Modification of Diet in Renal Disease study equation was used to calculate the eGFR (mL/min/1.73 m(2)). Dialysis was identified by International Classification of Diseases, Ninth Revision codes. Adjusted multivariable Cox proportional hazards models were used to determine the independent associations of eGFR with discharge disposition and in-hospital mortality. Adjusted individual models also examined whether the association of clinical and demographic factors with outcomes varied by eGFR level.
Results Of 232236 patients, 47.3% had an eGFR 60, 26.6% an eGFR 45 to 59, 16.8% an eGFR 30 to 44, 5.6% an eGFR 15 to 29, 0.7% an eGFR<15 without dialysis, and 2.8% were receiving dialysis. Of the total cohort, 11.8% died during the hospitalization or were discharged to hospice, and 38.6% were discharged home. After adjusting for other relevant variables, renal dysfunction was independently associated with an increased risk of in-hospital mortality that was highest among those with eGFR <15 without dialysis (odds ratio, 2.52; 95% confidence interval, 2.07-3.07). An eGFR 15 to 29 (odds ratio, 0.82; 95% confidence interval, 0.78-0.87), eGFR <15 (odds ratio, 0.72; 95% confidence interval, 0.61-0.86), and dialysis (odds ratio, 0.86; 95% confidence interval, 0.79-0.94) remained associated with lower odds of being discharged home. In addition, the associations of several clinical and demographic factors with outcomes varied by eGFR level.
Conclusions eGFR on admission is an important predictor of poststroke short-term outcomes.
C1 [El Husseini, Nada] Wake Forest Baptist Univ Hlth Sci, Dept Neurol, Winston Salem, NC USA.
[Ju, Christine; Hernandez, Adrian F.; Schulte, Phillip J.; Xian, Ying] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[El Husseini, Nada; Xian, Ying] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA.
[Fonarow, Gregg C.] Ronald Reagan UCLA, Med Ctr, UCLA Div Cardiol, Los Angeles, CA USA.
[Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 1N4, Canada.
[Schwamm, Lee H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Goldstein, Larry B.] Univ Kentucky, Dept Neurol, Lexington, KY 40506 USA.
RP El Husseini, N (reprint author), Wake Forest Baptist Med Ctr, Dept Neurol, Div Vasc Neurol, 6th Floor Janeway Tower,Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM nelhusse@wakehealth.edu
FU Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership; American Heart
Association Pharmaceutical Roundtable; Boehringer-Ingelheim; Merck;
National Institute of Diabetes and Digestive and Kidney Diseases
[P30DK096493]
FX The Get With The Guidelines (GWTG)-Stroke program is supported in part
by a charitable contribution from Bristol-Myers Squibb/Sanofi
Pharmaceutical Partnership and the American Heart Association
Pharmaceutical Roundtable. GWTG-Stroke has been funded in the past
through support from Boehringer-Ingelheim and Merck. This work was
supported by the National Institute of Diabetes and Digestive and Kidney
Diseases (P30DK096493).
NR 17
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD FEB
PY 2017
VL 48
IS 2
BP 327
EP 334
DI 10.1161/STROKEAHA.116.014601
PG 8
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA EL3HN
UT WOS:000394510300026
PM 28034963
ER
PT J
AU Man, SM
Cox, M
Patel, P
Smith, EE
Reeves, MJ
Saver, JL
Bhatt, DL
Xian, Y
Schwamm, LH
Fonarow, GC
AF Man, Shumei
Cox, Margueritte
Patel, Puja
Smith, Eric E.
Reeves, Mathew J.
Saver, Jeffrey L.
Bhatt, Deepak L.
Xian, Ying
Schwamm, Lee H.
Fonarow, Gregg C.
TI Differences in Acute Ischemic Stroke Quality of Care and Outcomes by
Primary Stroke Center Certification Organization
SO STROKE
LA English
DT Article
DE certification; ischemic stroke; outcome; primary stroke center; quality
of care
ID GUIDELINES-STROKE; PERFORMANCE-MEASURES; HOSPITALIZATION; THROMBOLYSIS;
ASSOCIATION; MORTALITY; ATTACK
AB Background and Purpose Primary stroke center (PSC) certification was established to identify hospitals providing evidence-based care for stroke patients. The numbers of PSCs certified by Joint Commission (JC), Healthcare Facilities Accreditation Program, Det Norske Veritas, and State-based agencies have significantly increased in the past decade. This study aimed to evaluate whether PSCs certified by different organizations have similar quality of care and in-hospital outcomes.
Methods The study population consisted of acute ischemic stroke patients who were admitted to PSCs participating in Get With The Guidelines-Stroke between January 1, 2010, and December 31, 2012. Measures of care quality and outcomes were compared among the 4 different PSC certifications.
Results A total of 477297 acute ischemic stroke admissions were identified from 977 certified PSCs (73.8% JC, 3.7% Det Norske Veritas, 1.2% Healthcare Facilities Accreditation Program, and 21.3% State-based). Composite care quality was generally similar among the 4 groups of hospitals, although State-based PSCs underperformed JC PSCs in a few key measures, including intravenous tissue-type plasminogen activator use. The rates of tissue-type plasminogen activator use were higher in JC and Det Norske Veritas (9.0% and 9.8%) and lower in State and Healthcare Facilities Accreditation Program certified hospitals (7.1% and 5.9%) (P<0.0001). Door-to-needle times were significantly longer in Healthcare Facilities Accreditation Program hospitals. State PSCs had higher in-hospital risk-adjusted mortality (odds ratio 1.23, 95% confidence intervals 1.07-1.41) compared with JC PSCs.
Conclusions Among Get With The Guidelines-Stroke hospitals with PSC certification, acute ischemic stroke quality of care and outcomes may differ according to which organization provided certification. These findings may have important implications for further improving systems of care.
C1 [Man, Shumei] Wright State Univ, Dept Neurol, Miami Valley Hosp, Boonshoft Sch Med, Dayton, OH 45435 USA.
[Cox, Margueritte; Xian, Ying] Duke Clin Res Ctr, Durham, NC USA.
[Patel, Puja] Amer Heart Assoc, Dept Advocacy & Qual, Dallas, TX USA.
[Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary, AB T2N 1N4, Canada.
[Reeves, Mathew J.] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA.
[Saver, Jeffrey L.] Univ Calif Los Angeles, Div Neurol, Los Angeles, CA USA.
[Bhatt, Deepak L.] Harvard Univ, Brigham & Womens Hosp, Heart & Vasc Ctr, Harvard Med Sch, Boston, MA 02115 USA.
[Xian, Ying] Duke Univ, Dept Neurol, Med Ctr, Durham, NC USA.
[Schwamm, Lee H.] Massachusetts Gen Hosp, Div Neurol, Boston, MA 02114 USA.
[Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA.
RP Fonarow, GC (reprint author), UCLA Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, 10833 LeConte Ave,Room 47-123 CHS, Los Angeles, CA 90095 USA.
EM gfonarow@mednet.ucla.edu
FU American Heart Association; Bristol-Myers Squibb/Sanofi Pharmaceutical
Partnership; American Heart Association Pharmaceutical Roundtable;
Boehringer-Ingelheim; Merck
FX The American Heart Association receives a portion of the fees paid by
hospitals to the Joint Commission for Primary Stroke Certification. The
GWTG-Stroke program is currently supported in part by a charitable
contribution from Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership
and the American Heart Association Pharmaceutical Roundtable.
GWTG-Stroke has been funded in the past through support from
Boehringer-Ingelheim and Merck. These funding agencies did not
participate in design or analysis, manuscript preparation, or approval
of this study.
NR 15
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD FEB
PY 2017
VL 48
IS 2
BP 412
EP 419
DI 10.1161/STROKEAHA.116.014426
PG 8
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA EL3HN
UT WOS:000394510300039
PM 28008094
ER
PT J
AU Liu, Y
Zheng, Y
Karatas, H
Wang, XY
Foerch, C
Lo, EH
van Leyen, K
AF Liu, Yu
Zheng, Yi
Karatas, Hulya
Wang, Xiaoying
Foerch, Christian
Lo, Eng H.
van Leyen, Klaus
TI 12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated
Hemorrhagic Transformation After Experimental Stroke
SO STROKE
LA English
DT Article
DE atrial fibrillation; brain; hemorrhage; stroke; warfarin
ID ACUTE ISCHEMIC-STROKE; ATRIAL-FIBRILLATION; INTRACEREBRAL HEMORRHAGE;
INTRACRANIAL HEMORRHAGE; CEREBRAL-ISCHEMIA; ANTICOAGULATION; THERAPY;
BRAIN; LIPOXYGENASE; MORTALITY
AB Background and Purpose For stroke prevention, patients with atrial fibrillation typically receive oral anticoagulation. The commonly used anticoagulant warfarin increases the risk of hemorrhagic transformation (HT) when a stroke occurs; tissue-type plasminogen activator treatment is therefore restricted in these patients. This study was designed to test the hypothesis that 12/15-lipoxygenase (12/15-LOX) inhibition would reduce HT in warfarin-treated mice subjected to experimental stroke.
Methods Warfarin was dosed orally in drinking water, and international normalized ratio values were determined using a Coaguchek device. C57BL6J mice or 12/15-LOX knockout mice were subjected to transient middle cerebral artery occlusion with 3 hours severe ischemia (model A) or 2 hours ischemia and tissue-type plasminogen activator infusion (model B), with or without the 12/15-LOX inhibitor ML351. Hemoglobin was determined in brain homogenates, and hemorrhage areas on the brain surface and in brain sections were measured. 12/15-LOX expression was detected by immunohistochemistry.
Results Warfarin treatment resulted in reproducible increased international normalized ratio values and significant HT in both models. 12/15-LOX knockout mice suffered less HT after severe ischemia, and ML351 reduced HT in wild-type mice. When normalized to infarct size, ML351 still independently reduced hemorrhage. HT after tissue-type plasminogen activator was similarly reduced by ML351.
Conclusions In addition to its benefits in infarct size reduction, 12/15-LOX inhibition also may independently reduce HT in warfarin-treated mice. ML351 should be further evaluated as stroke treatment in anticoagulated patients suffering a stroke, either alone or in conjunction with tissue-type plasminogen activator.
C1 [Liu, Yu; Zheng, Yi; Karatas, Hulya; Wang, Xiaoying; Lo, Eng H.; van Leyen, Klaus] Harvard Med Sch, Massachusetts Gen Hosp, Neuroprotect Res Lab, Charlestown, MA USA.
[Liu, Yu] Harbin Med Univ, Affiliated Hosp 2, Dept Neurol, Harbin, Peoples R China.
[Foerch, Christian] Goethe Univ, Dept Neurol, Frankfurt, Germany.
[Karatas, Hulya] Hacettepe Univ, Inst Neurol Sci & Psychiat, Ankara, Turkey.
RP van Leyen, K (reprint author), Massachusetts Gen Hosp, Neuroprotect Res Labs, 149 13th St,R 2401, Charlestown, MA 02129 USA.
EM klaus_vanleyen@hms.harvard.edu
FU National Institutes of Health [R01 NS069939, R01 NS049430]
FX Support from the National Institutes of Health (grants R01 NS069939 and
R01 NS049430 to Dr van Leyen) is gratefully acknowledged.
NR 35
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD FEB
PY 2017
VL 48
IS 2
BP 445
EP 451
DI 10.1161/STROKEAHA.116.014790
PG 7
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA EL3HN
UT WOS:000394510300043
PM 28057806
ER
PT J
AU Lubitz, SA
Yin, XY
McManus, DD
Weng, LC
Aparicio, HJ
Walkey, AJ
Romero, JR
Kase, CS
Ellinor, PT
Wolf, PA
Seshadri, S
Benjamin, EJ
AF Lubitz, Steven A.
Yin, Xiaoyan
McManus, David D.
Weng, Lu-Chen
Aparicio, Hugo J.
Walkey, Allan J.
Romero, Jose Rafael
Kase, Carlos S.
Ellinor, Patrick T.
Wolf, Philip A.
Seshadri, Sudha
Benjamin, Emelia J.
TI Stroke as the Initial Manifestation of Atrial Fibrillation: The
Framingham Heart Study
SO STROKE
LA English
DT Article
DE atrial fibrillation; atrial flutter; incidence; mass screening; stroke
ID COST-EFFECTIVENESS; COHORT; ECG
AB Background and Purpose-To prevent strokes that may occur as the first manifestation of atrial fibrillation (AF), screening programs have been proposed to identify patients with undiagnosed AF who may be eligible for treatment with anticoagulation. However, the frequency with which patients with AF present with stroke as the initial manifestation of the arrhythmia is unknown.
Methods-We estimated the frequency with which AF may present as a stroke in 1809 community-based Framingham Heart Study participants with first-detected AF and without previous strokes, by tabulating the frequencies of strokes occurring on the same day, within 30 days before, 90 days before, and 365 days before first-detected AF. Using previously reported AF incidence rates, we estimated the incidence of strokes that may represent the initial manifestation of AF.
Results-We observed 87 strokes that occurred 1 year before AF detection, corresponding to 1.7% on the same day, 3.4% within 30 days before, 3.7% within 90 days before, and 4.8% 1 year before AF detection. We estimated that strokes may present as the initial manifestation of AF at a rate of 2 to 5 per 10000 person-years, in both men and women.
Conclusions-We observed that stroke is an uncommon but measureable presenting feature of AF. Our data imply that emphasizing cost-effectiveness of population-wide AF-screening efforts will be important given the relative infrequency with which stroke represents the initial manifestation of AF.
C1 [Lubitz, Steven A.; Weng, Lu-Chen; Ellinor, Patrick T.] Boston Univ, Cardiovasc Res Ctr, Massachusetts Gen Hosp, Boston, MA 02215 USA.
[Lubitz, Steven A.; Ellinor, Patrick T.] Boston Univ, Cardiac Arrhythmia Serv, Massachusetts Gen Hosp, Boston, MA 02215 USA.
[Yin, Xiaoyan; Romero, Jose Rafael; Wolf, Philip A.; Seshadri, Sudha; Benjamin, Emelia J.] Natl Heart Lung & Blood Inst Framingham Heart Stu, Framingham, MA USA.
[McManus, David D.] Univ Massachusetts, Div Cardiol, Dept Med, Sch Med, Worcester, MA USA.
[Aparicio, Hugo J.; Romero, Jose Rafael; Wolf, Philip A.; Seshadri, Sudha; Benjamin, Emelia J.] Boston Univ, Sch Med, Boston, MA USA.
[Aparicio, Hugo J.; Romero, Jose Rafael; Kase, Carlos S.; Seshadri, Sudha] Boston Med Ctr, Dept Neurol, Boston, MA USA.
[Walkey, Allan J.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA USA.
[Walkey, Allan J.] Boston Univ, Sch Med, Sect Pulm & Crit Care Med, Boston, MA USA.
[Walkey, Allan J.] Boston Univ, Sch Med, Dept Med, Boston, MA USA.
[Benjamin, Emelia J.] Boston Univ, Sch Med, Prevent Med Sect, Dept Med, Boston, MA USA.
RP Lubitz, SA (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv & Cardiovascular Res Ctr, 55 Fruit St,GRB 109, Boston, MA 02114 USA.
EM slubitz@mgh.harvard.edu
FU National Institutes of Health grants [K23HL114724, 2R01HL092577,
1R01HL128914, 1R01HL102214, R01HL104156, K24HL105780, R01NS017950,
1U01HL105268-01, R01 HL126911, KL2TR000160, HHSN268201500001I,
N01-HC-25195]; Doris Duke Charitable Foundation Clinical Scientist
Development Award [2014105]; American Heart Association Established
Investigator Award [13EIA14220013]
FX This study was supported by National Institutes of Health grants
K23HL114724 (Dr Lubitz), 2R01HL092577, 1R01HL128914 (Drs Ellinor and
Benjamin), 1R01HL102214 (Dr Benjamin), R01HL104156, K24HL105780 (Dr
Ellinor), R01NS017950 (Dr Seshadri), 1U01HL105268-01, R01 HL126911 and
KL2TR000160 (Dr McManus), HHSN268201500001I, and N01-HC-25195
(Framingham Heart Study); Doris Duke Charitable Foundation Clinical
Scientist Development Award 2014105 (Dr Lubitz); and American Heart
Association Established Investigator Award 13EIA14220013 (Dr Ellinor).
NR 15
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD FEB
PY 2017
VL 48
IS 2
BP 490
EP 492
DI 10.1161/STROKEAHA.116.015071
PG 3
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA EL3HN
UT WOS:000394510300051
PM 28082669
ER
PT J
AU Barnes, SM
Bahraini, NH
Forster, JE
Stearns-Yoder, KA
Hostetter, TA
Smith, G
Nagamoto, HT
Nock, MK
AF Barnes, Sean M.
Bahraini, Nazanin H.
Forster, Jeri E.
Stearns-Yoder, Kelly A.
Hostetter, Trisha A.
Smith, Geoffrey
Nagamoto, Herbert T.
Nock, Matthew K.
TI Moving Beyond Self-Report: Implicit Associations about Death/Life
Prospectively Predict Suicidal Behavior among Veterans
SO SUICIDE AND LIFE-THREATENING BEHAVIOR
LA English
DT Article
ID RISK-ASSESSMENT; INJURIOUS THOUGHTS; IDEATION; ADOLESCENTS; DEPRESSION;
COGNITION; MIND
AB Reliance on self-report limits clinicians' ability to accurately predict suicidal behavior. In this study the predictive validity of an objective measure, the death/suicide Implicit Association Test (d/sIAT), was tested among psychiatrically hospitalized veterans. Following acute stabilization, 176 participants completed the d/sIAT and traditional suicide risk assessments. Participants had similar d/sIAT scores regardless of whether they had recently attempted suicide. However, d/sIAT scores significantly predicted suicide attempts during the 6-month follow-up above and beyond other known risk factors for suicidal behavior (OR=1.89; 95% CI: 1.15-3.12; based on 1SD increase). The d/sIAT may augment the accuracy of suicide risk assessment.
C1 [Barnes, Sean M.; Bahraini, Nazanin H.; Forster, Jeri E.; Stearns-Yoder, Kelly A.; Hostetter, Trisha A.; Smith, Geoffrey; Nagamoto, Herbert T.] Rocky Mt Mental Illness Res Educ & Clin Ctr, Denver, CO USA.
[Barnes, Sean M.; Bahraini, Nazanin H.; Nagamoto, Herbert T.] Univ Colorado, Sch Med, Dept Psychiat, Anschutz Med Campus, Aurora, CO USA.
[Bahraini, Nazanin H.; Forster, Jeri E.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Anschutz Med Campus, Aurora, CO USA.
[Forster, Jeri E.] Univ Colorado, Sch Med, Dept Biostat & Informat, Anschutz Med Campus, Aurora, CO USA.
[Nock, Matthew K.] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.
RP Barnes, SM (reprint author), Denver VA Med Ctr, Rocky Mt MIRECC, 1055 Clermont St, Denver, CO 80220 USA.
EM Sean.Barnes2@va.gov
FU Military Suicide Research Consortium, through the Office of the
Assistant Secretary of Defense for Health Affairs; Rocky Mountain Mental
Illness, Research, Education, and Clinical Center; U.S. Government.
Denver VA Medical Center [W81XWH-10-2-0178]
FX This research was funded by the Military Suicide Research Consortium,
through the Office of the Assistant Secretary of Defense for Health
Affairs, and by the Rocky Mountain Mental Illness, Research, Education,
and Clinical Center. Opinions, interpretations, conclusions, and
recommendations are those of the authors and are not necessarily
endorsed by the Military Suicide Research Consortium, Department of
Defense, Department of Veterans Affairs, or the U.S. Government. Denver
VA Medical Center Grant Number: W81XWH-10-2-0178.
NR 23
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0363-0234
EI 1943-278X
J9 SUICIDE LIFE-THREAT
JI Suicide Life-Threat. Behav.
PD FEB
PY 2017
VL 47
IS 1
BP 67
EP 77
DI 10.1111/sltb.12265
PG 11
WC Psychiatry; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA EL9QI
UT WOS:000394954700007
PM 27387836
ER
PT J
AU Bonatti, H
Sifri, CD
Larcher, C
Schneeberger, S
Kotton, C
Geltner, C
AF Bonatti, Hugo
Sifri, Costi D.
Larcher, Clara
Schneeberger, Stefan
Kotton, Camille
Geltner, Christian
TI Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir
in Solid Organ Recipients
SO SURGICAL INFECTIONS
LA English
DT Article
DE Cytomegalovirus; cidofovir; immunosuppression; solid organ
transplantation
ID HEART-TRANSPLANT RECIPIENT; SINGLE-CENTER EXPERIENCE; RESISTANT
CYTOMEGALOVIRUS; ORAL GANCICLOVIR; CMV DISEASE; VALGANCICLOVIR
PROPHYLAXIS; IMMUNOCOMPROMISED PATIENTS; CELL TRANSPLANTATION;
PREEMPTIVE THERAPY; VIRAL-INFECTIONS
AB Background: Solid organ transplantation (SOT) frequently is complicated by cytomegalovirus (CMV) infections. Cidofovir (CDV) is active against CMV, including many ganciclovir (GCV)-resistant mutants, but often is considered to be too nephrotoxic for use after organ transplantation.
Patients and Methods: Seven males and two females (median age 50.1 years), including two kidney/pancreas, four lung, one small bowel, and two hand recipients, received CDV for refractory CMV disease.
Results: Three recipients were CMV seronegative, but all nine received grafts from CMV-seropositive donors. Five patients were given antithymocyte globulin, four received daclizumab induction, seven experienced rejection (five with multiple episodes), and one suffered from common variable immunodeficiency. Six presented with other infections (five invasive fungal and four bacterial). Eight patients had received prophylactic GCV, and eight had been treated for CMV infection/disease (GCV eight; CMV immunoglobulin three; foscarnet three). The indications for CDV were UL97 CMV mutation (n = 2), GCV-induced neutropenia with continued CMV disease (n = 4), and clinical resistance to GCV (n = 3). Seven patients cleared CMV, and two had a partial response. Four experienced CMV relapse requiring GCV (n = 2), repeat CDV (n = 1), or CMV immunoglobulin (n = 1). Four patients had mild nephrotoxicity, and three developed renal failure, all in association with additional factors. No patient died directly from CMV disease alone. Two patients died of uncontrolled infections and concurrent CMV disease, one with invasive aspergillosis and another with nocardiosis.
Conclusions: Cidofovir was useful for the treatment of GCV-refractory CMV disease after SOT. Although nephrotoxicity was a common complication of CDV, several patients completed a course of therapy successfully and demonstrated effective treatment of CMV disease.
C1 [Bonatti, Hugo] Univ Maryland, Dept Surg, Shore Hlth Syst, 503 Dutchmans Lane, Easton, MD 21601 USA.
[Larcher, Clara] MB LAB Mikrobiol Labor, Innsbruck, Austria.
[Bonatti, Hugo; Schneeberger, Stefan] Med Univ Innsbruck, Dept Visceral Transplant & Thorac Surg, Innsbruck, Austria.
[Sifri, Costi D.] Univ Virginia Hlth Syst, Div Infect Dis & Int Hlth, Dept Med, Charlottesville, VA USA.
[Kotton, Camille] Harvard Med Sch, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA USA.
[Geltner, Christian] Klinikum Klagenfurt, Dept Pulmonol, Klagenfurt, Austria.
RP Bonatti, H (reprint author), Univ Maryland, Dept Surg, Shore Hlth Syst, 503 Dutchmans Lane, Easton, MD 21601 USA.
EM hugo.bonatti@dr.com
NR 80
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-2964
EI 1557-8674
J9 SURG INFECT
JI Surg. Infect.
PD FEB-MAR
PY 2017
VL 18
IS 2
BP 128
EP 136
DI 10.1089/sur.2015.266
PG 9
WC Infectious Diseases; Surgery
SC Infectious Diseases; Surgery
GA EL3DU
UT WOS:000394500600008
PM 27849440
ER
PT J
AU Ashong, CN
Raheem, SA
Hunter, AS
Mindru, C
Barshes, NR
AF Ashong, Chester N.
Raheem, Shazia A.
Hunter, Andrew S.
Mindru, Cezarina
Barshes, Neal R.
TI Methicillin-Resistant Staphylococcus aureus in Foot Osteomyelitis
SO SURGICAL INFECTIONS
LA English
DT Article
DE diabetes; MRSA; MSSA; osteomyelitis; staphylococcal infections
ID INFECTIONS; DIAGNOSIS; PATHOGENS; BONE
AB Background: Conflicting studies exist regarding the impact of methicillin-resistant Staphylococcus aureus (MRSA) on increased time to wound healing, future need for surgical procedures, and likelihood of treatment failure in patients with diabetic foot osteomyelitis. The purpose of this study is to determine the overall significance of MRSA in predicting treatment failure in bone infections of the foot and to determine an appropriate pre-operative and empiric post-operative antibiotic regimen.
Patients and Methods: Patients presenting with an initial episode of "probable" or "definite" foot osteomyelitis were included for review and analysis if the following criteria were met: (1) Osteomyelitis occurred in the foot (i.e., distal to the malleoli of the ankle); episodes occurring above the ankle were excluded. (2) Patients received either no antibiotics or only oral antibiotics for long-term treatment; episodes managed with long-term parenteral antibiotics were excluded. (3) The infection was managed initially with medical therapy or conservative surgical therapy; episodes managed with major (above-ankle) amputation as the initial treatment were excluded. The primary objective of this study was to assess whether episodes of foot osteomyelitis associated with MRSA resulted in treatment failure more frequently than not.
Results: Of 178 episodes included in the study, 50 (28.1%) episodes had treatment failure. Median time-to-treatment failure was 60 days (range 7-598 days). In 28.1% (9/32 episodes) in which treatment failure occurred and 39.0% (41/105) episodes in which no treatment failure occurred, MRSA was present. The presence of MRSA was not significantly associated with treatment failure (p = 0.99).
Conclusions: The presence of MRSA in bone culture and whether antibiotic use had anti-MRSA activity was not associated with increased treatment failure of diabetic foot osteomyelitis in our institution. Empiric antibiotic coverage of MRSA may not be necessary for many patients presenting with foot osteomyelitis.
C1 [Ashong, Chester N.; Raheem, Shazia A.; Hunter, Andrew S.] Michael E DeBakey VA Med Ctr, Dept Pharm, Houston, TX USA.
[Mindru, Cezarina] Michael E DeBakey VA Med Ctr, Dept Infect Dis, Houston, TX USA.
[Barshes, Neal R.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Vasc & Endovasc Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
RP Barshes, NR (reprint author), Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Div Vasc & Endovasc Surg, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM nbarshes@bcm.tmc.edu
FU Michael E. DeBakey Veterans Affairs Medical Center
FX We would like to acknowledge research support from the Michael E.
DeBakey Veterans Affairs Medical Center. Dr. Barshes has received
$25,000 from the Michael E. DeBakey Veterans Affairs Medical Center, a
federal institution, for the study of foot osteomyelitis.
NR 18
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-2964
EI 1557-8674
J9 SURG INFECT
JI Surg. Infect.
PD FEB-MAR
PY 2017
VL 18
IS 2
BP 143
EP 148
DI 10.1089/sur.2016.165
PG 6
WC Infectious Diseases; Surgery
SC Infectious Diseases; Surgery
GA EL3DU
UT WOS:000394500600010
PM 27898266
ER
PT J
AU O'Donnell, EK
Raje, NS
AF O'Donnell, Elizabeth K.
Raje, Noopur S.
TI New monoclonal antibodies on the horizon in multiple myeloma
SO THERAPEUTIC ADVANCES IN HEMATOLOGY
LA English
DT Review
DE monoclonal antibodies; multiple myeloma; novel therapies
ID CELL MATURATION ANTIGEN; LOW-DOSE DEXAMETHASONE; BONE-MARROW;
PLASMA-CELLS; OPEN-LABEL; DARATUMUMAB MONOTHERAPY; ACTIVATING FACTOR;
PHASE-2 TRIAL; CANCER CELLS; SINGLE-ARM
AB Across all cancers, monoclonal antibodies have emerged as a potential strategy for cancer therapy. Monoclonal antibodies target antigens expressed on the surface of cancer cells and accessory cells. This targeted approach uses the host's immune system to promote the killing of cancer cells. Multiple myeloma (MM) is the second most common hematologic malignancy that remains incurable in the majority of patients. The treatment of MM has evolved dramatically over the past decade and continues to evolve with the approval of four new drugs in 2015. Most recently the United States Food and Drug Administration (US FDA) approved two monoclonal antibodies for the treatment of this disease. Monoclonal antibodies are generally well-tolerated and offer a novel method of action for treated relapsed and refractory disease and are now being studied in the upfront setting. In this article, we review the evidence for the existing approved monoclonal antibodies and discuss promising targeted therapies and innovative strategies for the treatment of MM.
C1 [O'Donnell, Elizabeth K.; Raje, Noopur S.] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
RP O'Donnell, EK (reprint author), Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02114 USA.
EM ekodonnell@mgh.harvard.edu
NR 72
TC 0
Z9 0
U1 2
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 2040-6207
EI 2040-6215
J9 THER ADV HEMATOL
JI Ther. Adv. Hematol.
PD FEB
PY 2017
VL 8
IS 2
BP 41
EP 53
DI 10.1177/2040620716682490
PG 13
WC Hematology
SC Hematology
GA EL5NT
UT WOS:000394668500001
PM 28203341
ER
PT J
AU Shen, Q
Yu, WR
Fang, Y
Yao, M
Yang, PG
AF Shen, Qiong
Yu, Weirong
Fang, Yong
Yao, Min
Yang, Penggao
TI Beta-catenin can induce hair follicle stem cell differentiation into
transit-amplifying cells through c-myc activation
SO TISSUE & CELL
LA English
DT Article
DE Hair follicle stem cell; Transit-amplifying cell; beta-Catenin; c-myc
ID KERATINOCYTE DIFFERENTIATION; WNT/BETA-CATENIN; DERMAL PAPILLA; NICHE;
SKIN; EXPRESSION; WNT; REGENERATION; EPIDERMIS; GROWTH
AB Hair follicle stem cells play important roles in maintaining homeostasis and skin tissue self-renewal. Transit-amplifying cells represent the transition of cells from hair follicle stem cells into differentiated epidermal cells. Thus far, the signaling pathway and the molecular biological mechanism that regulate the proliferation and differentiation of hair follicle stem cells remain unclear. In this paper, we studied the relationship between beta-catenin and c-myc during the process of the differentiation of hair follicle stem cells into transit-amplifying cells. Based on our results, the expression of beta-catenin can activate the nuclear gene c-myc and regulate the expression of transit-amplifying cell markers K15, K19, a6-integrin and beta 1-integrin, indicating that beta-catenin is involved in the transformation process from hair follicle stem cells to transit-amplifying cells and suggesting that beta-catenin plays an important biological role in the induction of this differentiation process. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Shen, Qiong] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Ultrasound Diag, Sch Med, Shanghai 201999, Peoples R China.
[Yu, Weirong; Fang, Yong; Yao, Min; Yang, Penggao] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Burns & Plast Surg, Sch Med, Floor 15,Surg Bldg,280 Mohe Rd, Shanghai 201999, Peoples R China.
[Fang, Yong; Yao, Min] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai 201999, Peoples R China.
[Yao, Min] Harvard Med Sch, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Yang, PG (reprint author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Burns & Plast Surg, Sch Med, Floor 15,Surg Bldg,280 Mohe Rd, Shanghai 201999, Peoples R China.
EM ypg_999@163.com
FU Nature Science Foundation of Shanghai Ninth People's Hospital; Shanghai
JiaoTong University School of Medicine [644]
FX Nature Science Foundation of Shanghai Ninth People's Hospital, Shanghai
JiaoTong University School of Medicine; grant number: 644.
NR 43
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0040-8166
J9 TISSUE CELL
JI Tissue Cell
PD FEB
PY 2017
VL 49
IS 1
BP 28
EP 34
DI 10.1016/j.tice.2016.12.005
PG 7
WC Anatomy & Morphology; Cell Biology
SC Anatomy & Morphology; Cell Biology
GA EM7RB
UT WOS:000395508900005
PM 28049551
ER
PT J
AU Barroso-Sousa, R
Tolaney, SM
AF Barroso-Sousa, Romualdo
Tolaney, Sara M.
TI CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Article
DE Breast cancer (BC); cyclin-dependent kinase inhibitors; palbociclib;
abemaciclib; ribociclib
ID ENDOCRINE THERAPY; PALBOCICLIB; COMBINATION; ABEMACICLIB; RIBOCICLIB;
MUTATIONS; LETROZOLE; CDK6
AB Approximately 70% of breast cancers (BC) are classified as hormone receptor-positive (HRpositive), comprising those expressing estrogen receptors and/or progesterone receptors. BC deaths are ultimately caused by metastatic disease. In this setting, although estrogen pathway blockade is an initially highly effective therapy, virtually all patients will develop resistance to endocrine therapy (de novo or acquired). Further understanding of the underlying mechanisms related to endocrine therapy resistance is vital and can ultimately lead to new therapies for this population. Recently, cyclin-dependent kinase (CDK) 4/6 inhibitors have emerged as one of the most important groups of drugs that synergize with endocrine therapy. In this perspective article we will discuss the recent data from the phase III MONALEESA-2 trial, which evaluated the addition of ribociclib with letrozole in the first line of treatment for patients with advanced HR-positive BC, and we will put the results in context with clinical data of other CDK 4/6 inhibitors. In addition, we will discuss future directions in the field.
C1 [Barroso-Sousa, Romualdo; Tolaney, Sara M.] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Yawkey 1257, Boston, MA 02215 USA.
RP Tolaney, SM (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Yawkey 1257, Boston, MA 02215 USA.
EM Sara_Tolaney@dfci.harvard.edu
FU Pfizer; Lilly; Novartis; Merck; Genentech; AstraZeneca; Exelixis
FX SM Tolaney has research funding from Pfizer, Lilly, Novartis, Merck,
Genentech, AstraZeneca, and Exelixis.
NR 25
TC 0
Z9 0
U1 0
U2 0
PU AME PUBL CO
PI SHEUNG WAN
PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG
00000, PEOPLES R CHINA
SN 2218-676X
EI 2219-6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD FEB
PY 2017
VL 6
SU 1
BP S205
EP S209
DI 10.21037/tcr.2017.02.16
PG 5
WC Oncology
SC Oncology
GA EP3UB
UT WOS:000397306100055
ER
PT J
AU ten Hacken, E
Gruber, M
AF ten Hacken, Elisa
Gruber, Michaela
TI CRISPR made easy in human and murine hematopoietic precursors
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Editorial Material
ID EFFICIENCY; REPAIR; CELLS
C1 [ten Hacken, Elisa; Gruber, Michaela] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Gruber, Michaela] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Med 1, Vienna, Austria.
RP ten Hacken, E (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM Elisa_TenHacken@dfci.harvard.edu
NR 10
TC 0
Z9 0
U1 0
U2 0
PU AME PUBL CO
PI SHEUNG WAN
PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG
00000, PEOPLES R CHINA
SN 2218-676X
EI 2219-6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD FEB
PY 2017
VL 6
SU 1
BP S44
EP S46
DI 10.21037/tcr.2017.02.21
PG 3
WC Oncology
SC Oncology
GA EP3UB
UT WOS:000397306100016
ER
PT J
AU Mehta, SR
Logan, C
Kotton, CN
Kumar, D
Aslam, S
AF Mehta, Sanjay R.
Logan, Cathy
Kotton, Camille N.
Kumar, Deepali
Aslam, Saima
TI Use of organs from donors with bloodstream infection, pneumonia, and
influenza: Results of a survey of infectious diseases practitioners
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article
DE organ donor infection; solid organ transplant; survey
ID KIDNEY-TRANSPLANTATION; LIVER-TRANSPLANTATION; PRESERVATION FLUID;
RECIPIENTS; OUTCOMES; RISK; COMPLICATIONS; TRANSMISSION; COMPETITION;
ARTERITIS
AB BackgroundPotential organ donors may be admitted with an infection to an intensive care unit, or contract a nosocomial infection during their stay, increasing the risk of potential transmission to the recipient. Because of a lack of practice guidelines and large-scale data on this topic, we undertook a survey to assess the willingness of transplant infectious diseases (ID) physicians to accept such organs.
MethodsWe performed a 10-question survey of ID providers from the American Society of Transplantation Infectious Disease Community of Practice to determine the scope of practice regarding acceptance of organs from donors with bloodstream infection, pneumonia, and influenza prior to organ procurement, as well as management of such infections following transplantation.
ResultsAmong 60 respondents to our survey, a majority indicated that organs would be accepted from donors bacteremic with streptococci (76%) or Enterobacteriaceae (73%) without evidence of drug resistance. Acceptance rates varied based on infecting organism, type of organ, and center size. Ten percent of respondents would accept an organ from a donor bacteremic with a carbapenem-resistant organism. Over 90% of respondents would accept an organ other than a lung from a donor with influenza on treatment, compared with 52% that would accept a lung in the same setting.
ConclusionsThis study is the first to our knowledge to survey transplant ID providers regarding acceptance of organs based on specific infections in the donor. These decisions are often based on limited published data and experience. Better characterization of the outcomes from donors with specific types of infection could lead to liberalization of organ acceptance practices across centers.
C1 [Mehta, Sanjay R.; Logan, Cathy; Aslam, Saima] Univ Calif San Diego, Div Infect Dis, La Jolla, CA 92093 USA.
[Mehta, Sanjay R.] San Diego Vet Affairs Med Ctr, Div Infect Dis, San Diego, CA USA.
[Kotton, Camille N.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Kumar, Deepali] Univ Toronto, Div Infect Dis, Toronto, ON, Canada.
RP Mehta, SR (reprint author), Univ Calif San Diego, Div Infect Dis, La Jolla, CA 92093 USA.
EM srmehta@ucsd.edu
FU NIH [K23 AI093163]
FX This work was supported by NIH grants: K23 AI093163 (S.R.M.).
NR 23
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
PD FEB
PY 2017
VL 19
IS 1
DI 10.1111/tid.12645
PG 8
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA EL4HQ
UT WOS:000394582700022
ER
PT J
AU Farahmand, S
Safavi, S
Shahriarian, S
Arbab, M
Basirghafoori, H
Bagheri-Hariri, S
AF Farahmand, Shervin
Safavi, Somayeh
Shahriarian, Shahriar
Arbab, Mona
Basirghafoori, Hamed
Bagheri-Hariri, Shahram
TI Preferred view and transducer in lumbar ultrasound in overweight and
obese patients
SO ULTRASOUND
LA English
DT Article
DE Ultrasound; lumbar puncture
ID PUNCTURE; LANDMARKS
AB Background: Ultrasound can be used to facilitate lumbar puncture, especially in obese patients.
Methods: In this study, midline and paramedian approaches with curved and linear transducers were compared in patients with Body Mass Index (BMI) above 25 kg/m(2) for the identification of spinal landmarks. In each view, six major landmarks, including spinous process, ligamentum flavum, laminae, epidural space, subarachnoid space and posterior longitudinal ligament, were detected by emergency medicine residents and were then reviewed by radiologists.
Results: Sixty patients with a mean BMI of 29.18 enrolled in the study. This study showed that a curved transducer detected major landmarks more accurately compared to a linear transducer. There was also a poor kappa correlation between these transducers in the midline and paramedian approaches.
Conclusion: This study showed that ultrasound can detect lumbar landmarks in overweight and obese patients, with the paramedian approach and a curved transducer being superior to the midline approach and a linear transducer in detecting these landmarks.
C1 [Farahmand, Shervin; Safavi, Somayeh; Bagheri-Hariri, Shahram] Univ Tehran Med Sci, Dept Emergency Med, Tehran, Iran.
[Shahriarian, Shahriar] Univ Tehran Med Sci, Dept Radiol, Tehran, Iran.
[Arbab, Mona] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
[Basirghafoori, Hamed] Iran Univ Med Sci, Emergency Dept, Tehran, Iran.
RP Bagheri-Hariri, S (reprint author), Imam Khomeini Complex Hosp, Emergency Dept, Keshavarz Blvd, Tehran 1419733141, Iran.
EM hariri.shahram@gmail.com
NR 9
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1742-271X
EI 1743-1344
J9 ULTRASOUND
JI Ultrasound
PD FEB
PY 2017
VL 25
IS 1
BP 45
EP 52
DI 10.1177/1742271X16689590
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA EL5DM
UT WOS:000394641800006
PM 28228824
ER
PT J
AU Zhou, J
Chong, SY
Lim, A
Singh, BK
Sinha, RA
Salmon, AB
Yen, PM
AF Zhou, Jin
Chong, Shu Yun
Lim, Andrea
Singh, Brijesh K.
Sinha, Rohit A.
Salmon, Adam B.
Yen, Paul M.
TI Changes in macroautophagy, chaperone-mediated autophagy, and
mitochondrial metabolism in murine skeletal and cardiac muscle during
aging
SO AGING-US
LA English
DT Article
DE aging; muscle; heart; autophagy; chaperone-mediated autophagy (CMA);
fatty acid oxidation; ceramide
ID INSULIN-RESISTANCE; DISEASE; HUMANS; DYSFUNCTION; STRESS; OBESE;
STIMULATION; INHIBITION; LIPIDATION; SIGNATURE
AB Aging causes a general decline in cellular metabolic activity, and function in different tissues and whole body homeostasis. However, the understanding about the metabolomic and autophagy changes in skeletal muscle and heart during aging is still limited. We thus examined markers for macroautophagy, chaperone-mediated autophagy (CMA), mitochondrial quality control, as well as cellular metabolites in skeletal and cardiac muscle from young (5 months old) and aged (27 months old) mice. We found decreased autophagic degradation of p62 and increased ubiquitinated proteins in both tissues from aged mice, suggesting a decline in macroautophagy during aging. In skeletal muscle from aged mice, there also was a decline in LC3B-I conjugation to phosphatidylethanolamine (PE) possibly due to decreased protein levels of ATG3 and ATG12-ATG5. The CMA markers, LAMP-2A and Hsc70, and mitochondrial turnover markers, Drp1, PINK1 and PGC1 alpha also were decreased. Metabolomics analysis showed impaired a-oxidation in heart of aged mice, whereas increased branched-chain amino acids (BCAAs) and ceramide levels were found in skeletal muscle of aged mice that in turn, may contribute to insulin resistance in muscle. Taken together, our studies showed similar declines in macroautophagy but distinct effects on CMA, mitochondrial turnover, and metabolic dysfunction in muscle vs. heart during aging.
C1 [Zhou, Jin; Lim, Andrea; Singh, Brijesh K.; Sinha, Rohit A.; Yen, Paul M.] Duke NUS Med Sch Singapore, Program Cardiovas & Metab Disorders, Singapore 169857, Singapore.
[Chong, Shu Yun] Nanyang Technol Univ, Dept Biomed Sci, Singapore 637551, Singapore.
[Salmon, Adam B.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, Dept Mol Med, San Antonio, TX 78245 USA.
[Salmon, Adam B.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
[Yen, Paul M.] Duke Univ, Med Ctr, Duke Mol Physiol Inst, Dept Med & Pharmacol, Durham, NC 27710 USA.
[Yen, Paul M.] Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA.
RP Yen, PM (reprint author), Duke NUS Med Sch Singapore, Program Cardiovas & Metab Disorders, Singapore 169857, Singapore.; Yen, PM (reprint author), Duke Univ, Med Ctr, Duke Mol Physiol Inst, Dept Med & Pharmacol, Durham, NC 27710 USA.; Yen, PM (reprint author), Duke Univ, Med Ctr, Dept Canc Biol, Durham, NC 27710 USA.
EM paul.yen@duke-nus.edu.sg
FU Duke-NUS Medical School Faculty Funds; Singapore National Medical
Research Council grant [NMRC/CSA/0054/2013, NMRC/CIRG/1340/2012];
National Institute of Health [R01 AG050797]; American Heart Association
[15BGIA23220016]; Geriatric Research, Education and Clinical Center of
the South Texas Veterans Health Care System
FX This work was supported by Duke-NUS Medical School Faculty Funds (to
PMY), Singapore National Medical Research Council grant
NMRC/CSA/0054/2013 (to PMY), NMRC/CIRG/1340/2012 (to PMY), National
Institute of Health R01 AG050797 (to ABS), the American Heart
Association 15BGIA23220016 (to ABS) and the Geriatric Research,
Education and Clinical Center of the South Texas Veterans Health Care
System (to ABS).
NR 45
TC 0
Z9 0
U1 0
U2 0
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD FEB
PY 2017
VL 9
IS 2
BP 583
EP 599
DI 10.18632/aging.101181
PG 17
WC Cell Biology
SC Cell Biology
GA EO7TH
UT WOS:000396892500022
PM 28238968
ER
PT J
AU Khoury, CC
Chan, KE
AF Khoury, Charbel C.
Chan, Kevin E.
TI More monitoring: Non-vitamin K-dependent oral anticoagulant agent use in
chronic kidney disease patients
SO AMERICAN HEART JOURNAL
LA English
DT Editorial Material
ID ATRIAL-FIBRILLATION; RISK; PROGRESSION; INJURY
AB Non-vitamin K-dependent oral anticoagulant agents (NOACs) are increasingly becoming the drug of choice for preventing atrial fibrillation (AF) related strokes in the general population, given that these drugs have less drug interaction, require no INR monitoring, and have been shown to be equal if not superior to warfarin in pivotal phase 3 randomized trials. (1) However, the prescription of NOACs in AF patients with chronic kidney disease (CKD) requires special consideration and presents clinicians with specific challenges. All NOACs are dependent on the kidney for clearance and studies have shown that CKD is a progressive disease in that the creatinine clearance (CrCl) is expected to decline over time. Additionally, such patients are more prone to acute kidney injury (AKI), which associates with sudden decreases in renal drug clearance. (2) As such, the major challenge of NOAC use in CKD is adjusting the dose of the medication in line with the changes in renal clearance, in order to maintain NOAC drug levels within a therapeutic window. If NOAC dosing is not reduced when the creatinine clearance falls, drug levels can bioaccumalate and precipitate unintended major or fatal bleeding. When the creatinine clearance (CrCl) falls below 30 mL/min, NOAC use may become dangerous. The 2014 AHA/ACC/HRS guideline recommends warfarin as the anticoagulant of choice because these patients were excluded from phase 3 randomized NOAC trials and there is no data to support their efficacy and safety in patients with advanced CKD. (3)
C1 [Khoury, Charbel C.; Chan, Kevin E.] Massachusetts Gen Hosp, Div Nephrol, Boston, MA 02114 USA.
RP Chan, KE (reprint author), Massachusetts Gen Hosp, Renal Associates, Suite 302,165 Cambridge St, Boston, MA 02114 USA.
EM KECHAN@mgh.harvard.edu
NR 12
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD FEB
PY 2017
VL 184
DI 10.1016/j.ahj.2016.10.023
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EO0LJ
UT WOS:000396389000020
PM 28224929
ER
PT J
AU Shah, R
Yow, E
Jones, W
Kohl, LP
Kosinski, AS
Hoffmann, U
Lee, KL
Fordyce, CB
Mark, DB
Lowe, A
Douglas, PS
Patel, MR
AF Shah, Rohan
Yow, Eric
Jones, WilliamSchuyler
Kohl, Louis P., III
Kosinski, Andrzej S.
Hoffmann, Udo
Lee, Kerry L.
Fordyce, Christopher B.
Mark, Daniel B.
Lowe, Alicia
Douglas, Pamela S.
Patel, Manesh R.
TI Comparison of visual assessment of coronary stenosis with independent
quantitative coronary angiography: Findings from the Prospective
Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID INTEROBSERVER VARIABILITY; LESION SEVERITY; INTRAOBSERVER;
ARTERIOGRAPHY; ANGIOPLASTY; DISEASE
AB Background The outcomes in patients by visual assessment and quantitative coronary angiography (QCA) for obstructive coronary artery disease (CAD) are not known. Our objectives were to compare visual and QCA estimates of obstructive CAD and to assess their relationship to outcomes in stable patients with symptoms of CAD.
Methods The PROMISE trial randomized 10,003 patients with CAD symptoms to anatomical or functional testing. Site reports of invasive angiography detailing visual stenosis and independent, blinded QCA were performed for obstructive CAD (>= 50% stenosis). Disagreement between methods was determined and compared with outcomes (death, myocardial infarction, unstable angina hospitalization, or major procedural complications).
Results Of 929 patients (9.3% of PROMISE cohort) with angiograms assessed by sites and QCA, 593 (64%) had obstructive CAD per site reports, whereas 428 (46%) had stenosis >= 50% per QCA. Results differed in 177 patients (disagreement rate 19.1%, k = 0.63), of whom 171 had CAD per sites but not per QCA. One-year unadjusted Kaplan-Meier event rates were highest (5.1%) when QCA and visual assessment agreed for CAD, lowest (0.9%) when the 2 agreed for no obstructive CAD, and intermediate (3.1%) for patients who had CAD per visual assessment but not per QCA. Conclusions Visual estimation of angiograms results in more frequent diagnosis of obstructive CAD as compared with QCA.
Concordance of results for presence or absence of obstructive CAD was associated with high and low event rates, respectively. Disagreement was associated with intermediate event rates, suggesting that cardiologists integrated clinical information into routine visual assessment of angiograms.
C1 [Shah, Rohan; Yow, Eric; Jones, WilliamSchuyler; Kosinski, Andrzej S.; Lee, Kerry L.; Fordyce, Christopher B.; Mark, Daniel B.; Lowe, Alicia; Douglas, Pamela S.; Patel, Manesh R.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC 27715 USA.
[Jones, WilliamSchuyler; Mark, Daniel B.; Douglas, Pamela S.; Patel, Manesh R.] Duke Univ, Sch Med, Dept Med, Div Cardiol, Durham, NC 27715 USA.
[Kohl, Louis P., III] Hennepin Cty Med Ctr, Minneapolis, MN USA.
[Hoffmann, Udo] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hoffmann, Udo] Harvard Med Sch, Boston, MA USA.
RP Patel, MR (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, POB 17969,2400 Pratt St, Durham, NC 27715 USA.
EM manesh.patel@duke.edu
NR 17
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD FEB
PY 2017
VL 184
DI 10.1016/j.ahj.2016.10.014
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EO0LJ
UT WOS:000396389000003
ER
PT J
AU Voora, D
Coles, A
Lee, KL
Hoffmann, U
Wingrove, JA
Rhees, B
Huang, L
Daniels, SE
Monane, M
Rosenberg, S
Shah, SH
Kraus, WE
Ginsburg, GS
Douglas, PS
AF Voora, Deepak
Coles, Adrian
Lee, Kerry L.
Hoffmann, Udo
Wingrove, James A.
Rhees, Brian
Huang, Lin
Daniels, Susan E.
Monane, Mark
Rosenberg, Steven
Shah, Svati H.
Kraus, William E.
Ginsburg, Geoffrey S.
Douglas, Pamela S.
TI An age- and sex-specific gene expression score is associated with
revascularization and coronary artery disease: Insights from the
Prospective Multicenter Imaging Study for Evaluation of Chest Pain
(PROMISE) trial
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID NONDIABETIC PATIENTS; HEART-ASSOCIATION; ANGIOGRAPHY; BIOMARKERS;
STENOSIS; OUTCOMES; COMPASS; EXTENT; RISK
AB Background Identifying predictors of coronary artery disease (CAD)-related procedures and events remains a priority.
Methods We measured an age-and sex-specific gene expression score (ASGES) previously validated to detect obstructive CAD (oCAD) in symptomatic nondiabetic patients in the PROMISE trial. The outcomes were oCAD (>= 70% stenosis in >= 1 vessel or >= 50% left main stenosis on CT angiography [CTA]) and a composite endpoint of death, myocardial infarction, revascularization, or unstable angina.
Results The ASGES was determined in 2370 nondiabetic participants (47.5% male, median age 59.5 years, median follow-up 25 months), including 1137 with CTA data. An ASGES > 15 was associated with oCAD (odds ratio 2.5 [95% CI 1.6-3.8], P < .001) and the composite endpoint (hazard ratio [HR] 2.6 [95% CI 1.8-3.9], P < .001) in unadjusted analyses. After adjustment for Framingham risk, an ASGES > 15 remained associated with the composite endpoint (P = .02); the only component that was associated was revascularization (adjusted HR 2.69 [95% CI 1.52-4.79], P < .001). Compared to noninvasive testing, the ASGES improved prediction for the composite (increase in c-statistic = 0.036; continuous net reclassification index = 43.2%). Patients with an ASGES = 15 had a composite endpoint rate no different from those with negative noninvasive test results (3.2% vs. 2.6%, P = .29).
Conclusions A blood-based genomic test for detecting oCAD significantly predicts near-term revascularization procedures, but not non-revascularization events. Larger studies will be needed to clarify the risk with non-revascularization events.
C1 [Voora, Deepak; Ginsburg, Geoffrey S.] Duke Univ, Sch Med, Duke Ctr Appl Genom & Precis Med, 101 Sci Dr,DUMC 3382, Durham, NC 27710 USA.
[Voora, Deepak; Shah, Svati H.; Kraus, William E.; Ginsburg, Geoffrey S.; Douglas, Pamela S.] Duke Univ, Sch Med, Dept Med, Durham, NC 27710 USA.
[Coles, Adrian; Lee, Kerry L.; Shah, Svati H.; Douglas, Pamela S.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC 27710 USA.
[Hoffmann, Udo] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
[Wingrove, James A.; Rhees, Brian; Huang, Lin; Daniels, Susan E.; Monane, Mark; Rosenberg, Steven] CardioDx Inc, Redwood City, CA USA.
RP Voora, D (reprint author), Duke Univ, Sch Med, Duke Ctr Appl Genom & Precis Med, 101 Sci Dr,DUMC 3382, Durham, NC 27710 USA.
EM Deepak.voora@duke.edu
OI Voora, Deepak/0000-0003-0015-5179
FU National Heart, Lung, and Blood Institute (NHLBI) [R01 HL098237, R01
HL098236, R01 HL098305, R01 HL098235]
FX This PROMISE substudy was supported in part by CardioDx, Inc., which
performed all RNA sample processing, and generation of generated ASGES
in a blinded fashion, and shared in the interpretation of the data, and
preparation, review, and approval of the manuscript. An Executive
Committee of Duke/DCRI co-authors oversaw substudy design and study
conduct, final data review, and presentation and publication of results,
independently making the decision to publish. All analyses including the
definition of the composite and secondary endpoints were pre- specified
as part of a statistical analysis plan that was finalized before
analyses were performed. No authors from CardioDx had access to the
clinical data or were able to perform statistical analyses using the
data. Only two co-authors, both of whom are academic (AC and KLL), had
full access to the data and neither receives any financial support from
CardioDx. Duke/DCRI investigators independently drafted the manuscript
and take full responsibility for the accuracy and completeness of data
analyses.; The PROMISE trial was funded by National Heart, Lung, and
Blood Institute (NHLBI) grants R01 HL098237, R01 HL098236, R01 HL098305,
and R01 HL098235. The NHLBI had no role in the design and conduct of
this substudy; collection, management, analysis, and interpretation of
the data; preparation, review, or approval of the manuscript; and
decision to submit the manuscript for publication. The views expressed
in this article do not necessarily represent the official views of the
NHLBI. The authors are solely responsible for the design and conduct of
this study, all study analyses, the drafting and editing of the paper,
and its final contents.
NR 24
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD FEB
PY 2017
VL 184
DI 10.1016/j.ahj.2016.11.004
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EO0LJ
UT WOS:000396389000018
PM 28224927
ER
PT J
AU de Jong, D
Roemer, MGM
Chan, JKC
Goodlad, J
Gratzinger, D
Chadburn, A
Jaffe, ES
Said, J
Natkunam, Y
AF de Jong, Daphne
Roemer, Margaretha G. M.
Chan, John K. C.
Goodlad, John
Gratzinger, Dita
Chadburn, Amy
Jaffe, Elaine S.
Said, Jonathan
Natkunam, Yasodha
TI B-Cell and Classical Hodgkin Lymphomas Associated With Immunodeficiency
2015 SH/EAHP Workshop Report-Part 2
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE PD-L1; 9p24; Iatrogenic immunodeficiency; Posttransplant
lymphoproliferative disorder; Autoimmunity; Primary immunodeficiency;
Large B-cell lymphoma; Classical Hodgkin lymphoma;
T-cell/histiocyte-rich B-cell lymphoma; Marginal zone lymphoma
ID POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS; SOLID-ORGAN
TRANSPLANTATION; HEALTH-ORGANIZATION CLASSIFICATION; MARGINAL ZONE
LYMPHOMA; FRENCH REGISTRY; EXPRESSION; THERAPY; DISEASE; RISK;
MANAGEMENT
AB Objectives: The 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology submitted small and large B-cell lymphomas (BCLs), including classical Hodgkin lymphoma (CHL), in the context of immunodeficiency.
Methods: Clinicopathologic and molecular features were studied to explore unifying concepts in malignant B-cell proliferations across immunodeficiency settings.
Results: Cases submitted to the workshop spanned small BCLs presenting as nodal or extranodal marginal zone lymphoma and lymphoplasmacytic lymphoma, Epstein-Barr virus (EBV) positive in 75% of cases. Submitted large BCLs formed a spectrum from diffuse large B-cell lymphoma (DLBCL) to CHL across immunodeficiency settings. Additional studies demonstrated overexpression of PD-L1 and molecular 9p24 alterations in the large BCL spectrum and across different immunodeficiency settings.
Conclusions: Small BCLs occur in all immunodeficiency settings, and EBV positivity is essential for their recognition as immunodeficiency related. Large BCLs include a spectrum from DLBCL to CHL across all immunodeficiency settings; immunohistochemical and molecular features are suggestive of shared pathogenetic mechanisms involving PD-L1 immune checkpoints.
C1 [de Jong, Daphne; Roemer, Margaretha G. M.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands.
[Roemer, Margaretha G. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chan, John K. C.] Queen Elizabeth Hosp, Kowloon, Hong Kong, Peoples R China.
[Goodlad, John] St James Univ Hosp, HMDS, Leeds, W Yorkshire, England.
[Gratzinger, Dita; Natkunam, Yasodha] Stanford Univ, Sch Med, L235,300 Pasteur Dr, Stanford, CA 94305 USA.
[Chadburn, Amy] Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
[Jaffe, Elaine S.] NIH, Bldg 10, Bethesda, MD 20892 USA.
[Said, Jonathan] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA.
RP Natkunam, Y (reprint author), Stanford Univ, Sch Med, L235,300 Pasteur Dr, Stanford, CA 94305 USA.
EM yaso@stanford.edu
NR 63
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD FEB
PY 2017
VL 147
IS 2
BP 153
EP 170
DI 10.1093/ajcp/aqw216
PG 18
WC Pathology
SC Pathology
GA EP2QS
UT WOS:000397228900002
ER
PT J
AU Yarns, BC
Glass, OM
AF Yarns, Brandon C.
Glass, Oliver M.
TI Why Trainees Should Consider a Career in Geriatric Psychiatry:
Reflections From Two AAGP Trainee Board Members
SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
LA English
DT Editorial Material
C1 [Yarns, Brandon C.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med, 10940 Wilshire Blvd,Suite 710, Los Angeles, CA 90024 USA.
[Yarns, Brandon C.] VA Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA.
[Glass, Oliver M.] East Carolina Univ, Dept Psychiat & Behav Med, Greenville, NC USA.
RP Yarns, BC (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med, 10940 Wilshire Blvd,Suite 710, Los Angeles, CA 90024 USA.
EM byarns@mednet.ucla.edu
FU VA Office of Academic Affiliations through the VA National Clinician
Scholars Program [TPH 65-005]
FX Dr. Yarns was supported by the VA Office of Academic Affiliations
through the VA National Clinician Scholars Program, funding ID #TPH
65-005.
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1064-7481
EI 1545-7214
J9 AM J GERIAT PSYCHIAT
JI Am. J. Geriatr. Psychiatr.
PD FEB
PY 2017
VL 25
IS 2
BP 204
EP 206
DI 10.1016/j.jagp.2016.11.016
PG 3
WC Geriatrics & Gerontology; Gerontology; Psychiatry
SC Geriatrics & Gerontology; Psychiatry
GA EP1FF
UT WOS:000397130100014
PM 28040428
ER
PT J
AU Farvid, MS
Malekshah, AF
Pourshams, A
Poustchi, H
Sepanlou, SG
Sharafkhah, M
Khoshnia, M
Farvid, M
Abnet, CC
Kamangar, F
Dawsey, SM
Brennan, P
Pharoah, PD
Boffetta, P
Willett, WC
Malekzadeh, R
AF Farvid, Maryam S.
Malekshah, Akbar F.
Pourshams, Akram
Poustchi, Hossein
Sepanlou, Sadaf G.
Sharafkhah, Maryam
Khoshnia, Masoud
Farvid, Mojtaba
Abnet, Christian C.
Kamangar, Farin
Dawsey, Sanford M.
Brennan, Paul
Pharoah, Paul D.
Boffetta, Paolo
Willett, Walter C.
Malekzadeh, Reza
TI Dietary Protein Sources and All-Cause and Cause-Specific Mortality: The
Golestan Cohort Study in Iran
SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE
LA English
DT Article
ID PROCESSED MEAT CONSUMPTION; CANCER-RISK; ESOPHAGEAL CANCER; FISH
CONSUMPTION; ZEAXANTHIN CONCENTRATIONS; CARDIOVASCULAR-DISEASE;
PHASEOLUS-VULGARIS; COLORECTAL-CANCER; EGG CONSUMPTION; GASTRIC-CANCER
AB Introduction: Dietary protein comes from foods with greatly different compositions that may not relate equally with mortality risk. Few cohort studies from non-Western countries have examined the association between various dietary protein sources and cause-specific mortality. Therefore, the associations between dietary protein sources and all-cause, cardiovascular disease, and cancer mortality were evaluated in the Golestan Cohort Study in Iran.
Methods: Among 42,403 men and women who completed a dietary questionnaire at baseline, 3,291 deaths were documented during 11 years of follow up (2004-2015). Cox proportional hazards models estimated age-adjusted and multivariate-adjusted hazard ratios (HRs) and 95% CIs for all cause and disease-specific mortality in relation to dietary protein sources. Data were analyzed from 2015 to 2016.
Results: Comparing the highest versus the lowest quartile, egg consumption was associated with lower all-cause mortality risk (HR=0.88, 95% CI=0.79, 0.97, ptrend=0.03). In multivariate analysis, the highest versus the lowest quartile of fish consumption was associated with reduced risk of total cancer (HR=0.79, 95% CI=0.64, 0.98, ptrend=0.03) and gastrointestinal cancer (HR=0.75, 95% CI=0.56, 1.00, ptrend=0.02) mortality. The highest versus the lowest quintile of legume consumption was associated with reduced total cancer (HR=0.72, 95% CI=0.58, 0.89, ptrend=0.004), gastrointestinal cancer (HR=0.76, 95% CI=0.58, 1.01, ptrend=0.05), and other cancer (HR=0.66, 95% CI=0.47, 0.93, ptrend=0.04) mortality. Significant associations between total red meat and poultry intake and allcause, cardiovascular disease, or cancer mortality rate were not observed among all participants.
Conclusions: These findings support an association of higher fish and legume consumption with lower cancer mortality, and higher egg consumption with lower all-cause mortality. (C) 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.
C1 [Farvid, Maryam S.; Willett, Walter C.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Farvid, Maryam S.; Malekshah, Akbar F.; Pourshams, Akram; Sepanlou, Sadaf G.; Sharafkhah, Maryam; Malekzadeh, Reza] Univ Tehran Med Sci, Res Inst, Digest Dis Res Ctr, Digest Dis, Tehran, Iran.
[Farvid, Maryam S.] Massachusetts Gen Hosp, Harvard MGH Ctr Genom Vulnerable Populat & Hlth D, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Malekshah, Akbar F.; Poustchi, Hossein; Sepanlou, Sadaf G.] Univ Tehran Med Sci, Res Inst, Digest Oncol Res Ctr, Digest Dis, Tehran, Iran.
[Pourshams, Akram; Poustchi, Hossein; Sharafkhah, Maryam; Malekzadeh, Reza] Univ Tehran Med Sci, Digest Dis Res Inst, Shariati Hosp, Liver & Pancreatobiliary Dis Res Ctr, Tehran, Iran.
[Sharafkhah, Maryam] Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, Iran.
[Khoshnia, Masoud] Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, Iran.
[Farvid, Mojtaba] Linnaeus Univ, Vaxjo, Sweden.
[Abnet, Christian C.; Dawsey, Sanford M.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Kamangar, Farin] Morgan State Univ, Dept Publ Hlth Anal, Sch Community Hlth & Policy, Baltimore, MD 21239 USA.
[Brennan, Paul] Int Agcy Res Canc, Genet Epidemiol Grp, Lyon, France.
[Pharoah, Paul D.] Univ Cambridge, Dept Oncol, Cambridge, England.
[Pharoah, Paul D.] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.
[Boffetta, Paolo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
[Boffetta, Paolo] Icahn Sch Med Mt Sinai, Inst Translat Epidemiol, New York, NY 10029 USA.
[Willett, Walter C.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Willett, Walter C.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
[Willett, Walter C.] Harvard Med Sch, Boston, MA USA.
RP Farvid, MS (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.; Malekzadeh, R (reprint author), Shariati Hosp, Digest Dis Res Inst, Dis Res Ctr, N Kargar St, Tehran, Iran.
EM mfarvid@hsph.harvard.edu; malek@tums.ac.ir
FU Tehran University of Medical Sciences [82-603]; Cancer Research United
Kingdom [C20/A5860]; Intramural Research Program of the U.S. National
Cancer Institute at NIH National Institutes of Health [Z01 CP000185-03];
Social Security Organization of Iran, Golestan Branch; Takemi Fellowship
Program
FX This work was supported by Tehran University of Medical Sciences (Grant
No. 82-603), Cancer Research United Kingdom (grant No: C20/A5860), the
Intramural Research Program of the U.S. National Cancer Institute at NIH
National Institutes of Health (Z01 CP000185-03), and various
collaborative research agreements with the International Agency for
Research on Cancer. Many individuals have contributed to this study. We
wish to thank the study participants for their cooperation over many
years and the Behvarz' working in the study areas for their help. We
thank the directors of the public health districts of Gonbad and Kalaleh
for their collaboration. We express our special thanks to general
physicians, nurses, and nutritionists in the enrollment teams for their
collaboration and assistance. We received special support from the
Social Security Organization of Iran, Golestan Branch. We have enjoyed
the close collaboration of the Golestan health deputies and the Chief of
the Gonbad health district. Dr. Maryam Farvid would like to express
appreciation to the Japan Pharmaceutical Manufacturers Association for
their financial support of the Takemi Fellowship Program.
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0749-3797
EI 1873-2607
J9 AM J PREV MED
JI Am. J. Prev. Med.
PD FEB
PY 2017
VL 52
IS 2
BP 237
EP 248
DI 10.1016/j.amepre.2016.10.041
PG 12
WC Public, Environmental & Occupational Health; Medicine, General &
Internal
SC Public, Environmental & Occupational Health; General & Internal Medicine
GA EO9DP
UT WOS:000396989700016
PM 28109460
ER
PT J
AU Baker, K
Haydar, B
Mankad, S
AF Baker, Keith
Haydar, Bishr
Mankad, Shawn
TI A Feedback and Evaluation System That Provokes Minimal Retaliation by
Trainees
SO ANESTHESIOLOGY
LA English
DT Article
ID GRADE INFLATION; NATIONAL-SURVEY; T-TEST; PERFORMANCE; CLERKSHIP;
NORMALITY; DIRECTORS; CHOICE; SCALE; POWER
AB Background: Grade inflation is pervasive in educational settings in the United States. One driver of grade inflation may be faculty concern that assigning lower clinical performance scores to trainees will cause them to retaliate and assign lower teaching scores to the faculty member. The finding of near-zero retaliation would be important to faculty members who evaluate trainees.
Methods: The authors used a bidirectional confidential evaluation and feedback system to test the hypothesis that faculty members who assign lower clinical performance scores to residents subsequently receive lower clinical teaching scores. From September 1, 2008, to February 15, 2013, 177 faculty members evaluated 188 anesthesia residents (n = 27,561 evaluations), and 188 anesthesia residents evaluated 204 faculty members (n = 25,058 evaluations). The authors analyzed the relationship between clinical performance scores assigned by faculty members and the clinical teaching scores received using linear regression. The authors used complete dyads between faculty members and resident pairs to conduct a mixed effects model analysis. All analyses were repeated for three different epochs, each with different administrative attributes that might influence retaliation.
Results: There was no relationship between mean clinical performance scores assigned by faculty members and mean clinical teaching scores received in any epoch (P >= 0.45). Using only complete dyads, the authors' mixed effects model analysis demonstrated a very small retaliation effect in each epoch (effect sizes of 0.10, 0.06, and 0.12; P <= 0.01).
Conclusions: These results imply that faculty members can provide confidential evaluations and written feedback to trainees with near-zero impact on their mean teaching scores.
C1 [Baker, Keith] Harvard Med Sch, Boston, MA USA.
[Baker, Keith] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
[Haydar, Bishr] Univ Michigan, Dept Anesthesiol, Div Pediat Anesthesia, Ann Arbor, MI 48109 USA.
[Mankad, Shawn] Cornell Univ, Samuel Curtis Johnson Grad Sch Management, Ithaca, NY USA.
RP Baker, K (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02114 USA.
EM khbaker@partners.org
NR 42
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD FEB
PY 2017
VL 126
IS 2
BP 327
EP 337
PG 11
WC Anesthesiology
SC Anesthesiology
GA EO8CO
UT WOS:000396916700017
PM 27977462
ER
PT J
AU Raines, DE
AF Raines, Douglas E.
TI Flumazenil Modulation of the gamma-Aminobutyric Acid Type A Receptor:
Competitive versus Noncompetitive Antagonism at the Agonist-binding Site
SO ANESTHESIOLOGY
LA English
DT Letter
ID GABA(A) RECEPTORS
C1 [Raines, Douglas E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Raines, DE (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM draines@partners.org
NR 6
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD FEB
PY 2017
VL 126
IS 2
BP 350
EP 351
PG 3
WC Anesthesiology
SC Anesthesiology
GA EO8CO
UT WOS:000396916700023
PM 28098614
ER
PT J
AU Cardoso, F
Harbeck, N
Barrios, CH
Bergh, J
Cortes, J
El Saghir, N
Francis, PA
Hudis, CA
Ohno, S
Partridge, AH
Sledge, GW
Smith, IE
Gelmon, KA
AF Cardoso, F.
Harbeck, N.
Barrios, C. H.
Bergh, J.
Cortes, J.
El Saghir, N.
Francis, P. A.
Hudis, C. A.
Ohno, S.
Partridge, A. H.
Sledge, G. W.
Smith, I. E.
Gelmon, K. A.
TI Research needs in breast cancer
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE breast cancer; clinical research; medical needs
ID RANDOMIZED CONTROLLED-TRIAL; INTERNATIONAL CONSENSUS GUIDELINES;
CLINICAL-PRACTICE GUIDELINE; ADJUVANT ENDOCRINE THERAPY; PRIMARY TUMOR;
YOUNG-WOMEN; AMERICAN SOCIETY; INTRATUMOR HETEROGENEITY;
EUROPEAN-ORGANIZATION; TARGETED THERAPIES
AB New research questions emerge as medical needs continue to evolve and as we improve our understanding of cancer biology and treatment of malignancies. Although significant advances have been made in some areas of breast cancer research resulting in improvements in therapies and outcomes over the last few decades, other areas have not benefited to the same degree and we continue to have many gaps in our knowledge. This article summarizes the 12 short and medium-term clinical research needs in breast cancer deemed as priorities in 2016 by a panel of experts, in an attempt to focus and accelerate future research in the most needed areas: (i) de-escalate breast cancer therapies in early breast cancer without sacrificing outcomes; (ii) explore optimal adjuvant treatment durations; (iii) develop better tools and strategies to identify patients with genetic predisposition; (iv) improve care in young patients with breast cancer; (v) develop tools to speed up drug development in biomarker-defined populations; (vi) identify and validate targets that mediate resistance to chemotherapy, endocrine therapy and anti-HER2 therapies; (vii) evaluate the efficacy of local-regional treatments for metastatic disease; (viii) better define the optimal sequence of treatments in the metastatic setting; (ix) evaluate the clinical impact of intra-patient heterogeneity (intratumor, inter-tumor and inter-lesion heterogeneity); (x) better understand the biology and identify new targets in triplenegative breast cancer; (xi) better understand immune surveillance in breast cancer and further develop immunotherapies; and (xii) increase survivorship research efforts including supportive care and quality of life.
C1 [Cardoso, F.] Champalimaud Clin Ctr, Breast Unit, Ave Brasilia S-N, P-1400038 Lisbon, Portugal.
[Harbeck, N.] Univ Munich LMU, Dept Obstet & Gynaecol, Breast Ctr, Munich, Germany.
[Barrios, C. H.] Pontificia Univ Catolica Rio Grande do Sul, Sch Med, Porto Alegre, RS, Brazil.
[Bergh, J.] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden.
[Bergh, J.] Univ Hosp, Stockholm, Sweden.
[Cortes, J.] Hosp Ramon & Cajal, Breast Canc Unit, Madrid, Spain.
[Cortes, J.] VHIO, Dept Med Oncol, Barcelona, Spain.
[El Saghir, N.] Amer Univ Beirut, Med Ctr, NK Basile Canc Inst, Dept Internal Med, Beirut, Lebanon.
[Francis, P. A.] Univ Melbourne, St Vincents Hosp, Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Vic, Australia.
[Hudis, C. A.] Amer Soc Clin Oncol, Alexandria, VA USA.
[Ohno, S.] Canc Inst Hosp, Ctr Breast Oncol, Koto Ku, Tokyo, Japan.
[Partridge, A. H.] Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA.
[Sledge, G. W.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
[Smith, I. E.] Royal Marsden Hosp, Breast Unit, London, England.
[Gelmon, K. A.] BC Canc Agcy, Dept Med Oncol, Vancouver, BC, Canada.
RP Cardoso, F (reprint author), Champalimaud Clin Ctr, Breast Unit, Ave Brasilia S-N, P-1400038 Lisbon, Portugal.
EM fatimacardoso@fundacaochampalimaud.pt
NR 95
TC 1
Z9 1
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD FEB
PY 2017
VL 28
IS 2
BP 208
EP 217
DI 10.1093/annonc/mdw571
PG 10
WC Oncology
SC Oncology
GA EP3JJ
UT WOS:000397278300007
ER
PT J
AU Musto, P
Anderson, KC
Attal, M
Richardson, PG
Badros, A
Hou, J
Comenzo, R
Du, J
Durie, BGM
San Miguel, J
Einsele, H
Chen, WM
Garderet, L
Pietrantuono, G
Hillengass, J
Kyle, RA
Moreau, P
Lahuerta, JJ
Landgren, O
Ludwig, H
Larocca, A
Mahindra, A
Cavo, M
Mazumder, A
McCarthy, PL
Nouel, A
Rajkumar, SV
Reiman, A
Serra, ER
Sezer, O
Terpos, E
Turesson, I
Usmani, S
Weiss, BM
Palumbo, A
AF Musto, P.
Anderson, K. C.
Attal, M.
Richardson, P. G.
Badros, A.
Hou, J.
Comenzo, R.
Du, J.
Durie, B. G. M.
San Miguel, J.
Einsele, H.
Chen, W. M.
Garderet, L.
Pietrantuono, G.
Hillengass, J.
Kyle, R. A.
Moreau, P.
Lahuerta, J. J.
Landgren, O.
Ludwig, H.
Larocca, A.
Mahindra, A.
Cavo, M.
Mazumder, A.
McCarthy, P. L.
Nouel, A.
Rajkumar, S. V.
Reiman, A.
Serra, E. R.
Sezer, O.
Terpos, E.
Turesson, I.
Usmani, S.
Weiss, B. M.
Palumbo, A.
CA Int Myeloma Working Grp
TI Second primary malignancies in multiple myeloma: an overview and IMWG
consensus
SO ANNALS OF ONCOLOGY
LA English
DT Review
DE multiple myeloma; second primary malignancy; SPM; risk factors;
lenalidomide; International Myeloma Working Group
ID STEM-CELL TRANSPLANTATION; LOW-DOSE DEXAMETHASONE;
BORTEZOMIB-MELPHALAN-PREDNISONE; SECONDARY PRIMARY MALIGNANCIES;
MYELODYSPLASTIC SYNDROME; AUTOLOGOUS TRANSPLANTATION; LENALIDOMIDE
MAINTENANCE; DARATUMUMAB MONOTHERAPY; MYELOMONOCYTIC LEUKEMIA;
INELIGIBLE PATIENTS
AB Background: Therapeutic advancements following the introduction of autologous stem cell transplantation and ` novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has led to renewed concerns about the long-term risk of second primary malignancies (SPMs). This review outlines the most up-to-date knowledge of possible host-, disease-, and treatment-related risk factors for the development of SPMs in patients with MM, and provides practical recommendations to assist physicians.
Design: A Panel of International Myeloma Working Group members reviewed the most relevant data published in the literature as full papers, or presented at meetings of the American Society of Clinical Oncology, American Society of Hematology, European Hematology Association, or International Myeloma Workshops, up to June 2016. Here, we present the recommendations of the Panel, based on this literature review.
Results: Overall, the risk of SPMs in MM is low, multifactorial, and partially related to the length of patients' survival and MM intrinsic susceptibility. Studies suggest a significantly increased incidence of SPMs when lenalidomide is administered either following, or concurrently with, oral melphalan. Increased SPM incidence has also been reported with lenalidomide maintenance following high-dose melphalan, albeit to a lesser degree. In both cases, the risk of death from MM was significantly higher than the risk of death from SPMs, with lenalidomide possibly providing a survival benefit. No increase in SPM incidence was reported with lenalidomide plus dexamethasone (without melphalan), or with bortezomib plus oral melphalan, dexamethasone, or thalidomide.
Conclusion: In general, the risk of SPMs should not alter the current therapeutic decision- making process in MM. However, regimens such as lenalidomide plus dexamethasone should be preferred to prolonged exposure to lenalidomide plus oral melphalan. SPM risk should be carefully discussed with the patient in the context of benefits and risks of different treatment options.
C1 [Musto, P.] IRCCS CROB, Referral Canc Ctr Basilicata, Sci Direct, Via Padre Pio 1, I-85028 Rionero In Vulture, Pz, Italy.
[Anderson, K. C.; Richardson, P. G.] Dana Farber Canc Inst, Hematol Oncol, Boston, MA 02115 USA.
[Attal, M.] Inst Univ Canc Toulouse Oncopole, Hematol, Toulouse, France.
[Badros, A.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA.
[Hou, J.] Second Mil Med Univ, Changzheng Hosp, Myeloma & Lymphoma Ctr, Dept Hematol, Shanghai, Peoples R China.
[Comenzo, R.] Tufts Med Ctr, Hematol Oncol, Boston, MA USA.
[Durie, B. G. M.] Cedars Sinai Med Ctr, Samuel Oschin Canc Ctr, Los Angeles, CA 90048 USA.
[San Miguel, J.] Univ Navarra Clin, CIMA, Pamplona, Spain.
[Einsele, H.] Univ Hosp Wuerzburg, Internal Med 2, Wurzburg, Germany.
[Chen, W. M.] Capital Med Univ, Beijing Chaoyang Hosp, Beijing, Peoples R China.
[Garderet, L.] Hop St Antoine, Hematol Clin, Paris, France.
[Pietrantuono, G.] Referral Canc Ctr Basilicata, IRCCS CROB, Unit Hematol & Stem Cell Transplantat, Rionero In Vulture, Italy.
[Hillengass, J.] Heidelberg Univ, Dept Hematol & Oncol, Heidelberg, Germany.
[Hillengass, J.] German Canc Res Ctr, Heidelberg, Germany.
[Kyle, R. A.; Rajkumar, S. V.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
[Moreau, P.] Univ Hosp, Hematol, Nantes, France.
[Lahuerta, J. J.] Hosp Univ 12 Octubre, Spanish Myeloma Grp, Madrid, Spain.
[Landgren, O.] Mem Sloan Kettering Canc Ctr, Hematol Oncol, 1275 York Ave, New York, NY 10021 USA.
[Ludwig, H.] Wilhelminenspital Stat Wien, Med Dept & Oncol 1, Vienna, Austria.
[Larocca, A.; Palumbo, A.] Univ Torino, Div Hematol, Azienda Osped Univ Citta Salute & Sci Torino, Turin, Italy.
[Mahindra, A.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Cavo, M.] Univ Bolgona, Dept Specialized Expt & Diagnost Med, Bologna, Italy.
[Mazumder, A.] NYU Comprehens Canc Ctr, Med Oncol, New York, NY USA.
[McCarthy, P. L.] Roswell Pk Canc Ctr, Dept Med, Buffalo, NY USA.
[Nouel, A.] Hosp Univ Rutz & Paez, Dept Hematol, Bolivar, Venezuela.
[Reiman, A.] St Johns Hosp, Dept Oncol, St John, NB, Canada.
[Serra, E. R.] Hosp Clin Montevideo, Dept Hematol, Montevideo, Uruguay.
[Sezer, O.] Mem Hosp, Dept Hematol, Istanbul, Turkey.
[Terpos, E.] Univ Athens, Sch Med, Athens, Greece.
[Turesson, I.] Skane Univ Hosp, Dept Hematol & Coagulat Disorders, Malmo, Sweden.
[Usmani, S.] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA.
[Weiss, B. M.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
RP Musto, P (reprint author), IRCCS CROB, Referral Canc Ctr Basilicata, Sci Direct, Via Padre Pio 1, I-85028 Rionero In Vulture, Pz, Italy.
EM p.musto@crob.it
FU Italian Ministry of Health Current Research [RRC 2015-2360451, RRC
2016-2361120]; Celgene Corporation
FX This paper was supported by two Italian Ministry of Health Current
Research grants to IRCCS-CROB (Grant numbers RRC 2015-2360451 and RRC
2016-2361120). Medical writing support was provided by Baxter Jeffs and
Sandralee Lewis of the Investigator Initiated Research Writing Group (an
initiative from Ashfield Healthcare Communications, part of UDG
Healthcare plc), and was funded by Celgene Corporation.
NR 101
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD FEB
PY 2017
VL 28
IS 2
BP 228
EP 245
DI 10.1093/annonc/mdw606
PG 18
WC Oncology
SC Oncology
GA EP3JJ
UT WOS:000397278300009
ER
PT J
AU Yu, HA
Sima, C
Feldman, D
Liu, LL
Vaitheesvaran, B
Cross, J
Rudin, CM
Kris, MG
Pao, W
Michor, F
Riely, GJ
AF Yu, H. A.
Sima, C.
Feldman, D.
Liu, L. L.
Vaitheesvaran, B.
Cross, J.
Rudin, C. M.
Kris, M. G.
Pao, W.
Michor, F.
Riely, G. J.
TI Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as
initial treatment for patients with EGFR-mutant lung cancers
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE EGFR-mutant lung cancer; acquired resistance; evolutionary modeling;
EGFR T790M; pulse dose erlotinib
ID TYROSINE KINASE INHIBITORS; NERVOUS-SYSTEM METASTASES;
ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; DOSING SCHEDULES; OPEN-LABEL;
GEFITINIB; MUTATION; CHEMOTHERAPY; I/II
AB Background: Patients with EGFR-mutant lung cancers treated with EGFR tyrosine kinase inhibitors (TKIs) develop clinical resistance, most commonly with acquisition of EGFR T790M. Evolutionary modeling suggests that a schedule of twice weekly pulse and daily low-dose erlotinib may delay emergence of EGFR T790M. Pulse dose erlotinib has superior central nervous system (CNS) penetration and may result in superior CNS disease control.
Methods: We evaluated toxicity, pharmacokinetics, and efficacy of twice weekly pulse and daily low-dose erlotinib. We assessed six escalating pulse doses of erlotinib.
Results: We enrolled 34 patients; 11 patients (32%) had brain metastases at study entry. We observed 3 dose-limiting toxicities in dose escalation: transaminitis, mucositis, and rash. The MTD was erlotinib 1200mg days 1-2 and 50mg days 3-7 weekly. The most frequent toxicities (any grade) were rash, diarrhea, nausea, fatigue, and mucositis. 1 complete and 24 partial responses were observed (74%, 95% CI 60-84%). Median progression-free survival was 9.9 months (95% CI 5.8-15.4 months). No patient had progression of an untreated CNS metastasis or developed a new CNS lesion while on study (0%, 95% CI 0-13%). Of the 18 patients with biopsies at progression, EGFR T790M was identified in 78% (95% CI 54-91%).
Conclusion: This is the first clinical implementation of an anti-cancer TKI regimen combining pulse and daily low-dose administration. This evolutionary modeling-based dosing schedule was well-tolerated but did not improve progression-free survival or prevent emergence of EGFR T790M, likely due to insufficient peak serum concentrations of erlotinib. This dosing schedule prevented progression of untreated or any new central nervous system metastases in all patients.
C1 [Yu, H. A.; Feldman, D.; Rudin, C. M.; Kris, M. G.; Riely, G. J.] Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv, Div Solid Tumor Oncol, 1275 York Ave, New York, NY 10021 USA.
[Yu, H. A.; Rudin, C. M.; Kris, M. G.; Riely, G. J.] Weill Cornell Med Coll, New York, NY USA.
[Yu, H. A.; Rudin, C. M.; Kris, M. G.; Riely, G. J.] Weill Cornell Med Coll, New York, NY USA.
[Sima, C.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA.
[Liu, L. L.; Michor, F.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Liu, L. L.; Michor, F.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Pao, W.] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Catherine C Marron Canc Metab Ctr Vanderbilt Ingr, Dept Med, New York, NY USA.
RP Yu, HA (reprint author), Mem Sloan Kettering Canc Ctr, Dept Med, 300 East 66th St, New York, NY 10065 USA.
EM yuh@mskcc.org
FU Astellas Pharmaceutical Global Development, Inc; National Institutes of
Health [U54 CA193461, P01 CA129243, P30 CA008748]; Dallepezze
Foundation; Free to Breathe
FX This work was supported, in part, by Astellas Pharmaceutical Global
Development, Inc, the National Institutes of Health [U54 CA193461 to
F.M.,P01 CA129243 to M.K., P30 CA008748 to MSKCC], the Dallepezze
Foundation and a Young Investigator grant from Free to Breathe.
NR 39
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD FEB
PY 2017
VL 28
IS 2
BP 278
EP 284
DI 10.1093/annonc/mdw556
PG 7
WC Oncology
SC Oncology
GA EP3JJ
UT WOS:000397278300013
ER
PT J
AU Liao, Z
Rodrigues, MC
Poynter, JN
Amatruda, JF
Rodriguez-Galindo, C
Frazier, AL
AF Liao, Z.
Rodrigues, M. C.
Poynter, J. N.
Amatruda, J. F.
Rodriguez-Galindo, C.
Frazier, A. L.
TI Risk of second malignant neoplasms in women and girls with germ cell
tumors
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE germ cell tumors; SEER; second cancers; ovarian cancers
ID LONG-TERM SURVIVORS; TESTICULAR-CANCER; UNITED-STATES; TRENDS;
CHEMOTHERAPY
AB Background: While an elevated risk of second malignant neoplasms (SMNs) has been observed in men treated for germ cell tumors (GCTs), risk of SMNs have not been quantified in adult women or in girls treated for GCTs. Patients and methods: One-year survivors of primary GCTs diagnosed between January 1980 and December 2012 were identified from Surveillance, Epidemiology, and End Results (SEER 9) registries. Risk of SMNs was calculated using SEER* Stat. Results: Among 1507 patients, a total of 47 SMNs were identified. The overall risk of SMNs was not elevated in females overall or in females treated for GCT during adulthood although SMN sites (pancreas, soft tissue, bladder, kidney, and thyroid) and trends were comparable with those inmen. There were too few childhood GCT cases with SMNs for further analysis. Conclusions: Unlike men, women treated for GCTs did not have a statistically significant elevated risk of SMNs [ standardized incidence ratio = 1.11; 95% confidence interval (CI) = 0.81-1.47]. The fact that SMNs in women occur in sites similar to those observed in men indicate that long-term follow-up of a larger cohort of females treated for GCT is warranted.
C1 [Liao, Z.; Frazier, A. L.] Dana Farber Canc Inst, Div Hematol Oncol, Boston, MA 02115 USA.
[Liao, Z.] Wellesley Coll, Interdept Program Biochem, Wellesley, MA 02181 USA.
[Rodrigues, M. C.] Fac Ciencias Med Santa Casa Sao Paulo, Med Sci, Sao Paulo, Brazil.
[Poynter, J. N.] Univ Minnesota, Dept Pediat, Div Epidemiol & Clin Res, Minneapolis, MN 55455 USA.
[Poynter, J. N.] Univ Minnesota, Dept Pediat, Mason Canc Ctr, Minneapolis, MN 55455 USA.
[Amatruda, J. F.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA.
[Amatruda, J. F.] Univ Texas Southwestern Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA.
[Amatruda, J. F.] Childrens Med Ctr, Ctr Canc & Blood Disorders, Dallas, TX 75235 USA.
[Rodriguez-Galindo, C.] St Jude Childrens Res Hosp, Dept Global Pediat Med, 332 N Lauderdale St, Memphis, TN 38105 USA.
RP Frazier, AL (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,D-3127, Boston, MA 02216 USA.; Frazier, AL (reprint author), Boston Childrens Hosp, 450 Brookline Ave,D-3127, Boston, MA 02216 USA.
EM lindsay_frazier@dfci.harvard.edu
FU Global Engagement Internship; Department of Biological Sciences at
Wellesley College
FX Global Engagement Internship and Department of Biological Sciences at
Wellesley College. No grant number is applicable.
NR 10
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD FEB
PY 2017
VL 28
IS 2
BP 329
EP 332
DI 10.1093/annonc/mdw609
PG 4
WC Oncology
SC Oncology
GA EP3JJ
UT WOS:000397278300020
ER
PT J
AU Menzies, AM
Johnson, DB
Ramanujam, S
Atkinson, VG
Wong, ANM
Park, JJ
McQuade, JL
Shoushtari, AN
Tsai, KK
Eroglu, Z
Klein, O
Hassel, JC
Sosman, JA
Guminski, A
Sullivan, RJ
Ribas, A
Carlino, MS
Davies, MA
Sandhu, SK
Long, GV
AF Menzies, A. M.
Johnson, D. B.
Ramanujam, S.
Atkinson, V. G.
Wong, A. N. M.
Park, J. J.
McQuade, J. L.
Shoushtari, A. N.
Tsai, K. K.
Eroglu, Z.
Klein, O.
Hassel, J. C.
Sosman, J. A.
Guminski, A.
Sullivan, R. J.
Ribas, A.
Carlino, M. S.
Davies, M. A.
Sandhu, S. K.
Long, G. V.
TI Anti-PD-1 therapy in patients with advanced melanoma and preexisting
autoimmune disorders or major toxicity with ipilimumab
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE PD-1; immunotherapy; autoimmunity; autoimmune disorder; cancer; melanoma
ID CELL LUNG-CANCER; UNTREATED MELANOMA; NIVOLUMAB; PEMBROLIZUMAB;
CHEMOTHERAPY; DOCETAXEL; SAFETY; TRIAL
AB Background: Anti-PD-1 antibodies (anti-PD-1) have clinical activity in a number of malignancies. All clinical trials have excluded patients with significant preexisting autoimmune disorders (ADs) and only one has included patients with immunerelated adverse events (irAEs) with ipilimumab. We sought to explore the safety and efficacy of anti-PD-1 in such patients.
Patients and methods: Patients with advanced melanoma and preexisting ADs and/or major immune-related adverse events (irAEs) with ipilimumab (requiring systemic immunosuppression) that were treated with anti-PD-1 between 1 July 2012 and 30 September 2015 were retrospectively identified.
Results: One hundred and nineteen patients from 13 academic tertiary referral centers were treated with anti-PD-1. In patients with preexisting AD (N = 52), the response rate was 33%. 20 (38%) patients had a flare of AD requiring immunosuppression, including 7/13 with rheumatoid arthritis, 3/3 with polymyalgia rheumatica, 2/2 with Sjogren's syndrome, 2/2 with immune thrombocytopaenic purpura and 3/8 with psoriasis. No patients with gastrointestinal (N = 6) or neurological disorders (N = 5) flared. Only 2 (4%) patients discontinued treatment due to flare, but 15 (29%) developed other irAEs and 4 (8%) discontinued treatment. In patients with prior ipilimumab irAEs requiring immunosuppression (N = 67) the response rate was 40%. Two (3%) patients had a recurrence of the same ipilimumab irAEs, but 23 (34%) developed new irAEs (14, 21% grade 3-4) and 8 (12%) discontinued treatment. There were no treatment-related deaths.
Conclusions: In melanoma patients with preexisting ADs or major irAEs with ipilimumab, anti-PD-1 induced relatively frequent immune toxicities, but these were often mild, easily managed and did not necessitate discontinuation of therapy, and a significant proportion of patients achieved clinical responses. The results support that anti-PD-1 can be administered safely and can achieve clinical benefit in patients with preexisting ADs or prior major irAEs with ipilimumab.
C1 [Menzies, A. M.; Ramanujam, S.; Guminski, A.; Carlino, M. S.; Long, G. V.] Melanoma Inst Australia, Sydney, NSW, Australia.
[Menzies, A. M.; Ramanujam, S.; Guminski, A.; Carlino, M. S.; Long, G. V.] Univ Sydney, Sydney, NSW, Australia.
[Menzies, A. M.; Guminski, A.; Long, G. V.] Royal North Shore & Mater Hosp, Sydney, NSW, Australia.
[Johnson, D. B.; Sosman, J. A.] Vanderbilt Univ, Med Ctr, Nashville, TN USA.
[Atkinson, V. G.] Princess Alexandra Hosp, Brisbane, Qld, Australia.
[Atkinson, V. G.] Univ Queensland, Brisbane, Qld, Australia.
[Wong, A. N. M.; Sandhu, S. K.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Park, J. J.; Carlino, M. S.] Crown Princess Mary Canc Ctr Westmead, Sydney, NSW, Australia.
[McQuade, J. L.; Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Shoushtari, A. N.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
[Tsai, K. K.] Univ Calif San Francisco, Dept Med Oncol, San Francisco, CA 94143 USA.
[Eroglu, Z.] H Lee Moffitt Canc Ctr & Res Inst, Dept Med Oncol, Tampa, FL USA.
[Klein, O.] Austin Hlth, Olivia Newton John Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia.
[Klein, O.] Austin Hlth, Canc Res Inst, Melbourne, Vic, Australia.
[Hassel, J. C.] Heidelberg Univ, Dept Dermatol, Heidelberg, Germany.
[Sullivan, R. J.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Ribas, A.] Univ Calif Los Angeles, Div Hematol Oncol, Los Angeles, CA USA.
RP Menzies, AM (reprint author), Melanoma Inst Australia, 40 Rocklands Rd, Sydney, NSW 2060, Australia.
EM alexander.menzies@sydney.edu.au
FU Cancer Institute NSW fellowship
FX AMM had full access to all of the data in the study and takes
responsibility for the integrity of the data and the accuracy of the
data analysis. The authors wish to acknowledge the assistance of Anna
Hoadley RN, Georgia Cairns RN, Elizabeth Liniker MD and Maria Czupryn
RN. AMM is supported by a Cancer Institute NSW fellowship.
NR 22
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD FEB
PY 2017
VL 28
IS 2
BP 368
EP 376
DI 10.1093/annonc/mdw443
PG 9
WC Oncology
SC Oncology
GA EP3JJ
UT WOS:000397278300026
ER
PT J
AU Jacobs, JP
Lahey, SJ
Nichols, FC
Levett, JM
Johnston, GG
Freeman, RK
Louis, JDS
Painter, J
Yohe, C
Wright, CD
Kanter, KR
Mayer, JE
Naunheim, KS
Rich, JB
Bavaria, JE
AF Jacobs, Jeffrey P.
Lahey, Stephen J.
Nichols, Francis C.
Levett, James M.
Johnston, George Gilbert
Freeman, Richard K.
Louis, James D. St.
Painter, Julie
Yohe, Courtney
Wright, Cameron D.
Kanter, Kirk R.
Mayer, John E., Jr.
Naunheim, Keith S.
Rich, Jeffrey B.
Bavaria, Joseph E.
CA Soc Thoracic Surg Workforce Coding
TI How Is Physician Work Valued?
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID RELATIVE VALUE SCALE; VALUATION
AB Strategies to value physician work continue to evolve. The Society of Thoracic Surgeons and The Society of Thoracic Surgeons National Database have an increasingly important role in this evolution. An understanding of the Current Procedural Terminology (CPT) system (American Medical Association [AMA], Chicago, IL) and the Relative Value Scale Update Committee (RUC) is necessary to comprehend how physician work is valued.
In 1965, with the dawn of increasingly complex medical care, immense innovation, and the rollout of Medicare, the need for a common language describing medical services and procedures was recognized as being of critical importance. In 1966, the AMA, in cooperation with multiple major medical specialty societies, developed the CPT system, which is a coding system for the description of medical procedures and medical services.
The RUC was created by the AMA in response to the passage of the Omnibus Budget Reconciliation Act of 1989, legislation of the United States of America Federal government that mandated that the Centers for Medicare & Medicaid Services adopt a relative value methodology for Medicare physician payment. The role of the RUC is to develop relative value recommendations for the Centers for Medicare & Medicaid Services. These recommendations include relative value recommendations for new procedures or services and also updates to relative value recommendations for previously valued procedures or services. These recommendations pertain to all physician work delivered to Medicare beneficiaries and propose relative values for all physician services, including updates to those based on the original resource-based relative value scale developed by Hsaio and colleagues. In so doing, widely differing work and services provided can be reviewed and comparisons of their relative value (to each other) can be established. The resource-based relative value scale assigns value to physician services using relative value units (RVUs), which consist of three components: work RVU, practice expense RVU, and malpractice RVU, also known as professional liability insurance RVU. The Centers for Medicare & Medicaid Services retains the final decision-making authority on the RVUs associated with each procedure or service.
The purpose of this article is to discuss the role that the CPT codes and the RUC play in the valuation of physician work and to provide an example of how the methodology for valuation of physician work continues to evolve. (C) 2017 by The Society of Thoracic Surgeons
C1 [Jacobs, Jeffrey P.] Johns Hopkins Univ Sch Med, Dept Surg, Div Cardiac Surg, Baltimore, MD USA.
[Jacobs, Jeffrey P.] Johns Hopkins All Childrens Hosp, Johns Hopkins All Childrens Heart Inst, Dept Surg, Div Cardiovasc Surg, St Petersburg, FL USA.
[Jacobs, Jeffrey P.] Johns Hopkins All Childrens Hosp, Johns Hopkins All Childrens Heart Inst, Dept Surg, Div Cardiovasc Surg, Orlando, FL USA.
[Jacobs, Jeffrey P.] Florida Hosp Children, St Petersburg, FL USA.
[Jacobs, Jeffrey P.] Florida Hosp Children, Orlando, FL USA.
[Lahey, Stephen J.] Univ Connecticut Sch Med, Dept Surg, Div Cardiothorac Surg, Farmington, CT USA.
[Nichols, Francis C.] Mayo Clin, Div Gen Thorac Surg, Rochester, MN USA.
[Levett, James M.] Cedar Rapids, Clin Iowa, Iowa City, IA USA.
[Johnston, George Gilbert] US Dept State Off Med Serv, Washington, DC USA.
[Freeman, Richard K.] St Vincents Hlth & Hosp Syst, Indianapolis, IN USA.
[Louis, James D. St.] Univ Missouri, Kansas City Sch Med, Kansas City, MO 65211 USA.
[Painter, Julie] Med Reimbursement Anal & Solut, Thornton, CO USA.
[Yohe, Courtney] Govt Relat, Soc Thorac Surgeons, Washington, DC USA.
[Wright, Cameron D.] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA USA.
[Kanter, Kirk R.] Emory Univ, Atlanta, GA 30322 USA.
[Mayer, John E., Jr.] Harvard Med Sch, Boston Childrens Hosp, Dept Cardiac Surg, Boston, MA USA.
[Naunheim, Keith S.] St Louis Univ Sch Med, St Louis, MO USA.
[Rich, Jeffrey B.] Vue Based HealthCare Solut, Virginia Beach, VA USA.
[Bavaria, Joseph E.] Univ Penn, Philadelphia, PA 19104 USA.
[Soc Thoracic Surg Workforce Coding] Soc Thorac Surgeons, Chicago, IL USA.
RP Jacobs, JP (reprint author), Johns Hopkins All Childrens Hosp, Johns Hopkins All Childrens Heart Inst, 601 Fifth St S,Ste 607, St Petersburg, FL 33701 USA.; Jacobs, JP (reprint author), Florida Hosp Children, St Petersburg, FL 33701 USA.
EM jeffjacobs@jhmi.edu
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD FEB
PY 2017
VL 103
IS 2
BP 373
EP 380
DI 10.1016/j.athoracsur.2016.11.059
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA EP1SU
UT WOS:000397165400035
PM 28109347
ER
PT J
AU Badhwar, V
Rankin, JS
He, M
Jacobs, JP
Furnary, AP
Fazzalari, FL
O'Brien, S
Gammie, JS
Shahian, DM
AF Badhwar, Vinay
Rankin, J. Scott
He, Max
Jacobs, Jeffrey P.
Furnary, Anthony P.
Fazzalari, Frank L.
O'Brien, Sean
Gammie, James S.
Shahian, David M.
TI Performing Concomitant Tricuspid Valve Repair at the Time of Mitral
Valve Operations Is Not Associated With Increased Operative Mortality
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID RING ANNULOPLASTY; NORTH-AMERICA; REGURGITATION; SURGERY; REPLACEMENT;
MANAGEMENT; DISEASE; DILATATION; GUIDELINES; OUTCOMES
AB Background. The performance of concomitant tricuspid valve repair (TVr) at the time of mitral valve repair or replacement (MVRR) has previously been associated with elevated short-term risk. Outcomes were assessed at incremental grades of tricuspid regurgitation (TR) to quantify the contemporary risk of concomitant TVr.
Methods. Between July 2011 and June 2014, 88,473 patients undergoing MVRR were examined using The Society of Thoracic Surgeons database. Outcomes with or without TVr, after isolated MVRR (n = 62,118) and MVRR with coronary artery bypass graft surgery (CABG [n = 26,355]), were independently analyzed at three levels of TR: none-mild, moderate, and severe. Risk-adjusted morbidity and mortality associated with the performance of concomitant TVr were evaluated using multivariable logistic regression.
Results. The TR was graded as none-mild in 74.3% of patients (65,769 of 88,473), moderate in 17.2% (15,222 of 88,473), and severe in 8.5% (7,482 of 88,473). The rate of TVr by TR grade was 3.5% (2,308 of 65,769) for none-mild, 30.6% (4,661 of 15,222) for moderate, and 75.6% (5,654 of 7,482) for severe. Overall risk-adjusted occurrence of any morbidity associated with performance of TVr was increased in both groups (MVRR odds ratio [OR] 1.36, 95% confidence interval [CI]: 1.24 to 1.48; and MVRR plus CABG OR 1.33, 95% CI: 1.19 to 1.49). However, at all grades of TR, TVr was not associated with increased risk-adjusted mortality (MVRR OR 0.99, 95% CI: 0.84 to 1.17; and MVRR plus CABG OR 1.04, 95% CI: 0.85 to 1.27).
Conclusions. In contemporary patients, concomitant TVr is not associated with a risk-adjusted increase in mortality, regardless of TR severity. A more liberal approach to TVr at the time of MVRR may be justified when long-term benefits are thought to outweigh incremental short-term morbidity risk. Further investigation of longitudinal TVr outcomes is warranted. (C) 2017 by The Society of Thoracic Surgeons
C1 [Badhwar, Vinay] West Virginia Univ, Div Cardiothorac Surg, 1 Med Ctr Dr, Morgantown, WV 26506 USA.
Duke Clin Res Inst, Durham, NC USA.
Johns Hopkins Univ, Childrens Hosp, Childrens Heart Inst, Sch Med, St Petersburg, FL USA.
Johns Hopkins Univ, Childrens Hosp, Childrens Heart Inst, Sch Med, Baltimore, MD USA.
Starr Wood Cardiac Grp, Portland, OR USA.
Univ Michigan, Dept Cardiac Surg, Ann Arbor, MI USA.
Univ Maryland, Div Cardiac Surg, Baltimore, MD USA.
Massachusetts Gen Hosp, Dept Surg, Boston, MA USA.
Massachusetts Gen Hosp, Ctr Qual & Safety, Boston, MA USA.
RP Badhwar, V (reprint author), West Virginia Univ, Div Cardiothorac Surg, 1 Med Ctr Dr, Morgantown, WV 26506 USA.
EM vinay.badhwar@wvumedicine.org
FU Edwards Lifesciences
FX Dr Gammie discloses a financial relationship with Edwards Lifesciences.
NR 31
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD FEB
PY 2017
VL 103
IS 2
BP 587
EP 594
DI 10.1016/j.athoracsur.2016.06.004
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA EP1SU
UT WOS:000397165400064
PM 27570159
ER
PT J
AU Mihos, CG
Santana, O
AF Mihos, Christos G.
Santana, Orlando
TI Pay Attention to Mitral Valve Repair With Autologous Pericardial Leaflet
Augmentation Reply
SO ANNALS OF THORACIC SURGERY
LA English
DT Letter
C1 [Mihos, Christos G.] Massachusetts Gen Hosp, Harvard Med Sch, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
[Santana, Orlando] Columbia Univ, Mt Sinai Heart Inst, Miami Beach, FL USA.
RP Mihos, CG (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Cardiac Ultrasound Lab, Boston, MA 02114 USA.
EM cmihos@mgh.harvard.edu
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD FEB
PY 2017
VL 103
IS 2
BP 689
EP 690
PG 2
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA EP1SU
UT WOS:000397165400083
PM 28109360
ER
PT J
AU Osho, AA
Azzoli, CJ
Pai, S
Mino-Kenudson, M
Faquin, WC
Huynh, TG
Lanuti, M
Mathisen, DJ
Muniappan, A
AF Osho, Asishana A.
Azzoli, Christopher J.
Pai, Sara
Mino-Kenudson, Mari
Faquin, William C.
Huynh, Tiffany G.
Lanuti, Michael
Mathisen, Douglas J.
Muniappan, Ashok
TI Successful Treatment of an Aggressive Tracheal Malignancy With
Immunotherapy
SO ANNALS OF THORACIC SURGERY
LA English
DT Editorial Material
ID CELL LUNG-CANCER; DOCETAXEL; NIVOLUMAB
AB Immune checkpoint inhibitors are emerging as therapeutic options for oncology patients in whom conventional treatment regimens have failed. These immunotherapies counteract tumor-induced tolerance and have been shown to be effective in thoracic malignancies, including non-small cell lung cancer (NSCLC). This report highlights the successful use of nivolumab-an immunotherapeutic agent that binds to proteins involved in T-cell proliferation-for the management of recurrent tracheal squamous cell cancer after exhaustion of conventional surgical, chemotherapeutic, and radiation therapy options. Observations provide a strong indication of the potential value of checkpoint inhibitors for managing a wide array of thoracic malignancies. (C) 2017 by The Society of Thoracic Surgeons
C1 Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Thorac Surg, Boston, MA 02114 USA.
RP Muniappan, A (reprint author), Massachusetts Gen Hosp, Div Thorac Surg, 55 Fruit St,GRB 425, Boston, MA 02114 USA.
EM amuniappan@mgh.harvard.edu
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD FEB
PY 2017
VL 103
IS 2
BP E123
EP E125
DI 10.1016/j.athoracsur.2016.08.021
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA EP1SU
UT WOS:000397165400004
PM 28109369
ER
PT J
AU Gonzalez, DA
Soble, JR
Marceaux, JC
McCoy, KJM
AF Gonzalez, David Andres
Soble, Jason R.
Marceaux, Janice C.
McCoy, Karin J. M.
TI An Evaluation of the Texas Functional Living Scale's Latent Structure
and Subscales
SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY
LA English
DT Article
DE Everyday functioning; Test construction; Assessment
AB Objective: Performance-based functional assessment is a critical component of neuropsychological practice. The Texas Functional Living Scale (TFLS) has promise given its brevity, nationally representative norms, and co-norming with Wechsler scales. However, its subscale structure has not been evaluated. The purpose of this study was to evaluate the TFLS in a mixed clinical sample (n = 197).
Method: Reliability and convergent and discriminant validity coefficients were calculated with neurocognitive testing and collateral reports and factor analysis was performed.
Results: The Money and Calculation subscale had the best psychometric properties of the subscales. The evidence did not support solitary interpretation of the Time subscale. A three-factor latent structure emerged representing memory and semantic retrieval, performance and visual scanning, and financial calculation.
Conclusions: This study added psychometric support for interpretation of the TFLS total score and some of its subscales. Study limitations included sample characteristics (e.g., gender ratio) and low power for collateral report analyses.
C1 [Gonzalez, David Andres; Soble, Jason R.; Marceaux, Janice C.; McCoy, Karin J. M.] South Texas Vet Hlth Care Syst, Psychol Serv 116B, San Antonio, TX USA.
[Gonzalez, David Andres] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, 8300 Floyd Curl Dr MC 7883, San Antonio, TX 78229 USA.
RP Gonzalez, DA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, 8300 Floyd Curl Dr MC 7883, San Antonio, TX 78229 USA.
EM gonzalezD15@uthscsa.edu
NR 21
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0887-6177
EI 1873-5843
J9 ARCH CLIN NEUROPSYCH
JI Arch. Clin. Neuropsychol.
PD FEB
PY 2017
VL 32
IS 1
BP 104
EP 109
DI 10.1093/arclin/acw082
PG 6
WC Psychology, Clinical; Psychology
SC Psychology
GA EO9KJ
UT WOS:000397007300013
PM 28122769
ER
PT J
AU Renfroe, JB
Turner, TH
Hinson, VK
AF Renfroe, Jenna B.
Turner, Travis H.
Hinson, Vanessa K.
TI Assessing Visuospatial Skills in Parkinson's: Comparison of
Neuropsychological Assessment Battery Visual Discrimination to the
Judgment of Line Orientation
SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY
LA English
DT Article
DE Parkinson's disease; Assessment
ID MILD COGNITIVE IMPAIRMENT; SOCIETY TASK-FORCE; ALZHEIMERS-DISEASE;
BENTON JUDGMENT; LEWY BODIES; SHORT FORMS; DEMENTIA; CRITERIA
AB Objective: Judgment of Line Orientation (JOLO) test is widely used in assessing visuospatial deficits in Parkinson's disease (PD). The neuropsychological assessment battery (NAB) offers the Visual Discrimination test, with age and education correction, parallel forms, and co-normed standardization sample for comparisons within and between domains. However, NAB Visual Discrimination has not been validated in PD, and may not measure the same construct as JOLO.
Method: A heterogeneous sample of 47 PD patients completed the JOLO and NAB Visual Discrimination within a broader neuropsychological evaluation. Pearson correlations assessed relationships between JOLO and NAB Visual Discrimination performances.
Results: Raw and demographically corrected scores from JOLO and Visual Discrimination were only weakly correlated. NAB Visual Discrimination subtest was moderately correlated with overall cognitive functioning, whereas the JOLO was not.
Conclusions: Despite apparent virtues, results do not support NAB Visual Discrimination as an alternative to JOLO in assessing visuospatial functioning in PD.
C1 [Renfroe, Jenna B.; Turner, Travis H.; Hinson, Vanessa K.] Med Univ South Carolina, Dept Neurol, 208 B Rutledge Ave,MSC 108, Charleston, SC 29425 USA.
[Hinson, Vanessa K.] Ralph H Johnson VAMC, Neurol Serv, Charleston, SC USA.
RP Renfroe, JB (reprint author), Med Univ South Carolina, Dept Neurol, 208 B Rutledge Ave,MSC 108, Charleston, SC 29425 USA.
EM jennarenfroephd@gmail.com
FU Michael J. Fox Foundation
FX This work was supported by the Michael J. Fox Foundation.
NR 21
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0887-6177
EI 1873-5843
J9 ARCH CLIN NEUROPSYCH
JI Arch. Clin. Neuropsychol.
PD FEB
PY 2017
VL 32
IS 1
BP 123
EP 127
DI 10.1093/arclin/acw102
PG 5
WC Psychology, Clinical; Psychology
SC Psychology
GA EO9KJ
UT WOS:000397007300016
PM 28122771
ER
PT J
AU Provencher, MT
Sanchez, G
Schantz, K
Ferrari, M
Sanchez, A
Frangiamore, S
Mannava, S
AF Provencher, Matthew T.
Sanchez, George
Schantz, Katrina
Ferrari, Marcio
Sanchez, Anthony
Frangiamore, Salvatore
Mannava, Sandeep
TI Anatomic Humeral Head Reconstruction With Fresh Osteochondral Talus
Allograft for Recurrent Glenohumeral Instability With Reverse Hill-Sachs
Lesion
SO ARTHROSCOPY TECHNIQUES
LA English
DT Article
ID ANTERIOR SHOULDER INSTABILITY; BONE DEFECTS; FOLLOW-UP; MANAGEMENT;
REMPLISSAGE; DISLOCATION; DIAGNOSIS; LATARJET; CONTACT; REPAIRS
AB The treatment of recurrent glenohumeral instability, especially with a concomitant bony lesion, remains challenging. This is especially true in the case of posterior instability given its less common incidence. Moreover, the presence of an engaging reverse Hill-Sachs lesion in combination with posterior instability will result in the need for a more aggressive treatment option. In comparison with a Hill-Sachs lesion, a reverse Hill-Sachs lesion features greater chondral deficiency that must be addressed during treatment. We propose the talus allograft as a potential allograft for treatment of an engaging reverse Hill-Sachs lesion. The superior articular surface of the talus may be used to reconstruct the articular surface of the humeral head. In this technical note, we describe our preferred primary technique for treatment of an engaging reverse Hill-Sachs lesion with recurrent glenohumeral instability through use of a fresh osteochondral talus allograft, as well as discuss the advantages and disadvantages of this allograft option.
C1 [Provencher, Matthew T.; Sanchez, George; Ferrari, Marcio] Steadman Philippon Res Inst, Vail, CO USA.
[Provencher, Matthew T.; Frangiamore, Salvatore; Mannava, Sandeep] Steadman Clin, 181 W Meadow Dr,Ste 4000, Vail, CO 81657 USA.
[Schantz, Katrina] Massachusetts Gen Hosp, Sports Med Serv, Boston, MA 02114 USA.
[Sanchez, Anthony] Jackson Mem Hosp, Miami, FL 33136 USA.
RP Provencher, MT (reprint author), Steadman Clin, 181 W Meadow Dr,Ste 4000, Vail, CO 81657 USA.
EM mprovencher@thesteadmanclinic.com
FU Arthrex; JRF Ortho
FX M.T.P. receives support from Arthrex, JRF Ortho. Consultant. Patent
numbers (issued) 9226743, 20150164498, 20150150594, 20110040339.
Arthrex, SLACK. Publishing royalties.
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2212-6287
J9 ARTHROSC TEC
JI Arthrosc. Tec.
PD FEB
PY 2017
VL 6
IS 1
BP E255
EP E261
DI 10.1016/j.eats.2016.10.017
PG 7
WC Orthopedics
SC Orthopedics
GA EP4ZT
UT WOS:000397389300040
ER
PT J
AU Cao, HT
Gibson, TE
Bashan, A
Liu, YY
AF Cao, Hong-Tai
Gibson, Travis E.
Bashan, Amir
Liu, Yang-Yu
TI Inferring human microbial dynamics from temporal metagenomics data:
Pitfalls and lessons
SO BIOESSAYS
LA English
DT Article
DE dynamics inference; ecological modeling; human microbiome; temporal
metagenomics
ID LOTKA-VOLTERRA EQUATION; REPLICATOR DYNAMICS; VARIABLE SELECTION; GUT
MICROBIOTA; REGULARIZATION; CLASSIFICATION; REGRESSION; MODELS; MATLAB;
LASSO
AB The human gut microbiota is a very complex and dynamic ecosystem that plays a crucial role in health and well-being. Inferring microbial community structure and dynamics directly from time-resolved metagenomics data is key to understanding the community ecology and predicting its temporal behavior. Many methods have been proposed to perform the inference. Yet, as we point out in this review, there are several pitfalls along the way. Indeed, the uninformative temporal measurements and the compositional nature of the relative abundance data raise serious challenges in inference. Moreover, the inference results can be largely distorted when only focusing on highly abundant species by ignoring or grouping low-abundance species. Finally, the implicit assumptions in various regularization methods may not reflect reality. Those issues have to be seriously considered in ecological modeling of human gut microbiota.
C1 [Cao, Hong-Tai; Gibson, Travis E.; Bashan, Amir; Liu, Yang-Yu] Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Cao, Hong-Tai] Univ Southern Calif, Dept Elect Engn, Los Angeles, CA 90089 USA.
[Cao, Hong-Tai] Zhejiang Univ, Chu Kochen Honors Coll, Coll Elect Engn, Hangzhou, Zhejiang, Peoples R China.
[Bashan, Amir] Bar Ilan Univ, Dept Phys, Ramat Gan, Israel.
[Liu, Yang-Yu] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.
RP Liu, YY (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.; Liu, YY (reprint author), Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.
EM yyl@channing.harvard.edu
FU John Templeton Foundation [51977]
FX This work was partially supported by the John Templeton Foundation
(award number 51977).
NR 43
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0265-9247
EI 1521-1878
J9 BIOESSAYS
JI Bioessays
PD FEB
PY 2017
VL 39
IS 2
AR UNSP 1600188
DI 10.1002/bies.201600188
PG 12
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
Topics
GA EP2IK
UT WOS:000397206400008
ER
PT J
AU Montillo, M
O'Brien, S
Tedeschi, A
Byrd, JC
Dearden, C
Gill, D
Brown, JR
Barrientos, JC
Mulligan, SP
Furman, RR
Cymbalista, F
Plascencia, C
Chang, S
Hsu, E
James, DF
Hillmen, P
AF Montillo, M.
O'Brien, S.
Tedeschi, A.
Byrd, J. C.
Dearden, C.
Gill, D.
Brown, J. R.
Barrientos, J. C.
Mulligan, S. P.
Furman, R. R.
Cymbalista, F.
Plascencia, C.
Chang, S.
Hsu, E.
James, D. F.
Hillmen, P.
TI Ibrutinib in previously treated chronic lymphocytic leukemia patients
with autoimmune cytopenias in the RESONATE study
SO BLOOD CANCER JOURNAL
LA English
DT Letter
ID INHIBITION; DIAGNOSIS; ARTHRITIS; CELL
C1 [Montillo, M.; Tedeschi, A.] Niguarda Canc Ctr, Milan, Italy.
[O'Brien, S.] MD Anderson Canc Ctr, Houston, TX USA.
[Byrd, J. C.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
[Dearden, C.] Royal Marsden Hosp, London, England.
[Gill, D.] Princess Alexandra Hosp, Brisbane, Qld, Australia.
[Brown, J. R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Barrientos, J. C.] Hofstra Northwell Sch Med, Hempstead, NY USA.
[Mulligan, S. P.] Royal North Shore Hosp, Sydney, NSW, Australia.
[Furman, R. R.] New York Presbyterian Hosp, Weill Cornell Med College, York, NY USA.
[Cymbalista, F.] Hop Avicenne, Paris, France.
[Plascencia, C.; Chang, S.; Hsu, E.; James, D. F.] Pharmacyclics LLC, Sunnyvale, CA USA.
[Plascencia, C.; Chang, S.; Hsu, E.; James, D. F.] AbbVie Co, Sunnyvale, CA USA.
[Hillmen, P.] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England.
RP Montillo, M (reprint author), Niguarda Canc Ctr, Milan, Italy.
EM marco.montillo@ospedaleniguarda.it
FU Pharmacyclics LLC, an AbbVie Company
FX This study was supported by research funding from Pharmacyclics LLC, an
AbbVie Company. Ingrid Koo, PhD, a medical writer supported by funding
from Pharmacyclics LLC, an AbbVie Company, provided drafts and editorial
assistance to the authors during preparation of this manuscript.
NR 15
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044-5385
J9 BLOOD CANCER J
JI Blood Cancer J.
PD FEB
PY 2017
VL 7
AR e524
DI 10.1038/bcj.2017.5
PG 4
WC Oncology
SC Oncology
GA EO8BD
UT WOS:000396912900005
PM 28157216
ER
PT J
AU Swords, RT
Watts, J
Erba, HP
Altman, JK
Maris, M
Anwer, F
Hua, Z
Stein, H
Faessel, H
Sedarati, F
Dezube, BJ
Giles, FJ
Medeiros, BC
DeAngelo, DJ
AF Swords, R. T.
Watts, J.
Erba, H. P.
Altman, J. K.
Maris, M.
Anwer, F.
Hua, Z.
Stein, H.
Faessel, H.
Sedarati, F.
Dezube, B. J.
Giles, F. J.
Medeiros, B. C.
DeAngelo, D. J.
TI Expanded safety analysis of pevonedistat, a first-in-class
NEDD8-activating enzyme inhibitor, in patients with acute myeloid
leukemia and myelodysplastic syndromes
SO BLOOD CANCER JOURNAL
LA English
DT Letter
ID MLN4924; CANCER; CELLS
C1 [Swords, R. T.; Watts, J.] Sylvester Comprehens Canc Ctr, Leukemia Program, Miami, FL 33136 USA.
[Erba, H. P.] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI 48109 USA.
[Altman, J. K.; Giles, F. J.] Northwestern Univ, Northwestern Med Dev Therapeut Inst, Chicago, IL 60611 USA.
[Maris, M.] Colorado Blood Canc Inst, Denver, CO USA.
[Anwer, F.] Univ Arizona, Ctr Canc, Tucson, AZ USA.
[Hua, Z.; Stein, H.; Faessel, H.; Sedarati, F.; Dezube, B. J.] T Takeda Pharmaceut Int Co, Cambridge, MA USA.
[Medeiros, B. C.] Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA.
[DeAngelo, D. J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Swords, RT (reprint author), Sylvester Comprehens Canc Ctr, Leukemia Program, Miami, FL 33136 USA.
EM rswords@med.miami.edu
FU Takeda Pharmaceuticals, Inc.; NIH [1KL2TR000461]
FX This research was supported by Takeda Pharmaceuticals, Inc. This study
is registered with ClinicalTrials.gov, number NCT00677170. RTS received
support from grant NIH 1KL2TR000461.
NR 15
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044-5385
J9 BLOOD CANCER J
JI Blood Cancer J.
PD FEB
PY 2017
VL 7
AR e520
DI 10.1038/bcj.2017.1
PG 4
WC Oncology
SC Oncology
GA EO8BD
UT WOS:000396912900001
PM 28157218
ER
PT J
AU Sinha, N
Dauwels, J
Kaiser, M
Cash, SS
Westover, MB
Wang, YJ
Taylor, PN
AF Sinha, Nishant
Dauwels, Justin
Kaiser, Marcus
Cash, Sydney S.
Westover, M. Brandon
Wang, Yujiang
Taylor, Peter N.
TI Predicting neurosurgical outcomes in focal epilepsy patients using
computational modelling
SO BRAIN
LA English
DT Article
DE epilepsy; focal seizures; computational models; intracranial EEG;
surgical outcome prediction
ID TEMPORAL-LOBE EPILEPSY; STRUCTURAL CONNECTIVITY; FUNCTIONAL
CONNECTIVITY; PRESURGICAL EVALUATION; SEIZURE DYNAMICS; SURGERY;
NETWORK; EEG; ABNORMALITIES; OSCILLATIONS
AB Surgery can be a last resort for patients with intractable, medically refractory epilepsy. For many of these patients, however, there is substantial risk that the surgery will be ineffective. The prediction of who is likely to benefit from a surgical approach is crucial for being able to inform patients better, conduct principled prospective clinical trials, and ultimately tailor therapeutic approaches to these patients more effectively. Dynamical computational models, informed with patient data, can be used to make predictions and give mechanistic insight. In this study, we develop patient-specific dynamical network models of epileptogenic cortex. We infer the network connectivity matrix from non-seizure electrographic recordings of patients and use these connectivity matrices as the network structure in our model. The model simulates the dynamics of a bi-stable switch at every node in this network, meaning that every node starts in a background state, but has the ability to transit to a co-existing seizure state. Whether a transition happens in a node is partly determined by the stochastic nature of the input to the node, but also by the input the node receives from other connected nodes in the network. By conducting simulations with such a model, we can detect the average transition time for nodes in a given network, and therefore define nodes with a short transition time as highly epileptogenic. In a retrospective study, we found that in some patients the regions with high epileptogenicity in the model overlap with those identified clinically as the seizure onset zone. Moreover, it was found that the resection of these regions in the model reduces the overall likelihood of a seizure. Following removal of these regions in the model, we predicted surgical outcomes and compared these to actual patient outcomes. Our predictions were found to be 81.3% accurate on a dataset of 16 patients with intractable epilepsy. Intriguingly, in patients with unsuccessful outcomes, the proposed computational approach is able to suggest alternative resection sites. The model presented here gives mechanistic insight as to why surgery may be unsuccessful in some patients. This may aid clinicians in presurgical evaluation by providing a tool to explore various surgical options, offering complementary information to existing clinical techniques.
C1 [Sinha, Nishant; Dauwels, Justin] Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore, Singapore.
[Kaiser, Marcus; Wang, Yujiang; Taylor, Peter N.] Newcastle Univ, Fac Med Sci, Interdisciplinary Comp & Complex BioSyst ICOS, Newcastle Upon Tyne, Tyne & Wear, England.
[Kaiser, Marcus; Taylor, Peter N.] Newcastle Univ, Fac Med Sci, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England.
[Cash, Sydney S.; Westover, M. Brandon] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Cash, Sydney S.; Westover, M. Brandon] Harvard Med Sch, Boston, MA USA.
[Taylor, Peter N.] UCL, Inst Neurol, London, England.
RP Sinha, N (reprint author), Nanyang Technol Univ, Sch Elect & Elect Engn, Singapore, Singapore.; Taylor, PN (reprint author), Newcastle Univ, Fac Med Sci, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England.
EM nishant002@e.ntu.edu.sg; peter.taylor@newcastle.ac.uk
FU Ministry of Education (MOE) as a part of Complexity Institute, Nanyang
Technological University, Singapore [M4011102 RGC3/13]; Engineering and
Physical Sciences Research Council of the United Kingdom [EP/K026992/1];
Wellcome Trust [105617/Z/14/Z]; NIH-NINDS [R01 NS062092, K24 NS088568];
U.S. National Institute of Neurological Disorders and Stroke
[U24NS06930]; [EP/N031962/1]
FX N.S. and J.D. were supported by the Ministry of Education (MOE) Tier 1
Grant M4011102 RGC3/13 as a part of Complexity Institute, Nanyang
Technological University, Singapore. P.T. and M.K. were supported by the
Engineering and Physical Sciences Research Council of the United Kingdom
(EP/K026992/1) as part of the Human Green Brain Project. P.T. was
supported by Wellcome Trust (105617/Z/14/Z). M.K. was supported by grant
EP/N031962/1. SSC was supported by NIH-NINDS R01 NS062092 and K24
NS088568 grant. Access to the image(s) and/or data was supported by
Award number U24NS06930 from the U.S. National Institute of Neurological
Disorders and Stroke. The content of this publication/presentation is
solely the responsibility of the authors, and does not necessarily
represent the official views of the U.S. National Institute for
Neurological Disorders and Stroke or the U.S. National Institutes of
Health.
NR 75
TC 1
Z9 1
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD FEB
PY 2017
VL 140
BP 319
EP 332
DI 10.1093/aww332
PN 2
PG 14
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA EP3XV
UT WOS:000397315900017
PM 28011454
ER
PT J
AU Collins, JA
Montal, V
Hochberg, D
Quimby, M
Mandelli, ML
Makris, N
Seeley, WW
Gorno-Tempini, ML
Dickerson, BC
AF Collins, Jessica A.
Montal, Victor
Hochberg, Daisy
Quimby, Megan
Mandelli, Maria Luisa
Makris, Nikos
Seeley, William W.
Gorno-Tempini, Maria Luisa
Dickerson, Bradford C.
TI Focal temporal pole atrophy and network degeneration in semantic variant
primary progressive aphasia
SO BRAIN
LA English
DT Article
DE atrophy; resting state connectivity; primary progressive aphasia;
semantic dementia; temporal lobe
ID FRONTOTEMPORAL LOBAR DEGENERATION; MIDDLE LONGITUDINAL FASCICLE;
INTRINSIC FUNCTIONAL CONNECTIVITY; SURFACE-BASED ANALYSIS; HUMAN
CEREBRAL-CORTEX; ALZHEIMERS-DISEASE; WHITE-MATTER; HUMAN BRAIN;
STRUCTURAL CONNECTIVITY; RESTING-STATE
AB A wealth of neuroimaging research has associated semantic variant primary progressive aphasia with distributed cortical atrophy that is most prominent in the left anterior temporal cortex; however, there is little consensus regarding which region within the anterior temporal cortex is most prominently damaged, which may indicate the putative origin of neurodegeneration. In this study, we localized the most prominent and consistent region of atrophy in semantic variant primary progressive aphasia using cortical thickness analysis in two independent patient samples (n = 16 and 28, respectively) relative to age-matched controls (n = 30). Across both samples the point of maximal atrophy was located in the same region of the left temporal pole. This same region was the point of maximal atrophy in 100% of individual patients in both semantic variant primary progressive aphasia samples. Using resting state functional connectivity in healthy young adults (n = 89), we showed that the seed region derived from the semantic variant primary progressive aphasia analysis was strongly connected with a large-scale network that closely resembled the distributed atrophy pattern in semantic variant primary progressive aphasia. In both patient samples, the magnitude of atrophy within a brain region was predicted by that region's strength of functional connectivity to the temporopolar seed region in healthy adults. These findings suggest that cortical atrophy in semantic variant primary progressive aphasia may follow connectional pathways within a large-scale network that converges on the temporal pole.
C1 [Collins, Jessica A.; Hochberg, Daisy; Quimby, Megan; Dickerson, Bradford C.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA.
[Montal, Victor] Univ Autonoma Barcelona, Inst Invest Biomed St Pau, Dept Neurol, Hosp St Pau, Barcelona, Spain.
[Mandelli, Maria Luisa; Seeley, William W.; Gorno-Tempini, Maria Luisa] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Makris, Nikos] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA.
[Seeley, William W.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA.
RP Collins, JA (reprint author), MGH Frontotemporal Disorders Unit, 149 13th St, Charlestown, MA 02129 USA.
EM jcollins21@mgh.harvard.edu
FU National Institutes of Health [R21 NS077059, R01 NS050915, P01
AG005134]; National Institute of Biomedical Imaging and Bioengineering
(NIBIB), National Institutes of Health; NIH; [S10RR023401];
[S10RR023043]; [S10RR021110]
FX This work was supported by the following National Institutes of Health
Grants: R21 NS077059, R01 NS050915, P01 AG005134. This research was
carried out in whole or in part at the Athinoula A. Martinos Center for
Biomedical Imaging at the Massachusetts General Hospital, using
resources provided by the Center for Functional Neuroimaging
Technologies, P41EB015896, a P41 Biotechnology Resource Grant supported
by the National Institute of Biomedical Imaging and Bioengineering
(NIBIB), National Institutes of Health. This work also involved the use
of instrumentation supported by the NIH Shared Instrumentation Grant
Program and/ or High-End Instrumentation Grant Program; specifically,
grant number(s) S10RR023401, S10RR023043, S10RR021110. The content is
solely the responsibility of the authors and does not necessarily
represent the official views of the National Institute of Health.
NR 109
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD FEB
PY 2017
VL 140
BP 457
EP 471
DI 10.1093/brain/aww313
PN 2
PG 15
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA EP3XV
UT WOS:000397315900027
PM 28040670
ER
PT J
AU Darby, RR
Laganiere, S
Pascual-Leone, A
Prasad, S
Fox, MD
AF Darby, R. Ryan
Laganiere, Simon
Pascual-Leone, Alvaro
Prasad, Sashank
Fox, Michael D.
TI Finding the imposter: brain connectivity of lesions causing delusional
misidentifications
SO BRAIN
LA English
DT Article
DE Capgras; fregoli; delusions; delusional misidentifications; connectivity
ID CAPGRAS DELUSION; PREDICTION ERROR; NETWORKS; RECOGNITION; ATTENTION;
RESPONSES; BELIEF; CORTEX; MEMORY; DAMAGE
AB Focal brain injury can sometimes lead to bizarre symptoms, such as the delusion that a family member has been replaced by an imposter (Capgras syndrome). How a single brain lesion could cause such a complex disorder is unclear, leading many to speculate that concurrent delirium, psychiatric disease, dementia, or a second lesion is required. Here we instead propose that Capgras and other delusional misidentification syndromes arise from single lesions at unique locations within the human brain connectome. This hypothesis is motivated by evidence that symptoms emerge from sites functionally connected to a lesion location, not just the lesion location itself. First, 17 cases of lesion-induced delusional misidentifications were identified and lesion locations were mapped to a common brain atlas. Second, lesion network mapping was used to identify brain regions functionally connected to the lesion locations. Third, regions involved in familiarity perception and belief evaluation, two processes thought to be abnormal in delusional misidentifications, were identified using meta-analyses of previous functional magnetic resonance imaging studies. We found that all 17 lesion locations were functionally connected to the left retrosplenial cortex, the region most activated in functional magnetic resonance imaging studies of familiarity. Similarly, 16 of 17 lesion locations were functionally connected to the right frontal cortex, the region most activated in functional magnetic resonance imaging studies of expectation violation, a component of belief evaluation. This connectivity pattern was highly specific for delusional misidentifications compared to four other lesion-induced neurological syndromes (P < 0.0001). Finally, 15 lesions causing other types of delusions were connected to expectation violation (P < 0.0001) but not familiarity regions, demonstrating specificity for delusion content. Our results provide potential neuroanatomical correlates for impaired familiarity perception and belief evaluation in patients with delusional misidentifications. More generally, we demonstrate a mechanism by which a single lesion can cause a complex neuropsychiatric syndrome based on that lesion's unique pattern of functional connectivity, without the need for pre-existing or hidden pathology.
C1 [Darby, R. Ryan; Laganiere, Simon; Pascual-Leone, Alvaro; Fox, Michael D.] Harvard Med Sch, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA USA.
[Darby, R. Ryan; Laganiere, Simon; Pascual-Leone, Alvaro; Fox, Michael D.] Harvard Med Sch, Div Cognit Neurol, Dept Neurol, Beth Israel Deaconess Med Ctr, Boston, MA USA.
[Darby, R. Ryan; Fox, Michael D.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA.
[Darby, R. Ryan] Harvard Med Sch, McLean Psychiat Hosp, Dept Neurol, Belmont, MA USA.
[Prasad, Sashank] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurol, Boston, MA USA.
[Fox, Michael D.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
RP Darby, RR (reprint author), Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, 330 Brookline Ave,Kirstein Bldg KS 158, Boston, MA 02215 USA.
EM rdarby@bidmc.harvard.edu
FU Sidney R. Baer, Jr. Foundation; NIH [R01HD069776, R01NS073601, R21
NS082870, R21 MH099196, R21 NS085491, R21 HD07616, R25NS065743,
K23NS083741]; Football Players Health Study at Harvard University;
Harvard Catalyst | The Harvard Clinical and Translational Science Center
(NCRR and the NCATS NIH) [UL1 RR025758]; American Brain Foundation
FX This work was supported by funding from the Sidney R. Baer, Jr.
Foundation (R.D., S.L., M.F., A.P.L.), the NIH (R01HD069776,
R01NS073601, R21 NS082870, R21 MH099196, R21 NS085491, R21 HD07616 to
A.P.L.; R25NS065743, K23NS083741 to M.F.), the Football Players Health
Study at Harvard University (A.P.L.), and Harvard Catalyst | The Harvard
Clinical and Translational Science Center (NCRR and the NCATS NIH, UL1
RR025758 to A.P.L.), and the American Brain Foundation (M.F.).
NR 45
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD FEB
PY 2017
VL 140
BP 497
EP 507
DI 10.1093/brain/aww288
PN 2
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA EP3XV
UT WOS:000397315900030
PM 28082298
ER
PT J
AU Osborn, HA
Glicksman, JT
Brandt, MG
Doyle, PC
Fung, K
AF Osborn, Heather Ann
Glicksman, Jordan T.
Brandt, Michael G.
Doyle, Philip C.
Fung, Kevin
TI Primary care specialty career choice among Canadian medical students
Understanding the factors that influence their decisions
SO CANADIAN FAMILY PHYSICIAN
LA English
DT Article
ID FAMILY PHYSICIANS
AB Objective To identify which factors influence medical students' decision to choose a career in family medicine and pediatrics, and which factors influence their decision to choose careers in non-front-line specialties.
Design Survey that was created based on a comprehensive literature review to determine which factors are considered important when choosing practice specialty.
Setting Ontario medical school.
Participants An open cohort of medical students in the graduating classes of 2008 to 2011 (inclusive).
Main outcome measures The main factors that influenced participants' decision to choose a career in primary care or pediatrics, and the main factors that influenced participants' decision to choose a career in a non-frontline specialty.
Results A total of 323 participants were included in this study. Factors that significantly influenced participants' career choice in family medicine or pediatrics involved work-life balance (acceptable hours of practice [P =.005], acceptable on-call demands [P =.012], and lifestyle flexibility [P =.006]); a robust physician-patient relationship (ability to promote individual health promotion [P =.014] and the opportunity to form longterm relationships [P <.001], provide comprehensive care [P =.001], and treat patients and their families [P =.006]); and duration of residency program (P =.001). The career-related factors that significantly influenced participants' decision to choose a non-front-line specialty were as follows: becoming an expert (P <.001), maintaining a focused scope of practice (P <.001), having a procedure-focused practice (P =.001), seeing immediate results from one's actions (P <.001), potentially earning a high income (P <.001), and having a perceived status among colleagues (P <.001).
Conclusion In this study, 8 factors were found to positively influence medical students' career choice in family medicine and pediatrics, and 6 factors influenced the decision to choose a career in a non-front-line specialty. Medical students can be encouraged to explore a career in family medicine or pediatrics by addressing misinformation, by encouraging realistic expectations of career outcomes in the various specialties, and by demonstrating the capacity of primary care fields to incorporate specific motivating factors.
C1 [Osborn, Heather Ann] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Boston, MA USA.
[Glicksman, Jordan T.] Univ Penn, Philadelphia, PA USA.
[Brandt, Michael G.] Univ Toronto, Dept Otolaryngol Head & Neck Surg, Toronto, ON, Canada.
[Doyle, Philip C.] Univ Western Ontario, Sch Commun Sci & Disorders, Dept Otolaryngol Head & Neck Surg, London, ON, Canada.
[Fung, Kevin] Univ Western Ontario, Dept Otolaryngol Head & Neck Surg, Dept Oncol, London, ON, Canada.
RP Osborn, HA (reprint author), Harvard Med Sch, Massachusetts Eye & Ear Infirm, Boston, MA USA.
EM heather_osborn@meei.harvard.edu
NR 20
TC 0
Z9 0
U1 0
U2 0
PU COLL FAMILY PHYSICIANS CANADA
PI MISSISSAUGA
PA 2630 SKYMARK AVE, MISSISSAUGA, ONTARIO L4W 5A4, CANADA
SN 0008-350X
EI 1715-5258
J9 CAN FAM PHYSICIAN
JI Can. Fam. Phys.
PD FEB
PY 2017
VL 63
IS 2
BP E107
EP E113
PG 7
WC Primary Health Care; Medicine, General & Internal
SC General & Internal Medicine
GA EP1KA
UT WOS:000397142600004
PM 28209702
ER
PT J
AU Doughty, CT
Yawetz, S
Lyons, J
AF Doughty, Christopher T.
Yawetz, Sigal
Lyons, Jennifer
TI Emerging Causes of Arbovirus Encephalitis in North America: Powassan,
Chikungunya, and Zika Viruses
SO CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
LA English
DT Review
DE Arboviruses; Encephalitis; Zika virus; Chikungunya virus; Powassan virus
ID DEER TICK VIRUS; MALE SEXUAL TRANSMISSION; NEW-ENGLAND DEER; NEW-YORK;
REUNION ISLAND; UNITED-STATES; CASE SERIES; LA-REUNION; BORNE
FLAVIVIRUSES; AEDES-ALBOPICTUS
AB Arboviruses are arthropod-borne viruses transmitted by the bite of mosquitoes, ticks, or other arthropods. Arboviruses are a common and an increasing cause of human illness in North America. Powassan virus, Chikungunya virus, and Zika virus are arboviruses that have all recently emerged as increasing causes of neurologic illness. Powassan virus almost exclusively causes encephalitis, but cases are rare, sporadic, and restricted to portions of North America and Russia. Chikungunya virus has spread widely across the world, causing millions of infections. Encephalitis is a rare manifestation of illness but is more common and severe in neonates and older adults. Zika virus has recently spread through much of the Americas and has been associated mostly with microcephaly and other congenital neurologic complications. Encephalitis occurring in infected adults has also been recently reported. This review will discuss the neuropathogenesis of these viruses, their transmission and geographic distribution, the spectrum of their neurologic manifestations, and the appropriate method of diagnosis.
C1 [Doughty, Christopher T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Doughty, Christopher T.; Lyons, Jennifer] Brigham & Womens Hosp, Dept Neurol, Div Neurol Infect & Inflammatory Dis, 45 Francis St, Boston, MA 02115 USA.
[Doughty, Christopher T.; Yawetz, Sigal; Lyons, Jennifer] Harvard Med Sch, Boston, MA USA.
[Yawetz, Sigal] Brigham & Womens Hosp, Dept Internal Med, Div Infect Dis, Boston, MA 02115 USA.
RP Lyons, J (reprint author), Brigham & Womens Hosp, Dept Neurol, Div Neurol Infect & Inflammatory Dis, 45 Francis St, Boston, MA 02115 USA.; Lyons, J (reprint author), Harvard Med Sch, Boston, MA USA.
EM jlyons5@partners.org
NR 120
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1528-4042
EI 1534-6293
J9 CURR NEUROL NEUROSCI
JI Curr. Neurol. Neurosci. Rep.
PD FEB
PY 2017
VL 17
IS 2
AR 12
DI 10.1007/s11910-017-0724-3
PG 16
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA EO9TS
UT WOS:000397031600008
PM 28229397
ER
PT J
AU Hassan, RI
Gaffo, AL
AF Hassan, Romina I.
Gaffo, Angelo L.
TI Rituximab in ANCA-Associated Vasculitis
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Rituximab. Vasculitis; ANCA; Granulomatosis with polyangiitis (GPA);
Microscopic polyangiitis (MPA); Eosinophilicgranulomatosiswith
polyangiitis (EGPA)
ID ANTIBODY-ASSOCIATED VASCULITIS; WEGENERS-GRANULOMATOSIS;
RANDOMIZED-TRIAL; RENAL VASCULITIS; PLASMA-EXCHANGE; CYCLOPHOSPHAMIDE;
INDUCTION; REMISSION; THERAPY; MAINTENANCE
AB Purpose of Review The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV).
Recent Findings A PubMed search was carried out to track down articles published between February 2006 and February 2016. Randomized controlled trials (RCTs) that encompassed patients with AAV were included. The American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) 2014-2015 online abstracts were also reviewed whether they were RTCs or not. Ten PubMed RCTs were analyzed along with eight ACR and four EULAR abstracts. RTX was not inferior to cyclophosphamide (CYC) for remission induction in AAV; it was superior to CYC in patients with relapsing disease and superior for remission maintenance in comparison with azathioprine (AZA).
Summary Rituximab is a therapeutic option to induce and maintain remission in patients with AAV.
C1 [Hassan, Romina I.] JM Ramos Mejia Hosp, Div Rheumatol, 609 Gen Urquiza St, RA-1221 Buenos Aires, DF, Argentina.
[Gaffo, Angelo L.] Birmingham VA Med Ctr, 700 19th St S, Birmingham, AL 35233 USA.
[Gaffo, Angelo L.] Univ Alabama Birmingham, Div Rheumatol & Clin Immunol, 1825 Univ Blvd,SHEL 306, Birmingham, AL 35294 USA.
RP Hassan, RI (reprint author), JM Ramos Mejia Hosp, Div Rheumatol, 609 Gen Urquiza St, RA-1221 Buenos Aires, DF, Argentina.
EM rominahassan@gmail.com
NR 35
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3774
EI 1534-6307
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD FEB
PY 2017
VL 19
IS 2
AR 6
DI 10.1007/s11926-017-0632-1
PG 8
WC Rheumatology
SC Rheumatology
GA EP0XM
UT WOS:000397110000004
PM 28155022
ER
PT J
AU O'Malley, BW
Crowley, WF
AF O'Malley, Bert W.
Crowley, William F.
TI In Memoriam, P. Michael Conn, PhD (1949-2016)
SO ENDOCRINOLOGY
LA English
DT Biographical-Item
C1 [O'Malley, Bert W.] Baylor Coll Med, Mol & Cellular Biol, Houston, TX 77030 USA.
[Crowley, William F.] Harvard Med Sch, Massachusetts Gen Hosp, Reprod Endocrine Unit, Harvard Reprod Endocrine Sci Ctr,Dept Med, Boston, MA 02114 USA.
RP O'Malley, BW (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.
EM berto@bcm.edu
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD FEB
PY 2017
VL 158
IS 2
BP 197
EP 198
DI 10.1210/en.2016-1906
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EP0UH
UT WOS:000397101700001
ER
PT J
AU Hogan, MF
Liu, AW
Peters, MJ
Willard, JR
Rabbani, Z
Bartholomew, EC
Ottley, A
Hull, RL
AF Hogan, Meghan F.
Liu, Amy W.
Peters, Michael J.
Willard, Joshua R.
Rabbani, Zaheen
Bartholomew, Erik C.
Ottley, Adam
Hull, Rebecca L.
TI Markers of Islet Endothelial Dysfunction Occur in Male B6.BKS(D)-
Lepr(db)/J Mice and May Contribute to Reduced Insulin Release
SO ENDOCRINOLOGY
LA English
DT Article
ID GLYCATION END-PRODUCTS; PANCREATIC BETA-CELL; DIABETES-MELLITUS;
OXIDATIVE STRESS; BLOOD-VESSELS; DB/DB MICE; IN-VITRO; EXPRESSION;
MOUSE; RATS
AB Islet endothelial cells produce paracrine factors that support beta-cell function and growth. Endothelial dysfunction underlies diabetic microvascular complications; thus, we hypothesized that in diabetes, islet endothelial cells become dysfunctional, which may contribute to beta-cell secretory dysfunction. Islets/islet endothelial cells were isolated from diabetic B6.BKS(D)-Lepr(db)/J male (db/db) mice, treated with or without the glucose-lowering agent phlorizin, or from C57BL/6J mice fed a high-fat diet for 18 weeks and appropriate controls. Messenger RNA(mRNA) and/or the protein levels of the cell adhesion molecule E-selectin (Sele), proinflammatory cytokine interleukin-6 (II6), vasoconstrictor endothelin-1 (Edn1), and endothelial nitric oxide synthase (Nos3; Nos3) were evaluated, alongwith advanced glycation end product immunoreactivity. Furthermore, an islet endothelial cell line(MS-1) was exposed to diabetic factors (glucose, palmitate, insulin, and tumor necrosis factor-a) for six days. Conditioned media were collected from these cells, incubated with isolated islets, and glucose-stimulated insulin secretion and insulin content were assessed. Islet endothelial cells from db/db mice exhibited increased Sele, II6, and Edn1 mRNA levels, decreased Nos3 protein, and accumulation of advanced glycation end products. Phlorizin treatment significantly increased Nos3 protein levels but did not alter expression of the other markers. High-fat feeding in C57BL/6J mice resulted in increased islet Sele, II6, andEdn1 but no change in Nos3. Exposure of islets to conditionedmedia from MS-1 cells cultured in diabetic conditions resulted in a 50% decrease in glucose-stimulated insulin secretion and 30% decrease in insulin content. These findings demonstrate that, in diabetes, islet endothelial cells show evidence of a dysfunctional phenotype, which may contribute to loss of beta-cell function.
C1 [Hogan, Meghan F.; Liu, Amy W.; Peters, Michael J.; Willard, Joshua R.; Rabbani, Zaheen; Hull, Rebecca L.] Vet Affairs Puget Sound Hlth Care Syst, Div Metab Endocrinol & Nutr, Seattle, WA 98108 USA.
[Hogan, Meghan F.; Liu, Amy W.; Rabbani, Zaheen; Bartholomew, Erik C.; Ottley, Adam; Hull, Rebecca L.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
RP Hull, RL (reprint author), Vet Affairs Puget Sound Hlth Care Syst 151, 1660 South Columbian Way, Seattle, WA 98108 USA.
EM rhull@uw.edu
FU Department of Veterans Affairs, Veterans Affairs Puget Sound Health Care
System; National Institutes of Health (University of Washington Diabetes
Research Center) [R01DK088082, P30DK017047]; University of Washington
Royalty Research; HHMI Medical Research Fellows Program; National
Institute of Diabetes and Digestive Kidney Diseases Medical Research
Program in Diabetes [T32 DK007247]; University of Washington Medical
Student Research Training Program; [T32HL007028]; [F32DK109584]
FX This work was supported by the Department of Veterans Affairs, Veterans
Affairs Puget Sound Health Care System (Seattle, WA), National
Institutes of Health grants R01DK088082 (R.L.H.) and P30 DK017047
(University of Washington Diabetes Research Center), and a University of
Washington Royalty Research Fund Award. A.W.L. was supported by the HHMI
Medical Research Fellows Program and the National Institute of Diabetes
and Digestive and Kidney Diseases Medical Research Program in Diabetes
through grant T32 DK007247. M.F.H. was supported by grants T32 HL007028
and F32 DK109584. Z.R., A.O., and E.C.B. were supported by the
University of Washington Medical Student Research Training Program and
the National Institute of Diabetes and Digestive and Kidney Diseases
Medical Research Program in Diabetes through T32 DK007247.
NR 41
TC 1
Z9 1
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013-7227
EI 1945-7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD FEB
PY 2017
VL 158
IS 2
BP 293
EP 303
DI 10.1210/en.2016-1393
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EP0UH
UT WOS:000397101700012
PM 27870582
ER
PT J
AU Kessler, RC
van Loo, HM
Wardenaar, KJ
Bossarte, RM
Brenner, LA
Ebert, DD
de Jonge, P
Nierenberg, AA
Rosellini, AJ
Sampson, NA
Schoevers, RA
Wilcox, MA
Zaslavsky, AM
AF Kessler, R. C.
van Loo, H. M.
Wardenaar, K. J.
Bossarte, R. M.
Brenner, L. A.
Ebert, D. D.
de Jonge, P.
Nierenberg, A. A.
Rosellini, A. J.
Sampson, N. A.
Schoevers, R. A.
Wilcox, M. A.
Zaslavsky, A. M.
TI Using patient self-reports to study heterogeneity of treatment effects
in major depressive disorder
SO EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES
LA English
DT Article
DE Depression; epidemiology; evidence-based psychiatry; research design and
methods; treatment allocation
ID RANDOMIZED CONTROLLED-TRIAL; COLLABORATIVE RESEARCH-PROGRAM; SEROTONIN
REUPTAKE INHIBITORS; COGNITIVE-BEHAVIORAL THERAPY; LATE-LIFE DEPRESSION;
LONG-TERM COURSE; PSYCHOTHERAPY-PHARMACOTHERAPY COMBINATIONS; RECURSIVE
PARTITIONING ANALYSIS; NATIONAL-COMORBIDITY-SURVEY; INTERPERSONAL
PSYCHOTHERAPY
AB Backgrounds. Clinicians need guidance to address the heterogeneity of treatment responses of patients with major depressive disorder (MDD). While prediction schemes based on symptom clustering and biomarkers have so far not yielded results of sufficient strength to inform clinical decision-making, prediction schemes based on big data predictive analytic models might be more practically useful.
Method. We review evidence suggesting that prediction equations based on symptoms and other easily- assessed clinical features found in previous research to predict MDD treatment outcomes might provide a foundation for developing predictive analytic clinical decision support models that could help clinicians select optimal (personalised) MDD treatments. These methods could also be useful in targeting patient subsamples for more expensive biomarker assessments.
Results. Approximately two dozen baseline variables obtained from medical records or patient reports have been found repeatedly in MDD treatment trials to predict overall treatment outcomes (i. e., intervention nu. control) or differential treatment outcomes (i. e., intervention A v. intervention B). Similar evidence has been found in observational studies of MDD persistence-severity. However, no treatment studies have yet attempted to develop treatment outcome equations using the full set of these predictors. Promising preliminary empirical results coupled with recent developments in statistical methodology suggest that models could be developed to provide useful clinical decision support in personalised treatment selection. These tools could also provide a strong foundation to increase statistical power in focused studies of biomarkers and MDD heterogeneity of treatment response in subsequent controlled trials.
Conclusions. Coordinated efforts are needed to develop a protocol for systematically collecting information about established predictors of heterogeneity of MDD treatment response in large observational treatment studies, applying and refining these models in subsequent pragmatic trials, carrying out pooled secondary analyses to extract the maximum amount of information from these coordinated studies, and using this information to focus future discovery efforts in the segment of the patient population in which continued uncertainty about treatment response exists.
C1 [Kessler, R. C.; Ebert, D. D.; Rosellini, A. J.; Sampson, N. A.; Zaslavsky, A. M.] Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
[van Loo, H. M.; Wardenaar, K. J.; de Jonge, P.; Schoevers, R. A.] Univ Groningen, Univ Med Ctr Groningen, Interdisciplinary Ctr Psychopathol & Emot Regulat, Groningen, Netherlands.
[Bossarte, R. M.] Off Publ Hlth, Dept Vet Affairs, Washington, DC USA.
[Brenner, L. A.] Univ Colorado, VISN Mental Illness Res Educ & Clin Ctr 19, Anschutz Med Campus, Anschulz, CO USA.
[Ebert, D. D.] Friedrich Alexander Univ Nuremberg Erlangen, Dept Psychol Clin Psychol & Psychotherapy, Erlangen, Germany.
[Nierenberg, A. A.] Harvard Med Sch, Dept Psychiat, Boston, MA USA.
[Nierenberg, A. A.] Harvard Med Sch, Depress Clin & Res Program, Boston, MA USA.
[Nierenberg, A. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wilcox, M. A.] Janssen Res & Dev, Dept Epidemiol, Titusville, NJ USA.
RP Kessler, RC (reprint author), Harvard Med Sch, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.
EM Kessler@hcp.med.harvard.edu
FU National Institute of Mental Health(NIMH) [R01MH46376, R01MH070884];
National Institute on Drug Abuse(NIDA) [R01DA012058]; Netherlands
organisation for Scientific research (NWO-ZonMW) [91812607]; John D. and
Catherine T. MacArthur Foundation; US Public Health Service
[R13MH066849, R01MH069864, R01DA016558]; Pfizer Foundation; Fogarty
International Center (FIRCA) [R03TW006481]; Pan American Health
Organization; Eli Lilly and Company; Ortho-McNeil Pharmaceutical, Inc.;
GlaxoSmithKline; Bristol-Myers Squibb; Janssen Pharmaceuticals
FX The NCS data collection was supported by the National Institute of
Mental Health (NIMH; R01MH46376). The NCS-2 data collection was
supported by the National Institute on Drug Abuse (NIDA; R01DA012058).
Dr de Jonge was supported by a VICI grant (no. 91812607) from the
Netherlands organisation for Scientific research (NWO-ZonMW). The NCS
surveys were carried out in conjunction with the World Health
Organization World Mental Health (WMH) Survey Initiative, which was
supported by the National Institute of Mental Health (R01MH070884), the
John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation,
the US Public Health Service (R13MH066849, R01MH069864 and R01DA016558),
the Fogarty International Center (FIRCA R03TW006481), the Pan American
Health Organization, Eli Lilly and Company, Ortho-McNeil Pharmaceutical,
Inc., GlaxoSmithKline, and Bristol-Myers Squibb. Dr de Jonge was
supported by a VICI grant (no. 91812607) from the Netherlands
organization for Scientific research (NWO-ZonMW). Preparation of this
report was supported by Janssen Pharmaceuticals.
NR 136
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 2045-7960
EI 2045-7979
J9 EPIDEMIOL PSYCH SCI
JI Epidemiol. Psychiatr. Sci.
PD FEB
PY 2017
VL 26
IS 1
BP 22
EP 36
DI 10.1017/S2045796016000020
PG 15
WC Psychiatry
SC Psychiatry
GA EP0OJ
UT WOS:000397086300006
PM 26810628
ER
PT J
AU Kopans, DB
AF Kopans, Daniel B.
TI More misinformation on breast cancer screening
SO GLAND SURGERY
LA English
DT Article
DE Mammography; breast; breast cancer; screening
ID CARCINOMA MORTALITY; TUMOR SIZE; MAMMOGRAPHY; WOMEN; REDUCTION; UPDATE;
TRENDS; IMPACT; RISK; US
AB Unfortunately, a great deal of misinformation has accumulated in the breast cancer screening literature that is based on flawed analyses in an effort to reduce access to screening. Quite remarkably, much of this has come from publications in previously highly respected medical journals. In several papers the intervention (mammography screening) is faulted yet the analyses provided no data on who participated in mammography screening, and which cancers were detected by mammography screening. It is remarkable that a highly respected journal can fault an intervention with no data on the intervention. Claims of massive over diagnosis of invasive breast cancer due to breast cancer screening have been made using "guesses" that have no scientific basis. No one has ever seen a mammographically detected, invasive breast cancer, disappear on its own, yet analysts have claimed that this occurs thousands of times each year. In fact, the" miraculous" resolution, without intervention, of a handful of breast cancers have all been palpable cancers, yet there is no suggestion to stop treating palpable cancers. A review of several publications in the New England Journal of Medicine shows some of the flaws in these analyses. There is clearly a problem with peer review that is allowing scientifically unsupportable material, which is misleading women and their physicians, to be published in prestigious journals.
C1 [Kopans, Daniel B.] Harvard Med Sch Boston, Boston, MA USA.
RP Kopans, DB (reprint author), Harvard Med Sch, Radiol, 20 Manitoba Rd, Waban, MA 02468 USA.; Kopans, DB (reprint author), Massachusetts Gen Hosp, Breast Imaging Div, 20 Manitoba Rd, Waban, MA 02468 USA.
EM dkopans@partners.org
NR 33
TC 0
Z9 0
U1 0
U2 0
PU AME PUBL CO
PI SHEUNG WAN
PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG
00000, PEOPLES R CHINA
SN 2227-684X
EI 2227-8575
J9 GLAND SURG
JI Gland Surg.
PD FEB
PY 2017
VL 6
IS 1
BP 125
EP 129
DI 10.21037/gs.2016.12.15
PG 5
WC Surgery
SC Surgery
GA EP2YB
UT WOS:000397248400019
PM 28210564
ER
PT J
AU Khodyakov, D
Stockdale, SE
Smith, N
Booth, M
Altman, L
Rubenstein, LV
AF Khodyakov, Dmitry
Stockdale, Susan E.
Smith, Nina
Booth, Marika
Altman, Lisa
Rubenstein, Lisa V.
TI Patient engagement in the process of planning and designing outpatient
care improvements at the Veterans Administration Health-care System:
findings from an online expert panel
SO HEALTH EXPECTATIONS
LA English
DT Article
DE ExpertLens; modified Delphi; online expert panel; patient engagement;
quality improvement; VA
ID QUALITY-IMPROVEMENT; PUBLIC INVOLVEMENT; DECISION-MAKING; SERVICES;
PARTICIPATION; STRATEGIES; FRAMEWORK; CANCER
AB Context There is a strong interest in the Veterans Administration (VA) Health-care System in promoting patient engagement to improve patient care.
Methods We solicited expert opinion using an online expert panel system with a modified Delphi structure called ExpertLens (TM). Experts reviewed, rated and discussed eight scenarios, representing four patient engagement roles in designing and improving VA outpatient care (consultant, implementation advisor, equal stakeholder and lead stakeholder) and two VA levels (local and regional). Rating criteria included desirability, feasibility, patient ability, physician/ staff acceptance and impact on patient-centredness and care quality. Data were analysed using the RAND/UCLA Appropriateness Method for determining consensus.
Findings Experts rated consulting with patients at the local level as the most desirable and feasible patient engagement approach. Engagement at the local level was considered more desirable than engagement at the regional level. Being an equal stakeholder at the local level received the highest ratings on the patient-centredness and health-care quality criteria.
Conclusions Our findings illustrate expert opinion about different approaches to patient engagement and highlight the benefits and challenges posed by each. Although experts rated local consultations with patients on an as-needed basis as most desirable and feasible, they rated being an equal stakeholder at the local level as having the highest potential impact on patient-centredness and care quality.
C1 [Khodyakov, Dmitry; Booth, Marika; Rubenstein, Lisa V.] RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA.
[Stockdale, Susan E.; Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst 152, Ctr Study Healthcare Innovat Implementat & Policy, Med & Publ Hlth, VISN Vet Assessment & Improvement PACT Demonstrat, Los Angeles, CA USA.
[Smith, Nina] VA Greater Los Angeles Healthcare Syst 152, Ctr Implementat Practice & Res Support CIPRS, Los Angeles, CA USA.
[Rubenstein, Lisa V.] VA Greater Los Angeles Healthcare Syst 152, Ctr Implementat Practice & Res Support CIPRS, Med & Publ Hlth, Los Angeles, CA USA.
[Altman, Lisa] VA Greater Los Angeles Healthcare Syst GLA, Off Healthcare Transformat & Innovat, Healthcare Transformat, Los Angeles, CA USA.
[Stockdale, Susan E.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Altman, Lisa] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Khodyakov, D (reprint author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA.
EM Dmitry_Khodyakov@rand.org
FU VA Office of Patient-Centered Care and Cultural Transformation; VA
Quality Enhancement and Research Initiative's (QUERI's) Center for
Implementation Practice and Research Support (CIPRS) [TRA 08-379]
FX This study is co-funded by the VA Office of Patient-Centered Care and
Cultural Transformation and the VA Quality Enhancement and Research
Initiative's (QUERI's) Center for Implementation Practice and Research
Support (CIPRS) grant number TRA 08-379.
NR 48
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1369-6513
EI 1369-7625
J9 HEALTH EXPECT
JI Health Expect.
PD FEB
PY 2017
VL 20
IS 1
BP 130
EP 145
DI 10.1111/hex.12444
PG 16
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA EP0PK
UT WOS:000397089000013
PM 26914249
ER
PT J
AU Rozen, G
Ptaszek, L
Zilberman, I
Cordaro, K
Heist, EK
Beeckler, C
Altmann, A
Ying, Z
Liu, ZJ
Ruskin, JN
Govari, A
Mansour, M
AF Rozen, Guy
Ptaszek, Leon
Zilberman, Israel
Cordaro, Kevin
Heist, E. Kevin
Beeckler, Christopher
Altmann, Andres
Ying, Zhang
Liu, Zhenjiang
Ruskin, Jeremy N.
Govari, Assaf
Mansour, Moussa
TI Prediction of radiofrequency ablation lesion formation using a novel
temperature sensing technology incorporated in a force sensing catheter
SO HEART RHYTHM
LA English
DT Article
DE Radiofrequency; Catheter ablation; Lesion assessment; Contact force
sensing; Catheter orientation; Thermocouple
ID PULMONARY VEIN ISOLATION; TIME CONTACT FORCE; ATRIAL-FIBRILLATION;
TISSUE TEMPERATURE; IMPEDANCE DECREASE; TIP ABLATION; ELECTRODE;
FEASIBILITY; ARRHYTHMIAS; INSIGHTS
AB BACKGROUND Real-time radiofrequency (RF) ablation lesion assessment is a major unmet need in cardiac electrophysiology.
OBJECTIVE The purpose of this study was to assess whether improved temperature measurement using a novel thermocoupling (TC) technology combined with information derived from impedance change, contact force (CF) sensing, and catheter orientation allows accurate real-time prediction of ablation lesion formation.
METHODS RF ablation lesions were delivered in the ventricles of 15 swine using a novel externally irrigated-tip catheter containing 6 miniature TC sensors in addition to force sensing technology. Ablation duration, power, irrigation rate, impedance drop, CF, and temperature from each sensor were recorded. The catheter "orientation factor" was calculated using measurements from the different TC sensors. Information derived from all the sources was included in a mathematical model developed to predict lesion depth and validated against histologic measurements.
RESULTS A total of 143 ablation lesions were delivered to the left ventricle (n = 74) and right ventricle (n = 69). Mean CF applied during the ablations was 14.34 +/- 3.55g, and mean impedance drop achieved during the ablations was 17.5 +/- 6.41 ohm. Mean difference between predicted and measured ablation lesion depth was 0.72 +/- 0.56 mm. In the majority of lesions (91.6%), the difference between estimated and measured depth was <= 1.5 mm.
CONCLUSION Accurate real-time prediction of RF lesion depth is feasible using a novel ablation catheter-based system in conjunction with a mathematical prediction model, combining elaborate temperature measurements with information derived from catheter orientation, CF sensing, impedance change, and additional ablation parameters.
C1 [Rozen, Guy; Ptaszek, Leon; Cordaro, Kevin; Heist, E. Kevin; Ying, Zhang; Liu, Zhenjiang; Ruskin, Jeremy N.; Mansour, Moussa] Massachusetts Gen Hosp, Ctr Heart, Boston, MA 02114 USA.
[Zilberman, Israel; Beeckler, Christopher; Altmann, Andres; Govari, Assaf] Biosense Webster Inc, Diamond Bar, CA USA.
RP Mansour, M (reprint author), Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, GRB 109,55 Fruit St, Boston, MA 02114 USA.
EM mmansour@mgh.harvard.edu
FU Biosense Webster; Deane Institute for Integrative Research in Atrial
Fibrillation; Stroke at the Massachusetts General Hospital
FX The study was funded by a research grant from Biosense Webster and Deane
Institute for Integrative Research in Atrial Fibrillation and Stroke at
the Massachusetts General Hospital. Dr. Zilberman, Christopher Beeckler,
Andres Altmann, and Dr. Govari are employees of Biosense Webster. Dr.
Ruskin received consulting fees/honoraria from- Cardioinsight, Medtronic
Inc. Dr. Mansour received consulting fees/honoraria - Biosense Webster,
Inc., St. Jude Medical, Sentreheart. Research grants: Biosense Webster,
Inc., St. Jude Medical, Boston Scientific Corp. Drs. Rozen and Ptaszek
contributed equally to this study and manuscript preparation. Address
reprint requests and correspondence: Dr. Moussa Mansour, Cardiac
Arrhythmia Service, Massachusetts General Hospital, GRB 109, 55 Fruit
St, Boston, MA02114.
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
EI 1556-3871
J9 HEART RHYTHM
JI Heart Rhythm
PD FEB
PY 2017
VL 14
IS 2
BP 248
EP 254
DI 10.1016/j.hrthm.2016.11.013
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EP2WD
UT WOS:000397243400018
PM 28104089
ER
PT J
AU Tucker, NR
Mahida, S
Ye, JC
Abraham, EJ
Mina, JA
Parsons, VA
McLellan, MA
Shea, MA
Hanley, A
Benjamin, EJ
Milan, DJ
Lin, HH
Ellinor, PT
AF Tucker, Nathan R.
Mahida, Saagar
Ye, Jiangchuan
Abraham, Elizabeth J.
Mina, Julie A.
Parsons, Victoria A.
McLellan, Michael A.
Shea, Marisa A.
Hanley, Alan
Benjamin, Emelia J.
Milan, David J.
Lin, Honghuang
Ellinor, Patrick T.
TI Gain-of-function mutations in GATA6 lead to atrial fibrillation
SO HEART RHYTHM
LA English
DT Article
DE Atrial fibrillation; Mutation; Transcription factor; Genetics
ID TRANSCRIPTION FACTORS; FAMILIAL AGGREGATION; GENETIC-VARIATION; HEART;
EXPRESSION; VARIANTS; ENHANCER; DEFECTS
AB BACKGROUND The genetic basis of atrial fibrillation (AF) and congenital heart disease remains incompletely understood.
OBJECTIVE We sought to determine the causative mutation in a family with AF, atrial septal defects, and ventricular septal defects.
METHODS We evaluated a pedigree with 16 family members, 1 with an atrial septal defect, 1 with a ventricular septal defect, and 3 with AF; we performed whole exome sequencing in 3 affected family members. Given that early-onset AF was prominent in the family, we then screened individuals with early-onset AF, defined as an age of onset <66 years, for mutations in GATA6. Variants were functionally characterized using reporter assays in a mammalian cell line.
RESULTS Exome sequencing in 3 affected individuals identified a conserved mutation, R585L, in the transcription factor gene GATA6. In the Massachusetts General Hospital Atrial Fibrillation (MGH AF) Study, the mean age of AF onset was 47.1 +/- 10.9 years; 79% of the participants were men; and there was no evidence of structural heart disease. We identified 3 GATA6 variants (P91S, A177T, and A543G). Using wild-type and mutant GATA6 constructs driving atrial natriuretic peptide promoter reporter, we found that 3 of the 4 variants had a marked upregulation of luciferase activity (R585L: 4.1-fold, P<.0001; P91S: 2.5-fold, P=.0002; A177T; 1.7-fold, P=.03). In addition, when co-overexpressed with GATA4 and MEF2C, GATA6 variants exhibited upregulation of the alpha myosin heavy chain and atrial natriuretic peptide reporter activity.
CONCLUSION Overall, we found gain-of-function mutations in GATA6 in both a family with early-onset AF and atrioventricular septal defects as well as in a family with sporadic, early-onset AF.
C1 [Shea, Marisa A.; Milan, David J.; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
[Benjamin, Emelia J.] NHLBI, Framingham, MA USA.
[Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Framingham, MA USA.
[Benjamin, Emelia J.] Boston Univ, Sch Med, Dept Med, Prevent Med & Cardiovasc Med Sect, Boston, MA 02215 USA.
[Lin, Honghuang] Boston Univ, Sch Med, Dept Med, Computat Biomed Sect, Boston, MA 02215 USA.
RP Ellinor, PT (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 55 Fruit St,Gray109, Boston, MA 02114 USA.
EM ellinor@mgh.harvard.edu
FU Bayer Healthcare
FX The first 2 authors contributed equally to this work. Dr Ellinor is a
principal investigator of a grant from Bayer Healthcare to the Broad
Institute.
NR 30
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1547-5271
EI 1556-3871
J9 HEART RHYTHM
JI Heart Rhythm
PD FEB
PY 2017
VL 14
IS 2
BP 284
EP 291
DI 10.1016/j.hrthm.2016.10.014
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA EP2WD
UT WOS:000397243400024
PM 27756709
ER
PT J
AU Su, F
Green, PK
Berry, K
Ioannou, GN
AF Su, Feng
Green, Pamela K.
Berry, Kristin
Ioannou, George N.
TI The Association Between Race/Ethnicity and the Effectiveness of Direct
Antiviral Agents for Hepatitis C Virus Infection
SO HEPATOLOGY
LA English
DT Article
ID GENOTYPE 1 INFECTION; SUSTAINED VIROLOGICAL RESPONSE; SIMEPREVIR PLUS
SOFOSBUVIR; HEPATOCELLULAR-CARCINOMA; CHRONIC HCV; PEGINTERFERON
ALPHA-2A; TREATMENT-NAIVE; BLACK PATIENTS; LIVER-DISEASE; US VETERANS
AB Black race and Hispanic ethnicity were associated with lower rates of sustained virologic response (SVR) to interferonbased treatments for chronic hepatitis C virus infection, whereas Asian race was associated with higher SVR rates compared to white patients. We aimed to describe the association between race/ ethnicity and effectiveness of new direct-acting antiviral regimens in the Veterans Affairs health care system nationally. We identified 21,095 hepatitis C virus-infected patients (11,029 [52%] white, 6,171 [29%] black, 1,187 [6%] Hispanic, 348 [2%] Asian/ Pacific Islander/ American Indian/ Alaska Native, and 2,360 [11%] declined/ missing race or ethnicity) who initiated antiviral treatment with regimens containing sofosbuvir, simeprevir + sofosbuvir, ledipasvir/ sofosbuvir, or paritaprevir/ ombitasvir/ ritonavir/ dasabuvir during the 18-month period from January 1, 2014, to June 30, 2015. Overall SVR rates were 89.8% (95% confidence interval [CI] 89.2-90.4) in white, 89.8% (95% CI 89.0-90.6) in black, 86.0% (95% CI 83.7-88.0) in Hispanic, and 90.7% (95% CI 87.0-93.5) in Asian/ Pacific Islander/ American Indian/ Alaska Native patients. However, after adjustment for baseline characteristics, black (adjusted odds ratio 5 0.77, P < 0.001) and Hispanic (adjusted odds ratio = 0.76, P = 0.007) patients were less likely to achieve SVR than white patients, a difference that was not explained by early treatment discontinuations. Among genotype 1-infected patients treated with ledipasvir/ sofosbuvir monotherapy, black patients had significantly lower SVR than white patients when treated for 8 weeks but not when treated for 12 weeks.
Conclusion: Direct-acting antivirals produce high SVR rates in white, black, Hispanic, and Asian/ Pacific Islander/ American Indian/ Alaska Native patients; but after adjusting for baseline characteristics, black race and Hispanic ethnicity remain independent predictors of treatment failure. Short 8-week ledipasvir/ sofosbuvir monotherapy regimens should perhaps be avoided in black patients with genotype 1 hepatitis C virus.
C1 [Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, S-111Gastro,1660 S Columbian Way, Seattle, WA 98108 USA.
RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Div Gastroenterol, S-111Gastro,1660 S Columbian Way, Seattle, WA 98108 USA.
EM georgei@medicine.washington.edu
FU Clinical Science Research and Development, Office of Research and
Development, US Department of Veterans Affairs [I01CX000320,
I01CX001156]
FX Supported by Clinical Science Research and Development, Office of
Research and Development, US Department of Veterans Affairs (Merit
Review grants I01CX000320 and I01CX001156, to G. N. I.).
NR 48
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD FEB
PY 2017
VL 65
IS 2
BP 426
EP 438
DI 10.1002/hep.28901
PG 13
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EP3RZ
UT WOS:000397300700007
PM 27775854
ER
PT J
AU Jarraya, M
Diaz, LE
Arndt, WF
Roemer, FW
Guermazi, A
AF Jarraya, Mohamed
Diaz, Luis E.
Arndt, William F.
Roemer, Frank W.
Guermazi, Ali
TI Imaging of patellar fractures
SO INSIGHTS INTO IMAGING
LA English
DT Review
DE Patella; Fracture; Extensor mechanism rupture; Conventional radiograph;
MRI
ID DORSAL DEFECT; KNEE; BIPARTITE
AB Patellar fractures account for approximately 1% of all skeletal fractures and may result from direct, indirect, or combined trauma. Because of the importance of patellar integrity for knee extension and the risk of associated injury to the extensor mechanism, accurate reporting and description of fracture type is paramount for appropriate management. This pictorial essay aims to review the normal anatomy of the patella, the mechanisms of injury and different types of patellar fractures, with a brief introduction to therapeutic management.
Teaching Points
Patellar fractures are classified according to their morphology and degree of displacement.
Direct trauma results in stellate fractures.
Indirect trauma results in transverse fractures.
Displacement should raise suspicion for retinacular injury.
C1 [Jarraya, Mohamed] Mercy Catholic Med Ctr, Dept Radiol, 1500 Lansdowne Ave, Darby, PA 19023 USA.
[Jarraya, Mohamed; Guermazi, Ali] Boston Univ, Sch Med, Dept Radiol, Boston, MA 02118 USA.
[Diaz, Luis E.; Arndt, William F.] VA Boston Healthcare Syst, Dept Radiol, Boston, MA USA.
[Roemer, Frank W.] Univ Erlangen Nurnberg, Dept Radiol, Erlangen, Germany.
RP Jarraya, M (reprint author), Mercy Catholic Med Ctr, Dept Radiol, 1500 Lansdowne Ave, Darby, PA 19023 USA.; Jarraya, M (reprint author), Boston Univ, Sch Med, Dept Radiol, Boston, MA 02118 USA.
EM mohamedjarraya@gmail.com
NR 22
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1869-4101
J9 INSIGHTS IMAGING
JI Insights Imaging
PD FEB
PY 2017
VL 8
IS 1
BP 49
EP 57
DI 10.1007/s13244-016-0535-0
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA EP2WV
UT WOS:000397245200005
PM 27905071
ER
PT J
AU Karamouzian, M
Madani, N
Doroudi, F
Haghdoost, AA
AF Karamouzian, Mohammad
Madani, Navid
Doroudi, Fardad
Haghdoost, Ali Akbar
TI Improving the Quality and Quantity of HIV Data in the Middle East and
North Africa: Key Challenges and Ways Forward
SO INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT
LA English
DT Editorial Material
DE Data; Middle East and North Africa (MENA)
ID HIV/AIDS; IRAN; SURVEILLANCE; PREVALENCE; REGION
AB Although the HIV pandemic is witnessing a decline in the number of new infections in most regions of the world, the Middle East and North Africa (MENA) has a rapidly growing HIV problem. While generating HIV data has been consistently increasing since 2005, MENA's contribution to the global HIV literature is just over 1% and the existing evidence often falls behind the academic standards. Several factors could be at play that contribute to the limited quantity and quality of HIV data in MENA. This editorial tries to explore and explain the barriers to collecting high-quality HIV data and generating precise estimates in MENA. These barriers include a number of logistic and socio-political challenges faced by researchers, public health officials, and policy-makers. Looking at successful regional HIV programs, we explore examples were policies have shifted and lessons could be learned in developing appropriate responses to HIV across the region.
C1 [Karamouzian, Mohammad; Haghdoost, Ali Akbar] Kerman Univ Med Sci, HIV STI Surveillance Res Ctr, Kerman, Iran.
[Karamouzian, Mohammad; Haghdoost, Ali Akbar] Kerman Univ Med Sci, WHO Collaborating Ctr HIV Surveillance, Inst Futures Studies Hlth, Kerman, Iran.
[Karamouzian, Mohammad] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.
[Madani, Navid] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol & Virol, Dept Global Hlth & Social Med, Boston, MA USA.
[Doroudi, Fardad] UNAIDS, Tehran, Iran.
RP Haghdoost, AA (reprint author), Kerman Univ Med Sci, HIV STI Surveillance Res Ctr, Kerman, Iran.; Haghdoost, AA (reprint author), Kerman Univ Med Sci, WHO Collaborating Ctr HIV Surveillance, Inst Futures Studies Hlth, Kerman, Iran.
EM ahaghdoost@kmu.ac.ir
NR 32
TC 0
Z9 0
U1 0
U2 0
PU KERMAN UNIV MEDICAL SCIENCES
PI KERMAN
PA JAHAD BLVD, KERMAN, 7619813159, IRAN
SN 2322-5939
J9 INT J HEALTH POLICY
JI Int. J. Health Policy Manag.
PD FEB
PY 2017
VL 6
IS 2
BP 65
EP 69
DI 10.15171/ijhpm.2016.112
PG 5
WC Health Policy & Services
SC Health Care Sciences & Services
GA EO9WX
UT WOS:000397039900001
ER
PT J
AU Economopoulos, KP
Mylonas, KS
Stamou, AA
Theocharidis, V
Sergentanis, TN
Psaltopoulou, T
Richards, ML
AF Economopoulos, Konstantinos P.
Mylonas, Konstantinos S.
Stamou, Aliki A.
Theocharidis, Vasileios
Sergentanis, Theodoros N.
Psaltopoulou, Theodora
Richards, Melanie L.
TI Laparoscopic versus robotic adrenalectomy: A comprehensive meta-analysis
SO INTERNATIONAL JOURNAL OF SURGERY
LA English
DT Review
DE Laparoscopic adrenalectomy; Robot-assisted adrenalectomy; Robotic
adrenalectomy; Meta-analysis
ID POSTERIOR RETROPERITONEOSCOPIC ADRENALECTOMY; LUIS FELIPE BRANDAO; EUR
UROL 2014; TRANSPERITONEAL ADRENALECTOMY; RICCARDO AUTORINO;
CUSHINGS-SYNDROME; HUMBERTO LAYDNER; EXPERIENCE; PHEOCHROMOCYTOMA;
OUTCOMES
AB Background: The benefit of robotic adrenalectomy (RA) compared to laparoscopic adrenalectomy (LA) is still debatable. The purpose of this paper was to systematically review and synthesize all available evidence comparing RA to LA so as to evaluate which procedure provides superior clinical outcomes.
Methods: A systematic literature search of PubMed and Scopus databases was performed with respect to the PRISMA statement (end-of-search date: January 31, 2016). Data on perioperative variables were extracted by three independent reviewers. Data were pooled using a random-effects model.
Results: Twenty-seven studies were included in this review (13 comparative and 14 non-comparative). Overall, 1162 patients underwent adrenalectomy (747 treated with RA and 415 with LA). There was no significant difference between the robotic and the laparoscopic groups for intraoperative complications (OR: 1.20; 95% CI, 0.33-4.38), postoperative complications (OR: 0.69; 95% CI, 0.36-1.31), mortality (OR: 0.42; 95% CI, 0.07-2.72), conversion to laparotomy (OR: 0.51; 95% CI, 0.21-1.23), conversion to laparotomy or laparoscopy (OR: 0.73; 95% CI, 0.32-1.69) and blood loss (WMD: -9.78; 95%, -22.10 to 2.53). For patients treated with RA, there was a significantly shorter hospital stay (WMD: -0.40; 95% CI, -0.64 to -0.17) and a significantly longer operating time (WMD: 15.60; 95% CI, 2.12 to 29.08).
Conclusions: Robotic adrenalectomy is a safe and feasible procedure with similar clinical outcomes as the laparoscopic approach in selected patient populations. High quality RCTs as well as uniform and detailed reporting of outcomes are needed to determine the role and cost-effectiveness of robotic adrenal surgery in the years to come. (C) 2016 IJS Publishing Group Ltd.
C1 [Economopoulos, Konstantinos P.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA.
[Economopoulos, Konstantinos P.; Mylonas, Konstantinos S.; Stamou, Aliki A.; Theocharidis, Vasileios; Sergentanis, Theodoros N.] Soc Jr Doctors, Athens, Greece.
[Mylonas, Konstantinos S.] Aristotle Univ Thessaloniki, Sch Med, Thessaloniki, Greece.
[Stamou, Aliki A.; Theocharidis, Vasileios] Univ Athens, Sch Med, Athens, Greece.
[Sergentanis, Theodoros N.; Psaltopoulou, Theodora] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens, Greece.
[Richards, Melanie L.] Mayo Clin, Dept Surg, Rochester, MN USA.
RP Economopoulos, KP (reprint author), Harvard Med Sch, Simches Res Ctr, Massachusetts Gen Hosp, Dept Surg, 4th Floor,185 Cambridge Str, Boston, MA 02114 USA.
EM economopoulos@sni.gr
OI Mylonas, Konstantinos/0000-0002-2356-6694
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1743-9191
EI 1743-9159
J9 INT J SURG
JI Int. J. Surg.
PD FEB
PY 2017
VL 38
BP 95
EP 104
DI 10.1016/j.ijsu.2016.12.118
PG 10
WC Surgery
SC Surgery
GA EO9TK
UT WOS:000397030800025
PM 28043926
ER
PT J
AU Weng, QY
Raff, AB
Cohen, JM
Gunasekera, N
Okhovat, JP
Vedak, P
Joyce, C
Kroshinsky, D
Mostaghimi, A
AF Weng, Qing Yu
Raff, Adam B.
Cohen, Jeffrey M.
Gunasekera, Nicole
Okhovat, Jean-Phillip
Vedak, Priyanka
Joyce, Cara
Kroshinsky, Daniela
Mostaghimi, Arash
TI Costs and Consequences Associated With Misdiagnosed Lower Extremity
Cellulitis
SO JAMA DERMATOLOGY
LA English
DT Article
ID SOFT-TISSUE INFECTIONS; RISK-FACTORS; DERMATOLOGY CONSULTATION;
HOSPITALIZED-PATIENTS; LOWER-LIMB; SKIN; ERYSIPELAS; ANTIBIOTICS;
MANAGEMENT; DIARRHEA
AB IMPORTANCE Inflammatory dermatoses of the lower extremity are often misdiagnosed as cellulitis (aka "pseudocellulitis") and treated with antibiotics and/or hospitalization. There is limited data on the cost and complications from misdiagnosed cellulitis.
OBJECTIVE To characterize the national health care burden of misdiagnosed cellulitis in patients admitted for treatment of lower extremity cellulitis.
DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study using patients admitted from the emergency department (ED) of a large urban hospital with a diagnosis of lower extremity cellulitis between June 2010 and December 2012. Patients who were discharged with a diagnosis of cellulitis were categorized as having cellulitis, while those who were given an alternative diagnosis during the hospital course, on discharge, or within 30 days of discharge were considered to have pseudocellulitis. A literature review was conducted for calculation of large-scale costs and complication rates. We obtained national cost figures from the Medical Expenditure Panel Survey (MEPS), provided by the Agency for Healthcare Research and Quality (AHRQ) for 2010 to calculate the hospitalization costs per year attributed to misdiagnosed lower extremity pseudocellulitis.
EXPOSURES The exposed group was composed of patients who presented to and were admitted from the ED with a diagnosis of lower extremity cellulitis.
MAIN OUTCOMES AND MEASURES Patient characteristics, hospital course, and complications during and after hospitalization were reviewed for each patient, and estimates of annual costs of misdiagnosed cellulitis in the United States.
RESULTS Of 259 patients, 79 (30.5%) were misdiagnosed with cellulitis, and 52 of these misdiagnosed patients were admitted primarily for the treatment of cellulitis. Forty-four of the 52 (84.6%) did not require hospitalization based on ultimate diagnosis, and 48 (92.3%) received unnecessary antibiotics. We estimate cellulitis misdiagnosis leads to 50 000 to 130 000 unnecessary hospitalizations and $195 million to $515 million in avoidable health care spending. Unnecessary antibiotics and hospitalization for misdiagnosed cellulitis are projected to cause more than 9000 nosocomial infections, 1000 to 5000 Clostridium difficile infections, and 2 to 6 cases of anaphylaxis annually.
CONCLUSIONS AND RELEVANCE Misdiagnosis of lower extremity cellulitis is common and may lead to unnecessary patient morbidity and considerable health care spending.
C1 [Weng, Qing Yu; Raff, Adam B.; Vedak, Priyanka; Kroshinsky, Daniela] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Cohen, Jeffrey M.; Gunasekera, Nicole; Okhovat, Jean-Phillip; Mostaghimi, Arash] Brigham & Womens Hosp, Dept Dermatol, 75 Francis St, Boston, MA 02115 USA.
[Joyce, Cara] Tulane Sch Publ Hlth & Trop Med, Dept Biostat & Bioinformat, New Orleans, LA USA.
RP Mostaghimi, A (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Dept Dermatol, 15 Francis St,PBB-B 421, Boston, MA 02115 USA.
EM amostaghimi@bwh.harvard.edu
NR 33
TC 3
Z9 3
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD FEB 1
PY 2017
VL 153
IS 2
BP 141
EP 146
DI 10.1001/jamadermatol.2016.3816
PG 6
WC Dermatology
SC Dermatology
GA EM9ZT
UT WOS:000395670800007
ER
PT J
AU Liu, KX
Raff, AB
Lee, MS
AF Liu, Kevin X.
Raff, Adam B.
Lee, Margaret S.
TI Painful Ulcerative Lesions on Bilateral Lower Extremities
SO JAMA DERMATOLOGY
LA English
DT Editorial Material
ID ANTINEUTROPHIL CYTOPLASMIC ANTIBODY; LUPUS-LIKE SYNDROME; VASCULITIS;
METHIMAZOLE
C1 [Liu, Kevin X.] Harvard Med Sch, Boston, MA USA.
[Raff, Adam B.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA USA.
[Lee, Margaret S.] Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.
RP Lee, MS (reprint author), Boston Univ, Sch Med, Dept Dermatol, 609 Albany St, Boston, MA 02118 USA.
EM margaret.lee@bmc.org
NR 10
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD FEB 1
PY 2017
VL 153
IS 2
BP 223
EP 224
DI 10.1001/jamadermatol.2016.3401
PG 2
WC Dermatology
SC Dermatology
GA EM9ZT
UT WOS:000395670800023
ER
PT J
AU Stelmack, JA
Tang, XC
Wei, Y
Wilcox, DT
Morand, T
Brahm, K
Sayers, S
Massof, RW
AF Stelmack, Joan A.
Tang, X. Charlene
Wei, Yongliang
Wilcox, Denise Thomas
Morand, Timothy
Brahm, Karen
Sayers, Scott
Massof, Robert W.
CA LOVIT II Study Grp
TI Outcomes of the Veterans Affairs Low Vision Intervention Trial II (LOVIT
II)
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTIONING QUESTIONNAIRE; OF-THE-LITERATURE; MACULAR
DEGENERATION; IMPAIRED VISION; REHABILITATION; HEALTH; DEPRESSION;
PEOPLE; PARTICIPATION; IMPAIRMENTS
C1 [Stelmack, Joan A.; Sayers, Scott] Edward Hines Jr Vet Affairs Hosp, Blind Rehabil Ctr, Mail Stop 124,5000 S Fifth Ave, Hines, IL 60141 USA.
[Stelmack, Joan A.; Sayers, Scott] Univ Illinois, Sch Med, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
[Stelmack, Joan A.] Illinois Coll Optometry, Chicago, IL USA.
[Tang, X. Charlene; Wei, Yongliang] Edward Hines Jr Vet Affairs Hosp, Vet Affairs Cooperat Studies Program, Coordinating Ctr, Hines, IL USA.
[Wilcox, Denise Thomas] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA.
[Morand, Timothy] Dayton Vet Affairs Med Ctr, Rehabil Med Serv, Dayton, OH USA.
[Brahm, Karen] William S Middleton Mem Vet Adm Med Ctr, Surg Serv, Madison, WI USA.
[Massof, Robert W.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
RP Stelmack, JA (reprint author), Edward Hines Jr Vet Affairs Hosp, Blind Rehabil Ctr, Mail Stop 124,5000 S Fifth Ave, Hines, IL 60141 USA.
EM joan.stelmack@va.gov
FU Department of Veterans Affairs (VA) Rehabilitation Research and
Development [C6958R]; Department of Veterans Affairs Prosthetics Service
FX Funding for this research was provided by Department of Veterans Affairs
(VA) Rehabilitation Research and Development grant C6958R. Funding for
the low-vision devices prescribed and dispensed to veteran participants
was provided by the Department of Veterans Affairs Prosthetics Service.
NR 47
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD FEB 1
PY 2017
VL 135
IS 2
BP 96
EP 104
DI 10.1001/jamaophthalmol.2016.4742
PG 9
WC Ophthalmology
SC Ophthalmology
GA EM9PE
UT WOS:000395642800009
ER
PT J
AU Grotting, LA
Davoudi, S
Palenzuela, D
Papaliodis, GN
Sobrin, L
AF Grotting, Lindsay A.
Davoudi, Samaneh
Palenzuela, Deanna
Papaliodis, George N.
Sobrin, Lucia
TI Association of Low Vitamin D Levels With Noninfectious Anterior Uveitis
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID BEHCETS-DISEASE; 1,25-DIHYDROXYVITAMIN-D3; EXPRESSION; TH17
AB IMPORTANCE Vitamin D plays an important role in both the innate and adaptive immune systems. It has been shown to contribute to the etiology of T-cell-mediated autoimmune diseases through the upregulation of type 2 anti-inflammatory T helper cells and the suppression of type 1 T helper cells. Noninfectious uveitis is postulated to be caused by immune dysfunction.
OBJECTIVE To determine whether there is an association between vitamin D levels and noninfectious anterior uveitis.
DESIGN, SETTING, AND PARTICIPANTS This was a case-control study. We identified patients with and without noninfectious uveitis using the Massachusetts Eye and Ear Infirmary Ocular Inflammation Database and electronic medical records from March 1, 2008, to December 12, 2015, at the Massachusetts Eye and Ear Infirmary Uveitis and Comprehensive Ophthalmology Clinics. One hundred patients with noninfectious anterior uveitis and 100 patients without uveitis were recruited. Patients with noninfectious uveitis were diagnosed by fellowship-trained uveitis specialists after exclusion of infectious causes and neoplastic masquerades of uveitis. All patients included had a total 25-hydroxyvitamin D level recorded. Multivariate regression models were constructed to determine the association between vitamin D levels and the presence of uveitis.
MAIN OUTCOME AND MEASURE Presence of noninfectious anterior uveitis.
RESULTS We identified 100 patients (64 white, 8 African American, 25 Asian, and 3 Hispanic) with a mean (SD) age of 51.8 (15.9) years (26 men) and 100 control individuals (58 white, 23 African American, 8 Asian, and 11 Hispanic) with a mean (SD) age of 53.6 (16.2) years (27 men). Hypovitaminosis D was associated with noninfectious uveitis in the univariate analysis (odds ratio, 2.53; 95% CI, 1.42-4.51; P = .002). The association in multivariate regression after adjusting for age, sex, and race/ethnicity was 2.96 (95% CI, 1.60-5.50; P = .001). The odds of developing uveitis were 4% lower for every 1-ng/mL increase in vitamin D level (odds ratio, 0.96; 95% CI, 0.93-0.99; P = .01) in the main multivariate analysis.
CONCLUSIONS AND RELEVANCE In this retrospective study, lower vitamin D levels were associated with an increased risk of noninfectious anterior uveitis. However, this does not confirm a causal effect.
C1 [Grotting, Lindsay A.; Davoudi, Samaneh; Papaliodis, George N.; Sobrin, Lucia] Massachusetts Eye & Ear, Harvard Dept Ophthalmol, Boston, MA USA.
[Palenzuela, Deanna] Harvard Med Sch, Boston, MA USA.
RP Sobrin, L (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM lucia_sobrin@meei.harvard.edu
NR 11
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD FEB 1
PY 2017
VL 135
IS 2
BP 150
EP 153
DI 10.1001/jamaophthalmol.2016.4888
PG 4
WC Ophthalmology
SC Ophthalmology
GA EM9PE
UT WOS:000395642800018
ER
PT J
AU Osazuwa-Peters, N
Boakye, EA
Chen, BY
Clancy, J
Vallot, PL
Su, JL
Beck, GE
Varvares, MA
AF Osazuwa-Peters, Nosayaba
Boakye, Eric Adjei
Chen, Betty Y.
Clancy, Jennifer
Vallot, Patrice L.
Su, Jonathan L.
Beck, Geoffrey E.
Varvares, Mark A.
TI Sociodemographic Factors Associated With Knowledge and Risk Perception
of Human Papillomavirus and Human Papillomavirus-Associated
Oropharyngeal Squamous Cell Carcinoma Among a Predominantly Black
Population
SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Article
ID ORAL-CANCER KNOWLEDGE; UNITED-STATES; NECK-CANCER; PUBLIC AWARENESS; HPV
KNOWLEDGE; HEAD; VACCINATION; PREDICTORS; INFECTION; BEHAVIOR
AB IMPORTANCE The incidence of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing in the United States and may be underestimated among black individuals. Characterizing the current knowledge level among black individuals is critical to developing interventions to increase awareness.
OBJECTIVE To describe the sociodemographic correlates of knowledge and risk perception of HPV and HPV-associated OPSCC among a predominantly black population.
DESIGN, SETTING, AND PARTICIPANTS A cross-sectional surveywas conducted at a drag racing event on September 12 and 13, 2015, in Madison, Illinois. The setting was a community-based oral head and neck cancer screening and education initiative. Participants were 301 drag race attendees 18 years or older who were conveniently sampled from attendees at an annual drag racing event predominantly patronized by black individuals.
MAIN OUTCOMES AND MEASURES The primary outcomewas knowledge and risk perception of HPV and HPV-associated OPSCC. An electronic-based questionnaire elicited sociodemographic information and contained oral cancer knowledge and risk perception items, which were combined to form knowledge and risk perception scores. Multivariable linear regression analysis assessed estimates of knowledge and risk perception of HPV and HPV-associated OPSCC.
RESULTS Of the 301 participants (111 female and 190 male) completing the questionnaire, 194 (64.5%) were black. Overall, respondents ranged in age from 18 to 78 years, with a mean (SD) age of 48.0 (13.0) years. The mean (SD) knowledge score was 5.7 (4.6) of 15, and the mean (SD) risk perception score was 2.2 (1.4) of 6. Using multivariable linear regression, we found that, for every 1-year increase in age, knowledge of HPV-associated OPSCC decreased by 5.0% and was worse in men (beta = -1.26; 95% CI, -2.33 to -0.18), black vs white individuals (beta = -1.29; 95% CI, -2.35 to -0.23), and those with a high school diploma or less vs college graduates (beta = -3.23; 95% CI, -4.67 to -1.80). Black individuals also had lower perceived risk of developing HPV-associated OPSCC (beta = -0.36; 95% CI, -0.69 to -0.02) compared with white individuals, and participants with a high school diploma or less had lower perceived risk of developing HPV-associated OPSCC compared with those with a college degree or higher (beta = -0.59; 95% CI, -1.04 to -0.14).
CONCLUSIONS AND RELEVANCE Age and sex were independent correlates of knowledge of HPV-associated OPSCC, while race and education level were correlates of both knowledge and risk perception of HPV-associated OPSCC. These findings should inform future interventions targeted at increasing knowledge of HPV-associated OPSCC in black communities.
C1 [Osazuwa-Peters, Nosayaba] St Louis Univ, Dept Otolaryngol Head & Neck Surg, Sch Med, 3635 Vista Ave,Sixth Floor,Desloge Towers, St Louis, MO 63110 USA.
[Osazuwa-Peters, Nosayaba] St Louis Univ, Ctr Canc, St Louis, MO 63103 USA.
[Osazuwa-Peters, Nosayaba] St Louis Univ, Dept Epidemiol, Coll Publ Hlth & Social Justice, St Louis, MO 63103 USA.
[Boakye, Eric Adjei] St Louis Univ, Ctr Outcomes Res SLUCOR, St Louis, MO 63103 USA.
[Chen, Betty Y.; Clancy, Jennifer; Vallot, Patrice L.; Su, Jonathan L.; Beck, Geoffrey E.] St Louis Univ, Sch Med, St Louis, MO USA.
[Varvares, Mark A.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA USA.
RP Osazuwa-Peters, N (reprint author), St Louis Univ, Dept Otolaryngol Head & Neck Surg, Sch Med, 3635 Vista Ave,Sixth Floor,Desloge Towers, St Louis, MO 63110 USA.
EM nosazuwa@slu.edu
FU United Black Drag Racers Association
FX This study was supported by the United Black Drag Racers Association St
Louis members and executives; Scott Fosko, MD, Dell Yates, MA, and
Michell Nickerson, all from St Louis University Cancer Center; Rebecca
L. Rohde, BS, St Louis University School of Medicine; Tami Hanks, BS,
REDCap Product Manager, Ronald J. Walker, MD, Jastin Antisdel, MD, Josh
Hentzelman, MD, Sean T. Massa, MD, Lauren Cass, MD, MPH, Matt Gropler,
MD, Matt Leach, MD, and Zach Bear, MD, all from St Louis University; and
medical student volunteers. None received any compensation.
NR 37
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6181
EI 2168-619X
J9 JAMA OTOLARYNGOL
JI JAMA Otolaryngol-Head Neck Surg.
PD FEB
PY 2017
VL 143
IS 2
BP 117
EP 124
DI 10.1001/jamaoto.2016.2784
PG 8
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA EN0KM
UT WOS:000395698800004
PM 27711922
ER
PT J
AU Laury, AM
Bowe, SN
Lospinoso, J
AF Laury, Adrienne M.
Bowe, Sarah N.
Lospinoso, Joshua
TI Integrating Morbidity and Mortality Core Competencies and Quality
Improvement in Otolaryngology
SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Article
ID SURGICAL MORBIDITY; UTILITY
AB IMPORTANCE To date, an otolaryngology-specific morbidity and mortality (M&M) conference has never been reported or evaluated.
OBJECTIVE To propose a novel otolaryngology-specific M&M format and to assess its success using a validated assessment tool.
DESIGN, SETTING, AND PARTICIPANTS Preintervention and postintervention cohort study spanning 14 months (September 2014 to November 2015), with 32 faculty, residents, and medical students attending the department of otolaryngology M& M conference, conducted at the the San Antonio Uniformed Services Health Education Consortium.
INTERVENTIONS A novel quality assurance conference was implemented in the department of otolaryngology at the San Antonio Uniformed Services Health Education Consortium. This conference incorporates patient safety reports, otolaryngology-specific qualitymetrics, and individual case presentations. The revised format integrates the Accreditation Council for Graduate Medical Education (ACGME) core competencies and Quality Improvement and Patient Safety (QI/PS) system. This format was evaluated by faculty, residents, and medical students every other month for 14 months to assess changes in attitudes regarding the M&M conference as well as changes in presentation quality.
RESULTS Overall, 13 faculty, 12 residents, and 7 medical students completed 232 evaluations. Summary statistics of both resident and faculty attitudes about the success of the M&M format seem to improve over the 14 months between the prequestionnaires and postquestionnaires. General attitudes for both residents and faculty significantly improved from the pretest to posttest (odds ratio, 0.32 per month; 95% CI, 0.29-0.35). In the pretest period, "established presentation format" was considered the most necessary improvement, whereas in the posttest period this changed to "incorporate more QI." For resident presentations evaluated using the situation, background, assessment, and review/recommendations (SBAR) tool, all evaluations, from all participants, improved over time.
CONCLUSIONS AND RELEVANCE The M&M conference is an essential component of all otolaryngology residency programs and provides a unique opportunity to successfully incorporate the ACGME core competencies and regularly implement QI/PS.
C1 [Laury, Adrienne M.] San Antonio Uniformed Serv Hlth Educ Consortium, Dept Otolaryngol Head & Neck Surg, Ft Sam Houston, TX USA.
[Bowe, Sarah N.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA.
[Lospinoso, Joshua] Detachment Texas, Mil Intelligence Battal 782, Ft Sam Houston, TX USA.
RP Laury, AM (reprint author), San Antonio Uniformed Serv Hlth Educ Consortium, Dept Otolaryngol Head & Neck Surg, ATTN MCHE SDT Otolaryngol, JBSA, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.
EM Adrienne.laury@gmail.com
NR 17
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6181
EI 2168-619X
J9 JAMA OTOLARYNGOL
JI JAMA Otolaryngol-Head Neck Surg.
PD FEB
PY 2017
VL 143
IS 2
BP 135
EP 140
DI 10.1001/jamaoto.2016.2910
PG 6
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA EN0KM
UT WOS:000395698800007
PM 27768160
ER
PT J
AU Lin, BM
Hu, FB
Curhan, GC
AF Lin, Brian M.
Hu, Frank B.
Curhan, Gary C.
TI Association Between Benzodiazepine Receptor Agonists and Snoring Among
Women in the Nurses' Health Study
SO JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
LA English
DT Article
ID OBSTRUCTIVE SLEEP-APNEA; EXCESSIVE DAYTIME SLEEPINESS; RISK-FACTORS;
CARDIOVASCULAR-DISEASE; GENERAL-POPULATION; HYPERTENSION; SNORERS;
MORTALITY; HYPOPNEA; DURATION
AB IMPORTANCE Snoring is highly prevalent among adults. The use of benzodiazepine receptor agonists is also common, with higher prevalence of use with more advanced age. Benzodiazepine receptor agonists cause muscle relaxation, which may affect muscle tone and airway dynamics and thereby increase snoring. Previous studies examining the association between use of benzodiazepine receptor agonists and snoring were underpowered to detect clinically meaningful differences or did not report the magnitude of association. OBJECTIVE To investigate the association between use of benzodiazepine receptor agonists and snoring in women.
DESIGN, SETTING, AND PARTICIPANTS Women aged 62 to 86 years provided information on snoring and covariates of interest in the 2008 survey of the Nurses' Health Study, a cross-sectional cohort study of female registered nurses in the United States. Potential effect modification of the association between use of benzodiazepine receptor agonists and snoring by age, body mass index, waist circumference, smoking, alcohol consumption, and physical activity was explored. Logistic regression was used to adjust for potential confounders. Data analysis was conducted from November 2015 to March 2016.
MAIN OUTCOMES AND MEASURES Self-reported habitual snoring, defined as a few nights a week or more.
RESULTS Of 52 504 participants (mean [SD] age, 72.4 [6.7] years), 14 831 (28.2%) reported habitual snoring. There was a slightly higher prevalence of benzodiazepine receptor agonist use among habitual snorers (11.4%) compared with nonhabitual snorers (10.6%) (absolute difference, 0.8%; 95% CI, 0.2%-1.4%). After multivariable adjustment, use of benzodiazepine receptor agonists was not associated with snoring (odds ratio, 1.01; 95% CI, 0.95-1.07) compared with women who did not use benzodiazepine receptor agonists. Although there was no significant interaction with smoking, there were higher odds of snoring with use of benzodiazepine receptor agonists among current smokers (odds ratio, 1.34; 95% CI, 1.04-1.73).
CONCLUSIONS AND RELEVANCE Use of benzodiazepine receptor agonists is not associated with odds of snoring in middle-aged and elderly women.
C1 [Lin, Brian M.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
[Lin, Brian M.; Hu, Frank B.; Curhan, Gary C.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA.
[Lin, Brian M.; Hu, Frank B.; Curhan, Gary C.] Harvard Med Sch, Boston, MA USA.
[Lin, Brian M.; Hu, Frank B.; Curhan, Gary C.] Harvard Med Sch, Boston, MA USA.
[Hu, Frank B.; Curhan, Gary C.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Curhan, Gary C.] Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA.
RP Lin, BM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM brian_lin@meei.harvard.edu
FU National Institutes of Health [UM1CA186107, DK91417]
FX This work was supported by grants UM1CA186107 and DK91417 from the
National Institutes of Health.
NR 28
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6181
EI 2168-619X
J9 JAMA OTOLARYNGOL
JI JAMA Otolaryngol-Head Neck Surg.
PD FEB
PY 2017
VL 143
IS 2
BP 162
EP 167
DI 10.1001/jamaoto.2016.3174
PG 6
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA EN0KM
UT WOS:000395698800012
PM 27893000
ER
PT J
AU Dawes, AJ
Dawes, DM
Maggard-Gibbons, M
AF Dawes, Aaron J.
Dawes, Danielle M.
Maggard-Gibbons, Melinda
TI Corrected vs Uncorrected Obesity in Childbearing Women-What Really
Drives Fetal Risks
SO JAMA SURGERY
LA English
DT Editorial Material
C1 [Dawes, Aaron J.; Maggard-Gibbons, Melinda] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 757 Westwood Plaza,Room B711, Los Angeles, CA 90095 USA.
[Dawes, Danielle M.] Magella Med Grp Inc, Maternal Fetal Med Practice, Long Beach, CA USA.
[Maggard-Gibbons, Melinda] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Dawes, AJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, 757 Westwood Plaza,Room B711, Los Angeles, CA 90095 USA.
EM adawes@mednet.ucla.edu
NR 5
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD FEB
PY 2017
VL 152
IS 2
BP 135
EP 135
DI 10.1001/jamasurg.2016.3597
PG 1
WC Surgery
SC Surgery
GA EM9HZ
UT WOS:000395623800007
PM 27760247
ER
PT J
AU Klebanoff, MJ
Chhatwal, J
Nudel, JD
Corey, KE
Kaplan, LM
Hur, C
AF Klebanoff, Matthew J.
Chhatwal, Jagpreet
Nudel, Jacob D.
Corey, Kathleen E.
Kaplan, Lee M.
Hur, Chin
TI Cost-effectiveness of Bariatric Surgery in Adolescents With Obesity
SO JAMA SURGERY
LA English
DT Article
ID LAPAROSCOPIC SLEEVE GASTRECTOMY; MORBID-OBESITY; UNITED-STATES;
WEIGHT-LOSS; IMPACT; BYPASS; TRIAL; METAANALYSIS; CHILDHOOD; CHILDREN
AB IMPORTANCE Severe obesity affects 4% to 6% of US youth and is increasing in prevalence. Bariatric surgery for the treatment of adolescents with severe obesity is becoming more common, but data on cost-effectiveness are limited.
OBJECTIVE To assess the cost-effectiveness of bariatric surgery for adolescents with obesity using recently published results from the Teen-Longitudinal Assessment of Bariatric Surgery study.
DESIGN, SETTING, AND PATIENTS A state-transition model was constructed to compare 2 strategies: no surgery and bariatric surgery. In the no surgery strategy, patients remained at their initial body mass index (calculated as weight in kilograms divided by height in meters squared) over time. In the bariatric surgery strategy, patients were subjected to risks of perioperative mortality and complications as well as initial morbidity but also experienced longer-term quality-of-life improvements associated with weight loss. Cohort demographic information-of the 228 patients included, the mean (SD) age was 17 (1.6) years, the mean (range) body mass index was 53 (34-88), and 171 (75.0%) were female-surgery-related outcomes, and base case time horizon (3 years) were based on data from the Teen-Longitudinal Assessment of Bariatric Surgery study. One-way and probabilistic sensitivity analyses were performed.
MAIN OUTCOMES AND MEASURES Quality-adjusted life-years (QALYs), total costs (in US dollars adjusted to 2015-year values using the Consumer Price Index), and incremental cost-effectiveness ratios (ICERs). A willingness-to-pay threshold of $100 000 per QALY was used to assess cost-effectiveness.
RESULTS After 3 years, surgery led to a gain of 0.199 QALYs compared with no surgery at an incremental cost of $ 30 747, yielding an unfavorable ICER of $ 154 684 per QALY. When the clinical study results were extrapolated to 4 years, the ICER decreased to $ 114 078 per QALY and became cost-effective by 5 years with an ICER of $ 91 032 per QALY. Outcomes were robust in most 1-way and probabilistic sensitivity analyses.
CONCLUSIONS AND RELEVANCE Bariatric surgery incurs substantial initial cost and morbidity. We found that surgery could be a cost-effective treatment for adolescents with severe obesity if assessed over a time horizon of 5 years. Our study underscores the need for long-term clinical trials in adolescents with at least 5 years of follow-up data that capture financial and quality-of-life end points.
C1 [Klebanoff, Matthew J.; Chhatwal, Jagpreet; Hur, Chin] Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA.
[Klebanoff, Matthew J.; Chhatwal, Jagpreet; Corey, Kathleen E.; Kaplan, Lee M.; Hur, Chin] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Klebanoff, Matthew J.] Yale Sch Med, New Haven, CT USA.
[Chhatwal, Jagpreet; Nudel, Jacob D.; Corey, Kathleen E.; Kaplan, Lee M.; Hur, Chin] Harvard Med Sch, Boston, MA USA.
[Nudel, Jacob D.] Boston Univ, Dept Surg, Boston, MA 02215 USA.
RP Hur, C (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA.
EM chur@mgh.harvard.edu
NR 38
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD FEB
PY 2017
VL 152
IS 2
BP 136
EP 141
DI 10.1001/jamasurg.2016.3640
PG 6
WC Surgery
SC Surgery
GA EM9HZ
UT WOS:000395623800008
PM 27784062
ER
PT J
AU Fernandez-Bustamante, A
Frendl, G
Sprung, J
Kor, DJ
Subramaniam, B
Ruiz, RM
Lee, JW
Henderson, WG
Moss, A
Mehdiratta, N
Colwell, MM
Bartels, K
Kolodzie, K
Giquel, J
Melo, MFV
AF Fernandez-Bustamante, Ana
Frendl, Gyorgy
Sprung, Juraj
Kor, Daryl J.
Subramaniam, Bala
Ruiz, Ricardo Martinez
Lee, Jae-Woo
Henderson, William G.
Moss, Angela
Mehdiratta, Nitin
Colwell, Megan M.
Bartels, Karsten
Kolodzie, Kerstin
Giquel, Jadelis
Melo, Marcos Francisco Vidal
TI Postoperative Pulmonary Complications, Early Mortality, and Hospital
Stay Following Noncardiothoracic Surgery A Multicenter Study by the
Perioperative Research Network Investigators
SO JAMA SURGERY
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; RANDOMIZED CONTROLLED-TRIAL; TIDAL-VOLUME
VENTILATION; OPEN ABDOMINAL-SURGERY; NONCARDIAC SURGERY; PRACTICE
PATTERNS; PATIENT-CARE; LUNG INJURY; RISK; PREDICTORS
AB IMPORTANCE Postoperative pulmonary complications (PPCs), a leading cause of poor surgical outcomes, are heterogeneous in their pathophysiology, severity, and reporting accuracy.
OBJECTIVE To prospectively study clinical and radiological PPCs and respiratory insufficiency therapies in a high-risk surgical population.
DESIGN, SETTING, AND PARTICIPANTS We performed a multicenter prospective observational study in 7 US academic institutions. American Society of Anesthesiologists physical status 3 patients who presented for noncardiothoracic surgery requiring 2 hours or more of general anesthesia with mechanical ventilation from May to November 2014 were included in the study. We hypothesized that PPCs, even mild, would be associated with early postoperative mortality and use of hospital resources. We analyzed their association with modifiable perioperative variables.
EXPOSURE Noncardiothoracic surgery.
MAIN OUTCOMES AND MEASURES Predefined PPCs occurring within the first 7 postoperative days were prospectively identified. We used bivariable and logistic regression analyses to study the association of PPCs with ventilatory and other perioperative variables.
RESULTS This study included 1202 patients who underwent predominantly abdominal, orthopedic, and neurological procedures. The mean (SD) age of patients was 62.1 (13.8) years, and 636 (52.9%) were men. At least 1 PPC occurred in 401 patients (33.4%), mainly the need for prolonged oxygen therapy by nasal cannula (n = 235; 19.6%) and atelectasis (n = 206; 17.1%). Patients with 1 or more PPCs, even mild, had significantly increased early postoperative mortality, intensive care unit (ICU) admission, and ICU/hospital length of stay. Significant PPC risk factors included nonmodifiable (emergency [yes vs no]: odds ratio [OR], 4.47, 95% CI, 1.59-12.56; surgical site [abdominal/pelvic vs nonabdominal/pelvic]: OR, 2.54, 95% CI, 1.67-3.89; and age [in years]: OR, 1.03, 95% CI, 1.02-1.05) and potentially modifiable (colloid administration [yes vs no]: OR, 1.75, 95% CI, 1.03-2.97; preoperative oxygenation: OR, 0.86, 95% CI, 0.80-0.93; blood loss [in milliliters]: OR, 1.17, 95% CI, 1.05-1.30; anesthesia duration [in minutes]: OR, 1.14, 95% CI, 1.05-1.24; and tidal volume [in milliliters per kilogram of predicted body weight]: OR, 1.12, 95% CI, 1.01-1.24) factors.
CONCLUSIONS AND RELEVANCE Postoperative pulmonary complications are common in patients with American Society of Anesthesiologists physical status 3, despite current protective ventilation practices. Even mild PPCs are associated with increased early postoperative mortality, ICU admission, and length of stay (ICU and hospital). Mild frequent PPCs (eg, atelectasis and prolonged oxygen therapy need) deserve increased attention and intervention for improving perioperative outcomes.
C1 [Fernandez-Bustamante, Ana; Bartels, Karsten] Univ Colorado, Sch Med, Aurora, CO USA.
[Frendl, Gyorgy; Mehdiratta, Nitin] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Sprung, Juraj; Kor, Daryl J.] Mayo Clin, Coll Med, Rochester, MN USA.
[Subramaniam, Bala] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Ruiz, Ricardo Martinez; Giquel, Jadelis] Univ Miami, Palmetto Bay, FL USA.
[Lee, Jae-Woo; Kolodzie, Kerstin] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Henderson, William G.; Moss, Angela] Univ Colorado, Sch Med, Adult & Children Outcomes Res & Delivery Syst, Aurora, CO USA.
[Colwell, Megan M.; Melo, Marcos Francisco Vidal] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Fernandez-Bustamante, A (reprint author), Univ Colorado, Sch Med, Dept Anesthesiol, 12631 E 17th Ave,AO-1 Bldg,R2012,MS 8202, Aurora, CO 80045 USA.
EM ana.fernandez-bustamante@ucdenver.edu
FU National Institutes of Health [R34HL123438, K23HL112855]; Foundation for
Anesthesia Education and Research Mentored Research Training
Grant-Clinical/Translational
FX This work was partially supported by grants R34HL123438 (Drs Vidal Melo,
Fernandez-Bustamante, and Sprung) and K23HL112855 (Dr Kor) from the
National Institutes of Health, and by the 2012 Foundation for Anesthesia
Education and Research Mentored Research Training
Grant-Clinical/Translational (Dr Fernandez-Bustamante).
NR 32
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD FEB
PY 2017
VL 152
IS 2
BP 157
EP 166
DI 10.1001/jamasurg.2016.4065
PG 10
WC Surgery
SC Surgery
GA EM9HZ
UT WOS:000395623800014
PM 27829093
ER
PT J
AU Hall, DE
Arya, S
Schmid, KK
Blaser, C
Carlson, MA
Bailey, TL
Purviance, G
Bockman, T
Lynch, TG
Johanning, J
AF Hall, Daniel E.
Arya, Shipra
Schmid, Kendra K.
Blaser, Casey
Carlson, Mark A.
Bailey, Travis L.
Purviance, Georgia
Bockman, Tammy
Lynch, Thomas G.
Johanning, Jason
TI Development and Initial Validation of the Risk Analysis Index for
Measuring Frailty in Surgical Populations
SO JAMA SURGERY
LA English
DT Article
ID MORTALITY; MORBIDITY; SURGERY; SPECIALTIES; DISABILITY; PREDICTOR;
OUTCOMES; HEALTH; CARE
AB IMPORTANCE Growing consensus suggests that frailty-associated risks should inform shared surgical decision making. However, it is not clear how best to screen for frailty in preoperative surgical populations.
OBJECTIVE To develop and validate the Risk Analysis Index (RAI), a 14-item instrument used to measure surgical frailty. It can be calculated prospectively (RAI-C), using a clinical questionnaire, or retrospectively (RAI-A), using variables from the surgical quality improvement databases (Veterans Affairs or American College of Surgeons National Surgical Quality Improvement Projects).
DESIGN, SETTING, AND PARTICIPANTS Single-site, prospective cohort from July 2011 to September 2015 at the Veterans Affairs Nebraska-Western Iowa Heath Care System, a Level 1b Veterans Affairs Medical Center. The study included all patients presenting to the medical center for elective surgery.
EXPOSURES We assessed the RAI-C for all patients scheduled for surgery, linking these scores to administrative and quality improvement data to calculate the RAI-A and the modified Frailty Index.
MAIN OUTCOMES AND MEASURES Receiver operator characteristics and C statistics for each measure predicting postoperative mortality and morbidity.
RESULTS Of the participants, the mean (SD) age was 60.7 (13.9) years and 249 participants (3.6%) were women. We assessed the RAI-C 10 698 times, from which we linked 6856 unique patients to mortality data. The C statistic predicting 180-day mortality for the RAI-C was 0.772. Of these 6856 unique patients, we linked 2785 to local Veterans Affairs Surgeons National Surgical Quality Improvement Projects data and calculated the C statistic for both the RAI-A (0.823) and RAI-C (0.824), along with the correlation between the 2 scores (r = 0.478; P < .001). Of these 2785 patients, there were sufficient data to calculate the modified Frailty Index for 1021, in which the C statistics were 0.865 (RAI-A), 0.797 (RAI-C), and 0.811 (modified Frailty Index). The correlation between the RAI-A and RAI-C was 0.547, and the correlations of the modified Frailty Index to the RAI-A and RAI-C were 0.301 and 0.269, respectively (all P < .001). A cutoff of RAI-C of at least 21 classified 18.3% patients as "frail" with a sensitivity of 0.50 and specificity of 0.82, whereas the RAI-A was less sensitive (0.25) and more specific (0.97), classifying only 3.7% as "frail."
CONCLUSIONS AND RELEVANCE The RAI-C and RAI-A represent effective tools for measuring frailty in surgical populations with predictive ability on par with other frailty tools. Moderate correlation between the measures suggests convergent validity. The RAI-C offers the advantage of prospective, preoperative assessment that is proved feasible for large-scale screening in clinical practice. However, further efforts should be directed at determining the optimal components of preoperative frailty assessment.
C1 [Hall, Daniel E.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Hall, Daniel E.] Univ Pittsburgh, Pittsburgh, PA USA.
[Arya, Shipra] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA.
[Arya, Shipra] Emory Univ, Atlanta, GA 30322 USA.
[Schmid, Kendra K.; Blaser, Casey; Carlson, Mark A.; Johanning, Jason] Univ Nebraska Med Ctr, Omaha, NE USA.
[Carlson, Mark A.; Bailey, Travis L.; Purviance, Georgia; Bockman, Tammy; Johanning, Jason] Vet Affairs Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA.
[Bailey, Travis L.] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Lynch, Thomas G.] Vet Affairs Cent Off, Washington, DC USA.
RP Hall, DE (reprint author), UPMC Presbyterian, 200 Lothrop St,Ste 1264, Pittsburgh, PA 15213 USA.
EM hallde@upmc.edu
FU US Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development, Health Services Research and
Development [CDA 08-281]
FX This research was supported by the US Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development,
Health Services Research and Development (CDA 08-281; Dr Hall).
NR 24
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD FEB
PY 2017
VL 152
IS 2
BP 175
EP 182
DI 10.1001/jamasurg.2016.4202
PG 8
WC Surgery
SC Surgery
GA EM9HZ
UT WOS:000395623800017
PM 27893030
ER
PT J
AU Biederman, J
Fried, R
Tarko, L
Surman, C
Spencer, T
Pope, A
Grossman, R
McDermott, K
Woodworth, KY
Faraone, SV
AF Biederman, Joseph
Fried, Ronna
Tarko, Laura
Surman, Craig
Spencer, Thomas
Pope, Amanda
Grossman, Rebecca
McDermott, Katie
Woodworth, K. Yvonne
Faraone, Stephen V.
TI Memantine in the Treatment of Executive Function Deficits in Adults With
ADHD: A Pilot-Randomized Double-Blind Controlled Clinical Trial
SO JOURNAL OF ATTENTION DISORDERS
LA English
DT Article
DE ADHD; adult; adult ADHD treatment; executive function deficits;
memantine
ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; HYPERACTIVITY DISORDER;
SUBTHRESHOLD DIAGNOSES; STIMULANT MEDICATION; FUNCTION PERFORMANCE;
WORKING-MEMORY; LATE-ONSET; CHILDREN; METHYLPHENIDATE; GLUTAMATE
AB Objective: To evaluate the efficacy and safety of memantine hydrochloride as an adjunct to stimulant pharmacotherapy for treating executive function deficits (EFDs) in adults with ADHD. Method: This was a 12-week, double-blind, placebo-controlled, randomized clinical trial of memantine added to open-label treatment with stimulant medication. Because of the small sample size, we considered a standardized mean difference (equivalent to effect size) of 0.5 and odds ratios 2 as indicators of trend improvements. Results: Twelve participants received memantine and 14 received a placebo. Trend improvements favoring memantine were observed on Behavior Rating Inventory of Executive Functions-Adult Inhibition and Self-Monitor subscales when compared with Placebo. No significant changes were noted on the Cambridge Neuropsychological Test Automated Battery. Conclusion: Among adults with ADHD and EFDs, adjunct treatment with memantine to osmotic release oral system-methylphenidate (OROS-MPH) was associated with improvements in selective areas of executive functioning, supporting the need for further research.
C1 [Biederman, Joseph; Tarko, Laura; Surman, Craig; Spencer, Thomas; Pope, Amanda; Grossman, Rebecca; McDermott, Katie; Woodworth, K. Yvonne] Massachusetts Gen Hosp, Pediat Psychopharmacol & Adult ADHD Program, Boston, MA 02114 USA.
[Fried, Ronna] Massachusetts Gen Hosp, Pediat Psychopharmacol & Adult ADHD Program, Neuropsychol, Boston, MA 02114 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Med Genet Res Ctr, Syracuse, NY 13210 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Psychiat & Neurosci & Physiol, Syracuse, NY 13210 USA.
RP Biederman, J (reprint author), Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, 55 Fruit St,Warren 705, Boston, MA 02114 USA.; Biederman, J (reprint author), Massachusetts Gen Hosp, Clin & Res Program Adult ADHD, 55 Fruit St,Warren 705, Boston, MA 02114 USA.
EM jbiederman@partners.org
FU Pond Family Foundation/APSARD ADHD Research Fund
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This
research was funded by a grant to Dr. Biederman from the Pond Family
Foundation/APSARD ADHD Research Fund.
NR 51
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087-0547
EI 1557-1246
J9 J ATTEN DISORD
JI J. Atten. Disord.
PD FEB
PY 2017
VL 21
IS 4
BP 343
EP 352
DI 10.1177/1087054714538656
PG 10
WC Psychology, Developmental; Psychiatry
SC Psychology; Psychiatry
GA EO8KV
UT WOS:000396938900008
PM 24970718
ER
PT J
AU Bianchi, MT
Phillips, AJK
Wang, W
Klerman, EB
AF Bianchi, Matt T.
Phillips, Andrew J. K.
Wang, Wei
Klerman, Elizabeth B.
TI Statistics for Sleep and Biological Rhythms Research: From Distributions
and Displays to Correlation and Causation
SO JOURNAL OF BIOLOGICAL RHYTHMS
LA English
DT Article
DE statistics; correlations; biological rhythms; mathematical analyses;
circadian; rhythms
AB The Journal of Biological Rhythms will be publishing articles exploring analysis and statistical topics relevant to researchers in biological rhythms and sleep research. The goal is to provide an overview of the most common issues that arise in the analysis and interpretation of data in these fields. By using case examples and highlighting the pearls and pitfalls of statistical inference, the authors will identify and explain ways in which experimental scientists can avoid common analytical and statistical mistakes and use appropriate analytical and statistical methods in their research. In this first article, we address the first steps in analysis of data: understanding the underlying statistical distribution of the data and establishing associative versus causal relationships. These ideas are then applied to sample size, power calculations, correlation testing, differences between description and prediction, and the narrative fallacy.
C1 [Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, Wang 7 Neurology,55 Fruit St, Boston, MA 02114 USA.
[Bianchi, Matt T.; Phillips, Andrew J. K.; Wang, Wei; Klerman, Elizabeth B.] Harvard Med Sch, Div Sleep Med, Boston, MA USA.
[Phillips, Andrew J. K.; Wang, Wei; Klerman, Elizabeth B.] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, Boston, MA 02115 USA.
RP Bianchi, MT (reprint author), Massachusetts Gen Hosp, Dept Neurol, Wang 7 Neurology,55 Fruit St, Boston, MA 02114 USA.
EM mtbianchi@partners.org
FU NIH [K99 / R00 HL119618, K24-HL105664, R01-HL-114088, R01-GM-105018,
P01-AG009975]; NSBRI [HFP02802]; MGH Neurology Department (MTB)
FX The authors thank Ellen Frank, Karen Gamble, William J. Schwartz, and
Katie Sharkey for helpful discussions. This work was supported by NIH
K99 / R00 HL119618 (AJKP); NIH K24-HL105664 (EBK), R01-HL-114088,
R01-GM-105018 and P01-AG009975, and NSBRI HFP02802; MGH Neurology
Department (MTB).
NR 12
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0748-7304
EI 1552-4531
J9 J BIOL RHYTHM
JI J. Biol. Rhythms
PD FEB
PY 2017
VL 32
IS 1
BP 7
EP 17
DI 10.1177/0748730416670050
PG 11
WC Biology; Physiology
SC Life Sciences & Biomedicine - Other Topics; Physiology
GA EP2WI
UT WOS:000397243900002
PM 27836938
ER
PT J
AU Klerman, EB
Wang, W
Phillips, AJK
Bianchi, MT
AF Klerman, Elizabeth B.
Wang, Wei
Phillips, Andrew J. K.
Bianchi, Matt T.
TI Statistics for Sleep and Biological Rhythms Research: Longitudinal
Analysis of Biological Rhythms Data
SO JOURNAL OF BIOLOGICAL RHYTHMS
LA English
DT Article
DE statistics; longitudinal analyses; circadian rhythms; biological
rhythms; periodicity
ID CIRCADIAN PHASE; MATHEMATICAL-MODEL; MELATONIN
AB This article is part of a Journal of Biological Rhythms series exploring analysis and statistical topics relevant to researchers in biological rhythms and sleep research. The goal is to provide an overview of the most common issues that arise in the analysis and interpretation of data in these fields. In this article, we address issues related to the collection of multiple data points from the same organism or system at different times, since such longitudinal data collection is fundamental to the assessment of biological rhythms. Rhythmic longitudinal data require additional specific statistical considerations, ranging from curve fitting to threshold definitions to accounting for correlation structure. We discuss statistical analyses of longitudinal data including issues of correlational structure and stationarity, markers of biological rhythms, demasking of biological rhythms, and determining phase, waveform, and amplitude of biological rhythms.
C1 [Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Klerman, Elizabeth B.; Wang, Wei; Phillips, Andrew J. K.; Bianchi, Matt T.] Harvard Med Sch, Div Sleep Med, Boston, MA USA.
[Klerman, Elizabeth B.; Wang, Wei; Phillips, Andrew J. K.] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, Boston, MA 02115 USA.
RP Klerman, EB (reprint author), BWH, Div Sleep & Circadian Disorders, 221 Longwood Ave, Boston, MA 02115 USA.
EM ebklerman@hms.harvard.edu
FU NIH [K99/R00 HL119618, K24-HL105664, R01-HL-114088, R01-GM-105018,
P01-AG009975]; NSBRI [HFP02802]; MGH Neurology Department (MTB)
FX The authors thank Ellen Frank, Karen Gamble, William J. Schwartz, and
Katie Sharkey for helpful discussions. This work was supported by NIH
K99/R00 HL119618 (AJKP); NIH K24-HL105664 (EBK), R01-HL-114088,
R01-GM-105018 and P01-AG009975, and NSBRI HFP02802; MGH Neurology
Department (MTB).
NR 6
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0748-7304
EI 1552-4531
J9 J BIOL RHYTHM
JI J. Biol. Rhythms
PD FEB
PY 2017
VL 32
IS 1
BP 18
EP 25
DI 10.1177/0748730416670051
PG 8
WC Biology; Physiology
SC Life Sciences & Biomedicine - Other Topics; Physiology
GA EP2WI
UT WOS:000397243900003
PM 27836939
ER
PT J
AU Cain, SW
Chang, AM
Vlasac, I
Tare, A
Anderson, C
Czeisler, CA
Saxena, R
AF Cain, Sean W.
Chang, Anne-Marie
Vlasac, Irma
Tare, Archana
Anderson, Clare
Czeisler, Charles A.
Saxena, Richa
TI Circadian Rhythms in Plasma Brain-derived Neurotrophic Factor Differ in
Men and Women
SO JOURNAL OF BIOLOGICAL RHYTHMS
LA English
DT Article
DE brain derived neurotrophic factor; circadian; Val66Met; constant
routine; sex differences
ID RAT SUPRACHIASMATIC NUCLEUS; BDNF MESSENGER-RNA; SYNAPTIC PLASTICITY;
SEX-DIFFERENCES; PHASE; TRKB; METAANALYSIS; HIPPOCAMPUS; EXPRESSION;
PACEMAKER
AB The measurement of circulating levels of brain-derived neurotrophic factor (BDNF) has been proposed to be a marker of disease and an indicator of recovery. Thus, knowing the temporal pattern and influence of potential circadian rhythms is important. Although several studies have measured BDNF at different times of day, no studies have done so while controlling for potential masking influences such as sleep and activity. Further, no previous study has examined circadian rhythms within individuals. We examined circadian rhythms in plasma BDNF while minimizing masking from behavioral and environmental factors using a 30-h constant routine (CR) protocol. In a sample of 39 healthy adults, we found significant circadian rhythms in 75% of women and 52% of men. The timing of the acrophase of the BDNF rhythm, however, was unrelated to clock time in women, while it was related to clock time in men. These results indicate that the use of single-sample measures of plasma BDNF as a marker of disease will be unreliable, especially in women. Repeated plasma BDNF samples over a 24-h period within individuals would be needed to reveal abnormalities related to disease states.
C1 [Cain, Sean W.; Chang, Anne-Marie; Anderson, Clare; Czeisler, Charles A.; Saxena, Richa] Brigham & Womens Hosp, Dept Med, Div Sleep & Circadian Disorders, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Cain, Sean W.; Chang, Anne-Marie; Anderson, Clare; Czeisler, Charles A.] Harvard Med Sch, Div Sleep & Circadian Disorders, Boston, MA USA.
[Cain, Sean W.; Anderson, Clare] Monash Univ, Sch Psychol Sci, 18 Innovation Walk,Clayton Campus, Clayton, Vic 3800, Australia.
Monash Univ, Monash Inst Cognit & Clin Neurosci, Clayton, Vic 3800, Australia.
[Chang, Anne-Marie] Penn State Univ, Dept Biobehav Hlth, University Pk, PA USA.
[Vlasac, Irma; Tare, Archana; Saxena, Richa] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Anesthesia, Crit Care & Pain Med, Boston, MA 02114 USA.
[Saxena, Richa] Broad Inst Harvard, Med & Populat Genet, Cambridge, MA USA.
MIT, Cambridge, MA 02139 USA.
RP Cain, SW (reprint author), Monash Univ, Sch Psychol Sci, 18 Innovation Walk,Clayton Campus, Clayton, Vic 3800, Australia.
EM Sean.cain@monash.edu
FU National Space Biomedical Research Institute (NSBRI) [HFP01601];
National Center for Research Resources (NCRR) of the National Institutes
of Health (NIH) [UL1 RR025758]
FX We thank the study participants as well as the staff of the Harvard
Clinical and Translational Science Center (CTSC) and the Chronobiology
Core of the Division of Sleep Medicine of Brigham and Women's Hospital
(BWH) for their contributions. The work presented in this manuscript was
performed at the Division of Sleep and Circadian Disorders, Department
of Medicine and Department of Neurology, Brigham and Women's Hospital,
Boston, Massachusetts; the Division of Sleep Medicine, Harvard Medical
School, Boston, Massachusetts; and the Center for Human Genetic
Research, Massachusetts General Hospital, Boston, Massachusetts. This
study was supported by the National Space Biomedical Research Institute
(NSBRI) grant HFP01601. Inpatient studies were conducted in the CTSC and
supported in part by UL1 RR025758 from the National Center for Research
Resources (NCRR) of the National Institutes of Health (NIH). The content
is solely the responsibility of the authors and does not necessarily
represent the official views of the NSBRI, NCRR, NIH or BWH.
NR 45
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0748-7304
EI 1552-4531
J9 J BIOL RHYTHM
JI J. Biol. Rhythms
PD FEB
PY 2017
VL 32
IS 1
BP 75
EP 82
DI 10.1177/0748730417693124
PG 8
WC Biology; Physiology
SC Life Sciences & Biomedicine - Other Topics; Physiology
GA EP2WI
UT WOS:000397243900008
PM 28326910
ER
PT J
AU McMillan, S
Rader, C
Jorfi, M
Pickrell, G
Foster, EJ
AF McMillan, Sean
Rader, Chris
Jorfi, Mehdi
Pickrell, Gary
Foster, E. Johan
TI Mechanically switchable polymer fibers for sensing in biological
conditions
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE biomedical optics; polymers; materials; fiber optic sensors; fiber optic
applications
ID OPTICAL-FIBER; PH; SENSOR; FABRICATION; FLUORESCEIN; ABSORPTION;
EXPOSURE; PROBE
AB The area of in vivo sensing using optical fibers commonly uses materials such as silica and polymethyl methacrylate, both of which possess much higher modulus than human tissue. The mechanical mismatch between materials and living tissue has been seen to cause higher levels of glial encapsulation, scarring, and inflammation, leading to failure of the implanted medical device. We present the use of a fiber made from polyvinyl alcohol (PVA) for use as an implantable sensor as it is an easy to work with functionalized polymer that undergoes a transition from rigid to soft when introduced to water. This ability to switch from stiff to soft reduces the severity of the immune response. The fabricated PVA fibers labeled with fluorescein for sensing applications showed excellent response to various stimuli while exhibiting mechanical switchability. For the dry fibers, a tensile storage modulus of 4700 MPa was measured, which fell sharply to 145 MPa upon wetting. The fibers showed excellent response to changing pH levels, producing values that were detectable in a range consistent with those seen in the literature and in proposed applications. The results show that these mechanically switchable fibers are a viable option for future sensing applications. (c) 2017 Society of Photo-Optical Instrumentation Engineers (SPIE)
C1 [McMillan, Sean; Rader, Chris; Pickrell, Gary; Foster, E. Johan] Virginia Tech, Dept Mat Sci & Engn, Blacksburg, VA 24061 USA.
[Jorfi, Mehdi] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Jorfi, Mehdi] Massachusetts Gen Hosp, Harvard Med Sch, Ctr Engn Med, Boston, MA 02114 USA.
RP Foster, EJ (reprint author), Virginia Tech, Dept Mat Sci & Engn, Blacksburg, VA 24061 USA.
EM johanf@vt.edu
FU Virginia Tech Materials Science and Engineering Department; Digges
Faculty Fellowship
FX This work was financially supported by the Virginia Tech Materials
Science and Engineering Department and the Digges Faculty Fellowship.
NR 30
TC 0
Z9 0
U1 0
U2 0
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD FEB
PY 2017
VL 22
IS 2
AR 027001
DI 10.1117/1.JBO.22.2.027001
PG 7
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA EP3FJ
UT WOS:000397267900018
ER
PT J
AU Sakadzic, S
Boas, DA
Carp, S
AF Sakadzic, Sava
Boas, David A.
Carp, Stefan
TI Theoretical model of blood flow measurement by diffuse correlation
spectroscopy
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE diffuse correlation spectroscopy; diffusing-wave spectroscopy;
scattering; random media; autocorrelation function; blood flow;
correlation transfer equation; correlation diffusion equation
ID DEEP TISSUE; SCATTERING; VALIDATION; MOTION; WAVE; MRI
AB Diffuse correlation spectroscopy (DCS) is a noninvasive method to quantify tissue perfusion from measurements of the intensity temporal autocorrelation function of diffusely scattered light. However, DCS auto-correlation function measurements in tissue better match theoretical predictions based on the diffusive motion of the scatterers than those based on a model where the advective nature of blood flow dominates the stochastic properties of the scattered light. We have recently shown using Monte Carlo (MC) simulations and assuming a simplistic vascular geometry and laminar flow profile that the diffusive nature of the DCS autocorrelation function decay is likely a result of the shear-induced diffusion of the red blood cells. Here, we provide theoretical derivations supporting and generalizing the previous MC results. Based on the theory of diffusing-wave spectroscopy, we derive an expression for the autocorrelation function along the photon path through a vessel that takes into account both diffusive and advective scatterer motion, and we provide the solution for the DCS autocorrelation function in a semi-infinite geometry. We also derive the correlation diffusion and correlation transfer equation, which can be applied for an arbitrary sample geometry. Further, we propose a method to take into account realistic vascular morphology and flow profile. (C) 2017 Society of Photo-Optical Instrumentation Engineers (SPIE)
C1 [Sakadzic, Sava] Massachusetts Gen Hosp, Charlestown, MA USA.
Athinoula Martinos Ctr Biomed Imaging, Harvard Med Sch, Dept Radiol, Charlestown, MA USA.
RP Sakadzic, S (reprint author), Massachusetts Gen Hosp, Charlestown, MA USA.
EM sava.sakadzic@mgh.harvard.edu
FU National Institutes of Health [NS091230, EB015896, CA187595]
FX We would like to express our gratitude for support from the National
Institutes of Health under Grants Nos. NS091230, EB015896, and CA187595.
NR 24
TC 0
Z9 0
U1 0
U2 0
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD FEB
PY 2017
VL 22
IS 2
AR 027006
DI 10.1117/1.JBO.22.2.027006
PG 7
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA EP3FJ
UT WOS:000397267900023
PM 28241276
ER
PT J
AU O'Malley, BW
Crowley, WF
AF O'Malley, Bert W.
Crowley, William F.
TI In Memoriam, P. Michael Conn, PhD (1949-2016) IN MEMORIAM
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Biographical-Item
C1 [O'Malley, Bert W.] Baylor Coll Med, Mol & Cellular Biol, Houston, TX 77030 USA.
[Crowley, William F.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Harvard Reprod Endocrine Sci Ctr,Reprod Endocrine, Boston, MA 02114 USA.
RP O'Malley, BW (reprint author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.
EM berto@bcm.edu
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD FEB 1
PY 2017
VL 102
IS 2
BP 337
EP 338
DI 10.1210/jc.2016-3896
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EP2VE
UT WOS:000397240900001
ER
PT J
AU Ordonez-Mena, JM
Maalmi, H
Schottker, B
Saum, KU
Holleczek, B
Wang, TJ
Burwinkel, B
Brenner, H
AF Ordonez-Mena, Jose Manuel
Maalmi, Haifa
Schoettker, Ben
Saum, Kai-Uwe
Holleczek, Bernd
Wang, Thomas J.
Burwinkel, Barbara
Brenner, Hermann
TI Genetic Variants in the Vitamin D Pathway, 25( OH) D Levels, and
Mortality in a Large Population-Based Cohort Study
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID 25-HYDROXYVITAMIN D CONCENTRATIONS; GENOME-WIDE ASSOCIATION; MENDELIAN
RANDOMIZATION; PARATHYROID-HORMONE; ALL-CAUSE; HEALTH; METAANALYSIS;
DISEASE; OUTCOMES; GERMANY
AB Context: Low 25-hydroxyvitamin D[25(OH) D] concentrations have been consistently associated with excess mortality in epidemiological studies, but this association could be due to confounding by health impairments associated with low 25(OH) D levels. An association of vitamin D-related genetic variants with all-cause mortality could strengthen the claims of causality, because this association is assumed to be unaffected by confounding.
Objective: To assess the associations of low 25(OH) D with mortality in the presence or absence of genetic variants in the vitamin D pathway.
Design, Setting, and Participants: The study consisted of a population-based cohort of 8417 German older adults in whom genetic variants were genotyped.
Main Outcome Measures: The primary outcome measure was all-cause mortality.
Results: Two single nucleotide polymorphisms (SNPs), rs3755967 (GC) and rs11603330 (DHCR7), were associated with higher risk of low vitamin D status [odds ratio (95% confidence interval) per minor allele, 1.27 (1.18 to 1.36) and 1.16 (1.08 to 1.25), respectively]. Low 25(OH) D (less than the seasonspecific 33rd percentile) was associated with increased mortality. However, none of the SNPs was associated with increased mortality. Furthermore, the increase in mortality for those with low 25(OH) D was generally smaller in the presence of the risk alleles for low 25(OH) D ["genetically low 25(OH) D"] than in the absence of those risk alleles ["otherwise low 25(OH) D"].
Conclusions: Although we may have been limited by a low statistical power to detect small associations, our study showed that the strong relationship between low 25(OH) D and increased mortality may be at least partly due to other factors related to low 25(OH) D levels.
C1 [Ordonez-Mena, Jose Manuel; Maalmi, Haifa; Schoettker, Ben; Saum, Kai-Uwe; Brenner, Hermann] Div Clin Epidemiol & Aging Res, Heidelberg, Germany.
[Burwinkel, Barbara] German Canc Res Ctr, Mol Epidemiol, D-69120 Heidelberg, Germany.
[Ordonez-Mena, Jose Manuel; Maalmi, Haifa; Schoettker, Ben; Brenner, Hermann] Heidelberg Univ, Network Aging Res, D-69115 Heidelberg, Germany.
[Ordonez-Mena, Jose Manuel] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6GG, England.
[Holleczek, Bernd] Saarland Canc Registry, Saarbrucken 66119, Germany.
[Wang, Thomas J.] Harvard Med Sch, Massachusetts Gen Hosp, Cardiovascular Res Ctr, Boston, MA 02114 USA.
[Burwinkel, Barbara] Heidelberg Univ, Dept Gynecol & Obstet, Mol Biol Breast Canc, D-69120 Heidelberg, Germany.
RP Brenner, H (reprint author), Div Clin Epidemiol & Aging Res, Heidelberg, Germany.; Brenner, H (reprint author), Heidelberg Univ, Network Aging Res, D-69115 Heidelberg, Germany.
EM h.brenner@dkfz.de
FU Baden-Wurttemberg state Ministry of Science, Research and Arts
(Stuttgart, Germany); Federal Ministry of Education and Research
(Berlin, Germany); Federal Ministry of Family Affairs, Senior Citizens,
Women and Youth (Berlin, Germany); German Cancer Aid [108250, 108426]
FX The ESTHER study was funded by the Baden-Wurttemberg state Ministry of
Science, Research and Arts (Stuttgart, Germany), the Federal Ministry of
Education and Research (Berlin, Germany), and the Federal Ministry of
Family Affairs, Senior Citizens, Women and Youth (Berlin, Germany).
Measurements of 25(OH)D in men were conducted in the context of the
German Cancer Aid projects no. 108250 and 108426.
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD FEB 1
PY 2017
VL 102
IS 2
BP 470
EP 477
DI 10.1210/jc.2016-2468
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EP2VE
UT WOS:000397240900019
PM 27732326
ER
PT J
AU Anderson, JG
Hundt, E
Dean, M
Keim-Malpass, J
Lopez, RP
AF Anderson, Joel G.
Hundt, Elizabeth
Dean, Morgan
Keim-Malpass, Jessica
Lopez, Ruth Palan
TI "The Church of Online Support": Examining the Use of Blogs Among Family
Caregivers of Persons With Dementia
SO JOURNAL OF FAMILY NURSING
LA English
DT Article
DE family caregivers; dementia; blog; social media
ID DISEASE CLINICAL-TRIAL; ILLNESS BLOGS; SOCIAL MEDIA; HEALTH INFORMATION;
INTERNET USE; COMMUNICATION; CANCER; COMMUNITIES; NARRATIVES; CARE
AB Many individuals, including dementia caregivers, use blogs to share their experiences. These blogs contain rich narratives representing an untapped resource for understanding the psychosocial impact of caring for a person with dementia at the family level. The present study used blogs written by caregivers of persons with dementia to explore how these individuals leveraged this medium as part of the caregiving experience. Blogs written by self-identified informal caregivers of persons with dementia were identified using a systematic search method, and data were analyzed using a qualitative thematic analysis. Four themes emerged from the narratives: social support through communication and engagement, information gathering and seeking, reminiscing and legacy building, and altruism. By understanding the ways in which individuals providing care for persons with dementia use social media as part of the caregiving experience, family nurses can develop interventions and services aimed at improving caregiver burden and quality of life.
C1 [Anderson, Joel G.] Univ Tennessee, Coll Nursing, 1200 Volunteer Blvd,Room 153, Knoxville, TN 37996 USA.
[Hundt, Elizabeth; Dean, Morgan; Keim-Malpass, Jessica] Univ Virginia, Sch Nursing, Charlottesville, VA 22903 USA.
[Lopez, Ruth Palan] Massachusetts Gen Hosp, Inst Hlth Profess, Charlestown, MA USA.
RP Anderson, JG (reprint author), Univ Tennessee, Coll Nursing, 1200 Volunteer Blvd,Room 153, Knoxville, TN 37996 USA.
EM jande147@utk.edu
NR 67
TC 2
Z9 2
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1074-8407
EI 1552-549X
J9 J FAM NURS
JI J. Fam. Nurs.
PD FEB
PY 2017
VL 23
IS 1
BP 34
EP 54
DI 10.1177/1074840716681289
PG 21
WC Family Studies; Nursing
SC Family Studies; Nursing
GA EP2KG
UT WOS:000397211300003
ER
PT J
AU McFarland, EJ
Powell, TM
Onyango-Makumbi, C
Zhang, WM
Melander, K
Naluyima, P
Okurut, S
Eller, MA
Fowler, MG
Janoff, EN
AF McFarland, Elizabeth J.
Powell, Tina M.
Onyango-Makumbi, Carolyne
Zhang, Weiming
Melander, Kelsey
Naluyima, Prossy
Okurut, Samuel
Eller, Michael A.
Fowler, Mary Glenn
Janoff, Edward N.
TI Ontogeny of CD4(+) T Lymphocytes With Phenotypic Susceptibility to HIV-1
During Exclusive and Nonexclusive Breastfeeding in HIV-1-Exposed Ugandan
Infants
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1; breastfeeding; postnatal transmission; CD4+T lymphocytes;
lymphocyte activation; T cell homing; CCR5; alpha 4 beta 7.
ID ACUTE CYTOMEGALOVIRUS-INFECTION; UNINFECTED CHILDREN BORN; INTEGRIN
ALPHA(4)BETA(7); IMMUNODEFICIENCY-VIRUS; TRANSMISSION; CELLS; MOTHER;
EXPRESSION; MUCOSAL; GUT
AB Background. Among infants exposed to human immunodeficiency virus (HIV) type 1, mixed breastfeeding is associated with higher postnatal HIV-1 transmission than exclusive breastfeeding, but the mechanisms of this differential risk are uncertain.
Methods. HIV-1-exposed Ugandan infants were prospectively assessed during the first year of life for feeding practices and T-cell maturation, intestinal homing (beta 7(hi)), activation, and HIV-1 coreceptor (CCR5) expression in peripheral blood. Infants receiving only breast milk and those with introduction of other foods before 6 months were categorized as exclusive and nonexclusive, respectively.
Results. Among CD4(+) and CD8(+) T cells, the expression of memory, activation, and CCR5 markers increased rapidly from birth to week 2, peaking at week 6, whereas cells expressing the intestinal homing marker increased steadily in the central memory ( CM) and effector memory T cells over 48 weeks. At 24 weeks, when feeding practices had diverged, nonexclusively breastfed infants showed increased frequencies and absolute counts of beta 7(hi) CM CD4+ and CD8+ T cells, including the HIV-1-targeted cells with CD4(+)beta 7(hi)/CCR5(+) coexpression, as well as increased activation.
Conclusions. The T-cell phenotype associated with susceptibility to HIV-1 infection (CCR5(+), gut-homing, CM CD4+ T cells) was preferentially expressed in nonexclusively breastfed infants, a group of infants at increased risk for HIV-1 acquisition.
C1 [McFarland, Elizabeth J.; Powell, Tina M.] Univ Colorado Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Pediat, Aurora, CO USA.
[Melander, Kelsey; Janoff, Edward N.] Univ Colorado Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Med, Aurora, CO USA.
[Zhang, Weiming] Univ Colorado Anschutz Med Campus, Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
[McFarland, Elizabeth J.; Janoff, Edward N.] Univ Colorado Anschutz Med Campus, Mucosal & Vaccine Res Program Colorado Infect Dis, Aurora, CO USA.
[Janoff, Edward N.] Denver Vet Affairs Med Ctr, Denver, CO USA.
[Eller, Michael A.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD USA.
[Eller, Michael A.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA.
[Fowler, Mary Glenn] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Onyango-Makumbi, Carolyne; Fowler, Mary Glenn] Makerere Univ, Johns Hopkins Univ Res Collaborat, Kampala, Uganda.
[Naluyima, Prossy; Okurut, Samuel] Makerere Univ Walter Reed Project, Kampala, Uganda.
RP McFarland, EJ (reprint author), Univ Colorado, Childrens Hosp Colorado, Div Pediat Infect Dis, Anschutz Med Campus,13123 E 16th Ave, Aurora, CO 80045 USA.
EM betsy.mcfarland@ucdenver.edu
NR 49
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD FEB 1
PY 2017
VL 215
IS 3
BP 368
EP 377
DI 10.1093/infdis/jiw553
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA EP2HT
UT WOS:000397204700006
PM 27932619
ER
PT J
AU Neelamegam, R
Yokell, DL
Rice, PA
Furumoto, S
Kudo, Y
Okamura, N
El Fakhri, G
AF Neelamegam, Ramesh
Yokell, Daniel L.
Rice, Peter A.
Furumoto, Shozo
Kudo, Yukitsuka
Okamura, Nobuyuki
El Fakhri, Georges
TI A report of the automated radiosynthesis of the tau positron emission
tomography radiopharmaceutical, [(18F)]-THK-5351
SO JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS
LA English
DT Article
DE fluorine-18; PET; Tau; THK-5351
ID ALZHEIMERS-DISEASE; NEUROFIBRILLARY PATHOLOGY; IMAGING TRACERS; PET
TRACER; DERIVATIVES; LANSOPRAZOLE; RADIOLIGAND; ASTEMIZOLE; TANGLES;
T807
AB The radiotracer, [F-18]-THK-5351, is a highly selective and high-binding affinity PET imaging agent for aggregates of hyper-phosphorylated tau protein. Our report is a simplified 1-pot, 2-step radiosynthesis of [F-18]-THK-5351. This report is broadly applicable for routine clinical production and multi-center trials on account of favorable half-life of flourine-18 and the use of a commercially available radiosynthesis module, the GE TRACERlab T FXFN. First, the O-THP protected tosyl precursor underwent nucleophilic fluorinating reaction with potassium cryptand fluoride ([F-18] fluoride (K[F-18]/K222)) in Dimethyl sulfoxide at 110 degrees C for 10 minutes followed by O-THP removal by using diluted hydrochloric acid (HCl) at same temperature. [F-18]-THK-5351 was purified via semi-preparative high-performance liquid chromatography and formulated by using 10% EtOH, United States Pharmacopeia (USP) in 0.9% sodium chloride for injection, USP and an uncorrected radiochemical yield of 21 +/- 3.5%, with a specific activity of 153.11 +/- 25.9 GBq/mu mol (4138 +/- 700 mCi/mu mol) at the end of synthesis (63 minutes; n = 3).
C1 [Neelamegam, Ramesh; Yokell, Daniel L.; Rice, Peter A.; El Fakhri, Georges] Massachusetts Gen Hosp, Dept Radiol, Gordon Ctr Med Imaging, Boston, MA USA.
[Neelamegam, Ramesh; Yokell, Daniel L.; El Fakhri, Georges] Harvard Med Sch, Dept Radiol, Boston, MA USA.
[Furumoto, Shozo] Tohoku Univ, Div Radiopharmaceut Chem, Ctr Cyclotron & Radioisotope, Sendai, Miyagi, Japan.
[Kudo, Yukitsuka] Tohoku Univ, Div Neuroimaging, Inst Dev Aging & Canc, Sendai, Miyagi, Japan.
[Okamura, Nobuyuki] Tohoku Med & Pharmaceut Univ, Div Pharmacol, Fac Med, Sendai, Miyagi, Japan.
RP Yokell, DL (reprint author), Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Dept Radiol, 55 Fruit St,Edwards 019B, Boston, MA 02114 USA.
EM dyokell@mgh.harvard.edu
NR 34
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0362-4803
EI 1099-1344
J9 J LABELLED COMPD RAD
JI J. Label. Compd. Radiopharm.
PD FEB
PY 2017
VL 60
IS 2
BP 140
EP 146
DI 10.1002/jlcr.3482
PG 7
WC Biochemical Research Methods; Chemistry, Medicinal; Chemistry,
Analytical
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA EO9RC
UT WOS:000397024800007
PM 27859483
ER
PT J
AU Kesler, SR
Noll, K
Cahill, DP
Rao, G
Wefel, JS
AF Kesler, Shelli R.
Noll, Kyle
Cahill, Daniel P.
Rao, Ganesh
Wefel, Jeffrey S.
TI The effect of IDH1 mutation on the structural connectome in malignant
astrocytoma
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE IDH1; Astrocytoma; Connectome; Cognition; MRI
ID DEFAULT MODE NETWORK; COGNITIVE RESERVE; BREAST-CANCER; GRAY-MATTER;
BRAIN NETWORKS; RANDOM FORESTS; NORMATIVE DATA; GLIOMAS; AGE;
CLASSIFICATION
AB Mutation of the IDH1 gene is associated with differences in malignant astrocytoma growth characteristics that impact phenotypic severity, including cognitive impairment. We previously demonstrated greater cognitive impairment in patients with IDH1 wild type tumor compared to those with IDH1 mutant, and therefore we hypothesized that brain network organization would be lower in patients with wild type tumors. Volumetric, T1-weighted MRI scans were obtained retrospectively from 35 patients with IDH1 mutant and 32 patients with wild type malignant astrocytoma (mean age = 45 +/- 14 years) and used to extract individual level, gray matter connectomes. Graph theoretical analysis was then applied to measure efficiency and other connectome properties for each patient. Cognitive performance was categorized as impaired or not and random forest classification was used to explore factors associated with cognitive impairment. Patients with wild type tumor demonstrated significantly lower network efficiency in several medial frontal, posterior parietal and subcortical regions (p < 0.05, corrected for multiple comparisons). Patients with wild type tumor also demonstrated significantly higher incidence of cognitive impairment (p = 0.03). Random forest analysis indicated that network efficiency was inversely, though nonlinearly associated with cognitive impairment in both groups (p < 0.0001). Cognitive reserve appeared to mediate this relationship in patients with mutant tumor suggesting greater neuroplasticity and/or benefit from neuroprotective factors. Tumor volume was the greatest contributor to cognitive impairment in patients with wild type tumor, supporting our hypothesis that greater lesion momentum between grades may cause more disconnection of core neurocircuitry and consequently lower efficiency of information processing.
C1 [Kesler, Shelli R.; Noll, Kyle; Wefel, Jeffrey S.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, 1515 Holcombe Blvd,Unit 431, Houston, TX 77030 USA.
[Cahill, Daniel P.] Massachusetts Gen Hosp, Dept Neurosurg, Harvard Neurosurg Serv, Boston, MA 02114 USA.
[Rao, Ganesh] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA.
RP Kesler, SR (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, 1515 Holcombe Blvd,Unit 431, Houston, TX 77030 USA.
EM skesler@mdanderson.org
FU National Institutes of Health [1R01CA172145, 1R03CA191559, 1R01NR014195,
K08NS070928]
FX This work was supported by grants from the National Institutes of Health
(1R01CA172145 to S.R.K, 1R03CA191559 to S.R.K, 1R01NR014195 to
J.S.W./S.R.K. and K08NS070928 to G.R.).
NR 72
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD FEB
PY 2017
VL 131
IS 3
BP 565
EP 574
DI 10.1007/s11060-016-2328-1
PG 10
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA EP4CV
UT WOS:000397329100015
PM 27848136
ER
PT J
AU Kalpathy-Cramer, J
Chandra, V
Da, X
Ou, YM
Emblem, KE
Muzikansky, A
Cai, XZ
Douw, L
Evans, JG
Dietrich, J
Chi, AS
Wen, PY
Stufflebeam, S
Rosen, B
Duda, DG
Jain, RK
Batchelor, TT
Gerstner, ER
AF Kalpathy-Cramer, Jayashree
Chandra, Vyshak
Da, Xiao
Ou, Yangming
Emblem, Kyrre E.
Muzikansky, Alona
Cai, Xuezhu
Douw, Linda
Evans, John G.
Dietrich, Jorg
Chi, Andrew S.
Wen, Patrick Y.
Stufflebeam, Stephen
Rosen, Bruce
Duda, Dan G.
Jain, Rakesh K.
Batchelor, Tracy T.
Gerstner, Elizabeth R.
TI Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with
recurrent glioblastoma
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE Glioblastoma; Anti-angiogenesis; MRI; Progression-free survival; Overall
survival; Tivozanib
ID ENDOTHELIAL GROWTH-FACTOR; KINASE INHIBITOR; SOLID TUMORS; ANGIOGENESIS;
SURVIVAL; BRAIN; CEDIRANIB; BIOMARKER; NETWORK; GLIOMAS
AB Targeting tumor angiogenesis is a potential therapeutic strategy for glioblastoma because of its high vascularization. Tivozanib is an oral pan-VEGF receptor tyrosine kinase inhibitor that hits a central pathway in glioblastoma angiogenesis. We conducted a phase II study to test the effectiveness of tivozanib in patients with recurrent glioblastoma. Ten adult patients were enrolled and treated with tivozanib 1.5 mg daily, 3 weeks on/1 week off in 28-day cycles. Brain MRI and blood biomarkers of angiogenesis were performed at baseline, within 24-72 h of treatment initiation, and monthly thereafter. Dynamic contrast enhanced MRI, dynamic susceptibility contrast MRI, and vessel architecture imaging were used to assess vascular effects. Resting state MRI was used to assess brain connectivity. Best RANO criteria responses were: 1 complete response, 1 partial response, 4 stable diseases, and 4 progressive disease (PD). Two patients were taken off study for toxicity and 8 patients were taken off study for PD. Median progression-free survival was 2.3 months and median overall survival was 8.1 months. Baseline abnormal tumor vascular permeability, blood flow, tissue oxygenation and plasma sVEGFR2 significantly decreased and plasma PlGF and VEGF increased after treatment, suggesting an anti-angiogenic effect of tivozanib. However, there were no clear structural changes in vasculature as vessel caliber and enhancing tumor volume did not significantly change. Despite functional changes in tumor vasculature, tivozanib had limited anti-tumor activity, highlighting the limitations of anti-VEGF monotherapy. Future studies in glioblastoma should leverage the anti-vascular activity of agents targeting VEGF to enhance the activity of other therapies.
C1 [Kalpathy-Cramer, Jayashree; Chandra, Vyshak; Da, Xiao; Ou, Yangming; Emblem, Kyrre E.; Cai, Xuezhu; Douw, Linda; Evans, John G.; Stufflebeam, Stephen; Rosen, Bruce] Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Muzikansky, Alona; Dietrich, Jorg; Duda, Dan G.; Jain, Rakesh K.; Batchelor, Tracy T.; Gerstner, Elizabeth R.] Massachusetts Gen Hosp, Ctr Canc, Stephen E & Catherine Pappas Ctr Neurooncol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA.
[Emblem, Kyrre E.] Oslo Univ Hosp, Intervent Ctr, Oslo, Norway.
[Douw, Linda] Vrije Univ Amsterdam Med Ctr, VUmc CCA Brain Tumor Ctr Amsterdam, Dept Anat & Neurosci, Amsterdam, Netherlands.
[Wen, Patrick Y.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chi, Andrew S.] NYU, Laura & Isaac Perlmutter Canc Ctr, Langone Med Ctr, New York, NY USA.
RP Gerstner, ER (reprint author), Massachusetts Gen Hosp, Ctr Canc, Stephen E & Catherine Pappas Ctr Neurooncol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA.
EM egerstner@partners.org
FU National Comprehensive Cancer Network (NCCN) Oncology Research Program
from AVEO Pharmaceuticals, Inc.; National Cancer Institute [P01CA80124];
National Foundation for Cancer Research; [U24CA180918]; [U01CA154601];
[S10RR023043]; [P41RR14075]
FX This study was approved and funded by the National Comprehensive Cancer
Network (NCCN) Oncology Research Program from general research support
provided by AVEO Pharmaceuticals, Inc. (to E.G.). The research of R.K.J.
and D.G.D. is funded by National Cancer Institute Grant P01CA80124 and
the National Foundation for Cancer Research. Funding was also provided
by U24CA180918 and U01CA154601 (to J.K.C.) and S10RR023043 and
P41RR14075.
NR 33
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD FEB
PY 2017
VL 131
IS 3
BP 603
EP 610
DI 10.1007/s11060-016-2332-5
PG 8
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA EP4CV
UT WOS:000397329100019
PM 27853960
ER
PT J
AU Pardeshi, NN
Qi, W
Dahl, K
Caplan, L
Carpenter, JF
AF Pardeshi, Neha N.
Qi, Wei
Dahl, Kevin
Caplan, Liron
Carpenter, John F.
TI Microparticles and Nanoparticles Delivered in Intravenous Saline and in
an Intravenous Solution of a Therapeutic Antibody Product
SO JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE protein aggregation; microparticles; nanoparticles; IgG antibody;
protein delivery; adsorption; particle size
ID POLYVINYL-CHLORIDE BAGS; MONOCLONAL-ANTIBODY; PROTEIN AGGREGATION;
GROWTH-HORMONE; FACTOR-VIII; PARTICLES; STABILITY; INFUSION; MICE;
IMMUNOGENICITY
AB Intravenous ( IV) infusion is used for administration of a large proportion of biologic therapeutics, including most monoclonal antibody products. In this study, we determined the subvisible particle levels in IV solutions and after the solutions were processed with an IV administration setup that mimicked the typical clinical method of administration. IV saline in bags manufactured by both Hospira and Baxter contained 1600-8000 microparticles/mL and 4-73 x 10(6) nanoparticles/mL in solution. When IV immunoglobulin was diluted into the IV saline, 3700-23,000 microparticles/mL and 18-240 x 10(6) nanoparticles/mL were detected. During processing of the solution through the IV system, in-line filters removed most microparticles. However, there were still 1-21 x 10(6) nanoparticles/mL in IV saline and 7-83 x 10(6) nanoparticles/mL in IV immunoglobulin diluted in saline. Finally, in samples processed through in-line filters, we found relatively large microparticles ( 20-60 mm) that were composed of protein or polycarbonate. These particles resulted from shedding of polycarbonate and sloughing off of protein films downstream from the filter membrane. Overall, the results document that even with in-line filters in place, high levels of subvisible particles are delivered to patients and there is a need for improved, more effective filters and IV solutions with lower particle levels. (C) 2017 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
C1 [Pardeshi, Neha N.; Carpenter, John F.] Univ Colorado, Sch Pharm, Dept Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80045 USA.
[Qi, Wei; Dahl, Kevin] Malvern Instruments, Columbia, MD 21046 USA.
[Caplan, Liron] Univ Colorado, Denver Vet Affairs Hosp, Rheumatol Sect, Aurora, CO 80045 USA.
[Caplan, Liron] Univ Colorado, Sch Med, Aurora, CO 80045 USA.
RP Carpenter, JF (reprint author), Univ Colorado, Sch Pharm, Dept Pharmaceut Sci, Anschutz Med Campus, Aurora, CO 80045 USA.
EM john.carpenter@ucdenver.edu
FU NIH [5RO1 EB006006]
FX The authors would like to thank Beth Moran, RN, and Mary Cousins, RN,
for expert advice about the clinical practices for preparation and IV
infusion of therapeutic proteins and for their help in replicating the
IV infusion system in the laboratory. We gratefully acknowledge support
from NIH Grant 5RO1 EB006006.
NR 30
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3549
EI 1520-6017
J9 J PHARM SCI-US
JI J. Pharm. Sci.
PD FEB
PY 2017
VL 106
IS 2
BP 511
EP 520
DI 10.1016/j.xphs.2016.09.028
PG 10
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
Pharmacy
SC Pharmacology & Pharmacy; Chemistry
GA EP3KE
UT WOS:000397280400008
PM 27832839
ER
PT J
AU Murillo, R
Lambiase, MJ
Rockette-Wagner, BJ
Kriska, AM
Halbach, JP
Thurston, RC
AF Murillo, Rosenda
Lambiase, Maya J.
Rockette-Wagner, Bonny J.
Kriska, Andrea M.
Halbach, Jeffrey P.
Thurston, Rebecca C.
TI Racial/Ethnic Differences in the Associations Between Physical Activity
and Sleep Duration: A Population-Based Study
SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH
LA English
DT Article
DE health disparities; exercise; epidemiology
ID HEALTH DISPARITIES; MIDLIFE WOMEN; LEISURE-TIME; WORK; METAANALYSIS;
EXERCISE
AB Background: This study examined associations between physical activity (recreational, nonrecreational) and sleep duration among a nationally representative diverse sample of U.S. adults. Methods: We used cross-sectional data from 9,205 National Health and Nutrition Examination Survey 2007 to 2012 participants aged 20 to 65 years who identified as White, Black, or Hispanic. Activity (ie, recreation, occupation, and transportation activity) was categorized into quartiles. Sleep duration was categorized as short (56 hours/night) or normal (>6 to 59 hours/night). Logistic regression was used to estimate associations of activity with sleep duration. Results: Recommended levels of recreation activity and moderate levels of transportation activity were associated with normal sleep duration [Odds Ratio (OR): = 1.33, 95% Confidence Interval (CI) = 1.08, 1.65; OR = 1.28, 95% CI = 1.02, 1.62, respectively]. High occupation physical activity was associated with shorter sleep duration (OR = 0.59, 95% CI = 0:49, 0.71). Differences were observed by race/ethnicity in associations of recreation and occupation activity with sleep duration. Conclusions: White individuals who engaged in some recreation activity, relative to being inactive, had more favorable sleep duration; whereas, high levels of occupation activity were associated with worse sleep duration among White and Black individuals. Physical activity was not associated with sleep duration among Hispanics.
C1 [Murillo, Rosenda] Univ Houston, Dept Psychol Hlth & Learning Sci, Houston, TX 77004 USA.
[Lambiase, Maya J.] VA Pittsburgh Healthcare Syst, Dept Vet Affairs, Pittsburgh, PA USA.
[Rockette-Wagner, Bonny J.; Kriska, Andrea M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA.
[Halbach, Jeffrey P.] US Dept Vet Affairs, Hlth Serv Res & Dev, Washington, DC USA.
[Thurston, Rebecca C.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
RP Murillo, R (reprint author), Univ Houston, Dept Psychol Hlth & Learning Sci, Houston, TX 77004 USA.
EM rmurillo3@uh.edu
FU Department of Veterans Affairs Advanced Fellowship in Women's Health, VA
Pittsburgh Healthcare System
FX This work was supported by resources and funding from the Department of
Veterans Affairs Advanced Fellowship in Women's Health, VA Pittsburgh
Healthcare System. The contents do not represent the views of the
Department of Veterans Affairs, Department of Defense, or the United
States Government.
NR 36
TC 0
Z9 0
U1 0
U2 0
PU HUMAN KINETICS PUBL INC
PI CHAMPAIGN
PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA
SN 1543-3080
EI 1543-5474
J9 J PHYS ACT HEALTH
JI J. Phys. Act. Health
PD FEB
PY 2017
VL 14
IS 2
BP 138
EP 144
DI 10.1123/jpah.2015-0638
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EO8UB
UT WOS:000396964900009
PM 27918684
ER
PT J
AU Jassar, AS
Kim, JB
Sundt, TM
AF Jassar, Arminder S.
Kim, Joon Bum
Sundt, Thoralf M.
TI THE MORE I LEARN THE LESS I KNOW
SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
LA English
DT Letter
ID AORTIC-VALVE; ENDOCARDITIS; REPLACEMENT
C1 [Jassar, Arminder S.; Kim, Joon Bum; Sundt, Thoralf M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Jassar, AS (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5223
EI 1097-685X
J9 J THORAC CARDIOV SUR
JI J. Thorac. Cardiovasc. Surg.
PD FEB
PY 2017
VL 153
IS 2
BP 282
EP 283
DI 10.1016/j.jtcvs.2016.09.056
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA EO7TY
UT WOS:000396894200035
PM 28104193
ER
PT J
AU Roshanravan, B
Patel, KV
Fried, LF
Robinson-Cohen, C
de Boer, IH
Harris, T
Murphy, RA
Satterfield, S
Goodpaster, BH
Shlipak, M
Newman, AB
Kestenbaum, B
AF Roshanravan, Baback
Patel, Kushang V.
Fried, Linda F.
Robinson-Cohen, Cassianne
de Boer, Ian H.
Harris, Tamara
Murphy, Rachel A.
Satterfield, Suzanne
Goodpaster, Bret H.
Shlipak, Michael
Newman, Anne B.
Kestenbaum, Bryan
CA Hlth ABC Study
TI Association of Muscle Endurance, Fatigability, and Strength With
Functional Limitation and Mortality in the Health Aging and Body
Composition Study
SO JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL
SCIENCES
LA English
DT Article
DE Mobility; Muscle; Fatigue; Strength; Sarcopenia
ID CHRONIC KIDNEY-DISEASE; OLDER-ADULTS; WALKING SPEED; MOBILITY
DISABILITY; CYSTATIN C; GAIT SPEED; FRAILTY; PREVALENCE; CREATININE;
INCHIANTI
AB Background: Mobility limitation is highly prevalent among older adults and is central to the loss of functional independence. Dynamic isokinetic muscle fatigue testing may reveal increased vulnerability to disability and mortality beyond strength testing.
Methods: We studied community-dwelling older adults enrolled in the Health Aging and Body Composition study (age range: 71-82) free of mobility disability and who underwent isokinetic muscle fatigue testing in 1999-2000 (n = 1,963). Isokinetic quadriceps work and fatigue index was determined over 30 repetitions and compared with isometric quadriceps maximum torque. Work was normalized to leg lean mass accounting for gender-specific differences (specific work). The primary outcome was incident persistent severe lower extremity limitation (PSLL), defined as two consecutive reports of either having a lot of difficulty or being unable to walk 1/4 mile or climb 10 steps without resting. The secondary outcome was all-cause mortality.
Results: There were 608 (31%) occurrences of incident PSLL and 488 (25%) deaths during median follow-up of 9.3 years. After adjustment, lower isokinetic work was associated with significantly greater risks of PSLL and mortality across the full measured range. Hazard ratios per standard deviation lower specific isokinetic work were 1.22 (95% CI 1.12, 1.33) for PSLL and 1.21 (95% CI 1.13, 1.30) for mortality, respectively. Lower isometric strength was associated with PSLL, but not mortality. Fatigue index was not associated with PSLL or mortality.
Conclusions: Muscle endurance, estimated by isokinetic work, is an indicator of muscle health associated with mobility limitation and mortality providing important insight beyond strength testing.
C1 [Roshanravan, Baback; Robinson-Cohen, Cassianne; de Boer, Ian H.; Kestenbaum, Bryan] Univ Washington, Dept Med, Div Nephrol, Kidney Res Inst, 325 9th Ave,Room 3NJ350,Box 359606, Seattle, WA 98104 USA.
[Patel, Kushang V.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.
[Fried, Linda F.] Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA.
[Harris, Tamara] NIA, Lab Epidemiol & Populat Sci, Bethesda, MD 20892 USA.
[Murphy, Rachel A.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.
[Satterfield, Suzanne] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA.
[Goodpaster, Bret H.] Florida Hosp, Orlando, FL USA.
[Goodpaster, Bret H.] Sanford Burnham Presbys Translat Res Inst Metab &, Orlando, FL USA.
[Shlipak, Michael] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA.
[Newman, Anne B.] Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA 15260 USA.
RP Roshanravan, B (reprint author), Univ Washington, Dept Med, Div Nephrol, Kidney Res Inst, 325 9th Ave,Room 3NJ350,Box 359606, Seattle, WA 98104 USA.
EM broshanr@uw.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
[K23-DK099442]; National Institute on Aging (NIA) [N01-AG-6-2101,
N01-AG-6-2103, N01-AG-6-2106]; NIA [R01-AG028050]; NINR [R01-NR012459];
NIH, National Institute on Aging; Northwest Kidney Centers
FX This research was supported by the National Institute of Diabetes and
Digestive and Kidney Diseases (K23-DK099442 to B.R.); National Institute
on Aging (NIA) Contracts N01-AG-6-2101, N01-AG-6-2103, and
N01-AG-6-2106; NIA grant R01-AG028050; and NINR grant R01-NR012459. This
research was supported in part by the Intramural Research Program of the
NIH, National Institute on Aging. This work was also supported by an
unrestricted fund from the Northwest Kidney Centers (B.R.).
NR 30
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-5006
EI 1758-535X
J9 J GERONTOL A-BIOL
JI J. Gerontol. Ser. A-Biol. Sci. Med. Sci.
PD FEB
PY 2017
VL 72
IS 2
BP 284
EP 291
DI 10.1093/gerona/glw210
PG 8
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA EP2EC
UT WOS:000397194800019
PM 27907890
ER
PT J
AU Sigel, K
Wisnivesky, J
Crothers, K
Gordon, K
Brown, ST
Rimland, D
Rodriguez-Barradas, MC
Gibert, C
Goetz, MB
Bedimo, R
Park, LS
Dubrow, R
AF Sigel, Keith
Wisnivesky, Juan
Crothers, Kristina
Gordon, Kirsha
Brown, Sheldon T.
Rimland, David
Rodriguez-Barradas, Maria C.
Gibert, Cynthia
Goetz, Matthew Bidwell
Bedimo, Roger
Park, Lesley S.
Dubrow, Robert
TI Immunological and infectious risk factors for lung cancer in US veterans
with HIV: a longitudinal cohort study
SO LANCET HIV
LA English
DT Article
ID CIGARETTE-SMOKING; UNITED-STATES; ANTIRETROVIRAL THERAPY; CD4/CD8 RATIO;
AIDS; INDIVIDUALS; IMMUNODEFICIENCY; DISEASE; PEOPLE; PROGRESSION
AB Background HIV infection is independently associated with risk of lung cancer, but few data exist for the relation between longitudinal measurements of immune function and lung-cancer risk in people living with HIV.
Methods We followed up participants with HIV from the Veterans Aging Cohort Study for a minimum of 3 years between Jan 1, 1998, and Dec 31, 2012, and used cancer registry data to identify incident cases of lung cancer. The index date for each patient was the later of the date HIV care began or Jan 1, 1998. We excluded patients with less than 3 years' follow-up, prevalent diagnoses of lung cancer, or incomplete laboratory data. We used Cox regression models to investigate the relation between different time-updated lagged and cumulative exposures (CD4 cell count, CD8 cell count, CD4/CD8 ratio, HIV RNA, and bacterial pneumonia) and risk of lung cancer. Models were adjusted for age, race or ethnicity, smoking, hepatitis C virus infection, alcohol use disorders, drug use disorders, and history of chronic obstructive pulmonary disease and occupational lung disease.
Findings We identified 277 cases of incident lung cancer in 21 666 participants with HIV. In separate models for each time-updated 12 month lagged, 24 month simple moving average cumulative exposure, increased risk of lung cancer was associated with low CD4 cell count (p trend= 0.001), low CD4/CD8 ratio (p trend= 0.0001), high HIV RNA concentration (p=0.004), and more cumulative bacterial pneumonia episodes (12 month lag only; p trend= 0.0004). In a mutually adjusted model including these factors, CD4/CD8 ratio and cumulative bacterial pneumonia episodes remained significant (p trends 0.003 and 0.004, respectively).
Interpretation In our large HIV cohort in the antiretroviral therapy era, we found evidence that dysfunctional immune activation and chronic inflammation contribute to the development of lung cancer in the setting of HIV infection. These findings could be used to target lung-cancer prevention measures to high-risk groups.
C1 [Sigel, Keith; Wisnivesky, Juan; Brown, Sheldon T.] Icahn Sch Med Mt Sinai, Dept Med, 17 East 102nd St, New York, NY 10029 USA.
[Crothers, Kristina] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Gordon, Kirsha] VA Connecticut Healthcare Syst, Dept Med, New Haven, CT USA.
[Gordon, Kirsha] Yale Sch Med & Publ Hlth, New Haven, CT USA.
[Brown, Sheldon T.] James J Peters VA Med Ctr, Infect Dis Sect, Bronx, NY USA.
[Rimland, David] Atlanta VA Med Ctr, Infect Dis Sect, Decatur, GA USA.
[Rimland, David] Emory Univ, Sch Med, Decatur, GA 30033 USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Houston, TX 77030 USA.
[Gibert, Cynthia] George Washington Univ, Sch Med, Dept Med, Washington, DC USA.
[Gibert, Cynthia] Washington DC Vet Affairs Med Ctr, Washington, DC USA.
[Goetz, Matthew Bidwell] VA Los Greater Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Bedimo, Roger] VA North Texas Hlth Care Syst, Div Infect Dis, Dallas, TX USA.
[Park, Lesley S.] Stanford Univ, Sch Med, Ctr Populat Hlth Sci, Palo Alto, CA 94304 USA.
[Dubrow, Robert] Yale Sch Publ Hlth, Dept Chron Dis Epidemiol, New Haven, CT USA.
RP Sigel, K (reprint author), Icahn Sch Med Mt Sinai, Dept Med, 17 East 102nd St, New York, NY 10029 USA.
EM keith.sigel@mssm.edu
OI Sigel, Keith/0000-0002-4051-4861
FU US National Institutes of Health
FX US National Institutes of Health.
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD FEB
PY 2017
VL 4
IS 2
BP E67
EP E73
DI 10.1016/S2352-3018(16)30215-6
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA EP3EV
UT WOS:000397266500008
PM 27916584
ER
PT J
AU Spatz, JM
Ellman, R
Cloutier, AM
Louis, L
van Vliet, M
Dwyer, D
Stolina, M
Ke, HZ
Bouxsein, ML
AF Spatz, J. M.
Ellman, R.
Cloutier, A. M.
Louis, L.
van Vliet, M.
Dwyer, D.
Stolina, M.
Ke, H. Z.
Bouxsein, M. L.
TI Sclerostin antibody inhibits skeletal deterioration in mice exposed to
partial weight-bearing
SO LIFE SCIENCES IN SPACE RESEARCH
LA English
DT Article
DE Bone loss; Partial weight-bearing; Sclerostin antibody; Bone; Moon; Mars
ID INCREASES BONE-FORMATION; VAN-BUCHEM-DISEASE; SOST GENE; MINERAL
DENSITY; RAT MODEL; MASS; DELETION; OSTEOPOROSIS; POPULATION; DEFICIENCY
AB Whereas much is known regarding the musculoskeletal responses to full unloading, little is known about the physiological effects and response to pharmacological agents in partial unloading (e. g. Moon and Mars) environments. To address this, we used a previously developed ground-based model of partial weight-bearing (PWB) that allows chronic exposure to reduced weight-bearing in mice to determine the effects of murine sclerostin antibody (SclAbII) on bone microstructure and strength across different levels of mechanical unloading. We hypothesize that treatment with SclAbII would improve bone mass, microarchitecture and strength in all loading conditions, but that there would be a greater skeletal response in the normally loaded mice than in partially unloaded mice suggesting the importance of combined countermeasures for exploration-class long duration spaceflight missions. Eleven-week-old female mice were assigned to one of four loading groups: normal weight-bearing controls (CON) or weight-bearing at 20% (PWB20), 40% (PWB40) or 70% (PWB70) of normal. Mice in each group received either SclAbII (25 mg/kg) or vehicle (VEH) via twice weekly subcutaneous injection for 3 weeks. In partially-unloaded VEH-treated groups, leg BMD decreased -5 to -10% in a load-dependent manner. SclAbII treatment completely inhibited bone deterioration due to PWB, with bone properties in SclAbII-treated groups being equal to or greater than those of CON, VEH-treated mice. SclAbII treatment increased leg BMD from + 14 to + 18% in the PWB groups and 30 +/- 3% in CON (p < 0.0 0 01 for all). Trabecular bone volume, assessed by mu CT at the distal femur, was lower in all partially unloaded VEH-treated groups vs. CON-VEH (p < 0.05), and was 2-3 fold higher in SclAbII-treated groups (p < 0.001). Midshaft femoral strength was also significantly higher in SclAbII vs. VEH-groups in all-loading conditions. These results suggest that greater weight bearing leads to greater benefits of SclAbII on bone mass, particularly in the trabecular compartment. Altogether, these results demonstrate the efficacy of sclerostin antibody therapy in preventing astronaut bone loss during terrestrial solar system exploration. c 2017 The Committee on Space Research (COSPAR). Published by Elsevier Ltd. All rights reserved.
C1 [Spatz, J. M.; Ellman, R.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Spatz, J. M.; Ellman, R.; Cloutier, A. M.; Louis, L.; van Vliet, M.; Bouxsein, M. L.] Beth Israel Deaconess Med Ctr, Ctr Adv Orthoped Studies, Boston, MA 02215 USA.
[Spatz, J. M.; Bouxsein, M. L.] Massachusetts Gen Hosp, Div Endocrine, Boston, MA 02114 USA.
[Bouxsein, M. L.] Harvard Med Sch, Dept Orthopaed Surg, Boston, MA USA.
[Dwyer, D.; Stolina, M.] Amgen Inc, Thousand Oaks, CA USA.
[Ke, H. Z.] UCB Pharma, Bone Res, Slough, Berks, England.
RP Spatz, JM (reprint author), MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.; Spatz, JM (reprint author), Beth Israel Deaconess Med Ctr, Ctr Adv Orthoped Studies, Boston, MA 02215 USA.; Spatz, JM (reprint author), Massachusetts Gen Hosp, Div Endocrine, Boston, MA 02114 USA.
EM mbouxsei@bidmc.harvard.edu
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases of
the National Institutes of Health [R21 AR057522, S10RR017868]; NASA
[NNX10AE39G]; National Space Biomedical Research Institute through NASA
[NCC 9-58]; Amgen; NASA-Jenkins pre-doctoral fellowship; Northrop
Grumman Aerospace Systems
FX Research reported in this publication was supported by the National
Institute of Arthritis and Musculoskeletal and Skin Diseases of the
National Institutes of Health under Award Number R21 AR057522 and
S10RR017868. The work was also supported by NASA NNX10AE39G, the
National Space Biomedical Research Institute through NASA NCC 9-58, and
a research grant from Amgen. RE was supported by a NASA-Jenkins
pre-doctoral fellowship. JMS was supported by a Northrop Grumman
Aerospace Systems Ph.D. Training Fellowship and Hugh Hampton Young
Fellowship. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National
Institutes of Health.
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2214-5524
EI 2214-5532
J9 LIFE SCI SPACE RES
JI Life Sci. Space Res.
PD FEB
PY 2017
VL 12
BP 32
EP 38
DI 10.1016/j.lssr.2017.01.001
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EO9ZH
UT WOS:000397046100004
PM 28212706
ER
PT J
AU Ikeda, H
Souda, H
Puspitasari, A
Held, KD
Hidema, J
Nikawa, T
Yoshida, Y
Kanai, T
Takahashi, A
AF Ikeda, Hiroko
Souda, Hikaru
Puspitasari, Anggraeini
Held, Kathryn D.
Hidema, Jun
Nikawa, Takeshi
Yoshida, Yukari
Kanai, Tatsuaki
Takahashi, Akihisa
TI Development and performance evaluation of a three-dimensional clinostat
synchronized heavy-ion irradiation system
SO LIFE SCIENCES IN SPACE RESEARCH
LA English
DT Article
DE Microgravity; Three-dimensional clinostat; Space radiation; Heavy-ion;
Combined effects
ID DNA-DAMAGE; MICROGRAVITY; RADIATION; SPACEFLIGHT; REPAIR; SPACE; CELLS;
FIBROBLASTS
AB Outer space is an environment characterized by microgravity and space radiation, including high-energy charged particles. Astronauts are constantly exposed to both microgravity and radiation during long-term stays in space. However, many aspects of the biological effects of combined microgravity and space radiation remain unclear. We developed a new three-dimensional (3D) clinostat synchronized heavy-ion irradiation system for use in ground-based studies of the combined exposures. Our new system uses a particle accelerator and a respiratory gating system from heavy-ion radiotherapy to irradiate samples being rotated in the 3D clinostat with carbon-ion beams only when the samples are in the horizontal position. A Peltier module and special sample holder were loaded on a static stage (standing condition) and the 3D clinostat (rotation condition) to maintain a suitable temperature under atmospheric conditions. The performance of the new device was investigated with normal human fibroblasts 1BR-hTERT in a disposable closed cell culture chamber. Live imaging revealed that cellular adhesion and growth were almost the same for the standing control sample and rotation sample over 48 h. Dose flatness and symmetry were judged according to the relative density of Gafchromic films along the X-axis and Y-axis of the positions of the irradiated sample to confirm irradiation accuracy. Doses calculated using the carbon-ion calibration curve were almost the same for standing and rotation conditions, with the difference being less than 5% at 1 Gy carbon-ion irradiation. Our new device can accurately synchronize carbon-ion irradiation and simulated microgravity while maintaining the temperature under atmospheric conditions at ground level. (C) 2017 Published by Elsevier Ltd on behalf of The Committee on Space Research (COSPAR).
C1 [Ikeda, Hiroko; Souda, Hikaru; Yoshida, Yukari; Kanai, Tatsuaki; Takahashi, Akihisa] Gunma Univ, Heavy Ion Med Ctr, Maebashi, Gunma 3718511, Japan.
[Puspitasari, Anggraeini; Held, Kathryn D.] Gunma Univ, Initiat Adv Res, Maebashi, Gunma 3718511, Japan.
[Held, Kathryn D.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Hidema, Jun] Tohoku Univ, Grad Sch Life Sci, Dept Environm Life Sci, Sendai, Miyagi 9808577, Japan.
[Nikawa, Takeshi] Univ Tokushima, Grad Sch, Inst Med Nutr, Dept Nutr Physiol, Tokushima, Tokushima 7708503, Japan.
RP Takahashi, A (reprint author), Gunma Univ, Heavy Ion Med Ctr, Maebashi, Gunma 3718511, Japan.
EM a-takahashi@gunma-u.ac.jp
FU MEXT [JP15H05935]; unma University Initiative for Advanced Research
FX This work was supported by a MEXT Grant-in-Aid for Scientific Research
on Innovative Areas, Grant Number JP15H05935 "Living in Space", Research
Projects with Heavy Ions at the GHMC and the Gunma University Initiative
for Advanced Research. We thank Mr. Y. Kakehashi, Mr. N. Nakamura and
Mr. T. Harada (AES) for providing and improving the 3D clinostat, Mr. M.
Inaba (Konno Co.) for producing the special sample stage, Mr. Y. Kano
(Accelerator Engineering Co., Chiba, Japan) for supporting our
experiments, and Dr. P. A. Jeggo (Sussex University, UK) and Dr. A.
Shibata (Gunma University) for supplying 1BR-hTERT cells.
NR 38
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2214-5524
EI 2214-5532
J9 LIFE SCI SPACE RES
JI Life Sci. Space Res.
PD FEB
PY 2017
VL 12
BP 51
EP 60
DI 10.1016/j.lssr.2017.01.003
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EO9ZH
UT WOS:000397046100006
PM 28212708
ER
PT J
AU Cockrell, AS
Yount, BL
Scobey, T
Jensen, K
Douglas, M
Beall, A
Tang, XC
Marasco, WA
Heise, MT
Baric, RS
AF Cockrell, Adam S.
Yount, Boyd L.
Scobey, Trevor
Jensen, Kara
Douglas, Madeline
Beall, Anne
Tang, Xian-Chun
Marasco, Wayne A.
Heise, Mark T.
Baric, Ralph S.
TI A mouse model for MERS coronavirus-induced acute respiratory distress
syndrome
SO NATURE MICROBIOLOGY
LA English
DT Article
ID DIPEPTIDYL PEPTIDASE 4; MONOCLONAL-ANTIBODY; TRANSGENIC MICE; COV
INFECTION; PATHOLOGY; DISEASE; PATHOGENESIS; GENERATION; HUMANS; CELLS
AB Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel virus that emerged in 2012, causing acute respiratory distress syndrome (ARDS), severe pneumonia-like symptoms and multi-organ failure, with a case fatality rate of similar to 36%. Limited clinical studies indicate that humans infected with MERS-CoV exhibit pathology consistent with the late stages of ARDS, which is reminiscent of the disease observed in patients infected with severe acute respiratory syndrome coronavirus. Models of MERS-CoV-induced severe respiratory disease have been difficult to achieve, and small-animal models traditionally used to investigate viral pathogenesis (mouse, hamster, guinea-pig and ferret) are naturally resistant to MERS-CoV. Therefore, we used CRISPR-Cas9 gene editing to modify the mouse genome to encode two amino acids (positions 288 and 330) that match the human sequence in the dipeptidyl peptidase 4 receptor, making mice susceptible to MERS-CoV infection and replication. Serial MERS-CoV passage in these engineered mice was then used to generate a mouse-adapted virus that replicated efficiently within the lungs and evoked symptoms indicative of severe ARDS, including decreased survival, extreme weight loss, decreased pulmonary function, pulmonary haemorrhage and pathological signs indicative of end-stage lung disease. Importantly, therapeutic countermeasures comprising MERS-CoV neutralizing antibody treatment or a MERS-CoV spike protein vaccine protected the engineered mice against MERS-CoVinduced ARDS.
C1 [Cockrell, Adam S.; Yount, Boyd L.; Scobey, Trevor; Jensen, Kara; Douglas, Madeline; Beall, Anne; Baric, Ralph S.] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA.
[Tang, Xian-Chun; Marasco, Wayne A.] Harvard Med Sch, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
[Tang, Xian-Chun; Marasco, Wayne A.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA.
[Heise, Mark T.; Baric, Ralph S.] Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.
[Heise, Mark T.] Univ North Carolina Chapel Hill, Dept Genet, Chapel Hill, NC 27599 USA.
RP Cockrell, AS; Baric, RS (reprint author), Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA.; Heise, MT; Baric, RS (reprint author), Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.; Heise, MT (reprint author), Univ North Carolina Chapel Hill, Dept Genet, Chapel Hill, NC 27599 USA.
EM adam_cockrell@unc.edu; mark_heisem@med.unc.edu; rbaric@email.unc.edu
FU National Institute of Allergy and Infectious Disease of the US NIH
[HHSN272201000019I-HHSN27200003, AI106772, AI108197, AI110700, AI109761,
U19 AI100625]
FX These studies were supported by grants from the National Institute of
Allergy and Infectious Disease of the US NIH by awards
HHSN272201000019I-HHSN27200003 (R.S.B. and M.T.H.), AI106772, AI108197,
AI110700 and AI109761 (R.S.B.), and U19 AI100625 (R.S.B. and M.T.H.).
GOF research considerations involving MERS-0 in vivo passage in mice and
the current manuscript were both reviewed and approved by the funding
agency, the NIH. The content is solely the responsibility of the authors
and does not necessarily represent the official views of the NIH.
Generation of CRISPR-Cas9-modified mice was performed at the UNC Animal
Models Core Facility under the direction of Dale Cowley.
NR 37
TC 1
Z9 1
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2058-5276
J9 NAT MICROBIOL
JI NAT. MICROBIOL
PD FEB
PY 2017
VL 2
IS 2
AR 16226
DI 10.1038/nmicrobiol.2016.226
PG 11
WC Microbiology
SC Microbiology
GA EP0VN
UT WOS:000397104900018
PM 27892925
ER
PT J
AU van Gils, MJ
van den Kerkhof, TLGM
Ozorowski, G
Cottrell, CA
Sok, D
Pauthner, M
Pallesen, J
de Val, N
Yasmeen, A
de Taeye, SW
Schorcht, A
Gumbs, S
Johanna, I
Saye-Francisco, K
Liang, CH
Landais, E
Nie, XY
Pritchard, LK
Crispin, M
Kelsoe, G
Wilson, IA
Schuitemaker, H
Klasse, PJ
Moore, JP
Burton, DR
Ward, AB
Sanders, RW
AF van Gils, Marit J.
van den Kerkhof, Tom L. G. M.
Ozorowski, Gabriel
Cottrell, Christopher A.
Sok, Devin
Pauthner, Matthias
Pallesen, Jesper
de Val, Natalia
Yasmeen, Anila
de Taeye, Steven W.
Schorcht, Anna
Gumbs, Stephanie
Johanna, Inez
Saye-Francisco, Karen
Liang, Chi-Hui
Landais, Elise
Nie, Xiaoyan
Pritchard, Laura K.
Crispin, Max
Kelsoe, Garnett
Wilson, Ian A.
Schuitemaker, Hanneke
Klasse, Per Johan
Moore, John P.
Burton, Dennis R.
Ward, Andrew B.
Sanders, Rogier W.
TI An HIV-1 antibody from an elite neutralizer implicates the fusion
peptide as a site of vulnerability
SO NATURE MICROBIOLOGY
LA English
DT Article
ID CRYO-EM STRUCTURE; MONOCLONAL-ANTIBODIES; ENVELOPE TRIMERS; ENV TRIMERS;
CRYOELECTRON MICROSCOPY; GP41-GP120 INTERFACE; DEPENDENT EPITOPE;
VACCINE DESIGN; BINDING; BROAD
AB The induction by vaccination of broadly neutralizing antibodies (bNAbs) capable of neutralizing various HIV-1 viral strains is challenging, but understanding how a subset of HIV-infected individuals develops bNAbs may guide immunization strategies. Here, we describe the isolation and characterization of the bNAb ACS202 from an elite neutralizer that recognizes a new, trimer-specific and cleavage-dependent epitope at the gp120-gp41 interface of the envelope glycoprotein (Env), involving the glycan N88 and the gp41 fusion peptide. In addition, an Env trimer, AMC011 SOSIP.v4.2, based on early virus isolates from the same elite neutralizer, was constructed, and its structure by cryo-electron microscopy at 6.2 angstrom resolution reveals a closed, pre-fusion conformation similar to that of the BG505 SOSIP. 664 trimer. The availability of a native-like Env trimer and a bNAb from the same elite neutralizer provides the opportunity to design vaccination strategies aimed at generating similar bNAbs against a key functional site on HIV-1.
C1 [van Gils, Marit J.; van den Kerkhof, Tom L. G. M.; de Taeye, Steven W.; Schorcht, Anna; Gumbs, Stephanie; Johanna, Inez; Sanders, Rogier W.] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands.
[van Gils, Marit J.; Sok, Devin; Pauthner, Matthias; Saye-Francisco, Karen; Liang, Chi-Hui; Landais, Elise; Burton, Dennis R.] Scripps Res Inst, Scripps CHAVI ID IAVI Neutralizing Antibody Ctr, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
[van Gils, Marit J.; Ozorowski, Gabriel; Cottrell, Christopher A.; Sok, Devin; Pauthner, Matthias; Pallesen, Jesper; Saye-Francisco, Karen; Liang, Chi-Hui; Landais, Elise; Wilson, Ian A.; Burton, Dennis R.; Ward, Andrew B.] Scripps Res Inst, CAVD, La Jolla, CA 92037 USA.
[van den Kerkhof, Tom L. G. M.; Schuitemaker, Hanneke] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands.
[Ozorowski, Gabriel; Cottrell, Christopher A.; Pallesen, Jesper; de Val, Natalia; Wilson, Ian A.; Ward, Andrew B.] Scripps Res Inst, Dept Integrat Struct & Computat Biol, Scripps CHAVI ID IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.
[Yasmeen, Anila; Klasse, Per Johan; Moore, John P.; Sanders, Rogier W.] Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA.
[Nie, Xiaoyan; Kelsoe, Garnett] Duke Univ, Dept Immunol, Durham, NC 27710 USA.
[Nie, Xiaoyan; Kelsoe, Garnett] Duke Univ, Vaccine Inst, Durham, NC 27710 USA.
[Pritchard, Laura K.; Crispin, Max] Univ Oxford, Oxford Glycobiol Inst, Dept Biochem, Oxford OX1 3QU, England.
[Schuitemaker, Hanneke] Johnson & Johnson, Janssen Pharmaceut Co, Archimedesweg 4-6, NL-2301 CA Leiden, Netherlands.
[Burton, Dennis R.] MIT, Massachusetts Gen Hosp, Ragon Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
[Burton, Dennis R.] Harvard Univ, Cambridge, MA 02139 USA.
RP van Gils, MJ; Sanders, RW (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands.; van Gils, MJ (reprint author), Scripps Res Inst, Scripps CHAVI ID IAVI Neutralizing Antibody Ctr, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.; van Gils, MJ (reprint author), Scripps Res Inst, CAVD, La Jolla, CA 92037 USA.; Sanders, RW (reprint author), Cornell Univ, Dept Microbiol & Immunol, Weill Med Coll, New York, NY 10021 USA.
EM m.j.vangils@amc.uva.nl; r.w.sanders@amc.uva.nl
FU Center for Infectious Disease Control of The Netherlands National
Institute for Public Health and the Environment; Dutch Aids Fonds
[2012041]; EMBO [ASTF 260-2013]; Netherlands Organization for Scientific
Research [917.11.314, 918.66.628]; European Research Council
[ERC-StG-2011-280829-SHEV]; International AIDS Vaccine Initiative
through the Neutralizing Antibody Consortium [SFP1849]; NIH [R01
AI033292, P01 AI110657, R37 AI36082]; Center for HIV/AIDS Vaccine
Immunology and Immunogen Discovery [UM1AI100663]; Collaboration for AIDS
Vaccine Development (CAVD) [OPP1111923, OPP1132237]; Bill and Melinda
Gates Foundation [OPP1115782]; European Union [681137]; NIH
Interdisciplinary Training Program in Immunology [5T32AI007606-10]
FX The Amsterdam Cohort Studies (ACS) on HIV infection and AIDS, a
collaboration between the Amsterdam Health Service, the Academic Medical
Center of the University of Amsterdam, Sanquin Blood Supply Foundation
and the Jan van Goyen Clinic, are part of The Netherlands HIV Monitoring
Foundation and are financially supported by the Center for Infectious
Disease Control of The Netherlands National Institute for Public Health
and the Environment. M.J.v.G. is a recipient of a Dutch Aids Fonds
(grant no. 2012041) and EMBO short-term fellowship (ASTF 260-2013).
R.W.S. is a recipient of a Vidi grant from the Netherlands Organization
for Scientific Research (grant no. 917.11.314) and a Starting
Investigator Grant from the European Research Council
(ERC-StG-2011-280829-SHEV). This work was also supported by a Vici grant
to H.S. from The Netherlands Organization for Scientific Research (grant
no. 918.66.628), the International AIDS Vaccine Initiative through the
Neutralizing Antibody Consortium SFP1849 (to D.R.B. and A.B.W.), NIH R01
AI033292 (to D.R.B.), NIH P01 AI110657 (to J.P.M., A.B.W., I.A.W. and
R.W.S.), NIH R37 AI36082 (to J.P.M.), Center for HIV/AIDS Vaccine
Immunology and Immunogen Discovery Grant UM1AI100663 (to D.R.B., A.B.W.
and I.A.W.), Collaboration for AIDS Vaccine Development (CAVD) grants
OPP1111923 and OPP1132237 (to J.P.M. and R.W.S.) and OPP1115782 (A.B.W.)
from the Bill and Melinda Gates Foundation, and European Union's Horizon
2020 research and innovation programme under grant agreement no. 681137
(to R.W.S). Funding was also provided by the NIH Interdisciplinary
Training Program in Immunology 5T32AI007606-10 (to D.S.). The authors
thank D. Burton, M. Nussenzweig and J. Mascola for providing bNAbs.
NR 56
TC 3
Z9 3
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2058-5276
J9 NAT MICROBIOL
JI NAT. MICROBIOL
PD FEB
PY 2017
VL 2
IS 2
AR 16199
DI 10.1038/nmicrobiol.2016.199
PG 10
WC Microbiology
SC Microbiology
GA EP0VN
UT WOS:000397104900005
PM 27841852
ER
PT J
AU Ray, SK
Samantaray, S
Banik, NL
AF Ray, Swapan K.
Samantaray, Supriti
Banik, Naren L.
TI Future directions for using estrogen receptor agonists in the treatment
of acute and chronic spinal cord injury (vol 11, pg 1418, 2016)
SO NEURAL REGENERATION RESEARCH
LA English
DT Correction
C1 [Ray, Swapan K.] Univ South Carolina, Dept Pathol Microbiol & Immunol, Sch Med, Columbia, SC 29208 USA.
[Samantaray, Supriti] Med Univ South Carolina, Dept Neurosci, Columbia, SC USA.
[Banik, Naren L.] Med Univ South Carolina, Dept Neurol & Neurosurg, Charleston, SC USA.
[Banik, Naren L.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC USA.
RP Ray, SK (reprint author), Univ South Carolina, Dept Pathol Microbiol & Immunol, Sch Med, Columbia, SC 29208 USA.
EM swapan.ray@uscmed.sc.edu
NR 1
TC 0
Z9 0
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD FEB
PY 2017
VL 12
IS 2
BP 266
EP 266
DI 10.4103/1673-5374.200818
PG 1
WC Cell Biology; Neurosciences
SC Cell Biology; Neurosciences & Neurology
GA EO9QN
UT WOS:000397023300021
ER
PT J
AU Fan, JJ
Li, Y
Fu, XY
Li, LJ
Hao, XT
Li, SS
AF Fan, Jingjing
Li, Yi
Fu, Xinyu
Li, Lijuan
Hao, Xiaoting
Li, Shasha
TI Nonhuman primate models of focal cerebral ischemia
SO NEURAL REGENERATION RESEARCH
LA English
DT Review
DE nerve regeneration; stroke; cerebral ischemia; middle cerebral artery
occlusion; nonhuman primates; model selection; neural regeneration
ID DIFFUSION TENSOR MRI; ARTERY OCCLUSION; ISCHEMIA/REPERFUSION INJURY;
ANESTHETIZED BABOON; RHESUS MACAQUE; STROKE MODEL; REPERFUSION;
ENDOTHELIN; INFARCTION; MARMOSET
AB Rodents have been widely used in the production of cerebral ischemia models. However, successful therapies have been proven on experimental rodent stroke model, and they have often failed to be effective when tested clinically. Therefore, nonhuman primates were recommended as the ideal alternatives, owing to their similarities with the human cerebrovascular system, brain metabolism, grey to white matter ratio and even their rich behavioral repertoire. The present review is a thorough summary of ten methods that establish nonhuman primate models of focal cerebral ischemia; electrocoagulation, endothelin-1-induced occlusion, microvascular clip occlusion, autologous blood clot embolization, balloon inflation, microcatheter embolization, coil embolization, surgical suture embolization, suture, and photochemical induction methods. This review addresses the advantages and disadvantages of each method, as well as precautions for each model, compared nonhuman primates with rodents, different species of nonhuman primates and different modeling methods. Finally it discusses various factors that need to be considered when modelling and the method of evaluation after modelling. These are critical for understanding their respective strengths and weaknesses and underlie the selection of the optimum model.
C1 [Fan, Jingjing; Li, Yi; Fu, Xinyu; Li, Lijuan; Li, Shasha] Sichuan Univ, West China Hosp, Dept Rehabil Med, Chengdu, Sichuan, Peoples R China.
[Fan, Jingjing; Li, Yi; Fu, Xinyu; Li, Lijuan; Li, Shasha] Sichuan Univ, West China Hosp, Prov Key Lab Rehabil Med, Chengdu, Sichuan, Peoples R China.
[Hao, Xiaoting] Sichuan Univ, West China Hosp, Dept Neurol, Chengdu, Sichuan, Peoples R China.
[Li, Shasha] Harvard Med Sch, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA USA.
[Li, Shasha] Harvard Med Sch, Massachusetts Gen Hosp, Athinoula A Martions Ctr Biomed Imaging, Boston, MA USA.
RP Li, SS (reprint author), Sichuan Univ, West China Hosp, Dept Rehabil Med, Chengdu, Sichuan, Peoples R China.; Li, SS (reprint author), Sichuan Univ, West China Hosp, Prov Key Lab Rehabil Med, Chengdu, Sichuan, Peoples R China.; Li, SS (reprint author), Harvard Med Sch, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA USA.; Li, SS (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Athinoula A Martions Ctr Biomed Imaging, Boston, MA USA.
EM pmr.shashali@gmail.com
FU National Natural Science Foundation of China [81000852, 81301677]; AHA
[17POST32530004]; Science & Technology of Sichuan Province of China
[2012SZ0140]; Research Foundation of Zhejiang Province of China
[201022896]
FX This work was supported by the National Natural Science Foundation of
China, No. 81000852 and 81301677; the AHA Award, No. 17POST32530004; the
Supporting Project of Science & Technology of Sichuan Province of China,
No. 2012SZ0140; the Research Foundation of Zhejiang Province of China,
No. 201022896.
NR 50
TC 0
Z9 0
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 1673-5374
EI 1876-7958
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD FEB
PY 2017
VL 12
IS 2
BP 321
EP 328
DI 10.4103/1673-5374.200815
PG 8
WC Cell Biology; Neurosciences
SC Cell Biology; Neurosciences & Neurology
GA EO9QN
UT WOS:000397023300029
ER
PT J
AU Simonett, JM
Chan, EW
Chou, J
Skondra, D
Colon, D
Chee, CK
Lingam, G
Fawzi, AA
AF Simonett, Joseph M.
Chan, Errol W.
Chou, Jonathan
Skondra, Dimitra
Colon, Daniel
Chee, Caroline K.
Lingam, Gopal
Fawzi, Amani A.
TI Quantitative Analysis of En Face Spectral-Domain Optical Coherence
Tomography Imaging in Polypoidal Choroidal Vasculopathy
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID MACULAR DEGENERATION; RANIBIZUMAB; VERTEPORFIN
AB BACKGROUND AND OBJECTIVE: Spectral-domain optical coherence tomography (SD-OCT) imaging can be used to visualize polypoidal choroidal vasculopathy (PCV) lesions in the en face plane. Here, the authors describe a novel lesion quantification technique and compare PCV lesion area measurements and morphology before and after anti-vascular endothelial growth factor (VEGF) treatment.
PATIENTS AND METHODS: Volumetric SD-OCT scans in eyes with PCV before and after induction anti-VEGF therapy were retrospectively analyzed. En face SD-OCT images were generated and a pixel intensity thresholding process was used to quantify total lesion area.
RESULTS: Thirteen eyes with PCV were analyzed. En face SD-OCT PCV lesion area quantification showed good intergrader reliability (intraclass correlation coefficient = 0.944). Total PCV lesion area was significantly reduced after anti-VEGF therapy (2.22 mm(2) vs. 2.73 mm(2); P =.02). The overall geographic pattern of the branching vascular network was typically preserved.
CONCLUSION: PCV lesion area analysis using en face SD-OCT is a reproducible tool that can quantify treatment related changes.
C1 [Simonett, Joseph M.; Chou, Jonathan; Skondra, Dimitra; Colon, Daniel; Fawzi, Amani A.] Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, 645 N Michigan Ave, Chicago, IL 60611 USA.
[Chan, Errol W.] McGill Univ, McGill Univ Hlth Ctr, Dept Ophthalmol, Montreal, PQ, Canada.
[Chan, Errol W.; Chee, Caroline K.] Natl Univ Singapore, Hlth Syst, Dept Ophthalmol, Singapore, Singapore.
[Chan, Errol W.; Chee, Caroline K.] Yong Loo Lin Sch Med, Singapore, Singapore.
[Chou, Jonathan] Massachusetts Eye & Ear Infirm, Harvard Med Sch, Dept Ophthalmol, Boston, MA 02114 USA.
RP Fawzi, AA (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Ophthalmol, 645 N Michigan Ave, Chicago, IL 60611 USA.
EM afawzimd@gmail.com
FU National University Health System Clinician-Scientist Program Grant
(Singapore)
FX This study is supported by the National University Health System
Clinician-Scientist Program Grant (Singapore).
NR 19
TC 0
Z9 0
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD FEB
PY 2017
VL 48
IS 2
BP 126
EP +
DI 10.3928/23258160-20170130-06
PG 11
WC Ophthalmology; Surgery
SC Ophthalmology; Surgery
GA EP2TG
UT WOS:000397235600006
PM 28195615
ER
PT J
AU Linnstaedt, SD
Walker, MG
Riker, KD
Nyland, JE
Hu, JM
Rossi, C
Swor, RA
Jones, JS
Diatchenko, L
Bortsov, AV
Peak, DA
McLean, SA
AF Linnstaedt, Sarah D.
Walker, Margaret G.
Riker, Kyle D.
Nyland, Jennifer E.
Hu, JunMei
Rossi, Catherine
Swor, Robert A.
Jones, Jeffrey S.
Diatchenko, Luda
Bortsov, Andrey V.
Peak, David A.
McLean, Samuel A.
TI Genetic variant rs3750625 in the 3 ' UTR of ADRA2A affects
stress-dependent acute pain severity after trauma and alters a
microRNA-34a regulatory site
SO PAIN
LA English
DT Article; Proceedings Paper
CT Meeting of the American-Pain-Society
CY 2014
CL Tampa, FL
SP Amer Pain Soc
DE Motor vehicle collision; Sexual assault; Stress; Trauma; Musculoskeletal
pain; Polymorphism; Single nucleotide; microRNA; miR-34a; Adrenergic
receptor
ID ADRENERGIC-RECEPTOR IMMUNOREACTIVITY; PERITRAUMATIC DISTRESS INVENTORY;
MOTOR-VEHICLE COLLISION; EPSTEIN-BARR-VIRUS; RAT SPINAL-CORD; TARGET
RECOGNITION; MAMMALIAN-CELLS; SEXUAL ASSAULT; EXPRESSION; DISORDER
AB alpha 2A adrenergic receptor (alpha 2A-AR) activation has been shown in animal models to play an important role in regulating the balance of acute pain inhibition vs facilitation after both physical and psychological stress. To our knowledge, the influence of genetic variants in the gene encoding alpha 2A-AR, ADRA2A, on acute pain outcomes in humans experiencing traumatic stress has not been assessed. In this study, we tested whether a genetic variant in the 3 ' UTR of ADRA2A, rs3750625, is associated with acute musculoskeletal pain (MSP) severity following motor vehicle collision (MVC, n = 948) and sexual assault (n 5 84), and whether this influence was affected by stress severity. We evaluated rs3750625 because it is located in the seed binding region of miR-34a, a microRNA (miRNA) known to regulate pain and stress responses. In both cohorts, the minor allele at rs3750625 was associated with increased musculoskeletal pain in distressed individuals (stress rs3750625 P = 0.043 for MVC cohort and P = 0.007 for sexual assault cohort). We further found that (1) miR-34a binds the 3 ' UTR of ADRA2A, (2) the amount of repression is greater when the minor (risk) allele is present, (3) miR-34a in the IMR-32 adrenergic neuroblastoma cell line affects ADRA2A expression, (4) miR-34a and ADRA2A are expressed in tissues known to play a role in pain and stress, (5) following forced swim stress exposure, rat peripheral nerve tissue expression changes are consistent with miR-34a regulation of ADRA2A. Together, these results suggest that ADRA2A rs3750625 contributes to poststress musculoskeletal pain severity by modulating miR-34a regulation.
C1 [Linnstaedt, Sarah D.; Walker, Margaret G.; Riker, Kyle D.; Hu, JunMei; Bortsov, Andrey V.; McLean, Samuel A.] Univ N Carolina, TRYUMPH Res Program, Chapel Hill, NC USA.
[Linnstaedt, Sarah D.; Walker, Margaret G.; Riker, Kyle D.; Hu, JunMei; Bortsov, Andrey V.; McLean, Samuel A.] Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC USA.
[Nyland, Jennifer E.] Dept Battlefield Pain Res, Fort Sam, TX USA.
[Rossi, Catherine] Cone Hlth Syst, Family Med, Forens Nursing Program, Greensboro, NC USA.
[Swor, Robert A.] William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI USA.
[Jones, Jeffrey S.] Dept EmergencyMed, SpectrumHlth Butterworth Campus, Grand Rapids, MI USA.
[Diatchenko, Luda] McGill Univ, Allan Edwards Ctr Emergency Med, Montreal, PQ, Canada.
[Peak, David A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA.
[McLean, Samuel A.] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA.
RP Linnstaedt, SD (reprint author), Univ N Carolina, Med Sch Wing C, CB 7010, Chapel Hill, NC 27599 USA.
EM slinnstaedt@aims.unc.edu
FU NIAMS NIH HHS [R01 AR056328, R01 AR064700]
NR 62
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0304-3959
EI 1872-6623
J9 PAIN
JI Pain
PD FEB
PY 2017
VL 158
IS 2
BP 230
EP 239
DI 10.1097/j.pain.0000000000000742
PG 10
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA EO9NN
UT WOS:000397015500007
PM 27805929
ER
PT J
AU Beaudoin, FL
Gutman, R
Merchant, RC
Clark, MA
Swor, RA
Jones, JS
Lee, DC
Peak, DA
Domeier, RM
Rathlev, NK
McLean, SA
AF Beaudoin, Francesca L.
Gutman, Roee
Merchant, Roland C.
Clark, Melissa A.
Swor, Robert A.
Jones, Jeffrey S.
Lee, David C.
Peak, David A.
Domeier, Robert M.
Rathlev, Niels K.
McLean, Samuel A.
TI Persistent pain after motor vehicle collision: comparative effectiveness
of opioids vs nonsteroidal antiinflammatory drugs prescribed from the
emergency department-a propensity matched analysis
SO PAIN
LA English
DT Article
DE Opioid analgesics; Nonsteroidal antiinflammatory drugs; Acute pain;
Persistent pain; Chronic pain; Motor-vehicle collision; Causal
inference; Propensity matching
ID LOW-BACK-PAIN; CHRONIC WIDESPREAD PAIN; MULTIPLE IMPUTATION;
UNITED-STATES; TASK-FORCE; SENSITIZATION; PREDICTORS; SYMPTOMS;
OUTCOMES; DESIGN
AB Each year millions of Americans present to the emergency department (ED) for care after a motor vehicle collision (MVC); the majority (> 90%) are discharged to home after evaluation. Acute musculoskeletal pain is the norm in this population, and such patients are typically discharged to home with prescriptions for oral opioid analgesics or nonsteroidal antiinflammatory drugs (NSAIDs). The influence of acute painmanagement on subsequent pain outcomes in this commonEDpopulation is unknown. Weevaluated the effect of opioid analgesics vs NSAIDs initiated from the ED on the presence of moderate to severe musculoskeletal pain and ongoing opioid use at 6 weeks in a large cohort of adult ED patients presenting to the ED after MVC (n = 948). The effect of opioids vs NSAIDs was evaluated using an innovative quasi-experimental designmethod using propensity scores to account for covariate imbalances between the 2 treatment groups. No difference in risk for moderate to severe musculoskeletal pain at 6 weeks was observed between those discharged with opioid analgesics vs NSAIDs (risk difference = 7.2% [95% confidence interval: 25.2% to 19.5%]). However, at followup participants prescribed opioids were more likely than those prescribed NSAIDs to report use of prescription opioids medications at week 6 (risk difference = 17.5%[95% confidence interval: 5.8%-29.3%]). These results suggest that analgesic choice at ED discharge does not influence the development of persistent moderate to severe musculoskeletal pain 6 weeks after an MVC, but may result in continued use of prescription opioids. Supported by NIAMS R01AR056328 and AHRQ 5K12HS022998.
C1 [Beaudoin, Francesca L.; Merchant, Roland C.] Brown Univ, Alpert Med Sch, Dept Emergency Med, Providence, RI 02912 USA.
[Beaudoin, Francesca L.; Merchant, Roland C.; Clark, Melissa A.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA.
[Gutman, Roee] Brown Univ, Dept Biostat, Providence, RI 02912 USA.
[Clark, Melissa A.] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Swor, Robert A.] William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48072 USA.
[Jones, Jeffrey S.] Spectrum Hlth Butterworth Campus, Dept Emergency Med, Grand Rapids, MI USA.
[Lee, David C.] North Shore Univ Hosp, Dept Emergency Med, Manhasset, NY USA.
[Peak, David A.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Domeier, Robert M.] St Joseph Mercy Hosp, Dept Emergency Med, Yipsilanti, MI USA.
[Rathlev, Niels K.] Baystate Med Ctr, Dept Emergency Med, Springfield, MA USA.
[McLean, Samuel A.] Univ N Carolina, Dept Emergency Med, Chapel Hill, NC USA.
[McLean, Samuel A.] Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC USA.
[McLean, Samuel A.] Univ N Carolina, TRYUMPH Res Program, Chapel Hill, NC USA.
RP Beaudoin, FL (reprint author), Rhode Isl Hosp, Dept Emergency Med, 55 Claverick St,2nd Floor, Providence, RI 02903 USA.
EM Francesca_Beaudoin@brown.edu
FU AHRQ HHS [K12 HS022998]; NCATS NIH HHS [UL1 TR001111]; NIAMS NIH HHS
[R01 AR056328]
NR 45
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0304-3959
EI 1872-6623
J9 PAIN
JI Pain
PD FEB
PY 2017
VL 158
IS 2
BP 289
EP 295
DI 10.1097/j.pain.0000000000000756
PG 7
WC Anesthesiology; Clinical Neurology; Neurosciences
SC Anesthesiology; Neurosciences & Neurology
GA EO9NN
UT WOS:000397015500013
PM 28092325
ER
PT J
AU Engel, AJ
Kreiner, DS
Stojanovic, MP
AF Engel, Andrew J.
Kreiner, D. Scott
Stojanovic, Milan P.
TI Finding an Answer: Comments on a Randomized Trial of Epidural
Glucocorticoid Injections for Lumbar Spinal Stenosis
SO PAIN MEDICINE
LA English
DT Editorial Material
ID LOW-BACK-PAIN; CAUDA-EQUINA; INTERMITTENT CLAUDICATION; RADIOFREQUENCY
NEUROTOMY; TRANSFORAMINAL INJECTION; STEROID INJECTIONS; RADICULAR PAIN;
INFLAMMATION; COMPRESSION; HYPERTROPHY
C1 [Engel, Andrew J.] Affordable Pain Management, Chicago, IL USA.
[Kreiner, D. Scott] Ahwatukee Sport & Spine, Phoenix, AZ USA.
[Stojanovic, Milan P.] VA Boston Healthcare Syst, Crit Care & Pain Med Serv, Anesthesiol, Boston, MA USA.
RP Engel, AJ (reprint author), Affordable Pain Management, Chicago, IL USA.
NR 52
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1526-2375
EI 1526-4637
J9 PAIN MED
JI Pain Med.
PD FEB
PY 2017
VL 18
IS 2
BP 204
EP 210
DI 10.1093/pm/pnw127
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA EP0VB
UT WOS:000397103700002
PM 28204744
ER
PT J
AU Zhang, PP
Bookstaver, ML
Jewell, CM
AF Zhang, Peipei
Bookstaver, Michelle L.
Jewell, Christopher M.
TI Engineering Cell Surfaces with Polyelectrolyte Materials for
Translational Applications
SO POLYMERS
LA English
DT Review
DE polyelectrolyte; multilayer; cell modification; sensing and signaling;
drug delivery; vaccine and immunotherapy; surface protein; tissue
engineering; regenerative medicine
ID LYMPH-NODE MICROENVIRONMENT; STEM-CELLS; GENE-THERAPY; DRUG-DELIVERY;
LIVING CELLS; BIOMEDICAL APPLICATIONS; ISLET TRANSPLANTATION; MEDIATED
DELIVERY; INDIVIDUAL CELLS; CLINICAL-TRIALS
AB Engineering cell surfaces with natural or synthetic materials is a unique and powerful strategy for biomedical applications. Cells exhibit more sophisticated migration, control, and functional capabilities compared to nanoparticles, scaffolds, viruses, and other engineered materials or agents commonly used in the biomedical field. Over the past decade, modification of cell surfaces with natural or synthetic materials has been studied to exploit this complexity for both fundamental and translational goals. In this review we present the existing biomedical technologies for engineering cell surfaces with one important class of materials, polyelectrolytes. We begin by introducing the challenges facing the cell surface engineering field. We then discuss the features of polyelectrolytes and how these properties can be harnessed to solve challenges in cell therapy, tissue engineering, cell-based drug delivery, sensing and tracking, and immune modulation. Throughout the review, we highlight opportunities to drive the field forward by bridging new knowledge of polyelectrolytes with existing translational challenges.
C1 [Zhang, Peipei; Bookstaver, Michelle L.; Jewell, Christopher M.] Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA.
[Jewell, Christopher M.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
[Jewell, Christopher M.] Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
[Jewell, Christopher M.] US Dept Vet Affairs, Baltimore, MA 21201 USA.
RP Jewell, CM (reprint author), Univ Maryland, Fischell Dept Bioengn, College Pk, MD 20742 USA.; Jewell, CM (reprint author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.; Jewell, CM (reprint author), Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA.; Jewell, CM (reprint author), US Dept Vet Affairs, Baltimore, MA 21201 USA.
EM pzhang14@umd.edu; mlbooks@umd.edu; cmjewell@umd.edu
OI Jewell, Christopher/0000-0002-6668-6928
FU NSF CAREER Award [1351688]; Damon Runyon Foundation [DRR3415]; Young
Investigator of the Alliance for Cancer Gene Therapy [15051543];
Melanoma Research Alliance [348963]
FX This work was supported in part by NSF CAREER Award # 1351688.
Christopher M. Jewell is a Damon Runyon-Rachleff Innovator supported by
the Damon Runyon Foundation (# DRR3415), and a Young Investigator of the
Alliance for Cancer Gene Therapy (# 15051543) and the Melanoma Research
Alliance (# 348963).
NR 115
TC 0
Z9 0
U1 0
U2 0
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2073-4360
J9 POLYMERS-BASEL
JI Polymers
PD FEB
PY 2017
VL 9
IS 2
AR 40
DI 10.3390/polym9020040
PG 21
WC Polymer Science
SC Polymer Science
GA EP2RL
UT WOS:000397230800010
ER
PT J
AU Nelson, K
Taylor, L
Silverman, J
Kiefer, M
Hebert, P
Lessler, D
Krieger, J
AF Nelson, Karin
Taylor, Leslie
Silverman, Julie
Kiefer, Meghan
Hebert, Paul
Lessler, Dan
Krieger, James
TI Randomized Controlled Trial of a Community Health Worker Self-Management
Support Intervention Among Low-Income Adults With Diabetes, Seattle,
Washington, 2010-2014
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID BASE-LINE CHARACTERISTICS; GLYCEMIC CONTROL; CARE; ADHERENCE; VALIDITY;
PEOPLE; COMPLICATIONS; AMERICAN; DESIGN; IMPACT
AB Introduction
Community health workers (CHWs) can improve diabetes outcomes; however, questions remain about translating research findings into practical low-intensity models for safety-net providers. We tested the effectiveness of a home-based low-intensity CHW intervention for improving health outcomes among low-income adults with diabetes.
Methods
Low-income patients with glycated hemoglobin A 1c (HbA 1c) of 8.0% or higher in the 12 months before enrollment from 3 safetynet providers were randomized to a 12-month CHW-delivered diabetes self-management intervention or usual care. CHWs were based at a local health department. The primary outcome was change in HbA 1c from baseline enrollment to 12 months; secondary outcomes included blood pressure and lipid levels, quality of life, and health care use.
Results
The change in HbA 1c in the intervention group (n = 145) (unadjusted mean of 9.09% to 8.58%, change of -0.51) compared with the control group (n = 142) (9.04% to 8.71%, change of -0.33) was not significant (P =.54). In an analysis of participants with poor glycemic control (HbA 1c > 10%), the intervention group had a 1.23-point greater decrease in HbA 1c compared with controls (P =.046). For the entire study population, we found a decrease in reported physician visits (P <.001) and no improvement in healthrelated quality of life (P =.07) in the intervention group compared with the control group.
Conclusion
A low-intensity CHW-delivered intervention to support diabetes self-management did not significantly improve HbA 1c relative to usual care. Among the subgroup of participants with poor glycemic control (HbA 1c > 10% at baseline), the intervention was effective.
C1 [Nelson, Karin; Taylor, Leslie; Silverman, Julie; Kiefer, Meghan; Hebert, Paul] VA Hlth Serv Res & Dev, Seattle Denver Ctr Innovat Veteran Ctr & Value Dr, Seattle, WA USA.
[Nelson, Karin; Silverman, Julie; Kiefer, Meghan] VA Puget Sound Hlth Care Syst, Gen Internal Med Serv, Seattle, WA USA.
[Nelson, Karin; Silverman, Julie; Kiefer, Meghan; Hebert, Paul; Lessler, Dan; Krieger, James] Univ Washington, Sch Med, Seattle, WA USA.
[Nelson, Karin; Krieger, James] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Krieger, James] Publ Hlth Seattle & King Cty, Seattle, WA USA.
RP Nelson, K (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM Karin.Nelson@va.gov
FU National Institutes of Health, National Institute for Diabetes and
Digestive and Kidney Diseases [5R18DK088072]; Veterans Health
Administration (VHA) Diabetes Quality Enhancement Research Initiative
FX This study was supported by the National Institutes of Health, National
Institute for Diabetes and Digestive and Kidney Diseases grant
5R18DK088072 (K. Nelson and J. Krieger, co-principal investigators).
Supplemental funding was provided by the Veterans Health Administration
(VHA) Diabetes Quality Enhancement Research Initiative. The views
expressed in this article are those of the authors and do not
necessarily reflect the views of the US Department of Veterans Affairs.
The authors have no financial conflicts of interest to report.
NR 29
TC 0
Z9 0
U1 0
U2 0
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD FEB
PY 2017
VL 14
AR 160344
DI 10.5888/pcd14.160344
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EP1KW
UT WOS:000397144800006
ER
PT J
AU Johnson, RS
Stolar, AG
McGuire, JF
Mittakanti, K
Clark, S
Coonan, LA
Graham, DP
AF Johnson, R. Scott
Stolar, Andrea G.
McGuire, James F.
Mittakanti, Krithika
Clark, Sean
Coonan, Loretta A.
Graham, David P.
TI Predictors of Incarceration of Veterans Participating in US Veterans'
Courts
SO PSYCHIATRIC SERVICES
LA English
DT Article
AB Objective: Significant variability exists regarding the criteria and procedures used by different veterans' courts (VCs) across the country. Limited guidance is available regarding which VC model has the most successful outcomes. The purpose of this study was to examine factors associated with incarceration during VC participation.
Methods: This study used data for 1,224 veterans collected from the HOMES (Homeless Operations Management and Evaluation System) database of the Department of Veterans Affairs, as well as data from a national phone survey inventory of all U.S. VCs. To identify variables associated with incarceration during VC participation, four backward conditional logistic regressions were performed.
Results: The following variables were associated with higher rates of incarceration because of a veteran's noncompletion of the VC program: charges of probation or parole violations, longer stays in the VC program, end of VC participation because of incarceration for a new arrest or case transfer by the legal system, and requiring mental health follow-up but not undergoing treatment. The following variables were associated with lower rates of incarceration: stable housing and participating in a VC program that referred veterans for substance abuse treatment.
Conclusions: This study offers VCs a thorough review of an extensive set of recidivism data. Further investigation is necessary to understand the impact of VCs.
C1 [Johnson, R. Scott] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA.
[Johnson, R. Scott] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Stolar, Andrea G.; Mittakanti, Krithika] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[McGuire, James F.] Vet Hlth Adm, Vet Justice Program, Washington, DC USA.
[Clark, Sean] Vet Justice Outreach, Lexington, KY USA.
[Coonan, Loretta A.; Graham, David P.] Michael E DeBakey VA Med Ctr, Mental Hlth Care Line, Houston, TX USA.
RP Johnson, RS (reprint author), Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA.; Johnson, RS (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM rscottjohnson3@gmail.com
NR 16
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD FEB 1
PY 2017
VL 68
IS 2
BP 144
EP 150
DI 10.1176/appi.ps.201500266
PG 7
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA EP0PZ
UT WOS:000397090500009
PM 27745530
ER
PT J
AU Rosen, CS
Azevedo, KJ
Tiet, QQ
Greene, CJ
Wood, AE
Calhoun, P
Bowe, T
Capehart, BP
Crawford, EF
Greenbaum, MA
Harris, AHS
Hertzberg, M
Lindley, SE
Smith, BN
Schnurr, PP
AF Rosen, Craig S.
Azevedo, Kathryn J.
Tiet, Quyen Q.
Greene, Carolyn J.
Wood, Amanda E.
Calhoun, Patrick
Bowe, Thomas
Capehart, Bruce P.
Crawford, Eric F.
Greenbaum, Mark A.
Harris, Alex H. S.
Hertzberg, Michael
Lindley, Steven E.
Smith, Brandy N.
Schnurr, Paula P.
TI An RCT of Effects of Telephone Care Management on Treatment Adherence
and Clinical Outcomes Among Veterans With PTSD
SO PSYCHIATRIC SERVICES
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH TREATMENT; COGNITIVE
PROCESSING THERAPY; RANDOMIZED CONTROLLED-TRIAL; ADDICTION SEVERITY
INDEX; AFGHANISTAN VETERANS; MEDICATION ADHERENCE; TREATMENT ENGAGEMENT;
PROLONGED EXPOSURE; TREATMENT-SEEKING
AB Objective: This study assessed whether adding telephone care management to usual outpatient mental health care improved treatment attendance, medication compliance, and clinical outcomes of veterans with posttraumatic stress disorder (PTSD).
Methods: In a multisite randomized controlled trial, 358 veterans were assigned to either usual outpatient mental health treatment (N=165) or usual care plus twice-a-month telephone care management (TCM) and support in the first three months of treatment (N=193). Treatment utilization and medication refills were determined from U.S. Department of Veterans Affairs administrative data. PTSD, depression, quality of life, aggressive behavior, and substance use were assessed with self-report questionnaires at intake, four months, and 12 months.
Results: Telephone care managers reached 95% of TCM participants (N=182), completing an average 5.1 of 6.0 planned telephone calls. During the three-month intervention period, TCM participants completed 43% more mental health visits (M +/- SD=5.9 +/- 6.8) than did those in usual care (4.1 +/- 4.2) ( incident rate ratio=1.36, x(2)=6.56, df=1, p<.01).Treatment visits in the nine-month follow-up period and medication refills did not differ by condition. Only 9% of participants were scheduled to receive evidence-based psychotherapy. Slopes of improvement in PTSD, depression, alcohol misuse, drug problems, aggressive behavior, and quality of life did not differ by condition or treatment attendance.
Conclusions: TCM improved PTSD patients' treatment attendance but not their outcomes. TCM can enhance treatment engagement, but outcomes depend on the effectiveness of the treatments that patients receive.
C1 [Rosen, Craig S.] Vet Affairs VA Palo Alto Hlth Care Syst, Natl Ctr PTSD Disseminat & Training Div, Menlo Pk, CA 94025 USA.
[Rosen, Craig S.; Tiet, Quyen Q.; Lindley, Steven E.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Lindley, Steven E.] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA.
[Azevedo, Kathryn J.; Bowe, Thomas; Harris, Alex H. S.] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Hlth Serv Res & Dev Serv, Menlo Pk, CA USA.
[Harris, Alex H. S.] Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA.
[Greene, Carolyn J.] VA Off Mental Hlth Serv, Menlo Pk, CA USA.
[Wood, Amanda E.] VA Puget Sound Hlth Care Syst, Mental Hlth Serv Amer Lake Div, Tacoma, WA USA.
[Calhoun, Patrick] VA Midatlantic Mental Illness Res Educ & Clin Ctr, Durham, NC USA.
[Capehart, Bruce P.; Hertzberg, Michael] Durham VA Med Ctr, Dept Psychiat, Durham, NC USA.
[Calhoun, Patrick; Capehart, Bruce P.; Hertzberg, Michael] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC 27706 USA.
[Crawford, Eric F.] Midatlantic Reg MIRECC, Clin Core, Durham, NC USA.
[Crawford, Eric F.] Sheridan VA Med Ctr, Sheridan, WY USA.
[Greenbaum, Mark A.] VA Sierra Pacific MIRECC, Menlo Pk, CA USA.
[Schnurr, Paula P.] White River Junct VA Med Ctr, Natl Ctr PTSD Execut Div, White River Jct, VT USA.
[Schnurr, Paula P.] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA.
RP Rosen, CS (reprint author), Vet Affairs VA Palo Alto Hlth Care Syst, Natl Ctr PTSD Disseminat & Training Div, Menlo Pk, CA 94025 USA.
EM craig.rosen@va.gov
FU Congressionally Directed Medical Research Program [W81XWH-08-2-0096]
FX Dr. Rosen, Dr. Azevedo, Dr. Tiet, and Ms. Smith are with the National
Center for PTSD Dissemination and Training Division, Veterans Affairs
(VA) Palo Alto Health Care System, Menlo Park, California (e-mail:
craig.rosen@va.gov). Dr. Rosen and Dr. Tiet are also with the Department
of Psychiatry and Behavioral Sciences, Stanford University School of
Medicine, Stanford, California, where Dr. Lindley is affiliated. Dr.
Lindley is also with the VA Palo Alto Health Care System, Menlo Park.
Dr. Azevedo is also with the Center for Innovation to Implementation,
Health Services Research and Development Service, VA Palo Alto Health
Care System, Menlo Park, where Dr. Bowe and Dr. Harris are affiliated.
Dr. Harris is also with the Department of Surgery, Stanford University
School of Medicine, Stanford. Dr. Greene is with the VA Office of Mental
Health Services, Menlo Park. Dr. Wood is with Mental Health Services
American Lake Division, VA Puget Sound Health Care System, Tacoma,
Washington. Dr. Calhoun is with the VA Mid-Atlantic Mental Illness
Research, Education and Clinical Center (MIRECC). Dr. Capehart and Dr.
Hertzberg are with the Department of Psychiatry, Durham VA Medical
Center, Durham, North Carolina. Dr. Calhoun, Dr. Capehart, and Dr.
Hertzberg are also with the Department of Psychiatry and Behavioral
Sciences, Duke University School of Medicine, Durham. Dr. Crawford,
formerly with the Clinical Core, Mid-Atlantic Region MIRECC, Durham, is
now with the Sheridan VA Medical Center, Sheridan, Wyoming. Mr.
Greenbaum is with the VA Sierra-Pacific MIRECC, Menlo Park. Dr. Schnurr
is with the National Center for PTSD Executive Division, White River
Junction VA Medical Center, White River Junction, Vermont, and the
Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire.
This study is registered on Clinicaltrials.gov as NCT02655991. This
research was supported by the Congressionally Directed Medical Research
Program, grant W81XWH-08-2-0096 awarded to Dr. Rosen. The authors thank
the veterans who participated in this research; the VA staff members who
supported this study; study coordinator Emerald Adler; and Kathy Blau,
Julia Hernandez, Nate Hawkins, Niall Kavanagh, Caitlin McLean, and Olga
Rosito, who provided compassionate telephone support to the veterans in
this trial. The opinions expressed are those of the authors and do not
represent the position of the U.S. Department of Veterans Affairs.
NR 58
TC 0
Z9 0
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 1075-2730
EI 1557-9700
J9 PSYCHIAT SERV
JI Psychiatr. Serv.
PD FEB 1
PY 2017
VL 68
IS 2
BP 151
EP 158
DI 10.1176/appi.ps.201600069
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health;
Psychiatry
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health; Psychiatry
GA EP0PZ
UT WOS:000397090500010
PM 27745535
ER
PT J
AU Beck, AK
Forbes, E
Baker, AL
Kelly, PJ
Deane, FP
Shakeshaft, A
Hunt, D
Kelly, JF
AF Beck, Alison K.
Forbes, Erin
Baker, Amanda L.
Kelly, Peter J.
Deane, Frank P.
Shakeshaft, Anthony
Hunt, David
Kelly, John F.
TI Systematic Review of SMART Recovery: Outcomes, Process Variables, and
Implications for Research
SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS
LA English
DT Review
DE systematic review; SMART Recovery; mutual aid; self-help groups;
addiction
ID SUBSTANCE USE DISORDERS; ALCOHOL DEPENDENCE; INTERVENTIONS; PROGRAMS;
12-STEP; PARTICIPATION; QUALITY; PEOPLE
AB Clinical guidelines recommend Self-Management and Recovery Training (SMART Recovery) and 12-step models of mutual aid as important sources of long-term support for addiction recovery. Methodologically rigorous reviews of the efficacy and potential mechanisms of change are available for the predominant 12-step approach. A similarly rigorous exploration of SMART Recovery has yet to be undertaken. We aim to address this gap by providing a systematic overview of the evidence for SMART Recovery in adults with problematic alcohol, substance, and/or behavioral addiction, including (i) a commentary on outcomes assessed, process variables, feasibility, current understanding of mental health outcomes, and (ii) a critical evaluation of the methodology. We searched six electronic peer-reviewed and four gray literature databases for Englishlanguage SMART Recovery literature. Articles were classified, assessed against standardized criteria, and checked by an independent assessor. Twelve studies (including three evaluations of effectiveness) were identified. Alcohol-related outcomes were the primary focus. Standardized assessment of nonalcohol substance use was infrequent. Information about behavioral addiction was restricted to limited prevalence data. Functional outcomes were rarely reported. Feasibility was largely indexed by attendance. Economic analysis has not been undertaken. Little is known about the variables that may influence treatment outcome, but attendance represents a potential candidate. Assessment and reporting of mental health status was poor. Although positive effects were found, the modest sample and diversity of methods prevent us from making conclusive remarks about efficacy. Further research is needed to understand the clinical and public health utility of SMART as a viable recovery support option.
C1 [Beck, Alison K.; Forbes, Erin; Baker, Amanda L.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia.
[Kelly, Peter J.; Deane, Frank P.] Univ Wollongong, Sch Psychol, Wollongong, NSW, Australia.
[Shakeshaft, Anthony] Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW, Australia.
[Hunt, David] SMART Recovery Australia, Haymarket, NSW, Australia.
[Kelly, John F.] Massachusetts Gen Hosp, Recovery Res Inst, Boston, MA 02114 USA.
[Kelly, John F.] Harvard Med Sch, Dept Psychiat, Boston, MA USA.
RP Beck, AK (reprint author), Calvary Mater Newcastle, McCauley Ctr, Level 5,Edith St, Waratah, NSW 2298, Australia.
EM alison.beck@newcastle.edu.au
FU National Health and Medical Research Council
FX Alison K. Beck is supported by the National Health and Medical Research
Council's Centre of Research Excellence for Mental Health and Substance
Use. The funder had no involvement in the development, conduct, or
interpretation of this systematic review. We thank Mary Kumvaj for her
assistance with designing the search strategy. Protocol Registration:
PROSPERO CRD42015025574.
NR 38
TC 0
Z9 0
U1 1
U2 1
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0893-164X
EI 1939-1501
J9 PSYCHOL ADDICT BEHAV
JI Psychol. Addict. Behav.
PD FEB
PY 2017
VL 31
IS 1
BP 1
EP 20
DI 10.1037/adb0000237
PG 20
WC Substance Abuse; Psychology, Multidisciplinary
SC Substance Abuse; Psychology
GA EN1SZ
UT WOS:000395791600001
PM 28165272
ER
PT J
AU Wilson, SM
Krenek, M
Dennis, PA
Yard, SS
Browne, KC
Simpson, TL
AF Wilson, Sarah M.
Krenek, Marketa
Dennis, Paul A.
Yard, Samantha S.
Browne, Kendall C.
Simpson, Tracy L.
TI Daily Associations Between PTSD, Drinking, and Self-Appraised
Alcohol-Related Problems
SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS
LA English
DT Article
DE alcohol use disorder (AUD); posttraumatic stress disorder (PTSD);
psychiatric comorbidities; longitudinal; interactive voice recognition
(IVR)
ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY;
CONFIRMATORY FACTOR-ANALYSIS; TIMELINE FOLLOW BACK; ALL-CAUSE MORTALITY;
SUBSTANCE USE; BETWEEN-PERSON; CONDITIONS-III; LIFETIME PTSD;
WITHIN-PERSON
AB Alcohol dependence (AD) and posttraumatic stress disorder (PTSD) are highly comorbid, yet limited research has focused on PTSD and daily drinking as they relate to self-appraised alcohol-related problems. In treatment contexts, patients' appraisals of alcohol-related problems have implications for assessment, intervention strategies, and prognosis. This study investigated the moderating effect of within-person (daily symptoms) and between-person (overall severity) differences in PTSD on the association between daily drinking and same-day alcohol-related problems. Participants with comorbid AD and PTSD (N = 86) completed 1 week of Interactive Voice Recognition data collection, and logistic and gamma-adjusted multilevel models were used to estimate odds and magnitude of self-appraised alcohol-related problems. Results revealed that both within-person and between-person PTSD moderated the association between number of drinks and severity of self-appraised problems. As within-person and between-person PTSD symptoms increased, there was a weaker association between number of drinks consumed and perceived alcohol-related problems. Contrasts further revealed that on nondrinking and light-drinking days, PTSD (both daily symptoms and overall severity) was positively associated with ratings of alcohol-related problems. However, PTSD was not associated with alcohol-related problems on heavier drinking days. In conclusion, more severe PTSD is associated with a less directly contingent relationship between drinking quantity and perceived alcohol-related problems. These findings suggest the importance of further investigations of this moderating effect as well as clinical treatment of comorbid AD and severe PTSD with functional analysis of drinking.
C1 [Wilson, Sarah M.] Midatlantic Mental Illness Res Educ & Clin Ctr MI, 508 Fulton St, Durham, NC 27705 USA.
[Wilson, Sarah M.; Dennis, Paul A.] Durham VA Hlth Care Syst, Durham, NC USA.
[Krenek, Marketa; Browne, Kendall C.] VA Puget Sound Hlth Care Syst, VISN MIRECC 20, Seattle, WA USA.
[Dennis, Paul A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA.
[Yard, Samantha S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Browne, Kendall C.; Simpson, Tracy L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Simpson, Tracy L.] VA Puget Sound Hlth Care Syst, CESATE, Seattle, WA USA.
RP Wilson, SM (reprint author), Midatlantic Mental Illness Res Educ & Clin Ctr MI, 508 Fulton St, Durham, NC 27705 USA.
EM sarah.wilson@duke.edu
FU NIH/NIAAA [R21AA17130-01]; U.S. Department of Veterans Affairs Office of
Academic Affiliations, Advanced Fellowship Program in Mental Illness
Research and Treatment
FX This study was supported in part by a grant from NIH/NIAAA award
(R21AA17130-01; PI: TLS) and by resources from the Center of Excellence
in Substance Abuse Treatment and Education (CESATE; TLS), the VISN 20
and VISN 6 Mental Illness Research, Education, and Clinical Centers
(MIRECC), the U.S. Department of Veterans Affairs Office of Academic
Affiliations, Advanced Fellowship Program in Mental Illness Research and
Treatment (SMW, MK, SSY, and KCB), and the VA Puget Sound Health Care
System, Seattle, WA.
NR 50
TC 0
Z9 0
U1 0
U2 0
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0893-164X
EI 1939-1501
J9 PSYCHOL ADDICT BEHAV
JI Psychol. Addict. Behav.
PD FEB
PY 2017
VL 31
IS 1
BP 27
EP 35
DI 10.1037/adb0000238
PG 9
WC Substance Abuse; Psychology, Multidisciplinary
SC Substance Abuse; Psychology
GA EN1SZ
UT WOS:000395791600003
PM 28068120
ER
PT J
AU Fernandez, AC
Yurasek, AM
Merrill, JE
Miller, MB
Zamboanga, BL
Carey, KB
Borsari, B
AF Fernandez, Anne C.
Yurasek, Ali M.
Merrill, Jennifer E.
Miller, Mary Beth
Zamboanga, Byron L.
Carey, Kate B.
Borsari, Brian
TI Do Brief Motivational Interventions Reduce Drinking Game Frequency in
Mandated Students? An Analysis of Data From Two Randomized Controlled
Trials
SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS
LA English
DT Article
DE drinking games; brief intervention; motivational interviewing; college;
alcohol
ID COLLEGE-STUDENTS; ALCOHOL INTERVENTIONS; AUSTRALIAN UNIVERSITY; STEPPED
CARE; PARTICIPATION; CONSUMPTION; DRINKERS; DETERMINANTS; METAANALYSIS;
EFFICACY
AB College students frequently engage in drinking games (DGs) and experience a variety of consequences as a result. It is currently unknown whether brief motivational interventions (BMIs) that provide feedback on DG participation can reduce this high risk behavior. This study examined outcome data from 2 randomized clinical trials to examine whether BMIs facilitate change in DG frequency and how these changes may occur. Mandated college students (Trial 1, N = 198, 46% female; Trial 2, N = 412; 32% female) were randomized to BMI or comparison control conditions. Hierarchical linear modeling (HLM) was used to compare the BMI and comparison groups to determine whether the BMI reduced DG participation over time. Percent change talk (PCT) during the discussion of DG during the session was examined as a predictor of change in DG frequency, and gender was examined as a moderator of treatment effects. Controlling for regular drinking frequency, participants who received a BMI did not significantly reduce their DG frequency relative to the comparison group in either sample, and the BMI was equally ineffective at reducing DG behavior for men and women. DG-related PCT during the BMI was associated with lower DG frequency at the second follow-up in both trials. In Trial 1, PCT during the BMI was associated with less steep increases in DG frequency across the course of all follow-ups. Effects of PCT on DG behavior were not moderated by gender. Findings did not support hypothesized reductions in DG participation following a BMI. Future research should explore whether targeted DG-specific interventions could reduce DG participation and the role of in-session client language in facilitating such change.
C1 [Fernandez, Anne C.] Univ Michigan, Dept Psychiat, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.
[Yurasek, Ali M.] Univ Florida, Coll Hlth & Human Performance, Dept Hlth Educ & Behav, Gainesville, FL 32611 USA.
[Merrill, Jennifer E.; Miller, Mary Beth; Carey, Kate B.] Brown Univ, Ctr Alcohol & Addict Studies, Sch Publ Hlth, Providence, RI 02912 USA.
[Zamboanga, Byron L.] Smith Coll, Dept Psychol, Northampton, MA 01063 USA.
[Borsari, Brian] San Francisco VA Med Ctr, San Francisco, CA USA.
[Borsari, Brian] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.
RP Fernandez, AC (reprint author), Univ Michigan, Dept Psychiat, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.
EM acfernan@med.umich.edu
FU National Institute on Alcohol Abuse and Alcoholism [R01-AA015518, R01
AA017427, T32 AA007459]; VISN1 Career Development Award [V1CDA2012-18];
[R01 AA012518]
FX This work was supported by National Institute on Alcohol Abuse and
Alcoholism Grants R01-AA015518, R01 AA017427, and VISN1 Career
Development Award V1CDA2012-18 to Brian Borsari and Grant R01 AA012518
to Kate B. Carey. The contributions of Anne C. Fernandez, Ali M. Yurasek
and Mary Beth Miller were supported by Grant T32 AA007459 from the
National Institute on Alcohol Abuse and Alcoholism.
NR 50
TC 0
Z9 0
U1 0
U2 0
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0893-164X
EI 1939-1501
J9 PSYCHOL ADDICT BEHAV
JI Psychol. Addict. Behav.
PD FEB
PY 2017
VL 31
IS 1
BP 36
EP 45
DI 10.1037/adb0000239
PG 10
WC Substance Abuse; Psychology, Multidisciplinary
SC Substance Abuse; Psychology
GA EN1SZ
UT WOS:000395791600004
PM 27936818
ER
PT J
AU Magidson, JF
Robustelli, BL
Seitz-Brown, CJ
Whisman, MA
AF Magidson, Jessica F.
Robustelli, Briana L.
Seitz-Brown, C. J.
Whisman, Mark A.
TI Activity Enjoyment, Not Frequency, Is Associated With Alcohol-Related
Problems and Heavy Episodic Drinking
SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS
LA English
DT Article
DE alcohol-related problems; heavy drinking; depression; behavioral theory
ID BEHAVIORAL ACTIVATION TREATMENT; SUBSTANCE USE; USE DISORDERS;
DEPRESSION; PLEASANT; CHOICE; ADULTS; REINFORCEMENT; OUTCOMES; EVENTS
AB Depression and alcohol use disorder (AUD) commonly co-occur, and this comorbidity is associated with greater impairment and higher likelihood of relapse compared to either disorder alone. Identifying shared vulnerability across depression and AUD may aid in developing more parsimonious treatment approaches. Low levels of positive reinforcement for healthy behaviors have been implicated as a shared vulnerability across both depression and AUD. However, prior research in this area has largely been conducted among college students and has rarely examined depression and AUD symptoms together. This study aims to extend prior literature by examining the association between both the frequency and enjoyment of activities and AUD symptoms in a national sample of adults (n = 609) while also accounting for depressive symptoms. Study results indicated that low levels of enjoyment were associated with greater alcohol-related problems and frequency of heavy episodic drinking, above and beyond depressive symptoms. The frequency of potentially pleasurable activities was unrelated to alcohol-related problems or heavy episodic drinking. Findings extend prior literature by providing evidence for the association between enjoyment of activities and alcohol use, above and beyond depressive symptoms, among a national sample of adults. These results suggest that prioritizing enjoyment of activities, rather than frequency, may be important for behavioral intervention efforts to address heavy drinking and associated problems. Future longitudinal research using observational methods of behavior is needed to identify causal relationships between activity enjoyment and AUD symptoms.
C1 [Magidson, Jessica F.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Magidson, Jessica F.] Harvard Med Sch, Dept Psychiat, 1 Bowdoin Sq,7th Floor, Boston, MA 02108 USA.
[Robustelli, Briana L.; Whisman, Mark A.] Univ Colorado Boulder, Dept Psychol & Neurosci, Boulder, CO USA.
[Seitz-Brown, C. J.] Univ Maryland, Dept Psychol, College Pk, MD 20742 USA.
RP Magidson, JF (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.; Magidson, JF (reprint author), Harvard Med Sch, Dept Psychiat, 1 Bowdoin Sq,7th Floor, Boston, MA 02108 USA.
EM Jmagidson@mgh.harvard.edu
FU National Institute on Aging [P01-AG020166]; General Clinical Research
Centers Program [M01-RR023942, M01-RR00865]; Clinical and Translational
Science Award (CTSA) program of the National Center for Research
Resources, National Institutes of Health [1UL1RR025011]; John D. and
Catherine T. MacArthur Foundation Research Network on Successful Midlife
Development; National Institutes of Health [K23DA041901]; National
Insitutes of Health [F31DA039612]
FX This research was supported by a grant from the National Institute on
Aging (P01-AG020166) to conduct a longitudinal follow-up of the MIDUS
(Midlife in the U.S.) investigation and by grants M01-RR023942
(Georgetown), M01-RR00865 (UCLA) from the General Clinical Research
Centers Program, and 1UL1RR025011 (UW) from the Clinical and
Translational Science Award (CTSA) program of the National Center for
Research Resources, National Institutes of Health. The original study
was supported by the John D. and Catherine T. MacArthur Foundation
Research Network on Successful Midlife Development. Jessica F.
Magidson's time on this manuscript was supported by National Institutes
of Health Grant K23DA041901. C.J. Seitz-Brown's time on this manuscript
was supported by National Insitutes of Health Grant F31DA039612.
NR 26
TC 0
Z9 0
U1 0
U2 0
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0893-164X
EI 1939-1501
J9 PSYCHOL ADDICT BEHAV
JI Psychol. Addict. Behav.
PD FEB
PY 2017
VL 31
IS 1
BP 73
EP 78
DI 10.1037/adb0000220
PG 6
WC Substance Abuse; Psychology, Multidisciplinary
SC Substance Abuse; Psychology
GA EN1SZ
UT WOS:000395791600008
PM 27631613
ER
PT J
AU Brumpton, BM
Langhammer, A
Henriksen, AH
Camargo, CA
Chen, Y
Romundstad, PR
Mai, XM
AF Brumpton, Ben M.
Langhammer, Arnulf
Henriksen, Anne H.
Camargo, Carlos A., Jr.
Chen, Yue
Romundstad, Pl R.
Mai, Xiao-Mei
TI Physical activity and lung function decline in adults with asthma: The
HUNT Study
SO RESPIROLOGY
LA English
DT Article
DE forced expiratory volume in 1 s; forced vital capacity; leisure time;
peak expiratory flow; prospective
ID BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY-FUNCTION; NORD-TRONDELAG;
EXERCISE; POPULATION; SMOKING; PROGRAM; HEALTH; COHORT; MEN
AB Background and objective: People with asthma may seek advice about physical activity. However, the benefits of leisure time physical activity on lung function are unclear. We investigated the association between leisure time physical activity and lung function decline in adults with asthma.
Methods: In a population-based cohort study in Norway, we used multiple linear regressions to estimate the annual mean decline in lung function (and 95% CI) in 1329 people with asthma over a mean follow-up of 11.6 years. The durations of light and hard physical activity per week in the last year were collected by questionnaire. Inactive participants did not report any light or hard activity, while active participants reported light or hard activity.
Results: The mean decline in forced expiratory volume in 1 s (FEV1) was 37 mL/year among inactive participants and 32 mL/year in active participants (difference: -5 mL/year (95% CI: -13 to 3)). The mean decline in forced vital capacity (FVC) was 33 mL/year among inactive participants and 31 mL/year in active participants (difference: -2 mL/year (95% CI: -11 to 7)). The mean decline in FEV1/FVC ratio was 0.36%/year among inactive participants and 0.22%/year in active participants (difference: -0.14%/year (95% CI: -0.27 to -0.01)). The mean decline in peak expiratory flow (PEF) was 14 mL/ year among the inactive participants and 10 mL/year in active participants (difference: -4 mL/year (95% CI: -9 to 1)).
Conclusion: We observed slightly less decline in lung function in physically active than inactive participants with asthma, particularly for FEV1, FEV1/FVC ratio and PEF.
C1 [Brumpton, Ben M.; Langhammer, Arnulf; Romundstad, Pl R.; Mai, Xiao-Mei] Norwegian Univ Sci & Technol, NTNU, Dept Publ Hlth & Gen Practice, Fac Med, Trondheim, Norway.
[Henriksen, Anne H.] Norwegian Univ Sci & Technol, NTNU, Dept Circulat & Med Imaging, Trondheim, Norway.
[Henriksen, Anne H.] Univ Trondheim Hosp, Dept Thorac & Occupat Med, Trondheim, Norway.
[Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA.
[Camargo, Carlos A., Jr.] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Chen, Yue] Univ Ottawa, Fac Med, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada.
RP Brumpton, BM (reprint author), Norwegian Univ Sci & Technol NTNU, Dept Publ Hlth & Gen Practice, Fac Med, MTFS, Postbox 8905, NO-7491 Trondheim, Norway.
EM ben.brumpton@ntnu.no
FU Liaison Committee
FX The HUNT Study) is a collaboration between HUNT Research Centre (Faculty
of Medicine, Norwegian University of Science and Technology, NTNU),
Nord-Trondelag County Council, Central Norway Health Authority and the
Norwegian Institute of Public Health. B.M.B. received a post-doctoral
fellowship grant from the Liaison Committee between the Central Norway
Regional Health Authority and the Norwegian University of Science and
Technology.
NR 28
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1323-7799
EI 1440-1843
J9 RESPIROLOGY
JI Respirology
PD FEB
PY 2017
VL 22
IS 2
BP 278
EP 283
DI 10.1111/resp.12884
PG 6
WC Respiratory System
SC Respiratory System
GA EO6FS
UT WOS:000396788000009
PM 27696634
ER
PT J
AU Uraki, R
Hwang, J
Jurado, KA
Householder, S
Yockey, LJ
Hastings, AK
Homer, RJ
Iwasaki, A
Fikrig, E
AF Uraki, Ryuta
Hwang, Jesse
Jurado, Kellie Ann
Householder, Sarah
Yockey, Laura J.
Hastings, Andrew K.
Homer, Robert J.
Iwasaki, Akiko
Fikrig, Erol
TI Zika virus causes testicular atrophy
SO SCIENCE ADVANCES
LA English
DT Article
ID HUMAN LEYDIG-CELLS; SEXUAL TRANSMISSION; NEURAL PROGENITORS; MICE;
INFECTION; BRAIN; ORGANOIDS; EXPOSURE; LEADS; PERSISTENCE
AB Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that has recently been found to cause fetal infection and neonatal abnormalities, including microcephaly and neurological dysfunction. ZIKV persists in the semen months after the acute viremic phase in humans. To further understand the consequences of ZIKV persistence in males, we infected Ifnar1(-/-) mice via subcutaneous injection of a pathogenic but nonlethal ZIKV strain. ZIKV replication persists within the testes even after clearance from the blood, with interstitial, testosterone-producing Leydig cells supporting virus replication. We found high levels of viral RNA and antigen within the epididymal lumen, where sperm is stored, and within surrounding epithelial cells. Unexpectedly, at 21 days post-infection, the testes of the ZIKV-infected mice were significantly smaller compared to those of mock-infected mice, indicating progressive testicular atrophy. ZIKV infection caused a reduction in serum testosterone, suggesting that male fertility can be affected. Our findings have important implications for nonvector-borne vertical transmission, as well as long-term potential reproductive deficiencies, in ZIKV-infected males.
C1 [Uraki, Ryuta; Hwang, Jesse; Householder, Sarah; Hastings, Andrew K.; Fikrig, Erol] Yale Univ, Sch Med, Dept Internal Med, Sect Infect Dis, 333 Cedar St, New Haven, CT 06520 USA.
[Jurado, Kellie Ann; Yockey, Laura J.; Iwasaki, Akiko] Yale Univ, Sch Med, Dept Immunobiol, 333 Cedar St, New Haven, CT 06520 USA.
[Homer, Robert J.] Yale Univ, Sch Med, Dept Pathol, 333 Cedar St, New Haven, CT 06520 USA.
[Homer, Robert J.] US Dept Vet Affairs, Affairs Connecticut Healthcare Syst Pathol & Lab, West Haven, CT 06516 USA.
[Iwasaki, Akiko; Fikrig, Erol] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Fikrig, E (reprint author), Yale Univ, Sch Med, Dept Internal Med, Sect Infect Dis, 333 Cedar St, New Haven, CT 06520 USA.; Fikrig, E (reprint author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
EM erol.fikrig@yale.edu
FU NIH [5T32 AI007019-40, 4T32HL007974-15, T32 GM007205]
FX This work was supported by NIH grants 5T32 AI007019-40 (to K.A.J.),
4T32HL007974-15 (to J.H.), and T32 GM007205 (to L.J.Y.).
NR 43
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD FEB
PY 2017
VL 3
IS 2
AR e1602899
DI 10.1126/sciadv.1602899
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EO9WT
UT WOS:000397039500038
ER
PT J
AU Rai, SK
Avina-Zubieta, JA
McCormick, N
De Vera, MA
Shojania, K
Sayre, EC
Choi, HK
AF Rai, Sharan K.
Avina-Zubieta, J. Antonio
McCormick, Natalie
De Vera, Mary A.
Shojania, Kam
Sayre, Eric C.
Choi, Hyon K.
TI The rising prevalence and incidence of gout in British Columbia, Canada:
Population-based trends from 2000 to 2012
SO SEMINARS IN ARTHRITIS AND RHEUMATISM
LA English
DT Review
DE Gout; Epidemiology; Prevalence; Incidence; Urate-lowering therapy;
Prescription patterns; Canada
ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; US
GENERAL-POPULATION; PURINE-RICH FOODS; URIC-ACID LEVEL; PROSPECTIVE
COHORT; SOFT DRINKS; NEW-ZEALAND; FOLLOW-UP; RISK
AB Objectives: Gout is increasingly recognized as the most common form of inflammatory arthritis worldwide; however, no Canadian data on the disease burden of gout are available. We estimated the prevalence, incidence, prescription patterns, and comorbidity burden of gout in an entire Canadian province [British Columbia (BC)] over the last decade.
Methods: We utilized PopulationData BC, a province-wide database, to estimate temporal trends in the prevalence and incidence of gout from 2000 to 2012, as well as according to age category. Annual estimates were age-sex-standardized using 2012 as the reference. We also examined annual trends in prescription patterns of common gout medications and assessed the comorbidity burden among gout patients in 2012.
Results: The 2012 prevalence of gout was 3.8% among the overall population, and the incidence rate was 2.9 per 1000 person-years. Both gout prevalence and incidence increased substantially over the study period. This burden additionally increased according to age category, affecting over 8% of those ages 60-69 years in 2012. Approximately 22% of gout patients received a prescription for urate-lowering therapy (ULT), which remained stable over the study period, while colchicine and oral glucocorticoid use both increased modestly. By 2012, 72%, 52%, and 18% of prevalent gout patients had been diagnosed with hypertension, hyperlipidemia, and diabetes, respectively.
Conclusions: The burden of gout in BC, Canada, is substantial, and both the prevalence and incidence have increased over the past decade, while prescription of ULT remains low. These data support the need to improve gout prevention and care. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Rai, Sharan K.; Avina-Zubieta, J. Antonio; McCormick, Natalie; De Vera, Mary A.; Shojania, Kam; Sayre, Eric C.; Choi, Hyon K.] Arthrit Res Canada, Vancouver, BC, Canada.
[Rai, Sharan K.] Univ British Columbia, Dept Expt Med, Vancouver, BC, Canada.
[Avina-Zubieta, J. Antonio; Shojania, Kam] Univ British Columbia, Dept Med, Div Rheumatol, Vancouver, BC, Canada.
[McCormick, Natalie; De Vera, Mary A.] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada.
[Choi, Hyon K.] Harvard Med Sch, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Dept Med, 55 Fruit St,Bulfinch 165, Boston, MA 02114 USA.
RP Choi, HK (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Dept Med, 55 Fruit St,Bulfinch 165, Boston, MA 02114 USA.
EM hchoi@partners.org
FU Team Grant from the Canadian Institutes of Health Research, Canada
[135235]; National Institute of Arthritis and Musculoskeletal and Skin
Diseases, United States [R01AR065944]
FX This study was funded by a Team Grant from the Canadian Institutes of
Health Research, Canada (Grant ID 135235). This study was also supported
in part from a grant from the National Institute of Arthritis and
Musculoskeletal and Skin Diseases, United States (R01AR065944).
NR 44
TC 0
Z9 0
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0049-0172
EI 1532-866X
J9 SEMIN ARTHRITIS RHEU
JI Semin. Arthritis Rheum.
PD FEB
PY 2017
VL 46
IS 4
BP 451
EP 456
DI 10.1016/j.semarthrit.2016.08.006
PG 6
WC Rheumatology
SC Rheumatology
GA EO0JK
UT WOS:000396383900010
PM 28040245
ER
PT J
AU Rosenblau, G
Kliemann, D
Dziobek, I
Heekeren, HR
AF Rosenblau, Gabriela
Kliemann, Dorit
Dziobek, Isabel
Heekeren, Hauke R.
TI Emotional prosody processing in autism spectrum disorder
SO SOCIAL COGNITIVE AND AFFECTIVE NEUROSCIENCE
LA English
DT Article
DE emotion; prosody; behavioral assessment; fMRI; autism
ID SUPERIOR TEMPORAL SULCUS; HIGH-FUNCTIONING AUTISM; ASPERGER-SYNDROME;
DIAGNOSTIC INTERVIEW; MEANINGLESS SPEECH; SOCIAL COGNITION; BRAIN
MECHANISMS; RIGHT-HEMISPHERE; REVISED VERSION; NORMAL ADULTS
AB Individuals with Autism Spectrum Disorder (ASD) are characterized by severe deficits in social communication, whereby the nature of their impairments in emotional prosody processing have yet to be specified. Here, we investigated emotional prosody processing in individuals with ASD and controls with novel, lifelike behavioral and neuroimaging paradigms. Compared to controls, individuals with ASD showed reduced emotional prosody recognition accuracy on a behavioral task. On the neural level, individuals with ASD displayed reduced activity of the STS, insula and amygdala for complex vs basic emotions compared to controls. Moreover, the coupling between the STS and amygdala for complex vs basic emotions was reduced in the ASD group. Finally, groups differed with respect to the relationship between brain activity and behavioral performance. Brain activity during emotional prosody processing was more strongly related to prosody recognition accuracy in ASD participants. In contrast, the coupling between STS and anterior cingulate cortex (ACC) activity predicted behavioral task performance more strongly in the control group. These results provide evidence for aberrant emotional prosody processing of individuals with ASD. They suggest that the differences in the relationship between the neural and behavioral level of individuals with ASD may account for their observed deficits in social communication.
C1 [Rosenblau, Gabriela; Kliemann, Dorit; Dziobek, Isabel; Heekeren, Hauke R.] Free Univ Berlin, Cluster Excellence Languages Emot, D-14195 Berlin, Germany.
[Rosenblau, Gabriela; Kliemann, Dorit; Heekeren, Hauke R.] Free Univ Berlin, Dept Educ & Psychol, D-14195 Berlin, Germany.
[Rosenblau, Gabriela] Yale Univ, Yale Child Study Ctr, 230 S Frontage Rd, New Haven, CT 06519 USA.
[Kliemann, Dorit] MIT, McGovern Inst Brain Res, 43 Vassar St, Cambridge, MA 02139 USA.
[Kliemann, Dorit] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, 149 Thirteenth St, Charlestown, MA 02129 USA.
[Dziobek, Isabel] Humboldt Univ, Berlin Sch Mind & Brain, Unter Linden 6, D-10099 Berlin, Germany.
[Heekeren, Hauke R.] Freie Univ, Dahlem Inst Neuroimaging Emot, Berlin, Germany.
RP Rosenblau, G (reprint author), Yale Univ, Yale Child Study Ctr, Ctr Translat Dev Neurosci, 230 S Frontage Rd, New Haven, CT 06519 USA.
EM gabriela.rosenblau@yale.edu
FU German Research Foundation (DFG) [EXC 302]
FX The study was funded by a grant from the German Research Foundation
(DFG; EXC 302).
NR 76
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1749-5016
EI 1749-5024
J9 SOC COGN AFFECT NEUR
JI Soc. Cogn. Affect. Neurosci.
PD FEB
PY 2017
VL 12
IS 2
BP 224
EP 239
DI 10.1093/scan/nsw118
PG 16
WC Neurosciences; Psychology; Psychology, Experimental
SC Neurosciences & Neurology; Psychology
GA EP3WK
UT WOS:000397312200005
ER
PT J
AU Connell, NT
Abel, GA
Connors, JM
AF Connell, Nathan T.
Abel, Gregory A.
Connors, Jean M.
TI Low-molecular weight heparin versus vitamin K antagonists for the
treatment of cancer-associated thrombosis: A cost-effectiveness analysis
SO THROMBOSIS RESEARCH
LA English
DT Article
ID RECURRENT VENOUS THROMBOEMBOLISM; CLINICAL-PRACTICE GUIDELINES;
ANTICOAGULANT-THERAPY; SECONDARY PROPHYLAXIS; ORAL ANTICOAGULANTS;
AMERICAN-COLLEGE; ACTIVE CANCER; WARFARIN; PREVENTION; EVENTS
AB Introduction: Cancer-associated venous thromboembolism(VTE) is primarily treated with low-molecular weight heparin (LMWH), a strategy based on studies showing it to be superior to the vitamin K antagonist (VKA) warfarin for preventing VTE recurrence. Subsequent analyses suggest that the magnitude of this benefit might be less than previously determined. Neither patient-focused measures of utility nor the costs of each strategy have been evaluated in the current treatment era.
Methods: This is a cost-effectiveness analysis of VKA and LMWH for the treatment of cancer-associated thrombosis through use of a microsimulation model of outcomes for competing anticoagulation management strategies from a 2014 United States societal perspective.
Results: LMWH therapy added 0.27 QALYs relative to VKA treatment with an ICER of $217,007. One-way sensitivity analysis evaluating the utility of LMWH revealed that VKA was always the preferred strategy at a willingness to pay(WTP) threshold of $ 100,000 per QALY. Limitations include that the model incorporates a low VKA time in therapeutic range (TTR) and that the TTR in some centers may be higher thereby increasing the cost-effectiveness of the VKA strategy. Utilities for anticoagulation strategies were not derived from cancer patients, and preference is known to vary depending on how anticoagulation method is integrated with cancer treatment.
Conclusions: Our findings suggest that compared to LMWH, warfarin is a more cost-effective strategy to treat cancer-associated VTE. Although LMW His associated with a modest increase in life expectancy, this increase comes at significant cost. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Connell, Nathan T.; Connors, Jean M.] Brigham & Womens Hosp, Div Hematol, 75 Francis St,SR322, Boston, MA 02115 USA.
[Abel, Gregory A.] Dana Farber Canc Inst, Div Populat Sci, 450 Brookline Ave, Boston, MA 02115 USA.
[Connell, Nathan T.; Abel, Gregory A.; Connors, Jean M.] Harvard Med Sch, Boston, MA USA.
RP Connell, NT (reprint author), Brigham & Womens Hosp, Div Hematol, 75 Francis St,SR322, Boston, MA 02115 USA.
EM NTConnell@partners.org
NR 29
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
J9 THROMB RES
JI Thromb. Res.
PD FEB
PY 2017
VL 150
BP 53
EP 58
DI 10.1016/j.thromres.2016.12.017
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA EO9YY
UT WOS:000397045200010
PM 28039844
ER
PT J
AU Pine, AB
Lee, EJ
Sekeres, M
Steensma, DP
Zelterman, D
Prebet, T
DeZern, A
Komrokji, R
Litzow, M
Luger, S
Stone, R
Erba, HP
Garcia-Manero, G
Lee, AI
Podoltsev, NA
Barbarotta, L
Kasberg, S
Hendrickson, JE
Gore, SD
Zeidan, AM
AF Pine, Alexander B.
Lee, Eun-Ju
Sekeres, Mikkael
Steensma, David P.
Zelterman, Daniel
Prebet, Thomas
DeZern, Amy
Komrokji, Rami
Litzow, Mark
Luger, Selina
Stone, Richard
Erba, Harry P.
Garcia-Manero, Guillermo
Lee, Alfred I.
Podoltsev, Nikolai A.
Barbarotta, Lisa
Kasberg, Stephanie
Hendrickson, Jeanne E.
Gore, Steven D.
Zeidan, Amer M.
TI Wide variations in blood product transfusion practices among providers
who care for patients with acute leukemia in the United States
SO TRANSFUSION
LA English
DT Article
ID CLINICAL-PRACTICE GUIDELINE; ACUTE MYELOID-LEUKEMIA;
PLATELET-TRANSFUSION; CELL TRANSFUSION; RESTRICTIVE TRANSFUSION;
RISK-FACTORS; MANAGEMENT; SURGERY; AABB
AB BACKGROUND: Transfusion of blood products is a key component of the supportive management in patients with acute leukemia (AL). However high-quality trial evidence and clinical outcome data to support specific transfusion goals for blood products for patients with AL remain limited leading to diverse transfusion practices. The primary objective of this study was to determine the spectrum of transfusion patterns in a variety of care settings among providers who treat AL patients.
STUDY DESIGN AND METHODS: A 31-question survey queried providers caring for AL patients about the existence of institutional guidelines for transfusion of blood products, transfusion triggers for hemoglobin (Hb), platelets (PLTs), and fibrinogen in various settings including inpatient and outpatient and before procedures.
RESULTS: We analyzed 130 responses and identified divergent transfusion Hb goals in hospitalized and ambulatory patients, fibrinogen goals for cryoprecipitate transfusions, and variation in practice for use of certain PLTs and red blood cell products. The least variable transfusion patterns were reported for PLT goals in thrombocytopenia and in the setting of invasive procedures such as bone marrow biopsy and lumbar punctures.
CONCLUSIONS: This survey confirmed wide variations in blood product transfusion practices across several clinical scenarios in patients with AL. The findings emphasized the need for large prospective randomized trials to develop standardized evidence-based guidelines for blood product transfusions in patients with AL with the goal of limiting unnecessary transfusions without compromising outcomes.
C1 [Pine, Alexander B.; Barbarotta, Lisa; Kasberg, Stephanie] Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA.
[Lee, Eun-Ju; Prebet, Thomas; Lee, Alfred I.; Podoltsev, Nikolai A.; Gore, Steven D.; Zeidan, Amer M.] Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New Haven, CT 06510 USA.
[Hendrickson, Jeanne E.] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA.
[Zelterman, Daniel] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
[Sekeres, Mikkael] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA.
[Steensma, David P.; Stone, Richard] Dana Farber Canc Inst, Boston, MA 02115 USA.
[DeZern, Amy] Johns Hopkins Sch Med, Baltimore, MD USA.
[Komrokji, Rami] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA.
[Litzow, Mark] Mayo Clin, Rochester, MN USA.
[Luger, Selina] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Erba, Harry P.] Univ Alabama Birmingham, Birmingham, AL USA.
[Garcia-Manero, Guillermo] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
RP Zeidan, AM (reprint author), Yale Univ, Dept Internal Med, Sect Hematol, 333 Cedar St,POB 208028, New Haven, CT 06520 USA.
EM amer.zeidan@yale.edu
FU NCI NIH HHS [K24 CA111717, U10 CA013650, U10 CA015488, U10 CA016116, U10
CA021115, U10 CA073590, U10 CA180790, U10 CA180802, U10 CA180820, U10
CA180826, U10 CA180853, U10 CA180855, U10 CA180858, U10 CA180867]
NR 19
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0041-1132
EI 1537-2995
J9 TRANSFUSION
JI Transfusion
PD FEB
PY 2017
VL 57
IS 2
BP 289
EP 295
DI 10.1111/trf.13934
PG 7
WC Hematology
SC Hematology
GA EO9ZW
UT WOS:000397047600011
PM 27878822
ER
PT J
AU Hamada, T
Nishihara, R
Ogino, S
AF Hamada, Tsuyoshi
Nishihara, Reiko
Ogino, Shuji
TI Post-colonoscopy colorectal cancer: the key role of molecular
pathological epidemiology
SO TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Editorial Material
ID FUSOBACTERIUM-NUCLEATUM; TASK-FORCE; RISK; PREVENTION; CARCINOMA;
FEATURES; DISEASE; LESIONS
C1 [Hamada, Tsuyoshi; Nishihara, Reiko; Ogino, Shuji] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA.
[Nishihara, Reiko; Ogino, Shuji] Harvard Med Sch, Brigham & Womens Hosp, Div MPE Mol Pathol Epidemiol, Dept Pathol, Boston, MA USA.
[Nishihara, Reiko] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Nishihara, Reiko; Ogino, Shuji] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Nishihara, Reiko] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA.
[Ogino, Shuji] Harvard Med Sch, Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA USA.
RP Nishihara, R (reprint author), Brigham & Womens Hosp, Div MPE Mol Pathol Epidemiol, 75 Francis St,Room TH530a, Boston, MA 02115 USA.; Ogino, S (reprint author), Brigham & Womens Hosp, Div MPE Mol Pathol Epidemiol, 450 Brookline Ave,Room SM1036, Boston, MA 02215 USA.
EM rnishiha@hsph.harvard.edu; shuji_ogino@dfci.harvard.edu
FU U.S. National Institutes of Health (NIH) [R35 CA197735, K07 CA190673];
Dana-Farber Harvard Cancer Center; Friends of the Dana-Farber Cancer
Institute; Mitsukoshi Health and Welfare Foundation
FX This work was supported by U.S. National Institutes of Health (NIH)
grants (R35 CA197735 to Shuji Ogino and K07 CA190673 to Reiko
Nishihara); by Nodal Award from the Dana-Farber Harvard Cancer Center
(to Shuji Ogino); and by The Friends of the Dana-Farber Cancer
Institute. Tsuyoshi Hamada was supported by a fellowship grant from the
Mitsukoshi Health and Welfare Foundation.
NR 25
TC 0
Z9 0
U1 0
U2 0
PU AME PUBL CO
PI SHEUNG WAN
PA ROOM 604 6-F HOLLYWOOD CENTER, 77-91, QUEENS ROAD, SHEUNG WAN, HONG KONG
00000, PEOPLES R CHINA
SN 2224-476X
EI 2415-1289
J9 TRANSL GASTROENT HEP
JI Transl. Gastroenterol. Hepatol.
PD FEB
PY 2017
VL 2
AR 9
DI 10.21037/tgh.2017.01.05
PG 6
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EO0SH
UT WOS:000396407700002
PM 28275741
ER
PT J
AU Hu, KJ
Moses, ZB
Hutter, MM
Williams, Z
AF Hu, Kejia
Moses, Ziev B.
Hutter, Matthew M.
Williams, Ziv
TI Short-Term Adverse Outcomes After Deep Brain Stimulation Treatment in
Patients with Parkinson Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; Deep brain stimulation; Discharge destination; NSQIP;
Parkinson disease; Unplanned readmission
ID PREDICT DISCHARGE DESTINATION; QUALITY IMPROVEMENT PROGRAM;
OF-THE-LITERATURE; BODY-MASS INDEX; NATIONWIDE INPATIENT SAMPLE;
SUBTHALAMIC NUCLEUS; MOVEMENT-DISORDERS; UNITED-STATES; SUBARACHNOID
HEMORRHAGE; HARDWARE COMPLICATIONS
AB BACKGROUND: Despite ongoing progress in our understanding of long-term outcomes after neuromodulation procedures, acute adverse outcomes shortly after deep brain stimulation (DBS) treatment have remained remarkably limited.
OBJECTIVE: To identify risk factors associated with acute 30-day outcomes after DBS treatment in patients with Parkinson disease (PD).
METHODS: We evaluated patients who underwent DBS treatment for PD from 2005 to 2014 through the American College of Surgeons National Surgical Quality Improvement Program database. We used bivariate analysis and multivariate logistic regression to identify short-term postoperative outcomes, including 30-day complication, discharge destination, and unplanned readmission.
RESULTS: Overall, 650 patients with PD underwent DBS procedures and complications were identified in 32 patients (4.9%). Of 481 patients who had complete discharge data, 18 patients (3.7%) were discharged to a facility and 16 patients (3.3%) experienced an unplanned readmission. Patients with PD who were obese (P = 0.045), who had preoperative anemia (P = 0.008), and who experienced longer operative durations (P = 0.01) had increased odds of postoperative complications. Inpatient status (P = 0.001), dependent functional status (P < 0.001), and anemia (P =0.043) were all associated with discharge to a facility other than home. Longer operative duration (P = 0.013), anemia (P = 0.036), and dependent functional status (P = 0.03) were significantly associated with unplanned readmission. As expected, complications increased the likelihood of unplanned readmission (P < 0.001).
CONCLUSIONS: This study provides individualized estimates of the risks associated with short-term adverse outcomes based on patient demographics and comorbidities. These data can be used as an adjunct for short-term risk stratification of patients with PD being considered for DBS treatment.
C1 [Hu, Kejia; Moses, Ziev B.; Williams, Ziv] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA.
[Hutter, Matthew M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA.
[Moses, Ziev B.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA USA.
[Hu, Kejia] Fudan Univ, Huashan Hosp, Dept Microsurg, Shanghai, Peoples R China.
RP Williams, Z (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02115 USA.
EM zwilliams@mgh.harvard.edu
FU China Scholarship Council
FX We greatly thank Donna M. Antonelli and Sarah H. Bird, who assisted with
obtaining and using NSQIP datasets. We also thank Mohsen Jamali,
Raymundo Baez-Mendoza, Firas Bounni, Gabriel Friedman, William Li, Jonas
St Fleur, and Emma Mastrobattista in MGH-HMS Center for Nervous System
Repair for their insightful discussion. Kejia Hu also specially thanks
Professor Wendong Xu (Huashan Hospital, Fudan University), Professor
Bomin Sun (Ruijin Hospital, Shanghai Jiao Tong University School of
Medicine), Dr. Yu Zhu (Xuanwu Hospital, Capital Medical University) and
The China Scholarship Council for support and encouragement.
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2017
VL 98
BP 365
EP 374
DI 10.1016/j.wneu.2016.10.138
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA EO9SL
UT WOS:000397028300042
PM 27826085
ER
PT J
AU Muskens, IS
Senders, JT
Dasenbrock, HH
Smith, TRS
Broekman, MLD
AF Muskens, Ivo S.
Senders, Joeky T.
Dasenbrock, Hormuzdiyar H.
Smith, Timothy R. S.
Broekman, Marike L. D.
TI The Woven Endobridge Device for Treatment of Intracranial Aneurysms: A
Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Endovascular treatment; Intracranial aneurysm; WEB device
ID SINGLE-CENTER EXPERIENCE; ENDOVASCULAR TREATMENT; WEB DEVICE; UNRUPTURED
ANEURYSMS; EMBOLIZATION DEVICE; FLOW DISRUPTION; MULTICENTER; COILING;
TRIAL; COMPLICATIONS
AB INTRODUCTION: The Woven Endobridge (WEB) device is an innovative endovascular device for treatment of intracranial aneurysms, especially bifurcation and wide-neck aneurysms. Although not approved by the U.S. Food and Drug Administration, it has been available in Europe since 2011. The aim of this review is to evaluate the outcomes of WEB device use for intracranial aneurysm treatment.
METHODS: A systematic review was conducted with MEDLINE search engines PubMed and Embase from 2011. The search strategy provided 6229 articles, and 19 articles were included.
RESULTS: A total of 19 papers were identified describing the use of WEB devices in 687 patients with 718 aneurysms. The 2 largest prospective multi-center studies (WEBCAST and the French Observatory Trial) reported successful treatment, defined as complete closure or a neck remnant, in 85% and 79% of aneurysms, respectively. The use of a WEB device in combination with coiling or stenting was described with varying results in multiple small series. Outcomes of WEB device use in ruptured aneurysms in 2 studies showed 94% and 80% adequate treatment. Thromboembolic events were described in 71 patients (10.3% of all patients) and infarctions in 8 patients (1.2% of all patients).
CONCLUSIONS: Despite initial promising results, the WEB device should be used with caution given its potentially large learning curve and because it has primarily been investigated only in wide-neck and bifurcation aneurysms. In addition, currently available prospective studies have short follow-up, and the device has not been directly compared with other treatment modalities.
C1 [Muskens, Ivo S.; Senders, Joeky T.; Broekman, Marike L. D.] Univ Med Ctr Utrecht, Dept Neurosurg, Utrecht, Netherlands.
[Muskens, Ivo S.; Senders, Joeky T.; Dasenbrock, Hormuzdiyar H.; Smith, Timothy R. S.] Brigham & Womens Hosp, Harvard Med Sch, Cushing Neurosurg Outcomes Ctr, Dept Neurosurg, Boston, MA USA.
[Broekman, Marike L. D.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA USA.
RP Broekman, MLD (reprint author), Univ Med Ctr Utrecht, Dept Neurosurg, Utrecht, Netherlands.; Broekman, MLD (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA USA.
EM M.L.D.Broekman-4@umcutrecht.nl
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2017
VL 98
BP 809
EP 817
DI 10.1016/j.wneu.2016.11.020
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA EO9SL
UT WOS:000397028300100
PM 27856383
ER
PT J
AU Sonnenberg, A
AF Sonnenberg, Amnon
TI A Bias Toward Action in Gastrointestinal Bleeding
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Letter
C1 [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
RP Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.; Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Div Gastroenterol Hepatol, P3-GI,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM sonnenbe@ohsu.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD FEB
PY 2017
VL 112
IS 2
BP 395
EP 396
DI 10.1038/ajg.2016.558
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA EK7VP
UT WOS:000394133600042
PM 28154390
ER
PT J
AU O'Reilly, EJ
Liu, DW
Johns, DR
Cudkowicz, ME
Paganoni, S
Schwarzschild, MA
Leitner, M
Ascherio, A
AF O'Reilly, Eilis J.
Liu, Dawei
Johns, Donald R.
Cudkowicz, Merit E.
Paganoni, Sabrina
Schwarzschild, Michael A.
Leitner, Melanie
Ascherio, Alberto
TI Serum urate at trial entry and ALS progression in EMPOWER
SO AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION
LA English
DT Article
DE Survival; progression; urate; body mass index; biomarkers
ID AMYOTROPHIC-LATERAL-SCLEROSIS; URIC-ACID LEVELS; PARKINSON-DISEASE;
OXIDATIVE STRESS; CLINICAL-TRIALS; POPULATION; SURVIVAL; PREVALENCE;
CREATININE; PREDICTOR
AB Our objective was to determine whether serum urate predicts ALS progression. A study population comprised adult participants of EMPOWER (n = 942), a phase III clinical trial to evaluate the efficacy of dexpramipexole to treat ALS. Urate was measured in blood samples collected during enrollment as part of the routine block chemistry. We measured outcomes by combined assessment of function and survival rank (CAFs), and time to death, by 12 months. Results showed that in females there was not a significant relation between urate and outcomes. In males, outcomes improved with increasing urate (comparing highest to lowest urate quartile: CAFS was 53 points better with p for trend = 0.04; and hazard ratio for death was 0.60 with p for trend = 0.07), but with adjustment for body mass index (BMI) at baseline, a predictor of both urate levels and prognosis, associations were attenuated and no longer statistically significant. Overall, participants with urate levels equal to or above the median (5.1 mg/dl) appeared to have a survival advantage compared to those below (hazard ratio adjusted for BMI: 0.67; 95% confidence interval 0.47-0.95). In conclusion, these findings suggest that while the association between urate at baseline and ALS progression is partially explained by BMI, there may be an independent beneficial effect of urate.
C1 [O'Reilly, Eilis J.] Harvard TH Chan Sch Publ Hlth, Dept Nutr, Boston, MA USA.
[O'Reilly, Eilis J.; Ascherio, Alberto] Harvard Med Sch, Channing Div Network Med, Boston, MA USA.
[O'Reilly, Eilis J.; Ascherio, Alberto] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
[Liu, Dawei; Johns, Donald R.; Leitner, Melanie] Biogen, ALS Neurosci Discovery & Dev, Cambridge, MA USA.
[Cudkowicz, Merit E.; Paganoni, Sabrina; Schwarzschild, Michael A.] Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat Dis, Boston, MA 02114 USA.
[Paganoni, Sabrina] Harvard Med Sch, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA.
[Paganoni, Sabrina] VA Healthcare Syst, Boston, MA USA.
[Ascherio, Alberto] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol & Nutr, Boston, MA USA.
RP O'Reilly, EJ (reprint author), Harvard TH Chan Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
EM poeor@channing.harvard.edu
FU NIH [NS045893]; Target ALS; NIH Career Development Award
[2K12HD001097-16]; Biogen Idec
FX Funding for this study includes NIH grant awarded to AA [NS045893]. MAS
is funded by Target ALS. SP is funded by an NIH Career Development Award
[2K12HD001097-16]. The EMPOWER trial was designed by Biogen Idec and
Knopp Biosciences and sponsored by Biogen Idec.
NR 29
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2167-8421
EI 2167-9223
J9 AMYOTROPH LAT SCL FR
JI Amyotroph. Lateral Scher. Frontotemp. Degenerat.
PD FEB
PY 2017
VL 18
IS 1-2
BP 120
EP 125
DI 10.1080/21678421.2016.1214733
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA EL1TQ
UT WOS:000394404400017
PM 27677562
ER
PT J
AU Alday, PH
Bruzual, I
Nilsen, A
Pou, S
Winter, R
Ben Mamoun, C
Riscoe, MK
Doggett, JS
AF Alday, P. Holland
Bruzual, Igor
Nilsen, Aaron
Pou, Sovitj
Winter, Rolf
Ben Mamoun, Choukri
Riscoe, Michael K.
Doggett, J. Stone
TI Genetic Evidence for Cytochrome b Q(i) Site Inhibition by
4(1H)-Quinolone-3-Diarylethers and Antimycin in Toxoplasma gondii
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE Toxoplasma gondii; apicomplexan parasites; cytochrome b; cytochrome
bc(1); drug targets; experimental therapeutics; mechanisms of action;
mitochondria; parasitology; preclinical drug studies
ID ENDOCHIN-LIKE QUINOLONE; BC(1) COMPLEX; PLASMODIUM-FALCIPARUM; QUINONE
REDUCTION; CRYSTAL-STRUCTURE; BOUND SUBSTRATE; ATOVAQUONE; ENCEPHALITIS;
BABESIOSIS
AB Toxoplasma gondii is an apicomplexan parasite that causes fatal and debilitating brain and eye disease. Endochinlike quinolones (ELQs) are preclinical compounds that are efficacious against apicomplexan-caused diseases, including toxoplasmosis, malaria, and babesiosis. Of the ELQs, ELQ-316 has demonstrated the greatest efficacy against acute and chronic experimental toxoplasmosis. Although genetic analyses in other organisms have highlighted the importance of the cytochrome bc(1) complex Q(i) site for ELQ sensitivity, the mechanism of action of ELQs against T. gondii and the specific mechanism of ELQ-316 remain unknown. Here, we describe the selection and genetic characterization of T. gondii clones resistant to ELQ-316. A T. gondii strain selected under ELQ-316 drug pressure was found to possess a Thr222-Pro amino acid substitution that confers 49-fold resistance to ELQ-316 and 19-fold resistance to antimycin, a well-characterized Q(i) site inhibitor. These findings provide further evidence for ELQ Q(i) site inhibition in T. gondii and greater insight into the interactions of Q(i) site inhibitors with the apicomplexan cytochrome bc(1) complex.
C1 [Alday, P. Holland; Doggett, J. Stone] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA.
[Bruzual, Igor; Nilsen, Aaron; Pou, Sovitj; Winter, Rolf; Riscoe, Michael K.; Doggett, J. Stone] Portland VA Med Ctr, Dept Res & Dev, Portland, OR USA.
[Ben Mamoun, Choukri] Yale Sch Med, Infect Dis Sect, Dept Internal Med, New Haven, CT USA.
RP Doggett, JS (reprint author), Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA.; Doggett, JS (reprint author), Portland VA Med Ctr, Dept Res & Dev, Portland, OR USA.
EM doggettj@ohsu.edu
FU U.S. Department of Veterans Affairs Biomedical Laboratory Research and
Development [BX002440]; NIH [R01 AI100569]; Peer Reviewed Medical
Research Program Project [PR130649]; U.S. Department of Veterans Affairs
[BX003312]
FX This work was supported by Career Development Award BX002440 to J. Stone
Doggett from the U.S. Department of Veterans Affairs Biomedical
Laboratory Research and Development. We also acknowledge support for
Michael K. Riscoe from NIH R01 AI100569, Peer Reviewed Medical Research
Program Project PR130649, and VA Merit Review Funds from the U.S.
Department of Veterans Affairs BX003312.
NR 29
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD FEB
PY 2017
VL 61
IS 2
AR e01866-16
DI 10.1128/AAC.01866-16
PG 8
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA EK7JQ
UT WOS:000394102500042
ER
PT J
AU Lin, JJ
Riely, GJ
Shaw, AT
AF Lin, Jessica J.
Riely, Gregory J.
Shaw, Alice T.
TI Targeting ALK: Precision Medicine Takes on Drug Resistance
SO CANCER DISCOVERY
LA English
DT Review
ID CELL LUNG-CANCER; ANAPLASTIC LYMPHOMA KINASE; INFLAMMATORY
MYOFIBROBLASTIC TUMOR; RECEPTOR TYROSINE KINASE; GROWTH-FACTOR RECEPTOR;
EPITHELIAL-MESENCHYMAL TRANSITION; OF-THE-LITERATURE;
ACQUIRED-RESISTANCE; OPEN-LABEL; CRIZOTINIB RESISTANCE
AB Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK rearranged malignancies, including non-small cell lung cancer. However, the clinical benefi t of targeting ALK using tyrosine kinase inhibitors (TKI) is almost universally limited by the emergence of drug resistance. Diverse mechanisms of resistance to ALK TKIs have now been discovered, and these basic mechanisms are informing the development of novel therapeutic strategies to overcome resistance in the clinic. In this review, we summarize the current successes and challenges of targeting ALK.
Significance: Effective long-term treatment of ALK-rearranged cancers requires a mechanistic understanding of resistance to ALK TKIs so that rational therapies can be selected to combat resistance. This review underscores the importance of serial biopsies in capturing the dynamic therapeutic vulnerabilities within a patient's tumor and offers a perspective into the complexity of on-target and off-target ALK TKI resistance mechanisms. Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome. (C) 2017 AACR.
C1 [Lin, Jessica J.; Shaw, Alice T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Riely, Gregory J.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA.
RP Shaw, AT (reprint author), Massachusetts Gen Hosp, Ctr Canc, Dept Thorac Oncol, 32 Fruit St, Boston, MA 02114 USA.
EM ashaw1@mgh.harvard.edu
FU NCI [5R01CA164273]; National Foundation for Cancer Research; Be a Piece
of the Solution; LungStrong; Evan Spirito Foundation
FX This work was supported by grants from the NCI (5R01CA164273, to A.T.
Shaw) and the National Foundation for Cancer Research (to A.T. Shaw),
and by Be a Piece of the Solution, LungStrong, and The Evan Spirito
Foundation.
NR 184
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD FEB
PY 2017
VL 7
IS 2
BP 137
EP 155
DI 10.1158/2159-8290.CD-16-1123
PG 19
WC Oncology
SC Oncology
GA EN5AM
UT WOS:000396018000021
PM 28122866
ER
PT J
AU Montero, J
Stephansky, J
Cai, TY
Griffin, GK
Cabal-Hierro, L
Togami, K
Hogdal, LJ
Galinsky, I
Morgan, EA
Aster, JC
Davids, MS
LeBoeuf, NR
Stone, RM
Konopleva, M
Pemmaraju, N
Letai, A
Lane, AA
AF Montero, Joan
Stephansky, Jason
Cai, Tianyu
Griffin, Gabriel K.
Cabal-Hierro, Lucia
Togami, Katsuhiro
Hogdal, Leah J.
Galinsky, Ilene
Morgan, Elizabeth A.
Aster, Jon C.
Davids, Matthew S.
LeBoeuf, Nicole R.
Stone, Richard M.
Konopleva, Marina
Pemmaraju, Naveen
Letai, Anthony
Lane, Andrew A.
TI Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and
Sensitive to Venetoclax
SO CANCER DISCOVERY
LA English
DT Article
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; SEQUENCING
REVEALS; RECURRENT; INHIBITION; RESISTANCE; MUTATIONS; ABT-199; ABT-737;
DEATH
AB Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy with dismal outcomes for which no standard therapy exists. We found that primary BPDCN cells were dependent on the antiapoptotic protein BCL2 and were uniformly sensitive to the BCL2 inhibitor venetoclax, as measured by direct cytotoxicity, apoptosis assays, and dynamic BH3 profi ling. Animals bearing BPDCN patient-derived xenografts had disease responses and improved survival after venetoclax treatment in vivo. Finally, we report on 2 patients with relapsed/ refractory BPDCN who received venetoclax off-label and experienced signifi cant disease responses. We propose that venetoclax or other BCL2 inhibitors undergo expedited clinical evaluation in BPDCN, alone or in combination with other therapies. In addition, these data illustrate an example of precision medicine to predict treatment response using ex vivo functional assessment of primary tumor tissue, without requiring a genetic biomarker.
SIGNIFICANCE: Therapy for BPDCN is inadequate, and survival in patients with the disease is poor. We used primary tumor cell functional profi ling to predict BCL2 antagonist sensitivity as a common feature of BPDCN, and demonstrated in vivo clinical activity of venetoclax in patient-derived xenografts and in 2 patients with relapsed chemotherapy-refractory disease. (C) 2017 AACR.
C1 [Montero, Joan; Stephansky, Jason; Cabal-Hierro, Lucia; Togami, Katsuhiro; Hogdal, Leah J.; Galinsky, Ilene; Davids, Matthew S.; Stone, Richard M.; Letai, Anthony; Lane, Andrew A.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA.
[Cai, Tianyu; Konopleva, Marina; Pemmaraju, Naveen] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
[Griffin, Gabriel K.; Morgan, Elizabeth A.; Aster, Jon C.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA.
[LeBoeuf, Nicole R.] Harvard Med Sch, Dana Farber Brigham & Womens Canc Ctr, Ctr Cutaneous Oncol, Dept Dermatol, Boston, MA USA.
[Lane, Andrew A.] Broad Inst Harvard & MIT, Cambridge, MA USA.
RP Lane, AA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Mayer 413, Boston, MA 02215 USA.; Pemmaraju, N (reprint author), Univ Texas MD Anderson Canc Ctr, Unit 428, POB 301402, Houston, TX 77230 USA.; Letai, A (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Mayer 430, Boston, MA 02215 USA.
EM npemmaraju@mdanderson.org; anthony_letai@dfci.harvard.edu;
andrew_lane@dfci.harvard.edu
FU DFCI Medical Oncology Research Grant; Ludwig Cancer Research Foundation;
American Society of Hematology Scholar Award
FX This work was supported by a DFCI Medical Oncology Research Grant (A.
Letai and A.A. Lane), the Ludwig Cancer Research Foundation (J.
Stephansky and J.C. Aster), and an American Society of Hematology
Scholar Award (A.A. Lane).
NR 25
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD FEB
PY 2017
VL 7
IS 2
BP 156
EP 164
DI 10.1158/2159-8290.CD-16-0999
PG 9
WC Oncology
SC Oncology
GA EN5AM
UT WOS:000396018000022
PM 27986708
ER
PT J
AU Goddard, ET
Hill, RC
Nemkov, T
D'Alessandro, A
Hansen, KC
Maller, O
Mongoue-Tchokote, S
Mori, M
Partridge, AH
Borges, VF
Schedin, P
AF Goddard, Erica T.
Hill, Ryan C.
Nemkov, Travis
D'Alessandro, Angelo
Hansen, Kirk C.
Maller, Ori
Mongoue-Tchokote, Solange
Mori, Motomi
Partridge, Ann H.
Borges, Virginia F.
Schedin, Pepper
TI The Rodent Liver Undergoes Weaning-Induced Involution and Supports
Breast Cancer Metastasis
SO CANCER DISCOVERY
LA English
DT Article
ID MAMMARY-GLAND INVOLUTION; PROGNOSTIC-FACTORS; PREGNANCY; POSTPARTUM;
GROWTH; PROTEOMICS; COLLAGEN; NICHE; CELLS; RECRUITMENT
AB Patients with postpartum breast cancer are at increased risk for metastasis compared with age-matched nulliparous or pregnant patients. Here, we address whether circulating tumor cells have a metastatic advantage in the postpartum host and fi nd the postlactation rodent liver preferentially supports metastasis. Upon weaning, we observed liver weight loss, hepatocyte apoptosis, extracellular matrix remodeling including deposition of collagen and tenascin-C, and myeloid cell infl ux, data consistent with weaning-induced liver involution and establishment of a prometastatic microenvironment. Using intracardiac and intraportal metastasis models, we observed increased liver metastasis in post-weaning BALB/c mice compared with nulliparous controls. Human relevance is suggested by a similar to 3-fold increase in liver metastasis in patients with postpartum breast cancer (n = 564) and by liver-specifi c tropism (n = 117). In sum, our data reveal a previously unknown biology of the rodent liver, weaning-induced liver involution, which may provide insight into the increased liver metastasis and poor prognosis of women diagnosed with postpartum breast cancer.
SIGNIFICANCE: We fi nd that patients with postpartum breast cancer are at elevated risk for liver metastasis. We identify a previously unrecognized biology, namely weaning-induced liver involution, that establishes a prometastatic microenvironment, and which may account in part for the poor prognosis of patients with postpartum breast cancer. (C) 2017 AACR.
C1 [Goddard, Erica T.; Schedin, Pepper] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA.
[Hill, Ryan C.; Nemkov, Travis; D'Alessandro, Angelo; Hansen, Kirk C.] Univ Colorado Denver, Dept Biochem & Mol Genet, Aurora, CO USA.
[Maller, Ori] Univ Calif San Francisco, Dept Surg, Ctr Bioengn & Tissue Regenerat, San Francisco, CA 94143 USA.
[Mongoue-Tchokote, Solange; Mori, Motomi; Schedin, Pepper] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
[Mori, Motomi] Oregon Hlth & Sci Univ, Sch Publ Hlth, Portland, OR 97201 USA.
[Partridge, Ann H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Borges, Virginia F.] Univ Colorado, Dept Med, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA.
[Borges, Virginia F.] Univ Colorado, Ctr Canc, Aurora, CO USA.
[Borges, Virginia F.; Schedin, Pepper] Univ Colorado, Young Womens Breast Canc Translat Program, Anschutz Med Campus, Aurora, CO USA.
RP Schedin, P (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.; Borges, VF (reprint author), Univ Colorado, Anschutz Med Campus,12801 East 17th Ave,Room 8121, Aurora, CO 80045 USA.
EM virginia.borges@ucdenver.edu; schedin@ohsu.edu
FU NIH/NCI NRSA [F31CA186524]; NIH/NCATS Colorado CTSI [UL1 TR001082];
NIH/NCI [R33 CA183685, 5R01CA169175]; DOD [BC123567, BC123567P1]; Grohne
Family Foundation
FX Funding for this project includes NIH/NCI NRSA F31CA186524 (to E.T.
Goddard); NIH/NCATS Colorado CTSI UL1 TR001082 for proteomic support and
REDCap database support; NIH/NCI R33 CA183685 (to K.C. Hansen); DOD
BC123567 (to P. Schedin); BC123567P1 (to K. C. Hansen); NIH/NCI
5R01CA169175 (to V.F. Borges and P. Schedin); and the Grohne Family
Foundation.
NR 34
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD FEB
PY 2017
VL 7
IS 2
BP 177
EP 187
DI 10.1158/2159-8290.CD-16-0822
PG 11
WC Oncology
SC Oncology
GA EN5AM
UT WOS:000396018000024
PM 27974414
ER
PT J
AU Olsen, SN
Wronski, A
Castano, Z
Dake, B
Malone, C
De Raedt, T
Enos, M
DeRose, YS
Zhou, WH
Guerra, S
Loda, M
Welm, A
Partridge, AH
McAllister, SS
Kuperwasser, C
Cichowski, K
AF Olsen, Sarah Naomi
Wronski, Ania
Castano, Zafira
Dake, Benjamin
Malone, Clare
De Raedt, Thomas
Enos, Miriam
DeRose, Yoko S.
Zhou, Wenhui
Guerra, Stephanie
Loda, Massimo
Welm, Alana
Partridge, Ann H.
McAllister, Sandra S.
Kuperwasser, Charlotte
Cichowski, Karen
TI Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of
Luminal B Breast Cancers
SO CANCER DISCOVERY
LA English
DT Article
ID GTPASE-ACTIVATING PROTEINS; GENE-EXPRESSION PATTERNS; CELL-LINES;
MOLECULAR PORTRAITS; METASTASIS; DISEASE; KINASE; MUTATIONS; CARCINOMA;
SUBTYPES
AB Luminal breast cancers are typically estrogen receptor-positive and generally have the best prognosis. However, a subset of luminal tumors, namely luminal B cancers, frequently metastasize and recur. Unfortunately, the causal events that drive their progression are unknown, and therefore it is diffi cult to identify individuals who are likely to relapse and should receive escalated treatment. Here, we identify a bifunctional RasGAP tumor suppressor whose expression is lost in almost 50% of luminal B tumors. Moreover, we show that two RasGAP genes are concomitantly suppressed in the most aggressive luminal malignancies. Importantly, these genes cooperatively regulate two major oncogenic pathways, RAS and NF-kappa B, through distinct domains, and when inactivated drive the metastasis of luminal tumors in vivo. Finally, although the cooperative effects on RAS drive invasion, NF-kappa B activation triggers epithelial-to-mesenchymal transition and is required for metastasis. Collectively, these studies reveal important mechanistic insight into the pathogenesis of luminal B tumors and provide functionally relevant prognostic biomarkers that may guide treatment decisions.
SIGNIFICANCE: The lack of insight into mechanisms that underlie the aggressive behavior of luminal B breast cancers impairs treatment decisions and therapeutic advances. Here, we show that two RasGAP tumor suppressors are concomitantly suppressed in aggressive luminal B tumors and demonstrate that they drive metastasis by activating RAS and NF-kappa B. (C) 2017 AACR.
C1 [Olsen, Sarah Naomi; Malone, Clare; De Raedt, Thomas; Enos, Miriam; Guerra, Stephanie; Cichowski, Karen] Brigham & Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA.
[Olsen, Sarah Naomi; Castano, Zafira; Malone, Clare; De Raedt, Thomas; Enos, Miriam; Guerra, Stephanie; Partridge, Ann H.; McAllister, Sandra S.; Cichowski, Karen] Harvard Med Sch, 77 Ave Louis Pasteur, Boston, MA 02115 USA.
[Wronski, Ania; Dake, Benjamin; Zhou, Wenhui; Kuperwasser, Charlotte] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA.
[Wronski, Ania; Dake, Benjamin; Zhou, Wenhui; Kuperwasser, Charlotte] Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA.
[Castano, Zafira; McAllister, Sandra S.] Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA.
[Castano, Zafira; McAllister, Sandra S.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Castano, Zafira; McAllister, Sandra S.] Harvard Stem Cell Inst, Cambridge, MA USA.
[Loda, Massimo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[DeRose, Yoko S.; Welm, Alana] Huntsman Canc Inst, Salt Lake City, UT USA.
[Partridge, Ann H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cichowski, Karen] Dana Farber Harvard Canc Ctr, Ludwig Ctr, Boston, MA USA.
RP Cichowski, K (reprint author), Harvard Med Sch, 77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM kcichowski@rics.bwh.harvard.edu
FU Ludwig Center at DF/HCC; NCI [R01 1R01CA188659]
FX This work was supported by grants from the Ludwig Center at DF/HCC (K.
Cichowski) and the NCI (R01 1R01CA188659; K. Cichowski).
NR 42
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD FEB
PY 2017
VL 7
IS 2
BP 202
EP 217
DI 10.1158/2159-8290.CD-16-0520
PG 16
WC Oncology
SC Oncology
GA EN5AM
UT WOS:000396018000026
PM 27974415
ER
PT J
AU Perez-Gracia, JL
Sanmamed, MF
Bosch, A
Patino-Garcia, A
Schalper, KA
Segura, V
Bellmunt, J
Tabernero, J
Sweeney, CJ
Choueiri, TK
Martin, M
Fusco, JP
Rodriguez-Ruiz, ME
Calvo, A
Prior, C
Paz-Ares, L
Pio, R
Gonzalez-Billalabeitia, E
Hernandez, AG
Paez, D
Piulats, JM
Gurpide, A
Andueza, M
de Velasco, G
Pazo, R
Grande, E
Nicolas, P
Abad-Santos, F
Garcia-Donas, J
Castellano, D
Pajares, MJ
Suarez, C
Colomer, R
Montuenga, LM
Melero, I
AF Perez-Gracia, Jose Luis
Sanmamed, Miguel F.
Bosch, Ana
Patino-Garcia, Ana
Schalper, Kurt A.
Segura, Victor
Bellmunt, Joaquim
Tabernero, Josep
Sweeney, Christopher J.
Choueiri, Toni K.
Martin, Miguel
Pablo Fusco, Juan
Esperanza Rodriguez-Ruiz, Maria
Calvo, Alfonso
Prior, Celia
Paz-Ares, Luis
Pio, Ruben
Gonzalez-Billalabeitia, Enrique
Gonzalez Hernandez, Alvaro
Paez, David
Maria Piulats, Jose
Gurpide, Alfonso
Andueza, Mapi
de Velasco, Guillermo
Pazo, Roberto
Grande, Enrique
Nicolas, Pilar
Abad-Santos, Francisco
Garcia-Donas, Jesus
Castellano, Daniel
Pajares, Maria J.
Suarez, Cristina
Colomer, Ramon
Montuenga, Luis M.
Melero, Ignacio
TI Strategies to design clinical studies to identify predictive biomarkers
in cancer research
SO CANCER TREATMENT REVIEWS
LA English
DT Review
DE Biomarkers; Clinical trial design; Extreme phenotypes; Rearrangement;
Mutation
ID CELL LUNG-CANCER; GROWTH-FACTOR-RECEPTOR; GASTROINTESTINAL STROMAL
TUMORS; METASTATIC COLORECTAL-CANCER; TYROSINE KINASE INHIBITOR;
PHASE-III TRIAL; ANAPLASTIC LYMPHOMA KINASE; GENE-EXPRESSION PROFILES;
ADVANCED BREAST-CANCER; BRAF V600 MUTATIONS
AB The discovery of reliable biomarkers to predict efficacy and toxicity of anticancer drugs remains one of the key challenges in cancer research. Despite its relevance, no efficient study designs to identify promising candidate biomarkers have been established. This has led to the proliferation of a myriad of exploratory studies using dissimilar strategies, most of which fail to identify any promising targets and are seldom validated. The lack of a proper methodology also determines that many anti-cancer drugs are developed below their potential, due to failure to identify predictive biomarkers. While some drugs will be systematically administered to many patients who will not benefit from them, leading to unnecessary toxicities and costs, others will never reach registration due to our inability to identify the specific patient population in which they are active. Despite these drawbacks, a limited number of outstanding predictive biomarkers have been successfully identified and validated, and have changed the standard practice of oncology. In this manuscript, a multidisciplinary panel reviews how those key biomarkers were identified and, based on those experiences, proposes a methodological framework the DESIGN guidelines-to-standardize the clinical design of biomarker identification studies and to develop future research in this pivotal field. (C) 2017 The Authors. Published by Elsevier Ltd.
C1 [Perez-Gracia, Jose Luis; Pablo Fusco, Juan; Esperanza Rodriguez-Ruiz, Maria; Gurpide, Alfonso; Andueza, Mapi; Melero, Ignacio] Univ Navarra Clin, Dept Oncol, Avda Pio 12,36, Pamplona 31008, Spain.
[Perez-Gracia, Jose Luis; Patino-Garcia, Ana; Esperanza Rodriguez-Ruiz, Maria; Calvo, Alfonso; Pio, Ruben; Gurpide, Alfonso; Pajares, Maria J.; Montuenga, Luis M.; Melero, Ignacio] Hlth Res Inst Navarra IDISNA, Pamplona, Spain.
[Sanmamed, Miguel F.] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA.
[Bosch, Ana] Lund Univ, Dept Clin Sci, Div Oncol & Pathol, S-22100 Lund, Sweden.
[Patino-Garcia, Ana] Univ Navarra Clin, Dept Pediat, Pamplona, Spain.
[Patino-Garcia, Ana] Univ Navarra Clin, CIMA LAB Diagnost, Pamplona, Spain.
[Schalper, Kurt A.] Yale Sch Med, Dept Pathol, New Haven, CT USA.
[Segura, Victor] Univ Navarra, IDISNA, Navarra, Spain.
[Segura, Victor] Univ Navarra, Bioinformat Unit, Ctr Appl Med Res CIMA, Navarra, Spain.
[Bellmunt, Joaquim; Sweeney, Christopher J.; Choueiri, Toni K.; de Velasco, Guillermo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Bellmunt, Joaquim; Sweeney, Christopher J.; Choueiri, Toni K.; de Velasco, Guillermo] Harvard Med Sch, Boston, MA USA.
[Tabernero, Josep; Suarez, Cristina] Univ Autonoma Barcelona, Dept Med Oncol, Vall dHebron Univ Hosp, Barcelona, Spain.
[Tabernero, Josep; Suarez, Cristina] Univ Autonoma Barcelona, Inst Oncol VHIO, Barcelona, Spain.
[Martin, Miguel] Univ Complutense, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain.
[Esperanza Rodriguez-Ruiz, Maria; Melero, Ignacio] Univ Navarra, Ctr Appl Med Res CIMA, Pamplona, Spain.
[Calvo, Alfonso; Pajares, Maria J.; Montuenga, Luis M.] Univ Navarra, Sch Med, Dept Histol & Pathol, Pamplona, Spain.
[Prior, Celia] Univ Navarra, Dept Gene Therapy & Regulat Gene Express, Ctr Appl Med Res CIMA, Pamplona, Spain.
[Paz-Ares, Luis; Castellano, Daniel] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain.
[Pio, Ruben; Pajares, Maria J.; Montuenga, Luis M.] Univ Navarra, CIMA, Program Solid Tumors & Biomarkers, E-31080 Pamplona, Spain.
[Gonzalez-Billalabeitia, Enrique] Univ Catolica San Antonio de Murcia, Hosp Univ Morales Meseguer, Dept Hematol & Med Oncol, Murcia, Spain.
[Gonzalez Hernandez, Alvaro] Univ Navarra Clin, Dept Biochem, Pamplona, Spain.
[Paez, David] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain.
[Maria Piulats, Jose] Inst Catala Oncol, Dept Med Oncol, Barcelona, Spain.
[Pazo, Roberto] Hosp Univ Miguel Server, Dept Med Oncol, Zaragoza, Spain.
[Grande, Enrique] Hosp Univ Ramon y Cajal, Dept Med Oncol, Madrid, Spain.
[Nicolas, Pilar] Univ Basque Country, Chair Law & Human Genome, Bizkaia, Spain.
[Abad-Santos, Francisco] Univ Autonoma Madrid, Inst Invest Sanitaria Princesa IP, Clin Pharmacol Serv, Hosp Univ Princesa,Inst Teofilo Hernando, Madrid, Spain.
[Garcia-Donas, Jesus] HM Hosp Ctr Integral Oncol HM Clara Campal, Dept Med Oncol, Madrid, Spain.
[Colomer, Ramon] Hosp Univ Princesa, Dept Oncol, Madrid, Spain.
RP Perez-Gracia, JL (reprint author), Univ Navarra Clin, Dept Oncol, Avda Pio 12,36, Pamplona 31008, Spain.
EM jlgracia@unav.es
RI Pio, Ruben/F-5353-2017
OI Pio, Ruben/0000-0002-6831-6111
FU Spanish Society of Medical Oncology (SEOM); Fundacion SEOM and Fundacion
Salud; Health Department of Gobierno de Navarra, Spain
FX We are indebted to Paul Miller for revising the manuscript. Granted by
the Spanish Society of Medical Oncology (SEOM, 2010), by Fundacion SEOM
and Fundacion Salud 2000 (2014) and by the Health Department of Gobierno
de Navarra, Spain (2014).
NR 213
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0305-7372
EI 1532-1967
J9 CANCER TREAT REV
JI Cancer Treat. Rev.
PD FEB
PY 2017
VL 53
BP 79
EP 97
DI 10.1016/j.ctrv.2016.12.005
PG 19
WC Oncology
SC Oncology
GA EK6ZS
UT WOS:000394075400009
PM 28088073
ER
PT J
AU Bayona, AMD
Mroz, P
Thunshelle, C
Hamblin, MR
AF Bayona, Alejandra Martinez De Pinillos
Mroz, Pawel
Thunshelle, Connor
Hamblin, Michael R.
TI Design features for optimization of tetrapyrrole macrocycles as
antimicrobial and anticancer photosensitizers
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE bacteriochlorin; biodistribution; chlorin; pharmacodynamics;
photodynamic therapy; photosensitizer; phthalocyanine; porphyrin
ID STABLE SYNTHETIC BACTERIOCHLORINS; IN-VIVO PHARMACOKINETICS;
CHINESE-HAMSTER-CELLS; PHOTODYNAMIC THERAPY; SINGLET OXYGEN; CREMOPHOR
EL; ALUMINUM PHTHALOCYANINE; BIOLOGICAL-ACTIVITIES; TISSUE DISTRIBUTION;
ANTITUMOR-ACTIVITY
AB Photodynamic therapy (PDT) uses non-toxic dyes called photosensitizers (PS) and harmless visible light that combine to form highly toxic reactive oxygen species that kill cells. Originally, a cancer therapy, PDT, now includes applications for infections. The most widely studied PS are tetrapyrrole macrocycles including porphyrins, chlorins, bacteriochlorins, and phthalocyanines. The present review covers the design features in PS that can work together to maximize the PDT activity for various disease targets. Photophysical and photochemical properties include the wavelength and size of the long-wavelength absorption peak (for good light penetration into tissue), the triplet quantum yield and lifetime, and the propensity to undergo type I (electron transfer) or type II (energy transfer) photochemical mechanisms. The central metal in the tetrapyrrole macrocycle has a strong influence on the PDT activity. Hydrophobicity and charge are important factors that govern interactions with various types of cells (cancer and microbial) in vitro and the pharmacokinetics and biodistribution in vivo. Hydrophobic structures tend to be water insoluble and require a drug delivery vehicle for maximal activity. Molecular asymmetry and amphiphilicity are also important for high activity. In vivo some structures possess the ability to selectively accumulate in tumors and to localize in the tumor microvasculature producing vascular shutdown after illumination.
C1 [Bayona, Alejandra Martinez De Pinillos; Thunshelle, Connor; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Bayona, Alejandra Martinez De Pinillos] UCL, Royal Free Hosp, Div Surg & Intervent Sci, London, England.
[Mroz, Pawel] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
[Thunshelle, Connor] Harvard Univ, Cambridge, MA USA.
[Hamblin, Michael R.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA.
[Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.; Hamblin, MR (reprint author), Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA.; Hamblin, MR (reprint author), Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
EM hamblin@helix.mgh.harvard.edu
FU US NIH grant [R01AI050875]; Bogue Research Fellowship, from UCL
FX Michael R. Hamblin was supported by US NIH grant R01AI050875. Alejandra
Martinez De Pinillos Bayona was supported by the Bogue Research
Fellowship, from UCL.
NR 74
TC 0
Z9 0
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1747-0277
EI 1747-0285
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD FEB
PY 2017
VL 89
IS 2
BP 192
EP 206
DI 10.1111/cbdd.12792
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA EK5IA
UT WOS:000393958900003
ER
PT J
AU Rask-Madsen, C
Park, K
Li, Q
King, GL
AF Rask-Madsen, Christian
Park, Kyoungmin
Li, Qian
King, George L.
TI Letter by Rask-Madsen et al Regarding Article, "Selective Enhancement of
Insulin Sensitivity in the Endothelium In Vivo Reveals a Novel
Proatherosclerotic Signaling Loop"
SO CIRCULATION RESEARCH
LA English
DT Letter
ID ZUCKER FA/FA RATS; RESISTANCE; ATHEROSCLEROSIS; CELLS; MICE;
DYSFUNCTION; MUSCLE; LEADS; AKT
C1 [Rask-Madsen, Christian] Joslin Diabet Ctr, Boston, MA 02215 USA.
Harvard Med Sch, Boston, MA USA.
RP Rask-Madsen, C (reprint author), Joslin Diabet Ctr, Boston, MA 02215 USA.
FU NCI NIH HHS [R21 CA185196]
NR 18
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0009-7330
EI 1524-4571
J9 CIRC RES
JI Circ.Res.
PD FEB
PY 2017
VL 120
IS 4
BP E2
EP E3
DI 10.1161/CIRCRESAHA.116.310491
PG 2
WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular
Disease
SC Cardiovascular System & Cardiology; Hematology
GA EL2JP
UT WOS:000394446200001
PM 28209799
ER
PT J
AU Han, JH
Gordon, K
Womack, JA
Gibert, CL
Leaf, DA
Rimland, D
Rodriguez-Barradas, MC
Bisson, GP
AF Han, Jennifer H.
Gordon, Kirsha
Womack, Julie A.
Gibert, Cynthia L.
Leaf, David A.
Rimland, David
Rodriguez-Barradas, Maria C.
Bisson, Gregory P.
TI Comparative Effectiveness of Diabetic Oral Medications Among
HIV-Infected and HIV-Uninfected Veterans
SO DIABETES CARE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CORONARY-HEART-DISEASE; NUCLEOSIDE ANALOG;
CLINICAL-TRIALS; DATA-COLLECTION; TOTAL BILIRUBIN; ADVERSE EVENTS;
ASSOCIATION; MELLITUS; THERAPY
AB OBJECTIVE Type 2 diabetes is increasingly common in HIV-infected individuals. The objective of this study was to compare the glycemic effectiveness of oral diabetic medications among patients with and without HIV infection.
RESEARCH DESIGN AND METHODS A longitudinal cohort study was conducted among HIV-infected and uninfected veterans with type 2 diabetes initiating diabetic medications between 1999 and 2010. Generalized estimating equations were used to compare changes in hemoglobin A(1c) (HbA(1c)) through the year after medication initiation, adjusting for baseline HbA1c level and clinical covariates. A subanalysis using propensity scores was conducted to account for confounding by indication.
RESULTS A total of 2,454 HIV-infected patients and 8,892 HIV-uninfected patients initiated diabetic medications during the study period. The most commonly prescribed medication was metformin (n = 5,647, 50%), followed by a sulfonylurea (n = 5,554, 49%) and a thiazolidinedione (n = 145, 1%). After adjustment for potential confounders, there was no significant difference in the change in HbA(1c) level among the three groups of new users. HIV infection was not significantly associated with glycemic response (P = 0.24). Black and Hispanic patients had a poorer response to therapy compared with white patients, with a relative increase in HbA1c level of 0.16% (95% CI 0.08, 0.24) [1.7 mmol/mol (0.9, 2.6)] (P < 0.001) and 0.25% (0.11, 0.39) [2.7 mmol/mol (1.2, 4.3)] (P = 0.001), respectively.
CONCLUSIONS We found that glycemic response was independent of the initial class of diabetic medication prescribed among HIV-uninfected and HIV-infected adults with type 2 diabetes. The mechanisms leading to poorer response among black and Hispanic patients, who make up a substantial proportion of those with HIV infection and type 2 diabetes, require further investigation.
C1 [Han, Jennifer H.; Bisson, Gregory P.] Univ Penn, Dept Med, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA.
[Han, Jennifer H.; Bisson, Gregory P.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Han, Jennifer H.; Bisson, Gregory P.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Gordon, Kirsha; Womack, Julie A.] West Haven VA Med Ctr, Dept Internal Med, West Haven, CT USA.
[Womack, Julie A.] Yale Univ, Yale Sch Nursing, New Haven, CT USA.
[Gibert, Cynthia L.] George Washington Univ, Sch Med & Hlth Sci, Sect Infect Dis, Washington, DC 20052 USA.
[Gibert, Cynthia L.] Washington DC VA Med Ctr, Dept Med, Washington, DC USA.
[Leaf, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
[Leaf, David A.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA USA.
[Rimland, David] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA.
[Rimland, David] Atlanta VA Med Ctr, Div Infect Dis, Atlanta, GA USA.
[Rodriguez-Barradas, Maria C.] Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX USA.
[Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
RP Han, JH (reprint author), Univ Penn, Dept Med, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA.; Han, JH (reprint author), Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA.; Han, JH (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM jennifer.han@uphs.upenn.edu
FU Veterans Aging Cohort Study; National Institute on Alcohol Abuse and
Alcoholism [U10-AA-13566]
FX This study was supported by the Veterans Aging Cohort Study and by
National Institute on Alcohol Abuse and Alcoholism grant U10-AA-13566.
NR 37
TC 0
Z9 0
U1 0
U2 0
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2017
VL 40
IS 2
BP 218
EP 225
DI 10.2337/dc16-0718
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EL2ZL
UT WOS:000394489300020
PM 27634393
ER
PT J
AU Cefalu, WT
Buse, JB
Tuomilehto, J
Fleming, GA
Ferrannini, E
Gerstein, HC
Bennett, PH
Ramachandran, A
Raz, I
Rosenstock, J
Kahn, SE
AF Cefalu, William T.
Buse, John B.
Tuomilehto, Jaakko
Fleming, G. Alexander
Ferrannini, Ele
Gerstein, Hertzel C.
Bennett, Peter H.
Ramachandran, Ambady
Raz, Itamar
Rosenstock, Julio
Kahn, Steven E.
TI Update and Next Steps for Real-World Translation of Interventions for
Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors'
Expert Forum. Diabetes Care 2016; 39: 1186-1201
SO DIABETES CARE
LA English
DT Editorial Material
C1 [Cefalu, William T.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
[Buse, John B.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Tuomilehto, Jaakko] Natl Inst Hlth & Welf, Chron Dis Prevent Unit, Helsinki, Finland.
[Tuomilehto, Jaakko] Dasman Diabet Inst, Dasman, Kuwait.
[Tuomilehto, Jaakko] King Abdulaziz Univ, Saudi Diabet Res Grp, Jeddah, Saudi Arabia.
[Tuomilehto, Jaakko] Danube Univ Krems, Ctr Vasc Prevent, Krems, Austria.
[Fleming, G. Alexander] Kinexum, Harpers Ferry, WV USA.
[Ferrannini, Ele] CNR, Inst Clin Physiol, Pisa, Italy.
[Gerstein, Hertzel C.] McMaster Univ, Hamilton, ON, Canada.
[Gerstein, Hertzel C.] Hamilton Hlth Sci, Hamilton, ON, Canada.
[Bennett, Peter H.] NIH, Phoenix, AZ USA.
[Ramachandran, Ambady] India Diabet Res Fdn, Madras, Tamil Nadu, India.
[Ramachandran, Ambady] Dr A Ramachandrans Diabet Hosp, Madras, Tamil Nadu, India.
[Raz, Itamar] Hadassah Hebrew Univ Hosp, Dept Internal Med, Diabet Unit, Jerusalem, Israel.
[Rosenstock, Julio] Med City, Dallas Diabet Res Ctr, Dallas, TX 75390 USA.
[Rosenstock, Julio] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.
[Kahn, Steven E.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Kahn, Steven E.] Univ Washington, Seattle, WA 98195 USA.
RP Cefalu, WT (reprint author), Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA.
EM william.cefalu@pbrc.edu
FU National Institutes of Health (NIH) [1U54-GM-104940, P50-AT-002776]
FX W.T.C. is supported in part by National Institutes of Health (NIH) grant
1U54-GM-104940, which funds the Louisiana Clinical and Translational
Science Center, and NIH grant P50-AT-002776.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2017
VL 40
IS 2
BP E23
EP E24
DI 10.2337/dci16-0036
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EL2ZL
UT WOS:000394489300009
PM 28108540
ER
PT J
AU Garvey, WT
AF Garvey, W. Timothy
TI Update and Next Steps for Real-World Translation of Interventions for
Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors'
Expert Forum. Diabetes Care 2016; 39: 1186-1201
SO DIABETES CARE
LA English
DT Editorial Material
ID METABOLIC SYNDROME; OBESITY
C1 [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.
[Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
RP Garvey, WT (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA.; Garvey, WT (reprint author), Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
EM garveyt@uab.edu
FU National Institute of Diabetes and Digestive and Kidney Diseases
[DK-038765]; National Institute of Diabetes and Digestive and Kidney
Diseases (UAB Diabetes Research Center) [P30 DK079626]; U.S. Department
of Veterans Affairs (Merit Review program)
FX W.T.G. acknowledges support from grants awarded by the National
Institute of Diabetes and Digestive and Kidney Diseases (DK-038765 and
UAB Diabetes Research Center [P30 DK079626]) and the U.S. Department of
Veterans Affairs (Merit Review program).
NR 6
TC 1
Z9 1
U1 0
U2 0
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD FEB
PY 2017
VL 40
IS 2
BP E21
EP E22
DI 10.2337/dci16-0022
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA EL2ZL
UT WOS:000394489300008
PM 28108539
ER
PT J
AU Hammad, H
Kaltenbach, T
Soetikno, R
AF Hammad, Hazem
Kaltenbach, Tonya
Soetikno, Roy
TI Surveillance for dysplasia in inflammatory bowel disease: it is time to
move forward
SO ENDOSCOPY
LA English
DT Editorial Material
ID DEPRESSED COLORECTAL NEOPLASMS; STANDING ULCERATIVE-COLITIS; NONPOLYPOID
FLAT; COLONOSCOPY; MANAGEMENT; ENDOSCOPY; CONSENSUS; BIOPSIES
C1 [Hammad, Hazem] Univ Colorado, Div Gastroenterol & Hepatol, Anschutz Med Campus, Aurora, CO USA.
[Kaltenbach, Tonya] Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco Vet Affairs Med Ctr, San Francisco, CA USA.
[Soetikno, Roy] Grad Sch Business, Stanford, CA 94305 USA.
RP Soetikno, R (reprint author), Grad Sch Business, Stanford, CA 94305 USA.
EM soetikno@earthlink.net
NR 16
TC 0
Z9 0
U1 0
U2 0
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0013-726X
EI 1438-8812
J9 ENDOSCOPY
JI Endoscopy
PD FEB
PY 2017
VL 49
IS 2
BP 110
EP 112
DI 10.1055/s-0043-100097
PG 3
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA EK9PX
UT WOS:000394257500003
PM 28147393
ER
PT J
AU Francioli, LC
Cretu-Stancu, M
Garimella, KV
Fromer, M
Kloosterman, WP
Samocha, KE
Neale, BM
Daly, MJ
Banks, E
DePristo, MA
de Bakker, PIW
AF Francioli, Laurent C.
Cretu-Stancu, Mircea
Garimella, Kiran V.
Fromer, Menachem
Kloosterman, Wigard P.
Samocha, Kaitlin E.
Neale, Benjamin M.
Daly, Mark J.
Banks, Eric
DePristo, Mark A.
de Bakker, Paul I. W.
CA Genome Netherlands Consortium
TI A framework for the detection of de novo mutations in family-based
sequencing data
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID DISCOVERY; PATTERNS; DISEASE; HUMANS; RATES
AB Germline mutation detection from human DNA sequence data is challenging due to the rarity of such events relative to the intrinsic error rates of sequencing technologies and the uneven coverage across the genome. We developed PhaseByTransmission (PBT) to identify de novo single nucleotide variants and short insertions and deletions (indels) from sequence data collected in parent-offspring trios. We compute the joint probability of the data given the genotype likelihoods in the individual family members, the known familial relationships and a prior probability for the mutation rate. Candidate de novo mutations (DNMs) are reported along with their posterior probability, providing a systematic way to prioritize them for validation. Our tool is integrated in the Genome Analysis Toolkit and can be used together with the ReadBackedPhasing module to infer the parental origin of DNMs based on phase-informative reads. Using simulated data, we show that PBT outperforms existing tools, especially in low coverage data and on the X chromosome. We further show that PBT displays high validation rates on empirical parent-offspring sequencing data for whole-exome data from 104 trios and X-chromosome data from 249 parent-offspring families. Finally, we demonstrate an association between father's age at conception and the number of DNMs in female offspring's X chromosome, consistent with previous literature reports.
C1 [Francioli, Laurent C.; Cretu-Stancu, Mircea; Kloosterman, Wigard P.; de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Dept Med Genet, Ctr Mol Med, Utrecht, Netherlands.
[Francioli, Laurent C.; Fromer, Menachem; Samocha, Kaitlin E.; Neale, Benjamin M.; Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Francioli, Laurent C.; Fromer, Menachem; Samocha, Kaitlin E.; Neale, Benjamin M.; Daly, Mark J.; Banks, Eric; DePristo, Mark A.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA.
[Garimella, Kiran V.] Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford, England.
[Fromer, Menachem] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Fromer, Menachem] Icahn Sch Med Mt Sinai, Dept Genom Sci, New York, NY 10029 USA.
[de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Dept Epidemiol, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
RP Francioli, LC (reprint author), Univ Utrecht, Dept Med Genet, Heidelberglaan 100, Utrecht, Netherlands.
EM lfran@broadinstitute.org
RI Suchiman, H. Eka D./F-5024-2017;
OI Suchiman, H. Eka D./0000-0002-7168-5516; Karssen, Lennart
C./0000-0002-1959-342X
FU Genome of the Netherlands (GoNL) project by the Biobanking and
Biomolecular Research Infrastructure (BBMRI-NL) - Netherlands
Organization for Scientific Research (NWO project) [184.021.007]
FX This work was funded as part of the Genome of the Netherlands (GoNL)
project by the Biobanking and Biomolecular Research Infrastructure
(BBMRI-NL), which is financed by the Netherlands Organization for
Scientific Research (NWO project 184.021.007).
NR 19
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD FEB
PY 2017
VL 25
IS 2
BP 227
EP 233
DI 10.1038/ejhg.2016.147
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EK7RM
UT WOS:000394122900016
PM 27876817
ER
PT J
AU Chisholm, KM
Ohgami, RS
Tan, B
Hasserjian, RP
Weinberg, OK
AF Chisholm, Karen M.
Ohgami, Robert S.
Tan, Brent
Hasserjian, Robert P.
Weinberg, Olga K.
TI 6 Primary lymphoma of bone in the pediatric and young adult population
SO HUMAN PATHOLOGY
LA English
DT Article
DE Bone; Lymphoma; Pediatric; Primary lymphoma of bone
ID NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; MALIGNANT-LYMPHOMA; CHILDREN;
EXPERIENCE; THERAPY; TRIAL
AB Primary lymphoma of bone (PLB) accounts for 3% to 7% of primary neoplasms of bone and must be distinguished from more common bone tumors in the pediatric population such as osteosarcoma, Ewing sarcoma, and other small round blue cell tumors. In this study, pathology databases from 4 institutions were queried for PLB in individuals 1 to 21 years old. A total of 54 cases of PLB were identified, including 41 diffuse large B-cell lymphomas (DLBCL, 76%), 8 B-lymphoblastic lymphomas (BLL, 15%), 3 anaplastic large cell lymphomas (ALCL, 6%), and 2 low-grade follicular lymphomas (4%). The male/female ratio was 1.8:1 and median age was 16 years (range, 2-21). Patients with DLBCL were significantly older (P < .001), and patients with ALCL and BLL were significantly younger (P = .050 and P = .008, respectively) when compared with the other patients. Due to necrosis, crush artifact, and/or insufficient material, 30% of cases required multiple biopsies for diagnosis. The femur, tibia, pelvic bones, humerus, and vertebrae were most commonly involved. DLBCL patients had significantly more solitary bone involvement (P = .001), whereas BLL had significantly more polyostotic involvement (P < .001). Of the 37 patients with outcome data, all had no evidence of disease on last follow-up. This largest pediatric series of PLB identifies DLBCL as the most frequent subtype and documents rarer occurrences of BLL, ALCL, and follicular lymphomas. The differential diagnosis of bone neoplasms in pediatric patients, including those with necrosis, should include PLB. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Chisholm, Karen M.; Weinberg, Olga K.] Boston Childrens Hosp, Dept Pathol, 300 Longwood Ave,Bader 126-2, Boston, MA 02115 USA.
[Ohgami, Robert S.; Tan, Brent] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.
[Hasserjian, Robert P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Weinberg, Olga K.] Brigham Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Chisholm, Karen M.] Seattle Childrens Hosp, Dept Labs, Seattle, WA USA.
RP Weinberg, OK (reprint author), Boston Childrens Hosp, Dept Pathol, 300 Longwood Ave,Bader 126-2, Boston, MA 02115 USA.
EM olga.weinberg@childrens.harvard.edu
NR 34
TC 0
Z9 0
U1 1
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD FEB
PY 2017
VL 60
BP 1
EP 10
DI 10.1016/j.humpath.2016.07.028
PG 10
WC Pathology
SC Pathology
GA EK6XO
UT WOS:000394069800001
PM 27554207
ER
PT J
AU Nin, N
Muriel, A
Penuelas, O
Brochard, L
Lorente, JA
Ferguson, ND
Raymondos, K
R-Os, F
Violi, DA
Thille, AW
Gonzalez, M
Villagomez, AJ
Hurtado, J
Davies, AR
Du, B
Maggiore, SM
Soto, L
D'Empaire, G
Matamis, D
Abroug, F
Moreno, RP
Soares, MA
Arabi, Y
Sandi, F
Jibaja, M
Amin, P
Koh, Y
Kuiper, MA
Bulow, HH
Zeggwagh, AA
Anzueto, A
Sznajder, JI
Esteban, A
AF Nin, Nicolas
Muriel, Alfonso
Penuelas, Oscar
Brochard, Laurent
Angel Lorente, Jose
Ferguson, Niall D.
Raymondos, Konstantinos
R-Os, Fernando
Violi, Damian A.
Thille, Arnaud W.
Gonzalez, Marco
Villagomez, Asisclo J.
Hurtado, Javier
Davies, Andrew R.
Du, Bin
Maggiore, Salvatore M.
Soto, Luis
D'Empaire, Gabriel
Matamis, Dimitrios
Abroug, Fekri
Moreno, Rui P.
Soares, Marco Antonio
Arabi, Yaseen
Sandi, Freddy
Jibaja, Manuel
Amin, Pravin
Koh, Younsuck
Kuiper, Michael A.
Bulow, Hans-Henrik
Zeggwagh, Amine Ali
Anzueto, Antonio
Sznajder, Jacob I.
Esteban, Andres
CA VENTILA Grp
TI Severe hypercapnia and outcome of mechanically ventilated patients with
moderate or severe acute respiratory distress syndrome
SO INTENSIVE CARE MEDICINE
LA English
DT Article
DE Mechanical ventilation; Acute respiratory distress syndrome;
Hypercapnia; ICU mortality
ID ACUTE LUNG INJURY; END-EXPIRATORY PRESSURE; PERMISSIVE HYPERCAPNIA;
PROTECTIVE-VENTILATION; CARBON-DIOXIDE; PULMONARY-EDEMA; TIDAL VOLUME;
MORTALITY; ACIDOSIS; DYSFUNCTION
AB Purpose: To analyze the relationship between hypercapnia developing within the first 48 h after the start of mechanical ventilation and outcome in patients with acute respiratory distress syndrome (ARDS).
Patients and methods: We performed a secondary analysis of three prospective non-interventional cohort studies focusing on ARDS patients from 927 intensive care units (ICUs) in 40 countries. These patients received mechanical ventilation for more than 12 h during 1-month periods in 1998, 2004, and 2010. We used multivariable logistic regression and a propensity score analysis to examine the association between hypercapnia and ICU mortality.
Main outcomes: We included 1899 patients with ARDS in this study. The relationship between maximum PaCO2 in the first 48 h and mortality suggests higher mortality at or above PaCO2 of >= 50 mmHg. Patients with severe hypercapnia (PaCO2 >= 50 mmHg) had higher complication rates, more organ failures, and worse outcomes. After adjusting for age, SAPS II score, respiratory rate, positive end-expiratory pressure, PaO2/FiO(2) ratio, driving pressure, pressure/volume limitation strategy (PLS), corrected minute ventilation, and presence of acidosis, severe hypercapnia was associated with increased risk of ICU mortality [odds ratio (OR) 1.93, 95% confidence interval (CI) 1.32 to 2.81; p = 0.001]. In patients with severe hypercapnia matched for all other variables, ventilation with PLS was associated with higher ICU mortality (OR 1.58, CI 95% 1.04-2.41; p = 0.032).
Conclusions: Severe hypercapnia appears to be independently associated with higher ICU mortality in patients with ARDS.
Trial registration: Clinicaltrials.gov identifier, NCT01093482.
C1 [Nin, Nicolas] Hosp Torrejon, Madrid, Spain.
[Muriel, Alfonso] Hosp Ramon & Cajal, Dept Clin Biostat, IRICYS, Madrid, Spain.
[Muriel, Alfonso] CIBERESP, Madrid, Spain.
[Penuelas, Oscar; Angel Lorente, Jose; Esteban, Andres] CIBER Enfermedades Resp, Madrid, Spain.
[Brochard, Laurent] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada.
[Brochard, Laurent; Ferguson, Niall D.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.
[Ferguson, Niall D.] Univ Toronto, Dept Med, Toronto, ON, Canada.
[Ferguson, Niall D.] Univ Toronto, Dept Physiol, Toronto, ON, Canada.
[Raymondos, Konstantinos] Hannover Med Sch, Hannover, Germany.
[R-Os, Fernando] Hosp Nacl Alejandro Posadas, Buenos Aires, DF, Argentina.
[Violi, Damian A.] Hosp HIGA Guemes, Haedo, Argentina.
[Thille, Arnaud W.] Univ Hosp Poitiers, Poitiers, France.
[Gonzalez, Marco] Clin Medellin, Medellin, Colombia.
[Gonzalez, Marco] Univ Pontificia Bolivariana, Medellin, Colombia.
[Villagomez, Asisclo J.] Hosp Reg 1 Octubre, Mexico City, DF, Mexico.
[Hurtado, Javier] Hosp Espanol, Montevideo, Uruguay.
[Davies, Andrew R.] Alfred Hosp, Melbourne, Vic, Australia.
[Davies, Andrew R.] Monash Univ, Melbourne, Vic, Australia.
[Du, Bin] Beijing Union Med Coll Hosp, Beijing, Peoples R China.
[Maggiore, Salvatore M.] Univ Cattolica Sacro Cuore, Policlin Agostino Gemelli, Rome, Italy.
[Soto, Luis] Inst Nacl Torax Santiago, Santiago, Chile.
[D'Empaire, Gabriel] Hosp Clin Caracas, Caracas, Venezuela.
[Matamis, Dimitrios] Papageorgiou Hosp, Thessaloniki, Greece.
[Abroug, Fekri] Hosp Fattouma Bourguina, Monastir, Tunisia.
[Moreno, Rui P.] Ctr Hosp Lisboa Cent, EPE, UCINC, Hosp Sao Jose, Lisbon, Portugal.
[Soares, Marco Antonio] Hosp Univ Sao Jose, Belo Horizonte, MG, Brazil.
[Arabi, Yaseen] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia.
[Sandi, Freddy] Hosp Obrero 1, La Paz, Bolivia.
[Jibaja, Manuel] Hosp Eugenio Espejo, Quito, Ecuador.
[Amin, Pravin] Bombay Hosp Inst Med Sci, Bombay, Maharashtra, India.
[Koh, Younsuck] Univ Ulsan, Asan Med Ctr, Seoul, South Korea.
[Kuiper, Michael A.] Med Ctr Leeuwarden MCL, Leeuwarden, Netherlands.
[Bulow, Hans-Henrik] Univ Copenhagen, Holbaek Hosp, Copenhagen, Region Zealand, Denmark.
[Zeggwagh, Amine Ali] Hosp Ibn Sina, Rabat, Morocco.
[Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Sznajder, Jacob I.] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA.
[Esteban, Andres] Hosp Univ Getafe, Carretera Toledo,Km 12,500, Madrid 28905, Spain.
RP Esteban, A (reprint author), Hosp Univ Getafe, Carretera Toledo,Km 12,500, Madrid 28905, Spain.
EM aesteban@ucigetafe.com
OI Muriel, Alfonso /0000-0002-4805-4011
FU CIBER Enfermedades Respiratorias (CIBERES); CIBER en Epidemiologia y
Salud Publica (CIBERESP); Instituto de Salud Carlos III, Madrid, Spain;
Instituto Ramon y Cajal de Investigacion Sanitaria (IRYCIS), Madrid,
Spain; Canadian Institutes of Health Research New Investigator Award
(Ottawa, Canada); [HL-048129]; [HL-071643]; [HL-085534]
FX Funding for this study was provided by CIBER Enfermedades Respiratorias
(CIBERES), CIBER en Epidemiologia y Salud Publica (CIBERESP), Instituto
de Salud Carlos III, Madrid, Spain and the Instituto Ramon y Cajal de
Investigacion Sanitaria (IRYCIS), Madrid, Spain. Dr. Ferguson was
supported by a Canadian Institutes of Health Research New Investigator
Award (Ottawa, Canada). Dr. Sznajder is funded by HL-048129, HL-071643
and HL-085534.
NR 40
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0342-4642
EI 1432-1238
J9 INTENS CARE MED
JI Intensive Care Med.
PD FEB
PY 2017
VL 43
IS 2
BP 200
EP 208
DI 10.1007/s00134-016-4611-1
PG 9
WC Critical Care Medicine
SC General & Internal Medicine
GA EL0OE
UT WOS:000394320900005
PM 28108768
ER
PT J
AU Kleinman, RE
Nicklas, T
AF Kleinman, Ronald E.
Nicklas, Theresa
TI TheWomen, Infants, and Children Food Package and 100% Fruit Juice
SO JAMA PEDIATRICS
LA English
DT Letter
C1 [Kleinman, Ronald E.] Harvard Med Sch, MassGen Hosp Children, Dept Pediat, 175 Cambridge St,Ste 578, Boston, MA 02114 USA.
[Nicklas, Theresa] Baylor Coll Med, Childrens Nutr Res Ctr, Dept Pediat, Houston, TX 77030 USA.
RP Kleinman, RE (reprint author), Harvard Med Sch, MassGen Hosp Children, 175 Cambridge St,Ste 578, Boston, MA 02114 USA.
EM rkleinman@partners.org
FU Nutrition Impact
FX Dr Nicklas has received funding from Nutrition Impact and Dr Pepper
Snapple in the past 3 years. No other disclosures were reported.
NR 3
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6203
EI 2168-6211
J9 JAMA PEDIATR
JI JAMA Pediatr.
PD FEB
PY 2017
VL 171
IS 2
BP 197
EP 197
DI 10.1001/jamapediatrics.2016.4116
PG 1
WC Pediatrics
SC Pediatrics
GA EM9QN
UT WOS:000395646300027
PM 27992618
ER
PT J
AU Alberdi, T
Castro-Wagner, JB
Patel, B
Joychan, S
Lindsey, D
Laham, FR
Csomos, K
Ujhazi, B
Duff, CM
Trotter, J
Bleesing, JJ
Kumanovics, A
Chang, YH
Hale, JH
Sriaroon, P
Hale, G
Oshrine, BR
Notarangelo, L
Abraham, RS
Comeau, AM
Petrovic, A
Leiding, JW
Walter, JE
AF Alberdi, Taylor
Castro-Wagner, Johana B.
Patel, Bhumika
Joychan, Sonia
Lindsey, David
Laham, Frederico R.
Csomos, Krisztian
Ujhazi, Boglarka
Duff, Carla M.
Trotter, Jessica
Bleesing, Jack J.
Kumanovics, Attila
Chang, Yenhui
Hale, Jamie H.
Sriaroon, Panida
Hale, Greg
Oshrine, Benjamin R.
Notarangelo, Luigi
Abraham, Roshini S.
Comeau, Anne Marie
Petrovic, Aleksandra
Leiding, Jennifer W.
Walter, Jolan E.
TI An Atypical Severe Combined Immunodeficiency (SCID) Case Diagnosis
Complicated by Alternative Care in the Era of Newborn Screening (NBS)
for SCID
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology
(AAAAI)
CY MAR 03-16, 2017
CL Atlanta, GA
SP Amer Acad Allergy, Asthma & Immunol
C1 [Alberdi, Taylor; Lindsey, David; Ujhazi, Boglarka; Trotter, Jessica] Univ S Florida, Morsani Coll Med, Tampa, FL USA.
[Castro-Wagner, Johana B.; Patel, Bhumika; Joychan, Sonia; Sriaroon, Panida] Univ S Florida, Morsani Coll Med, St Petersburg, FL USA.
[Laham, Frederico R.] Arnold Palmer Hosp, Orlando, FL USA.
[Csomos, Krisztian] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Duff, Carla M.; Leiding, Jennifer W.] Univ S Florida, St Petersburg, FL USA.
[Bleesing, Jack J.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
[Kumanovics, Attila] Univ Utah, Dept Pathol, Salt Lake City, UT USA.
[Chang, Yenhui; Hale, Greg; Oshrine, Benjamin R.; Petrovic, Aleksandra] John Hopkins All Childrens Hosp, St Petersburg, FL USA.
[Hale, Jamie H.] UMass Med Sch, New England Newborn Screening Program, Boston, MA USA.
[Notarangelo, Luigi] Childrens Hosp, Boston, MA 02115 USA.
[Abraham, Roshini S.] Mayo Clin, Rochester, MN USA.
[Comeau, Anne Marie] UMass Med Sch, New England Newborn Screening Program, Jamaica Plain, MA USA.
[Walter, Jolan E.] Univ S Florida, Tampa, FL USA.
[Walter, Jolan E.] Johns Hopkins All Childrens Hosp, St Petersburg, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD FEB
PY 2017
VL 139
IS 2
SU S
MA 60
BP AB18
EP AB18
PG 1
WC Allergy; Immunology
SC Allergy; Immunology
GA EO8NM
UT WOS:000396946000061
ER
PT J
AU Haibach, JP
Haibach, MA
Hall, KS
Masheb, RM
Little, MA
Shepardson, RL
Dobmeyer, AC
Funderburk, JS
Hunter, CL
Dundon, M
Hausmann, LRM
Trynosky, SK
Goodrich, DE
Kilbourne, AM
Knight, SJ
Talcott, GW
Goldstein, MG
AF Haibach, Jeffrey P.
Haibach, Michael Ann
Hall, Katherine S.
Masheb, Robin M.
Little, Melissa A.
Shepardson, Robyn L.
Dobmeyer, Anne C.
Funderburk, Jennifer S.
Hunter, Christopher L.
Dundon, Margaret
Hausmann, Leslie R. M.
Trynosky, Stephen K.
Goodrich, David E.
Kilbourne, Amy M.
Knight, Sara J.
Talcott, Gerald W.
Goldstein, Michael G.
TI Military and veteran health behavior research and practice: challenges
and opportunities
SO JOURNAL OF BEHAVIORAL MEDICINE
LA English
DT Article
DE Military; Veteran; Servicemember; Health behavior; Health promotion;
Healthcare; Behavioral health
ID POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL;
SUBSTANCE-USE DISORDERS; DEPARTMENT-OF-DEFENSE; ACTIVE-DUTY MILITARY; US
AIR-FORCE; WEIGHT MANAGEMENT PROGRAM; ALCOHOL-RELATED OUTCOMES;
BODY-MASS INDEX; PRIMARY-CARE
AB There are 2.1 million current military servicemembers and 21 million living veterans in the United States. Although they were healthier upon entering military service compared to the general U.S. population, in the longer term veterans tend to be of equivalent or worse health than civilians. One primary explanation for the veterans' health disparity is poorer health behaviors during or after military service, especially areas of physical activity, nutrition, tobacco, and alcohol. In response, the Department of Defense and Department of Veterans Affairs continue to develop, evaluate, and improve health promotion programs and healthcare services for military and veteran health behavior in an integrated approach. Future research and practice is needed to better understand and promote positive health behavior during key transition periods in the military and veteran life course. Also paramount is implementation and evaluation of existing interventions, programs, and policies across the population using an integrated and person centered approach.
C1 [Haibach, Jeffrey P.; Kilbourne, Amy M.] US Dept Vet Affairs, Hlth Serv Res & Dev Serv, 810 Vermont Ave NW 10P9H, Washington, DC 20420 USA.
[Haibach, Michael Ann] US Air Force, Wright Patterson AFB, OH USA.
[Hall, Katherine S.] Durham VA Med Ctr, Durham, NC USA.
[Hall, Katherine S.] Duke Univ, Dept Med, Durham, NC USA.
[Masheb, Robin M.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Masheb, Robin M.] Yale Sch Med, New Haven, CT USA.
[Little, Melissa A.; Talcott, Gerald W.] Univ Tennessee, Ctr Hlth Sci, Ctr Populat Sci, Memphis, TN 38163 USA.
[Shepardson, Robyn L.; Funderburk, Jennifer S.] Syracuse VA Med Ctr, VA Ctr Integrated Healthcare, Syracuse, NY USA.
[Shepardson, Robyn L.; Funderburk, Jennifer S.] Syracuse Univ, Dept Psychol, Syracuse, NY USA.
[Dobmeyer, Anne C.] Deployment Hlth Clin Ctr, Def Ctr Excellence Psychol Hlth, Bethesda, MD USA.
[Dobmeyer, Anne C.] Deployment Hlth Clin Ctr, Def Ctr Traumat Brain Injury, Bethesda, MD USA.
[Funderburk, Jennifer S.] Univ Rochester, Dept Psychiat, Rochester, NY USA.
[Hunter, Christopher L.] Def Hlth Agcy, Patient Ctr Med Home Branch, Clin Support Div, Washington, DC USA.
[Dundon, Margaret; Goldstein, Michael G.] US Dept Vet Affairs, Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA.
[Hausmann, Leslie R. M.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
[Hausmann, Leslie R. M.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA.
[Trynosky, Stephen K.] US Dept Vet Affairs, Off Acad Affiliat, Washington, DC USA.
[Trynosky, Stephen K.] US Army Reserve, Med Serv Corps, Washington, DC USA.
[Goodrich, David E.] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA.
[Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA.
[Knight, Sara J.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Knight, Sara J.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA.
RP Haibach, JP (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv, 810 Vermont Ave NW 10P9H, Washington, DC 20420 USA.
EM Jeffrey.Haibach@va.gov; Michael.Glotfelter.1@us.af.mil;
Katherine.Hall@duke.edu; Robin.Masheb@yale.edu; Mlittl18@uthsc.edu;
Robyn.Shepardson@va.gov; Anne.C.Dobmeyer.mil@mail.mil;
Jennifer.Funderburk@va.gov; Christopher.L.Hunter16.mil@mail.mil;
Margaret.Dundon@va.gov; Leslie.Hausmann@va.gov; Steve.Trynosky@va.gov;
David.Goodrich2@va.gov; Amy.Kilbourne@va.gov; Sara.Knight@va.gov;
Wtalcott@uthsc.edu; Michael.Goldstein2@va.gov
NR 168
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0160-7715
EI 1573-3521
J9 J BEHAV MED
JI J. Behav. Med.
PD FEB
PY 2017
VL 40
IS 1
BP 175
EP 193
DI 10.1007/s10865-016-9794-y
PG 19
WC Psychology, Clinical
SC Psychology
GA EL0WK
UT WOS:000394342300013
PM 27678001
ER
PT J
AU Haibach, JP
Haibach, MA
Hall, KS
Masheb, RM
Little, MA
Shepardson, RL
Dobmeyer, AC
Funderburk, JS
Hunter, CL
Dundon, M
Hausmann, LRM
Trynosky, SK
Goodrich, DE
Kilbourne, AM
Knight, SJ
Talcott, GW
Goldstein, M
AF Haibach, Jeffrey P.
Haibach, Michael Ann
Hall, Katherine S.
Masheb, Robin M.
Little, Melissa A.
Shepardson, Robyn L.
Dobmeyer, Anne C.
Funderburk, Jennifer S.
Hunter, Christopher L.
Dundon, Margaret
Hausmann, Leslie R. M.
Trynosky, Stephen K.
Goodrich, David E.
Kilbourne, Amy M.
Knight, Sara J.
Talcott, Gerald W.
Goldstein, Michael
TI Military and veteran health behavior research and practice: challenges
and opportunities (vol 40, pg 175, 2017)
SO JOURNAL OF BEHAVIORAL MEDICINE
LA English
DT Correction
C1 [Haibach, Jeffrey P.; Kilbourne, Amy M.] US Dept Vet Affairs, Hlth Serv Res & Dev Serv, 810 Vermont Ave NW 10P9H, Washington, DC 20420 USA.
[Haibach, Michael Ann] US Air Force, Wright Patterson AFB, OH USA.
[Hall, Katherine S.] Durham VA Med Ctr, Durham, NC USA.
[Hall, Katherine S.] Duke Univ, Dept Med, Durham, NC USA.
[Masheb, Robin M.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Masheb, Robin M.] Yale Sch Med, New Haven, CT USA.
[Little, Melissa A.; Talcott, Gerald W.] Univ Tennessee, Ctr Hlth Sci, Ctr Populat Sci, Memphis, TN 38163 USA.
[Shepardson, Robyn L.; Funderburk, Jennifer S.] Syracuse VA Med Ctr, VA Ctr Integrated Healthcare, Syracuse, NY USA.
[Shepardson, Robyn L.; Funderburk, Jennifer S.] Syracuse Univ, Dept Psychol, Syracuse, NY USA.
[Dobmeyer, Anne C.] Deployment Hlth Clin Ctr, Def Ctr Excellence Psychol Hlth, Bethesda, MD USA.
[Dobmeyer, Anne C.] Deployment Hlth Clin Ctr, Def Ctr Traumat Brain Injury, Bethesda, MD USA.
[Funderburk, Jennifer S.] Univ Rochester, Dept Psychiat, Rochester, NY USA.
[Hunter, Christopher L.] Def Hlth Agcy, Patient Ctr Med Home Branch, Clin Support Div, Washington, DC USA.
[Dundon, Margaret; Goldstein, Michael] US Dept Vet Affairs, Natl Ctr Hlth Promot & Dis Prevent, Durham, NC USA.
[Hausmann, Leslie R. M.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA.
[Hausmann, Leslie R. M.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA.
[Trynosky, Stephen K.] US Dept Vet Affairs, Off Acad Affiliat, Washington, DC USA.
[Trynosky, Stephen K.] US Army Reserve, Med Serv Corps, Washington, DC USA.
[Goodrich, David E.] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA.
[Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA.
[Knight, Sara J.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Knight, Sara J.] Univ Alabama Birmingham, Div Prevent Med, Birmingham, AL USA.
RP Haibach, JP (reprint author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv, 810 Vermont Ave NW 10P9H, Washington, DC 20420 USA.
EM Jeffrey.Haibach@va.gov; Michael.Glotfelter.1@us.af.mil;
Katherine.Hall@duke.edu; Robin.Masheb@yale.edu; Mlittl18@uthsc.edu;
Robyn.Shepardson@va.gov; Anne.C.Dobmeyer.mil@mail.mil;
Jennifer.Funderburk@va.gov; Christopher.L.Hunter16.mil@mail.mil;
Margaret.Dundon@va.gov; Leslie.Hausmann@va.gov; Steve.Trynosky@va.gov;
David.Goodrich2@va.gov; Amy.Kilbourne@va.gov; Sara.Knight@va.gov;
Wtalcott@uthsc.edu; Michael.Goldstein2@va.gov
NR 1
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0160-7715
EI 1573-3521
J9 J BEHAV MED
JI J. Behav. Med.
PD FEB
PY 2017
VL 40
IS 1
BP 227
EP 228
DI 10.1007/s10865-016-9801-3
PG 2
WC Psychology, Clinical
SC Psychology
GA EL0WK
UT WOS:000394342300017
PM 27757768
ER
PT J
AU Jung, M
Kwon, D
Oh, JY
AF Jung, Minsoo
Kwon, Dongseok
Oh, Ji-young
TI Associated with Differences in Sexual Risk-Taking Behaviors Among
Migrants in South Korea
SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH
LA English
DT Article
DE Migrant; Homosexual; Sexually transmitted disease; HIV/AIDS; Sexual
risk-taking; South Korea
ID IMMIGRANT MEN; HIV RISK; ACCULTURATION; DETERMINANTS; SHANGHAI; WORKERS;
AIDS
AB We investigated influential factors on differences in sexual risk-taking among homosexual migrants. The data used in this paper are based on the survey and medical examination for migrants' sexual behaviors that was carried out by the Korea Federation for HIV/AIDS Prevention in 2011-2013 on participants living in South Korea. Among 1141 migrants, homosexuals were 0.54 times less likely to use condom than heterosexuals. Homosexuals were 2.93 times more likely to be infected with sexually transmitted diseases (STDs) than heterosexuals. Among 250 homosexual migrants, those who preferred risky sexual intercourse were 0.19 times less likely to use a condom than heterosexual migrants. Those who have a fixed sexual partner were 0.35 times less likely to be infected with HIV than their counterparts. Administrative programs for STDs prevention of migrants should be focused on their sexual risk-taking, which were limited to casual partnership, unprotected sex, and previous contraction of sexual diseases.
C1 [Jung, Minsoo] Dongduk Womens Univ, Dept Hlth Sci, Coll Nat Sci, 23-1 Wolgok Dong, Seoul 136714, South Korea.
[Jung, Minsoo] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
[Kwon, Dongseok; Oh, Ji-young] Korea Federat HIV AIDS Prevent, Seoul, South Korea.
RP Jung, M (reprint author), Dongduk Womens Univ, Dept Hlth Sci, Coll Nat Sci, 23-1 Wolgok Dong, Seoul 136714, South Korea.; Jung, M (reprint author), Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
EM mj748@dongduk.ac.kr
NR 45
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1912
EI 1557-1920
J9 J IMMIGR MINOR HEALT
JI J. Immigr. Minor. Health
PD FEB
PY 2017
VL 19
IS 1
BP 24
EP 32
DI 10.1007/s10903-015-0300-3
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EK8ZK
UT WOS:000394213200004
PM 26455719
ER
PT J
AU Caspi, CE
Tucker-Seeley, RD
Adamkiewicz, G
Roberto, CA
Stoddard, AM
Sorensen, GC
AF Caspi, Caitlin E.
Tucker-Seeley, Reginald D.
Adamkiewicz, Gary
Roberto, Christina A.
Stoddard, Anne M.
Sorensen, Glorian C.
TI Food Hardship and Obesity in a Sample of Low-Income Immigrants
SO JOURNAL OF IMMIGRANT AND MINORITY HEALTH
LA English
DT Article
DE Immigrant; Obesity; Hardship; Food insecurity
ID HOUSING RESIDENTS; AFRICAN REFUGEES; SECURITY STATUS; LATIN-AMERICAN;
INSECURITY; HEALTH; WOMEN; ACCULTURATION; OVERWEIGHT; WEIGHT
AB Very little work has examined the relationship between food hardship (having inconsistent financial resources to buy food) and obesity among immigrant groups. A cross-sectional study was conducted in a low-income, multi-racial/ethnic adult sample in greater Boston, MA (n = 828). Modified Poisson regression models estimated the association between food hardship obesity (BMI 30) among adults reporting food hardship; interactions were tested by place of birth. Body mass index (BMI) was based on anthropometric height and weight. In adjusted models, those experiencing food hardship were more likely to be obese (RR 1.17, CI 1.07, 1.29) than those not experiencing food hardship. Participants from Haiti reporting food hardship were more likely to be obese than those not reporting hardship (RR 1.58, CI 1.23, 2.04); this was not the case among other groups (US born, Puerto Rican, Latin American, Other). The relationship between food hardship and weight may vary among immigrant subgroups.
C1 [Caspi, Caitlin E.] Univ Minnesota, Dept Family Med & Community Hlth, Program Hlth Dispar Res, 717 Delaware St SE, Minneapolis, MN 55414 USA.
[Tucker-Seeley, Reginald D.; Sorensen, Glorian C.] Dana Farber Canc Inst, Ctr Community Based Res, 450 Brookline Ave, Boston, MA 02215 USA.
[Tucker-Seeley, Reginald D.; Roberto, Christina A.; Sorensen, Glorian C.] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington St, Boston, MA 02215 USA.
[Adamkiewicz, Gary] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, 677 Huntington St, Boston, MA 02215 USA.
[Roberto, Christina A.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, 423 Guardian Dr, Philadelphia, PA 19104 USA.
[Stoddard, Anne M.] New England Res Inst, 9 Galen St, Watertown, MA 02472 USA.
RP Caspi, CE (reprint author), Univ Minnesota, Dept Family Med & Community Hlth, Program Hlth Dispar Res, 717 Delaware St SE, Minneapolis, MN 55414 USA.
EM cecaspi@umn.edu
FU National Cancer Institutes [R01 CA111310-01A, R25 CA057713, R25
CA163184, K01 CA169041, K05 CA108663]; Robert Wood Johnson Foundation
Health & Society Scholars program
FX The authors would like to thank the research participants and the
Cambridge, Somerville and Chelsea Public Housing Authorities. The
authors also thank Marty Alvarez-Reeves, Ruth Lederman, Samuel Lipson,
Carol Lowenstein, Brianna Wadler, May Yang and Lorraine Wallace for
their contributions to the study design and implementation. This
research was supported by the National Cancer Institutes, grant numbers
R01 CA111310-01A (GS), R25 CA057713 (CEC), R25 CA163184 (CEC), K01
CA169041 (RTS), K05 CA108663 (GS), and by the Robert Wood Johnson
Foundation Health & Society Scholars program (CAR). The National Cancer
Institute and the Robert Wood Johnson Foundation had no role in the
design, analysis or writing of this article.
NR 52
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1557-1912
EI 1557-1920
J9 J IMMIGR MINOR HEALT
JI J. Immigr. Minor. Health
PD FEB
PY 2017
VL 19
IS 1
BP 130
EP 137
DI 10.1007/s10903-016-0344-z
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA EK8ZK
UT WOS:000394213200016
PM 26872640
ER
PT J
AU Swain, JD
Sharma, G
Rumma, RT
Fisichella, PM
Whang, E
AF Swain, JaBaris D.
Sharma, Gaurav
Rumma, Rowza T.
Fisichella, P. Marco
Whang, Edward
TI A Century of Surgical Innovation at a Boston Hospital
SO JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES
LA English
DT Article
DE innovation; surgery; Brigham and Women's Hospital
ID IDENTICAL-TWINS; ELECTROSURGERY; HOMOTRANSPLANTATION; CUSHING,HARVEY;
PRINCIPLES; LEGACY; LIFE; SKIN
AB Background: Innovation has been a central focus of the Department of Surgery at the Brigham and Women's Hospital since its very inception. Here we review examples of innovations originating in this Department and analyze factors that have been critical to successful innovation. Finally, we discuss challenges to sustainability of innovation in this Department.
Methods: Narrative review of the literature, interviews, and personal observations.
Results: Examples of innovations reviewed here were each dependent on three critical elements: 1) multi-disciplinary collaboration among surgical innovators and individuals outside of surgery who offered complementary skills and expertise, 2) a rich institutional environment that sustained a diverse complement of innovators working in close proximity, and 3) Department Chairmen who facilitated the work of innovators and promoted their contributions, rather than seeking personal prestige or financial gain. Contemporary challenges to sustainability of innovation include the prevailing emphasis on clinical efficiency and on cost containment.
Conclusion: We have identified factors critical to successful innovation in a Department of Surgery. The relevance of these factors is unlikely to be diminished, even in the changing landscape of modern medicine.
C1 [Swain, JaBaris D.; Sharma, Gaurav; Rumma, Rowza T.; Whang, Edward] Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.
[Fisichella, P. Marco; Whang, Edward] VA Boston Healthcare, Dept Surg, West Roxbury Campus, Boston, MA USA.
RP Fisichella, PM (reprint author), Boston VA Brigham & Womens, Dept Surg, West Roxbury, MA 02132 USA.
EM JLAST@liebertpub.com
NR 29
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1092-6429
EI 1557-9034
J9 J LAPAROENDOSC ADV S
JI J. Laparoendosc. Adv. Surg. Tech.
PD FEB
PY 2017
VL 27
IS 2
BP 156
EP 161
DI 10.1089/lap.2016.0531
PG 6
WC Surgery
SC Surgery
GA EL0ZV
UT WOS:000394351200011
PM 28068187
ER
PT J
AU Wiesel, O
Whang, B
Cohen, D
Fisichella, PM
AF Wiesel, Ory
Whang, Brian
Cohen, Daniel
Fisichella, P. Marco
TI Minimally Invasive Esophagectomy for Adenocarcinomas of the
Gastroesophageal Junction and Distal Esophagus: Notes on Technique
SO JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES
LA English
DT Article
DE esophagectomy; ivor-lewis esophagectomy; minimally invasive
esophagectomy
ID IVOR LEWIS ESOPHAGECTOMY; RANDOMIZED CONTROLLED-TRIAL; CANCER; SURGERY;
THERAPY; LYMPHADENECTOMY; INTERVENTION; IMPACT
AB In the last three decades, with the advancement of laparoscopic and thoracoscopic surgery, minimally invasive approaches for benign and malignant diseases of the esophagus have been developed and more experience is starting to accumulate across the world. Minimally invasive esophagectomy (MIE) has demonstrated acceptable lymph node retrieval, good postoperative outcomes, and low mortality. In this article, we review our preferred technique of MIE for adenocarcinomas of the gastroesophageal junction and distal esophagus.
C1 [Wiesel, Ory; Whang, Brian; Cohen, Daniel] Boston Healthcare Syst, Vet Hlth Adm, Brigham & Womens Hosp, Div Thorac Surg, Boston, MA USA.
[Fisichella, P. Marco] Boston Healthcare Syst, Vet Hlth Adm, Brigham & Womens Hosp, Dept Surg, Boston, MA USA.
RP Fisichella, PM (reprint author), Harvard Med Sch, Dept Surg, Brigham & Womens Hosp, Boston VA Healthcare Syst, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
EM piero.fisichella@va.gov
NR 32
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1092-6429
EI 1557-9034
J9 J LAPAROENDOSC ADV S
JI J. Laparoendosc. Adv. Surg. Tech.
PD FEB
PY 2017
VL 27
IS 2
BP 162
EP 169
DI 10.1089/lap.2016.0430
PG 8
WC Surgery
SC Surgery
GA EL0ZV
UT WOS:000394351200012
PM 27858584
ER
PT J
AU Sinha, S
Dedmon, MM
Naunheim, MR
Fuller, JC
Gray, ST
Lin, DT
AF Sinha, Sumi
Dedmon, Matthew M.
Naunheim, Matthew R.
Fuller, Jennifer C.
Gray, Stacey T.
Lin, Derrick T.
TI Update on Surgical Outcomes of Lateral Temporal Bone Resection for Ear
and Temporal Bone Malignancies
SO JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE
LA English
DT Article
DE lateral temporal bone resection; cancer; malignancy; outcomes
ID SQUAMOUS-CELL CARCINOMA
AB Objectives Review outcomes of lateral temporal bone resections for ear and temporal bone malignancy.
Design, Setting, and Participants Retrospective review of all lateral temporal bone resections performed from 2008 to 2015 at a single tertiary care center.
Main Outcome Measures Patient demographics, perioperative variables, overall survival, disease-free survival (DFS), and comparison of Kaplan-Meier curves.
Results Overall, 56 patients were identified with amean follow-up period of 2.3 +/- 1.8 years. The predominant histopathologic diagnosis was squamous cell carcinoma (SCC, 54%), followed by salivary gland tumors (18%), and basal cell carcinoma (9%). Tumor stages were T1-T2 in 23%, T3-T4 in 73%, and two unknown primary lesions. Mean overall survival was 4.6 +/- 0.4 years. Comparison of tumors with and without lymph node involvement or perineural invasion approached statistical significance for overall survival (p = 0.07 and 0.06, respectively). DFS was 2.5 +/- 0.3 years. Stratification by lymph node status had a statistically significant difference in DFS (p = 0.03). Subgroup analysis of SCC patients did not reveal significant differences.
Conclusions Based on our cohort, most patients with temporal bone malignancies present with advanced disease, making it difficult to achieve negative margins. Overall, lymph node status was the strongest predictor of survival in this group.
C1 [Sinha, Sumi; Dedmon, Matthew M.; Naunheim, Matthew R.; Fuller, Jennifer C.; Gray, Stacey T.; Lin, Derrick T.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
RP Dedmon, MM (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM matthew_dedmon@meei.harvard.edu
NR 14
TC 0
Z9 0
U1 0
U2 0
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 2193-6331
EI 2193-634X
J9 J NEUROL SURG PART B
JI Journal of Neurol. Surg. Part B
PD FEB
PY 2017
VL 78
IS 1
BP 37
EP 42
DI 10.1055/s-0036-1584310
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA EL0WF
UT WOS:000394341800007
PM 28180041
ER
PT J
AU Oduro, K
Masia, R
Sillero, MC
Ebb, D
Mark, E
Hedley-Whyte, ET
AF Oduro, Kwadwo
Masia, Ricard
Sillero, Maria Cobos
Ebb, David
Mark, Eugene
Hedley-Whyte, E. Tessa
TI Metastatic Atypical Teratoid Rhabdoid Tumor (ATRT) in an Adolescent
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 22
BP 9A
EP 9A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400023
ER
PT J
AU Chebib, I
Kurzawa, P
Mullen, JT
Johnstone, SE
Deshpande, V
Nielsen, GP
AF Chebib, Ivan
Kurzawa, Pawel
Mullen, John T.
Johnstone, Sarah E.
Deshpande, Vikram
Nielsen, G. Petur
TI Prognostic Value of Myogenic Differentiation in Dedifferentiated
Liposarcoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Med Sch, Boston, MA USA.
Poznan Univ Med Sci, Poznan, Poland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 42
BP 14A
EP 14A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400043
ER
PT J
AU Larque, AB
Deshpande, V
Nielsen, GP
Chebib, I
AF Larque, Ana B.
Deshpande, Vikram
Nielsen, G. Petur
Chebib, Ivan
TI Prognostic Features in Uniformly Treated Synovial Sarcoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Larque, Ana B.; Deshpande, Vikram; Nielsen, G. Petur; Chebib, Ivan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 62
BP 18A
EP 19A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400063
ER
PT J
AU Biernacka, A
Deshpande, V
Brachtel, E
AF Biernacka, Anna
Deshpande, Vikram
Brachtel, Elena
TI Loss of XIST - The Potential Breast Cancer X Factor
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Med Sch, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 118
BP 32A
EP 32A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400119
ER
PT J
AU Gonzales-Ericcson, P
Mayer, IA
Jovanovic, B
Lehmann, B
Estrada, MV
Kuba, G
Abramson, V
Mayer, E
Dillon, P
Aditya, B
Chang, J
Forero, A
Meszoely, I
Grau, A
Pietenpol, J
Sanders, M
AF Gonzales-Ericcson, Paula
Mayer, Ingrid A.
Jovanovic, Bojana
Lehmann, Brian
Estrada, Monica V.
Kuba, Gabriela
Abramson, Vandana
Mayer, Erica
Dillon, Patrick
Aditya, Bardia
Chang, Jenny
Forero, Andres
Meszoely, Ingrid
Grau, Ana
Pietenpol, Jennifer
Sanders, Melinda
TI Histopathologic Subgroups of AR plus TNBC Predict Pathologic Complete
Response to Neoadjuvant Chemotherapy in Localized Breast Cancer
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
Dana Farber Canc Ctr, Boston, MA USA.
Univ Virginia, Hlth Sci Ctr, Charlottesville, VA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Methodist Hosptal, Res Inst, Houston, TX USA.
Univ Alabama Birmingham, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 164
BP 43A
EP 43A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400164
ER
PT J
AU Kuba, MG
Lester, SC
Bowman, T
Garber, J
Dillon, DA
AF Kuba, Marta G.
Lester, Susan C.
Bowman, Teresa
Garber, Judy
Dillon, Deborah A.
TI Breast Cancer in Li-Fraumeni Syndrome: Morphologic Evaluation of
Invasive and In Situ Carcinomas
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 202
BP 53A
EP 53A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400202
ER
PT J
AU Papadodima, S
Masia, R
Stone, JR
AF Papadodima, Stavroula
Masia, Ricard
Stone, James R.
TI Cardiac Iron Overload Following Liver Transplantation in Patients
without Hemochromatosis
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Univ Athens, Athens, Greece.
Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 320
BP 84A
EP 84A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400320
ER
PT J
AU Darras, N
Agarwal, S
Faquin, WC
Wang, HH
Sacks, BA
Nishino, M
AF Darras, Natasha
Agarwal, Shweta
Faquin, William C.
Wang, Helen H.
Sacks, Barry A.
Nishino, Michiya
TI ThyroSeq Testing for Indeterminate Thyroid Nodules: An Institutional
Experience
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 358
BP 92A
EP 93A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400358
ER
PT J
AU Eng, G
Rao, RA
Chebib, I
AF Eng, George
Rao, Rema A.
Chebib, Ivan
TI Use of Novel Image Analysis to Characterize and Quantify Nuclear
Features of Papillary Thyroid Carcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
2New York Presbyterian Hosp, New York, NY USA.
Weill Cornell Med Coll, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 364
BP 94A
EP 94A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400364
ER
PT J
AU Hang, JF
Charu, V
Zhang, MJL
Vandenbussche, C
AF Hang, Jen-Fan
Charu, Vivek
Zhang, Mingjuan L.
Vandenbussche, Christopher
TI Maximum WC Ratio in the "Atypical Urothelial Cells" Category Correlates
with Follow-Up Malignant Results in Liquid-Based Voided Urine Specimens
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 375
BP 97A
EP 97A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400375
ER
PT J
AU Hoda, RS
Arpin, R
Rosenbaum, MW
Pitman, MB
AF Hoda, Raza S.
Arpin, Ronald
Rosenbaum, Matthew W.
Pitman, Martha B.
TI Risk of Malignancy in Pancreatic Cysts with High-Grade Atypical Cytology
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Hoda, Raza S.; Arpin, Ronald; Rosenbaum, Matthew W.; Pitman, Martha B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 378
BP 98A
EP 98A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400378
ER
PT J
AU Rosenbaum, MW
England, JS
Hoda, RS
Arpin, R
Le, L
Forcione, DG
Iafrate, A
Pitman, MB
AF Rosenbaum, Matthew W.
England, Jonathan S.
Hoda, Raza S.
Arpin, Ronald
Le, Long
Forcione, David G.
Iafrate, Anthony
Pitman, Martha B.
TI Next Generation Sequencing Adds Value to Cytology and Fluorescence In
Situ Hybridization in the Diagnosis of Bile Duct Brushing Specimens
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Rosenbaum, Matthew W.; England, Jonathan S.; Hoda, Raza S.; Arpin, Ronald; Le, Long; Forcione, David G.; Iafrate, Anthony; Pitman, Martha B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 438
BP 113A
EP 114A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400438
ER
PT J
AU Dewar, R
Tambouret, RH
AF Dewar, Rajan
Tambouret, Rosemary H.
TI Can Pathology Skills Be Learnt Exclusively Through Online Resources?:
MOOC for PAPs - A Massive Open Online Course to Raise Pap Smear
Cytoscreener Workforce in Low and Middle Income Countries
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Univ Michigan, Ann Arbor, MI 48109 USA.
Udhavum Ullangal NGO, Madras, Tamil Nadu, India.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Med Sch, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 549
BP 139A
EP 139A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400547
ER
PT J
AU Farhat, N
Xu, B
Onernek, AM
Tuttle, RM
Roman, B
Katabi, N
Nose, V
Sadow, PM
Tallini, G
Faquin, W
Ghossein, R
AF Farhat, Nada
Xu, Bin
Onernek, Ayse Mine
Tuttle, R. Michael
Roman, Benjamin
Katabi, Nora
Nose, Vania
Sadow, Peter M.
Tallini, Giovanni
Faquin, William
Ghossein, Ronald
TI Should Subcentimeter Non-Invasive Encapsulated, Follicular Variant of
Papillary Thyroid Carcinoma (NI-EFV PTC) Be Diagnosed as Non-Invasive
Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features
(NIFTP)?
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Bologna, Sch Med, Bologna, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 581
BP 147A
EP 147A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400579
ER
PT J
AU Hernandez-Prera, J
Machado, R
Asa, SL
Baloch, Z
Faquin, W
Ghossein, R
LiVolsi, VA
Lloyd, RV
Mete, O
Nikiforov, Y
Thompson, LDR
Turk, AT
Seethala, RR
Suster, S
Urken, ML
Wenig, BM
AF Hernandez-Prera, Juan
Machado, Rosalie
Asa, Sylvia L.
Baloch, Zubair
Faquin, William
Ghossein, Ronald
LiVolsi, Virginia A.
Lloyd, Ricardo V.
Mete, Ozgur
Nikiforov, Yuri
Thompson, Lester D. R.
Turk, Andrew T.
Seethala, Raja R.
Suster, Saul
Urken, Mark L.
Wenig, Bruce M.
TI Pathologic Reporting of Tall Call Variant of Papillary Thyroid Cancer:
Have We Reached Consensus?
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Mt Sinai Beth Israel, New York, NY USA.
Univ Toronto, Toronto, ON, Canada.
Univ Penn, Philadelphia, PA 19104 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
Univ Wisconsin, Madison, WI USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Southern Calif Permanente Med Grp, Woodland Hills, CA USA.
Columbia Univ, New York, NY USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 582
BP 147A
EP 148A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400580
ER
PT J
AU Arora, KS
Michelakos, T
Cai, L
Ting, DT
Ferrone, C
Ferrone, S
Deshpande, V
AF Arora, Kshitij S.
Michelakos, Theodoros
Cai, Lei
Ting, David T.
Ferrone, Cristina
Ferrone, Soldano
Deshpande, Vikram
TI Colonic Carcinomas with Sporadic Loss of Mismatch Repair Proteins Are
Associated with Loss of HLA Class I
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Arora, Kshitij S.; Michelakos, Theodoros; Cai, Lei; Ting, David T.; Ferrone, Cristina; Ferrone, Soldano; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 631
BP 159A
EP 159A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400629
ER
PT J
AU Choi, WT
Brown, I
Ushiku, T
Yozu, M
Setia, N
Srivastava, A
Johncilla, M
Pai, RK
Fukayama, M
Misdraji, J
Lauwers, GY
AF Choi, Won-Tak
Brown, Ian
Ushiku, Tetsuo
Yozu, Masato
Setia, Namrata
Srivastava, Amitabh
Johncilla, Melanie
Pai, Rish K.
Fukayama, Masashi
Misdraji, Joseph
Lauwers, Gregory Y.
TI Gastric Pyloric Gland Adenoma: A Multicenter Clinicopathologic Study of
65 Cases
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 UCSF, Med Ctr, San Francisco, CA USA.
Envoi Pathol, Kelvin Grove, Qld, Australia.
Univ Tokyo, Tokyo, Japan.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Chicago, Chicago, IL 60637 USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Mayo Clin, Phoenix, AZ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 662
BP 166A
EP 166A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400660
ER
PT J
AU Horvath, B
Brown, I
Setia, N
Mattia, A
Lamps, L
Lauwers, GE
Misdraji, J
AF Horvath, Bela
Brown, Ian
Setia, Namrata
Mattia, Anthony
Lamps, Laura
Lauwers, Gregory E.
Misdraji, Joseph
TI A Crohn's-Like Appearance Characterizes Actinomycotic Appendicitis
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Envoi Specialist Pathologists, Kelvin Grove, Qld, Australia.
Univ Chicago, Chicago, IL 60637 USA.
Univ Arkansas Med Sci, Little Rock, AR 72205 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 698
BP 175A
EP 175A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400696
ER
PT J
AU Jayakumar, R
Qin, J
Siddiqi, MA
Gupta, R
AF Jayakumar, Rajeswari
Qin, Jia
Siddiqi, M. A.
Gupta, Raavi
TI EZH2 as a Useful Diagnostic Tool for Grading Gastrointestinal (GI)
Neuroendocrine Tumors
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Suny Downstate Med Ctr, Brooklyn, NY 11203 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 707
BP 177A
EP 178A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400705
ER
PT J
AU Jeck, WR
Arora, KS
Brachtel, E
Deshpande, V
AF Jeck, William Richard
Arora, Kshitij S.
Brachtel, Elena
Deshpande, Vikram
TI Harnessing TCGA RNAseq Data as a Springboard to Novel Tumor Markers
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Jeck, William Richard; Arora, Kshitij S.; Brachtel, Elena; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 708
BP 178A
EP 178A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724400706
ER
PT J
AU Oduro, K
Arora, KS
Deshpande, V
AF Oduro, Kwadwo
Arora, Kshitij S.
Deshpande, Vikram
TI Chromogenic In Situ Hybridization (CISH) Based Tracking of Donor Derived
Lymphocytes Augments the Histologic Evaluation of Human Acute Graft
versus Host Disease (GVHD)
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Oduro, Kwadwo; Arora, Kshitij S.; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 765
BP 191A
EP 191A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401038
ER
PT J
AU Rosenbaum, MW
Bledsoe, JR
Kem, M
Huynh, T
Mino-Kenudson, M
AF Rosenbaum, Matthew W.
Bledsoe, Jacob R.
Kem, Marina
Huynh, Tiffany
Mino-Kenudson, Mari
TI Immune Checkpoint Expression and the Tumor Immune Environment in
Colorectal Carcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Massachusetts, Sch Med, Worcester, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 789
BP 197A
EP 197A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401062
ER
PT J
AU Calagua, C
Shaw, K
Russo, J
Schaefer, R
Lis, R
Zhang, ZW
Loda, M
Taplin, ME
Balk, SP
Sun, Y
Ye, HH
AF Calagua, Carla
Shaw, Kristin
Russo, Joshua
Schaefer, Rachel
Lis, Rosina
Zhang, Zhenwei
Loda, Massimo
Taplin, Mary-Ellen
Balk, Steven P.
Sun, Yue
Ye, Huihui
TI Effect of Neoadjuvant Intense Androgen Deprivation Therapy in PD-L1
Expression in Prostate Cancer
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 873
BP 217A
EP 217A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401146
ER
PT J
AU Elfandy, H
Pederzoli, F
Pullman, E
Tyekucheva, S
Schultz, N
Loda, M
AF Elfandy, Habiba
Pederzoli, Filippo
Pullman, Eli
Tyekucheva, Svitlana
Schultz, Nicholas
Loda, Massimo
TI Molecular Characterization of Prostatic Adenocarcinoma Gleason 4,
Cribriform Pattern
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA.
Cairo Univ, Natl Canc Inst, Cairo, Egypt.
Univ Vita Salute San Raffaele, Milan, Italy.
George Washington Univ, Washington, DC USA.
Harvard Sch Publ Hlth, Boston, MA USA.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
Harvard Med Sch, Boston, MA USA.
DFCI, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 897
BP 222A
EP 223A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401171
ER
PT J
AU Kandukuri, S
Choueiri, TK
Hirsch, MS
AF Kandukuri, Shivani
Choueiri, Toni K.
Hirsch, Michelle S.
TI PD-L1 Expression in High Grade Locally-Advanced Renal Cell Carcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 949
BP 234A
EP 234A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401223
ER
PT J
AU Montaser, L
Calagua, C
Schaefer, R
Lis, R
Zhang, ZW
Loda, M
Taplin, ME
Balk, SP
Ye, HH
AF Montaser, Laleh
Calagua, Carla
Schaefer, Rachel
Lis, Rosina
Zhang, Zhenwei
Loda, Massimo
Taplin, Mary-Ellen
Balk, Steven P.
Ye, Huihui
TI Effect of Neoadjuvant Intense Androgen Deprivation Therapy in
Neuroendocrine Differentiation of Prostate Cancer
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 East Tennessee State Univ, Johnson City, TN USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 987
BP 244A
EP 244A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401261
ER
PT J
AU Bennett, J
Nardi, V
Rouzbahman, M
Morales-Oyarvide, V
Kim, KR
Nielsen, GP
Oliva, E
AF Bennett, Jennifer
Nardi, Valentina
Rouzbahman, Marjan
Morales-Oyarvide, Vicente
Kim, Kyu-Rae
Nielsen, G. P.
Oliva, Esther
TI Inflammatory Myofibroblastic Tumor of the Uterus: A Clinicopathological,
Immunohistochemical, and Molecular Analysis of 13 Cases
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Lahey Hosp, Burlington, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Toronto Gen Hosp, Toronto, ON, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Ulsan, Seoul, South Korea.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1109
BP 275A
EP 276A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401385
ER
PT J
AU Bennett, J
Pesci, A
Badrinarain, J
Da Silva, A
Oliva, E
AF Bennett, Jennifer
Pesci, Anna
Badrinarain, Jason
Da Silva, Annacarolina
Oliva, Esther
TI Mismatch Repair Protein Expression in Endometrioid Carcinoma of the
Ovary: Incidence and Clinicopathologic Associations in 77 Cases
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Lahey Hosp, Burlington, MA USA.
Osped Sacro Cuore Don Calabria, Verona, Italy.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1110
BP 276A
EP 276A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401386
ER
PT J
AU Bosse, T
Nout, RA
McAlpine, JN
McConechy, M
Britton, H
Ganesan, R
Steele, JC
Harrison, BT
Oliva, E
Matias-Guiu, X
Gilks, B
Soslow, R
AF Bosse, Tjalling
Nout, Remi A.
McAlpine, Jessica N.
McConechy, Melissa
Britton, Heidi
Ganesan, Raji
Steele, Jane C.
Harrison, Beth T.
Oliva, Esther
Matias-Guiu, Xavier
Gilks, Blake
Soslow, Robert
TI Molecular Classification of Grade 3 Endometrioid Endometrial Cancers
Identifies Distinct Prognostic Subgroups
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Leiden Univ, Med Ctr, Leiden, Netherlands.
Univ British Columbia, Vancouver, BC, Canada.
BC Canc Agcy, Vancouver, BC, Canada.
Birmingham Womens HS Fdn Trust, Birmingham, W Midlands, England.
Massachussets Gen Hosp, Boston, MA USA.
Hosp Arnau Vilanova, Lleida, Spain.
Hosp Univ Bellvitge, Lleida, Spain.
Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
McGill Univ, Montreal, PQ, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1113
BP 277A
EP 277A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401389
ER
PT J
AU Chiang, S
Hensley, M
Antonescu, CR
Oliva, E
Soslow, R
AF Chiang, Sarah
Hensley, Martee
Antonescu, Cristina R.
Oliva, Esther
Soslow, Robert
TI BCOR Is a Robust Diagnostic Immunohistochemical Marker of
YWHAE-Rearranged High-Grade Endometrial Stromal Sarcoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1125
BP 280A
EP 280A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401401
ER
PT J
AU Howitt, BE
Garcia, E
Sholl, LM
Lindeman, NI
MacConaill, LE
Dong, F
Hirsch, MS
Nucci, MR
Crum, CP
McCluggage, WG
Mirkovic, J
AF Howitt, Brooke E.
Garcia, Elizabeth
Sholl, Lynette M.
Lindeman, Neal I.
MacConaill, Laura E.
Dong, Fei
Hirsch, Michelle S.
Nucci, Marisa R.
Crum, Christopher P.
McCluggage, W. Glenn
Mirkovic, Jelena
TI Targeted Genomic Profiling of Female Adnexal Tumors of Probable Wolffian
Origin
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Harvard Med Sch, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1162
BP 289A
EP 289A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401438
ER
PT J
AU Klystel-Whittemore, M
Oliva, E
AF Klystel-Whittemore, Melissa
Oliva, Esther
TI Patterns of Recurrences in Grade 1 Endometrioid Endometrial
Adenocarcinoma (EEC)
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Klystel-Whittemore, Melissa; Oliva, Esther] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1186
BP 294A
EP 295A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401462
ER
PT J
AU Stolnicu, S
Berman, I
Hoang, L
Terinte, C
Pesci, A
Aviel-Ronen, S
Kiyokawa, T
Alvarado-Cabrero, I
Park, K
Oliva, E
Soslow, R
AF Stolnicu, Simona
Berman, Iulia
Hoang, Lien
Terinte, Cristina
Pesci, Anna
Aviel-Ronen, Sarit
Kiyokawa, Takako
Alvarado-Cabrero, Isabel
Park, Kay
Oliva, Esther
Soslow, Robert
TI International Endocervical Criteria and Classification: Mucinous
Endocervical Adenocarcinomas (MEA)
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Univ Med & Pharm, Targu Mures, Romania.
Vancouver Gen Hosp, Vancouver, BC, Canada.
Inst Oncol, Iasi, Romania.
Osped Sacro Coure Don Calabria, Negrar, Italy.
Sheba Med Ctr, Tel Hashomer, Israel.
Jikei Univ, Sch Med, Tokyo, Japan.
Hosp Oncol, Mexico City, DF, Mexico.
MSKCC, New York, NY USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1245
BP 310A
EP 310A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401521
ER
PT J
AU Stolnicu, S
Barsan, J
Hoang, L
Terinte, C
Pesci, A
Aviel-Ronen, S
Kiyokawa, T
Alvarado-Cabrero, I
Park, K
Oliva, E
Soslow, R
AF Stolnicu, Simona
Barsan, Julia
Hoang, Lien
Terinte, Cristina
Pesci, Anna
Aviel-Ronen, Sarit
Kiyokawa, Takako
Alvarado-Cabrero, Isabel
Park, Kay
Oliva, Esther
Soslow, Robert
TI International Endocervical Adenocarcinoma Criteria and Classification
(IECC)
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Univ Med & Pharm, Targu Mures, Mures, Romania.
Vancouver Gen Hosp, Vancouver, BC, Canada.
Inst Oncol, Iasi, Romania.
Osped Sacro Coure Don Calabria, Negrar, Italy.
Sheba Med Ctr, Tel Hashomer, Israel.
Jikei Univ, Sch Med, Tokyo, Japan.
Hosp Oncol, Mexico City, DF, Mexico.
MSKCC, New York, NY USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1244
BP 310A
EP 310A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401520
ER
PT J
AU Wong, A
Borger, D
Oliva, E
AF Wong, Adele
Borger, Darrell
Oliva, Esther
TI Clinicopathological Features of Uterine Neuroendocrine Tumors (NET)s
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
KK Womens & Childrens Hosp, Singapore, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1265
BP 315A
EP 315A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401541
ER
PT J
AU Wong, A
Arora, KS
Ordulu, Z
Deshpande, V
Oliva, E
AF Wong, Adele
Arora, Kshitij S.
Ordulu, Zehra
Deshpande, Vikram
Oliva, Esther
TI TERRA Amplified (+) Primary Leiomyosarcomas (LMS) of the Gynecologic
(GYN)-Tract
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
KK Womens & Childrens Hosp, Singapore, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1266
BP 315A
EP 315A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401542
ER
PT J
AU Bundele, MM
Weinreb, I
Xu, B
Chiosea, S
Faquin, W
Dias-Santagata, D
Seethala, RR
AF Bundele, Manish M.
Weinreb, Ilan
Xu, Bin
Chiosea, Simon
Faquin, William
Dias-Santagata, Dora
Seethala, Raja R.
TI Mucoacinar Carcinoma: A Rare Intercalated Duct/Acinar Variant of
Mucoepidermoid Carcinoma, Hybrid Tumor, or Distinct Entity?
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Tan Tock Seng Hosp, Sg, Singapore.
Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Hlth Network, Toronto, ON, Canada.
Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1294
BP 322A
EP 322A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401570
ER
PT J
AU Jo, VY
Chau, NG
Hornick, JL
Krane, JF
Sholl, LM
AF Jo, Vickie Y.
Chau, Nicole G.
Hornick, Jason L.
Krane, Jeffrey F.
Sholl, Lynette M.
TI Recurrent IDH2 R172X Mutations Define Sinonasal Undifferentiated
Carcinoma
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
Harvard Med Sch, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1310
BP 326A
EP 326A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401586
ER
PT J
AU Boiocchi, L
Ferry, JA
Deshpande, V
AF Boiocchi, Leonardo
Ferry, Judith A.
Deshpande, Vikram
TI Lymph Node Fibrosis in IgG4-Related Disease
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Boiocchi, Leonardo; Ferry, Judith A.; Deshpande, Vikram] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1362
BP 339A
EP 339A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401638
ER
PT J
AU Boyer, D
McKelvie, P
de Leval, L
Edlefsen, KL
Ko, YH
Aberman, Z
Kovach, A
Masih, A
Nishino, H
Weiss, L
Meeker, A
Nardi, V
Palisoc, M
Shao, LN
Pittaluga, S
Ferry, JA
Harris, N
Sohani, A
AF Boyer, Daniel
McKelvie, Penelope
de Leval, Laurence
Edlefsen, Kerstin L.
Ko, Young-Hyeh
Aberman, Zachary
Kovach, Alexandra
Masih, Aneal
Nishino, Ha
Weiss, Lawrence
Meeker, Alan
Nardi, Valentina
Palisoc, Maryknoll
Shao, Lina
Pittaluga, Stefania
Ferry, Judith A.
Harris, Nancy
Sohani, Aliyah
TI Fibrin-Associated EBV plus Large B-Cell Lymphoma: An Indolent Neoplasm
Distinct from DLBCL-CI
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Univ Michigan, Ann Arbor, MI 48109 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
St Vincents Hosp, Melbourne, Vic, Australia.
CHU Vaudois, Lausanne, Switzerland.
Univ Washington, Seattle, WA 98195 USA.
Sungkyunkwan Univ, Seoul, South Korea.
Florida Int Univ, Miami, FL 33199 USA.
Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
Holmes Reg Med Ctr, Melbourne, FL USA.
North Shore Med Ctr, Salem, MA USA.
NeoGen Labs, Aliso Viejo, CA USA.
Johns Hopkins Univ, Baltimore, MD USA.
NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1363
BP 339A
EP 340A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401639
ER
PT J
AU Crotty, R
Pozdnyakova, O
Chen, YB
Ballen, K
Hassesjian, RP
AF Crotty, Rosy
Pozdnyakova, Olga
Chen, Yi-Bin
Ballen, Karen
Hassesjian, Robert P.
TI Lymphoid Proliferations Following Umbilical Cord Stem Cell Transplant
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1381
BP 344A
EP 344A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401657
ER
PT J
AU Margolskee, E
Mikita, G
Oak, J
Allen, MB
Zuo, Z
Wang, S
Arber, DA
George, T
Hasserjian, RP
Orazi, A
AF Margolskee, Elizabeth
Mikita, Geoffrey
Oak, Jean
Allen, M. B.
Zuo, Zhuang
Wang, Sa
Arber, Daniel A.
George, Tracy
Hasserjian, Robert P.
Orazi, Attilio
TI Acute Myeloid Leukemia with Erythroid Predominance: Are All Cases
MDS-Related?
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA.
Stanford Univ, Stanford, CA 94305 USA.
Univ New Mexico, Albuquerque, NM 87131 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1452
BP 362A
EP 362A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401728
ER
PT J
AU Matyamchik, E
Van Cott, EM
AF Matyamchik, Elena
Van Cott, Elizabeth M.
TI The Effects of Rivaroxaban on Activated Protein C Resistance and Protein
S Testing
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Matyamchik, Elena; Van Cott, Elizabeth M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1454
BP 363A
EP 363A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401730
ER
PT J
AU Shih, A
Bledsoe, JR
McKelvie, P
Harris, N
Zukerberg, L
AF Shih, Angela
Bledsoe, Jacob R.
McKelvie, Penny
Harris, Nancy
Zukerberg, Lawrence
TI CD5-Negative Mantle Cell Lymphoma Shows a More Indolent Outcome and
Variable SOX11 Staining
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 [Shih, Angela; Bledsoe, Jacob R.; McKelvie, Penny; Harris, Nancy; Zukerberg, Lawrence] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1513
BP 378A
EP 378A
PG 1
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724401789
ER
PT J
AU Tashakori, M
Sanchez, J
Michalowski, SM
Louissaint, A
Inamdar, KV
Gomez-Gelvez, J
Carey, JL
Menon, MP
AF Tashakori, Mehrnoosh
Sanchez, Jessica
Michalowski, Susan M.
Louissaint, Abner
Inamdar, Kedar V.
Gomez-Gelvez, Juan
Carey, John L.
Menon, Madhu P.
TI Follicular Lymphoma Transforming to Double and Triple Hit Lymphoma; a
Clinicopathologic, Morphologic and Cytogenetic Analysis
SO LABORATORY INVESTIGATION
LA English
DT Meeting Abstract
CT 106th Annual Meeting of the
United-States-and-Canadian-Academy-of-Pathology (USCAP)
CY MAR 04-10, 2017
CL San Antonio, TX
SP US & Canadian Acad Pathol
C1 Henry Ford Hlth Syst, Detroit, MI USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD FEB
PY 2017
VL 97
SU 1
MA 1525
BP 380A
EP 381A
PG 2
WC Medicine, Research & Experimental; Pathology
SC Research & Experimental Medicine; Pathology
GA EK1YT
UT WOS:000393724402009
ER
EF